UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 10-K

☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the fiscal year ended December 31, 2017

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from              to            

COMMISSION FILE NUMBER 001-33865

Triple-S Management Corporation
 
Puerto Rico
66-0555678
 (STATE OF INCORPORATION)
 
 (I.R.S. ID)

1441 F.D. Roosevelt Avenue, San Juan, PR 00920
(787) 749-4949
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
 
Name of each exchange on which registered
Class B common stock, $1.00 par value
 
New York Stock Exchange
 
Securities registered pursuant to Section 12(g) of the Act:   Class A common stock, $1.00 par value

Indicate by check mark if the registrant is well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
☐  Yes  ☑   No

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
☐  Yes  ☑   No

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

☑  Yes   ☐   No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
☑  Yes   ☐   No

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See definition of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
 
Large accelerated filer  ☐
Accelerated filer  ☑
Non-accelerated filer  ☐
Smaller reporting company  ☐
Emerging growth company  ☐
 
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).
  ☐  Yes  ☑  No
 
The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant as of June 30, 2017 was $397,286,415 for the Class B common stock (the only stock of the registrant that trades in a public market) and $950,968 for the Class A common stock (valued at its par value of $1.00 since it is not publicly traded).

As of February 26, 2018, the registrant had 950,968 of its Class A common stock outstanding and 22,358,325 of its Class B common stock outstanding.

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the definitive Proxy Statement to be delivered to shareholders in connection with the Annual Meeting of Shareholders to be held on April 27, 2018 are incorporated by reference into Parts II and III of this Annual Report on Form 10-K.
 


Triple-S Management Corporation

FORM 10-K

For The Fiscal Year Ended December 31, 2017
 
Table of Contents
 
3
   
 
3
 
29
 
54
 
54
 
54
 
54
   
55
   
 
55
 
57
 
58
 
86
 
89
 
91
 
92
 
93
   
93
   
 
93
 
93
 
93
 
93
 
94
   
94
   
 
94
 
94
 
99
 
Part I

Item 1.
Business

General Description of Business and Recent Developments

Triple-S Management Corporation (“Triple-S”, “TSM”, the “Company”, the “Corporation”, “we”, “us” or “our”) is one of the most significant players in the managed care industry in Puerto Rico, serving approximately 978,000 members, with a 27% market share in terms of premiums written in Puerto Rico for the nine-month period ended September 30, 2017.  We have the exclusive right to use the Blue Cross and Blue Shield (“BCBS”) name and mark throughout Puerto Rico, the U.S. Virgin Islands, Costa Rica, the British Virgin Islands and Anguilla and over 55 years of experience in the managed care industry.  We offer a broad portfolio of managed care and related products in the Commercial, Medicaid and Medicare markets. We market our managed care products through an extensive network of independent agents and brokers located throughout Puerto Rico as well as an internal salaried sales force. We provided administration services only or self-insured (“ASO”) managed care services to the Plan de Salud del Gobierno (similar to Medicaid) (“PSG” or “Medicaid”) island-wide until March 31, 2015.  Effective April 1, 2015, the government changed the Medicaid delivery model from an ASO to a risk-based model and we elected to participate in this sector as a fully-insured provider in only two of the eight regions of Puerto Rico.  PSG is funded by the Government of Puerto Rico and the U.S. Government.

We also offer complementary products and services, including life insurance, accident and disability insurance and property and casualty insurance.  We are one of the leading providers of life insurance policies in Puerto Rico.

A substantial majority of our premiums are from customers within Puerto Rico.  In addition, most of all of our long-lived assets, other than financial instruments, including deferred policy acquisition costs and value of business acquired, goodwill and other intangibles, and the deferred tax assets are related to Puerto Rico.

Operating revenues (with intersegment premiums/service revenues shown separately), operating income and total assets attributable to the reportable segments are set forth in note 26 of the audited consolidated financial statements for the years ended December 31, 2017, 2016 and 2015.

On October 2017, the Centers for Medicare & Medicaid Services (“CMS”) published the STAR Ratings for payment year 2018.  Our Health Maintenance Organization (“HMO”) contract, scored 4.0 overall on a 5.0 STAR rating system, and achieved 4.5 STARS in Part D. Our Preferred Provider Organization (“PPO”) contract, scored 3.5 overall, and achieved 5.0 STARS in Part D.  STAR ratings are calculated annually and are subject to change each year.
 
Our subsidiary Triple-S Salud, Inc. (“TSS”) was granted Utilization Review Accreditation Commission (“URAC”) effective March 1, 2017.  Reaccreditation is scheduled for 2020.  This is a requirement for the Federal Employees Program representing over $175 million in premiums. The accreditation is extensive to the whole Commercial and Medicaid lines of business since they are managed in the same operational platforms as the Federal Employees Program.  These achievements evidence the corporate commitment to quality in health services for our members and affiliates.
 
In August 2017, we announced the immediate commencement of a Class B $30.0 million share repurchase program, as authorized by our Board of Directors. In February 2018 the Board of Directors authorized a $25.0 million expansion to the existing $30.0 million Class B repurchase program. This program is conducted in accordance with Rules 10b5-1 and 10b-18 under the Securities Exchange Act of 1934.
 
On August 29, 2017, TSS and OptumInsight, Inc. (“Optum”) entered into a Master Services Agreement (the “Agreement”). Pursuant to the terms of the Agreement, Optum will provide healthcare technology and operations services, including information technology, claims processing and application development, to TSS and its affiliates.  The Agreement was effective August 31, 2017 (the “Effective Date”) and is expected to create further operating efficiencies, mostly in the Managed Care operations. The agreement has an initial term of ten (10) years but TSS has the right to extend the term of the Agreement for two (2) additional one (1) year terms.  Under the terms of the Agreement, Optum will: (i) continue providing services already provided to TSS and its affiliates, (ii) provide new services requested by TSS and (iii) provide services in support of any third party administrator arrangements entered into by TSS or its affiliates, in accordance with the terms of separate statements of work to be entered into by the parties. The different services being offered by Optum will be implemented in phases beginning in 2018. The Agreement is subject to the approval of the Puerto Rico Health Insurance Administration (“ASES” by its Spanish acronym).
 
In this Annual Report on Form 10-K, references to “shares” or “common stock” refer collectively to our Class A and Class B common stock, unless the context indicates otherwise.
 
Industry Overview

Managed Care

In response to an increasing focus on health care costs by employers, the government and consumers, there has been an increase in alternatives to traditional indemnity health insurance, such as HMOs and PPOs.  Through the introduction of these alternatives the managed care industry has attempted to contain the cost of health care by negotiating contracts with hospitals, physicians and other providers to deliver health care to plan members at favorable rates.  These products usually feature medical management and other quality and cost optimization measures such as pre-admission review and approval for certain non-emergency services, pre-authorization of certain outpatient surgical procedures, network credentialing to determine that network doctors and hospitals have the required certifications and expertise, and various levels of care management programs to help members better understand and navigate the medical system.  In addition, providers may have incentives to achieve certain quality measures or may share medical cost risk.  Members generally pay co-payments, coinsurance and deductibles when they receive services.  While the distinctions between the various types of plans have lessened over recent years, PPO products generally provide reduced benefits for out-of-network services, while traditional HMO products generally provide little to no reimbursement for non-emergency out-of-network utilization.  An HMO plan may also require members to select one of the network primary care physicians (“PCPs”) to coordinate their care and approve any specialist or other services.

The government of the United States of America (the “U.S. government” or “federal government”) provides hospital and medical insurance benefits to eligible people aged 65 and over as well as certain other qualified persons through the Medicare program, including the Medicare Advantage program.  The federal government also offers prescription drug benefits to Medicare eligibles, both as part of the Medicare Advantage program and on a stand-alone basis, pursuant to Medicare Part D (also referred to as “PDP stand-alone product” or “PDP”).  In addition, the Government of Puerto Rico provides managed care coverage to the medically indigent population of Puerto Rico.

Economic factors and greater consumer awareness have resulted in (a) the increasing popularity of products that offer larger, more extensive networks, more member choice related to coverage, physicians and hospitals, greater access to preventive care and wellness programs, and a desire for greater flexibility for customers to assume larger deductibles and co-payments in return for lower premiums and (b) products with lower benefits and a narrower network in exchange for lower premiums.  We believe we are well positioned to respond to these market preferences due to the breadth and flexibility of our product offering and size of our provider networks.

Life Insurance

Total annual premiums in Puerto Rico for the year ended December 31, 2016 for the life insurance market approximated $1.5 billion.  The main products in this market are ordinary life, cancer and other dreaded diseases, term life, disability and annuities.  The main distribution channels are independent agents.  Banks have established general agencies to cross sell life insurance products, such as term life and credit life.

Property and Casualty Insurance

The total property and casualty market in Puerto Rico in terms of gross premiums written for the nine months ended September 30, 2017 was approximately $1.3 billion.  Property and casualty insurance companies compete for the same accounts through aggressive pricing, more favorable policy terms and better quality of services.  The main lines of business in Puerto Rico are personal and commercial auto, commercial multi-peril, fire and allied lines and other general liabilities.  Approximately 67% of the market is written by the top six insurance groups or companies in terms of market share, and approximately 87% of the market is written by companies incorporated under the laws of and which operate principally in Puerto Rico.

The Puerto Rican property and casualty insurance market is highly dependent on reinsurance.  In September 2017 Puerto Rico was hit by two hurricanes causing severe damages and losses to the insurance market. Moreover, the reinsurance market was impacted even more by other natural catastrophes in the second semester of 2017.  As a result, reinsurance costs are expected to increase significantly in 2018 and subsequent periods; which will also have an effect in the insurance market in Puerto Rico.
 
Puerto Rico’s Economy

The dominant sectors of the Puerto Rico economy in terms of production and income are manufacturing and services.  The current manufacturing sector now places increased emphasis on higher wages, high technology industries, such as pharmaceuticals, biotechnology, computers, microprocessors, professional and scientific instruments, and certain high technology machinery and equipment with almost 90% of manufacturing generated by chemical and electronic products.  The services sector, which includes finance, insurance, real estate, wholesale and retail trade, transportation, communications and public utilities, and other services, plays a major role in the economy.  It ranks second to manufacturing in contribution to the gross domestic product and leads all sectors in providing employment.

The economy of Puerto Rico is affected by external factors determined by the U.S. economy and the policies and results of the U.S. Government.  These external factors include exports, direct investment, the amount of federal transfer payments, the level of interest rates, the rate of inflation, and revenues derived from tourism coming from the U.S.  Generally, the economy of Puerto Rico has followed the economic trends of the U.S. economy.  However, recently the economic growth in Puerto Rico has not been consistent with the performance of the U.S. economy.  The Government of Puerto Rico has faced a number of fiscal challenges, including an imbalance between its general fund revenues and expenditures, reaching its highest level in fiscal year 2009 with a deficit of $3.3 billion.  Recurrent budget deficits have substantially increased the amount of public sector debt.  The total outstanding public sector debt amounted to $68.7 billion as of July 31, 2016, the latest published information by the government.  In 2016, Puerto Rico defaulted on various types of debt, which included General Obligation bonds, after a local debt moratorium provision was evoked.

On June 30, 2016, the President of the United States signed the Puerto Rico Oversight, Management, and Economic Stability Act (“PROMESA”), which grants the Commonwealth of Puerto Rico (the “Government” or the “Commonwealth”) and its component units, access to an orderly mechanism to restructure their debts in exchange for significant federal oversight over the Commonwealth’s finances. In general, PROMESA seeks to provide Puerto Rico with fiscal and economic discipline through the creation of a control board, relief from creditor lawsuits through the enactment of a temporary stay on litigation, and two alternative methods to adjust unsustainable debt.

See “Item 1A.   Risk Factors—Risks Related to Our Business – Our business is geographically concentrated in Puerto Rico and weakness in the economy and the fiscal health of the government has adversely impacted and may continue to adversely impact us, particularly following Hurricanes Irma and Maria. ’’

Products and Services

Managed Care

Through our subsidiaries TSS and Triple-S Advantage, Inc. (“TSA”), we offer a broad range of managed care products, including HMO plans, PPO plans, Medicare Supplement, Medicare Advantage, and Medicaid plans.  Managed care products represented approximately 92% of our consolidated premiums earned before elimination, net for each of the years ended December 31, 2017, 2016 and 2015.  We design our products to meet the needs and objectives of a wide range of customers, including employers, professional and trade associations, individuals and government entities.  Our customers either contract with us to assume underwriting risk or they self-fund underwriting risk and rely on us for provider network access, medical cost management, claim processing, stop-loss insurance and other administrative services.  Our products vary with respect to the level of benefits provided, the costs paid by employers and members, including deductibles and co-payments, and the extent to which our members' access to providers is subject to referral or preauthorization requirements.

Managed care generally refers to a method of integrating the financing and delivery of health care within a system that manages the cost, accessibility and quality of care.  Managed care products can be further differentiated by the types of provider networks offered, the ability to use providers outside such networks and the scope of the medical management and quality assurance programs.  Our members receive medical care from our networks of providers in exchange for premiums paid by the individuals or their employers, including governmental entities, and, in some instances, a cost-sharing payment between the employer and the member.  We reimburse network providers according to pre-established fee arrangements and other contractual agreements.
 
We currently offer the following managed care plans:

Health Maintenance Organization (“HMO”).      We offer HMO plans that provide members with health care coverage for a fixed monthly premium in addition to applicable member co-payments.  Health care services can include emergency care, inpatient hospital and physician care, outpatient medical services and supplemental services such as dental, vision, behavioral and prescription drugs, among others.  Members must select a primary care physician within the network to provide and assist in managing care, including referrals to specialists.

Preferred Provider Organization (“PPO”).     We offer PPO managed care plans that provide our members and their dependent family members with health care coverage in exchange for a fixed monthly premium.  In addition, we provide our PPO members with access to a larger network of providers than our HMO.  In contrast to our HMO product, we do not require our PPO members to select a primary care physician or to obtain a referral to utilize in-network specialists.  We also provide coverage for PPO members who access providers outside of the network.  Out-of-network benefits are generally subject to a higher deductible and coinsurance.  We also offer national in-network coverage to our PPO members through the BlueCard program.

BlueCard.     For our members who purchase our PPO and selected members under ASO arrangements through our subsidiary TSS, we offer the BlueCard program.  The BlueCard program offers these members in-network benefits through the networks of the other BCBS plans in the United States and certain U.S. territories.  In addition, the BlueCard worldwide program provides our PPO members with coverage for medical assistance worldwide.  We believe that the national and international coverage provided through this program allows us to compete effectively with large national insurers.

Medicare Supplement.     We offer Medicare Supplement products, which provide supplemental coverage for many of the medical expenses that the Medicare Parts A and B programs do not cover, such as deductibles, coinsurance and specified losses that exceed these programs’ maximum benefits.

ASO.     In addition to our fully insured plans, we also offer our PPO products on a self-funded or ASO basis, under which we provide claims processing and other administrative services to employers.  Employers choosing to purchase our products on an ASO basis fund their own claims, but their employees are able to access our provider network at our negotiated discounted rates.  We administer the payment of claims to the providers but we do not bear any insurance risk in connection with claims costs because we are reimbursed in full by the employer, thus we are only subject to credit risk in this business.  For certain self-funded plans, we provide stop loss insurance pursuant to which we assume some of the medical risk for a premium.  The administrative fee charged to self-funded groups is generally based on the size of the group and the scope of services provided.

Life Insurance

We offer a wide variety of life, accident, disability and health and annuity products in Puerto Rico through our subsidiary Triple-S Vida, Inc. (“TSV”).  Life insurance premiums represented approximately 6% of our consolidated premiums earned, before elimination, for each of the years ended December 31, 2017, 2016 and 2015.  TSV markets in-home service life and supplemental health products through a network of company-employed agents.  Ordinary life, cancer and dreaded diseases (“Cancer” line of business), and pre-need life products are marketed through independent agents.  TSV is the leading distributor of life products in Puerto Rico.  We are the only home service company in Puerto Rico and offer guaranteed issue, funeral and cancer policies to the lower and middle income market segments directly to people in their homes.  We also market our group life and disability coverage through our independent producers.

Property and Casualty Insurance

We offer a wide range of property and casualty insurance products through our subsidiary Triple-S Propiedad, Inc. (“TSP”).  Property and casualty insurance net premiums earned represented approximately 3% of our consolidated premiums earned, net before elimination for each of the years ended December 31, 2017, 2016 and 2015.  Our predominant insurance products are commercial multi-peril package, personal package, commercial auto, hospital malpractice, commercial liability, and commercial property.  This segment’s commercial products target small to medium size accounts.
 
Due to our geographical location, property and casualty insurance operations in Puerto Rico are subject to natural catastrophic activity, in particular hurricanes, tropical storms and earthquakes.  As a result, local insurers, including ourselves, rely on the international reinsurance market.  The property and casualty insurance market is affected by the cost of reinsurance, which varies with the catastrophic experience.

We maintain a comprehensive reinsurance program as a means of protecting our surplus in the event of a catastrophe.  Our policy is to enter into reinsurance agreements with reinsurers considered to be financially sound.  Practically all our reinsurers have an A.M. Best rating of ‘‘A-’’ or better, or an equivalent rating from other rating agencies.  During the year ended December 31, 2017, 43.3% of the premiums written in the property and casualty insurance segment were ceded to reinsurers.  Although these reinsurance arrangements do not relieve us of our direct obligations to our insured, we believe that the risk of our reinsurers not paying balances due to us is low.

Marketing and Distribution

Our marketing activities are focused on promoting our strong brands, quality care, customer service efforts, size and quality of provider networks, flexibility of plan designs, financial strength and breadth of product offerings.  We distribute and market our products through several channels, including our salaried and commission-based internal sales force, direct mail, independent brokers and agents, telemarketing staff, traditional media (TV, Press, Billboards, Radio and Cinema) and Digital Media.  We recently added e-commerce as part of our distribution channels.

Branding and Marketing

Our branding and marketing efforts include “brand advertising”, which focuses on the Triple-S name and the BCBS brand for our managed care products and services, “acquisition marketing”, which focuses on attracting new customers, and “institutional advertising” which focuses on our overall corporate image. We believe that the strongest element of our brand identity is the Triple-S name.  We seek to leverage what we believe to be the strong name recognition and comfort level that many existing and potential customers associate with this brand.  Acquisition marketing consists of business-to-business marketing efforts to generate leads for brokers and our sales force as well as direct-to-consumer marketing efforts which are used to add new customers to our direct pay businesses.  Institutional advertising is used to promote key corporate interests and overall company image as well as communicating our company purpose.  We believe these efforts support and further our competitive brand advantage.  We will continue to utilize the Triple-S name and the BCBS brand for all managed care products and services in Puerto Rico, the U.S. Virgin Islands, Costa Rica, the British Virgin Islands and Anguilla.

Sales and Marketing

We employ a wide variety of sales and marketing activities.  Such activities are closely regulated by CMS and the Office of Personnel Management (“OPM”), the U.S. Department of Health and Human Services (“HHS”), Puerto Rico Office of the Insurance Commissioner (“Commissioner of Insurance”), Superintendencia General de Seguros de Costa Rica (“ Costa Rica Insurance Superintendence”) and other government of Puerto Rico agencies .  For example, our sales and marketing materials must be approved in advance by the applicable regulatory authorities, and they often impose other regulatory restrictions on our marketing activities.

Distribution

Managed Care Segment.    We rely principally on our internal sales force and a network of independent brokers and agents to market our products.  Individual policies are sold entirely through independent agents who exclusively sell our individual products, and Medicare Advantage and group products are sold through our 370 person internal sales force (promotors and sales representatives) as well through over 200 independent brokers and agents.  We believe that each of these marketing methods is optimally suited to address the specific needs of the customer base to which it is assigned.
 
Strong competition exists among managed care companies for brokers and agents with proven ability to secure new business and maintain existing accounts.  The basis of competition for the services of such brokers and agents are commission structure, support services, reputation and prior relationships, the ability to retain clients and the quality of products.  We pay commissions on a monthly basis based on premiums paid.  We believe that we have good relationships with our brokers and agents, and that our products, support services and commission structure are highly competitive in the marketplace.

Life Insurance Segment     In our life insurance segment, we offer our insurance products through our own network of both company-employed and independent agents.  The majority of our premiums (61.5% in 2017 and 64.0% in 2016) were placed through our home service distribution channel selling directly to customers in their homes.  TSV employs approximately 630 full-time active agents and managers and utilizes approximately 400 independent agents and brokers.  For individual policies, we advance first year commissions upon issuance and for group policies, we pay commissions on a monthly basis based on premiums received.

Property and Casualty Insurance Segment.   In our property and casualty insurance segment, business is primarily subscribed through approximately 15 general agencies, including our insurance agency, Triple-S Insurance Agency, Inc. (“TSIA”), where business is placed by independent insurance agents and brokers.  During the years ended December 31, 2017, 2016 and 2015 TSIA placed approximately 69%, 73% and 73% of TSP’s total premium volume, respectively.  General agencies contracted by TSP remit premiums net of their respective commission.
 
Customers

Managed Care

We offer our products in the managed care segment to three distinct market sectors in Puerto Rico.  The following table sets forth enrollment information with respect to each sector:
 
Market Sector
 
Enrollment at
December 31, 2017
   
Percentage of
Total Enrollment
 
Commercial
   
475,026
     
48.6
%
Medicare
   
118,451
     
12.1
%
Medicaid
   
384,462
     
39.3
%
Total
   
977,939
     
100.0
%
 
Commercial Sector

The commercial accounts sector includes corporate accounts, federal government employees, individual accounts, local government employees, and Medicare Supplement.

Corporate Accounts.      Corporate accounts consist of small (2 to 50 employees) and large employers (over 50 employees).  Employer groups may choose various funding options ranging from fully-insured to self-funded financial arrangements or a combination of both.  While self-funded clients participate in our managed care networks, the clients bear the insurance risk, except to the extent they maintain stop loss coverage.  This sector also includes professional and trade associations.

Federal Government Employees.     For over 40 years, we have maintained our leadership in providing managed care services to federal government employees in Puerto Rico.  We provide our services to these employees under the Federal Employees Health Benefits Program pursuant to a direct contract with OPM and through the Federal Employee Program of the BCBSA.  We are one of two companies in Puerto Rico that has such a contract with OPM.  Every year, OPM allows other insurance companies to compete for this business, provided such companies comply with the applicable requirements for service providers.  This contract is subject to termination in the event of a non-compliance that is not corrected to the satisfaction of OPM.
 
Individual Accounts.     We provide managed care services to individuals and their dependent family members who contract these services directly with us through our network of independent brokers.  We provide individual and family contracts.

Local Government Employees.     We provide full risk managed care services to the local government of Puerto Rico employees through a government-sponsored program.  Annually, the government qualifies the managed care companies that participate in this program and sets the coverage, including benefits, co-payments and amount to be contributed by the government.  Employees then select from one of the authorized companies and pays for the difference between the premium of the selected carrier and the amount contributed by the government.

Medicare Supplement.     We offer Medicare Supplement products, which provide supplemental coverage for many of the medical expenses that the Medicare Parts A and B programs do not cover, such as deductibles, coinsurance and specified losses that exceed the federal program’s maximum benefits.

Medicare Advantage Sector

Medicare is a federal program administered by CMS that provides a variety of hospital and medical insurance benefits to eligible persons aged 65 and over as well as to certain other qualified persons.  Medicare, with the approval of the Medicare Modernization Act, started promoting a managed care organizations (“MCO”) sponsored Medicare product that offers benefits similar to or better than the traditional Medicare product, but where the risk is assumed by the MCOs.  This program is called Medicare Advantage.  We have contracts with CMS to provide extended Medicare coverage to Medicare beneficiaries under our Dual and Non-Dual products.  Under these annual contracts, CMS pays us a set premium rate based on membership that is risk adjusted for health status.  Depending on the total benefits offered, for certain of our Medicare Advantage products the member will also be required to pay a premium.

Our Dual products target the sector of the population eligible for both Medicare and Medicaid, or dual-eligible beneficiaries.  The government of Puerto Rico has implemented a plan to allow dual-eligibles enrolled in Medicaid to move to a Medicare Advantage plan under which the government, rather than the insured, will assume all of the premiums for additional benefits not included in the Medicare Advantage programs, such as deductibles and co-payments of prescription drug benefits.

Medicaid

The government of Puerto Rico has privatized the delivery of services to the medically indigent population in Puerto Rico, as defined by the government, by contracting with private managed care companies instead of providing health services directly to such population.  The government divided Puerto Rico into eight geographical areas.  Each of the eight geographical areas is awarded to a managed care company doing business in Puerto Rico through a competitive bid process.  We currently provide healthcare services in the Metro-North and West regions to approximately 384,000 members.  As of December 31, 2017, this program provided healthcare coverage to over 1.2 million people.

This program is based on the Medicaid program, a joint federal and state health insurance program for medically indigent residents of the state.  The Medicaid program is structured to provide states the flexibility to establish eligibility requirements, benefits provided, payment rates, and program administration rules, subject to general federal guidelines.

Our agreement with the government of Puerto Rico is subject to termination in the event of a non-compliance event that is not corrected or cured to the satisfaction of the government entity overseeing Medicaid, or in the event that the government determines that there is an insufficiency of funds to finance the program.  See “Item 1A – Risks Factors – Risks Related to our Business – We are dependent on a small number of government contracts to generate a significant amount of the revenues of our managed care business”.
 
Life Insurance

Our life insurance customers consist primarily of individuals, who hold approximately 607,400 policies.  We also insure approximately 1,560 groups.
 
Property and Casualty Insurance

Our property and casualty insurance segment targets small to medium size accounts with low to average exposures to catastrophic losses.  The auto physical damage and auto liability customer bases are primarily of commercial accounts.  Personal business are primarily generated with sales of our personal package product, ProPack, that includes coverage for residences, personal property, and automobile.  Also, professional liability coverage is offered with hospital and medical malpractice products.

Underwriting and Pricing

Managed Care

We strive to maintain our market leadership by trying to provide all of our managed care members with the best health care coverage at a reasonable cost.  We believe that disciplined underwriting and appropriate pricing are core strengths of our business and important competitive advantages.  We continually review our underwriting and pricing guidelines on a product-by-product and customer group-by-group basis to maintain competitive rates in terms of both price and scope of benefits.  Pricing is based on the overall risk level and the estimated administrative expenses attributable to each particular segment.

Our claims database enables us to establish rates based on each renewing group claims experience, which provides us with important insights about the risks in our service areas.  We tightly manage the overall rating process and have processes in place to ensure that underwriting decisions are made by properly qualified personnel.  In addition, we have developed and implemented a utilization review and fraud and abuse prevention program.

We have been able to maintain relatively high retention rates, which is the percentage of existing clients retained in the renewal process, in the corporate accounts sector of our managed care business.  For 2017 and 2016 our corporate accounts retention factor was 92% and 88%, respectively.

Our managed care rates are set prospectively, meaning that a fixed premium rate is determined at the beginning of each contract year and revised at renewal.  We renegotiate the premiums of different groups in the corporate accounts as their existing annual contracts become due.  We set rates for individual contracts based on the most recent semi-annual claims data.  We consider the actual claims trend of each group when determining the premium rates for the following contract year.  Rates in the Medicare sector and for federal and local government employees are generally set on an annual basis through negotiations with the U.S. Federal and Puerto Rico Governments, as applicable.

Life Insurance

Our individual life insurance business has been priced using mortality, morbidity, lapses and expense assumptions which approximate actual experience for each line of business.  We review pricing assumptions on a regular basis.  Individual insurance applications are reviewed by utilizing common underwriting standards in use in the United States, and only those applications that meet these commonly-used underwriting requirements are approved for policy issuance.  Our group life insurance business is written on a group-by-group basis.  We develop the pricing for our group life business based on mortality and morbidity experience and estimated expenses attributable to each particular line of business.

Property and Casualty Insurance

The property and casualty insurance sector has experienced a soft market in Puerto Rico, principally as a result of economic conditions and reinsurance capacity, which is now changing due to the losses generated by the hurricanes in the current year.  Notwithstanding these conditions, our property and casualty segment has maintained its leadership position in the property insurance sector by following prudent underwriting and pricing practices.
 
Our core business is comprised of small and medium-sized accounts.  The volume of business is subject to attentive risk assessment and strict adherence to underwriting guidelines, combined with maintenance of competitive rates on above-par risks designed to maintain a relatively high retention ratio.  Underwriting strategies and practices are closely monitored by senior management and constantly updated based on market trends, risk assessment results and loss experience.  Commercial risks in particular are fully reviewed by our underwriters.

Quality Initiatives and Medical Management

We utilize a broad range of focused traditional cost containment and advanced care management processes across various product lines.  We continue to enhance our management strategies, which seek to control claims costs while striving to fulfill the needs of highly informed and demanding managed care consumers.  One of these strategies is the reinforcement of population and case management programs, which empower consumers by educating them and engaging them in actively maintaining or improving their own health.  Early identification of patients and inter-program referrals are the focus of these programs, which allow us to provide integrated services to our customers based on their specific conditions.  The population management programs include programs that target asthma, congestive heart failure, hypertension, diabetes, and a prenatal program that focuses on preventing prenatal complications and promoting adequate nutrition.  We developed a medication therapy management program aimed at plan members who are identified as having high drug utilization and unrelated diagnostics.  In addition, TSS, through a third party supplier, provides to our members a 24-hour telephone-based triage program and health information services.  TSS also provides utilization management services for our Medicare sector.  We intend to maximize utilization of population and case management programs among our insured populations.  Other strategies include innovative partnerships and business alliances with other entities to provide new products and services such as an employee assistance program and the promotion of evidence-based protocols and patient safety programs among our providers.  We also employ registered nurses and social workers to manage individual cases and coordinate healthcare services.  We have enhanced our hospital concurrent review program, the goal of which is to monitor the appropriateness of high admission rate diagnoses and unnecessary stays.  To expand the scope of the revision, we established a phone based review for low admissions hospitals, which freed resources to cover the biggest hospitals and allowed the onsite nurses to participate in the patient discharge planning, referral to programs, the quality of the services, including the occurrence of never events.  As part of the cost containment measures we have preauthorization services for certain procedures and the mandatory validation of member eligibility prior to accessing services.  In addition, we provide a variety of services and programs for the acute, chronic and complex populations.  These services and programs seek to enhance quality at physicians’ premises, thus reducing emergency care and hospitalizations.  We promote the use of a formulary for accessing medications, encouraging the use of generic drugs in the three-tier formulary, which offers three co-payment levels.

We have also established an exclusive pharmacy network with higher discounted rates than our broader network.  In addition, through arrangements with our pharmacy benefits manager, we are able to obtain discounts and rebates on certain medications based on formulary listing and market share.

We have designed a comprehensive Quality Improvement Program (“QIP”).  This program is designed with a strong emphasis on continuous improvement of clinical and service indicators, such as Health Employment Data Information Set (“HEDIS”) and Consumer Assessment of Healthcare Providers and Systems (“CAHPS”) measures.  Our QIP also includes a Physician Incentive Program (“PIP”) and a Hospital Quality Incentive Program (“HQIP”), which are directed to support corporate quality initiatives, utilizing clinical and benchmark criteria developed by governmental agencies and nationally recognized professional organizations.  The PIP encourages the participation of members in chronic care improvement programs and the achievement of specific clinical outcomes.  The HQIP encourages participating hospitals to achieve the national benchmarks related to the five core measures established by CMS and the Joint Commission.
 
Provider Arrangements

Approximately 99% of member services are provided through one of our contracted provider networks and the remainder is provided by out-of-network providers.  Our relationships with managed care providers, physicians, hospitals, other facilities and ancillary managed care providers are guided by standards established by applicable regulatory authorities for network development, reimbursement and contract methodologies.

We contract with our managed care providers in different forms, including capitation-based reimbursement.  For certain ancillary services, such as behavioral health services and primary care services in certain of our products, we generally enter into capitation arrangements with entities that offer broad based services through their own contracts with providers.  We attempt to provide market-based reimbursement along industry standards.  We seek to ensure that providers in our networks are paid in a timely manner, and we provide means and procedures for claims adjustments and dispute resolution.  We also provide a dedicated service center for our providers.  We seek to maintain broad provider networks to ensure member choice while implementing effective management programs designed to improve the quality of care received by our members.

We promote the use of electronic claims billing by our providers.  Approximately 93% of claims are submitted electronically through our fully automated claims processing system, and our “first-pass rate”, or rate at which a claim is approved for payment when first processed by our system without human intervention, for provider claims has averaged 92% in 2017.

We believe that physicians and other providers primarily consider member volume, reimbursement rates, timeliness of reimbursement and administrative service capabilities along with the “non-hassle” factor, or reduction of non-value adding administrative tasks, when deciding whether to contract with a managed care plan.  As a result of our established position in the Puerto Rican market, the strength of the Triple-S name and our association with the BCBSA, we believe we have strong relationships with hospital and provider networks leading to a strong competitive position in terms of hospital count, number of providers and number of in-network specialists.

Hospitals.     We generally contract for hospital services to be paid on an all-inclusive per diem basis, which includes all services necessary during a hospital stay.  We also contract some hospital services to be paid on diagnosis-related groups which is an all-inclusive rate per admission.   Negotiated rates vary among hospitals based on the complexity of services provided.  We annually evaluate these rates and revise them, if appropriate.

Physicians.    Fee-for-service is our predominant reimbursement methodology for physicians in our PPO products and for services referred by the independent practice associations (“IPAs”) under capitation agreements.  Our physician rate schedules applicable to services provided by in-network physicians are pegged to a resource-based relative value system fee schedule and then adjusted for competitive rates in the market.  This structure is similar to reimbursement agreement methodologies developed and used by the Medicare program and other major payers.   Payments to physicians under the Medicare Advantage program are based on Medicare fees.  For certain of our Medicare products we contract with IPAs in the form of capitation-based reimbursement for certain risks .  We have a network of IPAs that provide managed care services to our members in exchange for a capitation fee.  The IPAs assume the costs of certain primary care services provided and referred by their PCPs, including procedures and in-patient services not related to risks assumed by us.

Services are provided to our members through our network providers with whom we contract directly.  Members seeking medical treatment outside of Puerto Rico are served by providers in these areas through the BlueCard program, which offers access to the provider networks of the other BCBS plans.

Subcontracting.     We subcontract our triage call center, certain utilization management, mental and substance abuse health services, and pharmacy benefits management services through contracts with third parties.

In addition, we contract with a number of other ancillary service providers, including laboratory service providers, home health agency providers and intermediate and long-term care providers, to provide access to a wide range of services.  These providers are normally paid on either a fee schedule or fixed per day or per case basis.
 
On August 29, 2017, we entered into a Master Services Agreement in which OptumInsight, Inc. will provide healthcare technology and operations services, including information technology, claims processing and application development, to TSS and its affiliates.
 
Competition

The insurance industry in Puerto Rico is highly competitive and is comprised of both local and national entities.  The approval of the Gramm-Leach-Bliley Act of 1999, has opened the insurance market to new competition by allowing financial institutions such as banks to enter into the insurance business.  Several banks in Puerto Rico have established subsidiaries that operate as insurance agencies, brokers and reinsurers.

Managed Care

The managed care industry is highly competitive, both nationally and in Puerto Rico.  Competition continues to be intense due to aggressive marketing, business consolidations, a proliferation of new products and increased quality awareness and price sensitivity among customers.  Industry participants compete for customers based on the ability to provide a total value proposition which we believe includes quality of service and flexibility in benefit design, access to and quality of provider networks, brand recognition and reputation, price and financial stability.

Competitors in the managed care segment include national and local managed care plans.  At December 31, 2017, we had approximately 978,000 members enrolled in our managed care segment.  Our market share in terms of premiums written in Puerto Rico was estimated at approximately 27% for the nine-month period ended September 30, 2017.

We believe that our competitive strengths, including our leading presence in Puerto Rico, our BCBS license, the size and quality of our provider network, the broad range of our product offerings, our strong complementary businesses and our experienced management team, position us well to satisfy these competitive requirements.

Life Insurance

We are one of the leading providers of life insurance products in Puerto Rico.  In 2016, we were the second largest life insurance company in Puerto Rico, as measured by direct premiums, with a market share of approximately 10.5%.  We are the only life insurance company that distributes our products through home service.  However, we face competition in each of our product lines.  Excluding annuities, we are the largest company in the life insurance and cancer lines of business, with market shares of approximately to 19.8% and 20.6% respectively.

Property & Casualty Insurance

The property and casualty insurance market in Puerto Rico is extremely competitive.  In addition, soft market conditions have prevailed in Puerto Rico for a long period of time.  In the local market, such conditions mostly affected commercial risks, precluding rate increases and even provoking lower premiums on both renewals and new business.  After the hurricanes causing losses in Puerto Rico during September 2017, the commercial markets are experiencing increases in pricing and modifications on policy conditions, which is the typical reaction in the period following a natural catastrophic event.   Property and casualty insurance companies tend to compete for the same accounts through price, policy terms and quality of services.  We compete by reasonably pricing our products and providing efficient services to producers, agents and clients.

In the nine-month period ended September 30, 2017, we were the fourth largest property and casualty insurance company in Puerto Rico, as measured by direct premiums, with a market share approximating 8%.
 
Blue Cross and Blue Shield License

We have license agreements with BCBSA that permit us the exclusive use of the BCBS name and marks for the sale, marketing and administration of managed care plans and related services in Puerto Rico, the U.S. Virgin Islands, Costa Rica, the British Virgin Islands and Anguilla.  We believe that the BCBS name and marks are valuable brands of our products and services in the marketplace.  The license agreements, which have a perpetual term (but are subject to termination under circumstances described below), contain certain requirements and restrictions regarding our operations and our use of the BCBS name and marks.

Upon the occurrence of any event causing the termination of our license agreements, we would cease to have the right to use the BCBS name and marks.  We also would no longer have access to the networks of providers of the different plans that are members of the Association nor the BlueCard Program.  We would expect to lose a significant portion of our membership if we lose these licenses.  Loss of these licenses could significantly harm our ability to compete in our markets and could require payment of a significant fee to the BCBSA.  Furthermore, if our licenses were terminated, the BCBSA would be free to issue a new license to use the BCBS name and marks to another entity, which could have a material adverse effect on our business, financial condition and results of operations.  See “Item 1A   Risk Factors–Risks Related to Our Business – The termination or modification of our license agreements to use the BCBS name and marks could have a material adverse effect on our business, financial condition and results of operations.”

Events which could result in termination of our license agreements include, but are not limited to:

failure to maintain our total adjusted capital at or above 375% of Health Risk-Based Capital (“HRBC”) Authorized Control Level (“ACL”) as defined by the National Association of Insurance Commissioners (“NAIC”) for the for Primary Licensee (TSM) and Larger BCBS Controlled Affiliate (TSS) and 100% HRBC ACL for the Smaller BCBS Controlled Affiliate (TSA);

failure to maintain liquidity of greater than one month of underwritten claims and administrative expenses, as defined by the BCBSA, for two consecutive quarters;

failure to satisfy state-mandated statutory net worth requirements;

impending financial insolvency; and

a change of control not otherwise approved by the BCBSA or a violation of the BCBSA voting and ownership limitations on our capital stock.

The BCBSA license agreements and membership standards specifically permit a licensee to operate as a for-profit, publicly-traded stock company, subject to certain governance and ownership requirements.

Pursuant to our license agreements with BCBSA, at least 80% of the revenue that we earn from health care plans and related services in Puerto Rico, and at least 66.7% of the revenue that we earn from (or at least 66.7% of the enrollment for) health care plans and related services both in the United States and in Puerto Rico together, must be sold, marketed, administered, or underwritten through use of the BCBS name and marks.  This may limit the extent to which we will be able to expand our health care operations, whether through acquisitions of existing managed care providers or otherwise, in areas where a holder of an exclusive right to the BCBS name and marks is already present.  Currently, the BCBS name and marks are licensed to other entities in all markets of the continental United States, Hawaii, and Alaska.

As required by our BCBS license agreements, our articles of incorporation prohibit any institutional investor from owning 10% or more of our voting power, any person that is not an institutional investor from owning 5% or more of our voting power, and any person from beneficially owning shares of our common stock or other equity securities, or a combination thereof, representing a 20% or more ownership interest in us.  To the extent that a person, including an institutional investor, acquires shares in excess of these limits, our articles provide that we will have the power to take certain actions, including refusing to give effect to a transfer or instituting proceedings to enjoin or rescind a transfer, in order to avoid a violation of the ownership limitation in the articles.
 
Pursuant to the rules and license standards of the BCBSA, TSM guarantees TSS and Triple-S Blue, Inc. (“TSB”) contractual and financial obligations to their respective customers.  Also, TSS guarantees TSA’s contractual and financial obligations to their respective customers.  In addition, pursuant to the rules and license standards of the BCBSA, we have agreed to indemnify the BCBSA against any claims asserted against it resulting from our contractual and financial obligations.

Each license requires an annual fee to be paid to the BCBSA.  The fee is determined based on a per-contract charge from products using the BCBS name and marks.  The annual BCBSA fee for the year 2018 is $1,409,481.  During the years ended December 31, 2017 and 2016, we paid fees to the BCBSA in the amount of $1,444,069 and $2,395,808, respectively.  The BCBSA is a national trade association of 36 independent Primary Licensees (Plans), including TSM, the primary function of which is to promote and preserve the integrity of the BCBS name and marks, as well as to provide certain centralized services to entities licensed by the BCBSA (the “Member Plans”).  Each Member Plan is an independent legal organization and is not responsible for obligations of other BCBSA Member Plans.  With a few limited exceptions, we have no right to market products and services using the BCBS name and marks outside our BCBS licensed territory.

BlueCard.      Under the rules and license standards of the BCBSA, other Member Plans must make available their provider networks to members of the BlueCard Program in a manner and scope as consistent as possible to what such member would be entitled to in his or her home region.  Specifically, a plan (located where a member receives the service (each, a “Host Plan”) must pass on discounts to BlueCard members from other Member Plans that are at least as great as the discounts that the providers give to the Host Plan’s local members.  The BCBSA requires us to pay fees to any Host Plan whose providers submit claims for health care services rendered to our members who receive care in their service area.  Similarly, we are paid fees for submitting claims and providing other services to members of other Member Plans who receive care in our service area.

Trademarks

We consider our trademarks Triple-S and SSS to be very important and material to all segments in which we are engaged.  All of our trademarks, which we consider important, have been duly registered with the Department of State of Puerto Rico and the United States Patent and Trademark Office.  It is our policy to register all our important and material trademarks in order to protect our rights under applicable corporate and intellectual property laws.  In addition, we have the exclusive right to use the BCBS name and marks in Puerto Rico, Costa Rica, U.S. Virgin Islands, British Virgin Islands, and Anguilla.  See ‘‘—Blue Cross and Blue Shield License’’ .

Regulation

Our business operations are subject to comprehensive and detailed regulation in all the jurisdictions we conduct business.  Regulatory agencies include the Commissioner of Insurance of  Puerto Rico (the “Commissioner of Insurance”), the Health Department of Puerto Rico and the Puerto Rico Health Insurance Administration (“ASES” by its Spanish acronym) , which administers Medicaid, including the Medicare dual-eligible beneficiaries program, the Division of Banking and Insurance of the Office of the Lieutenant Governor of the U.S. Virgin Islands, the General Superintendence of Insurance of Costa Rica, the Insurance Division of the Financial Service Commission of British Virgin Islands and the Financial Services Commission of Anguilla.  Federal regulatory agencies that oversee our operations include the U.S. Department of Health and Human Services (“HHS”)—directly and through the Office of the Inspector General (“OIG”), the Office of Civil Rights (“OCR”) and Centers for Medicare and Medicaid Services (“CMS”)—, the U.S. Department of Justice (“DOJ”), the U.S. Department of Labor (“DOL”), and the U.S. Office of Personnel Management (“OPM”).  These government agencies have the right to:

grant, suspend and revoke licenses to transact business;

regulate many aspects of the products and services we offer, including the review and approval of health insurance rates in the individual and small group markets;

assess fines, penalties and/or sanctions;

monitor our solvency and the adequacy of our financial reserves; and

regulate our investment activities based on quality, diversification and other quantitative criteria, within the parameters of a list of permitted investments set forth in the insurance laws and regulations.
 
Our operations and accounts are subject to examination and audits at regular intervals by a number of these agencies.  In addition, the U.S federal and local governments continue to consider and enact many legislative and regulatory proposals that have impacted, or could materially impact, various aspects of the healthcare and insurance industries.  Some of the more significant current issues that may affect our business include:

initiatives to provide greater access to coverage for uninsured and under-insured populations without adequate funding to health plans or to be funded through taxes or other negative financial levies on health plans;

other efforts or specific legislative changes to the Medicare or Medicaid program, including changes in the bidding process or other means that materially reduce premiums;

local government regulatory changes;

increased government enforcement, or changes in interpretation or application of fraud and abuse laws; and

regulation that increase the operational burden on health plans or laws that increase a health plan’s exposure to liabilities, including efforts to expand the tort liability of health care plans.
 
The federal government and the government of Puerto Rico, including the Commissioner of Insurance, have adopted laws and regulations that govern our business activities in various ways.  These laws and regulations may restrict how we conduct our business and may result in additional burdens and costs to us.  Areas of governmental regulation include:
 
licensure;

policy forms, including plan design and disclosures;

premium rates and rating methodologies;

underwriting rules and procedures;

benefit mandates;

eligibility requirements;

security of electronically transmitted individually identifiable health information;

geographic service areas;

market conduct;

utilization review;

payment of claims, including timeliness and accuracy of payment;

special rules on contracts to administer government programs;

transactions with affiliated entities;

limitations on the ability to pay dividends;

payment rates to healthcare providers;
 
rate review and approval;
transactions resulting in a change of control;

member rights and responsibilities;

fraud and abuse;

sales and marketing activities;

quality assurance procedures;

privacy of medical and other information and permitted disclosures;

surcharges on payments to providers;

provider contract forms;

delegation of financial risk and other financial arrangements in rates paid to healthcare providers;

agent licensing;

financial condition (including reserves);

reinsurance;

issuance of new capital stock shares;

corporate governance;

permissible investments; and

guaranteed issue and renewability.
 
These laws and regulations are subject to amendments and changing interpretations in each jurisdiction.  Failure to comply with existing or future laws and regulations could materially and adversely affect our operations, financial condition and prospects.
 
Puerto Rico Insurance Laws

Our insurance subsidiaries are subject to the regulations and supervision of the Commissioner of Insurance.  The regulations and supervision of the Commissioner of Insurance consist primarily in the approval of certain policy forms, solvency standards, the nature of and limitations on investments, deposits of securities for the benefit of policyholders, methods of accounting, periodic examinations and the form and content of the financial reports, among others.  In general, such regulations are for the protection of policyholders rather than security holders.

Puerto Rico insurance laws prohibit any person from offering to purchase or sell voting stock of an insurance company with capital contributed by stockholders (a stock insurer) that constitutes 10% or more of the total issued and outstanding stock of such company or of the total issued and outstanding stock of a company that controls an insurance company, without the prior approval of the Commissioner of Insurance.  The proposed purchaser or seller must disclose any changes proposed to be made to the administration of the insurance company and provide the Commissioner of Insurance with any information reasonably requested.  The Commissioner of Insurance must make a determination within 30 days.  Such determination will be based on the evaluation of the transaction’s impact on the public interest, taking into account the experience, moral character and financial stability of the proposed purchaser; and whether the change of control could jeopardize the interests of insured, claimants or the Company’s other stockholders.

Puerto Rico insurance laws also require that stock insurers obtain the Commissioner of Insurance’s approval prior to any merger or consolidation.  The Commissioner of Insurance cannot approve any such transaction unless it determines that such transaction is fair, equitable, consistent with law, and that no reasonable objection exists.  The reinsurance of all or substantially all of the insurance of an insurance company by another insurance company is deemed to be a merger or consolidation.

Puerto Rico insurance laws further prohibit insurance companies and insurance holding companies, among other entities, from soliciting or receiving funds in exchange for any new issuance of its securities, other than through a stock dividend, unless the Commissioner of Insurance has granted a solicitation permit in respect of such transaction.  The Commissioner of Insurance will issue the permit unless it finds that the funds proposed to be secured are excessive for the purpose intended, the proposed securities and their distribution would be inequitable, or the issuance of the securities would jeopardize the interests of policyholders or security-holders.

In addition, Puerto Rico insurance laws limit insurance companies’ ability to reinsure risk.  Insurance companies can only accept reinsurance in respect of the types of insurance which they are authorized to transact directly.  Also, except for life and disability insurance, insurance companies cannot accept any reinsurance in respect of any risk resident, located, or to be performed in Puerto Rico, which was insured as direct insurance by an insurance company not then authorized to transact such insurance in Puerto Rico.  Insurance companies cannot reinsure 75% or more of their direct risk with respect to any type of insurance without first obtaining the approval of the Commissioner of Insurance.

Privacy of Financial and Health Information

Puerto Rico law requires that companies which manage individual financial, insurance and health information maintain the confidentiality of such information.  The Commissioner of Insurance has promulgated regulations relating to the privacy of such information.  As a result, our managed care subsidiaries must periodically inform our clients of our privacy policies, and in the case of our property and casualty and life insurance subsidiaries, allow our clients to opt-out if they do not want their financial information to be shared.  Also, Puerto Rico law requires that managed care providers provide patients with access to their health information within a specified time and that they not charge more than a predetermined amount for such access.  The law imposes various sanctions on managed care providers that fail to comply with these provisions.

Managed Care Provider Services

Participating managed care providers of the dual-eligible sector of the population, administered by ASES, are required to provide specific services to their subscribers.  Such services include access to a provider network that guarantees emergency and specialty services.  In addition, the Patient’s Solicitor Office (the “Solicitor”) is authorized to review and supervise the operations of entities contracted by the government of Puerto Rico to provide services to the dual-eligible sector of the population.  The Solicitor may investigate and adjudicate claims filed by Medicaid beneficiaries against the various service providers contracted by the government of Puerto Rico.  See “Business – Customers-Medicare Supplement and Medicare Advantage Sector” sections included in this Item for more information.
 
Capital and Reserve Requirements

Local insurers and health organizations are required by the Insurance Code to submit to the Puerto Rico Commissioner of Insurance Risk Based Capital (“RBC”) reports following the NAIC RBC Model Act, and accordingly are subject to certain regulatory actions if their capital levels do not meet minimum requirements.  Our minimum RBC requirement is currently 200% for the health maintenance organization and 300% for all TSS, TSV, TSB and TSP.

In addition, TSS, TSA, and TSB are subject to the capital and surplus licensure requirements of the BCBSA.  The capital and surplus requirements of the BCBSA are also based on the RBC Model Act and are intended to assess capital adequacy taking into account the risk characteristics of an insurer’s investments and products.  The RBC Model Act sets forth the formula for calculating the risk-based capital requirements, which are designed to take into account various risks, including insurance risks, interest rate risks and other relevant risks, with respect to an individual insurance company’s business.

The RBC Model Act requires increasing degrees of regulatory oversight and intervention as an insurance company’s risk-based capital declines.  The level of regulatory oversight ranges from requiring the insurance company to inform and obtain approval from the domiciliary insurance commissioner of a comprehensive financial plan for increasing its risk-based capital to mandatory regulatory intervention requiring an insurance company to be placed under regulatory control, in rehabilitation or liquidation proceeding.  The RBC Model Act provides for four different levels of regulatory attention depending on the ratio of the company’s total adjusted capital (defined as the total of its statutory capital, surplus, assets valuation reserve and dividend liability) to its risk-based capital.  At the “company action level”, occurring when a company’s total adjusted capital is less than 200% but greater than or equal to 150% of its risk-based capital, a company must submit a comprehensive plan to the regulatory authority which discusses proposed corrective actions to improve its capital position.  When a company’s adjusted capital is between 200% and 300% and it has a combined ratio greater than 150%, a “company action level” is triggered only if the Puerto Rico Commissioner of Insurance has implemented the health trend test.  As of December 31, 2017, the Commissioner of Insurance has not enacted the health trend test in its regulations.  The ‘‘regulatory action level’’ is triggered if a company’s total adjusted capital is less than 150% but greater than or equal to 100% of its risk-based capital.  At the regulatory action level, the regulatory authority will perform a special examination of the company and issue an order specifying corrective actions that must be followed.  The ‘‘authorized control level’’ is triggered if a company’s total adjusted capital is less than 100% but greater than or equal to 70% of its risk-based capital, at which level the regulatory authority may take any action it deems necessary, including placing the company under regulatory control.  The ‘‘mandatory control level’’ is triggered if a company’s total adjusted capital is less than 70% of its risk-based capital, at which level the regulatory authority must place the company under its control.

As of December 31, 2017, our insurance subsidiaries met and exceeded the minimum capital requirements established by the Commissioner of Insurance and the BCBSA, as applicable.

In addition to its catastrophic reinsurance coverage, TSP is required by local regulatory authorities to establish and maintain a reserve supported by a trust fund (the “Trust”) to protect policyholders against their dual exposure to hurricanes and earthquakes.  The funds in the Trust are solely to be used to pay catastrophic losses whenever qualifying catastrophic losses exceed 5% of catastrophe premiums or when authorized by the Commissioner of Insurance.  Contributions to the Trust, and accordingly additions to the reserve, are determined by a rate, imposed by the Commissioner of Insurance on the catastrophe premiums written in that year. As a result of the hurricanes affecting Puerto Rico in September 2017, TSP expects to withdraw $10.0 million from the Trust representing its net retention loss for the aforementioned event.

At December 31, 2017 and 2016, the reserve for catastrophes is $46.6 million and $44.7 million, respectively.  The supporting trust fund has assets of $48.4 million and $47.1 million as of December 31, 2017 and 2016, respectively.  Assets consist primarily of investment in securities available for sale, securities held for maturity, accrued investment income, cash and cash equivalents.  The income generated by investment securities deposited in the Trust becomes part of the Trust fund balance and are therefore considered an addition to the reserve.  For additional details see Note 16, Catastrophe Loss Reserve and Trust Fund, of the Notes to Consolidated Financial Statements, included in Item 8, Financial Statements and Supplementary Data , of this Annual Report on Form 10-K.
 
Dividend Restrictions

We are subject to the provisions of the General Corporation Law of Puerto Rico (“PRGCL”), which contains certain restrictions on the declaration and payment of dividends by corporations organized pursuant to the laws of Puerto Rico.  These provisions provide that Puerto Rico corporations may only declare dividends charged to their surplus or, in the absence of such surplus, net profits of the fiscal year in which the dividend is declared and/or the preceding fiscal year.  The PRGCL also contains provisions regarding the declaration and payment of dividends and directors’ liability for illegal payments.

Our ability to pay dividends is dependent on cash dividends from our subsidiaries.  Our insurance subsidiaries are subject to regulatory surplus requirements and additional regulatory requirements, which may restrict their ability to declare and pay dividends or distributions to us.  In addition, our secured term loan restricts our ability to pay dividends if a default thereunder has occurred and is continuing.  Please refer to “Item 7.   Management’s Discussion and Analysis of Financial Condition and Results of Operations – Liquidity and Capital Resources – Restrictions on Certain Payments by the Corporation’s Subsidiaries”.

Guaranty Fund Assessments

We are required by Puerto Rico law and by the BCBSA guidelines to participate in certain guarantee associations.  See “Item 7.   Management’s Discussion and Analysis of Financial Condition and Results of Operations – Other Contingencies—Guarantee Associations’’ for additional information.

Federal Regulation

Our business is subject to extensive federal law and regulation.  New laws, regulations or guidance or changes to existing laws, regulations or guidance or their enforcement, may materially impact our business financial condition and results of operations.

Medicare Generally

Medicare is the federal health insurance program created in 1965 for all people aged 65 and older (regardless of income or medical history), qualifying disabled persons, and persons suffering from end-stage renal disease.  Medicare is funded by the federal government and administered by the Centers for Medicare and Medicaid Services (CMS), with the day-to-day operations of the program (e.g., provider enrollment, claims payment) handled by private contractors under contract with CMS.  There are approximately 55 million Medicare beneficiaries.

Medicare is divided into 4 distinct parts:

Part A covers, among other things, inpatient hospital stays, skilled nursing facility stays, home health visits (also covered under Part B), and hospice care.

Part B covers physician visits, outpatient services, laboratory services, durable medical equipment, certain preventive services, and home health visits.  Enrollment in Part B is voluntary and subject to an annual deductible.

Part C, also known as Medicare Advantage, allows beneficiaries to enroll in private health plans and receive Medicare-covered benefits.  Currently, about 17 million Medicare beneficiaries are enrolled in the United States in a Medicare Advantage plan.  Under the Patient Protection and Affordable Care Act of 2010 (Pub. L No. 111-148), as amended by the Health Care and Education Reconciliation Act of 2010 (Pub. L. No. 111-152), on March 30, 2010 (referred to herein as “ACA”), payments to Medicare Advantage plans are generally being reduced over time, and bonus payments are available to certain plans based on quality ratings.  Medicare Advantage plans are required to maintain a medical loss ratio (“MLR”) of at least 85%, meaning, very basically, that if Medicare Advantage plans do not spend at least 85% of their revenue on patient care costs, may face various sanctions, including refunds, prohibition on enrolling new members, and contract termination. The Part C premium varies by plan.
 
Part D is the voluntary, subsidized outpatient prescription drug benefit created under the Medicare Modernization Act of 2003 (the “MMA”).  Part D includes subsidies for beneficiaries with low incomes that do not apply to Puerto Rico.  Part D is offered through private plans that contract with Medicare, including stand-alone prescription drug plans and Medicare Advantage prescription drug plans.  Part D plans are also subject to MLR requirements and their premium varies by plan.
 
There also exist Medicare supplement plans, commonly known as “Medigap”, to fill the gaps in traditional fee-for-service Medicare Part A and B coverage.  These Medigap policies are standardized by CMS, but funded and administered by private organizations.

Since the 1980’s, as an alternative to the traditional fee-for-service Medicare program, Medicare has also offered Medicare managed care benefits provided through contracted private health plans, currently known as Medicare Advantage plans.  Prior to 1997, CMS reimbursed health plans participating in the Medicare program primarily on the basis of the demographic data of the plans’ members.  Beginning in 1997, CMS gradually phased in a risk adjustment payment methodology that based its monthly premium payments to plans on various clinical and demographic factors.  This methodology uses two risk adjustment models: a Hierarchical Condition Category based model and an ESRD model, each applying to the corresponding population.  Beginning in 2003, Congress introduced a Medicare managed care approach, which itself has subsequently undergone several changes, and beginning in 2006, Congress introduced the Medicare Part D program, which offered a voluntary outpatient prescription drug benefit to fee-for-service as well as Medicare Advantage beneficiaries.  An Rx Hierarchical Condition Category Model is used in the determination of the Part D premium, and a Low Income Subsidy (LIS) is applied to Part D premiums for members that qualify.

Among other things, the ACA mandated several changes, implemented by CMS, to the Medicare Advantage and Medicare Part D programs, including strengthening CMS’ ability to remove poor performers from the Medicare Advantage and Part D programs beginning in 2015.  Beginning with Medicare contract year 2015, CMS has the authority to terminate its contract with any Medicare Advantage or Part D plan for substantial contract non-compliance, or refuse to renew such plan, if the plan fails to achieve an overall Star Rating of 3.0 stars (out of 5.0) for any consecutive three (3) year period.  Although CMS has issued annual Star Ratings for Part D plans since 2007 and for Medicare Advantage plans since 2008, CMS uses Star Ratings issued for Medicare contract years 2013 and beyond in implementing this provision. In April 2015, CMS announced that it would for the first time exercise its authority to terminate low performing Medicare Advantage and Part D plans beginning in 2016. CMS issues Star Ratings on a prospective basis, typically in the fall preceding the contract year.  CMS has the authority to use the lower Star Ratings as a means to invoke its existing authority under Section 1857(c)(2) of the Social Security Act to terminate a contract when CMS determines that the Medicare Advantage or Part D plan has failed to substantially carry out the contract or is carrying out the contract in a manner that is inconsistent with the efficient or effective administration of the Medicare Advantage or Part D program.

In addition, under the ACA, Medicare Advantage plan payment rates were subject to transitionally phased-in reductions intended to bring Medicare Advantage rates more in line with Medicare fee-for-service rates. The transition began in 2012 and was completed in 2017.
 
Payments to Medicare Advantage Participating Plans

Since 2006, Medicare Advantage has used a bidding system by which plans submit bids based on costs per enrollee for Part A and Part B covered services.  Medicare Advantage also pays plans for providing prescription drug benefits under Part D.   Bids are based on estimated costs per enrollee for the Medicare-covered services.  The bids are then analyzed against a benchmark established by federal statute, and which vary by county or region.  A Medicare Advantage plan’s actual payment rate is based on a complex statutory formula that takes into account a number of factors, including the relationship between the plan’s bid and the applicable benchmark. When a bid is higher than the benchmark, enrollees generally pay the difference (through an additional premium) between the benchmark and the bid, in addition to any other Medicare premiums.  If the bid is lower than the benchmark, the plan and Medicare generally share the difference, and the plan must use its share (known as a “rebate”) to provide additional benefits to enrollees.  For plans obtaining up to 3.0 STARS, the rebate share to the plan is 50%.  When the plan reaches 3.5 or 4.0 STARS, that rebate share rises to 65%, and when the plan reaches 4.5 or 5.0 STARS it rises to 70%.
 
Plans reaching 4.0 STARS or higher, also receive a 5% quality bonus payment (QBP), which could be doubled for certain qualifying counties.  The resulting benchmark plus QBP amount can be reduced to a cap determined for each county, so the effective bonus payment for such qualifying counties could be between 5% and 10%.  Rebates and QBPs only apply to Part C premium payments.

STARS Ratings for plans are calculated based on the results achieved by the plan on a contract in tens of measures (47 in the 2019 draft call letter) spanning four categories: Healthcare Effectiveness Data and Information Set (HEDIS) measures, Consumer Assessment of Healthcare Providers and Systems (CAHPS) and Health Outcomes Survey (HOS) measures, Administrative measures and Part D measures.  CMS assigns from one to five stars for each numeric measure score by applying one of two methods: relative distribution with significance testing (CAHPS) or clustering (all other measures).  Case-mix adjustments are applied to the survey results as part of the scoring.  CMS has recognized that socio-economic factors create significant variations in results for some metrics.  CMS’ interim response to address the within-contract disparity in performance associated with a contract’s percentages of beneficiaries with low income subsidy and dual eligible (LIS/DE) and disability status revealed in our comprehensive research conducted over multiple years culminated in the creation of the Categorical Adjustment Index (CAI).  Each measure is also assigned a relative weight used in the calculation of the Part C, Part D and overall STAR Rating.

Medicaid Generally

Medicaid is a public insurance program intended for low-income individuals and families.  Medicaid, as of November 2017, provides coverage to over 74 million Americans, including children, pregnant women, and individuals with disabilities. To participate in Medicaid, states must cover certain groups but have the flexibility to cover other population groups.  States may apply to CMS for waivers to provide coverage to populations beyond what is normally covered under the program.  States are able to establish eligibility criteria within federal minimum standards. States are allowed to set Medicaid provider payment rates, and may reimburse providers through fee-for-service or managed care.  They also have the flexibility to determine the type, amount, duration, and scope of services of their respective Medicaid programs, so long as within federal guidelines, although states are required to cover certain mandatory benefits.  In Puerto Rico, the Medicaid program is administered locally by ASES.

Medicaid is jointly funded by the federal government.  States receive a percentage of their Medicaid program expenditures from the federal government, through a formula known as the Federal Medical Assistance Percentage (“FMAP”). The FMAP varies by state based on factors such as per capita income.  The FMAP for Puerto Rico is 55%. FMAPs are adjusted based on a 3 year cycle.  Generally, during economic recessions such as the one that began in 2008, state revenues fall while Medicaid enrollment and spending rise.  To help alleviate the shortfall, the federal government temporarily increased its share of Medicaid costs through the American Recovery and Reinvestment Act of 2009.  However, that temporary fix ended in 2012, and while many states have enacted cost containment initiatives to help control costs, states continue to wrestle with falling revenue while Medicaid enrollment and spending increase.

The ACA expands Medicaid to an eligibility floor of 138% of the federal poverty level (“FPL”) beginning in 2014.  A 2012 U.S. Supreme Court decision regarding health care reform limited the federal government’s ability to enforce Medicaid expansion—meaning that the issue of Medicaid expansion is effectively left to each individual state.  Puerto Rico and the other U.S. territories were not included in the Medicaid expansion, instead Congress approved one billion in federal funding for Puerto Rico and the other U.S. territories to establish local affordable insurance exchanges or expand their Medicaid programs, at their option.  Puerto Rico elected to use the approximately $925 million made available by Congress to Puerto Rico for expanding its Medicaid program.   The Consolidated Appropriations Act of 2017 (P.L. 115-31) provided Puerto Rico with an additional $295.9 million.  Although these funds are available until December 2019, the government has estimated that, given the current burn rate of the approved funding, funds would be fully utilized in fiscal year 2018.  However, in February 2018, as part of the emergency supplemental legislation passed by Congress, Puerto Rico’s Medicaid spending cliff has been addressed for at least the next two years, because of the approval of $4.8 billion in Medicaid Funding.  This action will bring financial stability to Puerto Rico’s Medicaid program, and funding conditions related to compliance with program management standards will further promote stability and predictability.
 
Dual-Eligible Beneficiaries

A “dual-eligible” beneficiary is a person who is eligible for both Medicare, because of age or other qualifying status, and Medicaid, because of economic status.  Dual-eligibles are a high cost population that account for a disproportionate share of government health care expenditures.  As of August 2017, there are approximately 11 million dual-eligibles, receiving both Medicare and Medicaid benefits nationwide. Given the disproportionately high cost of treating dual-eligibles, there has been a spate of initiatives designed to address the issue.  The government of Puerto Rico established a model that wraps-around benefits included in Medicaid that were not included in Medicare Advantage benefits.  Dual-eligible beneficiaries in Puerto Rico have the option to participate in this model called Platino.  Health plans that offer Platino products receive premiums from CMS and the government of Puerto Rico.  In this plan the government, rather than the insured, will assume all of the premiums for additional benefits not included in traditional Medicare programs, such as prescription drug benefits.  By managing utilization and implementing disease management programs, many Medicare Advantage plans can profitably care for dual-eligible members.  The MMA established subsidies and reduced or eliminated deductibles for certain low-income beneficiaries, including dual-eligible individuals.  Pursuant to the MMA, dual-eligible individuals receive their drug coverage from the Medicare program rather than the Medicaid program.  Companies offering Medicare Part D stand-alone prescription drug plans with bids at or below the regional weighted average bid resulting from the annual bidding process received a pro-rata allocation and auto-enrollment of the dual-eligible beneficiaries within the applicable region.

Additionally, ACA created the Medicare-Medicaid Coordination Office to better integrate Medicare and Medicaid benefits and improve coordination between federal and state governments, which has, among other things implemented initiatives such as demonstration projects and limited coordinated care contracts, intended to improve quality and lower costs with respect to dual eligible beneficiaries. Under authority of the ACA, a number of states (not including Puerto Rico) have been awarded contracts to support the design of demonstration projects that aim to improve the coordination of care for people with Medicare and Medicaid coverage.

Special Needs Plans

Special Needs Plans are intended to address Medicare beneficiaries with special care needs, particularly those with chronic conditions.  In addition, the ACA created Fully Integrated Dual Eligible (FIDE) special needs plans, designed to promote the full integration and coordination of Medicare and Medicaid benefits for dual eligible beneficiaries by a single managed care organization, Essentially, Medicare Advantage Special Needs Plans (“SNPs”) are a type of Medicare Advantage Plan for people with certain chronic diseases and conditions or who have specialized needs (such as people who have both Medicare and Medicaid or people who live in certain institutions).  SNPs limit membership to people with specific diseases or characteristics, and tailor their benefits, provider choices, and drug formularies (list of covered drugs) to best meet the specific needs of the groups they serve.

Sales and Marketing.     Our sales and marketing activities are closely regulated by CMS, ASES, the Puerto Rico Office of the Commissioner of Insurance and the Solicitor General.  CMS regulations in this area preempt local law.

Fraud and Abuse Laws.     Insurance providers in Puerto Rico are subject to local and federal laws that prohibit fraud and abuse, and are required to have anti-fraud units in place.  In addition, entities, such as TSS and TSA, that receive federal funds from government health care programs, such as Medicare and Medicaid, are subject to a wide variety of federal fraud and abuse laws and enforcement activities.  Such laws include, among others, the federal anti-kickback laws and the False Claims Act.
 
Anti-kickback Laws .       Insurance providers in Puerto Rico are subject to local and federal anti-kickback laws.  These anti-kickback laws prohibit the payment, solicitation, offering or receipt of any form of remuneration (including kickbacks, bribes, and rebates) in exchange for business, and under federal law, the referral of federal healthcare program patients or any item or service that is reimbursed by any federal health care program.  In addition, the federal regulations include certain safe harbors that describe relationships that have been determined by CMS not to violate the federal Anti-Kickback Statute.  Relationships that do not fall within one of the enumerated safe harbors are not a per se violation of the federal law, but will be subject to enhanced scrutiny by regulatory authorities.  The ACA amended the intent requirement of the federal Anti-Kickback Statute, and other healthcare criminal fraud statutes, so that a person or entity no longer needs to have actual knowledge of the federal Anti-Kickback Statute and other healthcare criminal fraud statutes, or the specific intent to violate them, to have committed a violation. The ACA also provided that a violation of the federal Anti-Kickback Statute is grounds for the government or a whistleblower to assert that a claim for payment of items or services resulting from such violation constitutes a false or fraudulent claim for purposes of the federal False Claims Act. Failure to comply with the anti-kickback provisions, and other healthcare criminal fraud statuses, may result in civil damages and penalties, criminal sanctions, and administrative remedies, such as exclusion from the applicable federal health care program, and additional reporting requirements and oversight if subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance.
 
Federal False Claims Act.    Federal regulations also strictly prohibit the presentation of false claims or the submission of false information to the federal government.  Under the federal False Claims Act, any person or entity that has knowingly presented or caused to be presented a false or fraudulent request for payment from the federal government or who has made a false statement or used a false record in the submission of a claim may be subject to treble damages and penalties of up to $21,916 per claim.  The ACA codified federal government’s prior position that claims presented in relationships that violate the federal Anti-Kickback Statute may also be considered to be violations of the federal False Claims Act.  Furthermore, the federal False Claims Act permits private citizen “whistleblowers” to bring actions on behalf of the federal government for violations of the False Claims Act and to share in the settlement or judgment that may result from the lawsuit.  Financial recoveries from civil health care matters brought under the False Claims Act are significant.

HIPAA, HITECH, and Gramm-Leach-Bliley Act

Health care entities, such as TSS and TSA, are subject to laws, including the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”), as amended by the Health Information Technology for Economic and Clinical Health Act (“HITECH”), and their respective implementing regulations, and the Gramm-Leach-Bliley Act, that require the protection of certain health and other information.  HIPAA authorized HHS to issue standards for administrative simplification, as well as privacy and security of medical records and other individually identifiable health information.  The regulations pursuant to the HIPAA Administrative Simplification provisions and HITECH impose a number of additional obligations on issuers of health insurance coverage and health benefit plan sponsors.  These requirements apply to self-funded group plans, health insurers and HMOs, health care clearinghouses and health care providers who transmit health information electronically (collectively, “covered entities”) and their business associates that access, maintain, create, and/or receive individually identifiable health information (collectively “business associates”).  These regulations also establish significant criminal penalties and civil sanctions for non-compliance.

HHS also sets standards relating to the privacy of individually identifiable health information.  In general, these regulations restrict how covered entities and business associates may use and disclose medical records and other individually identifiable health information in any form, whether communicated electronically, on paper or orally, subject only to limited exceptions.  In addition, the regulations provide patients’ rights to understand and control how their health information is used.  HHS has also published security regulations designed to protect member health information from unauthorized use or disclosure and require notification to members, the Secretary of HHS, and in certain cases the media, in the event of a breach of unsecured individually identifiable health information.

In 2015 we entered into two agreements with federal and Puerto Rican regulators to resolve investigations in connection with privacy incidents at our Managed Care segment. The agreements include the payment of a combined amount of $5 million and the adoption of a three year corrective action plan. See, “Item 3. Legal Proceedings–Unauthorized Disclosure of Protected Health Information” for more information.
 
HHS has released rules mandating the use of standard formats in electronic health care transactions (for example, health care claims submission and payment, plan eligibility, precertification, claims status, plan enrollment and disenrollment, payment and remittance advice, plan premium payments and coordination of benefits). HHS also has published rules mandating the use of standardized code sets and unique identifiers for employers and providers.  Our managed care subsidiary believes that it is in material compliance with these requirements.  In addition,  the federal government required healthcare organizations, including health insurers, upgrade to updated and expanded standardized code sets used for describing health conditions by converting from the ICD-9 diagnosis and procedure code set to the ICD-10 diagnosis and procedure code by October 1, 2015.  Our conversion from the ICD-9 code set to the ICD-10 code set, which required a substantial investment, was successfully completed.

The Gramm-Leach-Bliley Act applies to financial institutions in the United States, including those domiciled in Puerto Rico, such as TSV and TSP.  The Gramm-Leach-Bliley Act generally placed restrictions on the disclosure of non-public information to non-affiliated third parties, and required financial institutions including insurers, to provide customers with notice regarding how their non-public personal information is used, including an opportunity to “opt out” of certain disclosures.  The Gramm-Leach-Bliley Act also gives banks and other financial institutions the ability to affiliate with insurance companies, which has led to new competitors in the insurance and health benefits fields in Puerto Rico.

Employee Retirement Income Security Act of 1974

The services we provide to certain employee welfare benefit plans maintained by private sector employers are subject to regulation under the Employee Retirement Income Security Act of 1974, as amended (“ERISA”), a complex set of laws and regulations subject to interpretation and enforcement by the Internal Revenue Service, the U.S. Department of Labor, and federal courts.  ERISA regulates certain aspects of the relationships between us, private sector employers who maintain employee welfare benefit plans subject to ERISA, and the participants and beneficiaries in such plans.  Some of our administrative services and other activities may also be subject to regulation under ERISA and its regulations.  In addition, certain states require licensure or registration of companies providing third-party claims administration services for benefit plans.  We provide a variety of products and services to employee welfare benefit plans that are covered by ERISA and its regulations.  Plans subject to ERISA can also be subject to state laws and the question of whether ERISA preempts a state law has been, and will continue to be, interpreted by federal and state courts.

Dodd-Frank Act

In 2010, Congress enacted the Dodd-Frank Wall-Street Reform and Consumer Protection Act (the “Dodd-Frank Act”) which provides for a number of reforms and regulations in the corporate governance, financial reporting and disclosure, investments, tax and enforcement areas that affect our subsidiaries.    Among other things, the Dodd-Frank Act creates a Federal Insurance Office (“FIO”) within the U.S. Department of the Treasury with powers that include information-gathering and subpoena authority. In 2013, as part of its initial task to study the state of the insurance industry, the FIO issued a report recommending that Congress consider direct federal involvement should the states fail to accomplish necessary modernization reforms in the near term. The FIO continues to support the current state-based regulatory regime, but may consider federal regulation should the states fail to take steps to greater uniformity.

In addition, the Dodd-Frank Act gives the Federal Reserve supervisory authority over a number of financial services companies, including insurance companies, if they are designated by the Financial Stability Oversight Council as “systemically important.” In such a case, the Federal Reserve’s supervisory authority could include the ability to impose heightened financial regulation upon that insurance company and could impact its capital, liquidity and leverage requirements as well as its business and investment conduct. We have not been designed as “systemically important” by the Financial Stability Oversight Council.
 
Although the FIO authorities do not extend to health insurance they extend to other parts of the business, primarily life and property and casualty insurance.  The FIO, however, does not have supervisory or regulatory authority over the insurance business.

Legislative and Regulatory Initiatives

Puerto Rico Initiatives

The Commissioner of Insurance adopted Rule No. 83, titled ‘‘Standards and Procedures to Regulate the Insurance Holding Company Systems and Criteria for Evaluating Changes in Control’’.  Rule No. 83 requires insurers and health services organizations authorized to do business in Puerto Rico and which are members of an insurance holding company system to register and file with the Commissioner of Insurance certain reports describing capital structure, ownership, financial condition, enterprise risks and general business operations.  In addition, Rule No. 83 establishes the criteria to be used to approve or refuse to approve any transaction that may constitute a change in control of a domestic insurer or health services organization.  Rule No. 83 also requires prior notice and approval of certain intercompany transactions, as well as payments of extraordinary dividends or distributions.

Federal Initiatives

On March 23, 2010, the federal health reform legislation, known as the Affordable Care Act, was enacted.  Most of the provisions of ACA with more significant effects on the health insurance marketplace went into effect on or before January 1, 2014, including a requirement that insurers guarantee the issuance of coverage to all individuals regardless of health status, strict rules on how health insurance is rated, and the assessment of new taxes and fees, including annual Health Insurance Providers Fee (“HIP Fee”), on health insurers that write certain types of health insurance on U.S. risks. The annual HIP Fee is allocated to health insurers based on the ratio of the amount of an insurer's net premium revenues written during the preceding calendar year to an adjusted amount of health insurance for all U.S. health risk for those certain lines of business written during the preceding calendar year.  The total HIP fee levied on the health insurance industry was $11.3 billion for 2016 and 2015, with increasing annual amounts thereafter, growing to $14.3 billion by 2018. The HIP Fee has been waived for 2017.  After 2018, the HIP Fee increases according to an index based on net premium growth. The assessment is being levied on certain health insurers that provide insurance in the assessment year, and is allocated to health insurers based on each health insurer's share of net premiums for all U.S health insurers in the year preceding the assessment.  We incurred $44.2 million, $34.6 million, and $27.7 million for the HIP fee in 2016, 2015 and 2014, respectively.

Over the past few months, Congress has passed a number of new laws that will have a significant effect on health insurers. In December 2017, Congress passed tax reform legislation that repealed the individual mandate requiring the purchase of health insurance coverage. Additionally, Congress passed a continuing resolution in January 2018 that will suspend the Health Insurance Tax for 2019. Finally, in February 2018, Congress passed emergency supplemental legislation that includes significant financial relief for Puerto Rico's Medicaid program.

On July 16, 2014, HHS notified the Commissioner of Insurance of Puerto Rico that the guarantee issue, community rating, single risk pool, rate review, MLR, and essential health benefits provisions under the ACA do not apply to U.S. territories, however they continue to apply to Puerto Rico by virtue of an amendment to the Health Insurance Code of Puerto Rico passed on July 22, 2013 to enact similar provisions in Puerto Rico. ACA affects all aspects of the health care delivery and reimbursement system in the United States, including health insurers, managed care organizations, healthcare providers, employers, and U.S. states and territories.

We do not anticipate significant debate regarding the repeal and replacement of the ACA in Washington this year.  However, various federal agencies, including, but not limited to, HHS, DOL, and the U.S. Department of the Treasury have issued and continue to issue Executive Orders and regulations related to the stabilization of the individual insurance market as well as their intentions to repeal the ACA in whole or in part.  Additionally, Congress continues to consider possible action related to insurance market stabilization, with action possible this spring.
 
As a result of the complexity of ACA, its impacts on health care in the United States and the uncertainty of its future, we cannot currently estimate the ultimate impact of ACA on our business, cash flows, financial condition and results of operations.  We will continue to assess ACA’s impact on us as additional regulations and guidance are issued.

As we think about the future of the ACA, or what may replace it, some of the more significant ACA issues that currently affect our managed care business, or may in the future, include:

Provisions requiring greater access to coverage for certain uninsured and under-insured populations and the elimination of certain underwriting practices without adequate funding to health plans or with negative financial levies on health plans such as restrictions in the ability to charge additional premium for additional risk. These include, among others, (i) extending dependent coverage for unmarried individuals until age 26 under their parents’ health coverage, (ii) limiting a health plan’s ability to rescind coverage and restricting the plan’s ability to establish annual and lifetime financial caps, (iii) eliminating the use of gender as a ratings factor, and (iv) limiting a health plan’s ability to deny or limit coverage on grounds of a person’s pre-existing medical condition;

Provisions restricting medical loss ratios and requiring premium refunds for non-compliance;

Provisions requiring health plans to report to their members and HHS certain quality performance measures and their wellness promotion activities;

Provisions that reduce premium payments to Medicare Advantage health plans and that tie such premium to the local Medicare fee for service costs.  The adjustment began in 2012 and is being phased in over 5 to 7 years;

Provisions that tie Medicare Advantage premiums to achievement of certain quality performance measures;

Other efforts or specific legislative changes to the Medicare and Medicaid programs, including changes in the bidding process, authority of CMS to deny bids, or other means of materially reducing premiums such as through further adjustments to the risk adjustment methodology;

Increased federal funding to the Medicaid program;

Funding provided to the government of Puerto Rico to enable it to fund the expansion of its Medicaid program, rather than establish a health insurance exchange;

Provisions that impose annual fees on health insurers;

Increased government funding to enforcement agencies and/or changes in interpretation or application of fraud and abuse laws;

Expanded scope of authority and/or funding to audit Medicare Advantage health plans and recoup premiums or other funds by the government or its representatives; and the increase in persons eligible for coverage under the Medicaid program in Puerto Rico, which may result in some persons currently insured by us in our commercial programs becoming eligible for, and thus moving to, the Medicaid program.

While all aspects of the ACA are expected to undergo significant changes throughout the repeal and replace process, some of the specific provisions we will be tracking include the following:  The ACA mandates significant changes to the rules regarding private health insurance to facilitate competition for market efficiency, promote prevention and wellness, increase pooling of risk, and prohibit discrimination for pre-existing conditions and/or health statues.  For example, HHS has issued rules specifically related to health insurance market reforms, essential benefits, and standards for wellness programs by employers who sponsor group health plans.  The market reform rules concerns the sale, pricing, and renewability of health insurance.  These rules apply to the individual and small group health insurance markets (whether or not in the health insurance exchanges).  The rules do not generally apply to grandfathered health plans.  The essential benefits rule establishes the standards for covered benefits under private health insurance coverage.  Under the rule, states have the ability to select a benchmark plan from ten popular private health plans.  Popularity is based on enrollment figures for the plans.  Should a state not select a plan, the default becomes the largest small group health plan.  A covered benefit under the benchmark plan will be considered an essential health benefit.  The Government of Puerto Rico selected one of our Medicare Advantage products, supplemented with additional benefits currently provided under the federal employee health plan, as the benchmark plan.  Under the ACA, health plans that are not grandfathered in the individual and small group market are required to cover essential health benefits.  While essential benefits are not specifically defined, the ACA outlines 10 categories of benefits that are required to be covered by plans, including: a) emergency services; b) ambulatory patient services; c) hospitalization; and d) preventive and wellness services and chronic disease manage ment.  The wellness rule amends an earlier regulation regarding the design and implementation of wellness programs offered by employers in group health plans.  See Part I, Item 1A “Risk Factors―The health care reform law and the implementation of the law c ould have a material effect on our business, financial condition, cash flows, or results of operations” for more information.
 
Budget Control Act

The Budget Control Act of 2011 was enacted to reduce the deficit and avoid default on the national debt.  When a joint committee of Congress established to develop debt reduction legislation failed to cut at least $1.5 trillion over the coming 10 years, an automatic process of across-the-board cuts (“sequestration”) split equally between defense and non-defense programs was triggered.  Under the sequestration, automatic spending cuts became effective beginning April 1, 2013, and these cuts have been extended through at least 2024 unless additional Congressional action is taken.  This resulted in cuts of 2% to Medicare funding.  Medicaid programs are not subject to automatic spending cuts.

Employees

As of December 31, 2017, we had 3,420 full-time employees and 193 temporary employees.  TSS has a collective bargaining agreement with the “Unión General de Trabajadores”, which represents approximately 28.3% of two of our managed care subsidiaries’ approximately 1,992 regular employees.  The collective bargaining agreement expires on November 30, 2019.  The Corporation considers its relations with employees to be good.

Available Information

We are an accelerated filer (as defined in Rule 12b-2 of the Securities Exchange Act of 1934, as amended) and are required, pursuant to Item 101 of Regulation S-K, to provide certain information regarding our website and the availability of certain documents filed with or furnished to the SEC.  Our internet website is www.triplesmanagement.com.  We make available free of charge, or through our internet website (http://triplesmanagement.com), our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and any amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 as soon as reasonably practicable after we electronically file such material with or furnish it to the SEC.  We also include on our internet website our Corporate Governance Guidelines, our Code of Business Conduct and Ethics and the charter of each standing committee of our Board of Directors.  In addition, we intend to disclose on our Internet website any amendments to, or waivers from, our Code of Business Conduct and Ethics that are required to be publicly disclosed pursuant to rules of the SEC and the New York Stock Exchange (“NYSE”).  The SEC maintains an internet site (http://www.sec.gov) that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC.  The website addresses listed above are provided for the information of the reader and are not intended to be an active link.  We will provide free of charge copies of our filings to any shareholder that requests them at the following address: Triple-S Management Corporation; Office of the Secretary; PO Box 363628; San Juan, P.R. 00936-3628.

Special Note Regarding Forward-Looking Statements

This Annual Report on Form 10-K and the documents we incorporated by reference in this report contains forward-looking statements, as such term is defined in the Private Securities Litigation Reform Act of 1995.  Forward-looking statements are statements that include information about possible or assumed future sales, results of operations, developments, regulatory approvals or other circumstances and may be found in the Items of this Annual Report on Form 10-K entitled “Item 1.   Business”, “Item 1A.   Risk Factors”, “Item 7   Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in this Annual Report on Form 10-K.  Statements that use the terms ‘‘believe’’, ‘‘expect’’, ‘‘plan’’, ‘‘intend’’, ‘‘estimate’’, ‘‘anticipate’’, ‘‘project’’, ‘‘may’’, ‘‘will’’, ‘‘shall’’, ‘‘should’’ and similar expressions, whether in the positive or negative, are intended to identify forward-looking statements.
 
All forward-looking statements in this Annual Report on Form 10-K reflect our current views about future events and are based on assumptions and subject to risks and uncertainties.  Consequently, actual results may differ materially from those anticipated in these forward-looking statements as a result of various factors, including all the risks discussed in “Item 1A.   Risk Factors” and elsewhere in this Annual Report on Form 10-K.

In addition, we operate in a highly competitive, constantly changing environment that is significantly influenced by very large organizations that have resulted from business combinations, aggressive marketing and pricing practices of competitors and regulatory oversight.  The following list is a summary of factors, the results of which, either individually or in combination, if markedly different from our planning assumptions, could cause our business results of operations, financial condition, cash flow, or prospect, to be materially adversely affected from those expressed in any forward-looking statements contained in this Annual Report on Form 10-K:

trends in health care costs and utilization rates;

ability to secure sufficient premium rate increases;

competitor pricing below market trends of increasing costs;

re-estimates of our policy and contract liabilities;

changes in government regulation of managed care, life insurance or property and casualty insurance;

significant acquisitions or divestitures by major competitors;

introduction and use of new prescription drugs and technologies;

a downgrade in our financial strength ratings;

litigation or legislation targeted at managed care, life insurance or property and casualty insurance companies;

ability to contract with providers and government agencies consistent with past practice;

ability to successfully implement our disease management and utilization management programs;

volatility in the securities markets and investment losses and defaults; and

general economic downturns, major disasters and epidemics.

The foregoing list should not be construed to be exhaustive.  We believe the forward-looking statements in this Annual Report on Form 10-K are reasonable; however, there is no assurance that the actions, events or results anticipated by the forward-looking statements will occur or, if any of them do, what impact they will have on our results of operations or financial condition.  In view of these uncertainties, you should not place undue reliance on any forward-looking statements, which are based on our current expectations at the time the statements are made.  Further, forward-looking statements speak only as of the date they are made, and, other than as required by applicable law, including the securities laws of the United States, we do not intend to update or revise any of them in light of new information or future events.

Item 1A.
Risk Factors

We must deal with several risk factors during the normal course of business.  You should carefully consider the following risks and all other information set forth in this Annual Report on Form 10-K.  The risks and uncertainties described below are not the only ones we face.  Additional risks and uncertainties not presently known to us or that are currently deemed insignificant may also impair our business operations.  The occurrence of any of the following risks could materially affect our business, financial condition, operating results, and cash flows.
 
While we consider the foregoing to be the overarching risks we face in 2018, they are not the only material risks we face. We face a numerous other challenges, as described elsewhere in this Annual Report, including below in this “Risk Factors” discussion, and other unanticipated risks may develop.
 
Risks Relating to our Capital Stock

Certain of our current and former providers may bring materially dilutive claims against us.

Beginning with our founding in 1959 and until 1994, we encouraged, and at times required, the doctors and dentists that comprised our provider network to acquire our shares.  Between approximately 1985 and 1994, our predecessor managed care subsidiary, Seguros de Servicios de Salud de Puerto Rico, Inc. (“SSS”), generally entered into an agreement with each new physician or dentist who joined our provider network to sell the provider shares of SSS at a future date (each agreement, a “share acquisition agreement”).  These share acquisition agreements were necessary because there were not enough authorized shares of SSS available during this period and afterwards for issuance to all new providers.  Each share acquisition agreement committed SSS to sell, and each new provider to purchase, five $40-par-value shares of SSS at $40 per share after SSS had increased its authorized share capital in compliance with the Puerto Rico Insurance Code and was in a position to issue new shares.  Despite repeated efforts in the 1990s, SSS was not successful in obtaining shareholder approval to increase its share capital, other than in connection with our reorganization in 1999, when SSS was merged into a newly-formed entity having authorized capital of 25,000 $40-par-value shares, or twice the number of authorized shares of SSS.  SSS’s shareholders did not, however, authorize the issuance of the newly formed entity’s shares to providers or any other third party.  In addition, subsequent to the reorganization, our shareholders did not approve attempts to increase our share capital in 2002 and 2003.

Notwithstanding the fact that TSS and its predecessor, SSS, were never in a position to issue new shares to providers as contemplated by the share acquisition agreements because shareholder approval for such issuance was never obtained, and the fact that SSS on several occasions in the 1990s offered providers the opportunity to purchase shares of its treasury stock and such offers were accepted by very few providers, providers who entered into share acquisition agreements may claim that the share acquisition agreements entitled them to acquire our or TSS’s shares at a subscription price equivalent to that provided for in the share acquisition agreements.  SSS entered into share acquisition agreements with approximately 3,000 providers, the substantial majority of whom never came to own shares of SSS.  Such share acquisition agreements provide for the purchase and sale of approximately 15,000 shares of SSS.  If we or TSS were required to issue a significant number of shares in respect of these agreements, the interest of our existing shareholders would be substantially diluted As of the date of this Annual Report on Form 10-K, only one judicial claim to enforce any of these agreements has been brought against the Company.  The case was settled by the parties and, on August 2013, dismissed by the court with prejudice. Additionally, we have received several inquiries with respect to share acquisition agreements.  Those agreements do not include anti-dilution protections and we do not believe that the amounts of any claims under the agreements with SSS should be multiplied to reflect the 3,000-for-one stock split effected by us on May 1, 2007.  However, we cannot provide assurances that claimants will not successfully seek to increase the size of their claims by reference to the stock split.

We have been advised by our counsel that, on the basis of a reasoned analysis, while the matter is not free from doubt and there are no applicable controlling precedents, we should prevail in any litigation of these claims because, among other defenses, the condition precedent to SSS’s obligations under the share acquisition agreements never occurred, and any obligation it may, or we may be deemed to, have had under the share acquisition agreements should be understood to have expired prior to our corporate reorganization, which took effect in 1999, although the share acquisition agreements do not expressly provide for any expiration.

We believe that we should prevail in any litigation with respect to these matters; however, we cannot predict the outcome of any such litigation, including with respect to the magnitude of any claims that may be asserted by any plaintiff, and the interests of our shareholders could be materially diluted to the extent that claims under the share acquisition agreements are successful.
 
Heirs of certain of our former shareholders may bring materially dilutive claims against us.

For much of our history, we and our predecessor entity have restricted the ownership or transferability of our shares, including by reserving to us or our predecessor a redemption right with respect to share transfers and by limiting ownership of such shares to physicians and dentists.  In addition, we and our predecessor, consistent with the requirements of our and our predecessor’s bylaws, have sought to repurchase shares of deceased shareholders at the amount originally paid for such shares by those shareholders.  Nonetheless, former shareholders’ heirs who were not eligible to own or be transferred shares because they were not physicians or dentists at the time of their purported inheritance (“non-medical heirs”), may claim an entitlement to our shares or to damages with respect to the repurchased shares notwithstanding applicable transfer and ownership restrictions.  Our records indicate that there may be as many as approximately 450 former shareholders whose non-medical heirs may claim to have inherited up to 10,500,000 shares after giving effect to the 3,000-for-one stock split.  As of the date of this Annual Report on Form 10-K, we are defending various judicial claims by non-medical heirs of former shareholders whose shares were repurchased upon their death seeking the return of such shares or compensation.  See “Item 3. Legal Proceedings – Claims by Heirs of Former Shareholders.”  In addition, from time to time, we receive inquiries from non-medical heirs with respect to shares we have redeemed.

We believe that we should prevail in litigation with respect to these matters; however, we cannot predict the outcome of any such litigation regarding these non-medical heirs.  The interests of our existing shareholders could be materially diluted to the extent that any such claims are successful.

The dual class structure may not successfully protect against significant dilution of your shares of Class B common stock.

We designed our dual class structure of capital stock to offset the potential impact on the value of our Class B common stock attributable to any issuance of shares of common stock for less than market value in respect of a successful claim against us under any share acquisition agreement or by a non-medical heir.  We believe that this mechanism will effectively protect investors in our shares of Class B common stock against any potential dilution attributable to the issuance of any shares in respect of such claims at below market prices.  We cannot, however, provide any assurances that this mechanism will be effective under all circumstances.

While we expect to prevail against any such claims brought against us and, to the extent that we do not prevail, would expect to issue Class A common stock in respect of any such claim, there can be no assurance that the claimants in any such lawsuit will not seek to acquire Class B common stock.  The issuance of a significant number of shares of Class B common stock, if followed by a material further issuance of shares of common stock to separate claimants could impair the effectiveness of the anti-dilution protections of the Class B common stock.  In addition, we cannot provide any assurances that the anti-dilution protections afforded our Class B common stock will not be challenged by share acquisition providers and/or non-medical heir claimants to the extent that these protections limit the percentage ownership of us that may be acquired by such claimants. We believe that such a challenge should not prevail, but cannot provide any assurances of the outcome.

In the event that claimants acquire shares of our managed care subsidiary, TSS, at less than fair value, we will not be able to prevent dilution of the value of the Class B shareholders’ ownership interest in us to the extent that the net value received by such claimants exceeds the value of our outstanding shares of Class A common stock.  Finally, the anti-dilution protection afforded by the dual class structure may cease to be of further effect at any time because all remaining shares of Class A common stock may, at the sole discretion of our board of directors and after considering relevant factors, including market conditions at the time, be converted into shares of Class B common stock.  On November 12, 2015, the Company converted 1,426,721 shares of Class A common stock to Class B common stock.

Future sales of our Class B common stock, or the perception that such future sales may occur, may have an adverse impact on its market price.

Sales of a substantial number of shares of our common stock in the public market, or the perception that large sales could occur, could cause the market price of our Class B common stock to decline.  Either of these limits our future ability to raise capital through an offering of equity securities. As of December 31, 2017 there were 22,627,077 shares of Class B common stock and 950,968 shares of Class A common stock.  Our Class A common stock is no longer subject to contractual lockup; thus, such shares are freely tradable without restriction or further registration under the Securities Act by persons other than our ‘‘affiliates’’ within the meaning of Rule 144 under the Securities Act, although such shares will continue not to be listed on the NYSE and will not be fungible with our listed shares of Class B common stock.  All or any portion of our shares of Class A common stock may at the sole discretion of our board of directors and after considering relevant factors, including market conditions at the time, be converted to shares of Class B common stock.
 
Risks Related to Our Business

Our inability to contain managed care costs may adversely affect our business and profitability.

A substantial portion of our managed care revenue is generated by premiums consisting of monthly payments per member that are established by contracts with our commercial customers, ASES or CMS (for our Medicare Advantage plans), all of which are typically renewable on an annual basis.  If our medical expenses exceed our estimates, except in very limited circumstances or as a result of risk score adjustments for member acuity in the case of the Medicare Advantage products, we will be unable to increase the premiums we receive under these contracts during the then-current terms.  As a result, our profitability in any year depends, to a significant degree, on our ability to adequately predict and effectively manage our medical expenses related to the provision of managed care services through underwriting criteria, medical management, product design and negotiation of favorable provider contracts with hospitals, physicians and other health care providers.  The aging of the population and other demographic characteristics and advances in medical technology continue to contribute to rising health care costs.  Government-imposed limitations on Medicare reimbursement have also caused the private sector to bear a greater share of increasing health care costs.  Also, we have in the past and may in the future enter into new lines of business in which it may be difficult to estimate anticipated costs.  Numerous factors affecting the cost of managed care, including changes in health care practices, inflation, new technologies such as genetic laboratory screening for diseases including breast cancer, electronic recordkeeping, the cost of prescription drugs, clusters of high cost cases, changes in the regulatory environment including the implementation of ACA, may adversely affect our ability to predict and manage managed care costs, as well as our business, financial condition and results of operations.

Introduction of new high cost specialty drugs and sudden costs spikes for existing drugs increase the risk that the pharmacy cost assumptions used to develop our rates are not adequate to cover the actual pharmacy costs, which jeopardizes the overall actuarial soundness of our rates. Bearing the high costs of new specialty drugs or the high cost inflation of generic drugs without an appropriate rate adjustment or other reimbursement mechanism adversely impacts our financial conditional and operational results.  In addition, evolving state and federal regulation may impact the ability of our health plans to continue to receive existing price discounts on pharmaceutical products for our members. Other factors affecting our pharmaceutical costs include, but are not limited to, geographic variation in utilization of new and existing pharmaceuticals, and changes in discounts. Although we will continue to work with state agencies in an effort to ensure that we receive appropriate and actuarially sound reimbursement for all new drug therapies and pharmaceuticals trends, there can be no assurance that we will always be successful.
 
Our profitability may be adversely affected if we are unable to maintain our current provider agreements and to enter into other appropriate agreements.

Our profitability is dependent upon our ability to contract on favorable terms with hospitals, physicians and other managed care providers. In recent years some groups of providers have been pressing for legislation that would allow them to collectively negotiate certain contract terms through cooperatives.  As a result, Puerto Rico enacted legislation authorizing providers to collectively negotiate the services fees through cooperatives, on a voluntary basis, with health insurance companies and other healthcare-related organizations. This legislation requires that the Public Corporation for the Supervision and Insurance of Cooperatives adopt regulation that may have a material adverse effect in our business. If collective negotiations with providers become mandatory or we are otherwise required to enter into collective negotiations with providers, it could become more difficult to maintain cost-effective managed care provider contracts, which could adversely affect our business.
 
We are dependent on a small number of government contracts to generate a significant amount of the revenues of our managed care business.

Our managed care business participates in government contracts that generate a significant amount of our consolidated operating revenues, including:

Commercial:     One of our managed care subsidiaries is a qualified contractor to provide managed care coverage to federal government employees within Puerto Rico.  Such coverage is provided pursuant to a contract with the OPM that is subject to termination in the event of non-compliance not corrected to the satisfaction of the OPM.  During each of the years ended December 31, 2017, 2016, and 2015 premiums generated under this contract represented 5.7%, 5.8% and 5.6% of our consolidated premiums earned, net, respectively.

Medicare:     We provide services through our Medicare Advantage products pursuant to a limited number of contracts with CMS.  These contracts generally have terms of one year and must be renewed each year.  Each of our contracts with CMS is cancellable for cause if we breach a material provision of the contract or violate relevant laws or regulations. If we are unable to renew, or to successfully re-bid or compete for any of these contracts, or if the process for bidding materially changes or if any of these contracts are terminated, our business could be materially impaired.  During each of the years ended December 31, 2017, 2016, and 2015, contracts with CMS represented 36.6%, 35.4% and 39.4% of our consolidated premiums earned, net, respectively.

Under the commercial business, we also provide health coverage to certain employees of the Government of Puerto Rico and its instrumentalities. Earned premium revenue related to such health plans represented 3.4%, 3.1% and 3.3% of our consolidated premiums earned, net, respectively.
 
Medicaid:     We participate in the government of Puerto Rico Health Reform Program (similar to Medicaid) to provide health coverage to medically indigent citizens in Puerto Rico.  Under the current agreement, TSS offers healthcare services on a fully-insured basis to Medicaid subscribers in the Metro North and West regions.  TSS is also responsible for providing medical, mental, pharmacy and dental healthcare services to Medicaid subscribers in these service regions on an at-risk basis. The current agreement ends on June 30, 2018.  The current agreement with ASES contains certain termination rights for both TSS and ASES, including ASES’s right to terminate the agreement as a result of insufficient government funds to pay ASES’s obligations under the contract and TSS’s right to terminate the agreement within 45 days before the end of each fiscal year if TSS and ASES have not agreed to the per member per month rate. For the years ended December 31, 2017, 2016 and 2015, premiums generated under our current agreement represented 26.6%, 27.1% and 21.8% of our consolidated premiums earned, net, respectively.  In early February 2018, the Government of Puerto Rico issued a Request for Proposal (“RFP”) for the administration of its Medicaid program that will introduce significant changes to the model, including the elimination of geographical areas and allowing participants to select insurance carriers. The Company is thoroughly evaluating the RFP and all aspects of the new model, including financial, clinical, operational and systems requirements and risks.

If any of these contracts is terminated for any reason, including by reason of any non-compliance by us, or not renewed or replaced by a comparable contract, our consolidated premiums and profitability earned could be materially adversely affected.  See also “Risks Relating to the Regulation of our Industry—As a Medicare Advantage program participant, we are subject to complex regulations.”
 
A change in our managed care commercial product mix may impact our profitability.

Our managed care products that involve greater potential risk, such as fully insured arrangements, generally tend to be more profitable than ASO products and those managed care products where employer groups retain the risk, such as self-funded financial arrangements.  There has been a trend in recent years among our Commercial customers of moving from fully-insured plans to ASO, or self-funded arrangements.  As of December 31, 2017 and 2016, 68% and 66% of our managed care commercial customers, respectively, had fully insured arrangements and 32% and 34%, respectively, had ASO arrangements.  Unfavorable changes in the relative profitability or customer participation among our various products could have a material adverse effect on our business, financial condition, and results of operations.

Our failure to accurately estimate incurred but not reported claims would affect our reported financial results.

A portion of the claim liabilities recorded by our insurance segments represents an estimate of amounts needed to pay and adjust anticipated claims with respect to insured events that have occurred, including events that have not yet been reported to us.  These amounts are based on estimates of the ultimate expected cost of claims and on actuarial estimation techniques.  Judgment is required in actuarial estimation to ascertain the relevance of historical payment and claim settlement patterns under each segment’s current facts and circumstances.  Accordingly, the ultimate liability may be in excess of or less than the amount provided.  We regularly compare prior period liabilities to re-estimate claim liabilities based on subsequent claims development; any difference between these amounts is adjusted in the operations of the period determined.  Additional information on how each reportable segment determines its claim liabilities, and the variables considered in the development of this amount, is included elsewhere in this Annual Report on Form 10-K under “Item 7.   Management’s Discussion and Analysis of Financial Condition and Results of Operations―Critical Accounting Estimates”.  Actual experience will likely differ from assumed experience, and to the extent the actual claims experience is less favorable than estimated based on our underlying assumptions, our incurred losses would increase and future earnings could be adversely affected.

The termination or modification of our license agreements to use the BCBS name and mark could have a material adverse effect on our business, financial condition and results of operations.

We are a party to license agreements with the BCBSA that entitle us to the exclusive use of the BCBS name and mark in Puerto Rico, the U.S. Virgin Islands, Costa Rica, the British Virgin Islands and Anguilla.  These license agreements contain certain standards, requirements and restrictions regarding our operations and our use of the BCBS name and mark which may be modified in certain instances by the BCBSA. Changes to the terms of our license agreements may restrict various potential business activities.  Failure to comply with the standards, requirements and restrictions established could result in the termination of a license agreement.  Events that could cause the termination of a license agreement with the BCBSA include failure to comply with minimum capital requirements imposed by the BCBSA, a change of control or violation of the BCBSA ownership limitations on our capital stock, impending financial insolvency and the appointment of a trustee or receiver or the commencement of any action against a licensee seeking its dissolution.  Upon termination of a license agreement, the BCBSA would impose a re-establishment fee upon us, which would allow the BCBSA to entitle another managed care company to use the BCBS name and marks in the service areas we currently serve.  This re-establishment fee is currently $98.33 per licensed enrollee.  If the re-establishment fee were applied to our total BCBS enrollees as of December 31, 2017, we would be assessed approximately $96.2 million by the BCBSA.

We believe that the BCBS name and mark are valuable identifiers of our products and services in the marketplace.  Termination of these license agreements, including modifications to the current term and conditions, could have a material adverse effect on our business, financial condition and results of operations. See “Item 1.   Business ―Blue Cross and Blue Shield License” for more information.
 
Our ability to manage our exposure to underwriting risks in our life insurance and property and casualty insurance businesses depends on the availability and cost of reinsurance coverage.

Reinsurance is the practice of transferring part of an insurance company’s liability and premium under an insurance policy to another insurance company.  We use reinsurance arrangements to limit and manage the amount of risk we retain, to stabilize our underwriting results and to increase our underwriting capacity.  During 2017, 43.3%, or $62.3 million, of the premiums written in the property and casualty insurance segment and 5.3%, or $8.8 million, of the premiums written in the life insurance segment were ceded to reinsurers.  Total premiums ceded, on a consolidated basis, represent 2.5%, or $71.1 million of our premiums.  The premiums ceded and the availability and cost of reinsurance is subject to changing market conditions and may vary significantly over time.  Any decrease in the amount of our reinsurance coverage will increase our risk of loss.  We may be unable to maintain our desired reinsurance coverage or obtain other reinsurance coverage in adequate amounts and at favorable rates.  If we are unable to renew our expiring coverage or obtain new coverage, it will be difficult for us to manage our underwriting risks and operate our business profitably.

It is also possible that the losses we experience on insured risks for which we have obtained reinsurance will exceed the coverage limits of the reinsurance.  See “Risks Related to Our Business-Large scale natural disasters may have a material adverse effect on our business, financial condition and results of operations.”  If the amount of our reinsurance coverage is insufficient, our insurance losses could increase substantially.

If our reinsurers do not pay our claims or do not pay them in a timely manner, we may incur losses.

We are subject to loss and credit risk with respect to the reinsurers with whom we deal.  In accordance with general industry practices, our property and casualty and life insurance subsidiaries annually purchase reinsurance to lessen the impact of large unforeseen losses and mitigate sudden and unpredictable changes in our net income and shareholders’ equity.  Reinsurance contracts do not relieve us from our obligations to policyholders.  In the event that all or any of the reinsurance companies are unable to meet their obligations under existing reinsurance agreements or pay on a timely basis, we will continue to be liable to our policyholders notwithstanding such defaults or delays.  If our reinsurers are not capable of fulfilling their financial obligations to us, our insurance losses would increase, which would negatively affect our financial condition and results of operations.

A downgrade in our A.M. Best rating could affect our ability to write new business or renew our existing business in our property and casualty segment.

Ratings assigned by A.M. Best are an important factor influencing the competitive position of the property and casualty insurance companies in Puerto Rico.  In 2017, A.M. Best classified our property and casualty insurance subsidiary’s rating as “A-” (the fourth highest of A.M. Best’s 16 financial strength ratings).  On October 13, 2017, A.M. Best released the updated Best’s Credit Rating Methodology (BCRM).  The BCRM is a reorganization of the core credit rating methodology.  Our property and casualty business was identified as being potentially affected by the implementation of the updated BCRM.  A.M. Best is assessing the effect that the updates to the BCRM have on our current rating and will complete a corresponding rating update in the near term.  Moreover, we expect that due consideration will be placed on the effects of Hurricanes Irma and Maria in the business.

A.M. Best ratings represent independent opinions of financial strength and ability to meet obligations to policyholders and are not directed toward the protection of investors.  Financial strength ratings are used by brokers and customers as a means of assessing the financial strength and quality of insurers.  A.M. Best reviews its ratings periodically and we may not be able to maintain our current ratings in the future.  A downgrade of our property and casualty segments rating could limit or prevent us from writing  and renewing certain types of business or accounts that requires insurers with stronger ratings.  Since the lines of business that this segment writes and the market in which it operates are particularly sensitive to changes in A.M. Best financial strength ratings.
 
We are dependent on the success of our relationships with third parties for various services and functions, including PBM services.
 
We contract with various third parties to perform certain functions and services and provide us with certain information technology systems. Certain of these third parties provide us with significant portions of our business infrastructure and operating requirements, and we could become overly dependent on key vendors, which could cause us to lose core competencies. A termination of our agreements with, or disruption in the performance of, one or more of these service providers could result in service disruptions or unavailability, reduced service quality and effectiveness, increased or duplicative costs or an inability to meet our obligations to our customers. In addition, we may also have to seek alternative service providers, which may be unavailable or only available on less favorable contract terms. Any of these outcomes could adversely affect our business, reputation, cash flows, financial condition and operating results.

TSS entered into a Master Services Agreement (“MSA”) with OptumInsight, Inc. (“Optum”), pursuant to which Optum will provide healthcare technology and operations services, including information technology, claims processing and application development, to Triple-S and its affiliates. As a result, we are now dependent on Optum for the provision of essential services to our business, and there can be no assurances that the quality of the services will be appropriate or that Optum will be able to continue to provide us with the necessary claims processing and technology services. Potential breakdowns or failures of Optum could harm our business by disrupting our delivery of services, which could have a material adverse impact on our financial condition and results of operations. The aforementioned contract is included as Exhibit 10.29 filed with this Annual Report on Form 10-K.
 
Significant competition and market conditions in Puerto Rico could negatively affect our ability to maintain or increase our profitability.

We are subject to strong competition in each line of business in which we operate.  Competition in the insurance industry is based on many factors, including premiums charged, services provided, speed of claim payments and reputation.  This competitive environment has produced and will likely continue to produce significant pressures in our profitability. The industry in which we operate has unique characteristics that, if we are unable to manage adequately, may adversely affect our business, financial conditions and results of operations.  Some of the trends and characteristics related to the competition we face in our different lines of business include the following:

       The managed care market in Puerto Rico is mature .  According to the U.S. Census Bureau, Puerto Rico’s population decreased by 2.2% between 2000 and 2010; however, the national population rate grew 9.7% during the same period.  According to the US Census Bureau, the older population is an important and growing segment of the United States population.  Between 2000 and 2010, the population 65 years and older increased at a faster rate (15.1%) than the total U.S. population.  In Puerto Rico, for the same period, the population 65 years and older increased by 27.5 %. As a result, in order to increase our profitability we believe that we must increase our membership in the Medicare Advantage program, increase market share in the commercial sector, improve our operating profit margins, make acquisitions or expand geographically.

       Local economy is in a downturn .  A challenging economy and a shrinking population in Puerto Rico continue to produce conditions that are adverse to the generation of new sources of business in this segment.  As a result, insurance companies compete for the same customers through pricing, policy terms and quality of services.  Also, our industry is also subject to aggressive marketing and sales practices that target our current and prospective customers. We may not be successful in attracting and retaining our customers.

       Our industry is highly regulated .  Future legislation at the federal and local levels may also result in increased competition, especially in the managed care segment.  While we do not anticipate that any of the current legislative proposals of which we are aware would increase the competition we face, future legislative proposals, if enacted, might do so.

       Market concentration . Concentration in our industry has created an increasingly competitive environment, both for customers and for potential acquisition targets, which may make it difficult for us to grow our business.  The parent companies of some of our competitors are larger and have greater financial and other resources than we do.  We may have difficulty competing with larger companies, which can create downward price pressures on premium rates.
 
We believe these trends will continue.  There can be no assurance that these competitive pressures will not adversely affect our business, financial condition and results of operations.

As a holding company, we are largely dependent on rental payments, dividends and other payments from our subsidiaries, although the ability of our regulated subsidiaries to pay dividends or make other payments to us is subject to the regulations of the Commissioner of Insurance, including maintenance of minimum levels of capital, as well as covenant restrictions in their indebtedness.

We are a holding company whose assets include, among other things, all of the outstanding shares of common stock of our subsidiaries, including our regulated insurance subsidiaries.  We principally rely on rental income and dividends from our subsidiaries to fund our debt service, dividend payments and operating expenses, although our subsidiaries may not declare dividends every year.  We also benefit to a lesser extent from income on our investment portfolio.

Our insurance subsidiaries are subject to the regulations of the Commissioner of Insurance requiring, among other things, to maintain certain levels of capital, thereby restricti ng the amount of earnings that can be distributed.  See “Risks Related to Our Business―Our insurance subsidiaries are subject to minimum capital requirements.  Our failure to meet these standards could subject us to regulatory actions.”  Our subsidiaries’ ability to make any payments to us will also depend on their earnings, the terms of their indebtedness, if any, and other business and legal restrictions.  Furthermore, our subsidiaries are not obligated to make funds available to us, and creditors of our subsidiaries have a superior claim to such subsidiaries’ assets.  Our subsidiaries may not be able to pay dividends or otherwise contribute or distribute funds to us in an amount sufficient for us to meet our financial obligations.  In addition, from time to time, we may find it necessary to provide financial assistance, either through subordinated loans or capital infusions to our subsidiaries that may adversely affect our financial condition.

Our results may fluctuate as a result of many factors, including cyclical changes in the insurance industry.

Results of companies in the insurance industry, and particularly the property and casualty insurance industry, historically have been subject to significant fluctuations and uncertainties.  The industry’s profitability can be affected significantly by:

rising levels of actual costs that are not known by companies at the time they price their products;

volatile and unpredictable developments, including man-made and natural catastrophes;

changes in reserves resulting from the general claims and legal environments as different types of claims arise and judicial interpretations relating to the scope of insurers’ liability develop; and

fluctuations in interest rates, inflationary pressures and other changes in the investment environment, which affect returns on invested capital.

Historically, the financial performance of the insurance industry has fluctuated in cyclical periods of low premium rates and excess underwriting capacity resulting from increased competition, followed by periods of high premium rates and a shortage of underwriting capacity resulting from decreased competition.  Fluctuations in underwriting capacity, demand and competition, and the impact on us of the other factors identified above, could have a negative impact on our results of operations and financial condition.  We believe that underwriting capacity and price competition in the current market is increasing.  This additional underwriting capacity may result in increased competition from other insurers seeking to expand the kinds or amounts of business they write or cause some insurers to seek to maintain market share at the expense of underwriting discipline.  We may not be able to retain or attract customers in the future at prices we consider adequate.
 
Our investment portfolios are subject to varying economic and market conditions.

We have exposure to market risk and credit risk in our investment activities.  The fair values of our investments vary from time to time depending on economic and market conditions.  Fixed maturity securities expose us to interest rate risk as well as credit risk.  Equity securities expose us to equity price risk.  Interest rates are highly sensitive to many factors, including governmental monetary policies and domestic and international economic and political conditions.  These and other factors also affect the equity securities owned by us.  The outlook of our investment portfolio depends on the future direction of interest rates, fluctuations in the equity markets and the amount of cash flows available for investment.  For additional information, see “Item 7A.   Quantitative and Qualitative Disclosures About Market Risk” for an analysis of our exposure to interest and equity price risks and the procedures in place to manage these risks.  Our investment portfolios may lose money in future periods, which could have a material adverse effect on our financial condition.

In addition, our insurance subsidiaries are subject to local laws and regulations that require diversification of our investment portfolios and limit the amount of investments in certain riskier investment categories, such as below-investment-grade fixed income securities, mortgage loans, and real estate and equity investments, among others, which could generate higher returns on our investments.  If we fail to comply with these laws and regulations, any investments exceeding regulatory limitations would be treated as non-admitted assets for purposes of measuring statutory surplus and risk-based capital.

The securities and credit markets could experience extreme volatility and disruption.

Adverse conditions in the U.S. and global capital markets could significantly and adversely affect the value of our investments in debt and equity securities, other investments, our profitability and our financial position.

As an insurer, we have a substantial investment portfolio that is comprised particularly of debt securities of issuers located in the U.S.  As a result, the income we earn from our investment portfolio is largely driven by the level of interest rates in the U.S. financial markets, volatility, uncertainty and/or disruptions in the global capital markets, particularly the U.S. credit markets, and governments’ monetary policy.  These factors can significantly and adversely affect the value of our investment portfolio, our profitability and/or our financial position by:

Significantly reducing the value of the debt securities we hold in our investment portfolio, and creating net realized capital losses that reduce our operating results and/or net unrealized capital losses that reduce our shareholders’ equity.

Lowering interest rates on high quality short-term debt securities and thereby materially reducing our net investment income and operating results.

Making it more difficult to value certain of our investment securities, for example if trading becomes less frequent, which could lead to significant period-to-period changes in our estimates of the fair values of those securities and cause period-to-period volatility in our operating results and shareholders’ equity.

Reducing our ability to issue other securities.

We evaluate our investment securities for other-than-temporary impairment on a quarterly basis.  This review is subjective and requires a high degree of judgment.  It also requires us to make certain assessments about the potential recovery of the assets we hold.  For the purpose of determining gross realized gains and losses, the cost of investment securities is based upon specific identification.

We believe our cash balances, investment securities, operating cash flows, and funds available under credit agreement, taken together, provide adequate resources to fund ongoing operating and regulatory requirements.  However, continuing adverse securities and credit market conditions could significantly affect the availability of credit.

For additional information, see “Item 7A.   Quantitative and Qualitative Disclosures About Market Risk” for an analysis of our exposure to interest and equity price risks and the procedures in place to manage these risks.  Our investment portfolios may lose money in future periods, which could have a material adverse effect on our financial condition.
 
In addition, our insurance subsidiaries are subject to local laws and regulations that require diversification of our investment portfolios and limit the amount of investments in certain riskier investment categories, such as below-investment-grade fixed income securities, mortgage loans, and real estate and equity investments, among others, which could generate higher returns on our investments. Notwithstanding, the Insurance Code of Puerto Rico requires insurers to invest an amount equal to no less than half of the insurer’s required capital in Puerto Rico Securities. Since February 2014, the credit ratings of bonds issued by the Government of Puerto Rico and most of Puerto Rico public corporations have been downgraded to below-investment grade. As a result, on March 2014, the Puerto Rico Legislative Assembly enacted legislation allowing insurance companies to hold investments that were acquired at an investment grade rating but subsequently downgraded below-investment grades for period not exceeding three years from the date of acquisition. This legislation also authorizes the Commissioner of Insurance, upon an insurer’s request, to provide a three-year extension of the holding period, or an exemption to dispose of the downgraded investment.  The Insurance Code requirement that insurers invest in Puerto Rico securities may affect our ability to invest in other securities with a higher investment credit rating, the overall value of our investment portfolio and our financial condition. If we fail to comply with these laws and regulations, any investments exceeding regulatory limitations would be treated as non-admitted assets for purposes of measuring statutory surplus and risk-based capital and may adversely affect our financial condition and results of operations.
 
Our business is geographically concentrated in Puerto Rico and weakness in the economy and the fiscal health of the government has adversely impacted and may continue to adversely impact us, particularly following Hurricanes Irma and Maria.

Our principal lines of business are concentrated in Puerto Rico, which is currently in the midst of a severe fiscal and economic crisis resulting primarily from a continuing economic recession, significant and recurrent budget deficits, accelerated out-migration, a high debt-to-revenue ratio, unfunded pension liabilities and the loss of access to the capital markets, among other factors. Such fiscal and economic crisis has been recently exacerbated as a result of the impact of hurricanes Irma and María in September 2017. The hurricanes have had an adverse impact on economic activity, have accelerated out-migration trends, and have required the government to incur substantial extraordinary expenditures while experiencing a significant decrease in tax and other revenues.
 
Even before the hurricanes, Puerto Rico was facing an enduring economic crisis. It’s gross national product (“GNP”) had contracted in real terms since fiscal year 2006. According to the latest Puerto Rico Planning Board estimates, released in April 2017 (before the impact of the hurricanes), GNP was projected to decrease by 1.7% and 1.5% in constant dollars for fiscal years 2017 and 2018, respectively. Following the hurricanes, however, the government projects an 11% contraction in real GNP during fiscal year 2018, followed by five fiscal years of economic growth (due primarily to the positive impact of Federal emergency assistance and significant recovery spending), according to the latest draft of the government’s proposed fiscal plan (further discussed below).
 
The weakness of Puerto Rico’s economy has also adversely affected employment.  Total employment in Puerto Rico decreased approximately 20% from fiscal year 2007 to fiscal year 2016.  The reduction in total employment began in the fourth quarter of fiscal year 2007 and continued consistently through the first half of fiscal year 2015 due to the current recession and the fiscal adjustment measures implemented by the government. According to the Household Survey, during fiscal year 2016, total employment increased by 1.8% when compared to the prior fiscal year, and the unemployment rate averaged 11.7%, compared to 13.0% for the prior fiscal year.  For the first five months of fiscal year 2017, total employment decreased by 0.4% with respect the first five months of fiscal year 2016. It is still too early to fully assess the impact of the hurricanes on employment levels. However, total employment may decrease, and total unemployment may increase, at least in the short-term, as a result of the hurricanes. Subsequently, Puerto Rico is expected to see some increased economic activity due to Island’s hurricane recovery efforts, reflecting expected funds from insurance payouts and federal aid.
 
Despite the implementation a number of extraordinary expense reduction, revenue increase and liquidity management measures, the Government’s structural deficit, coupled with the continuing recession, decreasing employment, lack of capital market access, and the insolvency of Government Development Bank for Puerto Rico, eventually resulted in the government being unable to make scheduled debt service payments while continuing to provide essential services in 2016. A moratorium on most debt service payments has been in place since then and the Commonwealth and certain of its instrumentalities are currently in the process of restructuring their debts pursuant to the debt restructuring mechanisms established by the Puerto Rico Oversight, Management and Economic Stability Act (“PROMESA”), which was enacted by the U.S. Congress in June 2016.
 
Pursuant to PROMESA, the Financial Oversight and Management Board for Puerto Rico (the “Oversight Board”), an oversight board for Puerto Rico created by the statute, certified fiscal plans for the Commonwealth and certain of its instrumentalities between June and August 2017.  In December 2017, however, the Oversight Board requested that the government submit revised fiscal plans, taking into account the impact of the hurricanes. The government has submitted various drafts of such fiscal plans to the Oversight Board, which are currently under its review. The Oversight Board has stated that it expects to certify revised fiscal plans for the Commonwealth, the Puerto Rico Electric Power Authority (“PREPA”) and the Puerto Rico Aqueduct and Sewer Authority (“PRASA”) by March 30, 2018. The fiscal plans (the ones certified by the Oversight Board last year and the most recent drafts of the revised fiscal plans) reflect that the government and its instrumentalities will not have sufficient revenues to pay their debts service obligations in full while continuing to provide essential services, implying a need for significant debt relief. Furthermore, the Commonwealth’s proposed fiscal plan states that it will need to access financing from the Federal government this fiscal year in order to cover its operating expenses and those of PREPA and PRASA.
 
The Commonwealth’s proposed fiscal plan also includes a number of measures intended to be implemented by the government to address its many fiscal and economic challenges.  As part of such measures, the Puerto Rico government proposes to make significant changes to the Government Health Plan, which the government expects will result in savings of approximately $795 million by fiscal year 2023. The changes being contemplated include the expansion of the current regional system to a single region, allowing members to choose their managed care organizations, and establishing limits to benefits based on the actual needs of the beneficiaries, among others.
 
We have significant direct exposure to the government through our contract with the Puerto Rico Health Services Administration, which administers the government health plan, and certain other business relationships with the Government of Puerto Rico and its instrumentalities. As a result, we may be adversely affected by the liquidity problems of such entities. Moreover, it is uncertain if any of the proposed reforms to the Government’s health insurance system will be implemented and, if implemented, what effect, if any, such reforms will have our business and results of operations. On the other hand, as part of the emergency supplemental legislation passed by Congress, Puerto Rico’s Medicaid spending cliff has been addressed for at least the next two years, because of the approval of $4.8 billion in Medicaid Funding.  This action will bring financial stability to Puerto Rico’s Medicaid program, and funding conditions related to compliance with program management standards will further promote stability and predictability.
 
Furthermore, our insureds’ financial capacity is affected by, among other things, the general economic conditions in Puerto Rico and other adverse conditions affecting Puerto Rico consumers and businesses.  The effects of the prolonged recession are reflected in a decrease in insured customers in our commercial lines of business and premiums earned, net. The amount of insured customers and premiums earned could also be further adversely impacted following the hurricanes. Moreover, the measures taken to address the fiscal crisis and those that may have to be taken in the near future, coupled with the effects of hurricanes Irma and María, will likely affect many of our insureds, which could result in a lower amount of insureds, insureds moving to lower premium plans, among others.  The foregoing could also result in decreased demand for our insurance products or migration to less profitable products.
 
If global or local economic conditions worsen or the Government of Puerto Rico is unable to manage its fiscal and economic challenges, including consummating an orderly restructuring of its debt obligations while continuing to provide essential services, the conditions described above could continue or worsen in ways that are unpredictable and outside of our control.  While PROMESA provides the Commonwealth with tools to restructure the debt obligations of the Commonwealth and its instrumentalities, these restructuring tools are new and untested.  Furthermore, the Commonwealth’s projections indicate the possibility of significant creditor losses. Both of these factors may make any debt restructuring process a lengthy and highly adversarial process. These factors could have a material adverse impact on our earnings and financial condition.
 
The success of our business depends on developing and maintaining effective information systems.

Our business and operations may be affected if we do not maintain and upgrade our information systems and the integrity of our proprietary information.  We are materially dependent on our information systems, including Internet-enabled products and information, for all aspects of our business operations.  Monitoring utilization and other factors, supporting our managed care management techniques, processing provider claims and providing data to our regulators, and our ability to compete depends on adopting technology on a timely and cost-effective basis.  Malfunctions in our information systems, fraud, error, communication and energy disruptions, security breaches or the failure to maintain effective and up-to-date information systems could disrupt our business operations, alienate customers, contribute to customer and provider disputes, result in regulatory violations and possible liability, increase administrative expenses or lead to other adverse consequences.  The use of member data by all of our businesses is regulated at federal and local levels.  These laws and rules change frequently and developments require adjustments or modifications to our technology infrastructure.

Our information systems and applications require an ongoing commitment of significant resources to maintain, upgrade and enhance existing systems and develop new systems in order to keep pace with continuing changes in information processing technology, evolving industry and regulatory standards, compliance with legal requirements (such as a new set of standardized diagnostic codes, known as ICD-10), and changing operational needs. In addition, we may from time to time obtain significant portions of our systems-related or other services or facilities from independent third parties, which may make our operations vulnerable to such third parties' failure to perform adequately.  If we are unable to comply with ICD-10 requirements, or to maintain effective and efficient information systems, or our failure to efficiently and effectively consolidate our information systems to eliminate redundant or obsolete applications, could have a material adverse effect on our business, financial condition and results of operations.  If the information we rely upon to run our business were found to be inaccurate or unreliable or if we fail to maintain our information systems and data integrity effectively we could suffer from, among other things, operational disruptions, such as the inability to pay claims or to make claims payments on a timely basis, have problems in determining medical cost estimates and establishing appropriate pricing and reserves, loss of members, and difficulty in attracting new members, regulatory problems, increases in operating expenses or suffer other adverse consequences.

Our business requires the secure transmission of confidential information over public networks.  Advances in computer capabilities, new discoveries in the field of cryptography or other events or developments could result in compromises or breaches of our security system and patient data stored in our information systems.  Anyone who circumvents our security measures could misappropriate our confidential information or cause interruptions in services or operations.  The internet is a public network and data is sent over this network from many sources.  In the past, computer viruses or software programs that disable or impair computers have been distributed and have rapidly spread over the internet.  Computer viruses could be introduced into our systems, or those of our providers or regulators, which could disrupt our operations, or make our systems inaccessible to our providers or regulators.

We may be required to expend significant capital and other resources to protect against the threat of security breaches or to alleviate problems caused by breaches.  Because of the confidential health information we store and transmit, security breaches could expose us to a risk of regulatory action, litigation, possible liability and loss.  We are taking all needed security measures to prevent security breaches, and ensure our business operations won’t be adversely affected by potential security breaches.
 
We face risks related to litigation.

We are subject to a variety of legal actions that affect any business, such as employment and employment discrimination-related suits, employee benefit claims, breach of contract actions, tort claims and intellectual property-related litigation.  In addition, because of the nature of our business, we are subject to a variety of legal actions relating to our business operations, including the design, management and offering of our products and services, claims relating to the denial of benefits or coverage, medical malpractice actions, allegations of anti-competitive and unfair business activities, provider disputes, broker and agent disputes, and claims by regulatory actions by agencies for non-compliance, among others.  Legal proceedings are inherently unpredictable and we cannot ascertain their outcome. We have insurance to cover liabilities relating to litigation; however, insurance coverage may not be sufficient to cover any such liability or our insurers could deny or dispute coverage.  Results of regulatory actions could require us to change our business practices and may affect our profitability. Substantial liability relating to legal or regulatory actions could adversely affect our cash flow, results of operations, and financial conditions.  See “Item 3. Legal Proceedings.”

Large-scale natural disasters may have a material adverse effect on our business, financial condition and results of operations.

Puerto Rico has historically been at a relatively high risk of natural disasters such as hurricanes and earthquakes.  If Puerto Rico were to experience a large-scale natural disaster, claims incurred by our managed care, property and casualty and life insurance segments would likely increase and our properties may incur substantial damage, which could have a material adverse effect on our business, financial condition and results of operations. Furthermore, unforeseen major public health issues following these catastrophic events, such as pandemics and epidemics, like mosquito-borne epidemics (Dengue, Zika, etc.), conditions for which vaccines may not exist, are not effective, or have not been widely administered, could have a material adverse effect on our business, financial condition, and results of operations. Claims in our property and casualty business increased in 2017 after the landing of Hurricanes Irma and Maria in Puerto Rico. The Puerto Rico Insurance Code requires the Company to resolve claims within a period of 90 days.  Due to the substantial increase in the volume of claims following a catastrophic event, there is a business risk that not all claims will be resolved within the timeframe stipulated in the Puerto Rico Insurance Code, which may result in penalties imposed by the Commissioner of Insurance of Puerto Rico.

Present and future covenants in our secured term loans and note purchase agreements may restrict our operations and adversely affect our ability to pursue desirable business opportunities.

The secured term loan and the note purchase agreements governing the notes contain financial and non-financial covenants that restrict, among other things, the granting of certain liens, limitations on acquisitions and limitations on changes in control.  These non-financial covenants could restrict our operations.  In addition, if we fail to make any required payment under our secured term loans or note purchase agreements governing the notes or to comply with any of the non-financial covenants included therein, we would be in default and the lenders or holders of our debt, as the case may be, could cause all of our outstanding debt obligations under our secured term loans or note purchase agreements to become immediately due and payable, together with accrued and unpaid interest and, in the case of the secured term loans, cease to make further extensions of credit.  If the indebtedness under our secured term loans or note purchase agreements is accelerated, we may be unable to repay or re-finance the amounts due and our business may be materially adversely affected.

We may incur additional indebtedness in the future.  Our debt service obligations may require us to use a portion of our cash flow to pay interest and principal on debt instead of for other corporate purposes, including funding future expansion.  If our cash flow and capital resources are insufficient to service our debt obligations, we may be forced to seek extraordinary dividends from our subsidiaries, sell assets, seek additional equity or debt capital or restructure our debt.  However, these measures might be prohibited by applicable regulatory requirements, unsuccessful or inadequate in permitting us to meet scheduled debt service obligations. We may also incur future debt obligations that might subject us to restrictive covenants that could affect our financial and operational flexibility.
 
Our breach or failure to comply with any of these covenants could result in a default under our secured term loan and note purchase agreements and the acceleration of amounts due thereunder.  Indebtedness could also limit our ability to pursue desirable business opportunities, and may affect our ability to maintain an investment grade rating for our indebtedness.

If we do not effectively manage the growth of our operations and our acquisitions, we may not be able to achieve our profitability targets.

Our growth strategy includes enhancing our market share in Puerto Rico, entering new geographic markets, introducing new insurance products and programs, further developing our relationships with independent agencies or brokers and pursuing acquisition opportunities.  Our growth strategy exposes us to additional risks, including our ability to:

identify profitable growth opportunities in current and additional markets;

transact successful acquisitions, capital investments and other growth initiatives;

determine the correct value of assets and investments;

implement adequate pricing and operational structure, including underwriting and claim management processes;

design attractive and profitable insurance and health products and services;

recruit required personnel for expanded operations, including officers, agents, brokers, medical providers, and other key personnel;

obtain regulatory permission required to operate in other jurisdictions or lines of business;

comply with regulatory requirements;

integrate acquired business to our operations, including integration of information technology, management and personnel, and administrative systems;

create the expected return over time; and

Implement new, or modify existing internal monitoring and control systems.
 
Additionally, our management and other key personnel may expend considerable time and effort which may distract them from their core activities. We may face risk associated to unknown or unidentified liabilities resulting from our investments or acquisitions. We may also be subject to changes in trade protection laws, policies and measures, and other regulatory requirements affecting our business, including the Foreign Corrupt Practices Act and laws prohibiting corrupt payments. Deterioration of social, political, labor or economic conditions in a specific country or region and difficulties in managing foreign operations may also adversely affect our operations or financial results.  Also, fluctuations in foreign currency rates could affect our financial results.

If our goodwill or intangible assets become impaired, it may adversely affect our financial condition and future results of operations.

As of December 31, 2017 we had approximately $25.4 million and $3.6 million of goodwill and intangible assets recorded on our balance sheet, primarily related to the TSA acquisition, that represent 0.9% of our total consolidated assets and 3.2% of our consolidated stockholders’ equity.  If we make additional acquisitions it is likely that we will record additional goodwill and intangible assets on our consolidated balance sheet.

In accordance with applicable accounting standards, we periodically evaluate our goodwill and other intangible assets to determine the recoverability of their carrying values.  Goodwill and other intangible assets with indefinite lives are tested for impairment at least annually.  Impairment testing requires us to make assumptions and judgments regarding the estimated fair value of our reporting units, including goodwill and other intangible assets (with indefinite lives).  Estimated fair values developed based on our assumptions and judgments might be significantly different if other reasonable assumptions and estimates were to be used.  If estimated fair values are less than the carrying values of the equity and other intangible assets with indefinite lives in future impairment tests, or if significant impairment indicators are noted relative to other intangible assets subject to amortization, we may be required to record significant impairment losses against future income.  Factors that may be considered a change in circumstances, indicating that the carrying value of the goodwill or amortizable intangible assets may not be recoverable, include reduced future cash flow estimates and slower growth rates in the industry.
 
Any future evaluations requiring an impairment of our goodwill and other intangible assets could adversely affect our results of operations and stockholders' equity in the period in which the impairment occurs.  A material decrease in stockholders' equity could, in turn, negatively impact our debt ratings or potentially impact our compliance with existing debt covenants.

In addition, the estimated value of our reporting units may be impacted as a result of the implementation of various Health Care Reform regulations.  Such regulations could have significant effects on our future operations, which in turn could unfavorably affect our ability to support the carrying value of certain goodwill and other intangible assets and result in significant impairment charges in future periods.  See “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations Critical Accounting Estimates Goodwill and Other Intangible Assets”.

The effectiveness of our Company’s strategy, talent management and alignment of talent to our business needs and risks to our brand and reputation present overarching risks our Company.

We expect to face significant business challenges and uncertainties in 2018. Effectiveness of our enterprise strategy, talent management and alignment of talent to our business needs and risks to our brand and reputation present overarching risks to our enterprise in 2018. There can be no assurance regarding the effectiveness of our enterprise strategy, our ability to manage and align our talent to our business needs or our ability to avoid harm to our brand and reputation. In addition, there can be no assurance that U.S. government fiscal policy, the implementation of the ACA, repeal or other changes to the ACA or additional changes to the U.S. health care system will not require us to revise the ways in which we conduct business, put us at risk of loss of business or materially adversely affect our business, cash flows, financial position or operating results.
 
Risks Relating to Taxation

If we are considered to be a controlled foreign corporation under the related person insurance income rules or a passive foreign investment company for United States federal income tax purposes, U.S. persons that own our shares of Class B common stock could be subject to adverse tax consequences.

We do not expect that we will be considered a controlled foreign corporation under the related person insurance income rules (a “RPII CFC”) for U.S. federal income tax purposes.  However, because RPII CFC status depends in part upon the correlation between an insurance company’s shareholders and such company’s insurance customers and the extent of such company’s insurance business outside its country of incorporation, there can be no assurance that we will not be a RPII CFC in any taxable year.  We do not intend to monitor whether we generate RPII or becomes a RPII CFC.

Based on our current business assets and operations, we do not expect that we will be considered a ‘‘passive foreign investment company’’ (a “PFIC”) for U.S. federal income tax purposes.  However, because PFIC status depends upon the composition of our income and assets and the market value of our assets (including, among others, less than 25 percent owned equity investments) in each year, which may be uncertain and may vary substantially over time, there can be no assurance that we will not be considered a PFIC for any taxable year.  Our belief that it is not a PFIC is based, in part, on the fact that the PFIC rules include provisions intended to provide an exception for bona fide insurance companies predominately engaged in an insurance business.  However, the scope of this exception is not entirely clear and there are no administrative pronouncements, judicial decisions or Treasury regulations that provide guidance as to the application of the PFIC rules to insurance companies.
 
If we were a RPII CFC in any taxable year or if the Company was treated as a PFIC for any taxable year, certain adverse consequences could apply to certain U.S. persons that own our shares of Class B common stock.

Legislative and other measures that may be taken by Puerto Rico governmental authorities could materially increase our tax burden.

In July 2015, Puerto Rico enacted legislation increasing the aggregate sales and use tax rate from 7% to 11.5% (10.5% payable to the Puerto Rico Department of the Treasury (the “Central Government SUT”) and 1% payable to the municipality (the “Municipal SUT”)) and imposing a 4% sales and use tax payable to the Puerto Rico Department of the Treasury on certain services previously covered by the business to business exemption and designated professional services. The increase from 7% to 11.5% became effective in July 1, 2015 and the 4% tax became effective October 1, 2015. Under the approved legislation the sales and use tax does not apply to Medicare and Medicaid services. Moreover, in light of Puerto Rico’s current fiscal and economic challenges, it is uncertain whether further tax-related legislation affecting the heath care or insurance industry may be enacted in an effort to increase Puerto Rico’s tax revenues.  Any increase in the amount of taxes we pay and the taxation of the customers we serve may have a material adverse effect to our financial condition, results of operations and cash flows.

Risks Relating to the Regulation of Our Industry

Changes in governmental regulations, or the application thereof, may adversely affect our business, financial condition and results of operations.

Our business is subject to substantial federal and local regulation and frequent changes to the applicable legislative and regulatory schemes, including general business regulations and laws relating to taxation, privacy, data protection, pricing, insurance, Medicare and health care fraud and abuse laws.  Please refer to “Item 1.   Business – Regulation”.  Changes in these laws, enactment of new laws or regulations, changes in interpretation of these laws or changes in enforcement of these laws and regulations may materially impact our business.  Such changes include without limitation:

initiatives to provide greater access to coverage for uninsured and under-insured populations without adequate funding to health plan or to be funded through taxes or other negative financial levy on health plans;

payments to health plans that are tied to achievement of certain quality performance measures and by health plans that do not satisfy applicable medical loss ratio requirements;

other efforts or specific legislative changes to the Medicare or Medicaid programs, including changes in the bidding process or other means of materially reducing premiums;

local government regulatory changes;

increased government enforcement, or changes in interpretation or application, of fraud and abuse and health information privacy laws; and

regulations that increase the operational burden on health plans that increase a health plan’s exposure to liabilities, including efforts to expand the tort liability of health plans.

Regulations promulgated by the Commissioner of Insurance, among other things, influence how our insurance subsidiaries conduct business and solicit subscriptions for shares of capital stock, and place limitations on investments and dividends.  Possible penalties for violations of such regulations include fines, orders to cease or change practices or behavior and possible suspension or termination of licenses.  The regulatory powers of the Commissioner of Insurance are designed to protect policyholders, not shareholders.  While we cannot predict the terms of future regulation, the enactment of new legislation could affect the cost or demand of insurance policies, limit our ability to obtain rate increases in those cases where rates are regulated, otherwise restrict our operations, limit the expansion of our business, expose us to expanded liability or impose additional compliance requirements.  In addition, we may incur additional operating expenses in order to comply with new legislation and may be required to revise the ways in which we conduct our business.
 
Future regulatory actions by the Commissioner of Insurance or other governmental agencies, including federal regulations, could have a material adverse effect on the profitability or marketability of our business, financial condition and results of operations, which in turn could impact the value of our business model and result in potential impairments of our goodwill and other intangible assets.

The health care reform law and the implementation of that law could have a material adverse effect on our business, financial condition, cash flows, or results of operations.

The ACA provides comprehensive changes to the U.S. health care system.  One key piece of the legislation imposes an annual insurance industry assessment, with increasing annual amounts based on premium growth, set to be $14.3 billion for 2018.  Such assessment may not be deductible for income tax purposes.  If the cost of the federal premium tax is not included in the calculation of our rates, or if we are unable to otherwise adjust our business model to address this new tax, our results of operations, financial position and liquidity may be materially adversely affected.

Also, health plans serving the individual market are subject to the guaranteed issue provisions under which the plans are required to issue coverage to individuals without regard to their health status of pre-existing conditions, which could lead to adverse selection by consumers.  On July 16, 2014, the Department of Health and Human Services sent a letter or the Commissioner of Insurance of Puerto Rico notifying that guarantee issue provisions under ACA are not applicable to U.S. territories. However, on July 22, 2013, similar guarantee issue and other market reforms provisions were enacted in Puerto Rico as part of amendments made to the Health Insurance Code of Puerto Rico. Although the Puerto Rico legislature is considering additional legislation to provide insurance companies more flexibility to comply with the additional requirements enacted in 2013, it is uncertain whether such legislation will in fact be enacted or the effect of any such additional legislation may have on our business. If we are unable to adapt our premium structure to address the guaranteed issue requirement, our results of operations, financial position and liquidity may be materially adversely affected.

In the years since its enactment, there have been, and continue to be, significant developments in, and continued legislative activity around, attempts to repeal or repeal and replace the ACA. For example, on October 12, 2017, President Trump signed an executive order requiring the implementation of regulations that would exempt certain association plans from complying with ACA requirements, easing restrictions on certain short-term health plans and health reimbursement arrangements and limiting hospital and insurance company consolidation while promoting competition and choice. Additionally, on January 22, 2018, President Trump signed a continuing resolution on appropriations for fiscal year 2018 that suspends the  implementation of the annual insurance industry assessment for tax year 2019. In February 2018 the Administration revealed a notice of proposed rulemaking to support short term, limited duration scope policies, and additional activity related to the individual market is anticipated through state waivers.  While Congress is no longer actively seeking to repeal and replace the ACA, additional changes are expected this year, largely through Administrative Actions.
 
As part of the emergency supplemental legislation passed by Congress, Puerto Rico’s Medicaid spending cliff has been addressed for at least the next two years, because of the approval of $4.8 billion in Medicaid Funding.  This action will bring financial stability to Puerto Rico’s Medicaid program, and funding conditions related to compliance with program management standards will further promote stability and predictability. Although we believe this legislation, together with the ACA, may provide us with significant opportunities to grow our business, the  implementation of enacted reforms, such as the continued cuts in the effective Medicare Advantage rates applicable to our plans, as well as future regulations and legislative changes, may in fact have a material adverse effect on our results of operations, financial position or liquidity.  If we fail to effectively implement our operational and strategic initiatives with respect to the implementation of health care reform, or do not do so as effectively as our competitors, our business may be materially adversely affected.
 
As a Medicare Advantage program participant, we are subject to complex regulations.  If we fail to comply with these regulations, we may be exposed to criminal sanctions and significant civil penalties, and our Medicare Advantage contracts may be terminated or our operations may be required to change in a manner that has a material impact on our business.

The laws and regulations governing Medicare Advantage program participants are complex, subject to interpretation and frequent change and can expose us to penalties for non-compliance.  If we fail to comply with these laws and regulations, we could be subject to criminal fines, civil penalties or other sanctions, including the termination of our Medicare Advantage contracts.  In addition, maintaining compliance with such laws and regulations as they change may, in some cases, entail substantial direct costs.

Under CMS regulations to implement certain ACA requirements that became effective on June 1, 2012, CMS has the authority not to renew our contracts beginning in 2015 based solely on the Star Ratings of our Medicare Advantage plans if their respective ratings do not achieve three or more stars (out of 5.0 stars) for three consecutive contract years.  See the subcaption “Federal Regulation” in Item 1 of this annual report on Form 10-K for detailed information of the Stars Ratings. In the final call letter to Medicare Advantage organizations dated April 6, 2015, CMS stated that it would not delay contract terminations based on a plan’s Star Ratings.

Historically, the TSA plans have received annual Star Ratings of three or more stars.  CMS provides a quality bonus to plans with Star Ratings of 3.5 or more. As of December 31, 2017, TSA’s HMO plan achieved 4.0 overall on a 5.0 star rating system, and achieved 4.5 stars in Part D and TSA’s PPO plan maintained its 3.5 stars and achieved 5.0 stars in Part D .

The Company is subject, and will likely continue to be subject, to audits from CMS in connection with the Medicare Advantage contracts. CMS audit may review the effectiveness of multiple matters, including the performance of the benefit administration, coverage determinations, process of appeals and grievances, dismissals, oversight of agents and brokers, and enrollment process.  CMS may impose civil monetary penalties as a result of their findings or require changes to our business practices that may adversely affect our profitability. CMS may also terminate any of our Medicare Advantage contracts if it determines that any of these plans have failed to substantially carry out the contract or is carrying out the contract in a manner that is inconsistent with the efficient or effective administration of the Medicare Advantage program.  Compliance with CMS requirements may require us to divert resources that may affect the results of our operations and financial condition. Any termination or non-renewal of our Medicare Advantage plans would have a material adverse effect on our business and financial results.

We may be subject to government audits, regulatory proceedings or investigative actions, which may find that our policies, procedures, practices or contracts are not compliant with, or are in violation of, applicable healthcare regulations.

Federal, Puerto Rico, and Costa Rica government authorities, including but not limited to the Commissioner of Insurance, ASES, CMS, the OIG, the Office of the Civil Rights of HHS, the U.S. Department of Justice, the U.S. Department of Labor, and the OPM, regularly make inquiries and conduct audits concerning our compliance with applicable insurance and other laws and regulations.  In addition, beginning in Medicare contract year 2016, CMS will have the right to require Medicare Advantage plan sponsors such as us to hire an independent auditor, working in accordance with CMS specifications, to validate if the deficiencies that were found during a CMS full or partial program audit have been corrected and provide CMS with a copy of the audit findings.   If, in the future, we were required by CMS to hire an independent auditor, such audit would entail direct costs to us, in addition to potential penalties in the event of negative audit findings.  We may also become the subject of non-routine regulatory or other investigations or proceedings brought by these or other authorities, and our compliance with and interpretation of applicable laws and regulations may be challenged.  In addition, our regulatory compliance may also be challenged by private citizens under the “whistleblower provisions” of applicable laws.  The defense of any such challenge could result in substantial cost, diversion of resources, and a possible material adverse effect on our business.

An adverse action could result in one or more of the following:

recoupment of amounts we have been paid pursuant to our government contracts;
 
mandated changes in our business practices;

imposition of significant civil or criminal penalties, fines or other sanctions on us and/or our key employees;

additional reporting requirements and oversight and mandated corrective action or remediation plans;

loss or non-renewal of our government contracts or loss of our ability to participate in Medicare or other federal or local governmental payor programs; damage to our reputation;

increased difficulty in marketing our products and services;

inability to obtain approval for future services or geographic expansions; and

loss of one or more of our licenses to act as an insurance company, preferred provider or managed care organization or other licensed entity or to otherwise provide a service.

Our failure to maintain an effective corporate compliance program may increase our exposure to civil damages and penalties, criminal sanctions and administrative remedies, such as program exclusion, resulting from an adverse review.  Any adverse review, audit or investigation could reduce our revenue and profitability and otherwise adversely affect our operating results.

Effective prevention, detection and control systems are critical to maintain regulatory compliance and prevent fraud and failure of these systems could adversely affect the Company.

Failure to prevent, detect or control systems related to regulatory compliance or the failure of employees to comply with our internal policies, including data systems security or unethical conduct by managers and employees, could adversely affect our reputation and also expose it to litigation and other proceedings, fines and penalties.  Federal and state governments have made investigating and prosecuting health care and other insurance fraud and abuse a priority.  Fraud and abuse prohibitions encompass a wide range of activities, including kickbacks for referral of members, billing for unnecessary medical services, improper marketing, and violations of patient privacy rights.  The regulations and contractual requirements applicable to the Company are complex and subject to change.  In addition, ongoing vigorous law enforcement, a highly technical regulatory scheme and the Dodd-Frank legislation and related regulations being adopted that enhance regulators’ enforcement powers and whistleblower incentives and protections, mean that its compliance efforts in this area will continue to require significant resources.

In addition, provider or member fraud that is not prevented or detected could impact our medical costs or those of our self-insured customers.  Further, during an economic downturn, our segments, including our Life Insurance and Property and Casualty segments may see increased fraudulent claims volume which may lead to additional costs because of an increase in disputed claims and litigation.

If we fail to comply with applicable privacy and security laws, regulations and standards, including with respect to third-party service providers that utilize sensitive personal information on our behalf, or if we fail to address emerging security threats or detect and prevent privacy and security incidents, our business, reputation, results of operations, financial position and cash flows could be materially and adversely affected.

The collection, maintenance, protection, use, transmission, disclosure and disposal of sensitive personal information are regulated at the federal, state, international and industry levels and requirements are imposed on us by contracts with customers.  HIPAA regulations also provide access rights and other rights for health plan beneficiaries with respect to their health information.  These regulations include standards for certain electronic transactions, including encounter and claims information, health plan eligibility and payment information.  Health plans are also subject to beneficiary notification and remediation obligations in the event of an authorized use or disclosure of personal health information.  HIPAA also requires business associates as well as covered entities to comply with certain privacy and security requirements.  Even though we provide for appropriate protections through our contracts with our third-party service providers and in certain cases assess their security controls, we still have limited oversight or control over their actions and practices.

Our facilities and systems and those of our third-party service providers may be vulnerable to privacy and security incidents; security attacks and breaches; acts of vandalism or theft; computer viruses; coordinated attacks by activist entities; emerging cybersecurity risks; misplaced or lost data; programming and/or human errors; or other similar events. Emerging and advanced security threats, including coordinated attacks, require additional layers of security which may disrupt or impact efficiency of operations.
 
Compliance with new privacy and security laws, regulations and requirements may result in increased operating costs, and may constrain our ability to manage our business model. In addition, HHS has expanded its HIPAA audit program to assess compliance efforts not only by covered entities, but also business associates.  Although we are not aware of HHS plans to audit any of our covered entities or business associates, an audit resulting in findings or allegations of non-compliance could have a material adverse effect on our results of operations, financial position and cash flows.   We are also subject to Puerto Rico Act No. 194 of August 25, 2000, also known as the Patient’s Rights and Responsibilities Act, including provisions more stringent than HIPAA.  There is uncertainty regarding many aspects of such state requirements which make compliance with applicable health information laws more difficult.  For these reasons, our total compliance costs may increase in the future.

We are subject, and will likely continue to be subject, to regulatory audits and investigations relating to our compliance with HIPAA and other related privacy requirements. On November 20, 2015, we entered into a resolution agreement with the HHS Office of Civil Rights (“OCR”), (the “Resolution Agreement”) to settle all incidents being investigated by OCR up to the date of execution of the Resolution Agreement.  As part of the Resolution Agreement, the Company agreed to pay $3.5 million, without admitting liability, implement a three year corrective action plan, and comply with other terms and conditions.  The foregoing summary of the terms and conditions of the Settlement Agreement is subject to, and qualified in its entirety by the full text of the Settlement Agreement included as Exhibit 10.24 filed with this Annual Report on Form 10-K.   Also, on November 20, 2015, we entered into a settlement agreement with ASES (the “ASES Settlement Agreement”) in connection with privacy incidents relating to beneficiaries of the government health plan up to the execution of the ASES Settlement Agreement. As part of the ASES Settlement Agreement, the Company did not admit any liability and agreed to pay ASES $1.5 million in full accord and satisfaction and settlement of any and all reported incidents. The foregoing summary of the terms and conditions of the ASES Settlement Agreement is subject to, and qualified in its entirety by the full text of the ASES Settlement Agreement included as Exhibit 10.23 filed with this Annual Report on Form 10-K.

Non-compliance or findings of non-compliance with applicable laws, regulations or requirements, or the occurrence of any privacy or security breach involving the misappropriation, loss or other unauthorized disclosure of sensitive personal information, whether by us or by one of our third-party service providers, could have a material adverse effect on our reputation and business, including mandatory disclosure to the media, significant increases in the cost of managing and remediating privacy or security incidents and material fines, penalties and litigation awards, among other consequences, any of which could have a material and adverse effect on our results of operations, financial position and cash flows.
 
The revised rate calculation system for Medicare Advantage, the payment system for the Medicare Part D and changes in the methodology and payment policies used by CMS to establish rates could reduce our profitability and the benefits we offer our beneficiaries.
 
Medicare Advantage managed care plans are paid based off a CMS-calculated “benchmark” amount, and plans submit competitive bids that reflect the costs they expect to incur in providing the base Medicare benefits.  A Medicare Advantage plan’s actual payment rate is based on a complex statutory formula that takes into account a number of factors, including the relationship between the plan’s bid and the benchmark.  In addition, under the ACA, Medicare Advantage plan payment rates were subject to transitionally phased in reductions intended to bring Medicare Advantage rates more in line with Medicare fee-for-service rates, which was fully phased in 2017.  Medicare generally will rebate a portion of the amount by which the benchmark amount exceeded the accepted bid for certain plans. For plans achieving star rating of at least 3.5 stars, the portion of the savings retained by the plan is higher.  For plans achieving star ratings of at least 4 stars, the starting benchmark amount from which the savings is computed is also higher (a “quality bonus”).  If the bid is greater than the benchmark, the plan will be required to charge a premium to enrollees equal to the difference between the bid and the benchmark, which could affect our ability to attract enrollees.  CMS reviews the methodology and assumptions used in bidding with respect to medical and administrative costs, profitability and other factors.  CMS could challenge such methodology or assumptions or seek to cap or limit plan profitability.  CMS also could administratively seek to implement certain methodological changes to the Medicare Advantage rate calculations that could result in functionally lower payment rates, and may have a material adverse effect on our revenue, financial position, results of operations or cash flow .
 
We also face the risk of reduced or insufficient government funding and we may need to terminate our Medicare Advantage contracts with respect to unprofitable markets, which may have a material adverse effect on our financial position, results of operations or cash flows.  In addition, as a result of the competitive bidding process, our ability to participate in the Medicare Advantage program is affected by the pricing and design of our competitors’ bids.  Moreover, we may in the future be required to reduce benefits or charge our members an additional premium in order to maintain our current level of profitability, either of which could make our health plans less attractive to members and adversely affect our membership.
 
In February 2018, CMS released its draft Advance Notice and Call Letter for Medicare Advantage reimbursement in 2019.  This draft notice contains a number of provisions that will have a significant effect on the operations of Puerto Rico’s MA program.  These proposals include provisions that may increase certain payments made to plans in Puerto Rico, but is also silent in key critical issues that if no action is taken could result in lower payments for Puerto Rico Medicare Advantage Organizations (MAO).  The draft call letter does not adequately address problems with the benchmark and payment disparity for Puerto Rico counties.  In addition, the draft letter does not commit to including the zero claims adjustment, embedded in the past two years, creating more uncertainty over actual payment rate changes for 2019.  The call letter will be finalized in early April.  Until then, it is uncertain whether any of CMS’s proposals will be implemented or, if implemented, the effect in our Medicare Advantage business.
 
CMS’s risk adjustment payment system and other Medicare Advantage funding pressures make our revenue and profitability difficult to predict and could result in material retroactive adjustments to our results of operations.
 
CMS has implemented a risk adjustment payment system for Medicare Advantage plans to improve the accuracy of payments and establish incentives for such plans to enroll and treat less healthy Medicare beneficiaries.  The risk adjusted premiums we receive are based on claims and encounter data that we submit to CMS within prescribed deadlines.  We develop our estimates for risk-adjusted premiums utilizing historical experience, or other data, and predictive models as sufficient member risk score data becomes available over the course of each CMS plan year. We recognize periodic changes to risk-adjusted premiums as revenue when the amounts are determinable and collection is reasonably assured, which are possible as additional diagnosis code information is reported to CMS, when the ultimate adjustment settlements are received from CMS, or we receive notification of such settlement amounts. CMS adjusts premiums on two separate occasions on a retrospective basis. The first retrospective adjustment for a given plan year generally occurs during the third quarter of that year. This initial settlement represents the update of risk scores for the current plan year based on the severity of claims incurred in the prior plan year. CMS then issues a final retrospective risk adjusted premium settlement for that plan year in the following year.  The data provided to CMS to determine members’ risk scores is subject to audit by CMS even after the annual settlements occur, which may result in the refund of premiums to CMS.  The result of these audits could materially reduce premium revenue in the year in which CMS determines a refund is required and could be material to our result of operations, financial position and cash flows.
 
CMS is making significant changes to the manner in which it determines risk adjustment payments, including introducing a new model for 2019 and continue to shift towards encounter based risk scores (ESD).  As a result of the risk adjustment process and CMS’s ability to modify the manner in which it applies such risk adjustments, it is difficult to predict with certainty our future revenue or profitability.  In addition, our own risk scores for any period may result in favorable or unfavorable adjustment to payment from CMS and our Medicare payment revenue.
 
Finally, we generally rely on providers, including certain network providers who are our employees, to appropriately document all medical data, including the diagnosis codes submitted with claims, as the basis for our risk scores under the program.  Thus, our ability to meet our premium revenue estimates depends largely on the success of third party efforts to collect and properly reflect medical data, including diagnosis codes that must be submitted with claims.  There is no assurance that our providers will be successful in accurately collecting such medical data and diagnosis codes and, to the extent their efforts are not successful, such failure may have a material adverse effect on our premium revenues.
 
If during the open enrollment season our Medicare Advantage members enroll in another Medicare Advantage plan, they will be automatically disenrolled from our plan, possibly without our immediate knowledge.

Pursuant to the MMA, members enrolled in one insurer’s Medicare Advantage program will be automatically disenrolled from that program if they enroll in another insurer’s Medicare Advantage program.  If our members enroll in another insurer’s Medicare Advantage program we may not discover that such member has been disenrolled from our program until such time as we fail to receive reimbursement from CMS in respect of such member, which may occur sometime after the disenrollment.  As a result, we may discover that a member has disenrolled from our program after we have already provided services to such individual.  Our profitability would be reduced as a result of such failure to receive payment from CMS if we had made related payments to providers and were unable to recoup such payments from them.
 
Medicare and Medicaid spending by the federal government could be decreased as part of the spending cuts associated with the debt ceiling.
 
The Sequestration Transparency Act of 2012 (P.L. 112-155) requires the President of the United States to submit to Congress a report on the potential sequestration triggered by the failure of the Joint Selective Committee on Deficit Reduction to propose, and Congress to enact, a plan to reduce the deficit by $1.2 trillion, as required by the Budget Control Act of 2011. Under the sequestration, automatic spending cuts became effective beginning April 1, 2013, and, following passage of the Bipartisan Budget Act of 2015, these cuts have been extended through at least 2025 unless additional Congressional action is taken.  This resulted in cuts of 2% to Medicare funding.  Medicaid programs are not subject to automatic spending cuts. In addition, in January 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several categories of healthcare providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.
 
We cannot predict whether Congress will take any action to change the automatic spending cuts.  Further, we cannot predict how states will react to any changes that occur at the federal level.
 
If we are deemed to have violated the insurance company change of control statutes in Puerto Rico, we may suffer adverse consequences.

We are subject to change of control statutes applicable to insurance companies.  These statutes regulate, among other things, the acquisition of control of an insurance company or a holding company of an insurance company.  Under these statutes, no person may make an offer to acquire or to sell the issued and outstanding voting stock of an insurance company, which constitutes 10% or more of the issued and outstanding stock of an insurance company, or of the total stock issued and outstanding of a holding company of an insurance company, or solicit or receive funds in exchange for the issuance of new shares of the holding company’s or its insurance subsidiaries’ capital stock, without the prior approval of the Commissioner of Insurance.  Our amended and restated articles of incorporation (the articles) prohibit any institutional investor from owning 10% or more of our voting power and any person that is not an institutional investor from owning 5% or more of our voting power.  We cannot, however, assure you that ownership of our securities will remain below these thresholds.  To the extent that a person, including an institutional investor, acquires shares in excess of these limits, our articles provide for the Company to take certain actions, including refusing to give effect to a transfer or instituting proceedings to enjoin or rescind a transfer, in order to avoid a violation of the ownership limitation in the articles.  If the Commissioner of Insurance determines that a change of control has occurred, we could be subject to fines and penalties, and in some instances the Commissioner of Insurance would have the discretion to revoke our operating licenses.

We are also subject to change of control limitations pursuant to our BCBSA license agreements.  The BCBSA ownership limits restrict beneficial ownership of our voting capital stock to less than 10% for an institutional investor and less than 5% for a non-institutional investor, both as defined in our articles.  In addition, no person may beneficially own shares of our common stock or other equity securities, or a combination thereof, representing a 20% or more ownership interest, whether voting or non-voting, in our company.  This provision in our articles cannot be changed without the prior approval of the BCBSA and the vote of holders of at least 75% of our common stock.

Our insurance subsidiaries are subject to minimum capital requirements.  Our failure to meet these standards could subject us to regulatory actions.

Puerto Rico insurance laws and the regulations promulgated by the Commissioner of Insurance, among other things, require insurance companies to maintain certain levels of capital, thereby restricting the amount of earnings that can be distributed by our insurance subsidiaries to us.  Although we are currently in compliance with these requirements, there can be no assurance that we will continue to comply in the future.  Failure to maintain required levels of capital or to otherwise comply with the reporting requirements of the Commissioner of Insurance could subject our insurance subsidiaries to corrective action, including government supervision or liquidation, or require us to provide financial assistance, either through subordinated loans or capital infusions, to our subsidiaries to ensure they maintain their minimum statutory capital requirements.

We are also subject to minimum capital requirements pursuant to our BCBSA license agreements.  See “Risks Related to Our Business The termination or modification of our license agreements to use the BCBS name and mark could have a material adverse effect on our business, financial condition and results of operations.”
 
Puerto Rico insurance laws and regulations and provisions of our articles and bylaws could delay, deter or prevent a takeover attempt that shareholders might consider to be in their best interests and may make it more difficult to replace members of our board of directors and have the effect of entrenching management.

Puerto Rico insurance laws and the regulations promulgated thereunder, and our articles and bylaws may delay, defer, prevent or render more difficult a takeover attempt that our shareholders might consider to be in their best interests.  For instance, they may prevent our shareholders from receiving the benefit from any premium to the market price of our common stock offered by a bidder in a takeover context.  Even in the absence of a takeover attempt, the existence of these provisions may adversely affect the prevailing market price of our common stock if they are viewed as discouraging takeover attempts in the future.

Our license agreements with the BCBSA require that our articles contain certain provisions, including ownership limitations. See “Risks Relating to the Regulation of Our Industry If we are deemed to have violated the insurance company change of control statutes in Puerto Rico, we may suffer adverse consequences.”

Our articles and bylaws have anti-takeover effects and may delay, defer or prevent a takeover attempt that our shareholders might consider to be in their best interests.  In particular, our articles and bylaws:

permit our board of directors to issue one or more series of preferred stock;

divide our board of directors into three classes serving staggered three-year terms;

limit the ability of shareholders to remove directors;

impose restrictions on shareholders’ ability to fill vacancies on our board of directors;

impose advance notice requirements for shareholder proposals and nominations of directors to be considered at meetings of shareholders; and

impose restrictions on shareholders’ ability to amend our articles and bylaws.

See also “Risks Relating to the Regulation of Our Industry If we are deemed to have violated the insurance company change of control statutes in Puerto Rico, we may suffer adverse consequences.”

Puerto Rico insurance laws and the regulations promulgated by the Commissioner of Insurance may also delay, defer, prevent or render more difficult a takeover attempt that our shareholders might consider to be in their best interests.  For instance, the Commissioner of Insurance must review any merger, consolidation or new issue of shares of capital stock of an insurer or its parent company and make a determination as to the fairness of the transaction.  Also, a director of an insurer must meet certain requirements imposed by Puerto Rico insurance laws.

These voting and other restrictions may operate to make it more difficult to replace members of our board of directors and may have the effect of entrenching management regardless of their performance.
 
Item 1B.
Unresolved Staff Comments

None.

Item 2.
Properties

We own a seven story building located at 1441 F.D. Roosevelt Avenue, in San Juan, Puerto Rico, and two adjacent buildings, as well as the adjoining parking lot, which is mainly used by the Managed Care segment.  In addition, we own five floors of a fifteen-story building located at 1510 F.D. Roosevelt Avenue, in Guaynabo, Puerto Rico, which is mainly used by the Property and Casualty segment.  We also own land and a multi-segment customer service center in the municipalities of Mayagüez and Ponce, Puerto Rico.  In addition to the properties described above, we or our subsidiaries are parties to operating leases that are entered into in the ordinary course of business.  Through a health clinic in which we have a controlling interest, we own land and a two-story medical facility in the municipality of Bayamón, Puerto Rico.  These properties are subject to liens under our credit facilities. In connection with our entrance to the Costa Rican market, we acquired a two-story building located in the city of San José, Costa Rica, which is used by the Life Insurance segment. See “Item 7—Management’s Discussion and Analysis of Financial Condition and Results of Operation – Liquidity and Capital Resources”.

We believe that our facilities are in good condition and that the facilities, together with capital improvements and additions currently underway, are adequate to meet our operating needs for the foreseeable future.  The need for expansion, upgrading and refurbishment of facilities is continually evaluated in order to keep facilities aligned with planned business growth and corporate strategy.

Item 3.
Legal Proceedings

Our business is subject to numerous laws and regulations promulgated by Federal, Puerto Rico, U.S. Virgin Islands, Costa Rica, British Virgin Islands, and Anguilla governmental authorities. Compliance with these laws and regulations can be subject to government review and interpretation, as well as regulatory actions unknown and unasserted at this time. The Commissioner of Insurance of Puerto Rico, as well as other Federal, Puerto Rico, U.S. Virgin Islands, Costa Rica, British Virgin Islands, and Anguilla government authorities, regularly make inquiries and conduct audits concerning the Company's compliance with such laws and regulations. Penalties associated with violations of these laws and regulations may include significant fines and exclusion from participating in certain publicly funded programs and may require the Company to comply with corrective action plans or changes in our practices.  For a description of our legal proceedings, see Note 23, Contingencies , of the Notes to Consolidated Financial Statements, included in Item 8, Financial Statements and Supplementary Data , of this Annual Report on Form 10-K.

Item 4.
Mine Safety Disclosures

None.
 
Part II

Item 5.
Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Market Information

Our Class B common stock is listed and began trading on the NYSE on December 7, 2007 under the trading symbol “GTS”.  Prior to this date our Class B common stock had no established public trading market.  There is no established public trading market for our Class A common stock.

The following table presents high and low closing prices of our Class B common stock for each quarter of the years ended December 31:
 
   
High
   
Low
 
2017
           
First quarter
 
$
21.47
   
$
16.60
 
Second quarter
   
18.62
     
16.09
 
Third quarter
   
24.71
     
15.16
 
Fourth quarter
   
28.87
     
23.37
 
2016
               
First quarter
 
$
26.83
   
$
19.99
 
Second quarter
   
27.50
     
21.60
 
Third quarter
   
26.55
     
21.51
 
Fourth quarter
   
23.68
     
19.00
 
 
On February 26, 2018 the closing price of our Class B common stock on the NYSE was $25.29.

Holders

As of February 26, 2018, there were 950,968 and 22,358,325 shares of Class A and Class B common Stock outstanding, respectively.  The number of our holders of Class A common stock as of February 26, 2018 was approximately 772.  The number of our holders of Class B common stock as of February 26, 2018 was approximately 4,200.

Dividends

Subject to the limitations under Puerto Rico corporation law and any preferential dividend rights of outstanding preferred stock, of which there is currently none outstanding, holders of common stock are entitled to receive their pro rata share of such dividends or other distributions as may be declared by our board of directors out of funds legally available therefore.

Our ability to pay dividends is dependent on cash dividends from our subsidiaries.  Our subsidiaries are subject to regulatory surplus requirements and additional regulatory requirements, which may restrict their ability to declare and pay dividends or distributions to us.  In addition, our secured term loan restricts our ability to pay dividends if a default thereunder has occurred and is continuing.  Please refer to “Item 7.   Management’s Discussion and Analysis of Financial Condition and Results of Operations – Liquidity and Capital Resources – Restriction on Certain Payments by the Corporation’s Subsidiaries”.  Also, see Note 17, Stockholders’ Equity, of the Notes to Consolidated Financial Statements, included in Item 8, Financial Statements and Supplementary Data , of this Annual Report on Form 10-K.
 
We did not declare any dividends during the two most recent fiscal years and do not expect to pay any cash dividends in the near future.  We currently intend to retain future earnings, if any, to finance operations and expand our business.  The ultimate decision to pay a dividend, however, remains within the discretion of our board of directors and may be affected by various factors, including our earnings, financial condition, capital requirements, level of indebtedness, statutory and contractual limitations and other considerations our board of directors deems relevant.
 
Securities Authorized for Issuance Under Equity Compensation Plan

See Note 20, Share-Based Compensation, of the Notes to Consolidated Financial Statements, included in Item 8, Financial Statements and Supplementary Data , of this Annual Report on Form 10-K.

Performance Graph

The following graph compares the price performance of our Class B common stock for the period from January 1, 2012 through December 31, 2017, with the price performance over such period of (i) the Standard and Poor’s 500 Stock Index (the “S&P 500 Index”) and (ii) the Standard & Poor’s 500 Managed Health Care Index (the “S&P MHC Index”).  The comparison assumes an investment of $100 on January 1, 2012 in each of our Class B common stock, the S&P 500 Index, and the S&P MHC Index.  The performance graph is not necessarily indicative of future performance.

The comparisons shown in the graph are based on historical data and the Corporation cautions that the stock price in the graph below is not indicative of, and is not intended to forecast, the potential future performance of our Class B common stock.  Information used in the preparation of the graph was obtained from Bloomberg; a source we believe to be reliable, however, the Corporation is not responsible for any errors or omissions in such information.

 
Ticker
Name
 
1/2/2013
   
12/31/2013
   
12/31/2014
   
12/31/2015
   
12/31/2016
   
12/31/2017
 
GTS US Equity
TRIPLE-S MANAGEMENT CORP
   
100.00
     
100.31
     
123.37
     
123.37
     
106.81
     
128.22
 
SPX Index
S&P 500 INDEX
   
100.00
     
126.39
     
140.79
     
139.76
     
153.09
     
182.82
 
S5MANH Index
S&P MHC Index
   
100.00
     
144.98
     
191.26
     
230.34
     
271.88
     
387.22
 
 
Recent Sales of Unregistered Securities

Not applicable.
 
Purchases of Equity Securities by the Issuer

The following table presents information related to our repurchases of common stock for the period indicated:
 
(Dollar amounts in millions, except per share data)
 
Total Number
of Shares
Purchased
   
Average
Price
Paid per
Share
   
Total Number of
Shares
Purchased as
Part of Publicly
Announced
Programs ¹
   
Approximate
Dollar Value of
Shares that May
Yet Be Purchased
Under the
Programs
 
October 1, 2017 to October 31, 2017
   
310,481
   
$
23.79
     
310,481
   
$
10.0
 
November 1, 2017 to November 30, 2017
   
11,900
     
23.95
     
11,900
     
9.8
 
December 1, 2017 to December 31, 2017
   
-
     
-
     
-
     
9.8
 
 
¹  In August 2017 the Company's Board of Directors authorized a $30.0 million Share Repurchase Program of its Class B common stock.
 
Item 6.
Selected Financial Data

Statement of Earnings Data
 
   
2017
   
2016
   
2015
   
2014
   
2013
 
(Dollar amounts in millions, except per share data)
                             
                               
Years ended December 31,
                             
Premiums earned, net
 
$
2,826.9
   
$
2,890.6
   
$
2,783.2
   
$
2,128.6
   
$
2,203.0
 
Administrative service fees
   
16.5
     
17.9
     
44.7
     
119.3
     
108.7
 
Net investment income
   
51.6
     
48.9
     
45.2
     
47.5
     
47.3
 
Other operating revenues
   
3.7
     
3.5
     
3.7
     
4.2
     
4.8
 
Total operating revenues
   
2,898.7
     
2,960.9
     
2,876.8
     
2,299.6
     
2,363.8
 
Net realized investments gains
   
10.8
     
17.4
     
18.9
     
18.2
     
2.6
 
Other income, net
   
6.6
     
6.5
     
7.0
     
2.3
     
15.3
 
Total revenues
   
2,916.1
     
2,984.8
     
2,902.7
     
2,320.1
     
2,381.7
 
Benefits and expenses:
                                       
Claims incurred
   
2,353.1
     
2,472.2
     
2,318.7
     
1,747.6
     
1,836.2
 
Operating expenses
   
477.2
     
493.9
     
518.7
     
497.2
     
478.2
 
Total operating costs
   
2,830.3
     
2,966.1
     
2,837.4
     
2,244.8
     
2,314.4
 
Interest expense
   
6.8
     
7.6
     
8.2
     
9.3
     
9.5
 
Total benefits and expenses
   
2,837.1
     
2,973.7
     
2,845.6
     
2,254.1
     
2,323.9
 
Income before taxes
   
79.0
     
11.1
     
57.1
     
66.0
     
57.8
 
Income tax expense (benefit)
   
24.5
     
(6.3
)
   
5.1
     
0.7
     
2.3
 
Net income
   
54.5
     
17.4
     
52.0
     
65.3
     
55.5
 
Net loss attributable to non-controlling interest
   
-
     
-
     
(0.1
)
   
(0.4
)
   
(0.4
)
Net income attributable to TSM
 
$
54.5
   
$
17.4
   
$
52.1
   
$
65.7
   
$
55.9
 
Basic net income per share (1):
 
$
2.27
   
$
0.71
   
$
2.03
   
$
2.42
   
$
2.02
 
                                         
Diluted net income per share:
 
$
2.26
   
$
0.71
   
$
2.02
   
$
2.41
   
$
2.01
 
 
Balance Sheet Data
 
   
2017
   
2016
   
2015
   
2014
   
2013
 
                               
Years ended December 31,
                             
Cash and cash equivalents
 
$
198.9
   
$
103.4
   
$
197.8
   
$
110.0
   
$
74.4
 
                                         
Total assets
 
$
3,116.8
   
$
2,219.0
   
$
2,206.1
   
$
2,145.7
   
$
2,047.6
 
                                         
Long-term borrowings
 
$
32.1
   
$
35.1
   
$
36.8
   
$
74.5
   
$
89.3
 
                                         
Total stockholders' equity
 
$
913.4
   
$
863.2
   
$
847.5
   
$
858.6
   
$
785.4
 
 
Additional Managed Care Data (2)
 
 
 
2017
   
2016
   
2015
   
2014
   
2013
 
                               
Years ended December 31,
                             
Medical loss ratio
   
85.6
%
   
88.6
%
   
86.2
%
   
85.9
%
   
86.7
%
                                         
Operating expense ratio
   
13.6
%
   
14.0
%
   
15.1
%
   
18.5
%
   
17.0
%
                                         
Medical membership (period end)
   
977,939
     
1,017,372
     
1,094,444
     
2,139,484
     
2,187,939
 
 
(1)
Further details of the calculation of basic and diluted earnings per share are set forth in Notes 2 and 21 of the audited consolidated financial statements for the years ended December 31, 2017, 2016 and 2015.

(2)
Does not reflect inter-segment eliminations.

Item 7.
Management’s Discussion and Analysis of Financial Condition and Results of Operations

This financial discussion contains an analysis of our consolidated financial position and financial performance as of December 31, 2017 and 2016, and consolidated results of operations for 2017, 2016 and 2015.  References to the terms "we", "our" or "us" used throughout this Management's Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”), refer to TSM and unless the context otherwise requires, its direct and indirect subsidiaries.  This analysis should be read in its entirety and in conjunction with the consolidated financial statements, notes and tables included elsewhere in this Annual Report on Form 10-K.

The structure of our MD&A is as follows:
 
I. Overview
59
   
II. Membership
62
   
III. Results of Operations
63
   
Consolidated Operating Results
63
   
Managed Care Operating Results
66
   
Life Insurance Operating Results
69
   
Property and Casualty Insurance Operating Results
70
   
IV. Liquidity and Capital Resources
72
   
V. Critical Accounting Estimates
76
   
VI. Recently Issued Accounting Standards
85
 
I. Overview

We are one of the most significant players in the managed care industry in Puerto Rico and have over 55 years of experience in this industry.  We offer a broad portfolio of managed care and related products in the Commercial, Medicaid and Medicare Advantage markets.  In the Commercial market we offer products to corporate accounts, U.S. federal government employees, local government employees, individual accounts and Medicare Supplement.  We also participate in the Government of Puerto Rico Health Reform (a managed care program for the medically indigent funded by the Puerto Rico and U.S. federal governments that is similar to the Medicaid program in the U.S.) (Medicaid).  The Island is divided in eight regions and we served all of them on an administrative service only basis (ASO) until March 31, 2015.  Effective April 1, 2015, the government changed the Medicaid delivery model from an ASO to a risk-based model and we elected to participate as a fully-insured provider in only two regions of Puerto Rico.

We have the exclusive right to use the BCBS name and mark throughout Puerto Rico, the U.S. Virgin Islands, Costa Rica, the British Virgin Islands and Anguilla.  As of December 31, 2017 we serve approximately 978,000 members across all regions of Puerto Rico.  For the years ended December 31, 2017 and 2016 respectively, our managed care segment represented approximately 92% of our total consolidated premiums earned, net.  We also participate in the life insurance and property and casualty insurance markets in Puerto Rico.

We participate in the managed care market through our subsidiaries, TSS, TSB and TSA.  TSS, TSA and TSB are BCBSA licensees.

We participate in the life insurance market through our subsidiary, TSV, and in the property and casualty insurance market through our subsidiary, TSP.

The Commissioner of Insurance of the Government of Puerto Rico (“Commissioner of Insurance of Puerto Rico”) recognizes only statutory accounting practices for determining and reporting the financial condition and results of operations of an insurance company, for determining its solvency under the Puerto Rico insurance laws, and for determining whether its financial condition warrants the payment of a dividend to its stockholders.  No consideration is given by the Commissioner of Insurance of Puerto Rico to financial statements prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) in making such determinations.  See Note 24, Statutory Accounting, of the Notes to Consolidated Financial Statements, included in Item 8, Financial Statements and Supplementary Data , of this Annual Report on Form 10-K.

2017 Consolidated Highlights

Key developments in our business during 2017 are described below:

·
Consolidated premiums earned, net decreased 2.2% year over year, to $2.8 billion, primarily reflecting lower Managed Care and Property and Casualty premiums.

·
The lower Managed Care premiums reflect lower membership in the segment’s Medicaid and Commercial businesses, the impact of the suspension of the HIP fee pass through in 2017, and lower Medicare additional risk score revenue.  These decreases were partially offset by higher average premium rates in the Commercial and Medicaid businesses, as well as by higher Medicare membership.

·
Consolidated claims for the year were $2.4 billion, down 4.8% over last year, primarily reflecting lower Managed Care membership, the ongoing improvement in our managed care operations, and the estimated decrease in the utilization of Managed Care services caused by Hurricanes Irma and Maria in September 2017.  These decreases were offset in part by the estimated $14.8 million net retained losses incurred by the Property and Casualty segment caused by the aforementioned Hurricanes.  The consolidated loss ratio was down 230 basis points, to 83.2%, and the Medical Loss Ratio (“MLR”) decreased 300 basis points, to 85.6%.

·
Consolidated operating expenses for the year were $477.2 million and the operating expense ratio was 16.8%.
 
·
Net income for the year was $54.5 million, an increase from a net income of $17.4 million in the prior year, primarily reflecting improvements in the Managed Care segment’s MLR.
 
Overview details

Intersegment revenues and expenses are reported on a gross basis in each of the operating segments but eliminated in the consolidated results.  Except as otherwise indicated, the numbers presented in this Annual Report on Form 10-K do not reflect intersegment eliminations.  These intersegment revenues and expenses affect the amounts reported on the financial statement line items for each segment, but are eliminated in consolidation and do not change net income.  The following table shows premiums earned, net and net fee revenue and operating income for each segment, as well as the intersegment premiums earned, service revenues and other intersegment transactions, which are eliminated in the consolidated results:
 
    Years ended December 31,
(Dollar amounts in millions)
 
2017
   
2016
   
2015
 
                   
Premiums earned, net:
                 
Managed care
 
$
2,590.0
   
$
2,648.5
   
$
2,549.5
 
Life insurance
   
161.8
     
156.9
     
148.1
 
Property and casualty insurance
   
77.2
     
87.9
     
87.6
 
Intersegment premiums earned
   
(2.1
)
   
(2.7
)
   
(2.0
)
Consolidated premiums earned, net
 
$
2,826.9
   
$
2,890.6
   
$
2,783.2
 
                         
Administrative service fees:
                       
Managed care
 
$
21.6
   
$
22.4
   
$
49.3
 
Intersegment administrative service fees
   
(5.1
)
   
(4.5
)
   
(4.6
)
Consolidated administrative service fees
 
$
16.5
   
$
17.9
   
$
44.7
 
                         
Operating income (loss):
                       
Managed care
 
$
55.0
   
$
(36.8
)
 
$
20.5
 
Life insurance
   
19.4
     
21.5
     
20.0
 
Property and casualty insurance
   
(6.0
)
   
12.1
     
8.3
 
Intersegment and other
   
-
     
(2.0
)
   
(9.4
)
Consolidated operating income (loss)
 
$
68.4
   
$
(5.2
)
 
$
39.4
 
 
Revenue

General.     Our revenue consists primarily of (i) premium revenue generated from our managed care business, (ii) administrative service fees received for services provided to self-insured employers, (iii) premiums we generate from our life insurance and property and casualty insurance businesses and (iv) investment income.

Premium Revenue.    Our revenue primarily consists of premiums earned from the sale of managed care products to the Commercial, Medicare Advantage and Medicaid sectors.  We receive a monthly payment from or on behalf of each member enrolled in our managed care plans (excluding ASO).  We recognize all premium revenue in our managed care business during the month in which we are obligated to provide services to an enrolled member.  Premiums we receive in advance of that date are recorded as unearned premiums.

Premiums are set prospectively, meaning that a fixed premium rate is determined at the beginning of each contract year and revised at renewal.  We renegotiate the premiums of different groups as their existing annual contracts become due.  Our Medicare Advantage contracts entitle us to premium payments from CMS on behalf of each Medicare beneficiary enrolled in our plans, generally on a per member per month (“PMPM”) basis.  We submit rate proposals to CMS in June for each Medicare Advantage product that will be offered beginning January 1 of the subsequent year in accordance with the competitive bidding process under the MMA.  Retroactive rate adjustments are made periodically with respect to our Medicare Advantage plans based on the aggregate health status and risk scores of our plan participants.  Premium rates for the Medicaid business are based on a bid contract with ASES and are revised each year to be effective each July 1, at which time rates are fixed for the plan year.
 
Premiums on traditional life insurance policies are reported as earned when due.  Premiums on accident and health and other short-term contracts are recognized as earned, primarily on a pro rata basis over the contract period.  Premiums on credit life policies are recognized as earned in proportion to the amounts of insurance in force.  Group insurance premiums are billed one month in advance and a grace period of one month is provided for premium payment.  If the insured fails to pay within the one-month grace period, we may cancel the policy.  We recognize premiums on property and casualty contracts as earned on a pro rata basis over the policy term.  Property and casualty policies are subscribed through general agencies, which bill policy premiums to their clients in advance or, in the case of new business, at the inception date and remit collections to us, net of commissions.  The portion of premiums related to the period prior to the end of coverage is recorded in the consolidated balance sheet as unearned premiums and is transferred to premium revenue as earned.

Administrative Service Fees.     Administrative service fees include amounts paid to us for administrative services provided to self-insured contracts.  We provide a range of customer services pursuant to our administrative services only (“ASO”) contracts, including claims administration, billing, access to our provider networks and membership services.  Administrative service fees are recognized in the month in which services are provided.

Investment Income.     Investment income consists of interest and dividend income from investment securities. See Note 4, Net Investment Income, of the Notes to Consolidated Financial Statements, included in Item 8, Financial Statements and Supplementary Data , of this Annual Report on Form 10-K.

Expenses

Claims Incurred.     Our largest expense is medical claims incurred, or the cost of medical services we arrange for our members.  Medical claims incurred include the payment of benefits and losses, mostly to physicians, hospitals, pharmacies, and other service providers, and to policyholders.  We generally pay our providers on one of three forms: (1) fee-for-service contracts based on negotiated fee schedules; (2) capitation arrangements, generally on a fixed PMPM payment basis, whereby the provider generally assumes some of the medical expense risk; and (3) risk-sharing arrangements, whereby we advance a PMPM payment and share the risk of certain medical costs of our members with the provider based on actual experience as measured against pre-determined sharing ratios.  Claims incurred also include claims incurred in our life insurance and property and casualty insurance businesses.  Each segment’s results of operations depend to a significant extent on our ability to accurately predict and effectively manage claims and losses.  A portion of the claims incurred for each period consists of claims reported but not paid during the period, as well as a management and actuarial estimate of claims incurred but not reported during the period.

The MLR, which is calculated by dividing managed care claims incurred by managed care premiums earned, net is one of our primary management tools for measuring these costs and their impact on our profitability.  The MLR is affected by the cost and utilization of services.  The cost of services is affected by many factors, in particular our ability to negotiate competitive rates with our providers.  The cost of services is also influenced by inflation and new medical discoveries, including new prescription drugs, therapies and diagnostic procedures.  Utilization rates, which reflect the extent to which beneficiaries utilize healthcare services, significantly influence our medical costs.  The level of utilization of services depends in large part on the age, health and lifestyle of our members, among other factors.  As the MLR is the ratio of claims incurred to premiums earned, net, it is affected not only by our ability to contain cost trends but also by our ability to increase premium rates to levels consistent with or above medical cost trends.  We use MLRs both to monitor our management of healthcare costs and to make various business decisions, including what plans or benefits to offer and our selection of healthcare providers.
 
Operating Expenses.     Operating expenses include commissions to external brokers, general and administrative expenses, cost containment expenses such as case and disease management programs, and depreciation and amortization.  The operating expense ratio is calculated by dividing operating expenses by premiums earned, net plus administrative service fees.  A significant portion of our operating expenses are fixed costs.  Accordingly, it is important that we maintain certain level of volume of business in order to compensate for the fixed costs.  Significant changes in our volume of business will affect our operating expense ratio and results of operations.  We also have variable costs, which vary in proportion to changes in volume of business.

II. Membership

Our results of operations depend in large part on our ability to maintain or grow our membership.  In addition to driving revenues, membership growth is necessary to successfully introduce new products, maintain an extensive network of providers and achieve economies of scale.  Our ability to maintain or grow our membership is affected principally by the competitive environment, the economy, and general market conditions.

The following table sets forth selected membership data as of the dates set forth below:
 
    As of December 31,
   
2017
   
2016
   
2015
 
                   
Commercial (1)
   
475,026
     
509,157
     
547,634
 
Medicare
   
118,451
     
110,297
     
123,888
 
Medicaid
   
384,462
     
397,918
     
422,922
 
Total
   
977,939
     
1,017,372
     
1,094,444
 
 
(1)
Commercial membership includes corporate accounts, self-funded employers, individual accounts, Medicare Supplement, federal government employees and local government employees.
 
III. Results of Operations

Consolidated Operating Results

The following table sets forth our consolidated operating results for the years ended December 31, 2017, 2016 and 2015. Further details of the results of operations of each reportable segment are included in the analysis of operating results for the respective segments.
 
(Dollar amounts in millions)
 
2017
   
2016
   
2015
 
                   
Years ended December 31,
                 
Revenues:
                 
Premiums earned, net
 
$
2,826.9
   
$
2,890.6
   
$
2,783.2
 
Administrative service fees
   
16.5
     
17.9
     
44.7
 
Net investment income
   
51.6
     
48.9
     
45.2
 
Other operating revenues
   
3.7
     
3.5
     
3.7
 
Total operating revenues
   
2,898.7
     
2,960.9
     
2,876.8
 
Net realized investment gains
   
10.8
     
17.4
     
18.9
 
Other income, net
   
6.6
     
6.5
     
7.0
 
Total revenues
   
2,916.1
     
2,984.8
     
2,902.7
 
Benefits and expenses:
                       
Claims incurred
   
2,353.1
     
2,472.2
     
2,318.7
 
Operating expenses
   
477.2
     
493.9
     
518.7
 
Total operating costs
   
2,830.3
     
2,966.1
     
2,837.4
 
Interest expense
   
6.8
     
7.6
     
8.2
 
Total benefits and expenses
   
2,837.1
     
2,973.7
     
2,845.6
 
Income before taxes
   
79.0
     
11.1
     
57.1
 
Income (benefit) tax expense
   
24.5
     
(6.3
)
   
5.1
 
Net income
   
54.5
     
17.4
     
52.0
 
Net loss attributable to non-controlling interest
   
-
     
-
     
(0.1
)
Net income attributable to TSM
 
$
54.5
   
$
17.4
   
$
52.1
 
 
Year ended December 31, 2017 compared with the year ended December 31, 2016

Operating Revenues

Premiums earned, net decreased by $63.7 million, or 2.2%, to $2.8 billion.  This decrease primarily reflects lower premiums in the Managed Care segment by $58.5 million mainly due to lower membership in the segment’s Medicaid and Commercial businesses, the impact of the suspension of the HIP fee pass through, and lower Medicare additional risk score revenue. These decreases were partially offset by higher average premium rates in the Commercial and Medicaid businesses as well as by higher Medicare membership.  Property and Casualty premiums decreased by $10.7 million year over year, mostly reflecting the $9.2 million estimated catastrophe reinsurance reinstatement costs following the impact of Hurricanes Irma and Maria in September 2017.

Administrative service fees decreased $1.4 million, or 7.8%, mainly due to lower membership enrolled in this business.

Net investment income increased $2.7 million, or 5.5%, to $51.6 million mostly as a result of higher invested balances.
 
Claims Incurred

Consolidated claims incurred decreased by $119.1 million, or 4.8%, to $2.4 billion, mostly due to lower claims in the Managed Care segment offset by an increase in claims in the Property and Casualty segment.  The decrease in Managed Care claims primarily reflects lower claims incurred across all businesses in the segment driven by the estimated decrease in utilization as a consequence of the aforementioned Hurricanes, lower enrollment in the Commercial and Medicaid enrollment, and favorable fluctuations in the prior period reserve developments in the Commercial and Medicare businesses. The Property and Casualty segment’s estimated net retained losses related to Hurricanes Irma and Maria were approximately $14.8 million after the application of reinsurance.  The consolidated loss ratio decreased by 230 basis points to 83.2%.  Excluding the impact of prior-period reserve developments, and moving the Medicare risk score revenue and other revenue adjustments to the corresponding period, the Managed Care MLR for the year was 83.7%, 100 basis points lower than the same metric from the prior year.

Operating Expenses

Consolidated operating expenses decreased by $16.7 million, or 3.4%, to $477.2 million.  The lower operating expenses are mostly the result of the decrease in the HIP Fee of $44.2 million due to the 2017 moratorium offset by increase in personnel costs, professional services, and business promotion expenses totaling approximately $30.4 million.

Income taxes

Consolidated income taxes increased by $30.8 million, to a net expense of $24.5 million.   The year over year change in income taxes primarily results from an increase in the taxable income from the Managed Care segment, which has a higher effective tax rate than our other segments.

Year ended December 31, 2016 compared with the year ended December 31, 2015

Operating Revenues

Premiums earned, net increased by $107.4 million, or 3.9%, to $2.9 billion.  This increase primarily reflects higher premiums in the Managed Care segment by $99.0 million as a result of the change in the Medicaid service model effective April 1, 2015, from an ASO agreement to a fully insured model, and higher premium rates in the Commercial business.   This increase was offset by lower member month enrollment in the Medicare and Commercial businesses and a decrease in the Medicare average premiums rates.

Administrative service fees decreased $26.8 million, or 60.0%, mostly as a result of the previously mentioned change in the Medicaid contract model.  Total administrative fees related to the previous Medicaid ASO agreement during the 2015 period amounted to $24.3 million.

Net investment income increased $3.7 million, or 8.2%, to $48.9 million mostly as a result of higher invested balances.

Claims Incurred

Consolidated claims incurred increased by $153.5 million, or 6.6%, to $2.5 billion, mostly due to higher claims in the Managed Care segment.  This increase primarily reflects higher claims incurred in the segment’s Medicaid business by $150.7 million after the contract changed to a fully insured model and the impact of Managed Care prior period reserve developments.  The consolidated loss ratio increased by 220 basis points to 85.5%.  Excluding the impact of prior period development, as well as moving the 2015 risk score revenue adjustments to its corresponding period, consolidated loss ratio was 84.1%, 70 basis points higher than last year.

Operating Expenses

Consolidated operating expenses decreased by $24.8 million, or 4.8%, to $493.9 million.  The decrease reflects lower expenses following the change in the Medicaid membership after we elected to reduce the number of regions we serve, from eight regions under an ASO agreement to only two regions when the contract changed to a fully-insured model.  The lower operating expenses also reflect a decrease in the provision for doubtful accounts, mostly due to the strengthening of the allowance for doubtful receivables in the 2015 period, lower payroll and related expenses resulting from accruals related to management changes and retirements impacting the 2015 period, as well as a $4.4 million expense related to settlement agreements entered with governmental agencies in 2015.  These decreases were partially offset by a new business-to-business tax implemented in Puerto Rico at the end of the third quarter 2015 and an increase in the Health Insurance Providers Fee, reflecting the at-risk Medicaid enrollment after the model changed in 2015.  For the year ended December 31, 2016, the consolidated operating expense ratio decreased 130 basis points to 17.0%, as the result of the increase in premiums and lower expenses.
 
Income taxes

Consolidated income taxes resulted in a benefit of $6.3 million. The tax benefit primarily results from the net effect of the following:

For the 2016 period the Managed Care segment, which has a higher effective tax rate than our other segments, incurred in a loss before taxes, resulting in the recording of a tax benefit during the period.

During the 2015 period, the Company executed a Closing Agreement between TSM and its subsidiaries and the Puerto Rico Treasury Department in connection with a local law that provided a temporary preferential tax rate in capital asset transactions.  These events allowed the Company to record a $3.1 million benefit in the 2015 period resulting from the enacted lower taxable rate and the reassessment of the realizability of some of its deferred taxes.

The Property and Casualty segment reassessed the tax rate used to measure several temporary differences; as a consequence such rate was increased from 20% to 39%, resulting in an increase to its deferred tax expense of approximately $3.6 million in 2016
 
Managed Care Operating Results

We offer our products in the managed care segment to three distinct market sectors in Puerto Rico: Commercial, Medicare Advantage and Medicaid.  For the year ended December 31, 2017, the Commercial, Medicare and Medicaid sectors represented 28.4%, 36.6% and 26.6% of our consolidated premiums earned, net, respectively.
 
(Dollar amounts in millions)
 
2017
   
2016
   
2015
 
                   
Operating revenues:
                 
Medical premiums earned, net:
                 
Commercial
 
$
803.3
   
$
841.4
   
$
844.6
 
Medicare
   
1,035.3
     
1,023.9
     
1,097.7
 
Medicaid
   
751.4
     
783.2
     
607.2
 
Medical premiums earned, net
   
2,590.0
     
2,648.5
     
2,549.5
 
Administrative service fees
   
21.6
     
22.4
     
49.3
 
Net investment income
   
16.6
     
15.1
     
11.8
 
Total operating revenues
   
2,628.2
     
2,686.0
     
2,610.6
 
Medical operating costs:
                       
Medical claims incurred
   
2,218.3
     
2,347.5
     
2,196.7
 
Medical operating expenses
   
354.9
     
375.3
     
393.4
 
Total medical operating costs
   
2,573.2
     
2,722.8
     
2,590.1
 
Medical operating income (loss)
 
$
55.0
   
$
(36.8
)
 
$
20.5
 
Additional data:
                       
Member months enrollment:
                       
Commercial:
                       
Fully-insured
   
3,981,347
     
4,209,920
     
4,492,395
 
Self-funded
   
1,967,668
     
2,144,621
     
2,221,327
 
Total Commercial member months
   
5,949,015
     
6,354,541
     
6,713,722
 
Medicare member months
   
1,457,363
     
1,394,272
     
1,447,420
 
Medicaid:
                       
Fully-insured
   
4,631,316
     
4,829,729
     
3,855,945
 
Self-funded
   
-
     
-
     
4,229,082
 
Total Medicaid member months
   
4,631,316
     
4,829,729
     
8,085,027
 
Total member months
   
12,037,694
     
12,578,542
     
16,246,169
 
Medical loss ratio
   
85.6
%
   
88.6
%
   
86.2
%
Operating expense ratio
   
13.6
%
   
14.1
%
   
15.1
%
 
Year ended December 31, 2017 compared with the year ended December 31, 2016

Medical Operating Revenues

Medical premiums earned decreased by $58.5 million, or 2.2%, to $2.6 billion.  This decrease is principally the result of the following:

·
Medical premiums generated by the Commercial business decreased by $38.1 million, or 4.5%, to $803.3 million.  This fluctuation primarily reflects lower fully-insured enrollment during the year of approximately 228,600 member months and $14.5 million related to the suspension of the HIP fee pass-through; offset by an increase in average premium rates of approximately 5%.

·
Medical premiums generated by the Medicare business increased by $11.4 million, or 1.1%, to $1,035.3 million, primarily reflecting an increase in member months enrollment of approximately 63,100 lives.  This increase is partially offset by lower additional risk score revenue by $30.9 million as well as lower average premium rates due to a reduction in the 2017 Medicare reimbursement rates.
 
·
Medical premiums generated by the Medicaid business decreased by $31.8 million to $751.4 million.  This decrease primarily reflects lower fully-insured member months enrollment by approximately 198,400 lives, $10.8 million related to the suspension of the HIP fee pass-through as a result of the 2017 moratorium and, the impact of the 2.5% excess profit accrual that increased 2016 premiums by $10.9 million.  Decreases are partially offset by a $12.2 million increase in premium collections related to our compliance with the contract’s quality incentive metrics and the impact of the new premium rates that were effective July 1st 2017, which increased average premium rates by approximately 9%.

Medical Claims Incurred

Medical claims incurred decreased by $129.2 million, or 5.5%, to $2.2 billion.  The MLR of the segment decreased 300 basis points during the 2017 period, to 85.6%.  These fluctuations are primarily attributed to the net effect of the following:

·
The medical claims incurred of the Commercial business decreased by $94.5 million, or 13.2%, during the 2017 period and its MLR, at 77.5%, was 770 basis points lower than the same period last year.  Adjusting for the effect of prior period reserve developments, the Commercial MLR would have been 77.9%, 590 basis points lower than the adjusted MLR for last year, primarily reflecting the estimated decrease in utilization caused by Hurricanes Irma and Maria in September 2017 as well as the ongoing claim trends that are lower than our premium trends following the continuity of our underwriting discipline.  The estimated decrease in utilization related to the aforementioned hurricanes account for approximately 310 of the 590 basis-points decrease in the adjusted MLR.

·
The medical claims incurred of the Medicare business decreased by $16.6 million, or 1.8%, during the 2017 period and its MLR decreased by 260 basis points, to 87.7 %.  Adjusting for the effect of prior period reserve developments in 2017 and 2016 and moving the additional risk score revenue adjustments to their corresponding period, the Medicare MLR would have been approximately 88.4%, about 80 basis points lower than last year. The estimated decrease in utilization caused by Hurricanes Irma and Maria mitigated the impact of the higher trends in Part B drugs and pharmacy benefits experienced by this business as well as the improvement of benefits in 2017 products taking advantage of the HIP fee moratorium.  The estimated decrease in utilization related to the aforementioned hurricanes lowered by approximately 270 basis points the adjusted MLR.

·
The medical claims incurred of the Medicaid business decreased by $18.2 million, or 2.6%, during the 2017 period and its MLR increased by 140 basis points, to 91.5%.  Adjusting for the effect of prior period reserve developments in 2017 and 2016, as well as for the impact of the 2.5% excess profit accrual and this year’s quality incentive premiums, the Medicaid MLR would have been approximately 91.8%, about 180 basis points higher than last year.  The higher MLR primarily reflects increased pharmacy and outpatient claim trends, partially offset by the estimated decrease in utilization caused by Hurricanes Irma and Maria, which lowered the adjusted MLR by 30 basis points, and the impact of the higher premium rates that were effective July 1 st 2017.

Medical Operating Expenses

Medical operating expenses decreased by $20.4 million, or 5.4%, to $354.9 million.  The operating expense ratio decreased by 50 basis points to 13.6% in 2017.  The lower operating expenses and expense ratio are mostly the result of the decrease in the HIP Fee of $44.2 million due to the 2017 moratorium offset by increase in personnel costs, professional services and business promotion expenses totaling approximately $28.1 million.
 
Year ended December 31, 2016 compared with the year ended December 31, 2015

Medical Operating Revenues

Medical premiums earned increased by $99.0 million, or 3.9%, to $2.6 billion.  This increase is principally the result of the following:

·
Medical premiums generated by the Commercial business decreased by $3.2 million, or 0.4%, to $841.4 million primarily resulting from a decrease in fully-insured member months enrollment, partially offset by an approximately 5% year over year increase in average premium rates.

·
Medical premiums generated by the Medicare business decreased by $73.8 million, or 6.7%, to $1,000 million.  This fluctuation primarily results from lower risk score revenue as compared with 2015, lower member months enrollment, and a reduction in 2016 Medicare reimbursement rates.

·
Medical premiums generated by the Medicaid business increased by $176.0 million to $783.2 million, primarily as the result of the change in the Medicaid service model, from an ASO agreement to a fully-insured model effective April 1, 2015.

Administrative service fees decreased by $26.9 million, or 54.6%, to $22.4 million mainly due to the previously mentioned change in the Medicaid contract effective April 1, 2015.

Medical Claims Incurred

Medical claims incurred increased by $150.8 million, or 6.9%, to $2.3 billion.  The MLR of the segment increased 240 basis points during the 2016 period, to 88.6%.  These fluctuations are primarily attributed to the net effect of the following:

·
The medical claims incurred of the Commercial business increased by $4.3 million, or 0.6%, during 2016, mostly reflecting the impact of prior period reserve developments, partially offset by lower member months enrollment.  The Commercial MLR was 85.2%, which is 100 basis points higher than the MLR for the prior year.  Excluding the effect of prior period reserve developments in 2016 and 2015, the MLR would have decreased by 270 basis points, reflecting the continuity of our underwriting discipline and premium trends higher than claims trends.

·
The medical claims incurred of the Medicare business decreased by $4.1 million, or 0.4%, during the 2016 period reflecting the previously mentioned decrease in membership and changes in benefit design included in 2016 products as the result of the decrease in reimbursement rates.  This decrease is offset by unfavorable prior period reserve developments.  The Medicare MLR was 90.3%, which is 570 basis points higher than the MLR for the prior year.  Adjusting for the effect of prior period reserve developments, and moving the 2015 final risk score revenue adjustments to its corresponding period, our Medicare MLR would have been 90.0%, about 530 basis points higher than last year.  The higher MLR primarily reflects higher Part B drug costs mainly related to cancer and rheumatoid arthritis, additional deterioration in the experience of End Stage Renal Disease (ESRD) and the effect of the decrease in 2016 Medicare reimbursement rates.

·
The medical claims incurred of the Medicaid business increased by $150.7 million during the 2016 period reflecting the previously mentioned change in the Medicaid contract effective April 1, 2015.

Medical Operating Expenses

Medical operating expenses decreased by $18.1 million, or 4.6%, to $375.3 million.  The decrease mostly reflects lower expenses following the change in the Medicaid membership after we elected to decrease the number of regions we serve, from eight regions under an ASO agreement to only two regions when the contract was changed to a fully-insured model.  The lower operating expenses also includes the effect of a decrease in the provision for doubtful accounts, mostly due to the strengthening of the allowance for doubtful receivables in the 2015 period, lower payroll and related expenses resulting from accruals related to management changes and retirements impacting the 2015 period, as well as to a $4.4 million expense related to settlement agreements entered with governmental agencies in 2015.  These decreases were partially offset by a new business-to-business tax implemented in Puerto Rico at the end of the third quarter 2015 and an increase in the Health Insurance Providers Fee, reflecting the at-risk Medicaid enrollment after the model changed in 2015.  The operating expense ratio increased 110 basis points to 14.0% in 2016 as a result of the increase in premiums and lower expenses.
 
Life Insurance Operating Results
 
(Dollar amounts in millions)
 
2017
   
2016
   
2015
 
                   
Years ended December 31,
                 
Operating revenues:
                 
Premiums earned, net:
                 
Premiums earned
 
$
166.4
   
$
161.3
   
$
153.8
 
Assumed earned premiums
   
4.2
     
4.4
     
3.9
 
Ceded premiums earned
   
(8.8
)
   
(8.8
)
   
(9.6
)
Premiums earned, net
   
161.8
     
156.9
     
148.1
 
Net investment income
   
24.8
     
24.9
     
24.5
 
Total operating revenues
   
186.6
     
181.8
     
172.6
 
Operating costs:
                       
Policy benefits and claims incurred
   
87.3
     
86.9
     
82.6
 
Underwriting and other expenses
   
79.9
     
73.4
     
70.0
 
Total operating costs
   
167.2
     
160.3
     
152.6
 
Operating income
 
$
19.4
   
$
21.5
   
$
20.0
 
                         
Additional data:
                       
Loss ratio
   
54.0
%
   
55.4
%
   
55.8
%
Expense ratio
   
49.4
%
   
46.8
%
   
47.3
%
 
Year ended December 31, 2017 compared with the year ended December 31, 2016

Operating Revenues

Premiums earned, net increased by $4.9 million, or 3.1% to $161.8 million, as the result of premium growth in the segment’s Individual Life and Cancer lines of business, as well as growth in the Costa Rica operations.

Policy Benefits and Claims Incurred

Policy benefits and claims incurred increased by $0.4 million, or 0.5%, to $87.3 million, mostly reflecting a higher volume of business during the year, particularly in the Cancer and Individual Life lines of business, which claims increased by $2.7 million, offset by a decrease of $2.3 million in actuarial reserves.

Underwriting and Other Expenses

Increase in underwriting and other expenses of $6.5 million, or 8.9%, to $79.9 million mostly reflects higher commissions following the segment’s premium growth mentioned above.   In addition, the segment has incurred in higher development and marketing expenses related to the expansion of the Costa Rica operations.  As a result, the segment’s operating expense ratio increased to 49.4%, or 260 basis points.
 
Year ended December 31, 2016 compared with the year ended December 31, 2015

Operating Revenues

Premiums earned, net increased by $8.8 million, or 5.9% to $156.9 million, reflecting improved policy retention and higher sales in the segment’s Individual Life and Cancer lines of business of $4.0 million and $2.7 million, respectively, as well as growth in the Costa Rica operations.

Policy Benefits and Claims Incurred

Policy benefits and claims incurred increased by $4.3 million, or 5.2%, to $86.9 million, mostly reflecting a higher volume of business during the year, particularly in the Cancer line of business, which claims increased by $2.7 million, as well as to an increase of $2.6 million in actuarial reserves.

Underwriting and Other Expenses

Underwriting and other expenses increased by $3.4 million, or 4.9%, primarily reflecting an increase in commissions expense following the segment’s premium growth mentioned above.  In addition, the segment has incurred in higher development and marketing expenses related to the development of the Costa Rica operations.  The segment’s operating expense ratio decreased 50 basis points to 46.8% in 2016, reflecting the increase in premiums during the period.
 
Property and Casualty Insurance Operating Results
 
(Dollar amounts in millions)
 
2017
   
2016
   
2015
 
                   
Years ended December 31,
                 
Operating revenues:
                 
Premiums earned, net:
                 
Premiums written
 
$
143.8
   
$
133.1
   
$
134.4
 
Premiums ceded
   
(62.3
)
   
(46.0
)
   
(48.7
)
Change in unearned premiums
   
(4.3
)
   
0.8
     
1.9
 
Premiums earned, net
   
77.2
     
87.9
     
87.6
 
Net investment income
   
9.5
     
8.9
     
8.7
 
Total operating revenues
   
86.7
     
96.8
     
96.3
 
Operating costs:
                       
Claims incurred
   
50.8
     
40.8
     
42.6
 
Underwriting and other operating expenses
   
41.9
     
43.9
     
45.4
 
Total operating costs
   
92.7
     
84.7
     
88.0
 
Operating (loss) income
 
$
(6.0
)
 
$
12.1
   
$
8.3
 
                         
Additional data:
                       
Loss ratio
   
65.8
%
   
46.4
%
   
48.6
%
Expense ratio
   
54.3
%
   
49.9
%
   
51.8
%
 
Year ended December 31, 2017 compared with the year ended December 31, 2016

Operating Revenues

Total premiums written increased by $10.7 million, or 8.0%, to $143.8 million, driven by higher sales of Commercial property and Commercial liability products, mainly as a result of the acquisition of a large account, as well as to higher sales of Personal package products.
 
The premiums ceded to reinsurers increased by $16.3 million, or 35.4%, mostly reflecting higher premiums written in Commercial insurance products during 2017 as well as adjustments related to the catastrophe reinsurance, including $9.2 million for catastrophe reinsurance reinstatement costs.

The change in unearned premiums mostly reflects the segments higher premiums written in 2017.

Claims Incurred

Claims incurred increased by $10.0 million, or 24.5%, to $50.8 million mostly driven by $14.8 million of net losses related to Hurricanes Irma and Maria. As a result, the segment’s loss ratio increased by 1,940 basis points, to 65.8% during this period.  Estimated gross losses related to Hurricanes Irma and Maria were $6.4 million and $687.0 million, respectively.  While the segment’s ultimate losses cannot be determined with certainty at this time, management believes the catastrophe coverage for losses and allocated loss expenses is sufficient to cover anticipated gross losses.

Underwriting and Other Expenses

Underwriting and other operating expenses decreased by $2.0 million, or 4.6%, to $41.9 million mostly due to lower personnel costs and net commissions The operating expense ratio increased by 440 basis points, to 54.3% in 2017.

Year ended December 31, 2016 compared with the year ended December 31, 2015

Operating Revenues

Total premiums written decreased by $1.3 million, or 1.0%, to $133.1 million, mostly resulting from lower sales of Commercial Package, offset by higher sales in the Compulsory Vehicle Liability insurance products.

The premiums ceded to reinsurers decreased by $2.7 million, or 5.5%, mostly reflecting favorable pricing in the market for nonproportional reinsurance treaties.

Claims Incurred

Claims incurred decreased by $1.8 million, or 4.2%, to $40.8 million.  The loss ratio decreased 220 basis points, to 46.4%, during this period, primarily as a result of favorable loss experience in the Commercial Package insurance products.

Underwriting and Other Expenses

Underwriting and other operating expenses decreased by $1.5 million, or 3.3%, to $43.9 million mostly due to lower net commission expenses driven by a decrease in net premiums earned. The operating expense ratio decreased by 190 basis points, to 50.0% in 2016.
 
IV. Liquidity and Capital Resources

Cash Flows

A summary of our major sources and uses of cash for the periods indicated is presented in the following table:
 
(Dollar amounts in millions)
 
2017
   
2016
   
2015
 
Sources (uses) of cash:
                 
Cash provided by operating activities
 
$
286.2
   
$
6.5
   
$
229.1
 
Net purchases of investment securities
   
(154.6
)
   
(80.9
)
   
(41.6
)
Net capital expenditures
   
(21.4
)
   
(4.8
)
   
(9.1
)
Proceeds from long-term borrowoings
   
24.3
     
-
     
-
 
Payments of long-term borrowings
   
(27.1
)
   
(1.7
)
   
(37.6
)
Proceeds from policyholder deposits
   
13.6
     
18.2
     
16.5
 
Surrenders of policyholder deposits
   
(22.1
)
   
(21.9
)
   
(18.8
)
Repurchase and retirement of common stock
   
(20.2
)
   
(21.4
)
   
(48.3
)
Other
   
12.2
     
11.6
     
(2.4
)
Net increase (decrease) in cash and cash equivalents
 
$
90.9
   
$
(94.4
)
 
$
87.8
 
 
Year ended December 31, 2017 compared to year ended December 31, 2016

Cash flow from operating activities increased by $279.7 million for the year ended December 31, 2017 as compared to the year ended December 31, 2016, principally due to, lower claims paid by $134.8 million, a decrease in cash paid to suppliers and employees of $191.6 million; offset by a decrease in premium collections of $55.1 million.

Increase in net purchases of investments in securities are part of our asset/liability management strategy using cash on hand.

Net capital expenditures increased by $16.6 million for the year ended December 31, 2017 mostly related to information technology initiatives in the Managed Care segment.

During the year 2017, we received the remaining $24.3 million from a loan with a commercial bank related with a credit agreement entered into in December 2016. These proceeds were used to prepay the outstanding principal amount of $24.0 million of the 6.6% senior unsecured notes.

In August 2017 the Company’s Board of Directors authorized a $30.0 million repurchase program of its Class B common stock.  Repurchases were conducted through open-market purchases of Class B shares only, in accordance with Rule 10b-18 under the Securities Exchange Act of 1934, as amended. During the year 2017, the Company repurchased and retired 861,415 shares of our Class B Common Stock shares at an average per share price of $23.38, for an aggregate cost of $20.2 million.

Year ended December 31, 2016 compared to year ended December 31, 2015

Cash flow from operating activities decreased by $222.6 million for the year ended December 31, 2016 as compared to the year ended December 31, 2015, principally as a result of higher claims paid by $257.4 million and an increase cash paid to suppliers and employees by $34.3 million, offset in part by an increase in premiums collections of $67.5 million.  The increase in claims paid and premiums collected is principally the result of the change in the Medicaid delivery model from an ASO agreement to a fully insured model effective April 1, 2015.

Increase in net purchases of investments in securities are part of our asset/liability management strategy using cash on hand.
 
Payments of long-term borrowings decreased by $35.9 million during the year ended December 31, 2016, primarily due to the payment of a repurchase agreement of $25.0 million that matured and a $11.0 million repayment of principal of certain senior unsecured notes during the 2015 period.

Repurchase and retirement of common stock amounted to $21.4 million reflecting the repurchase and retirement of 951,831 shares of common stock during the year ended December 31, 2016 under the Corporation’s Class B common stock repurchase programs.

The increase in other sources of cash for the year ended December 31, 2016 is attributed to changes in the amount of outstanding checks in excess of bank balances.

Stock Repurchase Program

The Company repurchases shares through open market transactions, in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended, under repurchase programs authorized by the Board of Directors.  Shares purchased under share repurchase programs are retired and returned to authorized and unissued status. See Note 18, Stock Repurchase Program , of the Notes to Consolidated Financial Statements, included in Item 8, Financial Statements and Supplementary Data , of this Annual Report on Form 10-K.

   Financing and Financing Capacity

We have several short-term facilities available to address timing differences between cash collections and disbursements.  These short-term facilities are mostly in the form of arrangements to sell securities under repurchase agreements.  As of December 31, 2017, we had $60.0 million of available credit under these facilities.  There are no outstanding short-term borrowings under these facilities as of December 31, 2017.

On December 28, 2016, TSM entered into a $35.5 million credit agreement with a commercial bank in Puerto Rico. The agreement consists of three term loans: (i) Term Loan A in the principal amount of $11.2 million, (ii) Term Loan B in the principal amount of $20.2 million and (iii) Term Loan C in the principal amount of $4.1 million. Term Loan A matures in October 2023 while the Term Loans B and C mature in January 2024.  Term Loan A was used to refinance a previous $41.0 million secured loan payable with the same commercial bank.  Pursuant to the credit agreement, interest is payable on the outstanding balance of the Loan at the following annual rate: (i) 1% over LIBOR for Term Loan A, (ii) 2.75% over LIBOR for Term Loan B, and (iii) 3.25% over LIBOR for Term Loan C.  The loan includes certain financial and non-financial covenants, which are customary for this type of facility, including but not limited to, restrictions on the granting of certain liens, limitations on acquisitions and limitations on changes in control and dividends.  Failure to meet these covenants may trigger the accelerated payment of the outstanding balance.  As of December 31, 2017 we are in compliance with these covenants.

On March 11, 2016 TSS entered into a $30.0 million revolving loan agreement with a commercial bank in Puerto Rico. This unused line of credit had an interest rate of LIBOR plus 220 basis points and contained certain financial and non-financial covenants that are customary for this type of facility. This revolving loan agreement matured on March 11, 2017, and was not renewed.

On April 18, 2017, TSA entered into a $10.0 million revolving loan agreement with a commercial bank in Puerto Rico. This line of credit has an interest rate of 30-day LIBOR plus 25 basis points, matures on April 17, 2018, and includes certain financial and non-financial covenants that are customary for this type of facility.  As of December 31, 2017, there were $2.0 million outstanding in this line of credit.

We anticipate that we will have sufficient liquidity to support our currently expected needs.
 
Contractual Obligations
 
Our contractual obligations impact our short and long-term liquidity and capital resource needs.  However, our future cash flow prospects cannot be reasonably assessed based solely on such obligations.  Future cash outflows, whether contractual or not, will vary based on our future needs.  While some cash outflows are completely fixed (such as commitments to repay principal and interest on borrowings), most are dependent on future events (such as the payout pattern of claim liabilities which have been incurred but not reported).
 
·
The table below describes the payments due under our contractual obligations, aggregated by type of contractual obligation, including the maturity profile of our debt, operating leases and other long-term liabilities, but excludes an estimate of the future cash outflows related to the following:
 
 
o
Alternative investments – The Company has $117.6 million of unfunded capital commitments related to alternative investments. These commitments were excluded from this disclosure due to the undeterminate nature of their cash flows.
 
o
Unearned premiums – This amount accounts for the premiums collected prior to the end of coverage period and does not represent a future cash outflow.  As of December 31, 2017, we had $86.3 million in unearned premiums.
 
o
Policyholder deposits – The cash outflows related to these instruments are not included because they do not have defined maturities, such that the timing of payments and withdrawals is uncertain.  There are currently no significant policyholder deposits in paying status.  As of December 31, 2017, our policyholder deposits had a carrying amount of $176.5 million.
 
o
Other long-term liabilities – Due to the indeterminate nature of their cash outflows, $107.9 million of other long-term liabilities are not reflected in the following table, including $33.7 million of liability for pension benefits, $21.9 million in deferred tax liabilities, and $52.3 million in liabilities to the Federal Employees’ Health Benefits Plan Program.

         
Contractual obligations by year
 
                                           
(Dollar amounts in millions)
 
Total
   
2018
   
2019
   
2020
   
2021
   
2022
   
Thereafter
 
                                           
Long-term borrowings (1)
 
$
37.4
   
$
4.2
   
$
4.3
   
$
4.2
   
$
4.0
   
$
3.9
   
$
16.8
 
Operating leases
   
11.6
     
4.2
     
3.8
     
2.0
     
0.6
     
1.0
     
-
 
Purchase obligations (2)
   
297.9
     
236.2
     
42.0
     
5.4
     
4.5
     
2.3
     
7.5
 
Claim liabilities (3)
   
464.4
     
370.1
     
56.6
     
11.6
     
8.1
     
7.4
     
10.6
 
Estimated obligation for future     policy benefits (4)
   
657.9
     
133.1
     
116.6
     
108.6
     
102.0
     
96.2
     
101.4
 
   
$
1,469.2
   
$
747.8
   
$
223.3
   
$
131.8
   
$
119.2
   
$
110.8
   
$
136.3
 

(1)
As of December 31, 2017, our long-term borrowings consist of a credit agreement entered with a commercial bank in Puerto Rico.  See the “Financing and Financing Capacity” section for additional information regarding our long-term borrowings.
 
(2)
Purchase obligations represent payments required by us under material agreements to purchase goods or services that are enforceable and legally binding and where all significant terms are specified, including: quantities to be purchased, price provisions and the timing of the transaction.  Other purchase orders made in the ordinary course of business for which we are not liable are excluded from the table above.  Estimated pension plan contributions amounting to $2.0 million were included within the total purchase obligations. However, this amount is an estimate which may be subject to change in view of the fact that contribution decisions are affected by various factors such as market performance, regulatory and legal requirements and plan funding policy.
 
(3)
Claim liabilities represent the amount of our claims processed and incomplete as well as an estimate of the amount of incurred but not reported claims and loss-adjustment expenses.  This amount does not include an estimate of claims to be incurred subsequent to December 31, 2017.  The expected claims payments are an estimate and may differ materially from the actual claims payments made by us in the future.  Also, claim liabilities are presented gross, and thus do not reflect the effects of reinsurance under which $642.5 million of reserves had been ceded at December 31, 2017.
 
(4)
Our life insurance segment establishes, and carries as liabilities, actuarially determined amounts that are calculated to meet its policy obligations when a policy matures or surrenders, an insured dies or becomes disabled or upon the occurrence of other covered events.  A significant portion of the estimated obligation for future policy benefits to be paid included in this table considers contracts under which we are currently not making payments and will not make payments until the occurrence of an insurable event not under our control, such as death, illness, or the surrender of a policy.  We have estimated the timing of the cash flows related to these contracts based on historical experience as well as expectations of future payment patterns.  The amounts presented in the table above represent the estimated cash payments for benefits under such contracts based on assumptions related to the receipt of future premiums and assumptions related to mortality, morbidity, policy lapses, renewals, retirements, disability incidence and other contingent events as appropriate for the respective product type.  All estimated cash payments included in this table are not discounted to present value nor do they take into account estimated future premiums on policies in-force as of December 31, 2017 and are gross of any reinsurance recoverable.  The $657.9 million total estimated cash flows for all years in the table is different from the liability of future policy benefits of $339.5 million included in our audited consolidated financial statements principally due to the time value of money.  Actual cash payments to policyholders could differ significantly from the estimated cash payments as presented in this table due to differences between actual experience and the assumptions used in the estimation of these payments.
 
Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future material effect on our financial condition, revenues and expenses, results of operations, liquidity, capital expenditures or capital resources.

Restriction on Certain Payments by the Corporation’s Subsidiaries

Our insurance subsidiaries are subject to the regulations of the Commissioner of Insurance of Puerto Rico.  These regulations, among other things, require insurance companies to maintain certain levels of capital, thereby restricting the amount of earnings that can be distributed by the insurance subsidiaries to TSM.  As of December 31, 2017, our insurance subsidiaries were in compliance with such minimum capital requirements.

These regulations are not directly applicable to TSM, as a holding company, since it is not an insurance company.

The $35.5 million credit agreement limits the amount of dividends or other distributions (including share repurchases) payable by the Corporation to $50 million per year.

We do not expect that any of the previously described dividend restrictions will have a significant effect on our ability to meet our cash obligations.

Solvency Regulation

To monitor the solvency of the operations, the BCBSA requires us, TSS, TSA, and TSB to comply with certain specified levels of Risk Based Capital (”RBC”).  RBC is designed to identify weakly capitalized companies by comparing each company’s adjusted surplus to its required surplus (RBC ratio).  The RBC ratio reflects the risk profile of insurance companies.  At December 31, 2017, TSM and TSS estimated RBC ratio was above the 375% minimum BCBSA RBC requirement to avoid monitoring.  At December 31, 2017, TSA estimated RBC ratio was above the minimum BCBSA RBC requirement of 100% for smaller controlled affiliate.

BCBSA’s primary licensees could be subject to monitoring if, over a 6 or 12 month period, its RBC ratio declines by 80 or more points and which results in a level that is below 500%.

Other Contingencies

Legal Proceedings

Various litigation claims and assessments against us have arisen in the course of our business, including but not limited to, our activities as an insurer and employer.  Furthermore, the Commissioner of Insurance, as well as other Federal, Puerto Rico, and Costa Rica government authorities, regularly make inquiries and conduct audits concerning our compliance with applicable insurance and other laws and regulations.
 
Given the inherent unpredictability of these matters, it is possible that an adverse outcome in certain matters could, from time to time, have an adverse effect on our operating results and/or cash flows.  For a description of our legal proceedings, see Note 23, Contingencies , of the Notes to Consolidated Financial Statements, included in Item 8, Financial Statements and Supplementary Data , of this Annual Report on Form 10-K.

Guarantee Associations and Other Regulatory Commitments

To operate in Puerto Rico, insurance companies, such as our insurance subsidiaries, are required to participate in guarantee associations, which are organized to pay policyholders contractual benefits on behalf of insurers declared insolvent.  These associations levy assessments, up to prescribed limits, on a proportional basis, to all member insurers in the line of business in which the insolvent insurer was engaged.  In accordance with insurance laws and regulations assessments are recoverable through policy surcharges.  It is the opinion of management that any possible future guarantee association assessments will not have a material effect on our operating results and/or cash flows, although there is no ceiling on these payment obligations.

Pursuant to the Puerto Rico Insurance Code, our property and casualty insurance subsidiary is a member of Sindicato de Aseguradores para la Suscripción Conjunta de Seguros de Responsabilidad Profesional Médico-Hospitalaria (SIMED).  The syndicate was organized for the purpose of underwriting medical-hospital professional liability insurance.  As a member, the property and casualty insurance segment shares risks with other member companies and, accordingly, is contingently liable in the event the syndicate cannot meet their obligations.  During 2017, 2016 and 2015, no assessment or payment was made for this contingency.  It is the opinion of management that any possible future syndicate assessments will not have a material effect on our operating results and/or cash flows, although there is no ceiling on these payment obligations.

In addition, our property and casualty insurance subsidiary is a member of the Compulsory Vehicle Liability Insurance Joint Underwriting Association (the “Association”).  The Association was organized in 1997 to underwrite insurance coverage of motor vehicle property damage liability risks effective January 1, 1998.  As a participant, the segment shares the risk proportionally with other members based on a formula established by the Insurance Code.  During the years 2016 and 2015, the Association distributed to the Company an amount based on the good experience of the business amounting to $0.5 million and $0.7 million, respectively.  In December 2015 the Association declared a special dividend of $21 million subject to a special tax of 15% that was retained upon distribution.  This special dividend was paid in three installments during 2016.  The share of the Property and Casualty segment in this special dividend was approximately $1.7 million, net of tax.  In June 2017, the Association declared a special dividend of $70 million as authorized by a recent amendment to the Act creating the Association.  The distribution was subject to a unique and special tax rate of 50% that was already paid to the Puerto Rico Treasury.  The dividend net of tax is payable in December 2018.  The share of the Property and Casualty segment in this distribution is $2.4 million

The Property and Casualty segment is also member of the Puerto Rico Fire and Allied Lines Underwriting Association and the Puerto Rico Auto Assign Plan.  These entities periodically impose assessments to cover operations and other charges.  The assessments recorded from these entities were $1 thousand in 2017, 2016 and 2015.

V. Critical Accounting Estimates

Our consolidated financial statements and accompanying notes included in this Annual Report on Form 10-K have been prepared in accordance with GAAP applied on a consistent basis.  The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  We continually evaluate the accounting policies and estimates we use to prepare our consolidated financial statements.  In general, management’s estimates are based on historical experience and various other assumptions it believes to be reasonable under the circumstances.  The following is an explanation of our accounting policies considered most significant by management.  These accounting policies require us to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes.  Such estimates and assumptions could change in the future as more information is known.  Actual results could differ materially from those estimates.
 
The policies discussed below are considered by management to be critical to an understanding of our consolidated financial statements because their application places the most significant demands on management’s judgment, with financial reporting results relying on estimation about the effect of matters that are inherently uncertain.  For all these policies, management cautions that future events may not necessarily develop as forecasted, and that the best estimates routinely require adjustment.  Management believes that the amounts provided for these critical accounting estimates are adequate.

Claim Liabilities

Claim liabilities by segment as of December 31, 2017 were as follows:
 
(Dollar amounts in millions)
     
       
Managed care
 
$
367.0
 
Property and casualty insurance
   
694.4
 
Life insurance
   
45.5
 
Consolidated
 
$
1,106.9
 
 
Management continually evaluates the potential impact of changes in the factors considered for its claim liabilities estimates, both positive and negative, and uses the results of these evaluations to adjust recorded claim liabilities and underwriting criteria.  Our profitability depends in large part on our ability to accurately predict and effectively manage the amount of claims incurred, particularly those of the Managed Care segment and the losses arising from the Property and Casualty and Life Insurance segment.  Management regularly reviews its premiums and benefits structure to reflect our underlying claims experience and revised actuarial data; however, several factors could adversely affect our underwriting results.  Some of these factors are beyond management’s control and could adversely affect its ability to accurately predict and effectively control claims incurred.  Examples of such factors include changes in health practices, economic conditions, change in utilization trends including those caused by epidemic conditions, healthcare costs, the advent of natural disasters, and malpractice litigation.  Costs in excess of those anticipated could have a material adverse effect on our results of operations.

We recognize claim liabilities as follows:

Managed Care Segment

At December 31, 2017, claim liabilities for the managed care segment amounted to $367.0 million and represented 33.1% of our total consolidated claim liabilities and 16.6% of our total consolidated liabilities.

Claim liabilities are determined employing actuarial methods that are commonly used by managed care actuaries and meet Actuarial Standards of Practice, which require that the claim liabilities be adequate under moderately adverse circumstances.  The segment determines the amount of the liability by following a detailed actuarial process that entails using both historical claim payment patterns as well as emerging medical cost trends to project a best estimate of claim liabilities.  Under this process, historical claims incurred dates are compared to actual dates of claims payment.  This information is analyzed to create “completion” or “development” factors that represent the average percentage of total incurred claims that have been paid through a given date after being incurred.  Completion factors are applied to claims paid through the financial statement date to estimate the ultimate claim expense incurred for the current period.  Actuarial estimates of claim liabilities are then determined by subtracting the actual paid claims from the estimate of the total expected claims incurred.  The majority of unpaid claims, both reported and unreported, for any period, are those claims which are incurred in the final months of the period.  Since the percentage of claims paid during the period with respect to claims incurred in those months is generally very low, the above-described completion factor methodology is less reliable for such months.  In order to complement the analysis to determine the unpaid claims, historical completion factors and payment patterns are applied to incurred and paid claims for the most recent twelve months and compared to the prior twelve month period.  Incurred claims for the most recent twelve months also take into account recent claims expense levels and health care trend levels (trend factors).  Using all of the above methodologies, our actuaries determine based on the different circumstances the unpaid claims as of the end of period.
 
Because the reserve methodology is based upon historical information, it must be adjusted for known or suspected operational and environmental changes.  These adjustments are made by our actuaries based on their knowledge and their estimate of emerging impacts to benefit costs and payment speed.

Managed care claim liabilities also include a provision for adverse deviation, which is an estimate for known environmental factors that are reasonably likely to affect the required level of reserves. This provision for adverse deviation is intended to capture the potential adverse development from known environmental factors such as our entry into new geographical markets, changes in our geographic or product mix, the introduction of new customer populations, variation in benefit utilization, disease outbreaks, changes in provider reimbursement, fluctuations in medical cost trend, variation in claim submission patterns and variation in claims processing speed and payment patterns, changes in technology that provide faster access to claims data or change the speed of adjudication and settlement of claims, variability in claim inventory levels, non-standard claim development, and/or exceptional situations that require judgmental adjustments in setting the reserves for claims.

Circumstances to be considered in developing our best estimate of reserves include changes in enrollment, utilization levels, unit costs, mix of business, benefit plan designs, provider reimbursement levels, processing system conversions and changes, claim inventory levels, regulatory and legislative requirements, claim processing patterns, and claim submission patterns.  A comparison or prior period liabilities to re-estimated claim liabilities based on subsequent claims development is also considered in making the liability determination.  In the actuarial process, the methods and assumptions are not changed as reserves are recalculated, but rather the availability of additional paid claims information drives our changes in the re-estimate of the unpaid claim liability.  Changes in such development are recorded as a change to current period benefit expense.  The re-estimates or recasts are done monthly for the previous four calendar quarters.  On average, about 92% of the claims are paid within three months after the last day of the month in which they were incurred and about 5% are within the next three months, for a total of 97% paid within six months after the last day of the month in which they were incurred.

Management regularly reviews its assumptions regarding claim liabilities and makes adjustments to claims incurred when necessary.  If management’s assumptions regarding cost trends and utilization are significantly different than actual results, our consolidated statement of earnings and financial position could be impacted in future periods.  Changes to prior year estimates may result in an increase in claims incurred or a reduction of claims incurred in the period the change is made.  Further, due to the considerable variability of health care costs, adjustments to claims liabilities are made in each period and are sometimes significant as compared to the net income recorded in that period.  Prior year development of claim liabilities is recognized immediately upon the actuary’s judgment that a portion of the prior year liability is no longer needed or that an additional liability should have been accrued.  Health care trends are monitored in conjunction with the claim reserve analysis.  Based on these analyses, rating trends are adjusted to anticipate future changes in health care cost or utilization.  Thus, the managed care segment incorporates those trends as part of the development of premium rates in an effort to keep premium rating trends in line with claims trends.
 
As described above, completion factors and claims trend factors can have a significant impact on determination of our claim liabilities.  The following example provides the estimated impact on our December 31, 2017 claim liabilities, assuming the indicated hypothetical changes in completion and trend factors:
 
(Dollar amounts in millions)
       
         
Completion Factor 1
   
Claims Trend Factor 2
 
(Decrease) Increase
   
(Decrease) Increase
 
In completion factor
   
In unpaid claim
liabilities
   
In claims trend
factor
   
In unpaid claim
liabilities
 
                     
 
-1.2%
 
 
$
18.1
     
1.5%
 
 
$
20.1
 
 
-0.8%
 
   
12.0
     
1.0%
 
   
13.5
 
 
-0.4%
 
   
6.0
     
0.5%
 
   
6.7
 
 
0.4%
 
   
(5.9)
 
   
-0.5%
 
   
(6.7)
 
 
0.8%
 
   
(11.8)
 
   
-1.0%
 
   
(13.5)
 
 
1.2%
 
   
(17.6)
 
   
-1.5%
 
   
(20.1)
 
 
(1)
Assumes (decrease) increase in the completion factors for the most recent twelve months.

(2)
Assumes (decrease) increase in the claims trend factors for the most recent twelve months.

The segments’ reserving practice is to consistently recognize the actuarial best estimate as the ultimate liability for claims within a level of confidence required by actuarial standards.  Management believes that the methodology for determining the best estimate for claim liabilities at each reporting date has been consistently applied.

Amounts incurred related to prior years vary from previously estimated liabilities as the claims are ultimately settled.  Liabilities at any year-end are continually reviewed and re-estimated as information regarding actual claims payments, or run-out becomes known.  This information is compared to the originally established year-end liability.  Negative amounts reported for incurred claims related to prior years result from claims being settled for amounts less than originally estimated.  The reverse is true of reserve shortfalls.  Medical claim liabilities are usually described as having a “short tail”, which means that they are generally paid within several months of the member receiving service from the provider.  Accordingly, the majority, or approximately 93%, of any redundancy or shortfall relates to claims incurred in the previous calendar year-end, with the remaining 7% related to claims incurred prior to the previous calendar year-end.  Management has not noted any significant emerging trends in claim frequency and severity and the normal fluctuations in enrollment and utilization trends from year to year.
 
The following table shows the variance between the segment’s incurred claims for current period insured events and the incurred claims for such years had they been determined retrospectively (the “Incurred claims related to current period insured events” for the year shown plus or minus the “Incurred claims related to prior period insured events” for the following year as included in Note 10, Claim Liabilities and Claim Adjustment Expenses, of the Notes to Consolidated Financial Statements, included in Item 8, Financial Statements and Supplementary Data , of this Annual Report on Form 10-K).  This table shows that the segments’ estimates of this liability have approximated the actual development.
 
(Dollar amounts in millions)
 
2016
   
2015
   
2014
 
                   
Years ended December 31,
                 
Total incurred claims:
                 
As reported (1)
 
$
2,356.6
   
$
2,216.3
   
$
1,665.3
 
On a retrospective basis
   
2,343.8
     
2,207.3
     
1,645.6
 
Variance
 
$
12.8
   
$
9.0
   
$
19.7
 
Variance to total incurred claims as reported
   
0.5
%
   
0.4
%
   
1.2
%
 
(1)
Includes total claims incurred less adjustments for prior year reserve development.

Management expects that substantially all of the development of the 2017 estimate of medical claims payable will be known during 2018.

In the event this segment experiences an unexpected increase in health care cost or utilization trends, we have the following options to cover claim payments:

·
Through the management of our cash flows and investment portfolio.

·
In the Commercial business we have the ability to increase the premium rates throughout the year in the monthly renewal process, when renegotiating the premiums for the following contract year of each group as they become due.  We consider the actual claims trend of each group when determining the premium rates for the following contract year.

·
We have available short-term borrowing facilities that from time to time address differences between cash receipts and disbursements.

For additional information on our credit facilities, see section “Financing and Financing Capacity” of this Item.

Life Insurance Segment

At December 31, 2017, claim liabilities for the life insurance segment amounted to $45.5 million and represented 4.1% of total consolidated claim liabilities and 2.1% of our total consolidated liabilities.

The claim liabilities related to the life insurance segment are based on methods and underlying assumptions in accordance with GAAP.  The estimate of claim liabilities for this segment is based on the amount of benefits contractually determined for reported claims, and on estimates based on past experience modified for current trends, for unreported claims.  This estimate relies on observations of ultimate loss experience for similar historical events.

Claim reserve reviews are generally conducted on a monthly basis, in light of continually updated information. We review reserves using current inventory of policies and claims data.  These reviews incorporate a variety of actuarial methods, judgments and analysis.

The key assumption with regard to claim liabilities for our life insurance segment is related to claims incurred prior to the end of the year, but not yet reported to our subsidiary.  A liability for these claims is estimated based upon experience with regards to amounts reported subsequent to the close of business in prior years.  There are uncertainties in the development of these estimates; however, in recent years our estimates have resulted in immaterial redundancies or deficiencies.
 
Property and Casualty Insurance Segment

At December 31, 2017, claim liabilities for the property and casualty insurance segment amounted to $694.4 million and represented 62.7% of the total consolidated claim liabilities and 31.5% of our total consolidated liabilities.  Claims liabilities related to losses caused by Hurricanes Irma and Maria amount to approximately $605 million.

Estimates of the ultimate cost of claims and loss-adjustment expenses of this segment are based largely on the assumption that past developments, with appropriate adjustments due to known or unexpected changes, are a reasonable basis on which to predict future events and trends, and involve a variety of actuarial techniques that analyze current experience, trends and other relevant factors.  Property and casualty insurance claim liabilities are categorized and tracked by line of business.  Medical malpractice policies are written on a claims-made basis.  Policies written on a claims-made basis require that claims be reported during the policy period.  Other lines of business are written on an occurrence basis. Hurricane losses include the use of models from industry recognized firms having data, historical and current information about the events, to estimate ultimate losses.  These estimates are supplemented by internal estimates of other costs deemed necessary to develop the ultimate losses.

Individual case estimates for reported claims are established by a claims adjuster and are changed as new information becomes available during the course of handling the claim.  Our property and casualty business, other than medical malpractice, is primarily short-tailed business, where losses (e.g. paid losses and case reserves) are generally reported quickly.

Claim reserve reviews are generally conducted on a quarterly basis, in light of continually updated information.  Our actuary certifies reserves for both current and prior accident years using current claims data.  These reviews incorporate a variety of actuarial methods, judgments, and analysis.  For each line of business, a variety of actuarial methods are used, with the final selections of ultimate losses that are appropriate for each line of business selected based on the current circumstances affecting that line of business.  These selections incorporate input from management, particularly from the claims, underwriting and operations divisions, about reported loss cost trends and other factors that could affect the reserve estimates.

Key assumptions are based on the consideration that past emergence of paid losses and case reserves is credible and likely indicative of future emergence and ultimate losses.  A key assumption is the expected loss ratio for the current accident year.  This expected loss ratio is generally determined through a review of the loss ratios of prior accident years and expected changes to earned pricing, loss costs, mix of business, and other factors that are expected to impact the loss ratio for the current accident year.  Another key assumption is the development patterns for paid and reported losses (also referred to as the loss emergence and settlement patterns).  The reserves for unreported claims for each year are determined after reviewing the indications produced by each actuarial projection method, which, in turn, rely on the expected paid and reported development patterns and the expected loss ratio for that year.

At December 31, 2017, the actuarial reserve range determined by the actuaries was from $638 million to $760 million.  Excluding Hurricanes losses, the range is $84 million to $99 million.  Management reviews the results of the reserve estimates in order to determine any appropriate adjustments in the recording of reserves.  Adjustments to reserve estimates are made after management’s consideration of numerous factors, including but not limited to the magnitude of the difference between the actuarial indication and the recorded reserves, improvement or deterioration of actuarial indications in the period, the maturity of the accident year, trends observed over the recent past and the level of volatility within a particular line of business.  In general, changes are made more quickly to more mature accident years and less volatile lines of business.  Varying the net expected loss ratio by +/-1% in all lines of business for the six most recent accident years would increase/decrease the claims incurred by approximately $5.4 million.

Liability for Future Policy Benefits

Our life insurance segment establishes, and carries as liabilities, actuarially determined amounts that are calculated to meet its policy obligations when a policy matures or surrenders, an insured dies or becomes disabled or upon the occurrence of other covered events.  We compute the amounts for actuarial liabilities in conformity with GAAP.
 
Liabilities for future policy benefits for whole life and term insurance products and active life reserves for accident and health products are computed by the net level premium method, using interest assumptions ranging from 3.90% to 5.75% and withdrawal, mortality, morbidity and maintenance expense assumptions appropriate at the time the policies were issued (or when a block of business was purchased, as applicable).  Accident and health unpaid claim reserves are stated at amounts determined by estimates on individual claims and estimates of unreported claims based on past experience.  Deferred annuity reserves are carried at the account value.

For deferred annuities, the liability for future policy benefits is equal to total policy account values.  The liabilities for all other products are based upon a variety of actuarial assumptions that are uncertain.  The most significant of these assumptions is the level of anticipated death and health claims.  Other assumptions that are less significant to the appropriate level of the liability for future policy benefits are anticipated policy persistency rates, investment yields, and operating expense levels.  These are reviewed frequently by our subsidiary’s external actuaries, to assure that the current level of liabilities for future policy benefits is sufficient, in combination with anticipated future cash flows, to provide for all contractual obligations.  For all products, except for deferred annuities, the basis for the liability for future policy benefits is established at the time of issuance of each contract and would only change if our experience deteriorates to the point that the level of the liability is not adequate to provide for future policy benefits.  We do not currently expect that level of deterioration to occur.

Deferred Policy Acquisition Costs and Value of Business Acquired

Certain costs for acquiring life and property and casualty insurance business are deferred.  Acquisition costs related to the managed care business are expensed as incurred.

The costs of acquiring new life business, principally commissions, and certain variable underwriting and policy issue expenses of our life insurance segment, have been deferred.  These costs, including value of business acquired (“VOBA”) recorded upon our acquisitions of TSV and TSB, are amortized to income over the premium-paying period of the related whole life and term insurance policies in proportion to the ratio of the expected annual premium revenue to the expected total premium revenue, and over the anticipated lives of universal life policies in proportion to the ratio of the expected annual gross profits to the expected total gross profits.  The expected premiums revenue and gross profits are based upon the same mortality and withdrawal assumptions used in determining the liability for future policy benefits.  For universal life and deferred annuity policies, changes in the amount or timing of expected gross profits result in adjustments to the cumulative amortization of these costs.  The effect on the amortization of deferred policy acquisition costs of revisions to estimated gross profits is reported in earnings in the period such estimated gross profits are revised.

The schedules of amortization of life insurance deferred policy acquisition costs (“DPAC”) and VOBA are based upon actuarial assumptions regarding future events that are uncertain.  For all products, other than universal life and deferred annuities, the most significant of these assumptions is the level of contract persistency and investment yield rates.  For these products the basis for the amortization of DPAC and VOBA is established at the issue of each contract and would only change if our segment’s experience deteriorates to the point that the level of the net liability is not adequate.  We do not currently expect that level of deterioration to occur.  For the universal life and deferred annuity products, amortization schedules are based upon the level of historic and anticipated gross profit margins, from the date of each contract’s issued (or purchase, in the case of VOBA).  These schedules are based upon several actuarial assumptions that are uncertain, are reviewed annually and are modified if necessary.  The most significant of these assumptions are claims, investment yield rates and contract persistency.  Based upon the most recent actuarial reviews of all of the assumptions, we do not currently anticipate material changes to the level of these amortization schedules.

The property and casualty business acquisition costs consist of commissions net of reinsurance commissions, during the production of business are deferred and amortized ratably over the terms of the policies.  The method used in calculating deferred acquisition costs limits the amount of such deferred costs to actual costs or their estimated realizable value, whichever is lower.
 
Impairment of Investments

Impairment of an investment exists if a decline in the estimated fair value is below the amortized cost of the security.  Management regularly monitors and evaluates the difference between the cost and estimated fair value of investments.  For investments with a fair value below cost, the process includes evaluating: (1) the length of time and the extent to which the estimated fair value has been less than amortized cost for fixed maturity securities, or cost for equity securities, (2) the financial condition, near-term and long-term prospects for the issuer, including relevant industry conditions and trends, and implications of rating agency actions, (3) the Company’s intent to sell or the likelihood of a required sale prior to recovery, (4) the recoverability of principal and interest for fixed maturity securities, or cost for equity securities, and (5) other factors, as applicable.  This process is not exact and further requires consideration of risks such as credit and interest rate risks.  Consequently, if an investment’s cost exceeds its estimated fair value solely due to changes in interest rates, other-than temporary impairment may not be appropriate.  Due to the subjective nature of our analysis, along with the judgment that must be applied in the analysis, it is possible that we could reach a different conclusion whether or not to impair a security if we had access to additional information about the investee.  Additionally, it is possible that the investee’s ability to meet future contractual obligations may be different than what we determined during its analysis, which may lead to a different impairment conclusion in future periods.  If after monitoring and analyzing impaired securities, management determines that a decline in the estimated fair value of any available-for-sale or held-to-maturity security below cost is other than temporary, the carrying amount of the security is reduced to its fair value according to current accounting guidance.  The new cost basis of an impaired security is not adjusted for subsequent increases in estimated fair value.  In periods subsequent to the recognition of an other-than-temporary impairment, the impaired security is accounted for as if it had been purchased on the measurement date of the impairment.  For debt securities, the discount (or reduced premium) based on the new cost basis may be accreted into net investment income in future periods based on prospective changes in cash flow estimates, to reflect adjustments to the effective yield.

Management reviews investment portfolios under our impairment review policy.  Given current market conditions and the significant judgments involved, there is a continuing risk that further declines in fair value may occur and material other-than-temporary impairments may be recorded in future periods.  Management from time to time may sell investments as part of its asset/liability management process or to reposition its investment portfolio based on current and expected market conditions.

During the year ended December 31, 2017, we recognized an other-than-temporary impairment amounting to $49 thousands on equity securities classified as available for sale.  The impairment analysis indicated that , none of the securities whose carrying amount exceeded its estimated fair value was considered other-than-temporarily impaired as of that date; however, several factors are beyond management’s control, such as the following: financial condition of the issuers, movement of interest rates, specific situations within corporations, among others.  Over time, the economic and market environment may provide additional insight regarding the estimated fair value of certain securities, which could change management’s judgment regarding impairment.  This could result in realized losses related to other-than-temporary declines being charged against future income.

Our fixed maturity securities are sensitive to interest rate and credit risk fluctuations, which impact the fair value of individual securities.  Our equity securities are sensitive to equity price risks, for which potential losses could arise from adverse changes in the value of equity securities.  For additional information on the sensitivity of our investments, see “Item 7A.   Quantitative and Qualitative Disclosures About Market Risk” in this Annual Report on Form 10-K.

A detail of the gross unrealized losses on investment securities and the estimated fair value of the related securities, aggregated by investment category and length of time that individual securities have been in a continuous unrealized loss position as of December 31, 2017 and 2016 is included in Note 3, Investment in Securities, of the Notes to Consolidated Financial Statements, included in Item 8, Financial Statements and Supplementary Data , of this Annual Report on Form 10-K
 
Allowance for Doubtful Receivables

We estimate the amount of uncollectible receivables in each period and establish an allowance for doubtful receivables considering, among other things, the continued deterioration of the local economy, the exposure to government accounts and the challenging business environment in the Island.  The allowance for doubtful receivables amounted to $35.9 million and $37.3 million as of December 31, 2017 and 2016, respectively.  As of December 31, 2017 and 2016, the Company had premiums and other receivables of $81.8 million and $57.8 million, respectively, from the Government of Puerto Rico, including its agencies, municipalities, and public corporations.  The related allowance for doubtful receivables as of December 31, 2017 and 2016 was $16.4 million and $18.9 million, respectively.  The amount of the allowance is based on the aging of unpaid accounts, information about the customer’s creditworthiness and other relevant information.  The estimates of uncollectible accounts are revised each period, and changes are recorded in the period they become known.  In determining the allowance, we use predetermined percentages applied to aged account balances, as well as individual analysis of large accounts.  These percentages are based on our collection experience and are periodically evaluated.  A significant change in the level of uncollectible accounts would have a material effect on our results of operations.

In addition to premium-related receivables, we evaluate the risk in the realization of other accounts receivable, including balances due from third parties related to overpayment of medical claims and rebates, among others.  These amounts are individually analyzed and the allowance determined based on the specific collectivity assessment and circumstances of each individual case.

We consider this allowance adequate to cover probable losses that may result from our inability to subsequently collect the amounts reported as accounts receivable.  However, such estimates may change significantly in the event that unforeseen economic conditions adversely impact the ability of third parties to repay the amounts due to us.

Goodwill and Other Intangible Assets

Our consolidated goodwill and other intangible assets at December 31, 2017 were $25.4 million and $3.6 million, respectively.  At December 31, 2016 the consolidated goodwill and other intangible assets were $25.4 million and $4.9 million, respectively.   The goodwill and other intangible assets balance for both years were primarily related to the acquisition of TSA in 2011.  As of December 31, 2017 and 2016, the TSA goodwill was $25.0 million.  As of December 31, 2017 and 2016 other intangible assets related to the TSA acquisition were $3.5 million and $4.6 million, respectively.

We account for goodwill and intangible assets with indefinite lives in accordance with Accounting Standard Codification (ASC) No. 350, Goodwill and Other Intangible Assets, which specifies the types of acquired intangible assets that are required to be recognized and reported separately from goodwill.  Under this guidance, goodwill is not amortized but is tested for impairment at least annually and more frequently if events and circumstances indicate that the asset might be impaired.  An impairment loss is recognized to the extent that the carrying amount exceeds the asset’s fair value.  For goodwill, the impairment determination is made at the reporting unit level and consists of two steps.

Our impairment tests involve the use of estimates related to the fair value of the reporting unit and require a significant degree of management judgment and the use of subjective assumptions.  The Company assesses qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, including goodwill.  If determined to be necessary, the two-step impairment test is used to identify potential goodwill impairment and measure the amount of a goodwill impairment loss to be recognized (if any).  First, the Company determines the fair value of a reporting unit and compares it to its carrying amount.  Second, if the carrying amount of a reporting unit exceeds its fair value, an impairment loss is recognized for any excess of the carrying amount of the reporting unit’s goodwill over the implied fair value of that goodwill.  The implied fair value of goodwill is determined by allocating the fair value of the reporting unit in a manner similar to a purchase price allocation.  The residual fair value after this allocation is the implied fair value of the reporting unit goodwill.
 
Our goodwill impairment test uses the income approach to estimate a reporting unit’s fair value.  Use of the income approach for our goodwill impairment test reflects our view that valuation methodology provides a reasonable estimate of fair value.  The income approach is developed using assumptions about future premiums, expected claims, MLR, operating expenses and net income derived from our internal planning process and historical trends.  These estimated future cash flows are then discounted. Our assumed discount rate is based on our industry’s weighted average cost of capital.  It assumes the effective implementation of measures to contain the utilization and cost trends. The company also uses the market approach as part of their impairment analysis.  Events or changes in circumstances, including a decrease in membership, an increase in MLR and/or operating expenses, could result in goodwill impairment.

As required by Financial Accounting Standard Board (“FASB”) guidance, we completed our annual impairment tests of existing goodwill during the fourth quarter of 2017 and 2016.  Certain interim impairment tests are also performed when potential impairment indicators exist or other changes in our business occur.  If we do not achieve our earnings objectives or the cost of capital rises significantly, the assumptions and estimates underlying these impairment evaluations could be adversely affected and result in future impairment charges that would negatively impact our operating results.  On the other hand, in October 2016 the TSA HMO contract scored 4.0 overall on a 5.0 star rating system, increasing 1.0 versus the prior year, and achieved 5 stars in Part D, all of this is expected to generate additional premiums in 2018.  The result of the impairment test performed in 2017 and 2016 indicated that the fair value of the TSA unit exceeded its carrying value by approximately 26% and 47%, respectively.

While we believe we have appropriately allocated the purchase price of our acquisitions, this allocation requires many assumptions to be made regarding the fair value of assets and liabilities acquired.  In addition, estimated fair values developed based on our assumptions and judgments might be significantly different if other reasonable assumptions and estimates were to be used.  If estimated fair values are less than the carrying values of the reporting unit or if significant impairment indicators are noted relative to other intangible assets subject to amortization, we may be required to record impairment losses against future income.

Other Significant Accounting Policies

We have other accounting policies that are important to an understanding of the consolidated financial statements.  See Note 2, Significant Accounting Policies, of the Notes to Consolidated Financial Statements, included in Item 8, Financial Statements and Supplementary Data , of this Annual Report on Form 10-K.

VI. Recently Issued Accounting Standards

For a description of our recently issued accounting standards, see Note 2, Significant Accounting Policies, of the Notes to Consolidated Financial Statements, included in Item 8, Financial Statements and Supplementary Data , of this Annual Report on Form 10-K.
 
Item 7A.
Quantitative and Qualitative Disclosures About Market Risk

We are exposed to certain market risks that are inherent in our financial instruments, which arise from transactions entered into in the normal course of business.  We are also subject to additional market risk with respect to certain of our financial instruments.  We must effectively manage, measure, and monitor the market risk associated with our invested assets and interest rate sensitive liabilities.  We have established and implemented comprehensive policies and procedures to minimize the effects of potential market volatility.

Market Risk Exposure

We have exposure to market risk mostly in our investment activities.  For purposes of this disclosure, “market risk” is defined as the risk of loss resulting from changes in interest rates and equity prices.  Analytical tools and monitoring systems are in place to assess each one of the elements of market risks.

Our investment portfolio consists mainly of investment grade fixed income and a smaller portion is held in equity securities and alternative investments. The investment portfolio is conservative, diversified across and within asset classes, and has the following objectives, in order of importance: capital preservation, liquidity, income generation and capital appreciation. The interest rate risk of both our investments and liabilities is regularly evaluated.

The investment portfolio is centrally managed by investment professionals and decisions are taken based on the guidelines and limitations described in our Investment Policy and the Puerto Rico Insurance Code. The Investment Policy is approved by the Board of Directors following the recommendation of the Investment and Financing Committee of the Board of Directors (the “Investment and Financing Committee”). The Investment and Financing Committee establishes guidelines to ensure the Investment Policy is adhered to and any exception must be reported to the Investment and Financing Committee.

We use a sensitivity analysis to measure the market risk related to our holdings of invested assets and other financial instruments.  This analysis estimates the potential changes in fair value of the instruments subject to market risk.  This sensitivity analysis is an estimate and should not be viewed as predictive of our future financial performance.  Our actual losses in any particular year could exceed the amounts indicated in the following paragraphs.  Limitations related to this sensitivity analysis include:

·
the market risk information is limited by the assumptions and parameters established in creating the related sensitivity analysis, including the impact of prepayment rates on mortgages; and

·
the model assumes that the composition of assets and liabilities remains unchanged throughout the year.

Accordingly, we use such models as tools and not as a substitute for the experience and judgment of our management.

Interest Rate Risk

Our exposure to interest rate changes results from our significant holdings of fixed maturity securities.  We are also exposed to interest rate risk from our variable interest secured term loan and from our policyholder deposits.

Equity Price Risk

Our investments in equity securities expose us to price risks, for which potential losses could arise from adverse changes in the value of these investments.

Risk Measurement

Our available-for-sale and held-to-maturity securities are a source of market risk.  As of December 31, 2017 approximately 76% and 100% of our investments in available-for-sale and held-to-maturity securities, respectively, consisted of fixed maturity securities.  The remaining balance of the available-for-sale portfolio is comprised of equity securities and alternative investments.  Available-for-sale securities are recorded at fair value and changes in the fair value of these securities, net of the related tax effect, are excluded from operations and are reported as a separate component of other comprehensive income (loss) until realized.  Held-to-maturity securities are recorded at amortized cost and adjusted for the amortization or accretion of premiums or discounts.  The fair value of the investments in our available-for-sale and held-to-maturity portfolios is exposed to both interest rate risk and equity price risk.
 
Interest Rate Risk

We have evaluated the net impact to the fair value of our fixed income investments of a significant one-time change in interest rate risk using a combination of both statistical and fundamental methodologies.  From these shocked values a resultant market price appreciation/depreciation can be determined after portfolio cash flows are modeled and evaluated over instantaneous 100, 200, and 300 basis point rate shifts.  Techniques used in the evaluation of cash flows include Monte Carlo simulation through a series of probability distributions over 200 interest rate paths.  Necessary prepayment speeds are compiled using Salomon Brothers Yield Book, which sources numerous factors in deriving speeds, including but not limited to: historical speeds, economic indicators, street consensus speeds, etc.  Securities evaluated by us under these scenarios include mortgage pass-through certificates and collateralized mortgage obligations of U.S. agencies, and private label structures, provided that cash flows information is available.  The following table sets forth the result of this analysis for the years ended December 31, 2017 and 2016.  The analysis does not consider any action that management can take to mitigate the impact of changes in market rates.
 
(Dollar amounts in millions)
                   
 
Change in Interest Rates
     
Expected
Fair Value
     
Amount of
Decrease
     
%
Change
 
  
                     
December 31, 2017:
                   
Base Scenario
   
$
1,219.3
             
+100 bp
 
   
1,163.4
     
(55.9
)
   
(4.6
)%
+200 bp
 
   
1,111.7
     
(107.6
)
   
(8.8
)%
+300 bp
 
   
1,062.4
     
(156.9
)
   
(12.9
)%
December 31, 2016:
                         
Base Scenario
   
$
1,154.6
                 
+100 bp
 
   
1,102.0
     
(52.6
)
   
(4.6
)%
+200 bp
 
   
1,053.2
     
(101.4
)
   
(8.9
)%
+300 bp
 
   
1,007.1
     
(147.5
)
   
(13.0
)%
 
We believe that an interest rate shift in a 12-month period of 100 basis points represents a moderately adverse outcome, while a 200 basis point shift is significantly adverse and a 300 basis point shift is unlikely given historical precedents.  Although we classify 99.8% of our fixed maturity securities as available-for-sale, our cash flows and the intermediate duration of our investment portfolio should allow us to hold securities until maturity, thereby avoiding the recognition of losses, should interest rates rise significantly.

Equity Price Risk

Our equity securities in the available-for-sale portfolio is composed of mutual funds whose underlying assets are comprised of domestic equity securities, international equity securities and higher risk fixed income instruments as well as certain alternative investments in the form of commitments to limited liability partnerships. The fixed income mutual funds invest in loan participations, high yield debt and emerging market debt.  The fixed income funds invest primarily in debt securities issued or guaranteed by corporations, financial institutions and governmental entities that are either unrated or have non-investment grade ratings from either Standard & Poor’s or Moody’s.
 
Our investments in mutual funds exposes us to equity price risk and, because of the underlying assets included in these mutual funds, result in an indirect exposure to credit risk.  We manage this indirect exposure to credit risk by closely monitoring the performance of these mutual funds.
 
Our alternative investments in the available-for-sale portfolio are comprised of commitments to limited liability partnerships. These private funds call capital over time and invest in traditional private equity, infrastructure equity, real estate debt and corporate debt. The investments are unrated, illiquid and expose us to a variety of underlying risks. We manage these exposures by closely monitoring the performance of these funds.

Assuming an immediate decrease of 10% in the market value of our equity securities as of December 31, 2017 and 2016, the hypothetical loss in the fair value of these investments would have been approximately $37.7 million and $27.0 million, respectively.

Other Risk Measurement

We are subject to interest rate risk on our variable interest secured term loan and our policyholder deposits.  Shifting interest rates do not have a material effect on the fair value of these instruments.  The secured term loan has a variable interest rate structure, which reduces the potential exposure to interest rate risk.  The policyholder deposits have short-term interest rate guarantees, which also reduce the accounts’ exposure to interest rate risk.
 
Item 8.
Financial Statements and Supplementary Data

Financial Statements

For our audited consolidated financial statements as of December 31, 2017 and 2016 and for each of the three years ended December 31, 2017, 2016 and 2015 see Index to consolidated financial statements in “Item 15.   Exhibits and Financial Statements   Schedules” to this Annual Report on Form 10-K.

Selected Quarterly Financial Data
 
   
2017
 
   
March 31
   
June 30
   
September 30
   
December 31
   
Total
 
                               
Revenues
                             
Premiums earned, net
 
$
702,273
   
$
722,891
   
$
714,325
   
$
687,443
   
$
2,826,932
 
Administrative service fees
   
4,379
     
4,548
     
3,391
     
4,196
     
16,514
 
Net investment income
   
12,016
     
12,698
     
12,395
     
14,506
     
51,615
 
Other operating revenues
   
965
     
1,121
     
941
     
633
     
3,660
 
Total operating revenues
   
719,633
     
741,258
     
731,052
     
706,778
     
2,898,721
 
Net realized investment gains (losses):
                                       
Total other-than-temporary impairment losses on securities
   
-
     
-
     
-
     
(49
)
   
(49
)
Net realized gains, excluding other-than-temporary impairment losses on securities
   
336
     
4,054
     
3,753
     
2,737
     
10,880
 
Total net realized investment gains
   
336
     
4,054
     
3,753
     
2,688
     
10,831
 
Other income, net
   
2,525
     
587
     
3,409
     
12
     
6,533
 
Total revenues
   
722,494
     
745,899
     
738,214
     
709,478
     
2,916,085
 
Benefits and expenses
                                       
Claims incurred
   
620,863
     
611,297
     
583,625
     
537,316
     
2,353,101
 
Operating expenses
   
110,946
     
118,720
     
119,145
     
128,402
     
477,213
 
Total operating costs
   
731,809
     
730,017
     
702,770
     
665,718
     
2,830,314
 
Interest expense
   
1,686
     
1,721
     
1,709
     
1,678
     
6,794
 
Total benefits and expenses
   
733,495
     
731,738
     
704,479
     
667,396
     
2,837,108
 
(Loss) income before taxes
   
(11,001
)
   
14,161
     
33,735
     
42,082
     
78,977
 
Income tax (benefit) expense
   
(6,658
)
   
1,456
     
11,824
     
17,874
     
24,496
 
Net (loss) income
   
(4,343
)
   
12,705
     
21,911
     
24,208
     
54,481
 
Less: Net loss attributable to non-controlling interest
   
1
     
-
     
1
     
3
     
5
 
Net (loss) income attributable to TSM
 
$
(4,342
)
 
$
12,705
   
$
21,912
   
$
24,211
   
$
54,486
 
Basic net (loss) income per share
 
$
(0.18
)
 
$
0.52
   
$
0.91
   
$
1.02
   
$
2.27
 
Diluted net (loss) income per share
 
$
(0.18
)
 
$
0.52
   
$
0.91
   
$
1.01
   
$
2.26
 
 
   
2016
 
   
March 31
   
June 30
   
September 30
   
December 31
   
Total
 
                               
Revenues
                             
Premiums earned, net
 
$
738,534
   
$
729,049
   
$
721,187
   
$
701,871
   
$
2,890,641
 
Administrative service fees
   
5,083
     
4,520
     
4,146
     
4,094
     
17,843
 
Net investment income
   
11,358
     
12,875
     
12,337
     
12,343
     
48,913
 
Other operating revenues
   
812
     
915
     
871
     
863
     
3,461
 
Total operating revenues
   
755,787
     
747,359
     
738,541
     
719,171
     
2,960,858
 
Net realized investment gains (losses):
                                       
Total other-than-temporary impairment losses on securities
   
-
     
(1,434
)
   
-
     
-
     
(1,434
)
Net realized gains, excluding other-than-temporary impairment losses on securities
   
58
     
2,954
     
5,376
     
10,425
     
18,813
 
Total net realized investment gains
   
58
     
1,520
     
5,376
     
10,425
     
17,379
 
Other income, net
   
875
     
3,859
     
734
     
1,101
     
6,569
 
Total revenues
   
756,720
     
752,738
     
744,651
     
730,697
     
2,984,806
 
Benefits and expenses
                                       
Claims incurred
   
626,694
     
622,087
     
629,169
     
594,241
     
2,472,191
 
Operating expenses
   
122,980
     
121,112
     
123,406
     
126,396
     
493,894
 
Total operating costs
   
749,674
     
743,199
     
752,575
     
720,637
     
2,966,085
 
Interest expense
   
1,882
     
1,954
     
1,893
     
1,906
     
7,635
 
Total benefits and expenses
   
751,556
     
745,153
     
754,468
     
722,543
     
2,973,720
 
Income (loss) before taxes
   
5,164
     
7,585
     
(9,817
)
   
8,154
     
11,086
 
Income tax expense (benefit)
   
1,709
     
3,707
     
(7,873
)
   
(3,888
)
   
(6,345
)
Net income (loss)
   
3,455
     
3,878
     
(1,944
)
   
12,042
     
17,431
 
Less: Net loss attributable to non-controlling interest
   
1
     
2
     
3
     
1
     
7
 
Net income (loss) attributable to TSM
 
$
3,456
   
$
3,880
   
$
(1,941
)
 
$
12,043
   
$
17,438
 
Basic net income (loss) per share
 
$
0.14
   
$
0.16
   
$
(0.08
)
 
$
0.49
   
$
0.71
 
Diluted net income (loss) per share
 
$
0.14
   
$
0.16
   
$
(0.08
)
 
$
0.49
   
$
0.71
 
 
Item 9.
Changes in and Disagreements with Accountants on Accounting and Financial Disclosures

There have been no changes in or disagreements with our independent registered public accounting firm on accounting or financial disclosures.

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Stockholders and the Board of Directors of Triple-S Management Corporation

Opinion on Internal Control over Financial Reporting

We have audited the internal control over financial reporting of Triple S Management Corporation and subsidiaries (the “Company”) as of December 31, 2017, based on criteria established in Internal Control — Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2017, based on criteria established in Internal Control — Integrated Framework (2013) issued by COSO.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated financial statements and financial statements schedules as of and for the year ended December 31, 2017, of the Company and our report dated March 7 , 2018, expressed an unqualified opinion on those financial statements.

Basis for Opinion

The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Managements Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

Definition and Limitations of Internal Control over Financial Reporting

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
 
/s/ DELOITTE & TOUCHE LLP
 
San Juan, Puerto Rico
March 7 , 2018
 
Stamp No. E308502
affixed to original.
 
Item 9A.
Controls and Procedures

Evaluation of Disclosure Controls and Procedures

In connection with the preparation of this Annual Report on Form 10-K, management, under the supervision and with the participation of the chief executive officer and the chief financial officer, conducted an evaluation of the effectiveness of our “disclosure controls and procedures” as of the end of this period (as such term is defined under Exchange Act Rule 13a-15(e)) of the Corporation and its subsidiaries.  Disclosure controls and procedures are designed to ensure that information required to be disclosed by the issuer in reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms and that such information is accumulated and communicated to management, including the chief executive officer and chief financial officer, to allow timely decisions regarding required disclosures.  A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.  There are inherent limitations to the effectiveness of any system of disclosure controls and procedures, including the possibility that judgments in decision-making can be faulty, and breakdowns as a result of simple errors or mistake.  Accordingly, even effective disclosure controls and procedures can only provide reasonable assurance of achieving their control objectives.  The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

Based on this evaluation, our chief executive officer and chief financial officer have concluded that as of December 31, 2017, which is the end of the period covered by this Annual Report on Form 10-K, our disclosure controls and procedures are effective to a reasonable level of assurance.

There were no significant changes in our disclosure controls and procedures, or in factors that could significantly affect internal controls, subsequent to the date the chief executive officer and chief financial officer completed the evaluation referred to above.

Management’s Report on Internal Control Over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting and for the assessment of the effectiveness of “internal control over financial reporting,” as defined under Exchange Act Rule 13a-15(f).  The Company’s internal control over financial reporting is a process designed by, or under the supervision of, the Company’s chief executive officer and chief financial officer, and effected by the Company’s board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the Company’s consolidated financial statements for external purposes in accordance with generally accepted accounting principles (“GAAP”), and includes those policies and procedures that:

·
pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company;

·
provide reasonable assurance that transactions are recorded as necessary to permit preparation of consolidated financial statements in accordance with GAAP and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and

·
provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company’s assets that could have a material effect on the consolidated financial statements.
 
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.  Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
 
Management, under the supervision and with the participation of the chief executive officer and chief financial officer, assessed the effectiveness of the Company’s internal control over financial reporting as of December 31, 2017 based on criteria described in the “Internal Control—Integrated Framework” issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) on May 14, 2013.  Based on that assessment and those criteria, management has concluded that the Company’s internal control over financial reporting was effective as of December 31, 2017 to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the Company’s consolidated financial statements for external reporting purposes in accordance with GAAP.

The effectiveness of our internal control over financial reporting as of December 31, 2017 has been audited by Deloitte & Touche, LLP, an independent registered public accounting firm, as stated in their report which is included in this Annual Report on Form 10-K.

Changes in Internal Control Over Financial Reporting

No changes in our internal control over financial reporting (as such term is defined in the Exchange Act Rule 13a-15(f)) occurred during the fiscal quarter ended December 31, 2017 that materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

9B.
Other Information

None.

Part III

Item 10.
Directors, Executive Officers and Corporate Governance

The Board has established a code of business conduct and ethics that applies to our employees, agents, independent contractors, consultants, officers and directors.  The complete text of the Code of Business Conduct and Ethics is available at the Corporation’s website at www.triplesmanagement.com.

The information required by this Item is incorporated herein by reference from our definitive Proxy Statement for our 2018 Annual Meeting of Shareholders, which will be filed with the SEC pursuant to Regulation 14A within 120 days after the end of our last fiscal year.

Item 11.
Executive Compensation

The information required by this Item is incorporated herein by reference from our definitive Proxy Statement for our 2018 Annual Meeting of Shareholders, which will be filed with the SEC pursuant to Regulation 14A within 120 days after the end of our last fiscal year.

Item 12.
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

The information required by this Item is incorporated herein by reference from our definitive Proxy Statement for our 2018 Annual Meeting of Shareholders, which will be filed with the SEC pursuant to Regulation 14A within 120 days after the end of our last fiscal year.

Item 13.
Certain Relationships and Related Transactions, and Director Independence

The information required by this Item is incorporated herein by reference from our definitive Proxy Statement for our 2018 Annual Meeting of Shareholders, which will be filed with the SEC pursuant to Regulation 14A within 120 days after the end of our last fiscal year.
 
Item 14.
Principal Accountant Fees and Services

The information required by this Item is incorporated herein by reference from our definitive Proxy Statement for our 2018 Annual Meeting of Shareholders, which will be filed with the SEC pursuant to Regulation 14A within 120 days after the end of our last fiscal year.
 
Part IV
 
Item 15.
Exhibits and Financial Statements Schedules

Financial Statements and Schedules
 
Financial Statements
Description
   
F-1
Report of Independent Registered Public Accounting Firm
   
F-2
Consolidated Balance Sheets as of December 31, 2017 and 2016
   
F-3
Consolidated Statements of Earnings for the years ended December 31, 2017, 2016 and 2015
   
F-4
Consolidated Statements of Comprehensive Income for the years ended December 31, 2017, 2016 and 2015
   
F-5
Consolidated Statements of Stockholders’ Equity for the years ended December 31, 2017, 2016 and 2015
   
F-6
Consolidated Statements of Cash Flows for the years ended December 31, 2017, 2016 and 2015
   
F-7
Notes to Consolidated Financial Statements – December 31, 2017, 2016 and 2015

Financial Statements
Schedules
Description
   
S-1
Schedule II – Condensed Financial Information of the Registrant
   
S-2
Schedule III – Supplementary Insurance Information
   
S-3
Schedule IV – Reinsurance
   
S-4
Schedule V – Valuation and Qualifying Accounts
   
S-5
Schedule VI – Supplementary Information Concerning Consolidated Property and Casualty Insurance Operations
 
Schedule I – Summary of Investments was omitted because the information is disclosed in the notes to the audited consolidated financial statements.
 
Item 16.
Form 10-K Summary
 
None
 
The exhibits listed on the Exhibits Index starting on page 94 of this report are filed herewith or are incorporated herein by reference.
 
Exhibits
 
Exhibits
Description
   
Amended and Restated Articles of Incorporation (incorporated herein by reference to Exhibit 3(i)(d) to TSM’s Annual Report on Form 10-K for the Year Ended December 31, 2007 (File No. 001-33865).
   
Amendment to Article Tenth of the Amended and Restated Articles of Incorporation of Triple-S Management Corporation, incorporated by reference to Exhibit 3(i)(b) to TSM’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2008 (File No. 001-33865).
 
Exhibits
Description
   
Articles of Incorporation of Triple-S Management Corporation, as currently in effect, incorporated by reference to Exhibit 3(i)(c) to TSM’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2008 (File No. 001-33865).
   
Amendments to Article Tenth and Thirteenth of the Amended and Restated Articles of Incorporation of Triple-S Management Corporation (incorporated herein by reference to Exhibit 3(i)(d) to TSM’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2017 (File No. 001-33865)).
   
Composite Amended and Restated Articles of Incorporation of Triple-S Management Corporation (incorporated herein by reference to Exhibit 3(i)(e) to TSM’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2017 (File No. 001-33865)).
   
Amended and Restated Bylaws of Triple-S Management Corporation (incorporated herein by reference to Exhibit 3.1 to TSM’s Current Report on Form 8-K filed on June 11, 2010 (File No. 001-33865)).
   
Amendment to the Contract between Administración de Seguros de Salud de Puerto Rico (ASES) and Triple-S Salud, Inc. to administer the provision of physical & behavioral health services under the Government Health Plan Program (File No. 001-33865).
   
Amended and Restated Agreement between the Puerto Rico Health Insurance Administration and TSS to administer the provision of the physical health component of the Medicaid program in designated service regions (incorporated herein by reference to Exhibit 10.1 to TSM’s Quarterly Report on Form 10-Q filed on August 8, 2013 (File No. 001-33865)).
   
Federal Employees Health Benefits Contract (incorporated herein by reference to Exhibit 10.5 to TSM's General Form of Registration of Securities on Form 10 (File No. 001-33865)).
   
Credit Agreement with FirstBank Puerto Rico in the amount of $41,000,000 (incorporated herein by reference to Exhibit 10.6 to TSM's General Form of Registration of Securities on Form 10 (File No. 001-33865)).
   
Credit Agreement with FirstBank Puerto Rico in the amount of $20,000,000 (incorporated herein by reference to Exhibit 10.7 to TSM's General Form of Registration of Securities on Form 10 (File No. 001-33865)).
   
Non-Contributory Retirement Program (incorporated herein by reference to Exhibit 10.8 to TSM's General Form of Registration of Securities on Form 10 (File No. 001-33865)).
   
Blue Shield License Agreement by and between BCBSA and TSM, including revisions, if any, adopted by Member Plans through the November 19, 2009 meeting (incorporated herein by reference to Exhibit 10.11 to TSM’s Annual Report on Form 10-K for the year ended December 31, 2009 (File No. 001-33865)).
   
Blue Shield Controlled Affiliate License Agreement by and among BCBSA, TSS and TSM, including revisions, if any, adopted by Member Plans through the November 19, 2009 meeting (incorporated herein by reference to Exhibit 10.12 to TSM’s Annual Report on Form 10-K for the year ended December 31, 2009 (File No. 001-33865)).
 
Exhibits
Description
   
Blue Cross License Agreements by and between BCBSA and TSM, including revisions, if any, adopted by Member Plans through the November 19, 2009 meeting (incorporated herein by reference to Exhibit 10.13 to TSM’s Annual Report on Form 10-K for the year ended December 31, 2009 (File No. 001-33865)).
   
Blue Cross Controlled Affiliate License Agreement by and among BCBSA, TSS and TSM, including revisions, if any, adopted by Member Plans through the November 19, 2009 meeting (incorporated herein by reference to Exhibit 10.14 to TSM’s Annual Report on Form 10-K for the year ended December 31, 2009 (File No. 001-33865)).
   
6.30% Senior Unsecured Notes Due September 2019 Note Purchase Agreement, dated September 30, 2004, between Triple-S Management Corporation, Triple-S, Inc. and various institutional accredited investors (incorporated herein by reference to Exhibit 10.15 to TSM’s Annual Report on Form 10-K for the year ended December 31, 2005 (File No. 001-33865)).
   
6.60% Senior Unsecured Notes Due December 2020 Note Purchase Agreement, dated December 15, 2005, between Triple-S Management Corporation and various institutional accredited investors (incorporated herein by reference to Exhibit 10.16 to TSM’s Annual Report on Form 10-K for the year ended December 31, 2005 (File No. 001-33865)).
   
6.70% Senior Unsecured Notes Due December 2021 Note Purchase Agreement, dated January 23, 2006, between Triple-S Management Corporation and various institutional accredited investors (incorporated herein by reference to Exhibit 10.1 to TSM’s Quarterly Report on Form 10-Q for the Quarter Ended March 31, 2006 (File No. 001-33865)).
   
TSM 2007 Incentive Plan, dated October 16, 2007 (incorporated herein by reference to Exhibit C to TSM’s 2007 Proxy Statement (File No. 001-33865)).
   
Software License and Maintenance Agreement between Quality Care Solutions, Inc, and TSS dated August 16, 2007 (incorporated herein by reference to Exhibit 10.15 to TSM’s Annual Report on Form 10-K for the year ended December 31, 2007 (File No. 001-33865)).
   
Addendum Number One to the Software License and Maintenance Agreement between Quality Care Solutions, Inc, and TSS (incorporated herein by reference to Exhibit 10.15(a) to TSM’s Annual Report on Form 10-K for the year ended December 31, 2007 (File No. 001-33865)).
   
Addendum Number Two to the Software License and Maintenance Agreement between Quality Care Solutions, Inc, and TSS (incorporated herein by reference to Exhibit 10.15(b) to TSM’s Annual Report on Form 10-K for the year ended December 31, 2007 (File No. 001-33865)).
   
Addendum Number Three to the Software License and Maintenance Agreement between Quality Care Solutions, Inc, and TSS (incorporated herein by reference to Exhibit 10.15(c) to TSM’s Annual Report on Form 10-K for the year ended December 31, 2007 (File No. 001-33865)).
   
Work Order Agreement between Quality Care Solutions, Inc. and TSS (incorporated herein by reference to Exhibit 10.16 to TSM’s Annual Report on Form 10-K for the year ended December 31, 2007 (File No. 001-33865)).


Exhibits
Description
   
Employment Contract between Ramón M. Ruiz Comas and TSM (incorporated herein by reference to Exhibit 10.1 to TSM’s Current Report on Form 8-K filed on November 5, 2012 (File No. 001-33865)).
   
Agreement between the Puerto Rico Health Insurance Administration and TSS for the provision of the physical & behavioral health services under the Government Health Plan Program (incorporated herein by reference to Exhibit 10.1 to TSM’s Annual Report on Form 10-K for the year ended December 31, 2014  (File No. 001-33865)).
   
Settlement and Release Agreement between Triple-S Management Corporation, Triple-S Salud, Inc., and the Health Insurance Administration of Puerto Rico (incorporated herein by reference to Exhibit 10.22 to TSM’s Annual Report on Form 10-K for the year ended December 31, 2015 (File No. 001-33865)).
   
Resolution Agreement between Triple-S Management Corporation, Triple-S Salud, Inc., and the Department of Health and Human Services (incorporated herein by reference to Exhibit 10.23 to TSM’s Annual Report on Form 10-K for the year ended December 31, 2015 (File No. 001-33865)).
   
Employment Contract between Roberto García-Rodríguez and TSM (incorporated herein by reference to Exhibit 10.1 to TSM’s Current Report on Form 8-K/A filed on January 6, 2016 (File No. 001-33865)).
   
Credit Agreement dated December 28, 2016 by and between Triple-S Management Corporation and FirstBank Puerto Rico (incorporated herein by reference to Exhibit 10.1 to TSM’s Current Report on Form 8-K filed on December 30, 2016 (File No. 001-33865)).
   
TSM 2017 Incentive Plan (incorporated herein by reference to Exhibit 99.1 to TSM’s Form S-8 dated May 11, 2017 (File No. 001-33865)).
   
Amendment to Extend Contract for the Provision of Physical & Behavioral Health Services under the Government Health Plan Program (incorporated herein by reference to Exhibit 10.1 to TSM’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2017 (File No. 001-33865)).
   
Master Services Agreement, dated as of August 29, 2017, by and between Triple-S Salud, Inc. and OptumInsight, Inc. (incorporated herein by reference to Exhibit 10.2 to TSM’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2017 (File No. 001-33865)).
   
Amendment to Extend Contract for the Provision of Physical & Behavioral Health Services under the Government Health Plan Program dated as of September 28, 2017, by and between the Administracion de Seguros de Salud de Puerto Rico and Triple-S Salud, Inc. (incorporated herein by reference to Exhibit 10.1 to TSM’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2017 (File No. 001-33865)).
   
11.1
Statement re computation of per share earnings; an exhibit describing the computation of the earnings per share has been omitted as the detail necessary to determine the computation of earnings per share can be clearly determined from the material contained in Part II of this Annual Report on Form 10-K.
   
List of Subsidiaries of TSM


Exhibits
Description
   
Consent of Independent Registered Public Accounting Firm (Deloitte & Touche LLP).
   
Certification of the President and Chief Executive Officer required by Rule 13a-14(a)/15d-14(a).
   
Certification of the Vice President of Finance and Chief Financial Officer required by Rule 13a-14(a)/15d-14(a).
   
Certification of the President and Chief Executive Officer required pursuant to 18 U.S. Section 1350.
   
Certification of the Vice President of Finance and Chief Financial Officer required pursuant to 18 U.S. Section 1350.
   
Incentive Compensation Recoupment Policy (incorporated herein by reference to Exhibit 99.1 to TSM’s Annual Report on Form 10-K for the   year ended December 31, 2010 (File No. 001-33865)) .
 
All other exhibits for which provision is made in the applicable accounting regulation of the SEC are not required under the related instructions or are inapplicable, and therefore have been omitted.

*  Filed herein.
 
SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
Triple-S Management Corporation
Registrant
 
By:
/s/ Roberto García-Rodríguez
 
Date:
March 7, 2018
 
 
Roberto García-Rodríguez
       
 
President and Chief Executive Officer
       
 
By:
/s/ Juan J. Román-Jiménez
 
Date:
March 7, 2018
 
 
Juan J. Román-Jiménez
       
 
Executive Vice President
       
 
and Chief Financial Officer
       
 
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
 
By:
/s/ Luis A. Clavell-Rodríguez
 
Date:
March 7, 2018
 
 
Luis A. Clavell-Rodríguez
       
 
Director and Chairman of the Board
       
 
By:
/s/ Cari M. Domínguez
 
Date:
March 7, 2018
 
 
Cari M. Domínguez
       
 
Director and Vice-Chairman of the Board
       
 
By:
/s/ David H. Chafey, Jr
 
Date:
March 7, 2018
 
 
David H. Chafey, Jr.
       
 
Director
       
 
By:
/s/ Jorge L. Fuentes-Benejam
 
Date:
March 7, 2018
 
 
Jorge L. Fuentes-Benejam
       
 
Director
       
 
By:
/s/ Antonio F. Faría-Soto
 
Date:
March 7, 2018
 
 
Antonio F. Faría-Soto
       
 
Director
       
 
By:
/s/ Manuel Figueroa-Collazo
 
Date:
March 7, 2018
 
 
Manuel Figueroa-Collazo
       
 
Director
       
 
By:
/s/ Joseph A.  Frick
 
Date:
March 7, 2018
 
 
Joseph A.  Frick
       
 
Director
       
 
By:
/s/ Roberto Santa María-Ros
 
Date:
March 7, 2018
 
 
Roberto Santa María-Ros
       
 
Director
       
 
By:
/s/ Gail B. Marcus
 
Date:
March 7, 2018
 
 
Gail B. Marcus
       
 
Director
       
 
Triple-S Management Corporation
Consolidated Financial Statements
December 31, 2017, 2016, and 2015
 
Page(s)
 
Report of Independent Registered Public Accounting Firm
1
   
Consolidated Financial Statements
2
   
Consolidated Balance Sheets
2
   
Consolidated Statements of Earnings
3
   
Consolidated Statements of Comprehensive Income
4
   
Consolidated Statements of Stockholders’ Equity
5
   
Consolidated Statements of Cash Flows
6
   
Notes to Consolidated Financial Statements
8–77
 
Report of Independent Registered Public Accounting Firm
 
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
 
To the Stockholders and Board of Directors of Triple-S Management Corporation
 
Opinion on the Financial Statements
 
We have audited the accompanying consolidated balance sheets of Triple-S Management Corporation and subsidiaries (the "Company") as of December 31, 2017 and 2016, the related consolidated statements earnings, comprehensive income, stockholders' equity, and cash flows, for each of the three years in the period ended December 31, 2017, and the related notes and the schedules listed in the Index at Item 15 (collectively referred to as the "consolidated financial statements"). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2017 and 2016, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2017, in conformity with accounting principles generally accepted in the United States of America.
 
We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2017, based on criteria established in Internal Control — Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated March  7, 2018, expressed an unqualified opinion on the Company's internal control over financial reporting.
 
Basis for Opinion
 
These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's consolidated financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
 
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
 
/s/ DELOITTE & TOUCHE LLP

San Juan, Puerto Rico
March 7 , 2018
 
Stamp No. E 308501
affixed to original.
 
We have served as the Company's auditor since 2015.
 
Triple-S Management Corporation
Consolidated Balance Sheets
December 31, 2017 and 2016
(dollar amounts in thousands, except share data)

 
Assets
 
2017
   
2016
 
Investments and cash
           
Securities available for sale, at fair value:
           
Fixed maturities (amortized cost of $1,171,651 in 2017 and $1,104,303 in 2016)
 
$
1,216,788
   
$
1,151,643
 
Equity securities (cost of $327,129 in 2017 and $240,699 in 2016)
   
377,293
     
270,349
 
Securities held to maturity, at amortized cost:
               
Fixed maturities (fair value of $2,475 in 2017 and $3,012 in 2016)
   
2,319
     
2,836
 
Policy loans
   
9,077
     
8,564
 
Cash and cash equivalents
   
198,941
     
103,428
 
Total investments and cash
   
1,804,418
     
1,536,820
 
Premium and other receivables, net
   
899,327
     
286,365
 
Deferred policy acquisition costs and value of business acquired
   
200,788
     
194,787
 
Property and equipment, net
   
74,716
     
66,369
 
Deferred tax asset
   
65,123
     
57,768
 
Goodwill
   
25,397
     
25,397
 
Other assets
   
46,996
     
51,493
 
Total assets
 
$
3,116,765
   
$
2,218,999
 
Liabilities and Stockholders’ Equity
               
Claim liabilities
   
1,106,876
     
487,943
 
Liability for future policy benefits
   
339,507
     
321,232
 
Unearned premiums
   
86,349
     
79,310
 
Policyholder deposits
   
176,534
     
179,382
 
Liability to Federal Employees’ Health Benefits and Federal Employees' Programs
   
52,287
     
34,370
 
Accounts payable and accrued liabilities
   
354,894
     
169,449
 
Deferred tax liability
   
21,891
     
18,850
 
Long term borrowings
   
32,073
     
35,085
 
Liability for pension benefits
   
33,672
     
30,892
 
Total liabilities
   
2,204,083
     
1,356,513
 
                 
Commitments and contingencies
               
                 
Stockholders’ equity
               
Triple-S Management Corporation stockholders' equity Common stock Class A, $1 par value. Authorized 100,000,000 shares; issued and outstanding 950,968 at December 31, 2017 and 2016
   
951
     
951
 
Common stock Class B, $1 par value. Authorized 100,000,000 shares; issued and outstanding 22,627,077 and 23,321,163 shares at December 31, 2017 and 2016, respectively
   
22,627
     
23,321
 
Additional paid-in capital
   
53,142
     
65,592
 
Retained earnings
   
785,390
     
730,904
 
Accumulated other comprehensive income, net
   
51,254
     
42,395
 
Total Triple-S Management Corporation stockholders' equity
   
913,364
     
863,163
 
Non-controlling interest in consolidated subsidiary
   
(682
)
   
(677
)
Total stockholders' equity
   
912,682
     
862,486
 
Total liabilities and stockholders’ equity
 
$
3,116,765
   
$
2,218,999
 

The accompanying notes are an integral part of these financial statements.
 
Triple-S Management Corporation
Consolidated Statements of Earnings
December 31, 2017, 2016, and 2015
(dollar amounts in thousands, except per share data)

 
   
2017
   
2016
   
2015
 
Revenues:
                 
Premiums earned, net
 
$
2,826,932
   
$
2,890,641
   
$
2,783,154
 
Administrative service fees
   
16,514
     
17,843
     
44,705
 
Net investment income
   
51,615
     
48,913
     
45,174
 
Other operating revenues
   
3,660
     
3,461
     
3,719
 
Total operating revenues
   
2,898,721
     
2,960,858
     
2,876,752
 
Net realized investment gains (losses):
                       
Total other-than-temporary impairment losses on securities
   
(49
)
   
(1,434
)
   
(5,212
)
Net realized gains, excluding other-than-temporary impairment losses on securities
   
10,880
     
18,813
     
24,153
 
Total net realized investment gains
   
10,831
     
17,379
     
18,941
 
                         
Other income, net
   
6,533
     
6,569
     
7,043
 
Total revenues
   
2,916,085
     
2,984,806
     
2,902,736
 
Benefits and expenses:
                       
Claims incurred (net of reinsurance of $683,421, $11,319 and $15,738)
   
2,353,101
     
2,472,191
     
2,318,715
 
Operating expenses
   
477,213
     
493,894
     
518,721
 
Total operating costs
   
2,830,314
     
2,966,085
     
2,837,436
 
Interest expense
   
6,794
     
7,635
     
8,169
 
Total benefits and expenses
   
2,837,108
     
2,973,720
     
2,845,605
 
Income before taxes
   
78,977
     
11,086
     
57,131
 
Income tax expense (benefit)
   
24,496
     
(6,345
)
   
5,099
 
Net income
   
54,481
     
17,431
     
52,032
 
Less: Net loss attributable to non-controlling interest
   
5
     
7
     
89
 
                         
Net income attributable to Triple-S Management Corporation
 
$
54,486
   
$
17,438
   
$
52,121
 
Earnings per share attributable to Triple-S Management Corporation
                       
Basic net income per share
 
$
2.27
   
$
0.71
   
$
2.03
 
Diluted net income per share
 
$
2.26
   
$
0.71
   
$
2.02
 
 
The accompanying notes are an integral part of these financial statements.
 
Triple-S Management Corporation
Consolidated Statements of Comprehensive Income
December 31, 2017, 2016, and 2015
(dollar amounts in thousands)

 
   
2017
   
2016
   
2015
 
Net income
 
$
54,481
   
$
17,431
   
$
52,032
 
Other comprehensive income (loss), net of tax:
                       
Net unrealized change in fair value of available for sale securities, net of taxes
   
13,867
     
(107
)
   
(38,989
)
Defined benefit pension plan:
                       
Actuarial (loss) gain, net
   
(5,028
)
   
18,232
     
16,105
 
Prior service credit, net
   
20
     
(1,353
)
   
(269
)
Total other comprehensive income (loss), net of tax
   
8,859
     
16,772
     
(23,153
)
Comprehensive income
   
63,340
     
34,203
     
28,879
 
Comprehensive loss attributable to non-controlling interest
   
5
     
7
     
89
 
Comprehensive income attributable to Triple-S Management Corporation
 
$
63,345
   
$
34,210
   
$
28,968
 

The accompanying notes are an integral part of these financial statements.
 
Triple-S Management Corporation
Consolidated Statements of Stockholders’ Equity
December 31, 2017, 2016, and 2015
(dollar amounts in thousands)

 
   
Class A
Common
Stock
   
Class B
Common
Stock
   
Additional
Paid-in
Capital
   
Retained
Earnings
   
Accumulated
Other
Comprehensive
Income (Loss)
   
Triple-S
Management
Corporation
Stockholders’
Equity
   
Non-controlling
Interest in
Consolidated
Subsidiary
   
Total
Stockholders’
Equity
 
                                                 
Balance, December 31, 2014
 
$
2,378
   
$
24,654
   
$
121,405
   
$
661,345
   
$
48,776
   
$
858,558
   
$
(532
)
 
$
858,026
 
Share-based compensation
   
-
     
202
     
8,088
     
-
     
-
     
8,290
     
-
     
8,290
 
Stock issued upon exercise of stock options
   
-
     
13
     
166
     
-
     
-
     
179
     
-
     
179
 
Common stock conversion
   
(1,427
)
   
1,427
     
-
     
-
     
-
     
-
     
-
     
-
 
Repurchase and retirement of common stock
   
-
     
(2,248
)
   
(46,221
)
   
-
     
-
     
(48,469
)
   
-
     
(48,469
)
Non-controlling interest decrease related to retirement of consolidated subsidiary common stock
   
-
     
-
     
-
     
-
     
-
     
-
     
(49
)
   
(49
)
Net change in comprehensive income (loss)
   
-
     
-
     
-
     
52,121
     
(23,153
)
   
28,968
     
(89
)
   
28,879
 
Balance, December 31, 2015
 
$
951
   
$
24,048
   
$
83,438
   
$
713,466
   
$
25,623
   
$
847,526
   
$
(670
)
 
$
846,856
 
Share-based compensation
   
-
     
223
     
2,576
     
-
     
-
     
2,799
     
-
     
2,799
 
Stock issued upon exercise of stock options
   
-
     
4
     
51
     
-
     
-
     
55
     
-
     
55
 
Repurchase and retirement of common stock
   
-
     
(954
)
   
(20,473
)
   
-
     
-
     
(21,427
)
   
-
     
(21,427
)
Net change in comprehensive income (loss)
   
-
     
-
     
-
     
17,438
     
16,772
     
34,210
     
(7
)
   
34,203
 
Balance, December 31, 2016
 
$
951
   
$
23,321
   
$
65,592
   
$
730,904
   
$
42,395
   
$
863,163
   
$
(677
)
 
$
862,486
 
Share-based compensation
   
-
     
167
     
6,909
     
-
     
-
     
7,076
     
-
     
7,076
 
Repurchase and retirement of common stock
   
-
     
(861
)
   
(19,359
)
   
-
     
-
     
(20,220
)
   
-
     
(20,220
)
Net change in comprehensive income (loss)
   
-
     
-
     
-
     
54,486
     
8,859
     
63,345
     
(5
)
   
63,340
 
Balance, December 31, 2017
 
$
951
   
$
22,627
   
$
53,142
   
$
785,390
   
$
51,254
   
$
913,364
   
$
(682
)
 
$
912,682
 

The accompanying notes are an integral part of these financial statements.
 
Triple-S Management Corporation
Consolidated Statements of Cash Flows
December 31, 2017, 2016, and 2015
(dollar amounts in thousands)

 
   
2017
   
2016
   
2015
 
Cash flows from operating activities
                 
Net income
 
$
54,481
   
$
17,431
   
$
52,032
 
Adjustments to reconcile net income to net cash provided by operating activities
                       
Depreciation and amortization
   
13,198
     
14,120
     
16,379
 
Net amortization of investments
   
10,114
     
8,671
     
6,854
 
Additions to the allowance for doubtful receivables
   
1,462
     
1,601
     
16,121
 
Deferred tax benefit
   
(9,916
)
   
(8,326
)
   
(5,070
)
Net realized investment gains on sale of securities
   
(10,831
)
   
(17,379
)
   
(18,941
)
Interest credited to policyholder deposits
   
5,677
     
3,794
     
5,690
 
Share-based compensation
   
7,076
     
2,463
     
8,290
 
(Increase) decrease in assets
                       
Premium and other receivables, net
   
(614,424
)
   
(5,320
)
   
6,399
 
Deferred policy acquisition costs and value of business acquired
   
(6,596
)
   
(7,286
)
   
(6,548
)
Deferred taxes
   
4,946
     
(4,799
)
   
3,616
 
Other assets
   
5,117
     
(9,009
)
   
(2,630
)
Increase (decrease) in liabilities
                       
Claim liabilities
   
618,933
     
(3,822
)
   
101,679
 
Liability for future policy benefits
   
18,275
     
31,702
     
18,146
 
Unearned premiums
   
7,039
     
(950
)
   
(2,396
)
Liability to FEHBP
   
17,917
     
7,675
     
11,029
 
Accounts payable and accrued liabilities
   
166,450
     
(24,095
)
   
18,444
 
Net cash provided by operating activities
   
288,918
     
6,471
     
229,094
 

The accompanying notes are an integral part of these financial statements.
 
Triple-S Management Corporation
Consolidated Statements of Cash Flows
December 31, 2017, 2016, and 2015
(dollar amounts in thousands)

 
   
2017
   
2016
   
2015
 
Cash flows from investing activities
                 
Proceeds from investments sold or matured
Securities available for sale
                 
Fixed maturities sold
 
$
463,232
   
$
400,848
   
$
355,045
 
Fixed maturities matured
   
18,893
     
56,988
     
67,615
 
Equity securities sold
   
59,963
     
109,049
     
100,152
 
Securities held to maturity
                       
Fixed maturities matured
   
2,712
     
1,538
     
640
 
Acquisition of investments
                       
Securities available for sale
                       
Fixed maturities
   
(560,304
)
   
(482,252
)
   
(469,198
)
Equity securities
   
(134,834
)
   
(163,119
)
   
(92,844
)
Securities held to maturity
                       
Fixed maturities
   
(2,197
)
   
(1,445
)
   
(624
)
Other investments
   
(2,064
)
   
(2,493
)
   
(2,427
)
Net disbursements for policy loans
   
(513
)
   
(663
)
   
(641
)
Net capital expenditures
   
(21,359
)
   
(4,750
)
   
(9,094
)
Net cash used in investing activities
   
(176,471
)
   
(86,299
)
   
(51,376
)
Cash flows from financing activities
                       
Repurchase and retirement of common stock
   
(20,220
)
   
(21,371
)
   
(48,287
)
Change in outstanding checks in excess of bank balances
   
12,683
     
12,250
     
(1,786
)
Repayments of long-term borrowings
   
(2,836
)
   
(1,742
)
   
(37,640
)
Net proceeds from revolving line of credit
   
1,964
     
-
     
-
 
Proceeds from policyholder deposits
   
13,557
     
18,224
     
16,563
 
Surrenders of policyholder deposits
   
(22,082
)
   
(21,923
)
   
(18,787
)
Net cash used in financing activities
   
(16,934
)
   
(14,562
)
   
(89,937
)
Net increase (decrease) in cash and cash equivalents
   
95,513
     
(94,390
)
   
87,781
 
Cash and cash equivalents
                       
Beginning of year
   
103,428
     
197,818
     
110,037
 
End of year
 
$
198,941
   
$
103,428
   
$
197,818
 

The accompanying notes are an integral part of these financial statements.
 
Triple-S Management Corporation
Notes to Consolidated Financial Statements
December 31, 2017, 2016, and 2015
(dollar amounts in thousands, except per share and share data)

 
1.
Nature of Business

Triple-S Management Corporation (the Corporation, the Company or TSM) was incorporated under the laws of the Commonwealth of Puerto Rico to engage, among other things, as the holding company of entities primarily involved in the insurance industry.

The Company has the following wholly owned subsidiaries: (1) Triple-S Salud, Inc. (TSS) and Triple-S Advantage, Inc. (TSA), managed care organizations that provide health benefits services to subscribers through contracts with hospitals, physicians, dentists, laboratories, and other organizations; (2) Triple-S Vida, Inc. (TSV) and Triple-S Blue, Inc. (TSB), which are engaged in the underwriting of life and accident and health insurance policies and the administration of annuity contracts; and (3)  Triple-S Propiedad, Inc. (TSP), which is engaged in the underwriting of property and casualty insurance policies.  The Company, TSS and TSA are members of the Blue Cross and Blue Shield Association (BCBSA). The Company and the above mentioned subsidiaries are subject directly or indirectly to the regulations of the Commissioner of Insurance of the Commonwealth of Puerto Rico (the Commissioner of Insurance), the General Superintendence of Insurance of Costa Rica, the U.S. Virgin Islands (USVI), the British Virgin Islands (BVI) Financial Services Commission, and the Anguilla Financial Services Commission.

The Company also owns a controlling interest in a health clinic in Puerto Rico, as part of our strategic initiatives.

Through our subsidiary TSS, we provide services to participants of the Commonwealth of Puerto Rico Health Insurance Plan (similar to Medicaid) (Medicaid).  Effective April 1, 2015, the government changed the Medicaid delivery model from an administrative service only (ASO) to a risk based model.  Under the risk based delivery model, TSS provides healthcare services to only two service regions.  This contract is effective until June 30, 2018.

The Company has another wholly owned subsidiary, Interactive Systems, Inc., which is mainly engaged in providing data processing services to the Company and its subsidiaries.

A substantial majority of the Company’s business activity is within Puerto Rico, and as such, the Company is subject to the risks associated with the Puerto Rico economy.
 
Triple-S Management Corporation
Notes to Consolidated Financial Statements
December 31, 2017, 2016, and 2015
(dollar amounts in thousands, except per share and share data)

 
2.
Significant Accounting Policies

The following are the significant accounting policies followed by the Company and its subsidiaries:

Basis of Presentation
The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (GAAP).  The consolidated financial statements include the financial statements of the Company and its subsidiaries.  Intercompany balances and transactions have been eliminated in consolidation.

Use of Estimates
The preparation of the consolidated financial statements in conformity with GAAP requires the Company to make a number of estimates and assumptions relating to the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenue and expenses during the period.  Actual results could differ from those estimates.

Cash Equivalents
The Company considers all highly liquid debt instruments with maturities of three months or less at the date of acquisition to be cash equivalents.  Cash and cash equivalents are recorded at cost, which approximates fair value.  Cash equivalents of $87,572 and $24,486 at December 31, 2017 and 2016, respectively, consist principally of money market funds and certificates of deposit with original maturities of three months or less.

Investments
Investment in securities at December 31, 2017 and 2016 consists mainly of obligations of government‑sponsored enterprises, U.S. Treasury securities and obligations of U.S. government instrumentalities, obligations of the Commonwealth of Puerto Rico and its instrumentalities, municipal securities, corporate bonds, residential mortgage-backed securities, collateralized mortgage obligations, and equity securities.  The Company classifies its debt and equity securities in one of two categories: available-for-sale or held-to-maturity.  Securities classified as held-to-maturity are those securities in which the Company has the ability and intent to hold until maturity.  All other securities not included in held-to-maturity are classified as available-for-sale.

Available-for-sale securities are recorded at fair value.  The fair values of debt securities (both available-for-sale and held-to-maturity investments) and equity securities are based on quoted market prices for those or similar investments at the reporting date.  Held-to-maturity debt securities are recorded at amortized cost, adjusted for the amortization or accretion of premiums and discounts, respectively.    Unrealized holding gains and losses, net of the related tax effect, on available-for-sale securities are excluded from earnings and are reported as a separate component of other comprehensive income until realized.  Realized gains and losses from the sale of available-for-sale securities are included in earnings and are determined on a specific‑identification basis.

Transfers of securities between categories are recorded at fair value at the date of transfer.  Unrealized holding gains or losses associated with transfers of securities from held-to-maturity to available-for-sale are recorded as a separate component of other comprehensive income.  The unrealized holding gains or losses included in the separate component of other comprehensive income for securities transferred from available-for-sale to held-to-maturity, are maintained and amortized into earnings over the remaining life of the security as an adjustment to yield in a manner consistent with the amortization or accretion of premium or discount on the associated security.
 
Triple-S Management Corporation
Notes to Consolidated Financial Statements
December 31, 2017, 2016, and 2015
(dollar amounts in thousands, except per share and share data)

 
If a fixed maturity security is in an unrealized loss position and the Company has the intent to sell the fixed maturity security, or it is more likely than not that the Company will have to sell the fixed maturity security before recovery of its amortized cost basis, the decline in value is deemed to be other-than-temporary and is recorded to other-than-temporary impairment losses recognized in earnings in the Company’s consolidated statements of earnings.  For impaired fixed maturity securities that the Company does not intend to sell or it is more likely than not that such securities will not have to be sold, but the Company expects not to fully recover the amortized cost basis, the credit component of the other-than-temporary impairment is recognized in other-than-temporary impairment losses recognized in earnings in the Company’s consolidated statements of earnings and the non-credit component of the other-than-temporary impairment is recognized in other comprehensive income.  Furthermore, unrealized losses entirely caused by non-credit related factors related to fixed maturity securities for which the Company expects to fully recover the amortized cost basis continue to be recognized in accumulated other comprehensive income.

The credit component of an other-than-temporary impairment is determined by comparing the net present value of projected future cash flows with the amortized cost basis of the fixed maturity security. The net present value is calculated by discounting the Company’s best estimate of projected future cash flows at the effective interest rate implicit in the fixed maturity security at the date of acquisition.

The unrealized gains or losses on the Company’s equity securities classified as available-for-sale are included in accumulated other comprehensive income as a separate component of  stockholders’ equity, unless the decline in value is deemed to be other-than-temporary and the Company does not have the intent and ability to hold such equity securities until their full cost can be recovered, in which case such equity securities are written down to fair value and the loss is charged to other-than-temporary impairment losses recognized in earnings.

A decline in the fair value of any available-for-sale or held-to-maturity security below cost that is deemed to be other-than-temporary results in an impairment to reduce the carrying amount to fair value.  The impairment is charged to earnings and a new cost basis for the security is established.  To determine whether an impairment is other-than-temporary, the Company considers whether it has the ability and intent to hold the investment until a market price recovery and considers whether evidence indicating the cost of the investment is recoverable outweighs evidence to the contrary.  Evidence considered in this assessment includes the reasons for the impairment, the severity and duration of the impairment, market conditions, changes in value subsequent to year-end, forecasted performance of the investee, and the general market condition in the geographic area or industry the investee operates in.

Premiums and discounts are amortized or accreted over the life of the related held-to-maturity or available-for-sale security as an adjustment to yield using the effective interest method.  Dividend and interest income are recognized when earned.

The Company regularly invests in mortgaged-backed securities and other securities subject to prepayment and call risk.  Significant changes in prevailing interest rates may adversely affect the timing and amount of cash flows on such securities.  In addition, the amortization of market premium and accretion of market discount for mortgaged-backed securities is based on historical experience and estimates of future payment speeds on the underlying mortgage loans.  Actual prepayment speeds may differ from original estimates and may result in material adjustments to amortization or accretion recorded in future periods.
 
Triple-S Management Corporation
Notes to Consolidated Financial Statements
December 31, 2017, 2016, and 2015
(dollar amounts in thousands, except per share and share data)

 
Revenue Recognition

 
a.
Managed Care

Subscriber premiums on the managed care business are billed in advance of their respective coverage period and the related revenue is recorded as earned during the coverage period.  Managed care premiums are billed in the month prior to the effective date of the policy with a grace period of up to two months.  If the insured fails to pay, the policy can be cancelled at the end of the grace period at the option of the Company.

Premiums for the Medicaid business are based on a bid contract with the Puerto Rico Health Insurance Administration (ASES by its Spanish acronym) and billed in advance of coverage period.  Under the risk-based Medicaid contract, there is an excess profit agreement which stipulates that the profit of TSS for each fiscal year of the contract term shall not exceed two and a half percentage (2.5%) of the fixed amount paid by ASES for each member.  In the event that the profit exceeds this amount, TSS and ASES shall share the excess profit in proportions of fifty percent (50%), subject to the compliance by TSS with certain quality metrics.  ASES retains the right to determine the outcome of the excess profit agreement that is based on audited financial statements of the contracted services submitted annually by TSS and the validation of the incurred-but-not-reported reserve by ASES’s actuary.  We estimate the effect of this arrangement on a monthly basis and reflect the adjustments to premium revenue in current operations.  We report any estimated net amounts due to ASES within accounts payable and accrued liabilities in the consolidated balance sheets. As the contract year progresses and additional information becomes available, any excess profit will be recorded in the operating results of the period in which the information becomes available.

Premiums for the Medicare Advantage (MA) business are based on a bid contract with the Centers for Medicare and Medicaid Services (CMS) and billed in advance of the coverage period.  We recognize premium revenue in the period in which we are obligated to provide services to our members. We record premiums earned but not received as premiums receivable and record premiums received in advance of the period of service as unearned premiums in the consolidated balance sheets. Unearned premiums are recognized as revenue throughout the related coverage period.  MA contracts are renewed annually and provide for a risk factor to adjust premiums paid for members that represent a higher or lower risk to the Company.  Retroactive rate adjustments are made periodically based on the aggregate health status and risk scores of the Company’s MA membership.  These risk adjustments are evaluated quarterly, based on actuarial estimates.  Actual results could differ from these estimates.  We recognize periodic changes to risk-adjusted premiums as revenue when the amounts are determinable and collections is reasonably assured, which is possible as additional diagnosis code information is reported to CMS, when the ultimate settlements are received from CMS, or we receive notification of such settlement amounts.  The data provided to CMS to determine members’ risk scores is subject to audit by CMS even after the annual settlements occur, which may result in the refund of premiums to CMS.  As additional information becomes available, the recorded estimate is revised and reflected in operating results in the period in which it becomes available.
 
Triple-S Management Corporation
Notes to Consolidated Financial Statements
December 31, 2017, 2016, and 2015
(dollar amounts in thousands, except per share and share data)

 
Prescription drug coverage is offered to Medicare eligible beneficiaries as part of MA plans (MA-PD).  Premiums are based on a bid contract with CMS that considers the estimated costs of providing prescription drug benefits to enrolled participants.  MA-PD premiums are subject to adjustment, positive or negative, based upon the application of risk corridors that compare the estimated prescription drug costs included in the bids to CMS to actual prescription drug costs.  Variances exceeding certain thresholds may result in CMS making additional payments or in CMS requesting a refund for a portion of the premiums collected.  The Company estimates and records adjustments to earned premiums related to estimated risk corridor payments based upon actual prescription drug costs for each reporting period as if the annual contract were to end at the end of each reporting period.

Administrative service fees include revenue from certain groups which have managed care contracts that provide for the group to be at risk for all or a portion of their claims experience.  For these groups, the Company is not at risk and only handles the administration of managed care coverage for an administrative service fee.  The Company pays claims under commercial self-funded arrangements from its own funds, and subsequently receives reimbursement from these groups.  Claims paid under self-funded arrangements are excluded from the claims incurred in the accompanying consolidated financial statements.  Administrative service fees under the self-funded arrangements are recognized based on the group’s membership or incurred claims for the period multiplied by an administrative fee rate plus other fees.  In addition, some of these self-funded groups purchase aggregate and/or specific stop-loss coverage.  In exchange for a premium, the group’s aggregate liability or the group’s liability on any one episode of care is capped for the year.  Premiums for the stop-loss coverage are actuarially determined based on experience and other factors and are recorded as earned over the period of the contract in proportion to the coverage provided.  This fully insured portion of premiums is included within the premiums earned, net in the accompanying consolidated statements of earnings.

b.
Life and Accident and Health Insurance
 
Premiums on life insurance policies are billed in advance of their respective coverage period and the related revenue is recorded as earned when due.  Premiums on accident and health and other short‑term policies are recognized as earned primarily on a pro rata basis over the contract period.  Premiums on credit life policies are recognized as earned in proportion to the amounts of insurance in‑force.  Revenues from universal life and interest sensitive policies represent amounts assessed against policyholders, including mortality charges, surrender charges actually paid, and earned policy service fees.  The revenues for limited payment contracts are recognized over the period that benefits are provided rather than on collection of premiums.
 
Triple-S Management Corporation
Notes to Consolidated Financial Statements
December 31, 2017, 2016, and 2015
(dollar amounts in thousands, except per share and share data)

 
c.
Property and Casualty Insurance

Premiums on property and casualty contracts are billed in advance of their respective coverage period and they are recognized as earned on a pro rata basis over the policy term.  The portion of premiums related to the period prior to the end of coverage is recorded in the consolidated balance sheets as unearned premiums and is transferred to premium revenue as earned.

Allowance for Doubtful Receivables
The allowance for doubtful receivables is based on management’s evaluation of the aging of accounts and such other factors which deserve current recognition, including the continued deterioration of the local economy, the exposure to government accounts, and the challenging business environment in the island.  This evaluation is performed individually on larger accounts and includes the use of all available information such as the customer’s credit worthiness and other relevant information.  Actual losses could differ from these estimates.  Receivables are charged-off against their respective allowance accounts when deemed to be uncollectible.

Deferred Policy Acquisition Costs and Value of Business Acquired
Certain direct costs of acquiring business in the life and accident and health, and property and casualty segments are deferred by the Company.  Substantially all acquisition costs related to the managed care segment are expensed as incurred.

In the life and accident and health segment, deferred acquisition costs (DAC) consist of commissions and certain expenses related to the production of life, annuity, accident and health, and credit business.  In the event that future premiums, in combination with policyholder reserves and anticipated investment income, could not provide for all future maintenance and settlement expenses, the amount of deferred policy acquisition costs would be reduced to provide for such amount.  The related amortization is provided over the anticipated premium-paying period of the related policies in proportion to the ratio of annual premium revenue to expected total premium revenue to be received over the life of the policies.  Interest is considered in the amortization of deferred policy acquisition cost and value of business acquired.  For these contracts interest is considered at a level rate at the time of issue of each contract, from 3.90% to 5.75% for 2017, 5.15% for 2016, and from 4.50% to 4.90% for 2015, and, in the case of the value of business acquired, at the time of any acquisition.

For certain other long-duration contracts, deferred amounts are amortized at historical and forecasted credited interest rates.  Expected premium revenue is estimated by using the same mortality and withdrawal assumptions used in computing liabilities for future policy benefits.  The method followed in computing deferred policy acquisition costs limits the amount of such deferred costs to their estimated net realizable value.  In determining estimated net realizable value, the computations give effect to the premiums to be earned, related investment income, losses and loss-adjustment expenses, and certain other costs expected to be incurred as the premium is earned.

Costs deferred on universal life and interest sensitive products are amortized as a level percentage of the present value of anticipated gross profits from investment yields, mortality, expenses and surrender charges.  Estimates used are based on the Company’s experience as adjusted to provide for possible adverse deviations.  These estimates are periodically reviewed and compared with actual experience.  When it is determined that future expected experience differs significantly from that assumed, the estimates are updated for current and future issues which may result in a change or release of deferred policy acquisition costs amortization through the consolidated statements of earnings.
 
Triple-S Management Corporation
Notes to Consolidated Financial Statements
December 31, 2017, 2016, and 2015
(dollar amounts in thousands, except per share and share data)

 
The value assigned to the life insurance in-force at the date of the acquisition is amortized using methods similar to those used to amortize the deferred policy acquisition costs of the life and accident and health segment.

In the property and casualty segment, acquisition costs consist of commissions incurred during the production of business and are deferred and amortized ratably over the terms of the policies.

Property and Equipment
Property and equipment are stated at cost.  Maintenance and repairs are expensed as incurred.  Depreciation is calculated on the straight-line method over the estimated useful lives of the assets.  Costs of computer equipment, programs, systems, installations, and enhancements are capitalized and amortized straight-line over their estimated useful lives.  The following is a summary of the estimated useful lives of the Company’s property and equipment:

Asset Category
 
Estimated
Useful Life
     
Buildings
 
20 to 50 years
Building improvements
 
3 to 5 years
Leasehold improvements
 
Shorter of estimated useful
   
life or lease term
Office furniture
 
5 years
Computer software
 
3 to 10 years
Computer equipment, equipment,
 
and automobiles
 
3 years

Long-Lived Assets, including Goodwill
Long‑lived assets, such as property and equipment, and purchased intangible assets subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.  Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset.  If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset.  The assets and liabilities of a disposal group classified as held for sale would be presented separately in the appropriate asset and liability sections of the consolidated balance sheets. During 2017, 2016 and 2015, impairment tests on intangible assets were performed and based on the results of the tests no impairment was recorded.

Goodwill and intangible assets that have indefinite useful lives are tested at least annually for impairment, and are tested for impairment more frequently if events or circumstances indicate that the asset might be impaired.  An impairment loss is recognized to the extent that the carrying amount exceeds the asset’s fair value.  For goodwill, the impairment determination is made at the reporting unit level.  The Company may perform a qualitative analysis under certain circumstances, or perform a two-step quantitative analysis. In the qualitative analysis, the Company determines if it is more likely than not that the fair value of a reporting unit is less than its carrying amount by assessing current events and circumstances. If there are factors present indicating potential impairment, the Company would proceed to the two-step quantitative analysis. The two-step impairment test is used to identify potential goodwill impairment and measure the amount of a goodwill impairment loss to be recognized (if any).   First, the Company determines the fair value of a reporting unit and compares it to its carrying amount.  Second, if the carrying amount of a reporting unit exceeds its fair value, an impairment loss is recognized for any excess of the carrying amount of the reporting unit’s goodwill over the implied fair value of that goodwill.  The implied fair value of goodwill is determined by allocating the fair value of the reporting unit in a manner similar to a purchase price allocation.  The residual fair value after this allocation is the implied fair value of the reporting unit goodwill.
 
Triple-S Management Corporation
Notes to Consolidated Financial Statements
December 31, 2017, 2016, and 2015
(dollar amounts in thousands, except per share and share data)

 
The annual impairment test is based on an evaluation of estimated future discounted cash flows. The Company also uses the market approach as part of their impairment analysis.  The estimated discounted cash flows are based on the best information available, including supportable assumptions and projections we believe are reasonable. Our discounted cash flow estimates use discount rates that correspond to a weighted-average cost of capital consistent with a market-participant view. The discount rates are consistent with those used for investment decisions and take into account the operating plans and strategies of our operating segments. Certain other key assumptions utilized, including changes in membership, premium, health care costs, operating expenses, fees, assessments and taxes and effective tax rates, are based on estimates consistent with those utilized in our annual budgeting and planning process that we believe are reasonable. However, if we do not achieve the results reflected in the assumptions and estimates, our goodwill impairment evaluations could be adversely affected, and we may impair a portion of our goodwill, which would adversely affect our operating results in the period of impairment. Impairments, if any, would be classified as an operating expense.

Claim Liabilities
Managed care claim liabilities mostly represent the Company’s estimate of medical costs incurred but not yet paid to providers based on experience and accumulated statistical data.  Loss-adjustment expenses related to such claims are currently accrued based on estimated future expenses necessary to process such claims.  Claim liabilities are the most significant estimate included in our consolidated financial statements.  Such estimate is developed consistently using standard actuarial methodologies based upon key assumptions, which vary by business segment.  The most significant assumptions used in the development of managed care claim liabilities include current payment experience, trend factors, and completion factors.  Managed care trend factors in our standard actuarial methodologies include contractual requirements, historic utilization trends, the interval between the date services are rendered and the date claims are paid, denied claims activity, disputed claims activity, benefit changes, expected health care cost inflation, seasonality patterns, maturity of lines of business, changes in membership and other factors.

Managed care claim liabilities also include a provision for adverse deviation, which is an estimate for known environmental factors that are reasonably likely to affect the required level of reserves. This provision for adverse deviation is intended to capture the potential adverse development from known environmental factors such as our entry into new geographical markets, changes in our geographic or product mix, the introduction of new customer populations, variation in benefit utilization, disease outbreaks, changes in provider reimbursement, fluctuations in medical cost trend, variation in claim submission patterns and variation in claims processing speed and payment patterns, changes in technology that provide faster access to claims data or change the speed of adjudication and settlement of claims, variability in claim inventory levels, non-standard claim development, and/or exceptional situations that require judgmental adjustments in setting the reserves for claims.

The Company contracts with various independent practice associations (IPAs) for certain medical care services provided to certain policies subscribers.  The IPAs are compensated on a capitation basis and capitation payables are included within claim liabilities. Capitation is amounts paid to the aforementioned IPAs on a fixed-fee per member per month basis.
 
Triple-S Management Corporation
Notes to Consolidated Financial Statements
December 31, 2017, 2016, and 2015
(dollar amounts in thousands, except per share and share data)

 
Claim liabilities also include unpaid claims and loss-adjustment expenses of the life and accident and health segment based on a case-basis estimate for reported claims, and on estimates, based on experience, for unreported claims and loss-adjustment expenses.  The liability for policy and contract claims and claims expenses has been established to cover the estimated net cost of insured claims.

Also included within the claim liabilities is the liability for losses and loss-adjustment expenses for the property and casualty segment which represents individual case estimates for reported claims and estimates for unreported losses, net of any salvage and subrogation based on past experience modified for current trends and estimates of expenses for investigating and settling claims.

Claim liabilities are necessarily based on estimates and, while management believes that the amounts are adequate, the ultimate liability may be in excess of or less than the amounts provided.  The methods for making such estimates and for establishing the resulting liability are continually reviewed, and any adjustments are reflected in the consolidated statements of earnings in the period determined.

Future Policy Benefits
The liability for future policy benefits has been computed using the level‑premium method based on estimated future investment yield, mortality, morbidity and withdrawal experience.  The assumptions are established at the time the policy is issued and are generally not changed during the life of the policy.  The Company periodically reviews the adequacy of reserves for these policies on an aggregate basis using actual experience. If actual experience is significantly adverse compared to the original assumptions and a premium deficiency is determined to exist, any remaining unamortized DAC balance would be expensed to the extent not recoverable and the establishment of a premium deficiency reserve may be required. The interest rate assumption ranges between 3.90% and 5.75% for all years in issue.

Mortality has been calculated principally on select and ultimate tables in common usage in the industry.  Withdrawals have been estimated principally based on industry tables, modified by Company’s experience.  The Company periodically reviews the adequacy of reserves for these policies on an aggregate basis using actual experience. If actual experience is significantly adverse compared to the original assumptions and a premium deficiency is determined to exist, any remaining unamortized DAC balance would be expensed to the extent not recoverable and the establishment of a premium deficiency reserve may be required.

Policyholder Deposits
Amounts received for annuity contracts are considered deposits and recorded as a liability along with the accrued interest and reduced for charges and withdrawals.  Interest incurred on such deposits, which amounted to $2,798, $3,182, and $3,379, during the years ended December 31, 2017, 2016, and 2015, respectively, is included within the interest expense in the accompanying consolidated statements of earnings.

Policyholder account balances for universal life and interest sensitive products are equal to policy account values. The policy account primarily comprises cumulative deposits received and interest credited to the policyholder less cumulative contract benefits, surrenders, withdrawals, maturities and contract charges for mortality or administrative expenses.  Interest rates credited to policyholder account balances during 2017 range from 2.0% to 4.5% and during 2016 range from 1.25% to 4.5% for universal life and interest sensitive products.  The universal life and interest sensitive products represented $75,956 and $69,445 of the policyholder deposits balance on the consolidated balance sheets as of December 31, 2017 and 2016, respectively.
 
Triple-S Management Corporation
Notes to Consolidated Financial Statements
December 31, 2017, 2016, and 2015
(dollar amounts in thousands, except per share and share data)

 
Reinsurance
In the normal course of business, the insurance-related subsidiaries seek to limit their exposure that may arise from catastrophes or other events that cause unfavorable underwriting results by reinsuring certain levels of risk in various areas of exposure with other insurance enterprises or reinsurers.

Reinsurance premiums, commissions, and expense reimbursements, related to reinsured business are accounted for on bases consistent with those used in accounting for the original policies issued and the terms of the reinsurance contracts.  Accordingly, reinsurance premiums are reported as prepaid reinsurance premiums and amortized over the remaining contract period in proportion to the amount of insurance protection provided.

Premiums ceded and recoveries of losses and loss-adjustment expenses have been reported as a reduction of premiums earned and losses and loss-adjustment expenses incurred, respectively.  Property and casualty commission and expense allowances received in connection with reinsurance ceded have been accounted for as a reduction of the related policy acquisition costs and are deferred and amortized accordingly.  Amounts recoverable from reinsurers are estimated in a manner consistent with the claim liability associated with the reinsured policy and are presented within premium and other receivables, net in the accompanying consolidated balance sheets.  Accounts payable and accrued liabilities within the accompanying consolidated balance sheets include $110,850 of advances received for hurricane related claims as of December 31, 2017.

Income Taxes
Income taxes are accounted for under the asset and liability method.  Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards.  Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.  The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the consolidated statements of earnings in the period that includes the enactment date.  The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained.  Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized.  Changes in recognition or measurement are reflected in the period in which the change in circumstances occurs.

The Company records any interest and penalties related to unrecognized tax benefits within the operating expenses in the consolidated statement of earnings.

Health Insurance Providers Fee
The Patient Protection and Affordable Care Act as amended by the Health Care and Education Reconciliation Act mandates an annual Health Insurance Providers Fee (HIP Fee).  The annual HIP Fee, which was effective January 1, 2014, becomes payable to the U.S. Treasury once the entity provides health insurance for any U.S. health risk each applicable calendar year.  The initial estimated annual fee is accrued as of January 1, with a corresponding deferred cost that is amortized over 12 months on a straight line basis. The fee payment is due on September 30 of each year.  During the year ended December 31, 2017, the HIP Fee was waived, for all health insurance providers.  The Company incurred approximately $44,100 and $34,500 of such fees in 2016 and 2015, respectively, which are presented within operating expenses in the accompanying consolidated statement of earnings.
 
Triple-S Management Corporation
Notes to Consolidated Financial Statements
December 31, 2017, 2016, and 2015
(dollar amounts in thousands, except per share and share data)

 
Insurance-Related Assessments
The Company records a liability for insurance-related assessments when the following three conditions are met: (1) the assessment has been imposed or the information available prior to the issuance of the consolidated financial statements indicates it is probable that an assessment will be imposed; (2) the event obligating an entity to pay (underlying cause of) an imposed or probable assessment has occurred on or before the date of the consolidated financial statements; and (3) the amount of the assessment can be reasonably estimated.  A related asset is recognized when the paid or accrued assessment is recoverable through either premium taxes or policy surcharges.

Commitments and Contingencies
Liabilities for loss contingencies arising from claims, assessments, litigation, fines, and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment and/or remediation can be reasonably estimated.  Legal costs incurred in connection with loss contingencies are expensed as incurred.  Recoveries of costs from third parties, which are probable of realization, are separately recorded as assets, and are not offset against the related liability.

Share‑Based Compensation
Share-based compensation is measured at the fair value of the award and recognized as an expense in the consolidated financial statements over the vesting period.

Earnings per Share
Basic earnings per share excludes dilution and is computed by dividing net income available to all classes of common stockholders by the weighted average number of all classes of common shares outstanding for the period, excluding non-vested restricted stocks.  Diluted earnings per share is computed in the same manner as basic earnings per share except that the number of shares is increased to include the number of additional common shares that would have been outstanding if the potentially dilutive common shares had been issued.  Dilutive common shares are included in the diluted earnings per share calculation using the treasury stock method.

Recently Issued Accounting Standards
On January 5, 2016, the Financial Accounting Standards Board (FASB) issued guidance to enhance the reporting model for financial instruments to provide users of financial statements with more decision-useful information.  Among the many targeted improvements to U.S. GAAP are (1) requiring equity investments, except those accounted for under the equity method of accounting or those that result in consolidation of the investee, to be measured at fair value with changes in fair value recognized in net income; (2) simplifying the impairment assessment of equity investments without readily determinable fair values by requiring a qualitative assessment to identify impairment; (3) eliminating the requirement to disclose the fair value of financial instruments measured at amortized cost for entities that are not public business entities; and (4) clarifying that an entity should evaluate the need for a valuation allowance on a deferred tax asset related to available-for-sale securities in combination with the entity’s other deferred tax assets.  This guidance applies to all entities that hold financial assets or owe financial liabilities. For public companies, these amendments are effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years.  The guidance for equity securities will be adopted effective January 1, 2018 as a cumulative-effect adjustment to the statement of financial position as of the beginning of the fiscal as of the implementation date.
 
Triple-S Management Corporation
Notes to Consolidated Financial Statements
December 31, 2017, 2016, and 2015
(dollar amounts in thousands, except per share and share data)

 
On February 25, 2016, the FASB issued guidance to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and by disclosing key information about leasing arrangements.  This guidance sets out the principles for the recognition, measurement, presentation and disclosure of leases for both lessors and lessees. It requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases today. The guidance requires lessors to account for leases using an approach that is substantially equivalent to existing guidance for sales-type leases, direct financing leases and operating leases. Companies are required to adopt the new guidance using a modified retrospective approach for annual and interim periods beginning after December 31, 2018.  We are currently evaluating the impact, if any, the adoption of this guidance may have on the Company's consolidated financial statements.

On May 9, 2016, the FASB issued guidance which affects only the narrow aspects of guidance related to revenue from contracts with customers that include: (1) clarification of the collectability criterion and the addition of a new criterion to clarify when revenue would be recognized for a contract that fails to meet the criteria in step 1 of the core principle of the guidance (i.e., identifying the contracts with a customer); (2) presentation of sales taxes and similar taxes collected from customers; (3) non-cash consideration; (4) contract modifications at transition; (5) completed contracts at transition; and (6) clarification that an entity that retrospectively applies in the guidance to each prior reporting period is not required to disclose the effect of the accounting change for the period of adoption, but is still required to disclose the effect of the changes on any prior periods retrospectively adjusted. On September 29, 2017, the FASB issued guidance amending prior Securities and Exchange Commission (SEC) Staff relief in adoption dates of the new revenue recognition and lease accounting rules for public business entities qualifying as such solely because their financial information must be included in the SEC filings of other companies. In addition, the guidance has been amended to rescind certain previous SEC Staff guidance on revenue recognition and lease accounting matters.  Based on the relief provided by the SEC Staff announcement, a calendar-year entity that is a public business entity only because its financial statements are required to be included in the SEC filing of another entity will be able to adopt the new revenue standard as of January 1, 2019, and the new lease standard as of January 1, 2020.  For public companies, these amendments are effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years.  We will adopt the guidance effective January 1, 2018, as the majority of the Company’s revenues are not subject to the new guidance, the adoption of this guidance will not have a material impact on the Company’s consolidated financial position, result of operations, equity or cash flows.

On June 16, 2016, the FASB issued guidance to provide financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date by replacing the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates.  For public companies, these amendments are effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years.  We are currently evaluating the impact the adoption of this guidance may have on the Company's consolidated financial statements.

On August 26, 2016, the FASB issued guidance to addresses stakeholders’ concerns regarding diversity in practice in how certain cash receipts and cash payments are presented and classified in the statement of cash flows under, Statement of Cash Flows , and other Topics.  In particular, the guidance addresses eight specific cash flow issues in an effort to reduce this diversity in practice: (1) debt prepayment or debt extinguishment costs; (2) settlement of zero-coupon bonds; (3) contingent consideration payments made after a business combination; (4) proceeds from the settlement of insurance claims; (5) proceeds from the settlement of corporate-owned life insurance policies, including bank-owned life insurance policies; (6) distributions received from equity method investees; (7) beneficial interests in securitization transactions; and (8) separately identifiable cash flows and application of the predominance principle.  For public companies, these amendments are effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years.  Guidance will be implemented effective January 1, 2018, the adoption of this guidance will not have a material impact on the Company’s consolidated financial position, result of operations, equity or cash flows.
 
Triple-S Management Corporation
Notes to Consolidated Financial Statements
December 31, 2017, 2016, and 2015
(dollar amounts in thousands, except per share and share data)

 
On January 26, 2017, the FASB issued guidance to simplify the manner in which an entity is required to evaluate goodwill for impairment by eliminating Step 2 from the goodwill impairment test.  Step 2 measures a goodwill impairment loss by comparing the implied fair value of a reporting unit’s goodwill with the carrying amount of that goodwill.  Instead, under the amendments in this guidance, an entity should (1) perform its annual or interim goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount, and (2) recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value, with the understanding that the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit.  Additionally, this guidance removes the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment and, if it fails such qualitative test, to perform Step 2 of the goodwill impairment test.  For public companies, these amendments, which should be applied on a prospective basis, are effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years.  We are currently evaluating the impact the adoption of this guidance may have on the Company's consolidated financial statements.

On March 10, 2017, the FASB issued guidance to improve the presentation of defined benefit costs in the income statement.  In particular, the guidance requires that an employer report the service cost component in the same line item(s) as other compensation costs arising from services rendered by the pertinent employees during the period. The other components of net benefit cost are required to be presented in the income statement separately from the service cost component and outside a subtotal of income from operations, if one is presented.  Additionally, this guidance allows only the service cost component to be eligible for capitalization, when applicable (e.g., as a cost of internally manufactured inventory or a self-constructed asset).  For public companies, these amendments, which should be applied on a prospective basis, are effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years.  Since, we do not present a subtotal of income from operations; the adoption of this guidance should not have a material impact on the presentation of the Company’s consolidated result of operations.

On May 10, 2017, the FASB issued guidance to provide clarity and reduce both (1) diversity in practice and (2) cost and complexity when applying the guidance in Topic 718, Compensation-Stock Compensation, to a change in the terms and conditions of a share-based payment award.  The amendments in this update affect any entity that changes the terms or conditions of a share-based payment award.  This guidance indicates an entity should account for the effects of a modification unless the following criteria are met: (1) the fair value (or calculated value or intrinsic value, if such an alternative measurement method is used) of the modified award is the same as the fair value (or calculated value or intrinsic value, if such an alternative measurement method is used) of the original award immediately before the original award is modified. If the modification does not affect any of the inputs to the valuation technique that the entity uses to value the award, the entity is not required to estimate the value immediately before and after the modification, (2) the vesting conditions of the modified award are the same as the vesting conditions of the original award immediately before the original award is modified, and (3) the classification of the modified award as an equity or liability instrument is the same as the classification of the original award immediately before the original award is modified. For all companies, these amendments, which should be applied on a prospective basis, are effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years.  The adoption of this guidance should not have a material effect on the Company's consolidated financial statements.
 
Triple-S Management Corporation
Notes to Consolidated Financial Statements
December 31, 2017, 2016, and 2015
(dollar amounts in thousands, except per share and share data)


Other than the accounting pronouncements disclosed above, there were no other new accounting pronouncements issued that could have a material impact in the Company’s financial position, operating results or financials statement disclosures.

Recently Adopted Accounting Standards
On March 30, 2016, the FASB issued guidance to reduce complexity in accounting standards.  The areas for simplification involve several aspects of the accounting for share-based payment transactions, including (1) accounting for income taxes, (2) classification of excess tax benefits on the statement of cash flow, (3) forfeitures; (4) minimum statutory tax withholding requirements, (5) classification of employee taxes paid on the statement of cash flows when an employer withholds shares for tax withholding purposes:, (6) the practical expedient for estimating the expected term, and (7) intrinsic value.  The guidance related to when excess tax benefits are recognized was adopted prospectively effective January 1, 2017.  The provisions related to the recognition of excess tax benefits in the income statements and classification in the statement of cash flows will be adopted prospectively.  The adoption of this guidance did not have a material impact on the Company’s consolidated financial position, result of operations, equity or cash flows.
 
Triple-S Management Corporation
Notes to Consolidated Financial Statements
December 31, 2017, 2016, and 2015
(dollar amounts in thousands, except per share and share data)

 
3.
Investment in Securities

The amortized cost for debt securities and cost for equity securities, gross unrealized gains, gross unrealized losses, and estimated fair value for available-for-sale and held-to-maturity securities by major security type and class of security as of December 31, were as follows:

   
2017
 
   
Amortized
Cost
   
Gross
Unrealized
Gains
   
Gross
Unrealized
Losses
   
Estimated
Fair
Value
 
                         
Securities available for sale
                       
Fixed maturities
                       
Obligations of government- sponsored enterprises
 
$
1,431
   
$
13
   
$
-
   
$
1,444
 
U.S. Treasury securities and obligations of U.S. government instrumentalities
   
118,858
     
41
     
(550
)
   
118,349
 
Obligations of the Commonwealth of Puerto Rico and its instrumentalities
   
8,059
     
34
     
-
     
8,093
 
Municipal securities
   
771,789
     
30,468
     
(1,467
)
   
800,790
 
Corporate bonds
   
217,046
     
17,767
     
(489
)
   
234,324
 
Residential mortgage-backed securities
   
32,465
     
2
     
(355
)
   
32,112
 
Collateralized mortgage obligations
   
22,003
     
10
     
(337
)
   
21,676
 
Total fixed maturities
   
1,171,651
     
48,335
     
(3,198
)
   
1,216,788
 
Equity securities
                               
Mutual Funds
   
292,459
     
50,072
     
(223
)
   
342,308
 
Alternative investments
   
34,670
     
559
     
(244
)
   
34,985
 
Total equity securities
   
327,129
     
50,631
     
(467
)
   
377,293
 
Total
 
$
1,498,780
   
$
98,966
   
$
(3,665
)
 
$
1,594,081
 
 
Triple-S Management Corporation
Notes to Consolidated Financial Statements
December 31, 2017, 2016, and 2015
(dollar amounts in thousands, except per share and share data)

 
   
2016
 
   
Amortized
Cost
   
Gross
Unrealized
Gains
   
Gross
Unrealized
Losses
   
Estimated
Fair
Value
 
                         
Securities available for sale
                       
Fixed maturities
                       
Obligations of government-sponsored enterprises
 
$
41,442
   
$
87
   
$
(15
)
 
$
41,514
 
U.S. Treasury securities and obligations of U.S. government instrumentalities
   
85,652
     
157
     
(9
)
   
85,800
 
Obligations of the Commonwealth of Puerto Rico and its instrumentalities
   
17,930
     
2,189
     
(68
)
   
20,051
 
Municipal securities
   
650,175
     
34,187
     
(559
)
   
683,803
 
Corporate bonds
   
263,351
     
12,182
     
(661
)
   
274,872
 
Residential mortgage-backed securities
   
684
     
34
     
-
     
718
 
Collateralized mortgage obligations
   
45,069
     
58
     
(242
)
   
44,885
 
Total fixed maturities
   
1,104,303
     
48,894
     
(1,554
)
   
1,151,643
 
Equity securities-Mutual funds and alternative investments
   
240,699
     
30,101
     
(451
)
   
270,349
 
Total
 
$
1,345,002
   
$
78,995
   
$
(2,005
)
 
$
1,421,992
 

   
2017
 
   
Amortized
Cost
   
Gross
Unrealized
Gains
   
Gross
Unrealized
Losses
   
Estimated
Fair
Value
 
                         
Securities held to maturity
                       
U.S. Treasury securities and obligations of U.S. government instrumentalties
 
$
617
   
$
154
   
$
-
   
$
771
 
Residential mortgage-backed securities
   
191
     
2
     
-
     
193
 
Certificates of deposits
   
1,511
     
-
     
-
     
1,511
 
   
$
2,319
   
$
156
   
$
-
   
$
2,475
 
 
Triple-S Management Corporation
Notes to Consolidated Financial Statements
December 31, 2017, 2016, and 2015
(dollar amounts in thousands, except per share and share data)

 
   
2016
 
   
Amortized
Cost
   
Gross
Unrealized
Gains
   
Gross
Unrealized
Losses
   
Estimated
Fair
Value
 
                         
Securities held to maturity
                       
U.S. Treasury securities and obligations of U.S. government instrumentalties
 
$
619
   
$
158
   
$
-
   
$
777
 
Residential mortgage-backed securities
   
191
     
18
     
-
     
209
 
Certificates of deposits
   
2,026
     
-
     
-
     
2,026
 
   
$
2,836
   
$
176
   
$
-
   
$
3,012
 

Gross unrealized losses on investment securities and the estimated fair value of the related securities, aggregated by investment category and length of time that individual securities have been in a continuous unrealized loss position as of December 31, were as follows:
 
 
2017
 
     
Less than 12 months
   
12 months or longer
   
Total
 
 
 
Estimated
Fair Value
   
Gross
Unrealized
Loss
   
Number of
Securities
   
Estimated
Fair Value
   
Gross
Unrealized
Loss
   
Number of
Securities
   
Estimated
Fair Value
   
Gross
Unrealized
Loss
   
Number of
Securities
 
                                                       
Securites available for sale
                                                     
Fixed maturities
                                                     
U.S. Treasury securities and obligations of U.S. governmental instrumentalities
 
$
96,617
   
$
(550
)
   
7
   
$
-
   
$
-
     
-
   
$
96,617
   
$
(550
)
   
7
 
Municipal securities
   
162,731
     
(1,467
)
   
27
     
-
     
-
     
-
     
162,731
     
(1,467
)
   
27
 
Corporate bonds
   
80,374
     
(489
)
   
16
     
-
     
-
     
-
     
80,374
     
(489
)
   
16
 
Residential mortgage-backed securities
   
31,736
     
(355
)
   
19
     
-
     
-
     
-
     
31,736
     
(355
)
   
19
 
Collateralized mortgage obligations
   
13,630
     
(239
)
   
3
     
7,294
     
(98
)
   
2
     
20,924
     
(337
)
   
5
 
Total fixed maturities
   
385,088
     
(3,100
)
   
72
     
7,294
     
(98
)
   
2
     
392,382
     
(3,198
)
   
74
 
Equity securities
                                                                       
Mutual funds
   
42,983
     
(223
)
   
6
     
-
     
-
     
-
     
42,983
     
(223
)
   
6
 
Alternative investments
   
9,986
     
(212
)
   
5
     
3,162
     
(32
)
   
1
     
13,148
     
(244
)
   
6
 
Total equity securities
   
52,969
     
(435
)
   
11
     
3,162
     
(32
)
   
1
     
56,131
     
(467
)
   
12
 
Total for securities available for sale
 
$
438,057
   
$
(3,535
)
   
83
   
$
10,456
   
$
(130
)
   
3
   
$
448,513
   
$
(3,665
)
   
86
 
 
Triple-S Management Corporation
Notes to Consolidated Financial Statements
December 31, 2017, 2016, and 2015
(dollar amounts in thousands, except per share and share data)

 
   
2016
 
   
Less than 12 months
   
12 months or longer
   
Total
 
   
Estimated
Fair Value
   
Gross
Unrealized
Loss
   
Number of
Securities
   
Estimated
Fair Value
   
Gross
Unrealized
Loss
   
Number of
Securities
   
Estimated
Fair Value
   
Gross
Unrealized
Loss
   
Number of
Securities
 
                                                       
Securites available for sale
                                                     
Fixed maturities
                                                     
Obligations of government-sponsored enterprises
 
$
9,483
   
$
(15
)
   
1
   
$
-
   
$
-
     
-
   
$
9,483
   
$
(15
)
   
1
 
U.S. Treasury securities and obligations of U.S. governmental instrumentalities
   
12,937
     
(9
)
   
1
     
-
     
-
     
-
     
12,937
     
(9
)
   
1
 
Obligations of the Commonwealth of Puerto Rico and its instrumentalities
   
7,758
     
(68
)
   
5
     
-
     
-
     
-
     
7,758
     
(68
)
   
5
 
Municipal securities
   
84,252
     
(559
)
   
13
     
-
     
-
     
-
     
84,252
     
(559
)
   
13
 
Corporate bonds
   
105,054
     
(661
)
   
22
     
-
     
-
     
-
     
105,054
     
(661
)
   
22
 
Collateralized mortgage obligations
   
32,120
     
(239
)
   
8
     
784
     
(3
)
   
1
     
32,904
     
(242
)
   
9
 
Total fixed maturities
   
251,604
     
(1,551
)
   
50
     
784
     
(3
)
   
1
     
252,388
     
(1,554
)
   
51
 
Equity securities-Mutual funds and alternative investments
   
22,615
     
(451
)
   
4
     
-
     
-
     
-
     
22,615
     
(451
)
   
4
 
Total for securities available for sale
 
$
274,219
   
$
(2,002
)
   
54
   
$
784
   
$
(3
)
   
1
   
$
275,003
   
$
(2,005
)
   
55
 
 
The Corporation regularly monitors and evaluates the difference between the amortized cost and estimated fair value of investments.  For investments with a fair value below amortized cost, the process includes evaluating: (1) the length of time and the extent to which the estimated fair value has been less than amortized cost for fixed maturity securities, or cost for equity securities, (2) the financial condition, near-term and long-term prospects for the issuer, including relevant industry conditions and trends, and implications of rating agency actions, (3) the Company’s intent to sell or the likelihood of a required sale prior to recovery, (4) the recoverability of principal and interest for fixed maturity securities, or cost for equity securities, and (5) other factors, as applicable.  This process is not exact and requires further consideration of risks such as credit and interest rate risks.  Consequently, if an investment’s cost exceeds its estimated fair value solely due to changes in interest rates, other-than temporary impairment may not be appropriate.

Due to the subjective nature of the Corporation’s analysis, along with the judgment that must be applied in the analysis, it is possible that the Corporation could reach a different conclusion whether or not to impair a security if it had access to additional information about the investee.  Additionally, it is possible that the investee’s ability to meet future contractual obligations may be different than what the Corporation determined during its analysis, which may lead to a different impairment conclusion in future periods.

If after monitoring and analyzing impaired securities, the Corporation determined that a decline in the estimated fair value of any available-for-sale or held-to-maturity security below cost is other-than-temporary, the carrying amount of the security is reduced to its fair value in accordance with current accounting guidance.  The new cost basis of an impaired security is not adjusted for subsequent increases in estimated fair value.  In periods subsequent to the recognition of an other-than-temporary impairment, the impaired security is accounted for as if it had been purchased on the measurement date of the impairment.  For debt securities, the discount (or reduced premium) based on the new cost basis may be accreted into net investment income in future periods based on prospective changes in cash flow estimates, to reflect adjustments to the effective yield.
 
Triple-S Management Corporation
Notes to Consolidated Financial Statements
December 31, 2017, 2016, and 2015
(dollar amounts in thousands, except per share and share data)

 
The Corporation’s process for identifying and reviewing invested assets for other-than-temporary impairments during any quarter includes the following:

Identification and evaluation of securities that have possible indications of other-than-temporary impairment, which includes an analysis of all investments with gross unrealized investment losses that represent 20% or more of their cost and all investments with an unrealized loss greater than $100.

For any other securities with a gross unrealized investment loss we might review and evaluate investee’s current financial condition, liquidity, near-term recovery prospects, implications of rating agency actions, the outlook for the business sectors in which the investee operates and other factors.

Consideration of evidential matter, including an evaluation of factors or triggers that may or may not cause individual investments to qualify as having other-than-temporary impairments.

Determination of the status of each analyzed security as other-than-temporary or not, with documentation of the rationale for the decision; and

Equity securities are considered to be impaired based on market conditions and the length of time the funds have been in a loss position .

The Corporation reviews the investment portfolios under the Corporation’s impairment review policy.  Given market conditions and the significant judgments involved, there is a continuing risk that declines in fair value may occur and material other-than-temporary impairments may be recorded in future periods.  The Corporation from time to time may sell investments as part of its asset/liability management process or to reposition its investment portfolio based on current and expected market conditions.

U.S. Treasury Securities, Obligations of U.S. Government Instrumentalities and Municipal Securities:   The unrealized losses on the Corporation’s investments in obligations of U.S. Treasury Securities, U.S. Government Instrumentalities, and Municipal Securities were mainly caused by fluctuations in interest rates and general market conditions.  The contractual terms of these investments do not permit the issuer to settle the securities at a price less than the par value of the investment.  In addition, these investments have investment grade ratings. Because the decline in fair value is attributable to changes in interest rates and not credit quality; because the Corporation does not intend to sell the investments and it is not more likely than not that the Corporation will be required to sell the investments before recovery of their amortized cost basis, which may be maturity; and because the Corporation expects to collect all contractual cash flows, these investments are not considered other-than-temporarily impaired.

Corporate Bonds:   The unrealized losses of these bonds were principally caused by fluctuations in interest rates and general market conditions.  All corporate bonds with an unrealized loss have investment grade ratings.  Because the decline in estimated fair value is principally attributable to changes in interest rates; because the Company does not intend to sell the investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost basis, which may be maturity; and because the Company expects to collect all contractual cash flows, these investments are not considered other-than-temporarily impaired.

Residential mortgage-backed securities and Collateralized mortgage obligations:  The unrealized losses on investments in residential mortgage-backed securities and collateralized mortgage obligations (“CMOs”) were mostly caused by fluctuations in interest rates and credit spreads.  The contractual cash flows of these securities, other than private CMOs, are guaranteed by a U.S. government-sponsored enterprise.  The Corporation does not consider these investments other-than-temporarily impaired because the decline in fair value is attributable to changes in interest rates and not credit quality; the Corporation does not intend to sell the investments and it is more likely than not that the Corporation will not be required to sell the investments before recovery of their amortized cost basis, which may be maturity; and because the Corporation expects to collect all contractual cash flows.
 
Triple-S Management Corporation
Notes to Consolidated Financial Statements
December 31, 2017, 2016, and 2015
(dollar amounts in thousands, except per share and share data)

 
Mutual Funds and Alternative Investments:   As of December 31, 2017, investments in mutual funds and alternative investments with unrealized losses are not considered other-than-temporarily impaired based on market conditions and the length of time the funds have been in a loss position.  During the years ended December 31, 2017, 2016 and 2015, positions with a total fair market value of $1,178, $11,582 and $13,189 were impaired by $49, $1,434 and $945, respectively.

Obligations of the Commonwealth of Puerto Rico and its Instrumentalities : As of December 31, 2017, our holdings in Puerto Rico municipals consist of escrowed bonds.  As of December 31, 2016, besides holdings in escrowed bonds, our exposure included senior liens bonds issued by Cofina, which were not impaired during the year ended December 31, 2016.  During the year ended December 31, 2015, impairments on Cofina bonds amounted to $4,267.

Maturities of investment securities classified as available for sale and held to maturity at December 31, 2017 were as follows:

   
Amortized
Cost
   
Estimated
Fair Value
 
             
Securities available for sale
           
Due in one year or less
 
$
10,696
   
$
10,792
 
Due after one year through five years
   
279,086
     
280,249
 
Due after five years through ten years
   
286,990
     
290,696
 
Due after ten years
   
540,411
     
581,263
 
Residential mortgage-backed securities
   
32,465
     
32,112
 
Collateralized mortgage obligations
   
22,003
     
21,676
 
   
$
1,171,651
   
$
1,216,788
 
Securities held to maturity
               
Due in one year or less
 
$
1,511
   
$
1,511
 
Due after ten years
   
617
     
771
 
Residential mortgage-backed securities
   
191
     
193
 
   
$
2,319
   
$
2,475
 

Expected maturities may differ from contractual maturities because some issuers have the right to call or prepay obligations with or without call or prepayment penalties.
 
Triple-S Management Corporation
Notes to Consolidated Financial Statements
December 31, 2017, 2016, and 2015
(dollar amounts in thousands, except per share and share data)

 
Investments with an amortized cost of $5,229 and $5,358 (fair value of $5,571 and $5,788) at December 31, 2017 and 2016, respectively, were deposited with the Commissioner of Insurance to comply with the deposit requirements of the Insurance Code of the Commonwealth of Puerto Rico (the Insurance Code).

Information regarding realized and unrealized gains and losses from investments for the years ended December 31, is as follows:
 
   
2017
   
2016
   
2015
 
                   
Realized gains (losses)
                 
Fixed maturity securities
                 
Securities available for sale
                 
Gross gains
 
$
1,460
   
$
3,086
   
$
8,208
 
Gross losses
   
(2,176
)
   
(2,744
)
   
(646
)
Gross losses from other-than-temporary impairments
   
-
     
-
     
(4,267
)
Total fixed maturity securities
   
(716
)
   
342
     
3,295
 
Equity securities
                       
Securities available for sale
                       
Gross gains
   
12,154
     
19,674
     
17,903
 
Gross losses
   
(558
)
   
(1,203
)
   
(1,312
)
Gross losses from other-than-temporary impairments
   
(49
)
   
(1,434
)
   
(945
)
Total equity securities
   
11,547
     
17,037
     
15,646
 
Net realized gains on securities
 
$
10,831
   
$
17,379
   
$
18,941
 


The other-than-temporary impairments on fixed maturity securities are attributable to credit losses.

   
2017
   
2016
   
2015
 
                   
Changes in unrealized gains (losses)
                 
Recognized in accumulated other comprehensive income (loss)
                 
Fixed maturities – available for sale
   
(2,203
)
   
1,953
     
(25,227
)
Equity securities – available for sale
   
20,514
     
2,172
     
(19,479
)
   
$
18,311
   
$
4,125
   
$
(44,706
)
Not recognized in the consolidated financial statements
                       
Fixed maturities – held to maturity
 
$
(20
)
 
$
(19
)
 
$
(24
)
 
Triple-S Management Corporation
Notes to Consolidated Financial Statements
December 31, 2017, 2016, and 2015
(dollar amounts in thousands, except per share and share data)

 
The deferred tax asset (liability) on unrealized gains (losses) change recognized in accumulated other comprehensive income during the years 2017, 2016, and 2015 was $(3,846), $(1,085), and $5,717, respectively.
 
As of December 31, 2017 and 2016 no individual investment in securities exceeded 10% of stockholders’ equity.

4.
Net Investment Income
 
Interest and/or dividend income the years ended December 31 were are as follows:
 
   
2017
   
2016
   
2015
 
                   
Fixed maturities
 
$
38,414
   
$
37,139
   
$
36,256
 
Equity securities
   
10,728
     
9,666
     
7,146
 
Policy loans
   
709
     
619
     
557
 
Cash equivalents and interest-bearing deposits
   
798
     
257
     
143
 
Other
   
966
     
1,232
     
1,072
 
Total
 
$
51,615
   
$
48,913
   
$
45,174
 
 
5.
Premium and Other Receivables, Net
 
Premium and other receivables, net as of December 31 were as follows:
 
   
2017
   
2016
 
             
Premium
 
$
103,027
   
$
91,528
 
Self-funded group receivables
   
39,859
     
57,728
 
FEHBP
   
13,346
     
14,321
 
Agent balances
   
32,818
     
25,495
 
Accrued interest
   
14,331
     
13,668
 
Reinsurance recoverable
   
661,679
     
58,295
 
Other
   
70,150
     
62,637
 
     
935,210
     
323,672
 
Less allowance for doubtful receivables:
               
Premium
   
26,490
     
27,320
 
Other
   
9,393
     
9,987
 
     
35,883
     
37,307
 
Premium and other receivables, net
 
$
899,327
   
$
286,365
 

As of December 31, 2017 and 2016, the Company had premiums and other receivables of $81,838 and $57,750, respectively, from the Government of Puerto Rico, including its agencies, municipalities and public corporations. The related allowance for doubtful receivables as of December 31, 2017 and 2016 were $16,436 and $18,812, respectively.
 
Triple-S Management Corporation
Notes to Consolidated Financial Statements
December 31, 2017, 2016, and 2015
(dollar amounts in thousands, except per share and share data)

 
Reinsurance recoverable as of December 31, 2017 includes $613,000 related to expected catastrophe losses covered by the Property and Casualty segment’s reinsurance program, reflecting the anticipated gross losses related to Hurricanes Irma and Maria, which made landfall in Puerto Rico during the month of September 2017.

6.
Deferred Policy Acquisition Costs and Value of Business Acquired

The movement of deferred policy acquisition costs (DPAC) and value of business acquired (VOBA) for the years ended December 31 is summarized as follows:

   
DPAC
   
VOBA
   
Total
 
                   
Balance, December 31, 2014
 
$
151,756
   
$
32,344
   
$
184,100
 
                         
Additions
   
48,599
     
-
     
48,599
 
VOBA interest at an average rate of 5.15%
   
-
     
1,543
     
1,543
 
Amortization
   
(38,624
)
   
(4,970
)
   
(43,594
)
Net change
   
9,975
     
(3,427
)
   
6,548
 
Balance, December 31, 2015
   
161,731
     
28,917
     
190,648
 
                         
Additions
   
47,742
     
-
     
47,742
 
VOBA interest at an average rate of 5.15%
   
-
     
1,381
     
1,381
 
Amortization
   
(40,848
)
   
(4,136
)
   
(44,984
)
Net change
   
6,894
     
(2,755
)
   
4,139
 
Balance, December 31, 2016
   
168,625
     
26,162
     
194,787
 
                         
Additions
   
48,701
     
-
     
48,701
 
VOBA interest at an average rate of 5.17%
   
-
     
1,253
     
1,253
 
Amortization
   
(39,605
)
   
(4,348
)
   
(43,953
)
Net change
   
9,096
     
(3,095
)
   
6,001
 
Balance, December 31, 2017
 
$
177,721
   
$
23,067
   
$
200,788
 

A portion of the amortization of the DPAC and VOBA is recorded as an amortization expense and included within the operating expenses in the accompanying consolidated statements of earnings.  The remaining portion of the DPAC and VOBA amortization includes the unrealized investment gains and losses that would have been amortized if such gains and losses had been realized, which for the years ended December 31, 2017 and 2016 amounted to $598 and $3,147, respectively, and is included within the unrealized gains on securities component of other comprehensive income.
 
Triple-S Management Corporation
Notes to Consolidated Financial Statements
December 31, 2017, 2016, and 2015
(dollar amounts in thousands, except per share and share data)

 
The estimated amount of the year-end VOBA balance expected to be amortized during the next five years is as follows:
 
Year ending December 31:
     
2018
 
$
3,019
 
2019
   
2,269
 
2020
   
2,003
 
2021
   
2,073
 
2022
   
1,478
 

7.
Property and Equipment, Net
 
Property and equipment, net as of December 31 are composed of the following:
 
   
2017
   
2016
 
             
Land
 
$
10,976
   
$
10,976
 
Buildings and leasehold improvements
   
64,856
     
64,828
 
Office furniture and equipment
   
35,070
     
24,234
 
Computer equipment and software
   
116,244
     
114,749
 
Automobiles
   
701
     
593
 
     
227,847
     
215,380
 
Less accumulated depreciation and amortization
   
153,131
     
149,011
 
Property and equipment, net
 
$
74,716
   
$
66,369
 

The Company recognized depreciation expense on property and equipment of $11,930, $12,335, and $13,284 for the years ended December 31, 2017, 2016, and 2015, respectively.

8.
Goodwill

Certain business combination transactions have resulted in goodwill, which represents the excess of the acquisition cost over the fair value of net assets acquired, and is assigned to reporting units.  Goodwill recorded as of December 31, 2017 and 2016 was $25,397 which is mostly attributable to the Medicare Advantage reporting unit within the Managed Care segment.

As required by accounting guidance, the 2017, 2016 and 2015 annual goodwill impairment tests were performed, and based on the results of the tests, no impairment charge was required.  If the Company does not achieve its earnings objectives or the cost of capital raises significantly, the assumptions and estimates underlying these impairment tests could be adversely affected and result in future impairment charges that would negatively impact its operating results.  Cumulative goodwill impairment charges were $2,369 as of December 31, 2017 and 2016.  All cumulative goodwill impairment is related to the health clinic reporting unit which has been fully impaired.
 
Triple-S Management Corporation
Notes to Consolidated Financial Statements
December 31, 2017, 2016, and 2015
(dollar amounts in thousands, except per share and share data)

 
9.
Fair Value Measurements

Assets recorded at fair value in the consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair value.  Level inputs, as defined by current accounting guidance for fair value measurements and disclosures, are as follows:

Level Input Definition:

Level 1
Inputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurement date.

Level 2
Inputs other than quoted prices included in Level 1 that are observable for the asset or liability through corroboration with market data at the measurement date.

Level 3
Unobservable inputs that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date.

The Corporation uses observable inputs when available. Fair value is based upon quoted market prices when available. The Corporation limits valuation adjustments to those deemed necessary to ensure that the security’s fair value adequately represents the price that would be received or paid in the marketplace. Valuation adjustments may include consideration of counterparty credit quality and liquidity as well as other criteria.  The estimated fair value amounts are subjective in nature and may involve uncertainties and matters of significant judgment for certain financial instruments. Changes in the underlying assumptions used in estimating fair value could affect the results.  The fair value measurement levels are not indicative of risk of investment.

The fair value of investment securities is estimated based on quoted market prices for those or similar investments.  Additional information pertinent to the estimated fair value of investment in securities is included in note 3.
 
Triple-S Management Corporation
Notes to Consolidated Financial Statements
December 31, 2017, 2016, and 2015
(dollar amounts in thousands, except per share and share data)

 
The following table summarizes fair value measurements by level at December 31, for assets measured at fair value on a recurring basis:

   
2017
 
   
Level 1
   
Level 2
   
Level 3
   
Total
 
                     
Securities available for sale
                       
Fixed maturity securities
                       
Obligations of government-sponsored enterprises
 
$
-
   
$
1,444
   
$
-
   
$
1,444
 
U.S. Treasury securities and obligations of U.S. government instrumentalities
   
118,349
     
-
     
-
     
118,349
 
Obligations of the Commonwealth of Puerto Rico and its instrumentalities
   
-
     
8,093
     
-
     
8,093
 
Municipal securities
   
-
     
800,790
     
-
     
800,790
 
Corporate bonds
   
-
     
234,324
     
-
     
234,324
 
Residential agency mortgage-backed securities
   
-
     
32,112
     
-
     
32,112
 
Collaterized mortgage obligations
   
-
     
21,676
     
-
     
21,676
 
Total fixed maturities
   
118,349
     
1,098,439
     
-
     
1,216,788
 
                                 
Equity securities - Mutual funds
   
193,159
     
149,149
     
-
     
342,308
 
Alternative investments - measured at net asset value
   
-
     
-
     
-
     
34,985
 
Total equity securities
   
193,159
     
149,149
     
-
     
377,293
 
 
$
311,508
   
$
1,247,588
   
$
-
   
$
1,594,081
 

   
2016
 
   
Level 1
   
Level 2
   
Level 3
   
Total
 
                         
Securities available for sale
                       
Fixed maturity securities
                       
Obligations of government-sponsored enterprises
 
$
-
   
$
41,514
   
$
-
   
$
41,514
 
U.S. Treasury securities and obligations of U.S. government instrumentalities
   
85,800
     
-
     
-
     
85,800
 
Obligations of the Commonwealth of Puerto Rico and its instrumentalities
   
-
     
20,051
     
-
     
20,051
 
Municipal securities
   
-
     
683,803
     
-
     
683,803
 
Corporate bonds
   
-
     
274,872
     
-
     
274,872
 
Residential agency mortgage-backed securities
   
-
     
718
     
-
     
718
 
Collaterized mortgage obligations
   
-
     
44,885
     
-
     
44,885
 
Total fixed maturities
   
85,800
     
1,065,843
     
-
     
1,151,643
 
                                 
Equity securities - Mutual funds and alternative investments
   
166,595
     
76,222
     
-
     
242,817
 
Alternative investments - measured at net asset value
   
-
     
-
     
27,532
     
27,532
 
Total equity securities
   
166,595
     
76,222
     
27,532
     
270,349
 
   
$
252,395
   
$
1,142,065
   
$
27,532
   
$
1,421,992
 
 
Triple-S Management Corporation
Notes to Consolidated Financial Statements
December 31, 2017, 2016, and 2015
(dollar amounts in thousands, except per share and share data)

 
Certain investments that are measured at fair value using the net asset value (NAV) per share practical expedient have not been classified in the fair value hierarchy.  The fair value amount presented in this table is intended to facilitate the reconciliation of the fair value hierarchy to the amounts presented in the statement of financial position.

The fair value of fixed maturity and equity securities included in the Level 2 category were based on market values obtained from independent pricing services, which use previously evaluated pricing models that vary by asset class and incorporate available trade, bid and other market information and for structured securities, cash flow and when available loan performance data.  Because many fixed income securities do not trade on a daily basis, the models used by independent pricing service providers to prepare evaluations apply available information, such as benchmark curves, benchmarking of like securities, sector groupings, and matrix pricing.  For certain equity securities, quoted market prices for the identical security are not always available and the fair value is estimated by reference to similar securities for which quoted prices are available.  The independent pricing service providers monitor market indicators, industry and economic events, and for broker-quoted only securities, obtain quotes from market makers or broker-dealers that they recognize to be market participants. The fair value of the investments in partnerships included in the Level 3 category was based on the net asset value (NAV) which is affected by the changes in the fair market value of the investments held in these partnerships.
 
Transfers into or out of the Level 3 category occur when unobservable inputs, such as the Company’s best estimate of what a market participant would use to determine a current transaction price, become more or less significant to the fair value measurement.  Transfers between levels, if any, are recorded as of the actual date of the event or change in circumstance that caused the transfer.  There were no transfers between Levels 1 and 2 during the years ended December 31, 2017 and 2016.

The alternative investments represent investments in partnerships which invest in several private debt and private equity funds.  Portfolios are diversified by vintage year, stage, geography, business sectors and number of investments. These investments are not redeemable with the funds. Distributions from each fund are received as the underlying investments of the funds are liquidated. It is estimated that the underlying assets of the funds will be liquidated in the next 5 to 12 years. The fair values of the investments in this class have been estimated using the NAV of the Company’s ownership interest in the partnerships. Total unfunded capital commitments for these positions as of December 31, 2017 amounted to $117,631.  The remaining average commitments period is approximately three years.

In addition to the preceding disclosures on assets recorded at fair value in the consolidated balance sheets, accounting guidance also requires the disclosure of fair values for certain other financial instruments for which it is practicable to estimate fair value, whether or not such values are recognized in the consolidated balance sheets.

Non-financial instruments such as property and equipment, other assets, deferred income taxes and intangible assets, and certain financial instruments such as claim liabilities are excluded from the fair value disclosures. Therefore, the fair value amounts cannot be aggregated to determine our underlying economic value.

The carrying amounts reported in the consolidated balance sheets for cash and cash equivalents, receivables, accounts payable and accrued liabilities, and short-term borrowings approximate fair value because of the short term nature of these items.  These assets and liabilities are not listed in the table below.
 
Triple-S Management Corporation
Notes to Consolidated Financial Statements
December 31, 2017, 2016, and 2015
(dollar amounts in thousands, except per share and share data)

 
The following methods, assumptions and inputs were used to estimate the fair value of each class of financial instrument:

(i)  Policy Loans

Policy loans have no stated maturity dates and are part of the related insurance contract. The carrying amount of policy loans approximates fair value because their interest rate is reset periodically in accordance with current market rates.

(ii)  Policyholder Deposits

The fair value of policyholder deposits is the amount payable on demand at the reporting date, and accordingly, the carrying value amount approximates fair value.

(iii)  Long-term Borrowings

The carrying amount of the loans payable to bank – variable approximates fair value due to its floating interest-rate structure.  The fair value of the loans payable to bank – fixed and senior unsecured notes payable was determined using broker quotations.

A summary of the carrying value and fair value by level of financial instruments not recorded at fair value on our consolidated balance sheets at December 31, 2017 and 2016 are as follows:

   
2017
 
   
Carrying
Value
   
Fair Value
 
 
Level 1
   
Level 2
   
Level 3
   
Total
 
Assets:
                             
Policy loans
 
$
9,077
   
$
-
   
$
9,077
   
$
-
   
$
9,077
 
                                         
Liabilities:
                                       
Policyholder deposits
 
$
176,534
   
$
-
   
$
176,534
   
$
-
   
$
176,534
 
Long-term borrowings - loans payable to bank - variable
   
32,350
     
-
     
32,350
     
-
     
32,350
 
Total liabilities
 
$
217,961
   
$
-
   
$
217,961
   
$
-
   
$
217,961
 

   
2016
 
   
Carrying
Value
   
Fair Value
 
 
Level 1
   
Level 2
   
Level 3
   
Total
 
Assets:
                             
Policy loans
 
$
8,564
   
$
-
   
$
8,564
   
$
-
   
$
8,564
 
                                         
Liabilities:
                                       
Policyholder deposits
 
$
179,382
   
$
-
   
$
179,382
   
$
-
   
$
179,382
 
Long-term borrowings:
                                       
Loans payable to bank - variable
   
11,187
     
-
     
11,187
     
-
     
11,187
 
6.6% senior unsecured notes payable
   
24,000
     
-
     
24,000
     
-
     
24,000
 
Total long-term borrowings
   
35,187
     
-
     
35,187
     
-
     
35,187
 
Total liabilities
 
$
214,569
   
$
-
   
$
214,569
   
$
-
   
$
214,569
 
 
Triple-S Management Corporation
Notes to Consolidated Financial Statements
December 31, 2017, 2016, and 2015
(dollar amounts in thousands, except per share and share data)

 
10.
Claim Liabilities and Claim Adjustment Expenses

A reconciliation of the beginning and ending balances of claim liabilities in 2017, 2016 and 2015 is as follows:

   
2017
 
   
Managed
Care
   
Other
Business
Segments *
   
Consolidated
 
                   
Claim liabilities at beginning of year
 
$
349,047
   
$
138,896
   
$
487,943
 
Reinsurance recoverable on claim liabilities
   
-
     
(38,998
)
   
(38,998
)
Net claim liabilities at beginning of year
   
349,047
     
99,898
     
448,945
 
Claims incurred
                       
Current period insured events
   
2,231,052
     
118,012
     
2,349,064
 
Prior period insured events
   
(12,782
)
   
(8,975
)
   
(21,757
)
Total
   
2,218,270
     
109,037
     
2,327,307
 
Payments of losses and loss-adjustment expenses
                       
Current period insured events
   
1,940,410
     
64,051
     
2,004,461
 
Prior period insured events
   
259,550
     
38,536
     
298,086
 
Total
   
2,199,960
     
102,587
     
2,302,547
 
Net claim liabilities at end of year
   
367,357
     
106,348
     
473,705
 
Reinsurance recoverable on claim liabilities
   
-
     
633,171
     
633,171
 
Claim liabilities at end of year
 
$
367,357
   
$
739,519
   
$
1,106,876
 
 
Triple-S Management Corporation
Notes to Consolidated Financial Statements
December 31, 2017, 2016, and 2015
(dollar amounts in thousands, except per share and share data)

 
   
2016
 
   
Managed
Care
   
Other
Business
Segments *
   
Consolidated
 
                   
Claim liabilities at beginning of year
 
$
348,297
   
$
143,468
   
$
491,765
 
Reinsurance recoverable on claim liabilities
   
-
     
(40,714
)
   
(40,714
)
Net claim liabilities at beginning of year
   
348,297
     
102,754
     
451,051
 
Claims incurred
                       
Current period insured events
   
2,356,594
     
103,049
     
2,459,643
 
Prior period insured events
   
(9,047
)
   
(7,157
)
   
(16,204
)
Total
   
2,347,547
     
95,892
     
2,443,439
 
Payments of losses and loss-adjustment expenses
                       
Current period insured events
   
2,083,552
     
58,091
     
2,141,643
 
Prior period insured events
   
263,245
     
40,657
     
303,902
 
Total
   
2,346,797
     
98,748
     
2,445,545
 
Net claim liabilities at end of year
   
349,047
     
99,898
     
448,945
 
Reinsurance recoverable on claim liabilities
   
-
     
38,998
     
38,998
 
Claim liabilities at end of year
 
$
349,047
   
$
138,896
   
$
487,943
 
 
Triple-S Management Corporation
Notes to Consolidated Financial Statements
December 31, 2017, 2016, and 2015
(dollar amounts in thousands, except per share and share data)

 
   
2015
 
   
Managed
Care
   
Other
Business
Segments *
   
Consolidated
 
                   
Claim liabilities at beginning of year
 
$
249,330
   
$
140,756
   
$
390,086
 
Reinsurance recoverable on claim liabilities
   
-
     
(40,635
)
   
(40,635
)
Net claim liabilities at beginning of year
   
249,330
     
100,121
     
349,451
 
Claims incurred
                       
Current period insured events
   
2,216,330
     
98,279
     
2,314,609
 
Prior period insured events
   
(19,637
)
   
(1,211
)
   
(20,848
)
Total
   
2,196,693
     
97,068
     
2,293,761
 
Payments of losses and loss-adjustment expenses
                       
Current period insured events
   
1,868,607
     
52,369
     
1,920,976
 
Prior period insured events
   
229,119
     
42,066
     
271,185
 
Total
   
2,097,726
     
94,435
     
2,192,161
 
Net claim liabilities at end of year
   
348,297
     
102,754
     
451,051
 
Reinsurance recoverable on claim liabilities
   
-
     
40,714
     
40,714
 
Claim liabilities at end of year
 
$
348,297
   
$
143,468
   
$
491,765
 
 
 
*
Other Business Segments include the Life Insurance and Property and Casualty segments, as well as intersegment eliminations.
 
As a result of differences between actual amounts and estimates of insured events in prior years, the amounts included as claims incurred for prior period insured events differ from anticipated claims incurred.
 
The favorable developments in the claims incurred and loss-adjustment expenses for prior period insured events for 2017, 2016 and 2015 are due primarily to better than expected utilization trends mostly in the Managed Care segment.  Reinsurance recoverable on unpaid claims is reported as premium and other receivables, net in the accompanying consolidated financial statements.
 
The claims incurred disclosed in this table exclude the portion of the change in the liability for future policy benefits amounting to $25,794, $28,752, and $24,954 that is included within the consolidated claims incurred during the years ended December 31, 2017, 2016 and 2015, respectively.
 
The following is information about incurred and paid claims development, net of reinsurance, as of December 31, 2017, as well as cumulative claim frequency.  Additional information presented includes total incurred-but-not-reported liabilities plus expected development on reported claims is included within the net incurred claims amounts.
 
The information about incurred and paid claims development for the year ended December 31, 2015 and previous years are presented as supplementary information and are unaudited where indicated. The average annual percentage payout of incurred claims by age as of December 31, 2017, is presented as required supplementary information.
 
Triple-S Management Corporation
Notes to Consolidated Financial Statements
December 31, 2017, 2016, and 2015
(dollar amounts in thousands, except per share and share data)
 
Managed Care

The Company estimates its liabilities for unpaid claims following a detailed actuarial process that entails using both historical claim payment patterns as well as emerging medical cost trends to project a best estimate of claim liabilities. This process includes comparing the historical claims incurred dates to the actual dates on claims payment.  Completion factors are applied to claims paid through the consolidated financial statements date to estimate the claim expense incurred for the current period.  The liability for claim adjustment expenses consists of adjustments made by our actuaries based on their knowledge and their estimate of emerging impacts to benefit costs and payment speed.

Incurred Claims and Allocated Claim
Adjustment Expenses, Net of Reinsurance
     
As of December 31, 2017
 
                 
         
(in thousands)
 
Incurred Year
2016
 
2017
 
Total of IBNR Liabilities
Plus Expected
Development on
Reported Claims
 
Cumulative
Number of
Reported Claims
 
2016
  $
2,356,592
     
2,343,812
     
798
     
20,270
 
2017
           
2,231,052
     
290,642
     
17,577
 
 
Total
   
$
4,574,864
                 
 
Cumulative Paid Claims and Allocated Claim Adjustment Expenses, Net of Reinsurance
 
           
Incurred Year
 
 
2016
 
2017
 
2016
    $
2,083,552
     
2,343,014
 
2017
             
1,940,410
 
 
Total
   
$
4,283,424
 
All outstanding liabilities before 2016, net of reinsurance      
75,917
 
Liabilities for claims and claim adjustment expenses, net of reinsurance    
$
367,357
 
 
Triple-S Management Corporation
Notes to Consolidated Financial Statements
December 31, 2017, 2016, and 2015
(dollar amounts in thousands, except per share and share data)
 
Property and Casualty

Claims liability for property and casualty represents individual case estimates for reported claims and estimates for unreported losses, net of any salvage and subrogation based on past experience modified for current trends and estimates of expense for investigating and setting claims.

Incurred Claims and Allocated Claim Adjustment Expenses, Net of Reinsurance
   
As of December 31, 2017
 
Incurred
Year
 
Incurred amount
   
Total of IBNR Plus
Expected Development
on Reported Claims
   
Cumulative Number
of reported claims
 
   
(unaudited)
   
(unaudited)
   
(unaudited)
   
(unaudited)
   
(unaudited)
   
(unaudited)
   
(unaudited)
   
(unaudited)
                         
   
2008
   
2009
   
2010
   
2011
   
2012
   
2013
   
2014
   
2015
   
2016
   
2017
             
2008
 
$
49,095
   
$
48,812
   
$
46,443
   
$
45,941
   
$
45,541
   
$
47,658
   
$
45,909
   
$
45,535
   
$
45,571
   
$
45,471
     
24
     
15,762
 
2009
           
51,778
     
51,760
     
50,848
     
51,298
     
51,564
     
51,315
     
51,485
     
51,293
     
51,563
     
188
     
16,089
 
2010
                   
54,226
     
54,090
     
55,266
     
56,400
     
57,115
     
57,386
     
57,242
     
56,960
     
174
     
18,010
 
2011
                           
51,315
     
50,287
     
51,105
     
50,776
     
51,895
     
52,099
     
51,729
     
342
     
20,914
 
2012
                                   
49,040
     
49,856
     
48,900
     
49,817
     
48,945
     
48,186
     
750
     
20,212
 
2013
                                           
52,343
     
51,030
     
49,606
     
49,168
     
48,229
     
1,104
     
22,351
 
2014
                                                   
48,430
     
45,410
     
43,707
     
42,547
     
1,924
     
22,026
 
2015
                                                           
45,067
     
40,175
     
37,271
     
2,944
     
20,044
 
2016
                                                                   
48,127
     
44,294
     
6,766
     
19,251
 
2017
                                                                           
60,694
     
16,958
     
33,917
 
                                                                   
Total
   
$
486,944
                 

Cumulative Paid claims and Allocated Claim Adjustment Expenses, Net of Reinsurance
 
Incurred
Year
                                                           
   
(unaudited)
2008
   
(unaudited)
2009
   
(unaudited)
2010
   
(unaudited)
2011
   
(unaudited)
2012
   
(unaudited)
2013
   
(unaudited)
2014
   
(unaudited)
2015
   
2016
   
2017
 
2008
 
$
23,715
   
$
32,835    
$
37,420
   
$
40,332    
$
41,847
   
$
43,787
   
$
44,426
   
$
44,703
   
$
44,867
   
$
44,911
 
2009
            23,843      
35,327
      41,810      
45,838
     
48,637
     
49,709
     
50,196
     
50,371
     
50,594
 
2010
                   
27,118
      38,964      
45,409
     
49,808
     
52,890
     
54,027
     
54,996
     
55,715
 
2011
                            24,534      
34,835
     
41,606
     
44,996
     
47,908
     
49,598
     
50,457
 
2012
                                    22,677      
33,620
     
40,406
     
43,663
     
45,607
     
46,094
 
2013
                                            21,376      
33,249
     
38,979
     
42,840
     
44,252
 
2014
                                                    18,752      
28,657
     
33,809
     
36,875
 
2015
                                                           
17,063
     
24,935
     
28,040
 
2016
                                                                   
20,099
     
28,996
 
2017
                                                                           
28,414
 
                                                                                 
                                                                           
$
414,348
 
All Outstanding liabilities before 2008, net of reinsurance      
1,568
 
Liabilities for claims and claims adjustment expenses, net of reinsurance    
$
74,164
 
 
The following table includes the annual percentage payout of incurred claims by age, net of reinsurance, for property and casualty segment as supplementary information as of December 31, 2017:

   
(unaudited)
2008
   
(unaudited)
2009
   
(unaudited)
2010
   
(unaudited)
2011
   
(unaudited)
2012
   
(unaudited)
2013
   
(unaudited)
2014
   
(unaudited)
2015
   
(unaudited)
2016
   
(unaudited)
2017
 
Average
   
46.7
%
   
21.7
%
   
11.7
%
   
7.2
%
   
4.5
%
   
2.5
%
   
1.4
%
   
0.7
%
   
0.4
%
   
0.1
%
 
Triple-S Management Corporation
Notes to Consolidated Financial Statements
December 31, 2017, 2016, and 2015
(dollar amounts in thousands, except per share and share data)
 
The reconciliation of the net incurred and paid claims development tables, by segment, to the liability for claims and claim adjustment expenses in the consolidated balance sheets is as follows:

   
As of December 31, 2017
 
       
Net outstanding liabilities
     
Managed Care
 
$
367,357
 
Property and Casualty
   
74,164
 
Other short-duration insurance lines
   
3,696
 
Liabilities for unpaid claims and claim adjustment expenses, net of reinsurance
   
445,217
 
         
Reinsurance recoverable on unpaid claims - Property and Casualty
   
620,280
 
         
Insurance lines other than short-duration
   
41,822
 
Intersegment elimination
   
(443
)
Total gross liability for unpaid claims and claim adjustment expense
 
$
1,106,876
 
 
Claim liabilities as of December 31, 2017 include approximately $605,200 of gross losses related to the impact of Hurricanes Irma and Maria which made landfall in Puerto Rico in September 2017.
 
11.
Federal Employees’ Health Benefits (FEHBP) and Federal Employees’ (FEP) Programs

FEHBP

In prior years, TSS entered into a contract, renewable annually, with the Office of Personnel Management (OPM) as authorized by the Federal Employees’ Health Benefits Act of 1959, as amended, to provide health benefits under the FEHBP.  The FEHBP covers postal and federal employees residing in the Commonwealth of Puerto Rico and the USVI as well as retirees and eligible dependents.  The FEHBP is financed through a negotiated contribution made by the federal government and employees’ payroll deductions.
 
Triple-S Management Corporation
Notes to Consolidated Financial Statements
December 31, 2017, 2016, and 2015
(dollar amounts in thousands , except per share and share data)
 
The accounting policies for the FEHBP are the same as those described in the Company’s summary of significant accounting policies.  Premium rates are determined annually by TSS and approved by the federal government.  Claims are paid to providers based on the guidelines determined by the federal government.  Operating expenses are allocated from TSS’s operations to the FEHBP based on applicable allocation guidelines (such as, the number of claims processed for each program) and are subject to contractual expense limitations.

The operations of the FEHBP do not result in any excess or deficiency of revenue or expense as this program has a special account available to compensate any excess or deficiency on its operations to the benefit or detriment of the federal government.  Any transfer to/from the special account necessary to cover any excess or deficiency in the operations of the FEHBP is recorded as a reduction/increment to the premiums earned.  The contract with OPM provides that the cumulative excess of the FEHBP earned income over health benefits charges and expenses represents a restricted fund balance denoted as the special account.  Upon termination of the contract and satisfaction of all the FEHBP’s obligations, any unused remainder of the special reserve would revert to the Federal Employees Health Benefit Fund.  In the event that the contract terminates and the special reserve is not sufficient to meet the FEHBP’s obligations, the FEHBP contingency reserve will be used to meet such obligations.  If the contingency reserve is not sufficient to meet such obligations, the Company is at risk for the amount not covered by the contingency reserve.

The contract with OPM allows for the payment to the Company of service fees as negotiated between TSS and OPM.

The Company also has funds available related to the FEHBP amounting to $68,425 and $50,789 as of December 31, 2017 and 2016, respectively, and are included within cash and cash equivalents in the accompanying consolidated balance sheets.  Such funds are used to cover health benefits charges, administrative expenses and service charges required by the FEHBP.

A contingency reserve is maintained by the OPM at the U.S. Treasury, and is available to the Company under certain conditions as specified in government regulations.  Accordingly, such reserve is not reflected in the consolidated balance sheets.  The balance of such reserve as of December 31, 2017 and 2016 was $32,928 and $26,180, respectively.  The Company received  $27, $6,687, and $4,763, of payments made from the contingency reserve fund of OPM during 2017, 2016, and 2015, respectively.

The claim payments and operating expenses charged to the FEHBP are subject to audit by the U.S. government.  Management is of the opinion that an adjustment, if any, resulting from such audits will not have a significant effect on the accompanying consolidated financial statements.  The claim payments and operating expenses reimbursed in connection with the FEHBP have been audited through 2011 by OPM.
 
Triple-S Management Corporation
Notes to Consolidated Financial Statements
December 31, 2017, 2016, and 2015
(dollar amounts in thousands, except per share and share data)
 
FEP

In prior years, TSS entered into a contract with the BCBSA as per Contract No. C.S. 1039 with OPM to provide health benefits under one Government-wide Service Benefit Plan as contemplated in Title 5, Chapter 89, United States Code. The FEP covers employees and annuitants residing in the Commonwealth of Puerto Rico and the USVI as well as eligible dependents. The FEP is financed through a negotiated contribution made by the federal government and employees’ payroll deductions.  The accounting methodology and operations of the FEP are similar to those of the FEHBP as described before.

The Company also has funds overdraft related to the FEP amounting to $1,812 at December 31, 2016 (none at December 31, 2017), and are included within cash and cash equivalents in the accompanying consolidated balance sheets.

The claims payments and operating expenses charged to the FEP are subject to audit by the BCBSA. Management is of the opinion that the adjustments, if any, resulting from such audits will not have a significant effect in the accompanying consolidated financial statements. Operating expenses reimbursed in connection with the FEP have been audited through 2015 by BCBSA.
 
Triple-S Management Corporation
Notes to Consolidated Financial Statements
December 31, 2017, 2016, and 2015
(dollar amounts in thousands, except per share and share data)
 
12.
Long-Term Borrowings

A summary of the borrowings entered by the Company as of December 31 is as follows:
 
   
2017
   
2016
 
             
Senior unsecured notes payable of $60,000 issued on December 2005; due December 2020. Interest was payable monthly at a fixed rate of 6.60%, fully paid in January 2017.
 
$
-
   
$
24,000
 
Secured loan payable of $11,187, payable in monthly installments of $137 through October 1, 2023, plus interest at a rate reset periodically of 100 basis points over selected LIBOR maturity (which was 2.37% at December 31, 2017).
   
9,547
     
11,187
 
Secured loan payable of $20,150, payable in monthly installments of $84 through January 1, 2024, plus interest at a rate reset periodically of 275 basis points over selected LIBOR maturity (which was 4.08% at December 31, 2017).
   
19,226
     
-
 
Secured loan payable of $4,116, payable in monthly installments of $49 through January 1, 2024, plus interest at a rate reset periodically of 325 basis points over selected LIBOR maturity (which was 4.58% at December 31, 2017).
   
3,577
     
-
 
                 
Total borrowings
   
32,350
     
35,187
 
                 
Less: unamortized debt issuance costs
   
277
     
102
 
                 
   
$
32,073
   
$
35,085
 

Aggregate maturities of the Company’s borrowings as of December 31, 2017 are summarized as follows:
 
Year ending December 31
     
2018
 
$
3,236
 
2019
   
3,236
 
2020
   
3,236
 
2021
   
3,236
 
2022
   
3,236
 
Thereafter
   
16,170
 
   
$
32,350
 
 
Triple-S Management Corporation
Notes to Consolidated Financial Statements
December 31, 2017, 2016, and 2015
(dollar amounts in thousands, except per share and share data)
 
On December 28, 2016, TSM entered into a $35,500 credit agreement with a commercial bank in Puerto Rico. The agreement consists of three term loans: (i) Term Loan A in the principal amount of $11,187, (ii) Term Loan B in the principal amount of $20,150 and (iii) Term Loan C in the principal amount of $4,116. Term Loan A matures in October 2023 while the Term Loans B and C mature in January 2024.  Term Loan A was used to refinance a previous $41,000 secured loan payable with the same commercial bank.  Proceeds from Term Loans B and C were received on January 11, 2017 and were used to prepay the outstanding principal amount plus accrued interest of the 6.6% Senior Unsecured Notes due December 2020 ($24,000), and fund a portion of a debt service reserve for the loan (approximately $200).  Interest payable commenced on January 1, 2017, in the case of Term Loan A, and on February 1, 2017, in the case of Term Loan B and Term Loan C.  The Credit Agreement includes certain financial and non-financial covenants, including negative covenants imposing certain restrictions on the Corporation’s business.  The Company was in compliance with all these covenants as of December 31, 2017.

This credit agreement is guaranteed by a first mortgage held by the bank on the Company’s land, building, and substantially all leasehold improvements, as collateral for the term of the loan under a continuing general security agreement.

The Company may, at its option, upon notice, as specified in the credit agreement, redeem and prepay prior to maturity, all or any part of the loan and from time to time upon the payment of a penalty fee of 3% during the first year, 2% during the second year and 1% during the third year, and thereafter, at par, as specified in the credit agreement, together with accrued and unpaid interest, if any, to the date of redemption specified by the Company.

Interest expense on the above borrowings amounted to $1,196, $1,763, and $2,435, for the years ended December 31, 2017, 2016, and 2015, respectively.

On March 11, 2016, TSS entered into a $30,000 revolving loan agreement with a commercial bank in Puerto Rico. This unused line of credit had an interest rate of LIBOR plus 220 basis points and contained certain financial and non-financial covenants that are customary for this type of facility. This revolving loan agreement matured on March 11, 2017, and was not renewed.

On April 18, 2017, TSA entered into a $10,000 revolving loan agreement with a commercial bank in Puerto Rico. This line of credit has an interest rate of 30-day LIBOR plus 25 basis points, matures on April 17, 2018, and includes certain financial and non-financial covenants that are customary for this type of facility.  As of December 31, 2017, there were $1,964 outstanding in this line of credit included as part of accounts payable and accrued liabilities in the accompanying consolidated statement of balance sheets.
 
Triple-S Management Corporation
Notes to Consolidated Financial Statements
December 31, 2017, 2016, and 2015
(dollar amounts in thousands, except per share and share data)
 
13.
Reinsurance Activity
 
The effect of reinsurance on premiums earned and claims incurred is as follows:

   
Premiums Earned
   
Claims Incurred (1)
 
   
2017
   
2016
   
2015
   
2017
   
2016
   
2015
 
                                     
Gross
 
$
2,893,765
   
$
2,945,017
   
$
2,843,086
   
$
3,010,728
   
$
2,454,758
   
$
2,309,499
 
Ceded
   
(71,295
)
   
(59,032
)
   
(64,134
)
   
(687,520
)
   
(15,008
)
   
(19,430
)
Assumed
   
4,462
     
4,656
     
4,202
     
4,099
     
3,689
     
3,692
 
Net
 
$
2,826,932
   
$
2,890,641
   
$
2,783,154
   
$
2,327,307
   
$
2,443,439
   
$
2,293,761
 
 
(1)
The claims incurred disclosed in this table exclude the portion of the change in the liability for future policy benefits amounting to $25,794, $28,752, and $24,954 that is included within the consolidated claims incurred during the years ended December 31, 2017, 2016 and 2015, respectively.

TSS, TSA, TSP and TSV, in accordance with general industry practices, annually purchase reinsurance to protect them from the impact of large unforeseen losses and prevent sudden and unpredictable changes in net income and stockholders’ equity of the Company.  Reinsurance contracts do not relieve any of the subsidiaries from their obligations to policyholders.  In the event that all or any of the reinsuring companies might be unable to meet their obligations under existing reinsurance agreements, the subsidiaries would be liable for such defaulted amounts.  During 2017, 2016, and 2015 TSP placed 14.88%, 13.16%, and 14.06% of its reinsurance business with one reinsurance company.

TSS has excess of loss reinsurance treaties whereby it cedes a portion of its premiums to third parties.  Reinsurance contracts are primarily for periods of one year, and are subject to modifications and negotiations at each renewal date.  Premiums ceded under these contracts amounted to $2,168, $3,148, and $3,678 in 2017, 2016 and 2015, respectively.  Claims ceded amounted to $463, $1,700, and $2,665, in 2017, 2016 and 2015, respectively.  Principal reinsurance agreements include an organ transplant excess of loss treaty, which covers:

·
For group policies, 80% of the claims up to a maximum of $800 (80% of $1,000), per person, per life. For other group policies with other options, the agreement covers 80% of the claims up to a maximum of $400 (80% of $500), per person, per life, or 80% of the claims up to a maximum of $200 (80% of $250), per person, per life.

·
For policies provided to the active and retired employees of the Commonwealth of Puerto Rico and its instrumentalities, the treaty covers 100% of the claims up to a maximum of $1,000 per person, per life with major medical coverage, only if the covered person uses providers that are members of TSS network.

·
For policies provided to the municipalities of Puerto Rico, the treaty covers 100% of the claims up to a maximum of $250, per person, per life, with plans with lifetime limits and all other plans 100% of the claims up to a maximum of $1,000, per person, per life.
 
Triple-S Management Corporation
Notes to Consolidated Financial Statements
December 31, 2017, 2016, and 2015
(dollar amounts in thousands, except per share and share data)
 
TSA has an excess of loss reinsurance treaty whereby it cedes a portion of its premiums to a third party.  This reinsurance contracts is for a period of one year, and is subject to modifications and negotiations in each renewal date.  Premiums ceded under this contract amounted to $1,224 in 2017. Claims ceded amounted to $1,360 in 2017.  This reinsurance agreement includes an excess of loss reinsurance coverage for certain hospital inpatient, hospital outpatient, ambulance, and physician services as well as pharmaceutical drugs. This agreement covers a maximum of $2,000 per person, per agreement term.

TSP utilized facultative reinsurance, pro rata, and excess of loss reinsurance treaties to manage its exposure to losses, including those from catastrophe events.  TSP has geographic exposure to catastrophe losses from hurricanes and earthquakes.  The incidence and severity of catastrophes are inherently unpredictable.  Under these treaties, TSP ceded premiums written were $62,268, $45,957, and $48,676, in 2017, 2016, and 2015, respectively.  In 2017, TSP ceded claims incurred amounting to $678,624 related to losses caused by Hurricanes Irma and Maria.

Reinsurance cessions are made on excess of loss and on a proportional basis.  Facultative reinsurance is obtained when coverage per risk is required.

All principal reinsurance contracts   are for a period of one year and are subject to modifications and negotiations in each renewal. Current property and catastrophe reinsurance program expires on March 31, 2018, following an extension request.  Other contracts were renewed as expiring on January 1, 2018.

Principal reinsurance agreements are as follows:

·
Casualty excess of loss treaty.  This treaty provides reinsurance for losses up to $12,000, subject to a retention of $225.

·
Medical malpractice excess of loss.  This treaty provides reinsurance for losses up to $3,000, subject to a retention of $150.

·
Surety quota share treaty covering contract and miscellaneous surety bond business. This treaty provides reinsurance of up to $5,000 for contract surety bonds, subject to an aggregate of $10,000 per contractor and $3,000 per miscellaneous surety bond.

Primary Reinsurance:

·
Commercial Property quota share contract .  This treaty covers a maximum of $30,000 for any one risk.  Under this treaty 30% of the risk is ceded to reinsurers.  The remaining exposure is covered by a Property Per Risk excess of loss contract that provides reinsurance in excess of $350 up to a maximum of $21,000, or the remaining 70% for any one risk.

·
Builders’ risk quota share and first surplus covering contractors’ risk.  This treaty provides protection on a 20/80 quota share basis for the initial $2,500 and a first surplus of $12,500 for a maximum of $14,500 for any one risk.

Catastrophic Reinsurance:

·
The commercial property quota share contract described above provides coverage for losses from a single event up to $200,000.
 
Triple-S Management Corporation
Notes to Consolidated Financial Statements
December 31, 2017, 2016, and 2015
(dollar amounts in thousands, except per share and share data)
 
·
Personal property catastrophe excess of loss.  This treaty provides protection from losses up to a maximum of $125,000, subject to a $5,000 retention.

·
Commercial property catastrophe excess of loss.  This treaty provides protection for losses up to a maximum of $135,000, subject to a $10,000 retention.

·
Property catastrophe excess of loss.  This treaty provides a protection of $285,000 in excess of the Personal and Commercial lines Catastrophe contracts.

·
In addition, the above combined $15,000 retention is further reduced to $10,000 by the Clash Cover Property Catastrophe excess of loss contract.   The losses would be net of any Facultative reinsurance. Also, the Company purchases personal and commercial Reinstatement Premium Protection contracts to cover the necessity of reinstating the catastrophe program in the event it is activated.

Facultative reinsurance is obtained when coverage per risk is required. All principal reinsurance contracts   are for a period of one year, on a calendar basis, and are subject to modifications and negotiations in each renewal.

The ceded unearned reinsurance premiums on TSP arising from these reinsurance transactions amounted to $12,393 and $9,202 as of December 31, 2017 and 2016, respectively, and are reported as other assets in the accompanying consolidated balance sheets.

TSV also cedes insurance with various reinsurance companies under a number of pro rata, excess of loss and catastrophe treaties. Under these treaties, TSV ceded premiums of $8,826, $8,838, and $9,596, in 2017, 2016, and 2015, respectively. Principal reinsurance agreements are as follows:

·
Group life insurance facultative agreement, reinsuring risk in excess of $25 of certain group life policies and a combined pro rata and excess of loss agreement effective July 1, 2008, reinsuring 50% of the risk up to $200 and ceding the excess.

·
Facultative pro rata agreements for the long‑term disability insurance, reinsuring 65% of the risk.

·
Several reinsurance agreements, mostly on an excess of loss basis up to a maximum retention of $50. For certain new life products that have been issued after 1999, the retention limit is $175, and for others issued after January 1, 2015, the retention limit is $200.

·
A quota share agreement for group major medical and an excess of loss agreements for group and individual major medical, where TSV cedes 40% of all claims up to a maximum retention of $100 and 70% of all claims over $100 up to a maximum of $2,000.

·
Excess of loss agreement for the Major Medical Business in Costa Rica reinsuring 100% of all claims over $25.

TSV participates in various retrocession reinsurance agreements since early 2014. The retrocessions are based on group life and health reinsurance business pools for which TSV has participations ranging from 6.7% to 15% of the total reinsurance facility. TSV share of the reinsurer’s gross liability is limited to a maximum that ranges depending on the agreement from $50 to $500 per covered life. The agreements cover new and renewal business for a period of twelve months and may be cancelled subject to ninety days written notice at any anniversary date.
 
Triple-S Management Corporation
Notes to Consolidated Financial Statements
December 31, 2017, 2016, and 2015
(dollar amounts in thousands, except per share and share data)
 
14.
Income Taxes

The Company and its subsidiaries are subject to Puerto Rico income taxes. Under Puerto Rico income tax law, the Company is not allowed to file consolidated tax returns with its subsidiaries. The Company’s insurance subsidiaries are also subject to U.S. federal income taxes for foreign source dividend income.  The Company is potentially subject to income tax audits in the Commonwealth of Puerto Rico for the taxable year 2015 and after, until the applicable statute of limitations expire. Tax audits by their nature are often complex and can require several years to complete.

Managed Care and Property and Casualty corporations are taxed essentially the same as other corporations, with taxable income primarily determined on the basis of the statutory annual statements filed with the insurance regulatory authorities. The corporations are also subject to an alternative minimum income tax, which is calculated based on the formula established by existing tax laws. Any alternative minimum income tax paid may be used as a credit against the excess, if any, of regular income tax over the alternative minimum income tax in future years up to a limit of 25% of the excess.

The Company, through one of its Managed Care corporations, has a branch in the USVI that is subject to a 5% premium tax on policies underwritten therein. As a qualified foreign insurance company, the Company is subject to income taxes in the USVI, which has implemented a mirror tax law based on the U.S. Internal Revenue Code.  The branch operations in the USVI had certain net operating losses for USVI tax purposes for which a valuation allowance has been recorded.

Companies within our Life Insurance segment operate as qualified domestic life insurance companies and are subject to the alternative minimum tax and taxes on its capital gains.

Federal income taxes recognized by the Company’s insurance subsidiaries amounted to approximately $985, $733, and $574, in 2017, 2016, and 2015, respectively.

All other corporations within the group are subject to Puerto Rico income taxes as regular corporations, as defined in the P.R. Internal Revenue Code, as amended.  The holding company within the TSA group of companies was a U.S.-based corporation subject to U.S. federal income taxes.  This U.S-based corporation within our group did not provide for U.S. deferred taxes on an outside basis difference created as a result of the business combination of TSA and cumulative earnings of its Puerto Rico-based subsidiaries since those earnings were considered to be indefinitely reinvested.  Effective July 1, 2017, as part of a corporate reorganization, this U.S-based corporation was liquidated without any tax consequences.
 
Triple-S Management Corporation
Notes to Consolidated Financial Statements
December 31, 2017, 2016, and 2015
(dollar amounts in thousands, except per share and share data)
 
On July 1, 2014, the Governor of Puerto Rico signed into law Act No. 77 including multiple amendments to the Puerto Rico tax code that had a direct impact on the tax liabilities of individual and corporate taxpayers.  Act No. 77 also allowed corporations to elect, during the period running from July 1, 2014 to October 31, 2014, to prepay at a reduced income tax rate of 12% the increase in value of long-term capital assets.  On December 22, 2014 and March 30, 2015, the Governor of Puerto Rico signed into law Act No. 238 and Act No. 44, respectively, providing further amendments to the provisions set forth by Act No.77, extending the period to prepay at the reduced tax rate of 12% on the increase in value of long-term capital assets until April 30, 2015.  In connection with this law, on April 15, 2015 and December 31, 2014, the group of corporations that comprise TSM entered into Closing Agreements with the Puerto Rico Department of Treasury.  The Closing Agreements, among other matters, were related with the payment of the preferential tax rate on the increase in value of some of its long-term capital assets, as permitted by Act No. 238 of 2014 and Act No. 44 of 2015.  The agreements also covered certain tax attributes of the Corporation.  As a result of the aforementioned tax laws and the Closing Agreements, the Company: (1) obtained a benefit from the lower tax rate provided under these statutes, (2) reassessed the realizability of some of its deferred taxes and (3) recorded a tax benefit of $2,524 for the year ended December 31, 2015.

The components of income tax expense (benefit) consisted of the following:
 
   
2017
   
2016
   
2015
 
                   
Current income tax expense
 
$
34,412
   
$
1,981
   
$
10,169
 
Deferred income tax benefit
   
(9,916
)
   
(8,326
)
   
(5,070
)
Total income tax expense (benefit)
 
$
24,496
   
$
(6,345
)
 
$
5,099
 
 
Triple-S Management Corporation
Notes to Consolidated Financial Statements
December 31, 2017, 2016, and 2015
(dollar amounts in thousands, except per share and share data)
 
The income tax (benefit) expense differs from the amount computed by applying the Puerto Rico statutory income tax rate to the income before income taxes as a result of the following:
 
   
2017
   
2016
   
2015
 
                   
Income before taxes
 
$
78,977
   
$
11,086
   
$
57,131
 
Statutory tax rate
   
39.00
%
   
39.00
%
   
39.00
%
                         
Income tax expense at statutory rate
   
30,801
     
4,324
     
22,281
 
(Decrease) increase in taxes resulting from
                       
Exempt interest income, net
   
(5,364
)
   
(5,158
)
   
(6,041
)
Effect of taxing life insurance operations as a qualified domestic life insurance company instead of as a regular corporation
   
(4,871
)
   
(5,033
)
   
(4,936
)
Effect of taxing capital gains at a preferential rate
   
(2,116
)
   
(3,799
)
   
(7,432
)
Dividends received deduction
   
-
     
-
     
270
 
Adjustment to deferred tax assets and liabilities for changes in effective tax rates
   
(120
)
   
1,669
     
(1,576
)
Other adjustments to deferred tax assets and liabilities
   
836
     
2,852
     
(58
)
Effect of extraordinary dividend distribution from the JUA Association - reported net of taxes in other income
   
(922
)
   
(151
)
   
(875
)
Charges against the catastrophe loss reserve
   
1,567
     
-
     
-
 
Allowance for doubtful receivables recapture
   
2,688
     
-
     
-
 
Effect of  net operating loss limitations
   
1,511
     
-
     
-
 
Tax credit benefit
   
(555
)
   
(709
)
   
(537
)
Tax returns to provision true up
   
363
     
(181
)
   
(1,084
)
Subtotal
   
(6,983
)
   
(10,510
)
   
(22,269
)
Other permanent disallowances, net:
                       
Disallowed resolution agreements expense
   
-
     
-
     
1,716
 
Disallowance of expenses related to exempt interest income
   
-
     
58
     
-
 
Disallowed dividend received deduction
   
-
     
-
     
3,598
 
Disallowed interest expense
   
-
     
8
     
12
 
Other
   
50
     
-
     
61
 
Total other permanent differences
   
50
     
66
     
5,387
 
Other adjustments
   
628
     
(225
)
   
(300
)
Total income tax expense (benefit)
 
$
24,496
   
$
(6,345
)
 
$
5,099
 
 
Triple-S Management Corporation
Notes to Consolidated Financial Statements
December 31, 2017, 2016, and 2015
(dollar amounts in thousands, except per share and share data)
 
Deferred income taxes reflect the tax effects of temporary differences between carrying amounts of assets and liabilities for financial reporting purposes and income tax purposes. The net deferred tax asset at December 31, 2017 and 2016 of the Company and its subsidiaries is composed of the following:

   
2017
   
2016
 
             
Deferred tax assets
           
Allowance for doubtful receivables
 
$
11,787
   
$
10,070
 
Liability for pension benefits
   
13,826
     
10,624
 
Employee benefits plan
   
-
     
1,580
 
Postretirement benefits
   
662
     
772
 
Deferred compensation
   
2,168
     
2,041
 
Accumulated depreciation
   
1,296
     
1,137
 
Impairment loss on investments
   
950
     
2,035
 
Contingency reserves
   
1,950
     
-
 
Share-based compensation
   
6,795
     
4,393
 
Alternative minimum income tax credit
   
1,874
     
1,991
 
Purchased tax credits
   
2,767
     
6,062
 
Net operating loss
   
38,839
     
33,081
 
Difference in tax basis of investments portfolio
   
-
     
3,049
 
Accrued liabilities
   
3,271
     
2,133
 
Other
   
873
     
772
 
Gross deferred tax assets
   
87,058
     
79,740
 
Less: valuation allowance
   
(8,283
)
   
(8,016
)
Deferred tax assets
   
78,775
     
71,724
 
                 
Deferred tax liabilities
               
Deferred policy acquisition costs
   
(7,323
)
   
(6,621
)
Catastrophe loss reserve
   
(6,371
)
   
(8,020
)
Unrealized gain on securities available for sale
   
(19,440
)
   
(15,804
)
Difference in tax basis of investments portfolio
   
(220
)
   
-
 
Unamortized debt issue costs
   
(108
)
   
(152
)
Intangible asset
   
(1,546
)
   
(2,195
)
Employee benefits plan
   
(535
)
   
-
 
Accumulated depreciation
   
-
     
(14
)
Gross deferred tax liabilities
   
(35,543
)
   
(32,806
)
Net deferred tax asset
 
$
43,232
   
$
38,918
 

The net deferred tax asset shown in the table above at December 31, 2017 and 2016 is reflected in the consolidated balance sheets as $65,123 and $57,768, respectively, in deferred tax assets and $21,891 and $18,850, in deferred tax liabilities, respectively, reflecting the aggregate deferred tax assets or liabilities of individual tax-paying subsidiaries of the Company.
 
Triple-S Management Corporation
Notes to Consolidated Financial Statements
December 31, 2017, 2016, and 2015
(dollar amounts in thousands, except per share and share data)
 
In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management believes that it is more likely than not that the Company will realize the benefits of these deductible differences.  The valuation allowance is mostly related with the net operating losses generated by the Company’s USVI and health clinic’s operations that based on the available evidence are not considered to be realizable at the reporting dates.

At December 31, 2017, the Company and its subsidiaries have net operating loss carry-forwards for Puerto Rico income tax purposes of approximately $91,000, which are available to offset future taxable income for up to December 2027. The carryforwards generally expire in 2026 through 2027. Except for the valuation allowance described in the previous paragraph, t he Company concluded that as of December 31, 2017, it is more likely than not that the entities that have these net operating loss carry-forwards will generate sufficient taxable income within the applicable net operating loss carry-forward periods to realize its deferred tax asset. This conclusion is based on the historical results of each entity, adjusted to exclude non-recurring conditions, and the forecast of future profitability.  Management will continue to evaluate, on a quarterly basis, if there are any significant events that will affect the Company’s ability to utilize these deferred tax assets.

15.
Pension Plans

Non-Contributory Defined‑Benefit Pension Plan
The Company sponsors a non-contributory defined-benefit pension plan for its employees and for the employees of certain subsidiaries.  Pension benefits begin to vest after five years of vesting service, as defined, and are based on years of service and final average salary, as defined. The funding policy is to contribute to the plan as necessary to meet the minimum funding requirements set forth in the Employee Retirement Income Security Act of 1974, as amended, plus such additional amounts as the Company may determine to be appropriate from time to time.  The measurement date used to determine pension benefit for the pension plan is December 31.
 
Triple-S Management Corporation
Notes to Consolidated Financial Statements
December 31, 2017, 2016, and 2015
(dollar amounts in thousands, except per share and share data)
 
The following table sets forth the plan’s benefit obligations, fair value of plan assets, and funded status as of December 31, 2017 and 2016, accordingly:

   
2017
   
2016
 
             
Change in benefit obligation
           
Benefit obligation at beginning of year
 
$
163,877
   
$
184,782
 
Service cost
   
223
     
3,640
 
Interest cost
   
7,186
     
8,749
 
Benefit payments
   
(10,503
)
   
(12,911
)
Actuarial loss
   
24,269
     
14,709
 
Liability gain due to curtailment
   
-
     
(35,092
)
Benefit obligation at end of year
 
$
185,052
   
$
163,877
 
Accumulated benefit obligation at end of year
 
$
185,052
   
$
163,877
 
Change in fair value of plan assets
               
Fair value of plan assets at beginning of year
 
$
140,398
   
$
130,061
 
Actual return on assets
   
24,984
     
13,248
 
Employer contributions
   
4,000
     
10,000
 
Benefit payments
   
(10,503
)
   
(12,911
)
Fair value of plan assets at end of year
 
$
158,879
   
$
140,398
 
Funded status at end of year
 
$
(26,173
)
 
$
(23,479
)
Amounts in accumulated other comprehensive income not yet recognized as a component of net periodic pension cost
               
Development of prior service credit
               
Balance at beginning of year
 
$
-
   
$
(2,223
)
Amortization
   
-
     
450
 
Curtailment/Settlement
   
-
     
1,773
 
Net prior service credit
   
-
     
-
 
Development of actuarial loss
               
Balance at beginning of year
   
27,060
     
55,716
 
Amortization
   
(369
)
   
(4,028
)
Loss arising during the year
   
8,025
     
10,464
 
Curtailment/Settlement gain during the year
   
-
     
(35,092
)
Actuarial net loss
   
34,716
     
27,060
 
Sum of deferrals
 
$
34,716
   
$
27,060
 
Net amount recognized
 
$
8,543
   
$
3,581
 
 
Triple-S Management Corporation
Notes to Consolidated Financial Statements
December 31, 2017, 2016, and 2015
(dollar amounts in thousands, except per share and share data)
 
The following assumptions were used on a weighted average basis to determine benefits obligations of the plan as of December 31, 2017 and 2016.
 
   
2017
   
2016
 
             
Discount rate
   
3.75
%
   
4.50
%
Rate of compensation increase
   
N/A
     
N/A
 

The amounts recognized in the consolidated balance sheets as of December 31, 2017 and 2016 consist of the following:

   
2017
   
2016
 
             
Pension liability
 
$
26,173
   
$
23,479
 
Accumulated other comprehensive loss, net of a deferred tax of $10,176 and $7,191 in 2017 and 2016, respectively
   
24,540
     
19,869
 
 
The components of net periodic benefit cost for 2017, 2016, and 2015 were as follows:
 
   
2017
   
2016
   
2015
 
                   
Components of net periodic benefit cost
                 
Service cost
 
$
223
   
$
3,640
   
$
4,137
 
Interest cost
   
7,186
     
8,749
     
8,281
 
Expected return on plan assets
   
(8,740
)
   
(9,003
)
   
(8,380
)
Prior service benefit
   
-
     
(450
)
   
(450
)
Actuarial loss
   
369
     
4,028
     
5,939
 
Net periodic benefit cost
 
$
(962
)
 
$
6,964
   
$
9,527
 

Net periodic benefit cost includes settlement charges as a result of retirees selecting lump-sum distributions. Settlement charges may increase in the future if the number of eligible participants deciding to receive distributions and the amount of their benefits increases.

In December 2016, the Company announced that effective January 31, 2017, it would freeze the pay and service amounts used to calculate pension benefits for active employees who participated in the pension plan. Therefore, as of the Effective Date, active employees in the pension plan do not accrue additional benefits for future service and eligible compensation received.  As a result of these changes, the Company recognized a pre-tax curtailment income of $1,773 during the year ended December 31, 2016.

The estimated net actuarial loss that will be amortized from accumulated other comprehensive loss into net periodic pension benefits cost during the next twelve months is $860.
 
Triple-S Management Corporation
Notes to Consolidated Financial Statements
December 31, 2017, 2016, and 2015
(dollar amounts in thousands, except per share and share data)
 
The following assumptions were used on a weighted average basis in computing the periodic benefit cost for the years ended December 31, 2017, 2016, and 2015:

   
2017
   
2016
   
2015
 
                   
Discount rate
   
4.50
%
   
4.75
%
   
4.25
%
Expected return on plan assets
   
6.50
%
   
7.00
%
   
7.00
%
Rate of compensation increase
   
N/A
   
Graded; 3.50
%  
Graded; 3.50
%
           
to 8.00
%  
to 8.00
%

The basis of the overall expected long-term rate of return on assets assumption is a forward-looking approach based on the current long-term capital market outlook assumptions of the assets categories in which the trust invests and the trust’s target asset allocation. At December 31, 2017, the assumed target asset allocation for the program is: 44% to 56% in equity securities, 34% to 46% in debt securities, and 6% to 14% in other securities. Using a mean-variance model to project returns over a 30-year horizon under the target asset allocation, the 35 to 65 percentile range of annual rates of return is 5.6% to 7.1%. The Company selected a rate from within this range of 6.50% for 2017 and 7.00% for 2016, which reflects the Company’s best estimate for this assumption based on the data described above, information on the historical returns on assets invested in the pension trust, and expected future conditions. This rate is net of both investment related expenses and a 0.15% reduction for other administrative expenses charged to the trust.

Plan Assets
Plan assets recorded at fair value are categorized based upon the level of judgment associated with the inputs used to measure their fair value. For level inputs and input definition, see note 9.
 
Triple-S Management Corporation
Notes to Consolidated Financial Statements
December 31, 2017, 2016, and 2015
(dollar amounts in thousands, except per share and share data)
 
The following table summarizes fair value measurements by level at December 31, 2017 and 2016 for assets measured at fair value on a recurring basis:

   
2017
 
   
Level 1
   
Level 2
   
Level 3
   
NAV
   
Total
 
                               
Government obligations
 
$
-
   
$
7,131
   
$
-
   
$
-
   
$
7,131
 
Non-agency backed securities
   
-
     
641
     
-
     
-
     
641
 
Corporate obligations
   
-
     
8,560
     
-
     
-
     
8,560
 
Limited Liability Corporations
   
-
     
-
     
-
     
119,581
     
-
 
Real estate
   
-
     
-
     
-
     
7,568
     
-
 
Registered investments
   
3,388
     
659
     
-
     
-
     
4,047
 
Hedge funds
   
-
     
8,808
     
-
     
1,972
     
8,808
 
Common stocks
   
1,920
     
-
     
-
     
-
     
1,920
 
Preferred stocks
   
23
     
17
     
-
     
-
     
40
 
Interest-bearing cash
   
501
     
-
     
-
     
-
     
501
 
Derivatives
   
(1
)
   
17
     
-
     
-
     
16
 
   
$
5,831
   
$
25,833
   
$
-
   
$
129,121
   
$
31,664
 
 
   
2016
 
   
Level 1
   
Level 2
   
Level 3
   
Total
 
                         
Government obligations
 
$
-
   
$
6,276
   
$
-
   
$
6,276
 
Non-agency backed securities
   
-
     
715
     
-
     
715
 
Corporate obligations
   
-
     
7,243
     
-
     
7,243
 
Partnership/Joint venture
   
-
     
-
     
932
     
932
 
Limited Liability Corporations
   
-
     
98,188
     
-
     
98,188
 
Real estate
   
-
     
-
     
6,617
     
6,617
 
Registered investments
   
3,839
     
1,869
     
-
     
5,708
 
Common/Collective trusts
   
-
     
7,334
     
-
     
7,334
 
Hedge funds
   
-
     
4,581
     
-
     
4,581
 
Common stocks
   
1,515
     
1
     
-
     
1,516
 
Preferred stocks
   
107
     
12
     
-
     
119
 
Forward foreign currency contracts
   
-
     
(1
)
   
-
     
(1
)
Interest-bearing cash
   
2,224
     
-
     
-
     
2,224
 
Derivatives
   
-
     
27
     
-
     
27
 
   
$
7,685
   
$
126,245
   
$
7,549
   
$
141,479
 
 
Triple-S Management Corporation
Notes to Consolidated Financial Statements
December 31, 2017, 2016, and 2015
(dollar amounts in thousands, except per share and share data)
 
A reconciliation of the beginning and ending balances of assets measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the year ended December 31, 2017 and 2016 is as follows:

   
Government
Obligations
   
Corporate
Obligations
   
Partnership/
Joint
Venture
   
Real
Estate
   
Hedge
Funds
   
Total
 
                                     
Beginning balance at December 31, 2015
 
$
-
   
$
-
   
$
567
   
$
5,929
   
$
-
   
$
6,496
 
Actual return on program assets:
                                               
Relating to assets still held at the reporting date
   
-
     
-
     
19
     
501
     
-
     
520
 
Relating to assets sold during the period
   
-
     
-
     
1
     
72
     
-
     
73
 
Purchases, issuances, and settlements
   
-
     
-
     
345
     
324
     
-
     
669
 
Transfer in and/or out
   
-
     
-
     
-
     
(209
)
   
-
     
(209
)
Ending balance at December 31, 2016
   
-
     
-
     
932
     
6,617
     
-
     
7,549
 
                                                 
Actual return on program assets:
                                               
Transfer in and/or out
   
-
     
-
     
(932
)
   
(6,617
)
   
-
     
(7,549
)
Ending balance at December 31, 2017
 
$
-
   
$
-
   
$
-
   
$
-
   
$
-
   
$
-
 
 
The Company’s plan assets are invested in the National Retirement Trust. The National Retirement Trust was formed to provide financial and legal resources to help members of the BCBSA offer retirement benefits to their employees.

The investment program for the National Retirement Trust is based on the precepts of capital market theory that are generally accepted and followed by institutional investors, who by definition are long‑term oriented investors. This philosophy holds that:

·
Increasing risk is rewarded with compensating returns over time, and therefore, prudent risk taking is justifiable for long-term investors.

·
Risk can be controlled through diversification of asset classes and investment approaches, as well as diversification of individual securities.

·
Risk is reduced by time, and over time the relative performance of different asset classes is reasonably consistent. Over the long-term, equity investments have provided and should continue to provide superior returns over other security types. Fixed-income securities can dampen volatility and provide liquidity in periods of depressed economic activity.  Lengthening duration of fixed income securities may reduce surplus volatility.

·
The strategic or long-term allocation of assets among various asset classes is an important driver of long‑term returns.

·
Relative performance of various asset classes is unpredictable in the short‑term and attempts to shift tactically between asset classes are unlikely to be rewarded.

Investments will be made for the sole interest of the participants and beneficiaries of the programs participating in the National Retirement Trust. Accordingly, the assets of the National Retirement Trust shall be invested in accordance with these objectives:

·
To ensure assets are available to meet current and future obligations of the participating programs when due.
 
Triple-S Management Corporation
Notes to Consolidated Financial Statements
December 31, 2017, 2016, and 2015
(dollar amounts in thousands, except per share and share data)
 
·
To earn the maximum return that can be realistically achieved in the markets over the long‑term at a specified and controlled level of risk in order to minimize future contributions.

·
To invest assets with consideration of the liability characteristics in order to better align assets and liabilities.

·
To invest the assets with the care, skill, and diligence that a prudent person acting in a like capacity would undertake. In the process, the Administration of the Trust has the objective of controlling the costs involved with administering and managing the investments of the National Retirement Trust.

Cash Flows

The Company expects to contribute $2,000 to its pension program in 2018.

The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid:
 
Year ending December 31
     
2018
 
$
9,048
 
2019
   
9,253
 
2020
   
9,585
 
2021
   
9,830
 
2022
   
9,799
 
2023 – 2027
   
51,294
 
 
Non-Contributory Supplemental Pension Plan
In addition, the Company sponsors a non-contributory supplemental pension plan. This plan covers employees with qualified defined benefit retirement plan benefits limited by the U.S. Internal Revenue Code maximum compensation and benefit limits.  At December 31, 2017 and 2016, the Company has recorded a pension liability of $7,499 and $7,413, respectively.  The charge to accumulated other comprehensive loss related to the non-contributory pension plan at December 31, 2017 and 2016 amounted to $445 and $107, respectively, net of a deferred tax asset of $290 and $73, respectively.

16.
Catastrophe Loss Reserve and Trust Fund

In accordance with Chapter 25 of the Puerto Rico Insurance Code, as amended, TSP is required to record a catastrophe loss reserve. This catastrophe loss reserve is supported by a trust fund for the payment of catastrophe losses. The reserve increases by amounts determined by applying a contribution rate, not in excess of 5%, to catastrophe written premiums as instructed annually by the Commissioner of Insurance, unless the level of the reserve exceeds 8% of catastrophe exposure, as defined. The reserve also increases by an amount equal to the resulting return in the supporting trust fund and decreases by payments on catastrophe losses or authorized withdrawals from the trust fund.  Additions to the catastrophe loss reserve are deductible for income tax purposes.

This trust may invest its funds in securities authorized by the Insurance Code, but not in investments whose value may be affected by hazards covered by the catastrophic insurance losses. The interest earned on these investments and any realized gains (loss) on investment transactions are part of the trust fund and are recorded as income (expense) of the Company. An amount equal to the investment returns is recorded as an addition to the trust fund.
 
Triple-S Management Corporation
Notes to Consolidated Financial Statements
December 31, 2017, 2016, and 2015
(dollar amounts in thousands, except per share and share data)
 
TSP has requested approval from the Commissioner of Insurance to withdraw $10,000 from the catastrophe fund following the payment for catastrophe losses related to the impact of Hurricanes Irma and Maria in September 2017.

The interest earning assets in this fund, which amounted to $48,363 and $47,630 as of December 31, 2017 and 2016, respectively, are to be used solely and exclusively to pay catastrophe losses covered under policies written in Puerto Rico.

TSP is required to contribute to the trust fund, if needed or necessary, on or before January 31 of the following year. Contributions are determined by a rate determined or established by the Commissioner of Insurance for the catastrophe policies written in that year. No contribution was required for 2017 and 2016 since the level of the catastrophe reserve exceeds 8% of the catastrophe exposure.

The amount in the trust fund may be withdrawn or released in the case that TSP ceases to underwrite risks subject to catastrophe losses. Also, authorized withdrawals are allowed when the catastrophe loss reserve exceeds 8% of the catastrophe exposure, as defined.

TSP retained earnings are restricted in the accompanying consolidated balance sheets by the total catastrophe loss reserve balance, which as of December 31, 2017 and 2016 amounted to $46,578 and $44,823, respectively.

17.
Stockholders’ Equity

a.
Common Stock

On November 12, 2015, the Company converted 1,426,721 issued and outstanding Class A shares into Class B common stock purchased pursuant to the provisions of the Articles of incorporation approved by Class A shareholders at the time of the Company’s Initial Public Offering.

b.
Preferred Stock

Authorized capital stock includes 100,000,000 of preferred stock with a par value of $1.00 per share. As of December 31, 2017 and 2016, there are no issued and outstanding preferred shares.

c.
Liquidity Requirements

As members of the BCBSA, the Company, TSS, and TSA are required by membership standards of this association to maintain liquidity as defined by BCBSA. That is, to maintain net worth exceeding the Company Action Level as defined in the National Association of Insurance Commissioners’ (NAIC) Risk-Based Capital for Insurers Model Act. The companies are in compliance with this requirement.
 
Triple-S Management Corporation
Notes to Consolidated Financial Statements
December 31, 2017, 2016, and 2015
(dollar amounts in thousands, except per share and share data)
 
d.
Dividends

As a holding company, the Company’s most significant assets are the common shares of its subsidiaries.  The principal sources of funds available to the Company are rental income and dividends from its subsidiaries, which are used to fund our debt service and operating expenses.

The Company is subject to the provisions of the General Corporation Law of Puerto Rico, which restricts the declaration and payment of dividends by corporations organized pursuant to the laws of Puerto Rico.  These provisions provide that Puerto Rico corporations may only declare dividends charged to their retained earnings or, in the absence of retained earnings, net profits of the fiscal year in which the dividend is declared and/or the preceding fiscal year.

The Company’s ability to pay dividends is dependent, among other factors, on its ability to collect cash dividends from its subsidiaries, which are subject to regulatory requirements, which may restrict their ability to declare and pay dividends or distributions.  In addition, an outstanding secured term loan restricts our ability to pay dividends in the event of default (see note 12).

The accumulated earnings of TSS, TSA, TSV, TSB and TSP are restricted as to the payment of dividends by statutory limitations applicable to domestic insurance companies. Under Puerto Rico insurance regulations, the regulated subsidiaries are permitted, without requesting prior regulatory approval, to pay dividends as long as the aggregate amount of all such dividends in any calendar year does not exceed the lesser of: (i) 10% of its surplus as of the end of the immediately preceding calendar year; or (ii) its statutory net gain from operations for the immediately preceding calendar year (excluding realized capital gains).  Regulated subsidiaries will be permitted to pay dividends in excess of the lesser of such two amounts only if notice of its intent to declare such a dividend and the amount thereof is filed with the Commissioner of Insurance and such dividend is not disapproved within 30 days of its filing. As of December 31, 2017, the dividends permitted to be distributed in 2018 by the regulated subsidiaries without prior regulatory approval from the Commissioner of Insurance amounted to approximately $21,856.

18.
Stock Repurchase Programs

The Company repurchases shares through open market transactions, in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended, under repurchase programs authorized by the Board of Directors.  Shares purchased under share repurchase programs are retired and returned to authorized and unissued status.

A summary of share repurchase programs in place during the three-year-period ended December 31, 2017 is as follows:

·
In October 2014 the Company’s Board of Directors authorized a $50,000 repurchase program (2014 $50,000 program) of its Class B common stock. This program was completed on October 7, 2015.

·
In November 2015 the Company’s Board of Directors authorized a $25,000 repurchase program (2015 $25,000 program) of its Class B common stock.  This program was completed on September 14, 2016.
 
Triple-S Management Corporation
Notes to Consolidated Financial Statements
December 31, 2017, 2016, and 2015
(dollar amounts in thousands, except per share and share data)
 
·
In August 2017 the Company’s Board of Directors authorized a $30,000 repurchase program (2017 $30,000 program) of its Class B common stock.

The stock repurchase activity under stock repurchase programs for the years ended December 31 is summarized as follows:
 
   
2017
   
2016
   
2015
 
                                                       
   
Shares
Repurchased
   
Average
Share
Price
   
Amount
Repurchased
   
Shares
Repurchased
   
Average
Share
Price
   
Amount
Repurchased
   
Shares
Repurchased
   
Average
Share
Price
   
Amount
Repurchased
 
                                                       
2017  $30,000 program
   
861,415
   
$
23.38
   
$
20,220
     
-
   
$
-
   
$
-
     
-
   
$
-
   
$
-
 
2015  $25,000 program
   
-
     
-
     
-
     
951,831
     
22.54
     
21,370
     
154,554
     
23.72
     
3,629
 
2014  $50,000 program
   
-
     
-
     
-
     
-
     
-
     
-
     
2,086,532
     
21.69
     
44,658
 
Total
   
861,415
   
$
23.38
   
$
20,220
     
951,831
   
$
22.54
   
$
21,370
     
2,241,086
   
$
21.87
   
$
48,287
 

19.
Comprehensive Income
 
The accumulated balances for each classification of other comprehensive income are as follows:

   
Unrealized
Gains on
Securities
   
Liability
for Pension
Benefits
   
Accumulated
Other
Comprehensive
Income
 
                   
Beginning balance at December 31, 2016
 
$
62,371
   
$
(19,976
)
 
$
42,395
 
Net current period change
   
22,836
     
(5,011
)
   
17,825
 
Reclassification adjustments for gains and losses reclassified in income
   
(8,969
)
   
3
     
(8,966
)
Ending balance at December 31, 2017
 
$
76,238
   
$
(24,984
)
 
$
51,254
 
 
Triple-S Management Corporation
Notes to Consolidated Financial Statements
December 31, 2017, 2016, and 2015
(dollar amounts in thousands, except per share and share data)
 
The related deferred tax effects allocated to each component of other comprehensive income in the accompanying consolidated statements of stockholders’ equity and comprehensive income in 2017, 2016 and 2015 are as follows:

   
2017
 
   
Before-Tax
Amount
   
Deferred Tax
(Expense)
Benefit
   
Net-of-Tax
Amount
 
                   
Unrealized holding gains on securities arising during the period
 
$
28,544
   
$
(5,708
)
 
$
22,836
 
Less reclassification adjustment for gains and losses realized in income
   
(10,831
)
   
1,862
     
(8,969
)
Net change in unrealized gain
   
17,713
     
(3,846
)
   
13,867
 
Liability for pension benefits:
                       
Reclassification adjustment for amortization of net losses from past experience and prior service costs
   
5
     
(2
)
   
3
 
Net change arising from assumptions and plan changes and experience
   
(8,215
)
   
3,204
     
(5,011
)
Net change in liability for pension benefits
   
(8,210
)
   
3,202
     
(5,008
)
Net current period change
 
$
9,503
   
$
(644
)
 
$
8,859
 
 
   
2016
 
   
Before-Tax
Amount
   
Deferred Tax
(Expense)
Benefit
   
Net-of-Tax
Amount
 
                   
Unrealized holding gains on securities arising during the period
 
$
18,357
   
$
(3,596
)
 
$
14,761
 
Less reclassification adjustment for gains and losses realized in income
   
(17,379
)
   
2,511
     
(14,868
)
Net change in unrealized gain
   
978
     
(1,085
)
   
(107
)
Liability for pension benefits:
                       
Reclassification adjustment for amortization of net losses from past experience and prior service costs
   
1,888
     
(737
)
   
1,151
 
Net change arising from assumptions and plan changes and experience
   
25,783
     
(10,055
)
   
15,728
 
Net change in liability for pension benefits
   
27,671
     
(10,792
)
   
16,879
 
Net current period change
 
$
28,649
   
$
(11,877
)
 
$
16,772
 
 
Triple-S Management Corporation
Notes to Consolidated Financial Statements
December 31, 2017, 2016, and 2015
(dollar amounts in thousands, except per share and share data)
 
   
2015
 
   
Before-Tax
Amount
   
Deferred Tax
(Expense)
Benefit
   
Net-of-Tax
Amount
 
                   
Unrealized holding gains on securities arising during the period
 
$
(25,765
)
 
$
3,153
   
$
(22,612
)
Less reclassification adjustment for gains and losses realized in income
   
(18,941
)
   
2,564
     
(16,377
)
Net change in unrealized gain
   
(44,706
)
   
5,717
     
(38,989
)
Liability for pension benefits:
                       
Reclassification adjustment for amortization of net losses from past experience and prior service costs
   
6,020
     
(2,348
)
   
3,672
 
Net change arising from assumptions and plan changes and experience
   
19,940
     
(7,776
)
   
12,164
 
Net change in liability for pension benefits
   
25,960
     
(10,124
)
   
15,836
 
Net current period change
 
$
(18,746
)
 
$
(4,407
)
 
$
(23,153
)

20.
Share-Based Compensation
 
In December 2007, the Company adopted the 2007 Incentive Plan (the 2007 plan), which permits the Board to grant stock options, restricted stock awards and performance awards to eligible officers, directors and employees. The 2007 plan authorized the granting of up to 4,700,000 of Class B common shares of authorized but unissued stock. The 2007 plan was terminated in April 2017, when the 2017 Incentive Plan (the 2017 plan) was adopted.  The 2017 plan permits the Board to grant stock options, stock appreciation rights (SARs), restricted stock, restricted stock units, performance awards, and other stock-based awards, to our officers and employees.  In addition, the 2017 plan authorizes the grant of equity-based compensation incentives to our directors and to any independent contractor and consultants.  The 2017 plan authorizes the granting of up to 1,700,000 of Class B common shares plus the number of shares that were subject to any outstanding awards under the 2007 plan that are forfeited, cancelled, expire, terminate or otherwise lapse, in whole or in part, without the delivery of the shares.  At December 31, 2017, there were 1,652,264 shares available for the Company to grant under the 2017 Plan.
 
Stock options and SARs can be granted with an exercise price, which shall not be less than the stock’s fair market value at the grant date. The term of each stock options and SARs shall be fixed by the Board of Directors but shall not exceed 10 years from the date of grant.  The restricted stock, restricted stock units, and performance awards are issued at the fair value of the stock on the grant date.  Restricted stock awards and restricted stock units vest in installments, as stipulated in each restricted stock agreement. Performance awards vest on the last day of the performance period, provided that at least minimum performance standards are achieved.
 
Triple-S Management Corporation
Notes to Consolidated Financial Statements
December 31, 2017, 2016, and 2015
(dollar amounts in thousands, except per share and share data)
 
There was no stock option activity during the year ended December 31, 2017.  There were 4,440, and 12,913 exercised options during 2016 and 2015, respectively.  No options were granted during the three years ended December 31, 2017, 2016 and 2015.  No cash was received from stock options exercises during the years ended December 31, 2017, 2016 and 2015.  During the years ended December 31, 2016 and 2015, 2,290 and 7,235 shares, respectively, were repurchased and retired as a result of non-cash exercise of stock options.  No shares were repurchased and retired as a result of non-cash exercise of stock options during year ended December 31, 2017.

A summary of the status of the Company’s non-vested restricted and performance shares as of December 31, 2017, and changes during the year ended December 31, 2017, are presented below:

   
Restricted Awards
   
Performance Awards
 
   
Number of
Shares
   
Weighted
Average
Fair
Value
   
Number of
Shares
   
Weighted
Average
Exercise
Price
 
                         
Outstanding balance at January 1, 2017
   
161,824
   
$
21.94
     
458,195
   
$
21.44
 
Granted
   
154,367
     
17.78
     
338,577
     
18.18
 
Lapsed
   
(90,583
)
   
21.51
     
(234,954
)
   
19.49
 
Forfeited (due to termination)
   
(7,921
)
   
19.48
     
(38,990
)
   
20.10
 
Quantity adjusted (due to performance payout more than 100%), net of forfeited
   
-
     
-
     
13,296
     
27.18
 
Outstanding balance at December 31, 2017
   
217,687
   
$
19.26
     
536,124
   
$
20.47
 

The weighted average grant date fair value of restricted shares granted during the year 2017, 2016 and 2015 were $17.78, $23.78, and $20.33, respectively. Total fair value of restricted stock vested during the year ended December 31, 2017, 2016 and 2015 was $1,948, $2,335 and $3,608, respectively.

At December 31, 2017, there was $7,821 of total unrecognized compensation cost related to non-vested share‑based compensation arrangements granted under the Plan. That cost is expected to be recognized over a weighted average period of 0.98 years. The Company currently uses authorized and unissued Class B common shares to satisfy share award exercises.
 
Triple-S Management Corporation
Notes to Consolidated Financial Statements
December 31, 2017, 2016, and 2015
(dollar amounts in thousands, except per share and share data)
 
21.
Net   Income Available to Stockholders and Basic Net Income per Share
 
The following table sets forth the computation of basic and diluted earnings per share for the three-year period ended December 31:

   
2017
   
2016
   
2015
 
                   
Numerator for earnings per share
                 
Net income attributable to TSM available to stockholders
 
$
54,486
   
$
17,438
   
$
52,121
 
Denominator for basic earnings per share –
                       
Weighted average of common shares
   
23,996,503
     
24,454,435
     
25,674,079
 
Effect of dilutive securities
   
71,083
     
56,658
     
87,662
 
Denominator for diluted earnings per share
   
24,067,586
     
24,511,093
     
25,761,741
 
Basic net income per share attributable to TSM
 
$
2.27
   
$
0.71
   
$
2.03
 
Diluted net income per share attributable to TSM
 
$
2.26
   
$
0.71
   
$
2.02
 

22.
Commitments
 
The Company leases its regional offices, certain equipment, and warehouse facilities under non-cancelable operating leases. Minimum annual rental commitments at December 31, 2017 under existing agreements are summarized as follows:

Year ending December 31
     
2018
 
$
4,178
 
2019
   
3,817
 
2020
   
2,027
 
2021
   
605
 
2022
   
939
 
Total
 
$
11,566
 

Rental expense for 2017, 2016, and 2015 was $7,991, $7,613, and $7,730 respectively.

Pursuant to the provisions of the Puerto Rico Insurance Code and Regulations, TSP is a member of the Compulsory Vehicle Liability Insurance Joint Underwriting Association (JUA).  As a participant, TSP shares the risk, proportionately with other members, based on a formula established by the Puerto Rico Insurance Code, of the results and financial condition of the JUA, and accordingly, may be subject to assessments to cover obligations of the JUA or may receive refund distributions for good experience.  In 2017, the JUA declared an extraordinary dividend to its members for $70,000, subject to a special tax rate of 50% as allowed by Act No. 26 of April 29, 2017. In 2015, the JUA declared an extraordinary dividend to its members for $21,000, subject to a special tax rate of 15% as allowed by Act No. 201 of December 7, 2015.  There were no extraordinary dividends in 2016.  The dividend is received net of tax from the JUA.  During the years ended December 31, 2017 and 2015, TSP recorded a special distribution of $2,363 and $1,672, net of tax, respectively, which is included as other income in the accompanying consolidated statements of earnings.
 
Triple-S Management Corporation
Notes to Consolidated Financial Statements
December 31, 2017, 2016, and 2015
(dollar amounts in thousands, except per share and share data)
 
23.
Contingencies

The Company’s business is subject to numerous laws and regulations promulgated by Federal, Puerto Rico, USVI, Costa Rica, BVI, and Anguilla governmental authorities. Compliance with these laws and regulations can be subject to government review and interpretation, as well as regulatory actions unknown and unasserted at this time. The Commissioner of Insurance of Puerto Rico, as well as other Federal, Puerto Rico, USVI, Costa Rica, BVI, and Anguilla government authorities, regularly make inquiries and conduct audits concerning the Company's compliance with such laws and regulations. Penalties associated with violations of these laws and regulations may include significant fines and exclusion from participating in certain publicly funded programs and may require the Company to comply with corrective action plans or changes in our practices.

As of December 31, 2017, the Company is involved in various legal actions arising in the ordinary course of business. The Company is also defendant in various other litigations and proceedings, some of which are described below.  Where the Company believes that a loss is both probable and estimable, such amounts have been recorded. Although the Company believes the estimates of such losses are reasonable, these estimates could change as a result of further developments in these matters. In other cases, it is at least reasonably possible that the Company may incur a loss related to one or more of the mentioned pending lawsuits or investigations, but the Company is unable to estimate the range of possible loss which may be ultimately realized, either individually or in the aggregate, upon their resolution.  The outcome of legal proceedings is inherently uncertain and pending matters for which accruals have not been established have not progressed sufficiently to enable us to estimate a range of possible loss, if any.  Given the inherent unpredictability of these matters, it is possible that an adverse outcome in one or more of these matters could have a material effect on the consolidated financial condition, operating results and/or cash flows of the Company.

Additionally, we may face various potential litigation claims that have not been asserted to date, including claims from persons purporting to have rights to acquire shares of the Company on favorable terms pursuant to agreements previously entered by our predecessor managed care subsidiary, Seguros de Servicios de Salud de Puerto Rico, Inc. (SSS), with physicians or dentists who joined our provider network to sell such new provider shares of SSS at a future date (Share Acquisition Agreements) or to have inherited such shares notwithstanding applicable transfer and ownership restrictions.

Claims by Heirs of Former Shareholders

The Company and TSS are defending eight individual lawsuits: Vera Sánchez, et al , v. Triple-S; Olivella Zalduondo, et al, v. Seguros de Servicios de Salud, et al .; Heirs of Dr. Juan Acevedo, et al ., v. Triple-S Management Corporation, et al .; Montilla López, et al . v. Seguros de Servicios de Salud, et al .; Cebollero Santamaría v. Triple-S Salud, Inc., et al .; Ruiz de Porras, et al , v. Triple-S Salud, Inc.; Irizarry Antonmattei, et al , v. Seguros de Servicios de Salud, et al .; and Allende Santos, et al , v. Triple-S Salud, et al . All claims were filed in the Puerto Rico Court of First Instance by persons who claim to have inherited a total of 113 shares of the Company or one of its predecessors or affiliates (before giving effect to the 3,000-for-one stock split). While each case presents unique facts and allegations, the lawsuits generally allege that the redemption of the shares by the Company pursuant to transfer and ownership restrictions contained in the Company’s (or its predecessors’ or affiliates’) articles of incorporation and bylaws was improper. Consequently, the remedy requested by the plaintiffs is to be recognized as shareholders of the Company in the corresponding proportion.

As a result of the Puerto Rico Supreme Court’s decision to deny the applicability of the statute of limitations contained in the local securities law, these claims are being litigated on their merits.
 
Triple-S Management Corporation
Notes to Consolidated Financial Statements
December 31, 2017, 2016, and 2015
(dollar amounts in thousands, except per share and share data)

Joint Underwriting Association Litigations

On August 19, 2011, plaintiffs, purportedly a class of motor vehicle owners, filed an action in the United States District Court for the District of Puerto Rico against the JUA and TSP, alleging violations under the Puerto Rico Insurance Code, the Puerto Rico Civil Code, the Racketeer Influenced and Corrupt Organizations Act (RICO) and the local statute against organized crime and money laundering. JUA is a private association created by law to administer a compulsory public liability insurance program for motor vehicles in Puerto Rico (CLI). As required by its enabling act, JUA is composed of all the insurers that underwrite private motor vehicle insurance in Puerto Rico and exceed the minimum underwriting percentage established in such act. TSP is a member of JUA.

In this lawsuit, entitled Noemí Torres Ronda, et al v. JUA, et al., plaintiffs allege that the defendants illegally charged and misappropriated a portion of the CLI premiums paid by motor vehicle owners in violation of the Puerto Rico Insurance Code. Specifically, they claim that because the defendants did not incur in acquisition or administration costs allegedly totaling 12% of the premium dollar, charging for such costs constitutes the illegal traffic of premiums. Plaintiffs also claim that the defendants, as members of JUA, violated RICO through various inappropriate actions designed to defraud motor vehicle owners located in Puerto Rico and embezzle a portion of the CLI premiums for their benefit.

Plaintiffs seek the reimbursement of funds for the class amounting to $406,600 treble damages under RICO, and equitable relief, including a permanent injunction and declaratory judgment barring defendants from their alleged conduct and practices, along with costs and attorneys’ fees. Discovery has been completed.

Since 2011, TSP has been defending this claim and, jointly with other defendants, has filed several pleas in connection with the certification of the class and the dismissal of the claim. On December 17, 2015, three defendants filed a joint motion informing the court that said defendants are conducting negotiations to settle the claim and requested a 60-day period in other to continue the negotiations.  Subsequently, the term to continue negotiations was extended until April 17, 2016. On April 22, 2016, plaintiff and the negotiating defendants filed a stipulation of settlement and release which is subject to approval of the court. TSP and the non-settling defendants have objected the filed settlement. Procedures are ongoing.

In re Blue Cross Blue Shield Antitrust Litigation

TSS is a co-defendant with multiple Blue Plans and the Blue Cross Blue Shield Association (BCBSA) in a multi-district class action litigation filed by a group of providers and subscribers on July 24, 2012 and October 1, 2012, respectively, that has since been consolidated by the United States District Court for the Northern District of Alabama, Southern Division, in the case captioned In re Blue Cross Blue Shield Association Antitrust Litigation . Essentially, provider plaintiffs allege that the exclusive service area requirements of the Primary License Agreements with the Blue Plans constitute an illegal horizontal market allocation under federal antitrust laws. As per provider plaintiffs, the quid pro quo for said “market allocation” is a horizontal price fixing and boycott conspiracy” implemented through the Inter-Plans Program Committee (“IPPC”) and whose benefits are allegedly derived through the BCBSA’s Blue Card/National Accounts Program. Among the remedies sought, provider plaintiffs seek increased compensation rates and operational changes. In turn, subscriber plaintiffs allege that the alleged conspiracy to allocate markets have prevented subscribers from being offered competitive prices and resulted in higher premiums for Blue Plan subscribers. Subscribers seek damages in the form of supra-competitive premiums allegedly charged by the Blue Plans and/or the difference between what subscribers have paid the Blues and the lower competitive premiums that non-competing Blues would have charged. Both actions seek injunctive relief.
 
Triple-S Management Corporation
Notes to Consolidated Financial Statements
December 31, 2017, 2016, and 2015
(dollar amounts in thousands, except per share and share data)
 
Prior to consolidation, motions to dismiss were filed by several plans, including TSS - whose request was ultimately denied by the court without prejudice. On April 6, 2015, plaintiffs filed suit in the United States District Court of Puerto Rico against TSS. Said complaint, nonetheless, is believed not to preclude TSS’ jurisdictional arguments. Since inception, the Company has joined BCBSA and other Blue Plans in vigorously contesting these claims. As of late, the court’s scheduling order and ruling of dispositive motions concerning the standard of review has been held in abeyance as a result of settlement negotiations between the parties through mediation. Both the subscriber and provider plaintiffs’ mediation sessions are presently ongoing.

Claims Relating to the Provision of Health Care Services

TSS is a defendant in several claims for collection of monies in connection with the provision of health care services. Among them are individual complaints filed before ASES by six community health centers alleging TSS breached their contracts with respect to certain capitation payments and other monetary claims. Such claims have an aggregate value of approximately $9,600. Discovery is ongoing, and given the early stage of the cases, the Company cannot assess the probability of an adverse outcome or the reasonable financial impact that any such outcome may have on the Company. TSS believes many of these complaints are time-barred and will continue to conduct a vigorous defense.

On April 17, 2015, ASES notified the Company of a complaint from a medical service provider demanding payment amounting to $5,073.  Claimant alleges that TSS did not pay the claims, paid them incorrectly, or recovered payments from the provider for which TSS did not have the right. TSS answered the complaint and counterclaimed.  TSS denies any wrongdoing and will continue to defend this matter vigorously.

On January 12, 2015, American Clinical Solutions LLC, a limited liability company that provides clinical laboratory services filed a complaint in Florida state court alleging that TSM and TSS failed to pay certain clinical laboratory services provided to Blue Cross Blue Shield members. TSS and TSM have filed a motion to dismiss alleging lack of jurisdiction. TSM and TSS also requested a transfer of the case to Puerto Rico. Plaintiff has requested jurisdictional discovery, which is ongoing. The claim amounts to $5,000. TSS and TSM will continue to vigorously oppose this claim.

ASES Audits

The Company is subject to numerous audits in connection with the provision of services to private and governmental entities.  These audits may include numerous aspects of our business, including claim payment practices, contractual obligations, service delivery, third-party obligations, and business practices, among others.  Deficiencies in audits could have a material adverse effect on our reputation and business, including termination of contracts, significant increases in the cost of managing and remediating deficiencies, payment of contractual penal clauses, and others, any of which could have a material and adverse effect on our results of operations, financial position and cash flows.
 
Triple-S Management Corporation
Notes to Consolidated Financial Statements
December 31, 2017, 2016, and 2015
(dollar amounts in thousands, except per share and share data)
 
On July 2, 2014, ASES notified TSS that the results of an audit conducted in connection with the government health plan contract for several periods between October 2005 and September 2013, reflected an overpayment of premiums made to TSS pursuant to prior contracts with ASES in the amount of $7,900. The alleged overpayments were related to duplicated payments or payments made for deceased members, and ASES requested the reimbursement of the alleged overpayment. On January 16, 2015, TSS filed an injunction against ASES under the case Triple-S Salud, Inc. v. Administración de Seguros de Salud de Puerto Rico. TSS contends that ASES’ request for reimbursement has no merits on several grounds, including a 2011 settlement between both parties covering the majority of the amount claimed by ASES, and that ASES, under the terms of the contracts, was responsible for certifying the membership. TSS also amended its claim to include the Puerto Rico Health Department (PRHD), as it asserts the PRHD is an indispensable party for the resolution of this matter and to seek the payment of approximately $5,000, since the premiums paid to TSS should have been higher than what ASES actually paid given the additional risk assumed by TSS. The case was assigned to a Special Commissioner, who on March 17, 2017 issued a report recommending the court to dismiss the complaint in favor of TSS. On May 26, 2017, the court issued a partial judgement dismissing the complaint in favor of TSS with respect to the alleged overpayments for the period between October 2005 and September 2010, which represented approximately $7,400 of the total alleged claim. After this partial dismissal, the only remaining claim pending to be adjudicated is for the alleged overpayments for the 2011-2013 period, which amounts to approximately $500. On July 27, 2017, ASES appealed the court’s partial judgement and on August 25, 2017 TSS filed its opposition to ASES’ appeal.  On January 31, 2018, the Puerto Rico Court of Appeals entered judgement in favor of the Company, thus validating the 2011 settlement agreement.  No plea for reconsideration nor a writ of certiorari was filed by ASES before the Court of Appeals or the Puerto Rico Supreme Court.  Settlement negotiations are ongoing for the remaining claim.
 
24.
Statutory Accounting

TSS, TSA, TSV, TSP and TSB (collectively known as the regulated subsidiaries) are regulated by the Commissioner of Insurance. The regulated subsidiaries are required to prepare financial statements using accounting practices prescribed or permitted by the Commissioner of Insurance, which uses a comprehensive basis of accounting other than GAAP. Specifically, the Commissioner of Insurance has adopted the NAIC’s Statutory Accounting Principles (NAIC SAP) as the basis of its statutory accounting practices, as long as they do not contravene the provisions of the Puerto Rico Insurance Code, its regulations and the Circular Letters issued by the Commissioner of Insurance. The Commissioner of Insurance may permit other specific practices that may deviate from prescribed practices and NAIC SAP. Statutory accounting principles that are established by state laws and permitted practices mandated by the Commissioner of Insurance may cause the statutory capital and surplus of the regulated subsidiaries to differ from that calculated under the NAIC SAP.

Prescribed statutory accounting practices in Puerto Rico allow TSP to disregard a deferred tax liability resulting from additions to the catastrophe loss reserve trust fund that would otherwise be required under NAIC SAP. The use of prescribed and permitted accounting practices, both individually and in the aggregate, did not change significantly the combined statutory capital and surplus that would have been reported following NAIC SAP, which as of December 31, 2017 and 2016 is approximately 1.0% and 1.3%, respectively, lower than the combined reported statutory capital and surplus.

The regulated subsidiaries are required by the NAIC and the Commissioner of Insurance to submit risk-based capital (RBC) reports following the NAIC’s RBC Model Act and accordingly, are subject to certain regulatory actions if their capital levels do not meet minimum specific RBC requirements.  RBC is a method developed by the NAIC to determine the minimum amount of statutory capital appropriate for an insurance company to support its overall business operations in consideration of its size and risk profile. The RBC is calculated by applying capital requirement factors to various assets, premiums and reserve items. The factor is higher for those items with greater underlying risk and lower for less risky items. The adequacy of an organization’s actual capital can then be measured by a comparison to its RBC as determined by the formula.
 
Triple-S Management Corporation
Notes to Consolidated Financial Statements
December 31, 2017, 2016, and 2015
(dollar amounts in thousands, except per share and share data)
 
The RBC Model Act requires increasing degrees of regulatory oversight and intervention as an organization’s risk-based capital declines. The level of regulatory oversight ranges from requiring organizations to inform and obtain approval from the domiciliary insurance commissioner of a comprehensive financial plan for increasing its RBC, to mandatory regulatory intervention requiring an insurance company to be placed under regulatory control, in a rehabilitation or liquidation proceeding.

The Commissioner of Insurance adopted in 2009 an RBC policy that requires that the regulated entities maintain statutory reserves at or above the “Company Action Level,” in order to avoid regulatory monitoring and intervention.  The Company action level is currently set at 200% of the RBC for TSA, since it is organized as a health service organization and 300% of the RBC for all other regulated subsidiaries.  As of December 31, 2017 and 2016 all regulated subsidiaries comply with minimum statutory reserve requirements, except for TSA for which we expect to remediate and implement corrective actions plans to comply with such requirements.

The following table sets forth the combined net admitted assets, capital and surplus, RBC requirement, which is our statutory capital and surplus requirement, and net income for the regulated subsidiaries at December 31, 2017, 2016 and 2015:
 
(dollar amounts in millions)
 
2017
   
2016
   
2015
 
                   
Net admitted assets
 
$
2,102
   
$
1,829
   
$
1,881
 
Capital and surplus
   
647
     
638
     
691
 
RBC requirement
   
301
     
278
     
301
 
Net income
   
87
     
24
     
73
 

As more fully described in note 16, a portion of the accumulated earnings and admitted assets of TSP are restricted by the catastrophe loss reserve and the trust fund balance as required by the Insurance Code.  The total catastrophe loss reserve and trust fund amounted to $27,843 and $48,363 as of December 31, 2017, respectively. The total catastrophe loss reserve and trust fund amounted to $44,823 and $47,630 as of December 31, 2016, respectively.  In addition, the admitted assets of the regulated subsidiaries are restricted by the investments deposited with the Commissioner of Insurance to comply with requirements of the Insurance Code (see note 3).  Investments with an amortized cost of $5,229 and $5,358 (fair value of $5,571 and $5,788) at December 31, 2017 and 2016, respectively, were deposited with the Commissioner of Insurance. As a result, the combined restricted assets for our regulated subsidiaries were $53,592 and $52,988 as of December 31, 2017 and 2016, respectively.
 
Triple-S Management Corporation
Notes to Consolidated Financial Statements
December 31, 2017, 2016, and 2015
(dollar amounts in thousands, except per share and share data)
 
25.
Supplementary Information on Cash Flow Activities
 
   
2017
   
2016
   
2015
 
                   
Supplementary information
                 
Noncash transactions affecting cash flow activities
                 
Change in net unrealized (gain) loss on securities available for sale, including deferred income tax liability (asset) of $3,846, $1,085, and  $(5,717) in 2017, 2016, and 2015, respectively
 
$
(13,867
)
 
$
107
   
$
38,989
 
Change in liability for pension benefits, and deferred income tax (asset) liability of $(3,202), $10,792, $10,124, in 2017, 2016, and 2015, respectively
 
$
5,008
   
$
(16,879
)
 
$
(15,836
)
Repurchase and retirement of common stock
 
$
(89
)
 
$
(56
)
 
$
(182
)
Exercise of stock options
 
$
-
   
$
55
   
$
179
 
Other
                       
Income taxes paid
 
$
10,363
   
$
11,549
   
$
6,437
 
Interest paid
 
$
6,794
   
$
7,635
   
$
4,792
 
 
26.
Segment Information
 
The operations of the Company are conducted principally through three reportable business segments: Managed Care, Life Insurance, and Property and Casualty Insurance.  Reportable business segments were identified according to the type of insurance products offered and consistent with the information provided to the chief operating decision maker. These segments and a description of their respective operations are as follows:

·
Managed Care segment – This segment is engaged in the sale of managed care products to the Commercial, Medicare and Medicaid market sectors.  The Commercial accounts sector includes corporate accounts, U.S. federal government employees, individual accounts, local government employees, and Medicare supplement. The following represents a description of the major contracts by sector:

The segment is a qualified contractor to provide health coverage to federal government employees within Puerto Rico and the USVI. Earned premiums revenue related to this contract amounted to $156,417, $163,556 and $155,821 for the years ended December 31, 2017, 2016, and 2015, respectively (see note 11).

Under its commercial business, the segment also provides health coverage to certain employees of the Commonwealth of Puerto Rico and its instrumentalities. Earned premium revenue related to such health plans amounted to $28,149, $29,475 and $30,607 for years ended December 31, 2017, 2016, and 2015, respectively.
 
Triple-S Management Corporation
Notes to Consolidated Financial Statements
December 31, 2017, 2016, and 2015
(dollar amounts in thousands, except per share and share data)
 
The segment provides services through its Medicare health plans pursuant to a limited number of contracts with CMS. Earned premium revenue related to the Medicare business amounted to $1,035,285, $1,023,904, and $1,097,657 for the years ended December 31, 2017, 2016, and 2015, respectively.

The segment also participates in the Medicaid program to provide health coverage to medically indigent citizens in Puerto Rico, as defined by the laws of the government of Puerto Rico.  We served all eight service regions on an administrative service only basis (ASO) until March 31, 2015.  Administrative service fees for the period ended December 31, 2015 amounted to $24,266.  Beginning on April 1, 2015, the segment began providing managed care services to two service regions on a fully-insured basis, earned premium revenue related to this business amounted to $751,393, $783,231, and $607,216 for the years ended December 31, 2017, 2016, and 2015, respectively.

·
Life Insurance segment – This segment offers primarily life and accident and health insurance coverage, and annuity products. The premiums for this segment are mainly subscribed through an internal sales force and a network of independent brokers and agents.

 
·
Property and Casualty Insurance segment –The predominant insurance products of this segment commercial package, commercial auto, and personal package. The premiums for this segment are originated through a network of independent insurance agents and brokers. Agents or general agencies collect the premiums from the insureds, which are subsequently remitted to the segment, net of commissions. Remittances are generally due 60 days after the closing date of the general agent’s account current.

The Company evaluates performance based primarily on the operating revenues and operating income of each segment.  Operating revenues include premiums earned (net), administrative service fees and net investment income.  Operating costs include claims incurred and operating expenses.  The Company calculates operating income or loss as operating revenues less operating costs.

The accounting policies for the segments are the same as those described in the summary of significant accounting policies included in the notes to consolidated financial statements.  The financial data of each segment is accounted for separately; therefore no segment allocation is necessary. However, certain operating expenses are centrally managed, therefore requiring an allocation to each segment. Most of these expenses are distributed to each segment based on different parameters, such as payroll hours, processed claims, or square footage, among others. In addition, some depreciable assets are kept by one segment, while allocating the depreciation expense to other segments. The allocation of the depreciation expense is based on the proportion of assets used by each segment. Certain expenses are not allocated to the segments and are kept within TSM’s operations.
 
Triple-S Management Corporation
Notes to Consolidated Financial Statements
December 31, 2017, 2016, and 2015
(dollar amounts in thousands, except per share and share data)
 
The following tables summarize the operations by operating segment for each of the years in the three‑year period ended December 31:

   
2017
   
2016
   
2015
 
                   
Operating revenues
                 
Managed care
                 
Premiums earned, net
 
$
2,588,692
   
$
2,647,169
   
$
2,548,270
 
Fee revenue
   
16,514
     
17,843
     
44,705
 
Intersegment premiums/fee revenue
   
6,362
     
5,918
     
5,860
 
Net investment income
   
16,659
     
15,102
     
11,779
 
Total managed care
   
2,628,227
     
2,686,032
     
2,610,614
 
Life
                       
Premiums earned, net
   
161,628
     
156,140
     
147,864
 
Intersegment premiums
   
218
     
716
     
251
 
Net investment income
   
24,819
     
24,877
     
24,457
 
Total life
   
186,665
     
181,733
     
172,572
 
Property and casualty
                       
Premiums earned, net
   
76,612
     
87,332
     
87,020
 
Intersegment premiums
   
613
     
613
     
613
 
Net investment income
   
9,489
     
8,891
     
8,706
 
Total property and casualty
   
86,714
     
96,836
     
96,339
 
Other segments*
                       
Intersegment service revenues
   
8,677
     
9,907
     
10,863
 
Operating revenues from external sources
   
3,763
     
3,563
     
3,875
 
Total other segments
   
12,440
     
13,470
     
14,738
 
Total business segments
   
2,914,046
     
2,978,071
     
2,894,263
 
TSM operating revenues from external sources
   
545
     
19
     
53
 
Elimination of intersegment premiums
   
(7,193
)
   
(7,247
)
   
(6,724
)
Elimination of intersegment service revenue
   
(8,677
)
   
(9,907
)
   
(10,863
)
Other intersegment eliminations
   
-
     
(78
)
   
23
 
Consolidated operating revenues
 
$
2,898,721
   
$
2,960,858
   
$
2,876,752
 

*
Includes segments that are not required to be reported separately, primarily the data processing services organization and the health clinic.
 
Triple-S Management Corporation
Notes to Consolidated Financial Statements
December 31, 2017, 2016, and 2015
(dollar amounts in thousands, except per share and share data)
 
   
2017
   
2016
   
2015
 
                   
Operating income (loss)
                 
Managed care
 
$
55,040
   
$
(36,777
)
 
$
20,514
 
Life
   
19,434
     
21,458
     
20,012
 
Property and casualty
   
(6,034
)
   
12,074
     
8,273
 
Other segments*
   
(391
)
   
(1,784
)
   
(301
)
Total business segments
   
68,049
     
(5,029
)
   
48,498
 
TSM operating revenues from external sources
   
545
     
19
     
53
 
TSM unallocated operating expenses
   
(9,787
)
   
(9,739
)
   
(18,858
)
Elimination of TSM charges
   
9,600
     
9,522
     
9,623
 
Consolidated operating income (loss)
   
68,407
     
(5,227
)
   
39,316
 
Consolidated net realized investment gains
   
10,831
     
17,379
     
18,941
 
Consolidated interest expense
   
(6,794
)
   
(7,635
)
   
(8,169
)
Consolidated other income, net
   
6,533
     
6,569
     
7,043
 
Consolidated income before taxes
 
$
78,977
   
$
11,086
   
$
57,131
 

   
2017
   
2016
   
2015
 
Depreciation and amortization expense
                 
Managed care
 
$
10,007
   
$
11,114
   
$
13,268
 
Life
   
1,203
     
1,030
     
1,094
 
Property and casualty
   
528
     
544
     
673
 
Other segments*
   
673
     
645
     
556
 
Total business segments
   
12,411
     
13,333
     
15,591
 
TSM depreciation expense
   
787
     
787
     
788
 
Consolidated depreciation and amortization expense
 
$
13,198
   
$
14,120
   
$
16,379
 

*
Includes segments that are not required to be reported separately, primarily the data processing services organization and the health clinic.
 
Triple-S Management Corporation
Notes to Consolidated Financial Statements
December 31, 2017, 2016, and 2015
(dollar amounts in thousands, except per share and share data)
 
   
2017
   
2016
   
2015
 
                   
Assets
                 
Managed care
 
$
1,092,715
   
$
1,013,872
   
$
1,034,725
 
Life
   
853,289
     
816,920
     
770,721
 
Property and casualty
   
1,094,773
     
349,159
     
350,514
 
Other segments*
   
19,027
     
26,034
     
25,629
 
Total business segments
   
3,059,804
     
2,205,985
     
2,181,589
 
Unallocated amounts related to TSM
                       
Cash, cash equivalents, and investments
   
81,169
     
17,033
     
12,304
 
Property and equipment, net
   
22,257
     
22,380
     
23,219
 
Other assets
   
22,763
     
21,646
     
31,732
 
     
126,189
     
61,059
     
67,255
 
Elimination entries – intersegment receivables and others
   
(69,228
)
   
(48,045
)
   
(42,699
)
Consolidated total assets
 
$
3,116,765
   
$
2,218,999
   
$
2,206,145
 

   
2017
   
2016
   
2015
 
Significant noncash items
                 
Net change in unrealized gain (loss) on securities available for sale
                 
Managed care
 
$
3,932
   
$
104
   
$
(15,505
)
Life
   
7,142
     
2,659
     
(13,005
)
Property and casualty
   
2,691
     
(2,984
)
   
(10,482
)
Other segments*
   
-
     
105
     
(10
)
Total business segments
   
13,765
     
(116
)
   
(39,002
)
Amount related to TSM
   
102
     
9
     
13
 
Consolidated net change in unrealized gain (loss) on securities available for sale
 
$
13,867
   
$
(107
)
 
$
(38,989
)

*
Includes segments that are not required to be reported separately, primarily the data processing services organization and the health clinic.
 
Triple-S Management Corporation and Subsidiaries
Notes to Consolidated Financial Statements
December 31, 2017, 2016, and 2015
(dollar amounts in thousands, except per share and share data)

27.
Subsequent Events

The Company evaluated subsequent events through the date the consolidated financial statements were issued.  No events, other than those described in these notes, have occurred that require adjustment or disclosure pursuant to current Accounting Standard Codification.
 
 
Triple-S Management Corporation
Schedule II
Condensed Financial Information of Triple-S Management Corporation
(Registrant)
Balance Sheets
(in thousands)

   
As of December 31,
 
   
2017
   
2016
 
             
Assets:
           
Cash and cash equivalents
   
17,541
   
$
14,153
 
Securities available for sale, at fair value:
               
Equity Securities (cost of $63,490 in 2017 and $2,869 in 2016)
   
63,628
     
2,880
 
Investment in subsidiaries
   
836,427
     
866,010
 
Notes receivable and accrued interest from subsidiaries
   
42,869
     
47,153
 
Due from subsidiaries
   
8,927
     
5,255
 
Deferred tax assets
   
18,186
     
14,976
 
Other assets
   
26,834
     
29,050
 
Total assets
 
$
1,014,412
   
$
979,477
 
                 
Liabilities:
               
Notes payable and accrued interest to subsidiary
   
17,267
     
16,475
 
Due to subsidiaries
   
66
     
22,661
 
Long-term borrowings
   
32,073
     
35,085
 
Liability for pension benefits
   
33,672
     
30,892
 
Other liabilities
   
17,970
     
11,201
 
Total liabilities
   
101,048
     
116,314
 
                 
Stockholders' equity:
               
Common stock, class A
   
951
     
951
 
Common stock, class B
   
22,627
     
23,321
 
Additional paid-in-capital
   
53,142
     
65,592
 
Retained earnings
   
785,390
     
730,904
 
Accumulated other comprehensive income, net
   
51,254
     
42,395
 
Total stockholders' equity
   
913,364
     
863,163
 
Total liabilities and stockholders' equity
 
$
1,014,412
   
$
979,477
 

The accompanying notes are an integral part of these condensed financial statements
 
Triple-S Management Corporation
Schedule II
Condensed Financial Information of Triple-S Management Corporation
Triple-S Management Corporation
Statements of Earnings
(in thousands)

   
2017
   
2016
   
2015
 
                   
Investment income
 
$
545
   
$
19
   
$
53
 
Other revenues
   
10,836
     
11,644
     
12,015
 
Total revenues
   
11,381
     
11,663
     
12,068
 
                         
Operating expenses:
                       
General and administrative expenses
   
9,787
     
9,739
     
18,858
 
Interest expense
   
1,196
     
1,763
     
2,435
 
Total operating expenses
   
10,983
     
11,502
     
21,293
 
Income (loss) before income taxes
   
398
     
161
     
(9,225
)
Income tax expense (benefit)
   
295
     
1,183
     
(1,071
)
Loss of parent company
   
103
     
(1,022
)
   
(8,154
)
Equity in net income of subsidiaries
   
54,383
     
18,460
     
60,275
 
Net income
 
$
54,486
   
$
17,438
   
$
52,121
 

The accompanying notes are an integral part of these condensed financial statements
 
 
 
 
 
Triple-S Management Corporation
Schedule II
Condensed Financial Information of Triple-S Management Corporation
(Registrant)
Statements of Cash Flows
(in thousands)

   
2017
   
2016
   
2015
 
Net income
 
$
54,486
   
$
17,438
   
$
52,121
 
Adjustment to reconcile net income to net cash provided by operating activities:
                       
Equity in net income of subsidiaries
   
(54,383
)
   
(18,460
)
   
(60,275
)
Depreciation and amortization
   
880
     
839
     
872
 
Shared- based compensation
   
7,076
     
2,799
     
8,290
 
Deferred income tax expense (benefit)
   
(33
)
   
1,042
     
(1,227
)
Dividends received from subsidiaries
   
90,000
     
19,000
     
47,000
 
Return of investment due to closing of subsidiary
   
7,731
     
-
     
-
 
Other
   
-
     
-
     
42
 
Changes in assets and liabilities:
                       
Accrued interest from subsidiaries, net
   
5,076
     
(646
)
   
(1,046
)
Due from subsidiaries
   
(3,672
)
   
(1,525
)
   
4,869
 
Other assets
   
1,917
     
(1,751
)
   
(1,953
)
Due to subsidiaries
   
(22,595
)
   
10,801
     
(2,162
)
Other liabilities
   
1,339
     
(4,812
)
   
4,614
 
Net cash provided by operating activities
   
87,822
     
24,725
     
51,145
 
Cash flows from investing activities:
                       
Acquisition of investment in securities classified as available for sale
   
(61,747
)
   
(2,869
)
   
-
 
Proceeds from sale and maturities of investment in securities classified as available for sale
    1,126       -       27,500  
Collection of note receivable from subsidiary
   
-
     
4,500
     
9,000
 
Issuance of note receivable to subsidiary
   
-
     
(1,394
)
   
(2,369
)
Net acquisition of property and equipment
   
(757
)
   
-
     
(3,676
)
Net cash provided by (used in) investing activities
   
(61,378
)
   
237
     
30,455
 
Cash flow from financing activities:
                       
Repayments of long-term borrowings
   
(2,836
)
   
(1,742
)
   
(37,640
)
Repurchase of common stock
   
(20,220
)
   
(21,371
)
   
(48,287
)
Net cash used in financing activities
   
(23,056
)
   
(23,113
)
   
(85,927
)
Net increase (decrease) in cash and cash equivalents
   
3,388
     
1,849
     
(4,327
)
Cash and cash equivalents, beginning of year
   
14,153
     
12,304
     
16,631
 
Cash and cash equivalents, end of year
 
$
17,541
   
$
14,153
   
$
12,304
 
 
The accompanying notes are an integral part of these condensed financial statements
 
 
Triple-S Management Corporation
(Parent Company Only)
Notes to Condensed Financial Statements
December 31, 2017, 2016 and 2015
(dollar amounts in thousands)

The accompanying notes to the condensed financial statements should be read in conjunction with the consolidated financial statements and the accompanying notes thereto included in Item 15 to the Annual Report on Form 10-K.
 
(1)
For purposes of these condensed financial statements, Triple‑S Management Corporation’s (the Company or TSM) investment in its wholly owned subsidiaries is recorded using the equity method of accounting.
 
(2)
Significant Accounting Policies
 
The significant accounting policies followed by the Company are set forth in the notes to the consolidated financial statements and the accompanying notes thereto.  Refer to Item 15 to the Annual Report on Form 10‑K.
 
(3)
Long‑Term Borrowings
 
A summary of the long‑term borrowings entered into by the Company at December 31, 2017 and 2016 follows:
 
 
 
2017
   
2016
 
             
Senior unsecured notes payable of $60,000 issued on December 2005; due December 2020. Interest was payable monthly at a fixed rate of 6.60%, fully paid in January 2017.
 
$
-
   
$
24,000
 
Secured loan payable of $11,187, payable in monthly installments of $137 through October 1, 2023, plus interest at a rate reset periodically of 100 basis points over selected LIBOR maturity (which was 2.37% at December 31, 2017).
   
9,547
     
11,187
 
Secured loan payable of $20,150, payable in monthly installments of $84 through January 1, 2024, plus interest at a rate reset periodically of 275 basis points over selected LIBOR maturity (which was 4.08% at December 31, 2017).
   
19,226
     
-
 
Secured loan payable of $4,116, payable in monthly installments of $49 through January 1, 2024, plus interest at a rate reset periodically of 325 basis points over selected LIBOR maturity (which was 4.58% at December 31, 2017).
   
3,577
     
-
 
Total borrowings
   
32,350
     
35,187
 
Less: unamortized debt issuance costs
   
277
     
102
 
 
 
$
32,073
   
$
35,085
 
 
Triple-S Management Corporation
(Parent Company Only)
Notes to Condensed Financial Statements
December 31, 2017, 2016 and 2015
(dollar amounts in thousands)
 
Aggregate maturities of the Company’s long term borrowings as of December 31, 2017 are summarized as follows:
 
Year ending December 31
     
2018
 
$
3,236
 
2019
   
3,236
 
2020
   
3,236
 
2021
   
3,236
 
2022
   
3,236
 
Thereafter
   
16,170
 
 
 
$
32,350
 

On December 28, 2016, the Company entered into a $35,500 credit agreement with a commercial bank in Puerto Rico. The agreement consists of three term loans: (i) Term Loan A in the principal amount of $11,187, (ii) Term Loan B in the principal amount of $20,150 and (iii) Term Loan C in the principal amount of $4,116. Term Loan A matures in October 2023 while the Term Loans B and C mature in January 2024.  Term Loan A was used to refinance a previous $41,000 secured loan payable with the same commercial bank.  Proceeds from Term Loans B and C were received on January 11, 2017 and were used to prepay the outstanding principal amount plus accrued interest of the 6.6% Senior Unsecured Notes due December 2020 ($24,000), and fund a portion of a debt service reserve for the Loan (approximately $200).  Interest payable commenced on January 1, 2017, in the case of Term Loan A, and on February 1, 2017, in the case of Term Loan B and Term Loan C.  The Credit Agreement includes certain financial and non-financial covenants, including negative covenants imposing certain restrictions on the Company’s business.  The Company was in compliance with all these covenants as of December 31, 2017.
 
This credit agreement is guaranteed by a first mortgage held by the bank on the Company’s land, building, and substantially all leasehold improvements, as collateral for the term of the loan under a continuing general security agreement.
 
The Company may, at its option, upon notice, as specified in the credit agreement, redeem and prepay prior to maturity, all or any part of the Loan and from time to time upon the payment of a penalty fee of 3% during the first year, 2% during the second year and 1% during the third year, and thereafter, at par, as specified in the credit agreement, together with accrued and unpaid interest, if any, to the date of redemption specified by the Company.
 
Interest expense on the above borrowings amounted to $1,196, $1,763, and $2,435, for the years ended December 31, 2017, 2016, and 2015, respectively.
 
 
Triple-S Management Corporation
(Parent Company Only)
Notes to Condensed Financial Statements
December 31, 2017, 2016 and 2015
(dollar amounts in thousands)
 
(4)
Transactions with Related Parties
 
The following are the significant related parties transactions made for the three‑year period ended December 31, 2017, 2016 and 2015:
 
   
2017
   
2016
   
2015
 
Rent charges to subsidiaries
 
$
7,807
   
$
7,801
   
$
7,801
 
Interest charged to subsidiaries on notes receivable
   
2,032
     
2,258
     
2,758
 
Interest charged from subsidiary on note payable
   
791
     
755
     
720
 

As of December 31, 2017 and 2016, the Company has two and three notes receivable from subsidiaries amounting to $25,000 and $30,750, respectively, pursuant to the provisions of Article 29.30 of the Puerto Rico Insurance Code. The notes receivable from subsidiaries are due on demand; however, pursuant to the requirements established by the Commissioner of Insurance, the parties agreed that no payment of the total principal nor the interest due on the loans will be made without first obtaining written authorization from the Commissioner of Insurance within at least 60 days prior to the proposed payment date. These notes bear interest at 4.7%.  Accrued interest at December 31, 2017 and 2016 amounted to $6,918 and $5,660, respectively.
 
In addition, as of December 31, 2017 and 2016, the Company has various notes receivable from a subsidiary amounting to $10,592 and $10,645, respectively.  Accrued interest at December 31, 2017 and 2016 amounted to $359 and $98, respectively.  These notes are due in different years, which due dates range from 2019 to 2020, and bear an average interest of 5.1%.
 
As of December 31, 2017 and 2016 the Company has a note payable to a subsidiary amounting to $15,000.  The note is due on December 31, 2022 and bears interest at 4.7%.  Accrued interest at December 31, 2017 and 2016 amounted to $2,267 and $1,475, respectively.
 
Triple-S Management Corporation and Subsidiaries
Schedule III - Supplementary Insurance Information
For the years ended December 31, 2017, 2016 and 2015
 
(Dollar amounts in thousands)
                                                           
Segment
 
Deferred
Policy
Acquisition
Costs and Value
of Business
Acquired
   
Claim
Liabilities
   
Liability for
Future
Policy
Benefits
   
Unearned
Premiums
   
Other
Policy Claims
and Benefits
Payable
   
Premium
Revenue
   
Net
Investment
Income
   
Claims
Incurred
   
Amortization of
Deferred Policy
Acquisition
Costs and Value
of Business
Acquired
   
Other
Operating
Expenses
   
Net
Premiums
Written
 
                                                                   
2017
                                                                 
                                                                   
Managed care
 
$
-
   
$
367,357
   
$
-
   
$
1,813
   
$
-
   
$
2,589,987
   
$
16,659
   
$
2,218,270
   
$
-
   
$
354,917
   
$
2,589,987
 
Life insurance
   
182,010
     
45,518
     
339,507
     
8,751
     
-
     
161,846
     
24,819
     
87,348
     
18,511
     
61,372
     
161,846
 
Property and casualty insurance
   
18,778
     
694,444
     
-
     
75,785
     
-
     
77,225
     
9,489
     
50,761
     
23,595
     
18,392
     
81,520
 
Other non-reportable segments, parent company operations and net consolidating entries.
   
-
     
(443
)
   
-
     
-
     
-
     
(2,126
)
   
648
     
(3,278
)
   
-
     
426
     
(2,126
)
                                     
-
                                                 
Total
 
$
200,788
   
$
1,106,876
   
$
339,507
   
$
86,349
   
$
-
   
$
2,826,932
   
$
51,615
   
$
2,353,101
   
$
42,106
   
$
435,107
   
$
2,831,227
 
                                                                                         
2016
                                                                                       
                                                                                         
Managed care
 
$
-
   
$
349,047
   
$
-
   
$
2,889
   
$
-
   
$
2,648,469
   
$
15,102
   
$
2,347,547
   
$
-
   
$
375,262
   
$
2,648,469
 
Life insurance
   
177,811
     
42,858
     
321,232
     
8,122
     
-
     
156,856
     
24,877
     
86,924
     
12,530
     
60,821
     
152,506
 
Property and casualty insurance
   
16,976
     
96,977
     
-
     
68,299
     
-
     
87,945
     
8,891
     
40,766
     
25,170
     
18,826
     
87,158
 
Other non-reportable segments, parent company operations and net consolidating entries.
   
-
     
(939
)
   
-
     
-
     
-
     
(2,629
)
   
43
     
(3,046
)
   
-
     
1,285
     
(2,629
)
                                     
-
                                                 
Total
 
$
194,787
   
$
487,943
   
$
321,232
   
$
79,310
   
$
-
   
$
2,890,641
   
$
48,913
   
$
2,472,191
   
$
37,700
   
$
456,194
   
$
2,885,504
 
                                                                                         
2015
                                                                                       
                                                                                         
Managed care
 
$
-
   
$
348,297
   
$
-
   
$
3,489
   
$
-
   
$
2,549,522
   
$
11,779
   
$
2,196,693
   
$
-
   
$
393,407
   
$
2,549,173
 
Life insurance
   
172,284
     
44,601
     
352,370
     
6,596
     
-
     
148,115
     
24,457
     
82,561
     
17,661
     
52,338
     
144,262
 
Property and casualty insurance
   
18,364
     
99,796
     
-
     
70,175
     
-
     
87,633
     
8,706
     
42,600
     
25,933
     
19,533
     
85,734
 
Other non-reportable segments, parent company operations and net consolidating entries.
   
-
     
(929
)
   
-
     
-
     
-
     
(2,116
)
   
232
     
(3,139
)
   
-
     
9,849
     
(2,116
)
                                     
-
                                                 
Total
 
$
190,648
   
$
491,765
   
$
352,370
   
$
80,260
   
$
-
   
$
2,783,154
   
$
45,174
   
$
2,318,715
   
$
43,594
   
$
475,127
   
$
2,777,053
 

See accompanying independent registered public accounting firm’s report and notes to financial statements.
 
84

Triple-S Management Corporation and Subsidiaries
Schedule IV - Reinsurance
For the years ended December 31, 2017, 2016 and 2015
 
(Dollar amounts in thousands)

   
Gross
Amount (1)
   
Ceded to
Other
Companies
   
Assumed
from Other
Companies
   
Net
Amount
   
Percentage
of Amount
Assumed
to Net
 
                               
2017
                             
                               
Life insurance in force
 
$
10,307,506
               
$
10,307,506
     
0.0
%
                                     
Premiums:
                                   
Life insurance
 
$
166,280
   
$
8,826
   
$
4,174
   
$
161,628
     
2.6
%
Accident and health insurance
   
2,591,796
     
3,392
     
288
     
2,588,692
     
0.0
%
Property and casualty insurance
   
135,689
     
59,077
     
-
     
76,612
     
0.0
%
Total premiums
 
$
2,893,765
   
$
71,295
   
$
4,462
   
$
2,826,932
     
0.2
%
     
 
     
 
             
 
         
2016
                                       
                                         
Life insurance in force
 
$
10,178,956
                   
$
10,178,956
     
0.0
%
                                         
Premiums:
                                       
Life insurance
 
$
160,628
   
$
8,838
   
$
4,350
   
$
156,140
     
2.8
%
Accident and health insurance
   
2,650,011
     
3,148
     
306
     
2,647,169
     
0.0
%
Property and casualty insurance
   
134,378
     
47,046
     
-
     
87,332
     
0.0
%
Total premiums
 
$
2,945,017
   
$
59,032
   
$
4,656
   
$
2,890,641
     
0.2
%
     
 
     
 
             
 
         
2015
                                       
                                         
Life insurance in force
 
$
10,129,123
                   
$
10,129,123
     
0.0
%
                                         
Premiums:
                                       
Life insurance
 
$
153,607
   
$
9,596
   
$
3,853
   
$
147,864
     
2.6
%
Accident and health insurance
   
2,552,699
     
4,778
     
349
     
2,548,270
     
0.0
%
Property and casualty insurance
   
136,780
     
49,760
     
-
     
87,020
     
0.0
%
Total premiums
 
$
2,843,086
   
$
64,134
   
$
4,202
   
$
2,783,154
     
0.2
%

(1)
Gross premiums amount is presented net of intercompany eliminations of $2,126, $3,457 and $4,402 for the years ended December 31, 2017, 2016, and 2015, respectively.
 
See accompanying independent registered public accounting firm’s report and notes to financial statements.
 
85

Triple-S Management Corporation and Subsidiaries
Schedule V - Valuation and Qualifying Accounts
For the years ended December 31, 2017, 2016 and 2015

(Dollar amounts in thousands)
 
         
Additions
             
   
Balance at
Beginning of
Period
   
Charged to
Costs and
Expenses
   
Charged (Reversal)
To Other Accounts
- Describe (1)
   
Deductions -
Describe (2)
   
Balance at
End of
Period
 
                               
2017
                             
                               
Allowance for doubtful receivables
 
$
37,307
     
5,210
     
(3,748
)
   
(2,886
)
 
$
35,883
 
                                         
2016
                                       
                                         
Allowance for doubtful receivables
 
$
37,244
     
1,295
     
306
     
(1,538
)
 
$
37,307
 
                                         
2015
                                       
                                         
Allowance for doubtful receivables
 
$
36,368
     
15,781
     
340
     
(15,245
)
 
$
37,244
 

(1)
Represents premiums adjustment to provide for unresolved reconciliation items with the Government of Puerto Rico and other entities.
 
(2)
Deductions represent the write-off of accounts deemed uncollectible.
 
86

Triple-S Management Corporation and Subsidiaries
Schedule VI - Supplementary Information Concerning Consolidated Property and Casualty Insurance Operations

(Dollar amounts in thousands)
 
   
As of December 31,
   
For the Years Ended December 31,
 
   
Deferred
Policy
   
Reserve for
Unpaid Claims
and Claims
               
Net
   
Claims and Claim Adjustment
Expenses Incurred
Related to
   
Amortization of
Deferred Policy
   
Paid Claims and
       
Year
 
Acquisition
Costs
   
Ajustment
Expenses
   
Unearned
Premiums
   
Earned
Premiums
   
Investment
Income
   
Current
Year
   
Prior
Years
   
Acquisition
Costs
   
Claim Adjustment
Expenses
   
Premiums
Written
 
                                                             
2017
 
$
18,778
   
$
694,444
   
$
75,785
   
$
77,225
   
$
9,489
   
$
60,696
   
$
(9,935
)
 
$
23,595
   
$
47,689
   
$
143,787
 
                                                                                 
2016
 
$
16,976
   
$
96,977
   
$
68,299
   
$
87,945
   
$
8,891
   
$
48,127
   
$
(7,361
)
 
$
25,170
   
$
42,887
   
$
133,115
 
                                                                                 
2015
 
$
18,364
   
$
99,796
   
$
70,175
   
$
87,633
   
$
8,706
   
$
45,067
   
$
(2,467
)
 
$
25,933
   
$
41,612
   
$
134,410
 

See accompanying independent registered public accounting firm’s report and notes to financial statements.
 
 
87


Exhibit 10.1
 
AMENDMENT TO THE CONTRACT BETWEEN
ADMINISTRACIÓN DE SEGUROS DE SALUD DE PUERTO RICO (ASES) and TRIPLE-S SALUD, INC.
 
to
 
ADMINISTER THE PROVISION OF PHYSICAL
AND BEHAVIORAL HEALTH SERVICES UNDER THE GOVERNMENT HEALTH
 
PLAN

CONTRACT NUMBER: 2015-000087I


THIS AMENDMENT TO THE CONTRACT BETWEEN ADMINISTRACIÓN DE SEGUROS DE SALUD DE PUERTO RICO (ASES) AND TRIPLE-S SALUD, INC. FOR THE PROVISION OF PHYSICAL AND BEHAVIORAL HEALTH SERVICES UNDER THE GOVERNMENT
HEALTH PLAN WITHIN THE METRO NORTH AND WEST SERVICE REGIONS (the
“Amendment”) is by and between Triple-S Salud, Inc. (“the Contractor”), an insurance company duly organized and authorized to do business under the laws of the Commonwealth of Puerto Rico, with employer identification number 66-0555677 and the Puerto Rico Health Insurance
Administration (Administración de Seguros de Salud de Puerto Rico, hereinafter referred to as “ASES” or “the Administration”), a public corporation of the Commonwealth of Puerto Rico, with employer identification number 66-0500678 .

WHEREAS , the Contractor and ASES executed a Contract for the provision of Physical Health and  Behavioral Health Services under the Government Health Plan within the Metro North and West Service Regions of the Commonwealth of Puerto Rico, on December 3rd, 2015 (hereinafter referred to as the “Contract”);

WHEREAS , the Contract provides, pursuant to Section 21.6, that ASES is granted the option to renew the Contract for an additional term of up to one (1) fiscal year, beginning on July 1, 2017 to June 30, 2018;

WHEREAS , ASES has exercised, through this Amendment and through previously executed agreements by the Parties to extend the Contract beyond its original expiration date of June 30, 2017 (the “Agreed Extensions”), the option to renew the Contract for an additional term of one (1) fiscal year;

WHEREAS , the Contract also provides, pursuant to Article 55, that the Parties may amend such Contract by mutual written consent; and

WHEREAS , all provisions of the Contract will remain in full force and effect as described therein, except as otherwise provided in this Amendment and the Agreed Extensions.
 
1

NOW, THEREFORE , and in consideration of the mutual promises herein contained and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree to clarify and/or amend the Contract as follows:

I.
RENEWAL OF CONTRACT

ASES has exercised its option to renew of the Contract for an additional one (1) fiscal year term, which shall begin on July 1, 2017 and end at midnight on June 30, 2018, in accordance with Section 21.6 of the Contract.

II.
DISCONTINUATION OF HIGH UTILIZERS PROGRAM

The Parties agree that the High Utilizers Program operated by the Contractor will be discontinued for the July 1, 2017 to June 30, 2018 renewal term.

III.
AMENDMENTS

1.
Immediately following Section 1.1.6, a new Section 1.1.7 shall be inserted stating as follows:

1.1.7 Pursuant to 42 CFR 438.602(i), the Contractor shall not be located outside of the United States.

2.
The following definitions in Article 2 shall be amended as follows:

Adverse Benefit Determination: The denial or limited authorization of a requested service, including the type or level of service; the reduction, suspension, or termination of a previously authorized service, requirements for medical necessity appropriateness, setting or effectiveness of a covered benefit; the denial, in whole or part, of payment for a service (including in circumstances in which an Enrollee is forced to pay for a service; the failure to provide services in a timely manner (within the timeframes established by this Contract or otherwise established by ASES); the failure of the Contractor to act within the timeframes provided in 42 CFR 438.408(b); or the denial of an Enrollee’s request to dispute a financial liability, including cost-sharing, co-payments, premiums, deductibles, coinsurance, and other Enrollee financial liabilities. For a resident of a rural area, the denial of an Enrollee's request to exercise his or her right, under 42 CFR 438.52(b)(2)(ii), to obtain services outside the network.

Emergency Medical Condition: As defined in 42 C.F.R. 438.114, a medical or Behavioral Health condition, regardless of diagnosis or symptoms, manifesting itself in acute symptoms of sufficient severity (including severe pain) that a prudent layperson, who possesses an average knowledge of health and medicine, could reasonably expect the absence of immediate medical attention to result in placing the health of the individual (or, with respect to a pregnant woman, the health of the woman or her unborn child) in serious jeopardy, serious impairments of bodily functions, serious dysfunction of any bodily organ or part, serious harm to self or other due to an alcohol or drug abuse emergency, serious injury to self or bodily harm to others, or the lack of adequate time for a pregnant women having contractions to safely reach a another hospital before delivery.  The Contractor may not impose limits on what constitutes an Emergency Medical Condition based only, or exclusively, on diagnoses or symptoms.
 
2

Emergency Services: As defined in 42 CFR 438.114, any Physical or Behavioral Health Covered Services (as described in Section 7.5.9) furnished by a qualified Provider in an emergency room that are needed to evaluate or stabilize an Emergency Medical Condition or a Psychiatric Emergency that is found to exist using the prudent layperson standard.

Excess Profit: The excess over two point five percent (2.5%) of the annual profit before income taxes as reported in the audited financial statements for the period of July 1, 2017 to June 30, 2018. Excess Profits are to be shared between the Contractor or the Subcontractors and ASES, as provided in Sections 22.1.18 and 22.1.19.

Overpayment: Any funds that a person or entity receives which that person or entity is not entitled to under Title XIX of the Social Security Act. Overpayments shall not include funds that have been subject to a payment suspension or that have been identified as a Third Party Liability as set forth in Section 23.4.

Performance Improvement Projects (PIPs): Projects consistent with 42 CFR 438.330.

Primary Care: All health care services and laboratory services customarily furnished by or through a general practitioner, family physician, internal medicine physician, obstetrician/gynecologist, pediatrician, or other licensed practitioner as authorized by ASES, to the extent the furnishing of those services is legally authorized where the practitioner furnishes them.

Subcontractor: Any organization or person, including the Contractor’s parent, subsidiary or Affiliate, who has a contract or written arrangement with the Contractor to provide any function or service for the Contractor specifically related to securing or fulfilling the Contractor’s obligations to the Commonwealth under the terms of this Contract. Subcontractors do not include Providers unless the Provider is responsible for services other than providing Covered Services pursuant to a Provider participation agreement.

3.
The following definitions in Article 2 shall be inserted as follows:

Formulary of Medications Covered (“FMC”):   A published subset of pharmaceutical products used for the treatment of physical and Behavioral Health conditions developed by the PPA after clinical recommendations from the Pharmacy and Therapeutics (P&T) Committee and financial review from the Pharmacy Benefits Financial Committee.
 
3

List of Medications by Exception (“LME”):   List of medications that are not included in the FMC, but that have been evaluated and approved by ASES’s Pharmacy and Therapeutics (P&T) Committee to be covered only through an exception process if certain clinical criteria are met. Covered outpatient drugs that are not included on the LME may still be covered under an Exception Request in compliance with Section 7.5.12.10.1.2, unless statutorily excluded.

4.
The definition of Preferred Drug List (“PDL”) in Article 2 shall be deleted in its entirety.  The acronym of PDL in Article 3 shall be deleted in its entirety.

5.
The following acronyms in Article 3 shall be inserted as follows:

FMC    
Formulary of Medications Covered
LME   
List of Medications by Exception
 
6.
The following acronyms in Article 3 shall be amended as follows:
 
QIP
Quality Incentive Program
US or USA  
United States of America
 
7.
All subsequent references within the Contract to the following defined terms and acronyms shall be replaced as follows, unless otherwise stated in this Amendment:

a.
All references to the defined term “Action” shall be deleted and replaced with the defined term “Adverse Benefit Determination.”

b.
All references to the defined term “Preferred Drug List” shall be deleted and replaced with the defined term “Formulary of Medications Covered.”  All references to the acronym “PDL” shall be deleted and replaced with the acronyms
“FMC.”

c.
All references to the defined term “Master Formulary” shall be deleted and replaced with the defined term “List of Medications by Exception” or the acronym “LME.”

d.
All references to the former “Quality Improvement Procedure” shall be deleted and replaced with “Quality Incentive Program.”

8.
Section 4.5.1 shall be amended and replaced in its entirety as follows:

4.5.1
ASES shall conduct readiness reviews of the Contractor’s operations three (3) months before the start of a new managed care program and when the Contractor will provide or arrange for the provision of covered benefits to new eligibility groups.  Such review will include, at a minimum, one (1) on-site review, at dates and times to be determined by ASES.  These reviews may include, but are not limited to, desk and on-site reviews of documents provided by the Contractor, walk-through(s) of the Contractor’s facilities, Information System demonstrations, and interviews with the Contractor’s staff. ASES will conduct the readiness review to confirm that the Contractor is capable and prepared to perform all Administrative Functions and to provide high-quality services to GHP Enrollees.
 
4

9.
Section 4.5.3.12 shall be amended and replaced in its entirety as follows:

4.5.3.12
Financial management, including financial reporting and monitoring and financial solvency;

10.
Section 4.5.3.14 shall be amended and replaced in its entirety as follows:

4.5.3.14
Information Systems management, including claims management, encounter data and enrollment information management, systems performance, interfacing capabilities, and security management functions and capabilities; and

11.
Section 5.2.1.1 shall be amended and replaced in its entirety as follows:

5.2.1.1
The Contractor shall accept all Potential Enrollees into its Plan without restrictions.  The Contractor shall not discriminate against individuals eligible to enroll on the basis of religion, race, color, national origin, sex,  sexual orientation, gender identity, or disability, and will not use any policy or practice that has the effect of discriminating on the basis of religion, race, color, national origin, sex, sexual orientation, gender identity, or disability on the basis of health, health status, pre-existing condition, or need for health care services.

12.
Section 5.2.2 shall be amended and replaced in its entirety as follows:

5.2.2
Effective Date of Enrollment

5.2.2.1
Except as provided below, Enrollment, whether chosen or automatic, will be effective (hereinafter referred to as the “Effective Date of Enrollment”) the same date as the period of eligibility specified on the MA-10.
 
5.2.2.2
Effective Date of Enrollment for Newborns. The Effective Date of Enrollment for Medicaid and CHIP Eligible newborns is the date of his or her birth. The Effective Date of Enrollment for Commonwealth Population newborns is the date the newborn is registered with the Puerto Rico Medicaid Program. A newborn shall be Auto-Enrolled pursuant to the procedures set forth in Section 5.2.6.
 
5

5.2.2.3
Re-Enrollment Policy and Effective Date of Re-Enrollment for Mothers Who are Minor Dependents .  In the event that a female Enrollee who is included in a family group for coverage under the GHP as a Dependent child becomes pregnant, the Enrollee shall be referred to the Puerto Rico Medicaid Program.  She will effectively establish a new family with the diagnosis of her pregnancy and will become the Contact Member of the new family.  The eligibility period of the new family will begin on the date of the first diagnosis of the pregnancy, and the Enrollee shall be AutoEnrolled, effective as of this date.  The mother shall be Auto-Assigned to the PMG and PCP to which she was assigned before the Re-Enrollment.

5.2.2.4
Effective   Date of Re-Enrollment for Enrollees Who Lose Eligibility. If an Enrollee who is a Medicaid- or - CHIP Eligible Person or member of the Commonwealth Population loses eligibility for the GHP for a period of two (2) months or less, Enrollment in the Contractor’s Plan shall be reinstated.  Upon notification from ASES of the Recertification, the Contractor shall Auto-Enroll the person, with Enrollment effective as of the eligibility period specified on the MA-10.

13.
Section 5.2.4.2 shall be amended and replaced in its entirety as follows:

5.2.4.2
The Auto-Enrollment process will include Auto-Assignment of a PMG and a PCP (see Section 5.4 of this Contract).  A new Enrollee who is a Dependent of a current GHP Enrollee (the “Contact Member’) shall be automatically assigned to the same PMG as his or her Contact Member, as identified by the Contact Member number.

14.
Section 5.2.5.2 shall be amended and replaced in its entirety as follows:

5.2.5.2
Once the Enrollee calls or visits the Contractor’s office to execute the right of changing the assigned PMG, PCP, or both, the Contractor shall request that the Enrollee select a new PMG and PCP.  During the visit or call, the Contractor shall issue to the Enrollee an Enrollee ID Card and a notice of Enrollment, as well as an Enrollee Handbook and Provider Directory either in paper or electronic form, subject to requirements of Sections 6.9.8 and 6.9.9; or, such notice of Enrollment, an ID Card, a Handbook, and a Provider Directory may be sent to the Enrollee via surface mail or electronically, subject to the requirements of Sections 6.9.8 and 6.9.9 within five (5) Business Days of the Enrollee’s request to change the Auto-Enrollment assignments.
 
6

15.
Immediately following Section 5.2.5.3, a new Section 5.2.2.3.1 shall be inserted stating as follows:

5.2.5.3.1
All Enrollees must also be notified at least annually of their disenrollment rights as set forth in Section 5.3 and 42 CFR 438.56.  Such notification must clearly explain the process for exercising this disenrollment right, as well as the alternatives available to the Enrollee based on their specific circumstance.

16.
Section 5.2.6.4 shall be amended and replaced in its entirety as follows:

5.2.6.4
If the mother has not made a PCP and PMG selection at the time of the child’s birth, the Contractor shall, within one (1) Business Day of the birth, auto-assign the newborn to a PCP who is a pediatrician and to the Contact Member’s PMG.

17.
Section 5.3.3.3 shall be amended and replaced in its entirety as follows:

5.3.3.3
If what would otherwise be the Effective Date of Disenrollment under this Section 5.3.3 falls:

5.3.3.3.1
When the Enrollee is an inpatient at a hospital, ASES shall postpone the Effective Date of Disenrollment so that it occurs on the last day of the month in which the Enrollee is discharged from the hospital, or the last day of the month following the month in which Disenrollment would otherwise be effective, whichever occurs earlier;

5.3.3.3.2
During a month in which  a Medicaid, CHIP or Commonwealth Enrollee is pregnant, or on the date the pregnancy ends, ASES shall postpone the Effective Date of Disenrollment so that it occurs on the last day of the month in which the 60-day post-partum period ends;

5.3.3.3.3
When the Enrollee is in the process of appealing a Disenrollment though either the Grievance System, ASES’s Administrative Law Hearing process, or the Puerto Rico Medicaid Department’s dedicated hearing process on Disenrollments, as applicable, then ASES shall postpone the Effective Date of Disenrollment until a decision is rendered after the hearing;  or
 
5.3.3.3.4
During a month in which an Enrollee is diagnosed with a Terminal Condition, ASES shall postpone the Effective Date of Disenrollment so that it occurs on the last day of the following month. 
          
18.
Immediately following Section 5.3.5, a new Section 5.3.5.1 shall be inserted stating as follows, and the remaining Section 5.3.5 shall be renumbered accordingly, including any references thereto:

5.3.5.1
All Enrollees must be notified at least annually of their disenrollment rights as set forth in Section 5.3 and 42 CFR 438.56.  Such notification must clearly explain the process for exercising this disenrollment right, as well as the coverage alternatives available to the Enrollee based on their specific circumstance.
 
7

19.
Original Section 5.3.5.2, renumbered by this Amendment as 5.3.5.3, shall be amended and replaced in its entirety as follows:

5.3.5.3
An Enrollee may request Disenrollment from the Contractor’s Plan without cause during the ninety (90) Calendar Days following the Effective Date of Enrollment with the Plan or the date that the Contractor sends the Enrollee notice of the Enrollment, whichever is later.  An Enrollee may request Disenrollment without cause every twelve (12) months thereafter or if, upon automatic re-enrollment of an Enrollee disenrolled solely because he or she loses eligibility for a period of two (2) months or less, the temporary loss of Medicaid eligibility has caused the Enrollee to miss the annual disenrollment opportunity.  In addition, an Enrollee may request Disenrollment without cause in the event that ASES notifies the Enrollee that ASES has imposed or intends to impose on the Contractor the intermediate sanctions set forth in 42 CFR 438.702(a)(3).

20.
Immediately following Original Section 5.3.5.3.1, renumbered by this Amendment as 5.3.5.4.1, a new Section 5.3.5.4.2 shall be inserted stating as follows, and the remaining Section 5.3.5.4 shall be renumbered accordingly, including any references thereto:

5.3.5.4.2
The Contractor’s Plan does not, due to moral or religious objections, cover the health service the Enrollee seeks.

21.
Original Section 5.3.5.4, renumbered by this Amendment as 5.3.5.5, shall be amended and replaced in its entirety as follows:

5.3.5.5
If the Contractor fails to refer a Disenrollment request within the timeframe specified in Section 5.3.3, or if ASES fails to make a Disenrollment determination so that the Enrollee may be disenrolled by the first day of the second month following the month when the Disenrollment request was made, per Section 5.3.3, the Disenrollment shall be deemed approved for the effective date that would have been established had ASES or the Contractor complied with Section 5.3.3.

22.
Section 5.3.8.2 shall be amended and replaced in its entirety as follows:

5.3.8.2
The Contractor shall notify the Puerto Rico Medicaid Program Immediately when the Enrollment database is updated to reflect a change in the place of residence of an Enrollee or an Enrollee’s death.
 
8

23.
Section 6.1.1 shall be amended and replaced in its entirety as follows:
 
6.1.1
The Contractor shall have policies and procedures, prior approved by ASES and submitted in accordance with Attachment 12, that explain how it will ensure that Enrollees and Potential Enrollees:

6.1.1.1
Are aware of their rights and responsibilities;

6.1.1.2
How to obtain physical and Behavioral Health Services;

6.1.1.3
What to do in an emergency or urgent medical situation;

6.1.1.4
How to request a Grievance, Appeal, or Administrative Law Hearing;

6.1.1.5
How to report suspected Incident of Fraud, Waste, and Abuse;

6.1.1.6
Have basic information on the basic features of managed care; and

6.1.1.7
Understand the MCO’s responsibilities to coordinate Enrollee care.

24.
Section 6.1.2 shall be amended and replaced in its entirety as follows:

6.1.2
The Contractor’s informational materials must convey to Enrollees and Potential Enrollees that GHP is an integrated program that includes both physical and Behavioral Health Services, and must also explain the concepts of Primary Medical Groups and Preferred Provider Networks.

25.
Immediately following Section 6.1.6, a new Section 6.1.7 shall be inserted stating as follows:

6.1.6
The Contractor shall use the definitions for managed care terminology set forth by ASES in all of its written and verbal communications with Enrollees, in accordance with 42 CFR 438.10(c)(4)(i).

26.
Section 6.2.4.3 shall be amended and replaced in its entirety as follows:

6.2.4.3
Standard letters and notifications, such as the notice of Enrollment required in Section 5.2.5.3, the notice of Redetermination required in Section 5.2.7.1, and the notice of Disenrollment required in Section 5.3.2.  The Contractor shall use model Enrollee notices developed by ASES.
 
9

27.
Section 6.3.2 shall be amended and replaced in its entirety as follows:

6.3.2
The Contractor shall make all written materials available through auxiliary aids and services or alternative formats, and in a manner that takes into consideration the Enrollee’s or Potential Enrollee’s special needs, including Enrollees and Potential Enrollees who are visually impaired or have limited reading proficiency.  The Contractor shall notify all Enrollees and Potential Enrollees that Information is available in alternative formats, and shall instruct them on how to access those formats.  Consistent with Section 1557 of PPACA and 42 C.F.R. 438.10(d)(3), all written materials must also include taglines in the prevalent languages, as well as large print, with a font size of no smaller than 18 point, to explain the availability of written and oral translation to understand the Information provided and the toll-free and TTY/TDY telephone number of the GHP Service Line.

28.
Section 6.3.3 shall be amended and replaced in its entirety as follows:

6.3.3
Once an Enrollee has requested a written material in an alternative format or language, the Contractor shall at no cost to the Enrollee or Potential Enrollee (i) make a notation of the Enrollee or Potential Enrollee’s preference in the Contractor’s system and (ii) provide all subsequent written materials to the Enrollee or Potential Enrollee in such format unless the Enrollee or Potential Enrollee requests otherwise.

29.
Section 6.3.4 shall be amended and replaced in its entirety as follows:

6.3.4
Except as provided in Sections 1.1.5 and 6.4 (Enrollee Handbook) and subject to Section 6.3.8, the Contractor shall make all written information available in Spanish on other applicable Prevalent Non-English Language, as defined in Section 6.3.8 below, with a language block in English, explaining that (i) Enrollees may access an English translation of the Information if needed, and (ii) the Contractor will provide oral interpretation services into any language other than Spanish or English, if needed.  Such translation or interpretation shall be provided by the Contractor at no cost to the Enrollee. The language block and all other content shall comply with 42 CFR 438.10(d)(2) and Section 1557 of PPACA.

30.
Section 6.3.5 shall be amended and replaced in its entirety as follows:

6.3.5
If oral interpretation services are required in order to explain the Benefits covered under the GHP to a Potential Enrollee who does not speak either English or Spanish, the Contractor must, at its own cost, make such services available in a third language, in compliance with 42 CFR 438.10(d)(4).
 
10

31.
Section 6.3.8 shall be amended and replaced in its entirety as follows:

6.3.8
Within ninety (90) Calendar Days of a notification from ASES that ASES has identified a Prevalent Non-English Language other than Spanish or English (with “Prevalent Non-English Language” defined as a language that is the primary language of more than five percent (5%) of the population of Puerto Rico), all written materials provided to Enrollees and Potential Enrollees shall be translated into and made available in such language.

32.
Section 6.4.1 shall be amended and replaced in its entirety as follows:

6.4.1
The Contractor shall produce at its sole cost, and shall mail or make electronically available, subject to the requirements of Section 6.9.8 and 6.9.9, to all new Enrollees, an Enrollee Handbook including information on physical health, Behavioral Health, and all other Covered Services offered under the GHP.    The Contractor shall distribute the Handbook either simultaneously with the notice of Enrollment referenced in Section 5.2.5.3 or within five (5) Calendar Days of sending the notice of Enrollment via surface mail.

33.
Section 6.4.3 shall be amended and replaced in its entirety as follows:

6.4.3
The Contractor shall either:

6.4.3.1
Mail or make electronically available, subject to the requirements of Sections 6.9.8 and 6.9.9, to all Enrollees an Enrollee Handbook on at least an annual basis, after the initial distribution of the Handbook at Enrollment; or

6.4.3.2
At least annually, as required by 42 CFR 438.10, mail or make electronically available, subject to the requirements of Sections 6.9.8 and 6.9.9, to all Enrollees a Handbook supplement that includes Information on the following:

6.4.3.2.1
The Contractor’s service area;

6.4.3.2.2
Benefits covered under the GHP;

6.4.3.2.3
Any cost-sharing imposed by the Contractor; and

6.4.3.2.4
To the extent available, quality and performance indicators, including Enrollee satisfaction.

6.4.3.3
The Contractor is not required to mail an Enrollee Handbook to an Enrollee who may have been disenrolled and subsequently reenrolled if Enrollee was provided a Enrollee Handbook within the past year.  The Contractor is also not required to mail an Enrollee Handbook to new Enrollees under the age of twenty-one (21) if an Enrollee Handbook has been mailed within the past year to a member of that Enrollee’s household.  However, this exception does not apply to pregnant Enrollees under the age of twenty-one (21).
 
11

34.
Section 6.4.5.9 shall be amended and replaced in its entirety as follows:

6.4.5.9
Information on the amount, duration and scope of Benefits and Covered Services, including how the scope of Benefits and services differs between Medicaid- and CHIP Eligibles and Other Eligible Persons.  This must include Information on the EPSDT Benefit and how Enrollees under the age of twentyone (21) and entitled to the EPSDT Benefit may access component services;
 
35.
Section 6.4.5.12 shall be amended and replaced in its entirety as follows:

6.4.5.12
An explanation of any service limitations or exclusions from coverage, including any restrictions on the Enrollee’s freedom of choice among network Providers;

36.
Section 6.4.5.27.3.2 shall be amended and replaced in its entirety as follows:

6.4.5.27.3.2
No Co-Payments shall be charged for Medicaid and CHIP children under twenty-one (21) years under any circumstances.

37.
Section 6.4.5.29.9 shall be amended and replaced in its entirety as follows:

6.4.5.29.9
Information on the family planning services and supplies, including the extent to which, and how, Enrollees may obtain such services or supplies from out-of-network providers, and that an Enrollee cannot be required to obtain a referral before choosing a family planning Provider.

38.
Immediately following Section 6.4.5.29.9, new Sections 6.4.5.29.10 and 6.4.5.29.11 shall be inserted stating as follows:

6.4.5.29.10
Information on non-coverage of counseling or referral services based on Contractor’s moral or religious objections, as specified in Section 7.13 and how to access these services from ASES; and

6.4.5.29.11
Instructions on how to access oral or written translation services, Information in alternative formats, and auxiliary aids and services, as specified in Sections 6.3 and 6.11.
 
12

39.
Section 6.5.1.16 shall be amended and replaced in its entirety as follows:

6.5.1.16
Only be responsible for cost-sharing in accordance with 42 CFR 447.50 through 42 CFR 447.82 and as permitted by the Puerto Rico Medicaid and CHIP State Plans and Puerto Rico law as applicable to the Enrollee.

40.
Section 6.6.1 shall be amended and replaced in its entirety as follows:

6.6.1
The Contractor shall develop, maintain, and mail or make electronically available, subject to the requirements of Sections 6.9.8 and 6.9.9 to all new Enrollees a Provider Directory that includes Information on both physical and Behavioral Health Providers under the GHP.   The Contractor shall distribute the Provider Directory, within five (5) Calendar Days of sending the notice of Enrollment referenced in Section 5.2.5.3.

6.6.1.1
The Contractor is not required to mail a Provider Directory to an Enrollee who may have been disenrolled and subsequently reenrolled if Enrollee was provided a Provider Directory within the past year.  The Contractor is also not required to mail a Provider Directory to new Enrollees under the age of twenty-one (21) if a Provider Directory has been mailed within the past year to a member of that Enrollee’s household.  However, this exception does not apply to pregnant Enrollees under the age of twentyone (21).

41.
Section 6.6.2 shall be amended and replaced in its entirety as follows:

6.6.2
The Contractor shall update the paper Provider Directory once a month and distribute it to Enrollees upon Enrollee request.

42.
Section 6.6.3 shall be amended and replaced in its entirety as follows:

6.6.3
The Contractor shall make the Provider Directory available on its website in a machine readable file and format as specified by CMS.

43.
Section 6.6.4 shall be amended and replaced in its entirety as follows:

6.6.4
The Provider Directory shall include the names, provider group affiliations, locations, office hours, telephone numbers, websites, cultural and linguistic capabilities, completion of Cultural Competency training, and accommodations for people with physical disabilities of current Network Providers.  This includes, at a minimum, Information sorted by Service Region on PCPs, specialists, dentists, FQHCs and RHCs, Behavioral Health Providers, and pharmacies in each Service Region, hospitals, including locations of emergency settings and Post-Stabilization Services, with the name, location, hours of operation, and telephone number of each facility/setting.  The Provider Directory shall also identify all Network Providers that are not accepting new patients. Any subcontractors of ASES, such as the PBM, will collaborate with the Contractor to provide information in a format mutually agreed upon for the generation of the Provider Directory.
 
13

44.
Section 6.7.2.10 shall be amended and replaced in its entirety as follows:

6.7.2.10
The applicable Co-Payment levels for various services outside the Enrollee’s PPN and the assurance that no Co-Payment will be charged for a Medicaid Eligible Person and for CHIP children under twenty-one (21) years under any circumstances;

45.
Immediately following Section 6.9.7, new Sections 6.9.8 and 6.9.9 shall be inserted stating as follows:

6.9.8
Any Enrollee Information required under 42 CFR 438.10, including the Enrollee Handbook, Provider Directory, and Enrollee notices, may not be provided electronically or on the Contractor’s website unless such Information (1) is readily accessible, (2) is placed on the Contractor’s website in a prominent location, (3) is provided in a form that can be electronically retained and printed, and (4) includes notice to the Enrollee that the Information is available in paper form without charge and can be provided upon request within five (5) Business Days.

6.9.9
The Enrollee Handbook and Provider Directory may be provided electronically instead of paper form if all required elements of Section 6.9.8 are satisfied.  However, the Contractor must provide the Enrollee Handbook and Provider Directory in paper form upon request by the Enrollee at no charge and within five (5) Business Days.  If the Enrollee Handbook is provided by e-mail, the Contractor must first obtain the Enrollee’s agreement to receive the Enrollee Handbook by e-mail.  If the Enrollee Handbook is posted on the Contractor’s website, the Contractor must first advise the Enrollee in paper or electronic form that the information is available on the internet, and must include the applicable website address, provided that Enrollees with disabilities who cannot access this information online are provided auxiliary aids and services upon request and at no cost.

46.
Section 6.10.1 shall be amended and replaced in its entirety as follows:

6.10.1
In accordance with 42 CFR 438.206, the Contractor shall have a comprehensive written Cultural Competency plan describing how the Contractor will ensure that services are provided in a culturally competent manner to all Enrollees.  The Cultural Competency plan must describe how the Providers, individuals, and systems within the Contractor’s Plan will effectively provide services to people of all diverse cultural and ethnic backgrounds, disabilities, and regardless of gender, sexual orientation, gender identity, or religion in a manner that recognizes values, affirms, and respects the worth of the individual Enrollees and protects and preserves the dignity of each individual.
 
14


47.
Section 6.11.1 shall be amended and replaced in its entirety as follows:

6.11.1
The Contractor shall provide oral interpreter services to any Enrollee or Potential Enrollee who speaks any language other than English or Spanish as his or her primary language, regardless of whether the Enrollee or Potential Enrollee speaks a language that meets the threshold of a Prevalent Non-English Language.  This also includes the use of auxiliary aids and services such as TTY/TDY and the use of American Sign Language. The Contractor is required to notify its Enrollees of the availability of oral interpretation services and to inform them of how to access oral interpretation services.  There shall be no charge to an Enrollee or Potential Enrollee for interpreter services or other auxiliary aids.
 
48.
Section 6.14.1 shall be amended and replaced in its entirety as follows:

6.14.1
Prohibited Activities.  The Contractor is prohibited from engaging in the following activities:

6.14.1.1
Directly or indirectly engaging in door-to-door, telephone, e-mail, texting or other Cold-Call Marketing activities;

6.14.1.2
Offering any favors, inducements or gifts, promotions, or other insurance products that are designed to induce Enrollment in the Contractor’s Plan;

6.14.1.3
Distributing plans and materials that contain statements that ASES determines are inaccurate, false, or misleading.  Statements considered false or misleading include, but are not limited to, any assertion or statement (whether written or oral) that the Contractor’s plan is endorsed by the Federal Government or Commonwealth, or similar entity;

6.14.1.4
Distributing materials that, according to ASES, mislead or falsely describe
the Contractor’s Provider Network, the participation or availability of Network Providers, the qualifications and skills of Network Providers (including their bilingual skills); or the hours and location of network services;

6.14.1.5
Seeking to influence Enrollment in conjunction with the sale or offering of any private insurance; and

6.14.1.6
Asserting or stating in writing or verbally that the Enrollee or Potential Enrollee must enroll in the Contractor’s plan to obtain or retain Benefits.
 
15

49.
Section 7.1.4.1 shall be amended and replaced in its entirety as follows:

7.1.4.1
The Enrollee paid the Provider for the service. This rule does not apply in circumstances where a Medicaid or CHIP Eligible Enrollee incurs out-ofpocket expenses for Emergency Services provided in the other USA jurisdictions. In such a case, the expenses will be reimbursed under the GHP; or

50.
Section 7.5.2.1.19 shall be amended and replaced in its entirety as follows:

7.5.2.1.19
Organ and tissue transplants, except skin, bone and corneal transplants.  Such skin, bone and corneal transplants shall be covered only in accordance with ASES’s written standards providing for similarly situated individuals to be treated alike, and, for any restriction on facilities or practitioners providing such services, to be consistent with the accessibility of high quality care to Enrollees; and

51.
Section 7.5.7.11 shall be amended and replaced in its entirety as follows:

7.5.7.11
The Contractor shall be responsible for timely payment for emergency transportation services in the other USA jurisdictions for Enrollees who are Medicaid or CHIP Eligibles, if the emergency transportation is associated with an Emergency Service in the other USA jurisdictions covered under Section 7.5.9.3.1.2 of this Contract.  If, in an extenuating circumstance, a Medicaid or CHIP Eligible Enrollee incurs out-of-pocket expenses for emergency transportation services provided in the other USA jurisdictions, the Contractor shall reimburse the Enrollee for such expenses in a timely manner, and the reimbursement shall be considered a Covered Service.

52.
Section 7.5.8.4.7 shall be amended and replaced in its entirety as follows:

7.5.8.4.7
Other FDA approved contraceptive medications or methods not covered by sections 7.5.8.4.5 or 7.5.8.4.6 of the Contract, when it is Medically Necessary and approved through a Prior Authorization or through an exception process and the prescribing Provider can demonstrate at least one of the following situations:

7.5.8.4.7.1
Contra-indication with drugs that are in the FMC or LME that the Enrollee is already taking, and no other methods available in the  FMC or LME  that can be  used  by the  Enrollee.

7.5.8.4.7.2
History of adverse reaction by the Enrollee to the contraceptive methods covered as specified by ASES; or

7.5.8.4.7.3
History of adverse reaction by the Enrollee to the contraceptive medications that are on the FMC or LME.
 
16

53.
Immediately following Section 7.5.8.4.7.3, a new Section 7.5.8.5 shall be inserted stating as follows:

7.5.8.5
Maternity services, including family planning and postpartum services, must be covered for a sixty (60) day period, beginning on the day the pregnancy ends.  These services will also be covered for any remaining days in the month in which the sixtieth (60 th ) day falls.

54.
Section 7.5.9.1 shall be amended and replaced in its entirety as follows:

7.5.9.1
The Contractor shall cover and pay for Emergency Services where necessary to treat an Emergency Medical Condition or a Psychiatric Emergency.  The Contractor shall ensure that Medical and Psychiatric Emergency Services are available twenty-four (24) hours a day, seven (7) days per Week.  The Contractor shall ensure that emergency rooms and other Providers qualified to furnish Emergency Services have appropriate personnel to provide physical and Behavioral Health Services. All Emergency Services must be billed appropriately to the Contractor based on the applicable treatment and site of care.  No Prior Authorization will be required for Emergency Services, and the Contractor shall not deny payment for treatment if a representative of the Contractor instructed the Enrollee to seek Emergency Services.

55.
Section 7.5.9.2 shall be amended and replaced in its entirety as follows:

7.5.9.2
Emergency Services shall include, but are not limited to, the following:

7.5.9.2.1
Emergency room visits, including medical attention and routine and necessary services;

7.5.9.2.2
Trauma services;

7.5.9.2.3
Operating room use;

7.5.9.2.4
Respiratory therapy;

7.5.9.2.5
Specialist and sub-specialist treatment when required by the emergency room physician;

7.5.9.2.6
Anesthesia;
 
17

7.5.9.2.7
Surgical material;

7.5.9.2.8
Laboratory tests and X-Rays;

7.5.9.2.9
Post-Stabilization Services, as provided in Section 7.5.9.4 below;

7.5.9.2.10
Care as necessary in the case of a Psychiatric Emergency in an emergency room setting;

7.5.9.2.11
Drugs, medicine and intravenous solutions used in the emergency room; and

7.5.9.2.12
Transfusion of blood and blood plasma services, without limitations, including:

7.5.9.2.12.1
Authologal and irradiated blood;

7.5.9.2.12.2
Monoclonal factor IX with a certified hematologist Referral;

7.5.9.2.12.3
Intermediate purity concentrated ant hemophilic factor (Factor VIII);

7.5.9.2.12.4
Monoclonal type anti-hemophilic factor with a certified hematologist’s authorization; and

7.5.9.2.12.5
Activated protrombine complex (Autoflex and Feiba) with a certified hematologist’s authorization.

56.
Section 7.5.9.3 shall be amended and replaced in its entirety as follows:

7.5.9.3
Emergency Services Within and Outside Puerto Rico

7.5.9.3.1
The Contractor shall make Emergency Services available:

7.5.9.3.1.1
For all Enrollees, throughout Puerto Rico, including outside the Contractor’s Service Regions, and notwithstanding whether the Emergency Services Provider is a Network Provider; and

7.5.9.3.1.2
For Medicaid and CHIP Eligibles, in Puerto Rico or in the other USA jurisdictions, when the services are Medically Necessary and could not be anticipated, notwithstanding that Emergency Services Providers outside of Puerto Rico are not Network Providers.  The Contractor shall be responsible for fulfilling payment for Emergency Services rendered in the other USA jurisdictions in a timely manner.  If, in an extenuating circumstance, a Medicaid or CHIP Eligible Enrollee incurs out-of-pocket expenses for Emergency Services provided in the other USA jurisdictions, the Contractor shall reimburse the Enrollee for such expenses in a timely manner, and the reimbursement shall be considered a Covered Service.
 
18

7.5.9.3.2
In covering Emergency Services provided by Puerto Rico Providers outside the Contractor’s Network, or by Providers in the other USA jurisdictions, the Contractor shall pay the Provider at least the average rate paid to Network Providers.

57.
Section 7.5.9.4.2 shall be amended and replaced in its entirety as follows:

7.5.9.4.2
An Enrollee who has been treated for an Emergency Medical Condition or Psychiatric Emergency shall not be held liable for any subsequent screening or treatment necessary to stabilize or diagnose the specific condition in order to stabilize the Enrollee.

58.
Immediately following Section 7.5.9.4.3.1, a new Section 7.5.9.4.3.2 shall be inserted stating as follows, and the remaining Section 7.5.9.4.3 shall be renumbered accordingly, including any references thereto:

7.5.9.4.3.2
The Contractor must limit cost-sharing for Post-Stabilization Services upon inpatient admission to Enrollees to amounts no greater than what the Contractor would charge Enrollee if services were obtained through the Contractor’s General Network.

59.
Section 7.5.9.6.2 shall be amended and replaced in its entirety as follows:

7.5.9.6.2
No Co-Payments shall be charged for Medicaid and CHIP children under twenty-one (21) years of age under any circumstances.

60.
Section 7.5.9.7.2 shall be amended and replaced in its entirety as follows:

7.5.9.7.2
The Contractor shall not refuse to cover an Emergency Medical Condition or a Psychiatric Emergency based on the emergency room Provider, hospital, or fiscal Agent not notifying the Enrollee’s PCP or the Contractor of the Enrollee’s screening or treatment within ten (10) Calendar Days following the Enrollee’s presentation for Emergency Services.

61.
Section 7.5.12.1 shall be amended and replaced in its entirety as follows:

7.5.12.1
The Contractor shall provide in accordance with Section 1927 of the Social Security Act pharmacy services under the GHP, including the following:
 
19

7.5.12.1.1
All costs related to prescribed medications for Enrollees, excluding the Enrollee’s Co-Payment where applicable;

7.5.12.1.2
Drugs on the Formulary of Medications Covered (FMC);

7.5.12.1.3
Drugs included on the LME, but not in the FMC (through the exceptions process explained in Section 7.5.12.10); and

7.5.12.1.4
In some instances, through the exceptions process, drugs that are not included on either the FMC or the LME.

62.
Section 7.5.12.4.1 shall be amended and replaced in its entirety as follows:

7.5.12.4.1
Consistent with the requirements of Section 1927(d)(5) of the Social Security Act, some or all prescription drugs may be subject to Prior Authorization, which shall be implemented and managed by the PBM or the Contractor, according to policies and procedures established by the ASES Pharmacy and Therapeutic (“P&T”) Committee and decided upon in consultation with the Contractor when applicable.

63.
Section 7.5.12.4.2.1 shall be amended and replaced in its entirety as follows:

7.5.12.4.2.1
The decision whether to grant a Prior Authorization of a prescription must not exceed twenty-four (24) hours from the receipt of the Enrollee’s Service Authorization Request and the standard information needed to make a determination is provided. Such standard information to make a determination includes the following:  the prescription, a supporting statement setting forth the clinical justification and medical necessity for the prescribed medication, and expected duration of treatment, as required by the protocol for the medication. The Contractor shall provide notice on a Prior Authorization request by telephone or other telecommunication device in the required timeframes. In circumstances where the Contractor or the Enrollee’s Provider determines that the Enrollee’s life or health could be endangered by a delay in accessing the prescription drug, the Contractor shall provide at least a seventy-two (72) hour supply of the prescription drug unless the drug is statutorily excluded from coverage under Section 1927(d)(2) of the Social Security Act. In such cases, Prior Authorization must be provided as expeditiously as the Enrollee’s health requires, and no later than within twenty-four (24) hours following the Service Authorization Request.
 
20

64.
Section 7.5.12.10.1.2 shall be amended and replaced in its entirety as follows:

7.5.12.10.1.2
The Contractor shall cover a drug that is not included on either the FMC or the LME, only as part of an exceptions process, provided that the drug is being prescribed for a use approved by the FDA or for a medically accepted indication, as defined in Section 1927(k)(6) of the Social Security Act for the treatment of the condition.

65.
Section 7.5.12.10.2 shall be amended and replaced in its entirety as follows:

7.5.12.10.2
In addition to demonstrating that the drug is being prescribed for a medically accepted indication, as defined in Section 1927(k)(6) of the Social Security Act and as referenced in Section 7.5.12.10.1.2 above, a Provider prescribing a drug not on the FMC or LME must provide the Contractor with the necessary medical documentation to demonstrate that:

7.5.12.10.2.1
The drug does not have any bioequivalent on the market; and

7.5.12.10.2.2
The drug is clinically indicated because of:

7.5.12.10.2.2.1
Contra-indication with drugs that are in the FMC or LME that the Enrollee is already taking, and scientific literature’s indication of the possibility of serious adverse health effects related to the taking the drug;

7.5.12.10.2.2.2
History of adverse reaction by the Enrollee to drugs that are on the FMC or LME;

7.5.12.10.2.2.3
Therapeutic failure of all available alternatives on the FMC or LME; or

7.5.12.10.2.2.4
Other special circumstances.

66.
Section 7.5.12.14 shall be amended and replaced in its entirety as follows:

7.5.12.14
Formulary Management Program

7.5.12.14.1
The Contractor shall   select two (2) members of its staff to serve on a cross-functional committee, the Pharmacy Benefit Financial Committee, tasked with rebate maximization and/or evaluating recommendations regarding the FMC and LME from the P&T Committee and the PPA and PBM as applicable.  The Pharmacy Benefit Financial Committee will also review the FMC and LME from time to time and evaluate additional recommendations on potential cost-saving pharmacy initiatives, under the direction and approval of ASES.
 
21

7.5.12.14.2
The Contractor shall select a member of its staff to serve on a crossfunctional subcommittee tasked with assisting in the evaluation of additional potential cost-saving pharmacy initiatives as needed.

67.
Section 7.5.12.15 shall be amended and replaced in its entirety as follows:

7.5.12.15
Utilization Management and Reports.  The Contractor shall:

7.5.12.15.1
Perform drug Utilization reviews that meet the standards established by both ASES and Federal authorities, including the operation of a drug utilization review program as required in 42 CFR Part 456, Subpart K;

7.5.12.15.2
Develop and distribute protocols that will be subject to ASES approval, when necessary; and

7.5.12.15.3
Provide to ASES annually a detailed description of its drug utilization program activities.

68.
Section 7.5.12.16.2 shall be amended and replaced in its entirety as follows:

7.5.12.16.2
The Contractor shall advise Providers that they may not outright deny medication because it is not included on ASES’s FMC or LME.  A medication not on the FMC or LME may be provided through the exceptions process described in Section 7.5.12.10.

69.
Section 7.5.12.17 shall be amended and replaced in its entirety as follows:

7.5.12.17
Cooperation with the Pharmacy Program Administrator (“PPA”)

7.5.12.17.1
The Contractor shall receive updates to the FMC and LME from the PPA. The Contractor shall adhere to these updates.

7.5.12.17.2
Any rebates shall be negotiated by the PPA and retained in their entirety by ASES.  The Contractor shall neither negotiate, collect, nor retain any pharmacy rebate for Enrollee Utilization of brand drugs included on ASES’s FMC or LME.

70.
Immediately following Section 7.5.12.17.2, a new Section 7.5.12.18 shall be inserted stating as follows:

7.5.12.18
Information on Pharmacy Benefits Coverage.  The Contractor shall provide Information on the FMC and LME in electronic or paper form, including which generic or brand medications are covered, and what formulary tier each medication is on.  Drug lists that are published on the Contractor’s website must be in a machine readable file and format as specified by CMS.
 
22

71.
Section 7.7.8 shall be amended and replaced in its entirety as follows:

7.7.8
The Contractor shall complete, monitor, and routinely update a treatment plan for each Enrollee who is registered for Special Coverage at least every twelve (12) months, or when the Enrollee’s circumstances or needs change significantly, or at the request of the Enrollee.

7.7.8.1
The treatment plan shall be developed by the Enrollee’s PCP, with the Enrollee’s participation, and in consultation with any specialists caring for the Enrollee.  The Contractor shall require, in its Provider Contracts with PCPs, that Special Coverage registration treatment plans be submitted to the Contractor for review and approval in a timely manner.

72.
Section 7.8.2.3 shall be amended and replaced in its entirety as follows:

7.8.2.3
The Contractor’s Care Management system shall emphasize prevention, continuity of care, and coordination of care, including between settings of care and appropriate discharge planning for short- and long-term hospital and institutional stays.  The system will advocate for, and link Enrollees to, services as necessary across Providers, including community and social support Providers, and settings.  Care Management functions include:

7.8.2.3.1
Assignment of a specific Care Manager to each enrollee qualified for Care Management;

7.8.2.3.2
Management of Enrollee to Care Manager ratios that have been reviewed and approved by ASES;

7.8.2.3.3
Identification of Enrollees who have or may have chronic or severe Behavioral Health needs, including through use of the screening tools MCHAT for the detection of Autism, ASQ, ASQ-SE, Conners Scale (ADHD screen), DAST-10, GAD, and PC-PTSD, and other tools available for diagnosis of Behavioral Health disorders;

7.8.2.3.4
Assessment of an Enrollee’s physical and Behavioral Health needs utilizing a standardized needs assessment within thirty (30) Calendar  Days of Referral to Care Management that has been reviewed and given written approval by ASES.  The Contractor shall also make its best efforts to perform this needs assessment for all new Enrollees within ninety (90) Calendar Days of the Effective Date of Enrollment, and to comply with all other requirements for such assessments set forth in 42 CFR 438.208(b);
 
23

7.8.2.3.5
Development of a plan of care within sixty (60) Calendar Days of the needs assessment;

7.8.2.3.6
Referrals and assistance to ensure timely Access to Providers;

7.8.2.3.7
Coordination of care actively linking the Enrollee to Providers, medical services, residential, social, and other support services where deemed necessary;

7.8.2.3.8
Monitoring of the Enrollees needs for assistance and additional services via face-to-face or telephonic contact at least quarterly (based on high- or low-risk;

7.8.2.3.9
Continuity and transition of care; and

7.8.2.3.10
Follow-up and documentation, including the review and/or revision of a plan of care upon reassessment of need, at least every twelve (12) months, or when the Enrollee’s circumstances or needs change significantly, or at the request of the Enrollee. 

73.
Section 7.10.1 shall be amended and replaced in its entirety as follows:

7.10.1
In compliance with 42 CFR 438.3 (j)(1) and (2), 42 CFR 422.128(a), 42 CFR 422.128(b), 42 CFR 489.102(a), and Law No. 160 of November 17, 2001, the Contractor shall maintain written policies and procedures for Advance Directives.  Such Advance Directives shall be included in each Enrollee’s Medical Record.  The Contractor shall provide these policies and procedures written at a fourth (4 th ) grade reading level in English and Spanish to all Enrollees eighteen (18) years of age and older and shall advise Enrollees of:

7.10.1.1
Their rights under the laws of Puerto Rico, including the right to accept or refuse medical or surgical treatment and the right to formulate Advance Directives;

7.10.1.2
The Contractor’s written policies respecting the implementation of those rights, including a statement of any limitation that incorporates the requirements set forth under 42 CFR 422.128(b)(1)(ii) regarding the implementation of Advance Directives as a matter of conscience; and

24

7.10.1.3
The Enrollee’s right to file Complaints concerning noncompliance with Advance Directive requirements directly with ASES or with the Puerto Rico Office of the Patient Advocate.

74.
Section 7.11.4.2 shall be amended and replaced in its entirety as follows:

7.11.4.2
No Co-Payments shall be charged for Medicaid and CHIP children under twenty-one (21) years of age under any circumstances.

75.
Immediately following Section 7.12.2, new Sections 7.12.3 and 7.12.3.1 shall be inserted stating as follows:

7.12.3
The Contractor must enter into a Coordination of Benefits Agreement with Medicare within sixty (60) days from the Effective Date of the Contract and participate in the automated claims crossover process in order to appropriately allocate reimbursement for Dual Eligible Beneficiaries. Any crossover claims not appropriately reimbursed by the applicable Medicaid program will be considered an Overpayment and shall be reported and returned in accordance with Section 22.1.19.

7.12.3.1
ASES may extend the sixty (60) day time frame set forth in Section 7.12.3 if the Contractor can provide evidence, satisfactory to ASES, that documents the Contractor’s reasonable efforts to enter into a Coordination of Benefits Agreement with Medicare.

76.
Section 7.13.2 shall be amended and replaced in its entirety as follows:

7.13.2
The Contractor shall furnish information about the services it does not cover based on a moral or religious objection to ASES with its GHP Program application.  The Contractor acknowledges that such objections will be factored into the calculation of rates paid to the Contractor and, when made during the course of the Contract period, may serve as grounds for recalculation of the rates paid.

77.
Section 10.3.1.22 shall be amended and replaced in its entirety as follows:

10.3.1.22
Specify that ASES, CMS, the Office of Inspector General, the Comptroller General, the Medicaid Fraud Control Unit, and their designees, shall have the right at any time to inspect, evaluate, and audit any pertinent records or documents, and may inspect the premises, physical facilities, and equipment where activities or work related to the GHP program is conducted.  The right to audit exists for ten (10) years from the final date of the contract period or from the date of completion of any audit, whichever is later;
 
25

78.
Section 10.4.3 shall be amended and replaced in its entirety as follows:

10.4.3
The Contractor shall, within fifteen (15) Calendar Days of issuance of a notice of termination to a Provider, provide written notice of the termination to Enrollees who received his or her Primary Care from, or was seen on a regular basis by, the terminated Provider, and shall assist the Enrollee as needed in finding a new Provider.

79.
Section 10.5.1.5 shall be amended and replaced in its entirety as follows:

10.5.1.5
With the exceptions noted below, the Contractor shall negotiate rates with Providers, and such rates shall be specified in the Provider Contract.  Payment arrangements may take any form allowed under Federal law and the laws of Puerto Rico, including Capitation payments, Fee-for-Service payment, and salary, if any, subject to Section 10.6 concerning permitted risk arrangements.  However, the Contractor must consider the use of maximum provider reimbursement rates equaling eighty percent (80%) of the 2016 Medicare fee schedule for the reimbursement of non-facility professional services related to cardiology and nuclear medicine services, and seventy percent (70%) of the 2016 Medicare fee schedule for the reimbursement of non-facility professional services related to all other specialties except radiation oncology, hematology/oncology, urology, interventional radiology and dialysis services.  Any use of the 2016 Medicare fee schedule to set maximum provider reimbursement rates shall not obligate the Contractor to increase current provider reimbursement rates that have been previously negotiated. The Contractor shall inform ASES in writing when it enters any Provider payment arrangement other than Fee-for-Service.

80.
Section 10.5.1.6 shall be amended and replaced in its entirety as follows:

10.5.1.6
Any Capitation payment made by the Contractor to Providers shall be based on sound actuarial methods in accordance with 42 C.F.R. 438.4. The Contractor shall submit data on the basis of which ASES will certify the actuarial soundness of Capitation payments, including the base data generated by the Contractor. All Provider payments by the Contractor shall be reasonable, and the amount paid shall not jeopardize or infringe upon the quality of the services provided.

81.
Section 11.2.5 shall be amended and replaced in its entirety as follows:

11.2.5
If the Contractor delegates any of its utilization management responsibilities under this Section 11.2 or 11.4 to any delegated Utilization Management agent or Subcontractor, such agent or Subcontractor must also comply with written policies and procedures for processing requests for authorizations of services in accordance with 42 CFR 438.210(b)(1).
 
26

82.
Section 11.4.1.5 shall be amended and replaced in its entirety as follows:

11.4.1.5
Neither the Contractor nor any Provider or Subcontractor may impose a requirement that Referrals be submitted for the approval of committees, boards, Medical Directors, etc.  The Contractor shall strictly enforce this directive and shall issue Administrative Referrals (see Section 11.4.1.4) whenever it deems medically necessary.

83.
Section 11.4.2.1.1 shall be amended and replaced in its entirety as follows:

11.4.2.1.1
With the exception of Prior Authorization of covered prescription drugs as described in Section 7.5.12.4.2, the decision to grant or deny a Prior Authorization must not exceed seventy-two (72) hours from the time of the Enrollee’s Service Authorization Request for all Covered Services; except that, where the Contractor or the Enrollee’s Provider determines that the Enrollee’s life or health could be endangered by a delay in accessing services, the Prior Authorization must be provided as expeditiously as the Enrollee’s health requires, and no later than twenty-four (24) hours from the Service Authorization Request.

84.
Section 11.4.6.1 shall be amended and replaced in its entirety as follows:

11.4.6.1
Neither a Referral nor Prior Authorization shall be required for any Emergency Service, no matter whether the Provider is within the PPN, and notwithstanding whether there is ultimately a determination that the condition for which the Enrollee sought treatment  from an Emergency Services Provider was not an Emergency Medical Condition or Psychiatric Emergency.

85.
Section 12.1.4 shall be amended and replaced in its entirety as follows:

12.1.4
ASES, in strict compliance with 42 CFR 438.340 and other Federal and Puerto Rico regulations, shall evaluate the delivery of health care by the Contractor. Such quality monitoring shall include monitoring of   all the Contractor’s Quality Management/Quality Improvement (“QM/QI”) programs described in this Article 12 of this Contract.

86.
Section 12.2.2 shall be amended and replaced in its entirety as follows:

12.2.2
For Medicaid and CHIP Eligibles, the QAPI program shall be in compliance with Federal requirements specified at 42 CFR 438.330.
 
27

87.
Section 12.2.3.1 shall be amended and replaced in its entirety as follows:

12.2.3.1
A method of monitoring, analyzing, evaluating, and improving the delivery, quality and appropriateness of health care furnished to all Enrollees (including over, under, and inappropriate Utilization of services) and including those with special health care needs, as defined by ASES in the quality strategy;

88.
Immediately following Section 12.2.6, a new Section 12.2.7 shall be inserted stating as follows:

12.2.7
As per 42 CFR 438.332(a) and (b), the Contractor shall inform ASES as to whether it has been accredited by a private, independent accrediting entity, and if so, shall provide or authorize the accrediting entity to provide ASES, as applicable, a copy of its most recent accreditation review (including its accreditation status, expiration date of the accreditation, and survey type and level) recommended actions or improvements, corrective action plans, and summaries of findings.

89.
Section 12.3.1 shall be amended and replaced in its entirety as follows:

12.3.1
At a minimum, the Contractor shall have a PIPs work plan and activities that are consistent with Federal and Puerto Rico statutes, regulations, and Quality Assessment and Performance Improvement Program requirements for pursuant to 42 C.F.R. 438.330. For more detailed information refer to the “EQR Managed Care Organization Protocol” available at http://www.medicaid.gov/ Medicaid-CHIP-Program-Information/By-Topics/Quality-of-Care/Quality-ofCare-External- Quality-Review.html.

90.
Section 12.7.1 shall be amended and replaced in its entirety as follows:

12.7.1
In compliance with Federal requirements at 42 CFR 438.358, ASES will contract with an External Quality Review Organization (“EQRO”) to conduct annual, external, independent reviews of the quality outcomes, timeliness of, and Access to, the services covered in this Contract.  The Contractor shall collaborate with ASES’s EQRO to develop studies, surveys, and other analytic activities to assess the quality of care and services provided to Enrollees and to identify opportunities for program improvement.  To facilitate this process the Contractor shall supply Data, including but not limited to Claims Data and Medical Records, to the EQRO. Upon the request of ASES, the Contractor shall provide its protocols for providing Information, participating in review activities, and using the results of the reviews to improve the quality of the services and programs provided to Enrollees.
 
28

91.
Section 13.1.2 shall be amended and replaced in its entirety as follows:

13.1.2
For Medicaid and CHIP Eligibles, the Contractor’s internal controls, policies, and procedures shall comply with all Federal requirements regarding Fraud, Waste, and Abuse and program integrity, including but not limited to Sections 1128, 1128A, 1156, 1842(j)(2), and 1902(a)(68) of the Social Security Act, Section 6402(h) of PPACA, 42 CFR 438.608, the CMS Medicaid Integrity program, and the Deficit Reduction Act of 2005.  The Contractor shall exercise diligent efforts to ensure that no payments are made to any person or entity that has been excluded from participation in Federal health care programs.  (See State Medicaid Director Letter #09-001, January 16, 2009.)

92.
Section 13.2.2.2 shall be amended and replaced in its entirety as follows:

13.2.2.2
Require the designation of a compliance officer and a compliance committee that are accountable to the Contractor’s senior management.  The compliance officer must have express authority to provide unfiltered reports directly to the Contractor’s most senior leader and governing body;

93.
Section 13.2.3 shall be amended and replaced in its entirety as follows:

13.2.3
The Contractor, and any Subcontractors delegated the responsibility by the Contractor for coverage of services and payment of claims under this Contract, shall include in all employee handbooks a specific discussion of the False Claims Act and its Fraud, Waste, and Abuse policies and procedures, the rights of employees to be protected as whistleblowers, and the Contractor and Subcontractor’s procedures for detecting and preventing Fraud, Waste, and Abuse.

94.
Section 13.4.1.2.3 shall be amended and replaced in its entirety as follows:

13.4.1.2.3
Any Subcontractor or other person with an employment, consulting, or other arrangement with the Contractor for the provision of items or services that are significant and material the Contractor’s obligations under this Contract.

95.
Section 13.5.3 shall be amended and replaced in its entirety as follows:

13.5.3
The Contractor shall Immediately report to ASES the identity of any Provider or other person who is debarred, suspended, or otherwise prohibited from participating in procurement activities.  ASES shall promptly notify the Secretary of Health and Human Services of the noncompliance, as required by 42 CFR 438.610(d).
 
29

96.
Section 14.1.1 shall be amended and replaced in its entirety as follows:

14.1.1
In accordance with 42 CFR Part 438, Subpart F, the Contractor shall establish an internal Grievance System under which Enrollees, or Providers acting on their behalf, may express dissatisfaction with the Contractor or challenge the denial of coverage of, or payment for, Covered Services.

97.
Section 14.1.10 shall be amended and replaced in its entirety as follows:

14.1.10
The Contractor shall include information regarding the Grievance System in the Provider Guidelines and upon joining the Contractor’s Network, all Providers and Subcontractors, as applicable shall receive training and education regarding the Contractor’s Grievance System, which includes but is not limited to:

14.1.10.1
The Enrollee’s right to file Complaints, Grievances and, Appeals and the requirements and timeframes for filing;

14.1.10.2
The Enrollee’s right to file a Complaint, Grievance, or Appeal with the Patient Advocate Office;

14.1.10.3
The Enrollee’s right to an Administrative Law Hearing, how to obtain an Administrative Law Hearing, and representation rules at an Administrative Law Hearing;

14.1.10.4
The availability of assistance in filing a Complaint, Grievance, or Appeal;

14.1.10.5
The toll-free numbers to file oral Complaints, Grievances, and Appeals;

14.1.10.6
The Enrollee’s right to request continuation of Benefits during an Appeal, or an Administrative Law Hearing filing,  and that  if the Contractor’s Adverse Benefit Determination is upheld in an Administrative Law Hearing, the Enrollee may be liable for the cost of any continued Benefits; and

14.1.10.7
Any Puerto Rico-determined Provider Appeal rights to challenge the failure of the Contractor to cover a service.

98.
Section 14.1.14 shall be amended and replaced in its entirety as follows:

14.1.14
The Contractor shall ensure that the individuals who make decisions on Grievances and Appeals are individuals:

14.1.14.1
Who were not involved in any previous level of review or decisionmaking, or who were subordinates of any individual involved in a previous review or decision-making;
 
30

14.1.14.2
Who, if deciding any of the following, are Providers who have the appropriate clinical expertise, as determined by ASES, in treating the Enrollee’s condition or disease if deciding any of the following:

  14.1.14.2.1
An Appeal of a denial that is based on lack of Medical Necessity;

14.1.14.2.2
A Grievance regarding denial of expedited resolutions of Appeal; and

14.1.14.2.3
Any Grievance or Appeal that involves clinical issues; and

14.1.14.3
Who take into account all comments, documents, records and other information submitted by Enrollee without regard to whether such information was submitted or considered in the initial Adverse Benefit Determination.

99.
Section 14.1.16 shall be amended and replaced in its entirety as follows:

14.1.16
The Contractor and Subcontractors, as applicable, shall have a system in place to collect, analyze, and integrate Data regarding Complaints, Grievances, and Appeals. At a minimum, the record must be accessible to ASES and available upon request to CMS and include the following information:
 
14.1.16.1
Date Complaint, Grievance, or Appeal was received;

14.1.16.2
Enrollee’s name;

14.1.16.3
Enrollee’s Medicaid ID number, if applicable;

14.1.16.4
Name of the individual filing the Complaint, Grievance, or Appeal on behalf of the Enrollee;

14.1.16.5
Date of acknowledgement that receipt of Grievance or Appeal was mailed to the Enrollee;

14.1.16.6
Summary of Complaint, Grievance, or Appeal;

14.1.16.7
Date of each review or review meeting and resolution at each level, if applicable;

14.1.16.8
Date Notice of Disposition or Notice of Adverse Benefit Determination was mailed to the Enrollee;

14.1.16.9
Corrective Action required; and
 
31

14.1.16.10
Date of resolution.

100.
Section 14.2.3 shall be amended and replaced in its entirety as follows:

14.2.3
An Enrollee or Enrollee’s Authorized Representative shall file a Complaint within fifteen (15) Calendar Days after the date of occurrence that initiated the Complaint. If the Enrollee or Enrollee’s Authorized Representative attempts to file a Complaint beyond the fifteen (15) Calendar Days, the Contractor shall instruct the Enrollee or Enrollee’s Authorized Representative to file a Grievance.

101.
Section 14.2.5 shall be amended and replaced in its entirety as follows:

14.2.5
The Contractor shall resolve each Complaint within seventy-two (72) hours of the time the Contractor received the initial Complaint, whether orally or in writing.  If the Complaint is not resolved within this timeframe, the Complaint shall be treated as a Grievance. The Contractor cannot require the Enrollee to file a separate Grievance before proceeding to Appeal.

102.
Section 14.3.2 shall be amended and replaced in its entirety as follows:

14.3.2
An Enrollee may file a Grievance at any time.

103.
Section 14.3.4 shall be amended and replaced in its entirety as follows:

14.3.4
The Contractor shall provide written notice of the disposition of the Grievance as expeditiously as the Enrollee’s health condition requires, but in any event, within ninety (90) Calendar Days from the day the Contractor receives the Grievance. If the Grievance originated from a Complaint that was not resolved within the seventy-two (72) hour timeframe set forth in Section 14.2.5, the time already spent by the Contractor to resolve the original Complaint must be deducted from this ninety (90) Calendar Day timeframe.

104.
Section 14.3.6 shall be amended and replaced in its entirety as follows:

14.3.6
The Contractor may extend the timeframe to provide a written notice of disposition of a Grievance for up to fourteen (14) Calendar Days if the Enrollee requests the extension or the Contractor demonstrates (to the satisfaction of ASES, upon its request) that there is a need for additional Information and how the delay is in the Enrollee’s interest.  If the Contractor extends the timeframe, it shall, for any extension not requested by the Enrollee:

14.3.6.1
Make reasonable efforts to provide Enrollee prompt oral notice of the delay;
 
32

14.3.6.2
Give the Enrollee written notice of the reason for the delay within two (2) Calendar Days; and

14.3.6.3
Inform the Enrollee of the right to file a Grievance if the Enrollee  disagrees with the decision to extend the timeframe; and .

105.
Section 14.4.1 shall be amended and replaced in its entirety as follows:

14.4.1
Pursuant to 42 CFR 438.210(a), the Contractor shall provide written notice to the requesting Provider and the Enrollee of any decision by the Contractor to deny a Service Authorization Request, or to authorize a service in an amount, duration, or scope that is less than requested. The Contractor’s notices shall meet the requirements of 42 CFR 438.404.

106.
Immediately following Section 14.4.3.2, a new Section 14.4.3.3 shall be inserted stating as follows, and the remaining Section 14.4.3 shall be renumbered accordingly, including any references thereto:

14.3.3.3
The right of Enrollee to be provided, upon request and at no expense to Enrollee, reasonable access to and copies of all documents, records and other information relevant to the Adverse Benefit Determination.

107.
Section 14.4.4.4 shall be amended and replaced in its entirety as follows:

14.4.4.4
If the Contractor extends the timeframe for the authorization decision and issuance of Notice of Adverse Benefit Determination according to Section 14.4.3, the Contractor shall give the Enrollee written notice of the reasons for the decision to extend if he or she did not request the extension and the Enrollee’s right to file a Grievance if he or she disagrees with that decision. The Contractor shall issue and carry out its determination as expeditiously as the Enrollee’s health requires and no later than the date the extension expires.

108.
Section 14.5.3 shall be amended and replaced in its entirety as follows:

14.5.3
The requirements of the Appeal process shall be binding for all types of Appeals, including expedited Appeals, unless otherwise established for expedited Appeals.  Only one (1) level of Appeal is permitted before proceeding to an Administrative Law Hearing.
 
33

109.
Section 14.5.7 shall be amended and replaced in its entirety as follows:

14.5.7
The Appeals process shall provide the Enrollee, the Enrollee’s Authorized Representative, or the Provider acting on behalf of the Enrollee with the Enrollee’s written consent, opportunity, before and during the Appeals process, to examine the Enrollee’s case file, including Medical Records, and any other documents and records considered during the Appeals process and provide copies of documents contained therein without charge and sufficiently in advance of the resolution timeframe for the Appeal.

110.
Section 14.5.9 shall be amended and replaced in its entirety as follows:

14.5.9
The Contractor shall resolve each standard Appeal and provide written notice of the disposition, as expeditiously as the Enrollee’s health condition requires but no more than  thirty (30) Calendar Days from the date the Contractor receives the Appeal.

111.
Section 14.5.11 shall be amended and replaced in its entirety as follows:

14.5.11
The Contractor shall resolve each expedited Appeal and provide a written Notice of Disposition, as expeditiously as the Enrollee’s health condition requires, but no longer than seventy-two (72) hours after the Contractor receives the Appeal and make reasonable efforts to provide oral notice.

112.
Section 14.5.12 shall be amended and replaced in its entirety as follows:

14.5.12
If the Contractor denies an Enrollee’s request for expedited review, it shall utilize the timeframe for standard Appeals specified herein and shall make reasonable efforts to give the Enrollee prompt oral notice of the denial, and follow-up within two (2) Calendar Days with a written notice. If the Enrollee disagrees with the decision to extend the prescribed timeframe, he or she shall be informed of the right to file a Grievance and the Grievance shall be resolved within twenty-four (24) hours.  The Contractor shall also make reasonable efforts to provide oral notice for resolution of an expedited review of an Appeal.

113.
Section 14.5.13 shall be amended and replaced in its entirety as follows:

14.5.13
The Contractor may extend the timeframe for standard or expedited resolution of the Appeal by up to fourteen (14) Calendar Days if the Enrollee, Enrollee’s Authorized Representative, or the Provider acting on behalf of the Enrollee with the Enrollee’s written consent, requests the extension or the Contractor demonstrates (to the satisfaction of ASES, upon its request) that there is need for additional information and how the delay is in the Enrollee’s interest.  If the Contractor extends the timeframe, it shall, for any extension not requested by the Enrollee:

14.5.13.1
Make reasonable efforts to provide Enrollee prompt oral notice of the delay;
 
34

14.5.13.2
Give the Enrollee written notice of the reason for the delay within two (2) Calendar Days;

14.5.13.3
Inform the Enrollee of the right to file a Grievance if the Enrollee disagrees with the decision to extend the timeframe; and

14.5.13.4
Resolve the Appeal as expeditiously as the Enrollee’s health condition requires, and no later than the date the extension expires.

114.
Section 14.5.15 shall be amended and replaced in its entirety as follows:

14.5.15
The written notice of Disposition shall be in a format and language that, at a minimum, meets applicable notification standards and shall include:

14.5.15.1
The results and date of the Appeal resolution; and

14.5.15.2
For decisions not wholly in the Enrollee’s favor:

14.5.15.3
The right to request an Administrative Law Hearing;

14.5.15.4
How to request an Administrative Law Hearing;

14.5.15.5
The right to continue to receive Benefits pending an Administrative Law Hearing;

14.5.15.6
How to request the continuation of Benefits; and

14.5.15.7
Notification that if the Contractor’s Adverse Benefit Determination is upheld in a hearing, the Enrollee may liable for the cost of any continued Benefits.

115.
Section 14.6.1 shall be amended and replaced in its entirety as follows:

14.6.1
The Contractor is responsible for explaining the Enrollee’s right to and the procedures for an Administrative Law Hearing, including that the Enrollee must exhaust the Contractor’s Grievance, Complaints, and Appeals process before requesting an Administrative Law Hearing.  However, if the Contractor fails to adhere to all notice and timing requirements set forth in 42 CFR 438.408, the Enrollee is deemed to have exhausted the Contractor’s Appeals process and may proceed with initiating an Administrative Law Hearing.
 
35

116.
Section 14.6.4 shall be amended and replaced in its entirety as follows:

14.6.4
ASES shall permit the Enrollee to request an Administrative Law Hearing within one hundred and twenty (120) Calendar Days of the Notice of Resolution of the Appeal.

117.
Section 14.7.2 shall be amended and replaced in its entirety as follows:

14.7.2
The Contractor shall continue the Enrollee’s Benefits if the Enrollee or the Enrollee’s Authorized Representative files the Appeal within sixty (60) Calendar Days following the date on the Adverse Benefit Determination notice; the Appeal involves the termination, suspension, or reduction of a previously authorized course of treatment; the services were ordered by an authorized Provider; the period covered by the original authorization has not expired; and the Enrollee timely files for continuation of the Benefits.

118.
Section 14.7.5 shall be amended and replaced in its entirety as follows:

14.7.5
If the Contractor or ASES reverses a decision to deny, limit, or delay services that were not furnished while the Appeal / Administrative Law Hearing was pending, the Contractor shall authorize or provide the disputed services promptly and as expeditiously as the Enrollee’s health condition requires but no later than seventy-two (72) hours from the date the Contractor receives notice reversing the determination.

119.
Section 16.4 shall be amended and replaced in its entirety as follows:

16.4
The Contractor shall not pay any Claim submitted by a Provider during the period of time when such Provider is excluded or suspended from the Medicare, Medicaid, CHIP or Title V Maternal and Child Health Services Block Grant programs for Fraud, Waste, or Abuse or otherwise included on the Department of Health and Human Services Office of the Inspector General exclusions list, or employs someone on this list, and when the Contractor knew, or had reason to know, of that exclusion, after a reasonable time period after reasonable notice has been furnished to the Contractor.  The Contractor shall not pay any Claim submitted by a Provider that is on Payment Hold.

120.
Section 16.6 shall be amended and replaced in its entirety as follows:

16.6
Network Providers may not receive payment other than by the Contractor for services covered under this Agreement, except when such payments are specifically required to be made by ASES under Title XIX of the Social Security Act, or its implementing regulations, or when ASES makes direct payments to Network Providers for graduate medical education costs approved under the Medicaid State Plan. The Contractor is prohibited from making payment on any amount expended for any  item or service not covered under the Medicaid State Plan.
 
36

121.
Section 16.13.2 shall be amended and replaced in its entirety as follows:

16.13.2
The Provider will have a period of sixty (60) Calendar Days to make the requested payment, to agree to Contractor retention of said payment, or to dispute the recovery action following the process described in Section 16.11.6.

122.
Section 17.2.4.6 shall be amended and replaced in its entirety as follows:

17.2.4.6
Be maintained for ten (10) years in either live and/or archival systems.  The duration of the retention period may be extended at the discretion of and as indicated to the Contractor by ASES as needed for ongoing audits or other purposes.

123.
Section 17.3.3 shall be amended and replaced in its entirety as follows:

17.3.3
Each month the Contractor shall generate Encounter Data files from its Claims management system(s) and/or other sources. Such files must be submitted in standardized Accredited Standards Committee (ASC) X12N 837 and National Council for Prescription Drug Programs (NCPDP) formats, and the ASC X12N 835 format as appropriate. The files will contain settled Claims and Claim adjustments and Encounter Data from Providers for the most recent month for which all such transactions were completed.  The Contractor shall provide these files electronically to ASES and/or its Agent at a frequency and level of detail to be specified by CMS and ASES based on program administration, oversight, and program integrity needs, and in adherence to the procedure, content standards and format indicated in Attachment 9.  The Contractor shall make changes or corrections to any systems, processes or Data transmission formats as needed to comply with Encounter Data quality standards as originally defined or subsequently amended.

124.
Immediately following Section 17.3.5, a new Section 17.3.6 shall be inserted stating as follows:

17.3.6
Revisions to the Modified Adjusted Gross Income (“MAGI”) are expected to be implemented on July 1, 2017.  To comply with MAGI requirements, Contractor must update its Information Systems in accordance with the procedures and timelines set forth in Attachment 9 and any other subsequent guidance issued by ASES.
 
37

125.
Section 18.1.1 shall be amended and replaced in its entirety as follows:

18.1.1
ASES may, at its discretion, require the Contractor to submit additional reports or any other data, documentation or information relating to the performance of the Contractor’s obligations both on an ad hoc and recurring basis as required by ASES or CMS. If ASES requests any revisions to the reports already submitted, the Contractor shall make the changes and re-submit the reports, according to the time period and format specified by ASES.

126.
Immediately following Section 18.2.5.6, a new Section 18.2.5.7 shall be inserted stating as follows:

18.2.5.7
The Contractor shall submit a quarterly Provider Preventable Conditions Report describing any identified Provider preventable conditions as defined in Sections 7.1.1.1.1 and 7.1.1.1.2 of this Contract.  The report shall include but not be limited to, a description of each identified instance of a provider preventable condition, the name of the applicable Provider, and a summary of corrective actions taken by the Contractor or Provider to address any underlying causes of the provider preventable condition.

127.
Section 19.1.4.3.3 shall be amended and replaced in its entirety as follows:

19.1.4.3.3
The Contractor has taken actions that have caused substantial risk to Enrollees’ health;

128.
Section 19.4.1 shall be amended and replaced in its entirety as follows:

19.4.1
The Contractor has the right within fifteen (15) Calendar Days following receipt of the notice of imposition of intermediate sanctions to seek administrative review in writing of ASES’s determination and any such intermediate sanctions, pursuant to Act 72 or under any other applicable law or regulation. This time period can be extended for an additional fifteen (15) days if the Contractor submits a written request that includes a credible explanation of why it needs additional time, the request is received by ASES before the end of the initial period, and ASES has determined that the Contractor’s conduct does not pose a threat to an Enrollee’s health or safety.

129.
Section 19.4.5 shall be amended and replaced in its entirety as follows:

19.4.5
In addition to the actions described under Section 19.4.3, the examining officer may recommend the delivery and implementation of a Corrective Action Plan with respect to Contractor’s failure to comply with the terms of this Contract as set forth in ASES’ notice of intermediate sanctions.
 
38

130.
Section 19.5 shall be amended and replaced in its entirety as follows:

19.5
Judicial Review - To the extent administrative review is sought by the Contractor pursuant to Section 19.4, the Contractor has the right to seek judicial review of ASES’s actions by the Puerto Rico Court of Appeals, San Juan Panel, within thirty (30) Calendar Days of the notice of final determination issued by ASES.

131.
Section 22.1.2 shall be amended and replaced in its entirety as follows:

22.1.2
ASES will have the discretion to recoup payments made to the Contractor for ineligible Enrollees, including, but not limited to, the following:

22.1.2.1
Enrollees incorrectly enrolled with more than one Contractor;

22.1.2.2
Enrollees who die prior to the Enrollment month for which the payment was made;

22.1.2.3
Enrollees whom ASES later determines were not eligible for Medicaid during the Enrollment month for which payment was made.

22.1.2.4
Enrollees whom were not domiciled in Puerto Rico during the Enrollment month for which payment was made; or

22.1.2.5
Enrollees whom were incarcerated during the Enrollment month for which payment was made.

132.
Section 22.1.5 shall be amended and replaced in its entirety as follows:

22.1.5
The PMPM Payment for Enrollees not enrolled for the full month shall be determined on a pro rata basis by dividing the monthly Capitation amount by the number of days in the month and multiplying the result by the number of days including and following the Effective Date of Enrollment or the number of days prior to and including the Effective Date of Disenrollment, as applicable.  The Contractor is entitled to a PMPM Payment for each Enrollee as of the Effective Date of Enrollment, including the period referred to in Section 5.2.2.  The Contractor is entitled to a PMPM Payment for each Enrollee up to the Effective Date of Disenrollment, including the period referred to in Section 5.3.

133.
Section 22.1.17 shall be amended and replaced in its entirety as follows:

22.1.17
The profit of the Contractor and Subcontractors for each fiscal year of the Contract Term shall not exceed two point five percent (2.5 %) of the PMPM Payment (Excess Profit).  In the event that the profit exceeds this amount as a result of the positive impact the high quality services provided by the Contractor and Sub-Contractors had on the Enrollees Health, the Parties shall share the Excess Profit in proportions of fifty percent (50%) for the Contractor and Subcontractors, and fifty percent (50%) for ASES. For the purpose of this section high quality services will be measured on the Contractor’s compliance with eighty-five percent (85%) of the QIP quality metrics as established by ASES in Attachment 19. In the event ASES discovers the existence of Excess Profit by means of an audit during the Control and Supervision Plan or the Contractor does not meet the high quality services standard mentioned in this section, ASES is entitled to one hundred percent (100%) of the Excess Profit.
 
39

22.1.17.1
Excess Profit and any other incentive arrangements between ASES and the Contractor must comply the requirements set forth by CMS in 42 CFR 438.6(b)(2).

134.
Section 22.1.18 shall be amended and replaced in its entirety as follows:

22.1.18
The Contractor shall initially determine its Excess Profit for each fiscal year and shall submit a sworn certification annually to attest to the truth and accuracy of its Excess Profit and the assumptions on which it is calculated to ASES. After receipt of the Contractor’s sworn certification, ASES will audit the Contractor’s Excess Profit based on the Contractor’s sworn certification and the Contractor’s and Subcontractors’ audited financial statements submitted annually to ASES pursuant to Sections 23.1.3 and 18.2.9.8 of this Contract, and the validation of the IBNR reserve by ASES’s actuary.  The Excess Profit calculation will include the entire fiscal year (total aggregated earned premium for all Service Regions).  ASES will audit the Excess Profit certified by the Contractor using the actual medical expenses and the contracted administrative fee portion of the PMPM. ASES shall notify the Contractor of ASES’s determination of the Contractor’s Excess Profit within forty-five (45) Calendar Days of receipt by ASES of the Contractor’s audited financial statement.  The Contractor shall remit the portion of Excess Profit payable to ASES within fifteen (15) Calendar Days of receiving the notice of Excess Profit determination from ASES.  The same regulations shall apply to any and all Subcontractors.

135.
Immediately following Section 22.1.18, a new Section 22.1.19 shall be inserted stating as follows, and the remaining Section 22.1 shall be renumbered accordingly, including any references thereto:

22.1.19
The Contractor shall include in its calculation of Excess Profit, as reported under this Section 22.1, all of the profit of its partially- or wholly-owned subsidiaries or Affiliates realized from services rendered in relation to this contract (the “Affiliated Profit”), unless the Contractor demonstrates and ASES agrees that the Affiliated Profit did not result from preferential contractual terms included in the Contractor’s contracts or arrangements with its partially- or wholly-owned subsidiaries and Affiliates.
 
40

22.1.19.1
Preferential contractual terms are those that result in a cost or expense that exceeds fair market value, or those that exceed any other terms for the provisioning of same or similar goods and services as would be agreed to by a reasonable person under the same or similar circumstances prevailing at the time the decision was made for that same or similar good or service.  In determining whether preferential contract terms exist, consideration must be given to factors including “sound business practices,” “arm’slength bargaining” and “market prices for comparable goods and services for the geographical area.”  Contractual terms shall also be deemed preferential if the Contractor’s partially- or wholly-owned subsidiaries or Affiliates charge the Contractor a higher price for the same or similar goods or services than the lowest price charged by the Contractor’s partially- or wholly-owned subsidiaries or Affiliates to any and all other clients.

22.1.19.2
Notwithstanding the above, if a Contractor’s subsidiary or Affiliate charges the Contractor for goods or services provided under or associated with the GHP program, and such charges exceed 60% of the total revenue of the subsidiary or Affiliate, such charges must be at cost.  If such charges are not at cost, any excess amounts above cost must be included in the calculation of the Contractor’s Excess Profit.

22.1.19.3
Contractor shall report to ASES’s Office of Finance all related-party transactions within thirty (30) Calendar Days and provide a copy of the contract for each transaction detailing the amounts paid or to be paid, charged or transferred and goods or services to be provided under the contract.  A certification under penalty from criminal perjury from the Contractor’s President, Vice-President, Chief Financial Officer, or Treasurer specifying what are the “at cost” and/or “fair market value” amounts of the contract, as applicable, shall be included with each submission.

136.
Original Section 22.1.18, renumbered by this Amendment as 22.1.20, shall be amended and replaced in its entirety as follows:

22.1.20
To comply with 42 CFR 438.608(d) and 433.312, the Contractor shall, consistent with the procedures set forth in Attachment 23, refund (i) the share  of the Overpayment due to ASES within eleven (11) months of the discovery and (ii) the share of an Overpayment due to ASES within fifteen (15) Calendar Days from a final judgment on a Fraud, Waste,   or Abuse Action.  The Contractor must also require and have a mechanism for a Provider to report to the Contractor when it has received an Overpayment, to return that Overpayment to the Contractor with a written reason for the Overpayment within sixty (60) Calendar Days after the date on which the Overpayment was identified.  The Contractor shall report annually to ASES on their recoveries of all Overpayments.
 
41

137.
Immediately following Section 22.1, a new Section 22.2 shall be inserted stating as follows, and the remaining Article 22 shall be renumbered accordingly, including any references thereto:

22.2
Medical Loss Ratio

22.2.1
The Contractor shall report a Medical Loss Ratio and related data, including the data on the basis of which ASES will determine the compliance of the Contractor with the Medical Loss Ratio Requirement, as required under 42 CFR 438.8(k) for each rating period.  Such reporting shall be provided to ASES no later than March 31 st of the following year.

22.2.2
The Contractor shall calculate its Medical Loss Ratio and related data based on the methodology set forth in 42 CFR 438.8 and any other instructions issued by CMS or ASES.  Effective July 1, 2017, the Contractor is expected to achieve a target medical loss ratio standard, as calculated under 42 CFR 438.8, of at least ninety-one percent (91%) for the contract year.

22.2.3
The calculation of administrative expenses for the purposes of determining the Medical Loss Ratio in accordance with 42 CFR 438.8 shall not be affected by the methodology used to calculate Excess Profit as set forth in Sections 22.1.18 and 22.1.19.

138.
Original Section 22.3.1, renumbered by this Amendment as 22.4.1, shall be amended and replaced in its entirety as follows:

22.4.1
ASES shall maintain a Retention Fund of the PMPM Payment each month as part of the Quality Incentive Program described in Section 12.5 according to the following table:

Retention Fund Percentage (RFP) Breakdown
 
Baseline FY 2016
 
Time Period (Incurred service
from Contract Term)
Retention Fund
Percentage
Performance
Measures
Preventive Clinical
Programs
Emergency Room
Use Indicators
7/1/2017 through 9/30/2017
2% of PMPM
40% of RFP
30% of RFP
30% of RFP
10/31/2017 through 12/31/2017
2% of PMPM
40% of RFP
30% of RFP
30% of RFP
1/31/2018 through 3/30/2018
2% of PMPM
40% of RFP
30% of RFP
30% of RFP
4/30/2018 through 6/30/2018
2% of PMPM
40% of RFP
30% of RFP
30% of RFP
 
42

139.
Original Section 22.3.2.1, renumbered by this Amendment as 22.4.2.1, shall be amended and replaced in its entirety as follows:

22.4.2.1
The Contractor shall submit a quarterly report no later than ninety (90) Calendar Days after the end of each quarter regarding each of the performance indicators to be evaluated, as determined by ASES (from those listed in Section 12.5);

140.
Immediately following Original Section 22.3.2.3, renumbered by this Amendment as 22.4.2.3, a new Section 22.4.3 shall be inserted stating as follows:

22.4.3
The Quality Incentive Program and any other withhold incentive arrangements between ASES and the Contractor must comply the requirements set forth by CMS in 42 CFR 438.6(b)(3).

141.
Section 23.1.4 shall be amended and replaced in its entirety as follows:

23.1.4
The Contractor shall provide to ASES a copy of its Annual Report required to be filed with the Puerto Rico Office of the Insurance Commissioner (OIC Report), as applicable, in the format agreed upon by the National Association of Insurance Commissioners (NAIC), for the year ended on December 31, 2014, and subsequently thereafter, during the Contract Term and any renewals, not later than March 31 of each year. The Contractor shall submit to ASES a reconciliation of the OIC Report with its annual audited financial statements filed pursuant to Section 23.1.3 and Section 18.2.9.8.

142.
Section 23.2.3 shall be amended and replaced in its entirety as follows:

23.2.3
The Contractor shall provide assurances to ASES that its provision against the risk of insolvency is adequate, in compliance with the Federal standards set forth in 42 CFR 438.116, and shall submit data on the basis of which ASES will determine that the Contractor has made adequate provision against the risk of insolvency.  In particular, the Contractor shall, according to the timeframe specified in Attachment 12 to this Contract, furnish documentation, certified by a Certified Public Accountant, of:

23.2.3.1
The relationship between PMPM Payments and capital, with the optimal relationship being 10:1, in order to prove capacity to assume risk;

23.2.3.2
A debt level of less than seventy-five percent (75%).and
 
43

23.2.3.3
Relationship of current assets to total liabilities shall be, at least, 80%.
 
143.
Section 23.3.3 shall be amended and replaced in its entirety as follows:

23.3.3
The Contractor shall establish a stop-loss limit amount that is in compliance with the limits specified in 42 CFR 422.208(f).  The limit shall be activated when the expense of providing Covered Services to an Enrollee, including all outpatient and inpatient expenses, reaches this sum.  The Contractor shall have mechanisms in place to identify the stop loss once it is reached for an Enrollee, and shall establish monthly reports to inform PMGs of Enrollees who have reached the stop-loss limit.  The Contractor shall assume all losses exceeding the limit.

144.
Section 23.6.1 shall be amended and replaced in its entirety as follows:

23.6.1
Any Physician Incentive Plans established by the Contractor shall comply with Federal and Puerto Rico regulations, including 42 CFR 422.208 and 422.210, and 42 CFR 438.3(i), and with the requirements in Section 10.7 of this Contract.

145.
Section 23.7.4.1 shall be amended and replaced in its entirety as follows:

23.7.4.1
Definition of A Party in Interest – As defined in Section 1318(b) of the Public Health Service Act, a party in interest is:

23.7.4.1.1
(i) Any director, officer, partner, or employee responsible for management or administration of the Contractor; (ii) any person or legal entity that is directly or indirectly the beneficial owner of more than five percent (5%) of the equity of the Contractor; (iii) any person or legal entity that is the beneficial owner of a mortgage, deed of trust, note, or other interest secured by, and valuing more than five percent (5%) of the Contractor; or, (iv) in the case of a Contractor organized as a nonprofit corporation, an incorporator or enrollee of such corporation under applicable Commonwealth corporation law;

23.7.4.1.2
Any organization in which a person or a legal entity described in Section 23.7.4.1.1 is director, officer or partner; has directly or indirectly a beneficial interest of more than five percent (5%) of the equity of the Contractor; or has a mortgage, deed of trust, note, or other interest valuing more than five percent (5%) of the assets of the Contractor;

23.7.4.1.3
Any person directly or indirectly controlling, controlled by, or under common control with the Contractor; or

23.7.4.1.4
Any spouse, child, or parent of an individual described in Sections 23.7.4.1.1-23.7.4.1.3.
 
44

146.
Section 23.7.4.4 shall be amended and replaced in its entirety as follows:
 
23.7.4.4
As per 42 CFR 455.105 the Contractor, within thirty-five (35) Calendar Days  of the date of request by the HHS Secretary, ASES or the Commonwealth Medicaid agency, and on an annual basis to ASES and the Commonwealth Medicaid agency, shall report full and complete information about:

23.7.4.4.1
The ownership of any subcontractor with whom the provider has had business transactions totaling more than $25,000 during the 12-month period ending on the day of the request; and

23.7.4.4.2
Any significant business transactions between the provider and any wholly owned supplier, or between the provider and any subcontractor, during the five (5)-year period ending on the date of the request.

147.
Immediately following Section 23.7.4.4.2, a new Section 23.7.4.5 shall be inserted stating as follows:

23.7.4.5
Disclosures of Information on Annual Business Transactions or other reports of transactions between the Contractor and parties in interest provided to ASES or other agencies must be made available to Enrollees upon reasonable request.

148.
Section 29.1 shall be amended and replaced in its entirety as follows:

29.1
ASES is prohibited by law from entering into contracts with any person or entity that has been, or whose affiliated subsidiary companies, or any of its shareholders, partners, officers, principals, managing employees, subsidiaries, parent companies, officers, directors, board members, or ruling bodies have been, under investigation for, accused of, convicted of, or sentenced to imprisonment, in Puerto Rico, the other USA jurisdictions, or any other jurisdiction, for any crime involving corruption, fraud, embezzlement, or unlawful appropriation of public funds, pursuant to Act 458, as amended, and Act 84 of 2002 .

149.
Section 30.1.4 shall be amended and replaced in its entirety as follows:

30.1.4
All contracts between the Contractor and Subcontractors must be in writing, must comply with all applicable Medicaid laws and regulations, including subregulatory guidance and provisions set forth in this Agreement, as applicable, and must specify the activities and responsibilities delegated to the Subcontractor containing terms and conditions consistent with this Contract.  The contracts must also include provisions for revoking delegation or imposing other sanctions if the Subcontractor’s performance is inadequate. The Contractor and the Subcontractors must also make reference to a business associates agreement between the Parties.
 
45

150.
Section 30.1.8 shall be amended and replaced in its entirety as follows:
 
30.1.8
ASES shall have the right to review all financial or business transactions between the Contractor and a Subcontractor at any time upon request.  ASES, CMS, or Office of Inspector General may inspect, evaluate and audit the Subcontractor at any time if ASES, CMS or Office of Inspector General determines there is a reasonable possibility of fraud or similar risk.  ASES shall also retain the right to review all criminal background checks for all employees of the Subcontractor, as referenced in Article 29, as well as any past exclusions from Federal programs.

151.
Immediately following Section 30.1.11, a new Section 30.1.12 shall be inserted stating as follows, and the remaining Article 30.1 shall be renumbered accordingly, including any references thereto:

30.1.12
Pursuant to the requirements of 42 CFR 438.230(c)(3)(i) and 42 CFR 438.3(k), ASES, CMS, the Office of Inspector General, the Comptroller General, and their respective designees shall have the right at any time to inspect, evaluate, and audit any books, records, contractors, computer or other electronic systems of the Subcontractor, or of the Subcontractor’s contractor, that pertain to any aspect of services and activities performed or determination of amounts payable under this Agreement.

152.
Original Section 30.1.12, renumbered by this Amendment as 30.1.13, shall be amended and replaced in its entirety as follows:

30.1.13
All Subcontractors must fulfill the requirements of 42 CFR 438.3, 438.6 and 438.230 as appropriate. Subcontractors shall also retain, as applicable, enrollee grievance and appeal records as per 42 CFR 438.416, base data for setting actuarially sound capitation rates as per 42 CFR 438.5(c), Medical Loss Ratio reports as per 42 CFR 438.8(k), and the data, information and documentation specified in 42 CFR 438.604, 438.606, 438.608, and 610 for a period of no less than ten (10) years, as set forth in Section 33.1.1.

153.
Original Section 30.1.12 shall be deleted in its entirety, including any references thereto.

154.
Section 30.2.1 shall be amended and replaced in its entirety as follows:

30.2.1
The Contractor shall submit to ASES, and shall require any Subcontractors hereunder to submit to ASES, cost or pricing Data for any subcontract to this Contract prior to award.  The Contractor shall also certify that the information submitted by the Subcontractor is, to the best of the Contractor’s knowledge and belief, accurate, complete and current as of the date of agreement, or the date of the negotiated price of the Subcontract or amendment to the Contract.  The Contractor shall insert the substance of this Section in each Subcontract hereunder.
 
46

155.
Section 33.1.1 shall be amended and replaced in its entirety as follows:

33.1.1
The Contractor and its Subcontractors, if any, shall preserve and make available all of its records pertaining to the performance under this Contract for inspection or audit, as provided below, throughout the Contract Term, for a period of ten (10) years from the date of final payment under this Contract, and for such period, if any, as is required by applicable statute or by any other section of this Contract.  If the Contract is completely or partially terminated, the records relating to the work terminated shall be preserved and made available for period of  ten (10) years from the Termination Date of the Contract or of any resulting final settlement.  The Contractor is responsible to preserve all records pertaining to its performance under this Contract, and to have them available and accessible in a timely manner, and in a reasonable format that assures their integrity. Records that relate to Appeals, litigation, or the settlements of Claims arising out of the performance of this Contract, or costs and expenses of any such agreements as to which exception has been taken by the  Contractor or any of its duly Authorized Representatives, shall be retained by Contractor until such Appeals, litigation, Claims or exceptions have been disposed of.

156.
Section 33.2.3 shall be amended and replaced in its entirety as follows:

33.2.3
Pursuant to the requirements of 42 CFR 434.6(a)(5) and 42 CFR 434.38, ASES, CMS, the Office of Inspector General, the Comptroller General, and their respective designees shall have the right at any time to inspect, evaluate, and audit any pertinent records or documents of the Contractor and Subcontractors, and may inspect the premises, physical facilities, equipment, computers or other electronic systems where activities or work related to the GHP program is conducted.  The right to audit exists for ten (10) years from the final date of the contract period or from the date of completion of any audit, whichever is later.  Any records requested hereunder shall be produced Immediately for on-site review or sent to the requesting authority by mail within fourteen (14) Calendar Days following a request.  All records shall be provided at the sole cost and expense of the Contractor.  ASES shall have unlimited rights to use, disclose, and duplicate all Information and Data in any way relating to this Contract in accordance with applicable Puerto Rico and Federal laws and regulations.
 
47


157.
Immediately following Section 38.2.2, a new Section 38.2.3 shall be inserted stating as follows, and the remaining Article 38 shall be renumbered accordingly, including any references thereto:

38.2.3
At the request of either party, ASES will evaluate any enacted Federal, state or local legislative or regulatory changes with applicability to the GHIP program that materially impact the PMPM Payment.  If after a process of actuarial evaluation, using credible data, ASES determines that the enacted legislative and/or regulatory changes materially impact the PMPM Payment, ASES will adjust the PMPM rates for Metro North and West Service Regions to reflect the above-referenced changes after the adjusted rates are approved by CMS.  Any revisions to the PMPM Payments under this Section would be applicable only from January 1, 2018 until June 30, 2018, or from the effective date of any new law or regulation, whichever is later.  “Materially impact” shall mean that a recalculation of current PMPM Payments is required in order to remain actuarially sound.

158.
Section 40.1 shall be amended and replaced in its entirety as follows:

40.1
This Contract shall be governed in all respects by the laws of Puerto Rico.  Any lawsuit or other action brought against ASES or the Commonwealth based upon or arising from this Contract shall be brought in a court of competent jurisdiction in Puerto Rico.

159.
Section 54.1 shall be amended and replaced in its entirety as follows:

54.1
The Contractor and Subcontractors shall disclose, and ASES shall review, financial statements for each person or corporation with an ownership or control interest of five percent (5%) or more of its entity.  For the purposes of this Section, a person or corporation with an ownership or control interest shall mean a person or corporation:

54.1.1
That owns directly or indirectly five percent (5%) or more of the Contractor’s/Subcontractor’s capital or stock or received five percent (5%) or more of its profits;

54.1.2
That has an interest in any mortgage, deed of trust, note, or other obligation secured in whole or in part by the Contractor/Subcontractor or by its property or assets, and that interest is equal to or exceeds five percent (5%) of the total property and assets of the Contractor/Subcontractor; and

54.1.3
That is an officer or director of the Contractor/Subcontractor (if it is organized as a corporation) or is a partner in the Contractor’s/ Subcontractor’s organization (if it is organized as a partnership).
 
48

160.
Section 55.2 shall be amended and replaced in its entirety as follows:

55.2
ASES reserves the authority to seek an amendment to this Contract at any time if such an amendment is necessary in order for the terms of this Contract to comply with Federal law, the laws of Puerto Rico or the Government of Puerto Rico Fiscal Plan as certified by the Financial Oversight and Management Board for Puerto Rico pursuant to the Puerto Rico Oversight, Management and Economic Stability Act of 2016. The Contractor shall consent to any such amendment.

161.
The following amended attachments, copies of which are included, are substituted in this Agreement as follows:

a.
ATTACHMENT 5:  FORMULARY OF MEDICATIONS COVERED AND LIST OF MEDICATIONS BY EXCEPTION

b.
ATTACHMENT 8:  COST-SHARING

c.
ATTACHMENT 9:  ENROLLMENT MANUAL

d.
ATTACHMENT 11:  PER MEMBER PER MONTH PAYMENTS

e.
ATTACHMENT 19:  QUALITY INCENTIVE PROGRAM MANUAL

IV.
RATIFICATION

All other terms and provisions of the original Contract, as amended by Contracts Number 2015000087A, 2015-000087B, 2015-000087C, 2015-000087D, 2015-000087E, 2015-000087F, 2015000087G, and of any and all documents incorporated by reference therein, not specifically deleted or modified herein shall remain in full force and effect.  The parties hereby affirm their respective undertakings and representations as set forth therein, as of the date thereof. Capitalized terms used in this Amendment, if any, shall have the same meaning assigned to such terms in the Contract.

V.
EFFECT;CMS APPROVAL

The Parties acknowledge that this Amendment is subject to approval by the United States Department of Health and Human Services Centers for Medicare and Medicaid Services (“CMS”), and ASES shall submit the Amendment for CMS approval.  Pending CMS approval, this Amendment shall serve as a binding letter of agreement between the Parties.

VI.
AMENDMENT EFFECTIVE DATE

Unless a provision contained in this Amendment specifically indicates a different effective date, for purposes of the provisions contained herein, this Amendment shall become effective retroactively July 1, 2017 and end on June 30 th , 2018.
 
49

VII.
ENTIRE AGREEMENT

This Amendment constitutes the entire understanding and agreement of the parties with regards to the subject matter hereof, and the parties by their execution and delivery of this Seventh Amendment to the Contract hereby ratify all of the terms and conditions of the Contract, as amended by Contracts Number 2015-000087A, 2015-000087B, 2015-000087C, 2015-000087D, 2015-000087E, 2015-000087F, 2015-000087G, and as supplemented by this Agreement.

 The Parties agree that ASES will be responsible for the submission and registration of this Amendments in the Office of the Comptroller General of the Commonwealth, as required under law and applicable regulations.

IN WITNESS WHEREOF , the parties hereto execute this Amendment to the Contract by their duly authorized representatives as of the dates set out below and set their signatures.
 
ADMINISTRACIÓN DE SEGUROS DE SALUD DE PUERTO RICO (ASES)

 /s/ Angela M. Avila Marrero
     
 
12/26/2017
 
Ms. Angela M. Avila Marrero, Executive Director
 
Date
 
EIN: 66-0500678
     
       
       
TRIPLE-S SALUD, INC.
     
     
 /s/ Madeline Hernandez Urquiza
     
 
12/26/2017
 
Ms. Madeline Hernandez Urquiza, President
 
 Date
 
EIN : 66-0555677
 
Account No.: 252-000-5010-5035
 
50

ATTACHMENT 5:  FORMULARY OF MEDICATIONS COVERED AND LIST OF MEDICATIONS BY EXCEPTION
 

PLAN DE SALUD DEL GOBIERNO
Lista de Medicamentos por Excepción (LME)
 
2017
 
Therapeutic Category [Categoría Terapéutica]
Therapeutic
Class [Clase Terapéutica]
Drug
Description
[Descripción de
la Droga]
Preautorization
[Preautorización]
Y=Yes
ADHD/ANTI-NARCOLEPSY/ANTIOBESITY/ANOREXIANTS
Stimulants - Misc.
Modafinil Oral Tablet 100 MG
Y
ADHD/ANTI-NARCOLEPSY/ANTIOBESITY/ANOREXIANTS
Stimulants - Misc.
Modafinil Oral Tablet 200 MG
Y
ADHD/ANTI-NARCOLEPSY/ANTIOBESITY/ANOREXIANTS
Stimulants - Misc.
Provigil Oral Tablet 100 MG
Y
ADHD/ANTI-NARCOLEPSY/ANTIOBESITY/ANOREXIANTS
Stimulants - Misc.
Provigil Oral Tablet 200 MG
Y
ANALGESICS - ANTIINFLAMMATORY
Interleukin-1 Receptor Antagonist (IL-1Ra)
Kineret Subcutaneous Solution Prefilled Syringe 100 MG/0.67ML
Y
ANTHELMINTICS
ANTHELMINTICS
Albenza Oral Tablet 200 MG
Y
ANTHELMINTICS
ANTHELMINTICS
Ivermectin Oral Tablet 3 MG
Y
ANTHELMINTICS
ANTHELMINTICS
Stromectol Oral Tablet 3 MG
Y
ANTIDOTES AND SPECIFIC ANTAGONISTS
Antidotes - Chelating Agents
Exjade Oral Tablet Soluble 125 MG
Y
ANTIDOTES AND SPECIFIC ANTAGONISTS
Antidotes -
Chelating Agents
Exjade Oral Tablet Soluble 250 MG
Y
 

ANTIDOTES AND SPECIFIC ANTAGONISTS
Antidotes - Chelating Agents
Exjade Oral Tablet Soluble 500 MG
Y
ANTIDOTES AND SPECIFIC ANTAGONISTS
Antidotes - Chelating Agents
Jadenu Oral Tablet 90 MG
Y
ANTIDOTES AND SPECIFIC ANTAGONISTS
Antidotes - Chelating Agents
Jadenu Oral Tablet 180 MG
Y
ANTIDOTES AND SPECIFIC ANTAGONISTS
Antidotes - Chelating Agents
Jadenu Oral Tablet 360 MG
Y
ANTIEMETICS
Substance P/Neurokinin 1 (NK1) Receptor Antagonists
Aprepitant Oral Capsule 80 MG
Y

Therapeutic Category [Categoría Terapéutica]
Therapeutic Class
[Clase Terapéutica]
Drug Description
[Descripción de la
Droga]
Preautorization
[Preautorización]
Y=Yes
ANTIEMETICS
Substance P/Neurokinin 1 (NK1) Receptor Antagonists
Aprepitant Oral Capsule 125 MG
Y
ANTIEMETICS
Substance P/Neurokinin 1 (NK1) Receptor Antagonists
Emend Oral Capsule 80 MG
Y
ANTIEMETICS
Substance P/Neurokinin 1 (NK1) Receptor Antagonists
Emend Oral Capsule 125 MG
Y
ANTIEMETICS
Substance P/Neurokinin 1 (NK1) Receptor Antagonists
Aprepitant Oral Capsule 40 MG
Y
ANTIEMETICS
Substance P/Neurokinin 1 (NK1) Receptor Antagonists
Emend Oral Capsule 40 MG
Y
 

ANTIEMETICS
Substance P/Neurokinin 1 (NK1) Receptor Antagonists
Emend Oral Capsule 80 & 125 MG
Y
ANTIEMETICS
Substance P/Neurokinin 1 (NK1) Receptor Antagonists
Emend Oral Suspension Reconstituted 125 MG
Y
ANTIEMETICS
Substance P/Neurokinin 1 (NK1) Receptor Antagonists
Aprepitant Oral Capsule 80 & 125 MG
Y
ANTI-INFECTIVE AGENTS - MISC.
Antiprotozoal Agents
Mepron Oral Suspension 750 MG/5ML
Y
ANTI-INFECTIVE AGENTS - MISC.
Antiprotozoal Agents
Atovaquone Oral Suspension 750 MG/5ML
Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES
Alkylating Agents
Cyclophosphamide Oral Capsule 25 MG
Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES
Alkylating Agents
Cyclophosphamide Oral Capsule 50 MG
Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES
Antineoplastic Antibiotics
Novantrone Intravenous Concentrate 20 MG/10ML
Y

Therapeutic Category
[Categoría Terapéutica]
Therapeutic Class
[Clase Terapéutica]
Drug Description
[Descripción de la
Droga]
Preautorization
[Preautorización]
Y=Yes
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES
Antineoplastic Antibiotics
Mitoxantrone HCl Intravenous Concentrate 25 MG/12.5ML
Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES
Antineoplastic Antibiotics
Mitoxantrone HCl Intravenous Concentrate 20 MG/10ML
Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES
Antineoplastic Antibiotics
Mitoxantrone HCl Intravenous Concentrate 30 MG/15ML
Y
 

ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES
Antimetabolites
Tabloid Oral Tablet 40 MG
Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES
Antineoplastic - Antibodies
Rituxan Intravenous Solution 100 MG/10ML
Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES
Antineoplastic - Antibodies
Rituxan Intravenous Solution 500 MG/50ML
Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES
Antineoplastic - Hedgehog Pathway Inhibitors
Erivedge Oral Capsule 150 MG
Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES
Antineoplastic - Hormonal and Related Agents
Xtandi Oral Capsule 40 MG
Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES
Antineoplastic - Hormonal and Related Agents
Lysodren Oral Tablet 500 MG
Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES
Antineoplastic - Hormonal and Related Agents
Fareston Oral Tablet 60 MG
Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES
Antineoplastic Enzyme Inhibitors
Sutent Oral Capsule 37.5 MG
Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES
Antineoplastic Enzyme Inhibitors
Votrient Oral Tablet 200 MG
Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES
Antineoplastic Enzyme Inhibitors
Tykerb Oral Tablet 250 MG
Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES
Antineoplastic Enzyme Inhibitors
Sutent Oral Capsule 12.5 MG
Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES
Antineoplastic Enzyme Inhibitors
Sutent Oral Capsule 50 MG
Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES
Antineoplastic Enzyme Inhibitors
Sutent Oral Capsule 25 MG
Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES
Antineoplastic Enzyme Inhibitors
Tarceva Oral Tablet 25 MG
Y
 


Therapeutic Category
[Categoría Terapéutica]
Therapeutic Class
[Clase Terapéutica]
Drug Description
[Descripción de la
Droga]
Preautorization
[Preautorización]
Y=Yes
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES
Antineoplastic Enzyme Inhibitors
Tarceva Oral Tablet 100 MG
Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES
Antineoplastic Enzyme Inhibitors
Tarceva Oral Tablet 150 MG
Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES
Antineoplastic Enzyme Inhibitors
Bosulif Oral Tablet 500 MG
Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES
Antineoplastic Enzyme Inhibitors
Bosulif Oral Tablet 100 MG
Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES
Antineoplastic Enzyme Inhibitors
Afinitor Disperz Oral Tablet Soluble 2 MG
Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES
Antineoplastic Enzyme Inhibitors
Afinitor Disperz Oral Tablet Soluble 3 MG
Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES
Antineoplastic Enzyme Inhibitors
Afinitor Disperz Oral Tablet Soluble 5 MG
Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES
Antineoplastic Enzyme Inhibitors
Tafinlar Oral Capsule 50 MG
Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES
Antineoplastic Enzyme Inhibitors
Tafinlar Oral Capsule 75 MG
Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES
Antineoplastic Enzyme Inhibitors
Mekinist Oral Tablet 0.5 MG
Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES
Antineoplastic Enzyme Inhibitors
Mekinist Oral Tablet 2 MG
Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES
Antineoplastic Enzyme Inhibitors
Imbruvica Oral Capsule 140 MG
Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES
Antineoplastic Enzyme Inhibitors
Zelboraf Oral Tablet 240 MG
Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES
Antineoplastic Enzyme Inhibitors
Ibrance Oral Capsule 75 MG
Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES
Antineoplastic Enzyme Inhibitors
Ibrance Oral Capsule 100 MG
Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES
Antineoplastic Enzyme Inhibitors
Ibrance Oral Capsule 125 MG
Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES
Antineoplastic Enzyme Inhibitors
Cotellic Oral Tablet 20 MG
Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES
Antineoplastic Enzyme Inhibitors
Ninlaro Oral Capsule 2.3 MG
Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES
Antineoplastic Enzyme Inhibitors
Ninlaro Oral Capsule 3 MG
Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES
Antineoplastic Enzyme Inhibitors
Ninlaro Oral Capsule 4 MG
Y
 


Therapeutic Category
[Categoría Terapéutica]
Therapeutic Class
[Clase Terapéutica]
Drug Description
[Descripción de la
Droga]
Preautorization
[Preautorización]
Y=Yes
ANTIPSYCHOTICS/ANTIMANIC AGENTS
Benzisoxazoles
Risperdal Consta Intramuscular Suspension Reconstituted 12.5 MG
Y
ANTIPSYCHOTICS/ANTIMANIC AGENTS
Benzisoxazoles
Risperdal Consta Intramuscular Suspension Reconstituted 37.5 MG
Y
ANTIPSYCHOTICS/ANTIMANIC AGENTS
Benzisoxazoles
Risperdal Consta Intramuscular Suspension Reconstituted 50 MG
Y
ANTIPSYCHOTICS/ANTIMANIC AGENTS
Benzisoxazoles
Risperdal Consta Intramuscular Suspension Reconstituted 25 MG
Y
ANTIPSYCHOTICS/ANTIMANIC AGENTS
Dibenzapines
Quetiapine Fumarate ER Oral Tablet Extended Release 24 Hour 200 MG
Y
ANTIPSYCHOTICS/ANTIMANIC AGENTS
Dibenzapines
Quetiapine Fumarate ER Oral Tablet Extended Release 24 Hour 300 MG
Y
ANTIPSYCHOTICS/ANTIMANIC AGENTS
Dibenzapines
Quetiapine Fumarate ER Oral Tablet Extended Release 24 Hour 400 MG
Y
 

ANTIPSYCHOTICS/ANTIMANIC AGENTS
Dibenzapines
Quetiapine Fumarate ER Oral Tablet Extended Release 24 Hour 50 MG
Y
ANTIPSYCHOTICS/ANTIMANIC AGENTS
Dibenzapines
Quetiapine Fumarate ER Oral Tablet Extended Release 24 Hour 150 MG
Y
ANTIPSYCHOTICS/ANTIMANIC AGENTS
Dibenzapines
Clozaril Oral Tablet 100 MG
Y
ANTIPSYCHOTICS/ANTIMANIC AGENTS
Dibenzapines
Clozaril Oral Tablet 25 MG
Y
ANTIPSYCHOTICS/ANTIMANIC AGENTS
Dibenzapines
Clozapine Oral Tablet 100 MG
Y
ANTIPSYCHOTICS/ANTIMANIC AGENTS
Dibenzapines
Clozapine Oral Tablet 25 MG
Y
ANTIVIRALS
Hepatitis Agents
Hepsera Oral Tablet 10 MG
Y
ANTIVIRALS
Hepatitis Agents
Adefovir Dipivoxil Oral Tablet 10 MG
Y
ANTIVIRALS
Hepatitis Agents
Entecavir Oral Tablet 0.5 MG
Y
 

Therapeutic Category
[Categoría Terapéutica]
Therapeutic Class
[Clase Terapéutica]
Drug Description
[Descripción de la
Droga]
Preautorization
[Preautorización]
Y=Yes
ANTIVIRALS
Hepatitis Agents
Entecavir Oral Tablet 1 MG
Y
ANTIVIRALS
Hepatitis Agents
Baraclude Oral Tablet 0.5 MG
Y
ANTIVIRALS
Hepatitis Agents
Baraclude Oral Tablet 1 MG
Y
CORTICOSTEROIDS
Glucocorticosteroid s
Entocort EC Oral Capsule Delayed Release Particles 3 MG
Y
CORTICOSTEROIDS
Glucocorticosteroid s
Budesonide Oral Capsule Delayed Release Particles 3 MG
Y
DERMATOLOGICALS
Antipsoriatics
Tazorac External Gel 0.05 %
Y
DERMATOLOGICALS
Antipsoriatics
Tazorac External Gel 0.1 %
Y
DERMATOLOGICALS
Antipsoriatics
Tazorac External Cream 0.05 %
Y
DERMATOLOGICALS
Antipsoriatics
Tazorac External Cream 0.1 %
Y
ENDOCRINE AND METABOLIC AGENTS - MISC.
Bone Density Regulators
Forteo Subcutaneous Solution 600 MCG/2.4ML
Y
ENDOCRINE AND METABOLIC AGENTS - MISC.
Bone Density Regulators
Reclast Intravenous Solution 5 MG/100ML
Y
ENDOCRINE AND METABOLIC AGENTS - MISC.
Bone Density Regulators
Zoledronic Acid Intravenous Solution 5 MG/100ML
Y
ENDOCRINE AND METABOLIC AGENTS - MISC.
Bone Density Regulators
Pamidronate Disodium Intravenous Solution 30 MG/10ML
Y
ENDOCRINE AND METABOLIC AGENTS - MISC.
Bone Density Regulators
Pamidronate Disodium Intravenous Solution 90 MG/10ML
Y
ENDOCRINE AND METABOLIC AGENTS - MISC.
Bone Density Regulators
Pamidronate Disodium Intravenous Solution 6 MG/ML
Y
ENDOCRINE AND METABOLIC AGENTS - MISC.
Bone Density Regulators
Alendronate Sodium Oral Tablet 40 MG
Y
ENDOCRINE AND METABOLIC AGENTS - MISC.
Bone Density Regulators
Fosamax Oral Tablet 40 MG
Y
ENDOCRINE AND METABOLIC AGENTS - MISC.
Bone Density Regulators
Prolia Subcutaneous Solution 60 MG/ML
Y
 

Therapeutic Category
[Categoría Terapéutica]
Therapeutic Class
[Clase Terapéutica]
Drug Description
[Descripción de la
Droga]
Preautorization
[Preautorización]
Y=Yes
ENDOCRINE AND METABOLIC AGENTS - MISC.
Hormone Receptor Modulators
Raloxifene HCl Oral Tablet 60 MG
Y
ENDOCRINE AND METABOLIC AGENTS - MISC.
Hormone Receptor Modulators
Evista Oral Tablet 60 MG
Y
ENDOCRINE AND METABOLIC AGENTS - MISC.
Growth Hormone Receptor Antagonists
Somavert Subcutaneous Solution Reconstituted 10 MG
Y
ENDOCRINE AND METABOLIC AGENTS - MISC.
Growth Hormone Receptor Antagonists
Somavert Subcutaneous Solution Reconstituted 15 MG
Y
ENDOCRINE AND METABOLIC AGENTS - MISC.
Growth Hormone Receptor Antagonists
Somavert Subcutaneous Solution Reconstituted 20 MG
Y
ENDOCRINE AND METABOLIC AGENTS - MISC.
Growth Hormone Receptor Antagonists
Somavert Subcutaneous Solution Reconstituted 25 MG
Y
ENDOCRINE AND METABOLIC AGENTS - MISC.
Growth Hormone Receptor Antagonists
Somavert Subcutaneous Solution Reconstituted 30 MG
Y
HEMATOLOGICAL AGENTS - MISC.
Antihemophilic Products
Feiba NF Intravenous Solution Reconstituted
Y
HEMATOLOGICAL AGENTS - MISC.
Antihemophilic Products
Feiba VH Immuno Intravenous Solution Reconstituted
Y
HEMATOLOGICAL AGENTS - MISC.
Antihemophilic Products
Feiba Intravenous Solution Reconstituted
Y
HEMATOLOGICAL AGENTS - MISC.
Antihemophilic Products
Eloctate Intravenous Solution Reconstituted 250 UNIT
Y
 

HEMATOLOGICAL AGENTS - MISC.
Antihemophilic Products
Eloctate Intravenous Solution Reconstituted 500 UNIT
Y
HEMATOLOGICAL AGENTS - MISC.
Antihemophilic Products
Eloctate Intravenous Solution Reconstituted 750 UNIT
Y
HEMATOLOGICAL AGENTS - MISC.
Antihemophilic Products
Eloctate Intravenous Solution Reconstituted 1000 UNIT
Y
HEMATOLOGICAL AGENTS - MISC.
Antihemophilic Products
Eloctate Intravenous Solution Reconstituted 1500 UNIT
Y

Therapeutic Category
[Categoría Terapéutica]
Therapeutic Class
[Clase Terapéutica]
Drug Description
[Descripción de la Droga]
Preautorization
[Preautorización]
Y=Yes
HEMATOLOGICAL AGENTS - MISC.
Antihemophilic Products
Eloctate Intravenous Solution Reconstituted 2000 UNIT
Y
HEMATOLOGICAL AGENTS - MISC.
Antihemophilic Products
Eloctate Intravenous Solution Reconstituted 3000 UNIT
Y
HEMATOLOGICAL AGENTS - MISC.
Platelet Aggregation Inhibitors
Effient Oral Tablet 5 MG
Y
HEMATOLOGICAL AGENTS - MISC.
Platelet Aggregation Inhibitors
Effient Oral Tablet 10 MG
Y
MISCELLANEOUS THERAPEUTIC CLASSES
Immunosuppressive Agents
Zortress Oral Tablet 0.25 MG
Y
MISCELLANEOUS THERAPEUTIC CLASSES
Immunosuppressive Agents
Zortress Oral Tablet 0.75 MG
Y
MISCELLANEOUS THERAPEUTIC CLASSES
Immunosuppressive Agents
Zortress Oral Tablet 0.5 MG
Y
MISCELLANEOUS THERAPEUTIC CLASSES
Systemic Lupus Erythematosus Agents
Benlysta Intravenous Solution Reconstituted 120 MG
Y
 

MISCELLANEOUS THERAPEUTIC CLASSES
Systemic Lupus Erythematosus Agents
Benlysta Intravenous Solution Reconstituted 400 MG
Y
NEUROMUSCULAR AGENTS
Neuromuscular Blocking Agent - Neurotoxins
Botox Injection Solution Reconstituted 200 UNIT
Y
NEUROMUSCULAR AGENTS
Neuromuscular Blocking Agent - Neurotoxins
Botox Injection Solution Reconstituted 100 UNIT
Y
OPHTHALMIC AGENTS
Ophthalmic Steroids
Tobradex Ophthalmic Suspension 0.3-0.1 %
Y
OPHTHALMIC AGENTS
Ophthalmic Steroids
Tobramycin- Dexamethasone Ophthalmic Suspension 0.3-0.1 %
Y
OPHTHALMIC AGENTS
Prostaglandins - Ophthalmic
Travatan Z Ophthalmic Solution 0.004 %
Y
OPHTHALMIC AGENTS
Prostaglandins - Ophthalmic
Lumigan Ophthalmic Solution 0.01 %
Y
PASSIVE IMMUNIZING AND TREATMENT AGENTS
Immune Serums
Gammagard S/D Intravenous Solution Reconstituted 5 GM
Y

Therapeutic Category
[Categoría Terapéutica]
Therapeutic Class
[Clase Terapéutica]
Drug Description
[Descripción de la
Droga]
Preautorization
[Preautorización]
Y=Yes
PASSIVE IMMUNIZING AND TREATMENT AGENTS
Immune Serums
Gammagard S/D Intravenous Solution Reconstituted 10 GM
Y
PASSIVE IMMUNIZING AND TREATMENT AGENTS
Immune Serums
Gammagard S/D Less IgA Intravenous Solution Reconstituted 5 GM
Y
PASSIVE IMMUNIZING AND TREATMENT AGENTS
Immune Serums
Gammagard S/D Less IgA Intravenous Solution Reconstituted 10 GM
Y
PASSIVE IMMUNIZING AND TREATMENT AGENTS
Immune Serums
Gamunex-C Injection Solution 1 GM/10ML
Y
 

PASSIVE IMMUNIZING AND TREATMENT AGENTS
Immune Serums
Gamunex-C Injection Solution 2.5 GM/25ML
Y
PASSIVE IMMUNIZING AND TREATMENT AGENTS
Immune Serums
Gamunex-C Injection Solution 5 GM/50ML
Y
PASSIVE IMMUNIZING AND TREATMENT AGENTS
Immune Serums
Gamunex-C Injection Solution 20 GM/200ML
Y
PASSIVE IMMUNIZING AND TREATMENT AGENTS
Immune Serums
Gamunex-C Injection Solution 10 GM/100ML
Y
PASSIVE IMMUNIZING AND TREATMENT AGENTS
Immune Serums
Gammaked Injection Solution 1 GM/10ML
Y
PASSIVE IMMUNIZING AND TREATMENT AGENTS
Immune Serums
Gammaked Injection Solution 2.5 GM/25ML
Y
PASSIVE IMMUNIZING AND TREATMENT AGENTS
Immune Serums
Gammaked Injection Solution 5 GM/50ML
Y
PASSIVE IMMUNIZING AND TREATMENT AGENTS
Immune Serums
Gammaked Injection Solution 10 GM/100ML
Y
PASSIVE IMMUNIZING AND TREATMENT AGENTS
Immune Serums
Gammaked Injection Solution 20 GM/200ML
Y
PASSIVE IMMUNIZING AND TREATMENT AGENTS
Immune Serums
Gammagard Injection Solution 1 GM/10ML
Y
PASSIVE IMMUNIZING AND TREATMENT AGENTS
Immune Serums
Gammagard Injection Solution 2.5 GM/25ML
Y
PASSIVE IMMUNIZING AND TREATMENT AGENTS
Immune Serums
Gammagard Injection Solution 5 GM/50ML
Y
PASSIVE IMMUNIZING AND TREATMENT AGENTS
Immune Serums
Gammagard Injection Solution 10 GM/100ML
Y
PASSIVE IMMUNIZING AND TREATMENT AGENTS
Immune Serums
Gammagard Injection Solution 20 GM/200ML
Y
PASSIVE IMMUNIZING AND TREATMENT AGENTS
Immune Serums
Gammagard Injection Solution 30 GM/300ML
Y
 

Therapeutic Category
[Categoría Terapéutica]
Therapeutic Class
[Clase Terapéutica]
Drug Description
[Descripción de la
Droga]
Preautorization
[Preautorización]
Y=Yes
RESPIRATORY AGENTS - MISC.
Cystic Fibrosis Agents
Pulmozyme Inhalation Solution 1 MG/ML
Y
TETRACYCLINES
TETRACYCLINES
Tetracycline HCl Oral Capsule 250 MG
Y
TETRACYCLINES
TETRACYCLINES
Tetracycline HCl Oral Capsule 500 MG
Y
TETRACYCLINES
TETRACYCLINES
Demeclocycline HCl Oral Tablet 150 MG
Y
TETRACYCLINES
TETRACYCLINES
Demeclocycline HCl Oral Tablet 300 MG
Y
TETRACYCLINES
TETRACYCLINES
Declomycin Oral Tablet 300 MG
Y
VASOPRESSORS
Anaphylaxis Therapy Agents
Epinephrine Injection Solution Auto-injector 0.15 MG/0.3ML
Y
VASOPRESSORS
Anaphylaxis Therapy Agents
Epinephrine Injection Solution Auto-injector 0.15 MG/0.15ML
Y
VASOPRESSORS
Anaphylaxis Therapy Agents
Epinephrine Injection Solution Auto-injector 0.3 MG/0.3ML
Y
 

VIH-SIDA
 
Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/
Límites]
THERAPEUTIC CATEGORY [CATEGORÍA TERAPÉUTICA]
Therapeutic Class [Clase Terapéutica]
ANESTHETICS [ANEST   ÉSICOS]
Local Anesthetics [Anestésicos Locales]
lidocaine viscous 2 %   mouth/throat soln
1
Preferred
XYLOCAINE
 
ANTIBACTERIALS [ANTIBACTERIANOS]
Macrolides [Macrólidos]
azithromycin 250 mg tab,   500 mg tab
1
Preferred
ZITHROMAX
 
azithromycin 1 gm pckt, 100 mg/5ml susp, 200 mg/5ml susp, 600 mg tab
2
Preferred
ZITHROMAX
 
clarithromycin 125 mg/5ml susp, 250 mg tab, 500 mg tab
2
Preferred
BIAXIN
 
clarithromycin 250 mg/5ml susp
3
Preferred
BIAXIN
 
ERY-TAB 500 mg tab dr
3
Preferred
   
erythromycin base 250 mg cap dr prt, 250 mg tab, 500 mg tab
3
Preferred
ERY-TAB
 
erythromycin ethylsuccinate 400 mg tab
3
Preferred
E.E.S.
 
ERYTHROCIN STEARATE 250 mg tab
4
Non-Preferred
   
E.E.S. GRANULES 200 mg/5ml susp
5
Preferred
   
ERYPED 200 200 mg/5ml susp
5
Preferred
   
ERYPED 400 400 mg/5ml susp
6
Preferred
   
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización
Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 9 for monthly net cost range [Ver página 9 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado
Preferido]
 Página
 

VIH-SIDA

Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/
Límites]
Miscellaneous Antibacterials [Antibacterianos Misceláneos]
clindamycin hcl 150 mg cap,   300 mg cap, 75 mg cap
1
Preferred
CLEOCIN
 
Penicillins [Penicilinas]
amoxicillin 125 mg/5ml susp   , 200 mg/5ml susp, 250 mg cap, 250 mg/5ml susp, 400 mg/5ml susp, 500 mg cap, 500 mg tab, 875 mg tab
1
Preferred
AMOXIL
 
amoxicillin-pot clavulanate 200-28.5 mg/5ml susp, 40057 mg/5ml susp, 500-125 mg tab, 875-125 mg tab
1
Preferred
AUGMENTIN
 
ampicillin 125 mg/5ml susp, 250 mg cap, 250 mg/5ml susp, 500 mg cap
1
Preferred
PRINCIPEN
 
penicillin v potassium 125 mg/5ml soln, 250 mg tab, 250 mg/5ml soln, 500 mg tab
1
Preferred
VEETIDS
 
amoxicillin-pot clavulanate 250-125 mg tab, 250-62.5 mg/5ml susp
3
Preferred
AUGMENTIN
 
BICILLIN L-A 600000 unit/ml im susp
3
Non-Preferred
   
penicillin g procaine 600000 unit/ml im susp
3
Non-Preferred
BICILLIN LA
 
BICILLIN L-A 1200000 unit/2ml im susp
4
Non-Preferred
   
BICILLIN L-A 2400000 unit/4ml im susp
5
Non-Preferred
   
Quinolones [Quinolonas]
ciprofloxacin hcl 250 mg tab,   500 mg tab, 750 mg tab
1
Preferred
CIPRO
 
levofloxacin 250 mg tab, 500 mg tab, 750 mg tab
1
Preferred
LEVAQUIN
 
ciprofloxacin 500 mg/5ml (10%) susp
3
Preferred
CIPRO
 
 

VIH-SIDA
 
Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/
Límites]
ciprofloxacin 250 mg/5ml (5%) susp
4
Preferred
CIPRO
 
Sulfonamides [Sulfonamidas]
sulfamethoxazole   -tmp ds 800-160 mg tab
1
Preferred
SEPTRA
 
sulfamethoxazoletrimethoprim 200-40 mg/5ml susp, 400-80 mg tab
1
Preferred
SEPTRA
 
sulfadiazine 500 mg tab
4
Preferred
SULFADIAZINE
 
Tetracyclines [Tetraciclinas]
minocycline hcl   100 mg cap, 50 mg cap, 75 mg cap
1
Preferred
MINOCIN
 
doxycycline monohydrate 50  mg cap, 100 mg cap
2
 
Non-Preferred
MONODOX
 
ANTIMYCOBACTERIALS [ANTIMICOBACTERIANOS]
Antituberculars [Antituberculosos]
isoniazid 100 mg tab, 300   mg tab
1
Preferred
ISONIAZID
 
rifampin 150 mg cap
1
Preferred
RIFADIN
 
ethambutol hcl 100 mg tab
2
Non-Preferred
MYAMBUTOL
 
pyrazinamide 500 mg tab
2
Non-Preferred
PYRAZINAMIDE
 
rifampin 300 mg cap
2
Preferred
RIFADIN
 
ethambutol hcl 400 mg tab
3
Non-Preferred
MYAMBUTOL
 
isoniazid 50 mg/5ml syr
5
Non-Preferred
ISONIAZID
 
rifabutin 150 mg cap
   
MYCOBUTIN
Puerto Rico Health
Department
Tuberculosis
Control
Program
cycloserine 250 mg cap
   
SEROMYCIN
RIFAMATE 50-300 mg cap
     
TRECATOR 250 mg tab
     
CAPASTAT 1 gm inj
     
 

VIH-SIDA
 
Miscellaneous Antimycobacterials [Antimicobacterianos Misceláneos]
dapsone 100 mg tab, 25 mg   tab
2
Preferred
DAPSONE
 
ANTIMYCOTIC AGENTS [ANTIMICÓTICOS]
Antifungals [Antifungales]
fluconazole 10 mg/ml susp,   100 mg tab, 150 mg tab, 200 mg tab, 50 mg tab
1
Preferred
DIFLUCAN
 
 
Drug Name [Nombre
del Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/
Límites]
ketoconazole 200 mg tab
1
Preferred
NIZORAL
 
terbinafine hcl 250 mg tab
1
Preferred
LAMISIL
 
fluconazole 40 mg/ml susp
2
Preferred
DIFLUCAN
 
voriconazole 40 mg/ml susp
4
Preferred
VFEND
 
itraconazole 100 mg cap
5
Preferred
SPORANOX
 
SPORANOX 10 mg/ml soln
6
Preferred
   
voriconazole 50 mg tab
8
Preferred
VFEND
 
voriconazole 200 mg tab
10
Preferred
VFEND
 
ANTIPARASITICS [ANTIPARASITARIOS]
Anthelmintics [Antihelmínticos]
ALBENZA 200 mg tab
9
Preferred
   
Antimalarials [Antimaláricos]
DARAPRIM 25 mg tab
7
Non-Preferred
 
PA
Antiprotozoals - Non-Antimalarials [Antiprotozoarios No-Antimalaráricos]
NEBUPENT 300 mg inh soln
4
Preferred
   
atovaquone 750 mg/5ml susp
9
Non-Preferred
MEPRON
 
ANTIVIRALS [ANTIVIRALES]
Anti-Cytomegalovirus (CMV) Agents [Agentes Anti-Citomegalovirus]
valganciclovir hcl 450 mg   tab
13
Non-Preferred
VALCYTE
 
 

VIH-SIDA
 
Antiherpetic Agents [Agentes Antiherpéticos]
acyclovir 200 mg cap, 400   mg tab, 800 mg tab
1
Preferred
ZOVIRAX
 
acyclovir 200 mg/5ml susp
2
Preferred
ZOVIRAX
 
Non-Nucleoside Reverse Transcriptase Inhibitors [Inhibidores No Nucleósidos De La Transciptasa Reversa]
nevirapine 200 mg tab           
1
Preferred
VIRAMUNE
 
nevirapine 50 mg/5ml susp
5
Non-Preferred
VIRAMUNE
 
RESCRIPTOR 200 mg tab
6
Non-Preferred
   
SUSTIVA 200 mg cap
6
Preferred
 
P
nevirapine er 100 mg tab er 24 hr, 400 mg tab er 24 hr
7
Non-Preferred
VIRAMUNE XR
SUSTIVA 50 mg cap, 600 mg tab
7
Preferred
 
P
zidovudine 300 mg tab
2
Non-Preferred
RETROVIR
 

Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/
Límites]
Nucleoside/Nucleotide Reverse Transcriptase Inhibitors [Inhibidores Nucleósidos/Nucleótidos De La Transcriptasa Reversa]
stavudine 1 mg/ml soln, 15   mg cap, 20 mg cap, 30 mg cap, 40 mg cap
3
Preferred
ZERIT
 
didanosine 125 mg cap dr, 200 mg cap dr, 250 mg cap dr
4
Non-Preferred
VIDEX EC
 
lamivudine 10 mg/ml soln
4
Preferred
EPIVIR
 
lamivudine 150 mg tab
4
Preferred
EPIVIR
 
zidovudine 100 mg cap, 50 mg/5ml syr
4
Non-Preferred
RETROVIR
 
abacavir sulfate 300 mg tab
5
Non-Preferred
ZIAGEN
 
didanosine 400 mg cap dr
5
Non-Preferred
VIDEX EC
 
lamivudine 300 mg tab
5
Preferred
EPIVIR
 
VIDEX 2 gm soln
5
Non-Preferred
   
lamivudine 100 mg tab
6
Preferred
EPIVIR
PA
lamivudine-zidovudine 150300 mg tab
6
Preferred
COMBIVIR
 
ZIAGEN 20 mg/ml soln
6
Non-Preferred
   
abacavir-lamivudinezidovudine 300-150-300 mg tab
10
Non-Preferred
TRIZIVIR
 
 

VIH-SIDA
 
BLOOD MODIFIERS [MODIFICADORES DE LA SANGRE]
Erythropoiesis-Stimulating Agents [Agentes Estimulantes De Eritropoiesis]
ARANESP (ALBUMIN FREE) 100 mcg/0.5ml inj soln
1
Preferred
 
PA, P
PROCRIT 3000 unit/ml inj soln
5
Preferred
 
PA, P
ARANESP (ALBUMIN FREE) 25 mcg/0.42ml inj soln, 25 mcg/ml inj soln
6
Preferred
 
PA, P
PROCRIT 10000 unit/ml inj soln
6
Preferred
 
PA, P
ARANESP (ALBUMIN FREE) 40 mcg/0.4ml inj soln
7
Preferred
 
PA, P

Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/
Límites]
ARANESP (ALBUMIN FREE) 40 mcg/ml inj soln, 60 mcg/ml inj soln
8
Preferred
 
PA, P
ARANESP (ALBUMIN FREE) 150 mcg/0.3ml inj soln, 150 mcg/0.75ml inj soln, 200 mcg/0.4ml inj soln, 200 mcg/ml inj soln, 300 mcg/0.6ml inj soln, 300 mcg/ml inj soln, 500 mcg/ml inj soln, 60 mcg/0.3ml inj soln
9
Preferred
 
PA, P
ARANESP (ALBUMIN FREE) 100 mcg/ml inj soln
11
Preferred
 
PA, P
PROCRIT 40000 unit/ml inj soln
11
Preferred
 
PA, P
Iron [Hierro]
iron 325 (65 fe) mg tab
1
Preferred
IRON
 
 

VIH-SIDA
 
CHEMOTHERAPIES [QUIMIOTERAPIAS]
Antineoplastic Progestins [Antineoplásicos De Progestina]
megestrol acetate 20 mg   tab, 40 mg tab
1
Preferred
MEGACE
 
megestrol acetate 40 mg/ml susp, 400 mg/10ml susp
2
Preferred
MEGACE
 
Folic Acid Antagonists Rescue Agents [Antagonistas De Ácido Fólico]
leucovorin calcium 5 mg tab
3
Preferred
LEUCOVORIN
 
leucovorin calcium 10 mg tab, 15 mg tab
4
Preferred
LEUCOVORIN
 
leucovorin calcium 25 mg tab
9
Preferred
LEUCOVORIN
 
leucovorin calcium 50 mg inj, 100 mg inj, 200 mg inj, 350 mg inj, 500 mg inj
9
Non-Preferred
LEUCOVORIN
 
DENTAL AND ORAL AGENTS [AGENTES DENTALES Y ORALES]
Antifungals [Antifungales]
clotrimazole 10 mg   mouth/throat lozenge, 10 mg mouth/throat troche
1
Preferred
MYCELEX
 

Drug Name [Nombre del Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/
Límites]
nystatin 100000 unit/ml mouth/throat susp
1
Preferred
MYCOSTATIN
 
HORMONAL AGENTS [AGENTES HORMONALES]
Mineralocorticoids [Mineralocorticoides]  
fludrocortisone acetate 0.1   mg tab
1
Preferred
FLORINEF
 
 

VIH-SIDA
 
IMMUNOSUPPRESSANTS [IMMUNOSUPRESORES]
Glucocorticosteroids [Glucocorticoides]  
dexamethasone 0.5 mg tab,   0.5 mg/5ml oral elix, 0.5 mg/5ml soln, 0.75 mg tab, 1 mg tab, 1.5 mg tab, 2 mg tab, 4 mg tab, 6 mg tab
1
Preferred
DECADRON
 
MEDROL 2 mg tab
1
Preferred
   
methylprednisolone 32 mg tab, 4 mg tab
1
Preferred
MEDROL
 
methylprednisolone (pak) 4 mg tab
1
Preferred
MEDROL
 
prednisolone 15 mg/5ml soln, 15 mg/5ml syr
1
Preferred
PRELONE
 
prednisone 1 mg tab, 10 mg tab, 2.5 mg tab, 20 mg tab, 5 mg tab, 50 mg tab
1
Preferred
DELTASONE
 
prednisone (pak) 10 mg tab, 5 mg tab
1
Preferred
DELTASONE
 
hydrocortisone 10 mg tab, 20 mg tab, 5 mg tab
2
Preferred
CORTEF
 
methylprednisolone 16 mg tab, 8 mg tab
2
Preferred
MEDROL
 
 

NEFROLOGIA
 
Drug Name [Nombre del
Medicamento]
Net Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/
Límites]
THERAPEUTIC CATEGORY [CATEGORÍA TERAPÉUTICA]
Therapeutic Class [Clase Te rapéutica]
ANALGESICS [ANALGÉ SICOS]
Nonsteroidal Anti-Inflammatory Agents (Nsaids) [Anti-Inflamatorios No Esteroidales]
indomethacin 25 mg cap, 50 mg cap
 
1
 
Non-Preferred
 
INDOCIN
 
ANTIBACTERIALS [ANTIBACTERIANOS]
First Generation Cephalosporins [Cefalosporinas De Primera Generación]
cephalexin 125 mg/5ml   susp, 250 mg cap, 500 mg cap
1
Preferred
KEFLEX
 
cefadroxil 250 mg/5ml susp
2
Non-Preferred
DURICEF
AL ≤ 12 años
cephalexin 250 mg/5ml susp
2
 
KEFLEX
 
cefadroxil 500 mg/5ml susp
3
Non-Preferred
DURICEF
AL≤ 12 años
Macrolides [Macrólidos]
azithromycin 250 mg tab,   500 mg tab
1
Preferred
ZITHROMAX
 
azithromycin 1 gm pckt, 100 mg/5ml susp, 200 mg/5ml susp, 600 mg tab
2
Preferred
ZITHROMAX
 
clarithromycin 125 mg/5ml susp, 250 mg tab, 500 mg tab
2
Preferred
BIAXIN
 
clarithromycin 250 mg/5ml susp
3
Preferred
BIAXIN
 
ERY-TAB 500 mg tab dr
3
Preferred
   
XI ycin base 250 mg cap dr prt, 250 mg tab, 500 mg tab
3
Preferred
ERY-TAB
 
erythromycin ethylsuccinate 400 mg tab
3
Preferred
E.E.S.
 
ERYTHROCIN STEARATE 250 mg tab
4
Non-Preferred
   
E.E.S. GRANULES 200 mg/5ml susp
5
Preferred
   
ERYPED 200 200 mg/5ml susp
5
Preferred
   
 
Página 1 de 14
Revisado 5/18/2017

NEFROLOGIA
 
Drug Name [Nombre del
Medicamento]
Net Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/
Límites]
ERYPED 400 400 mg/5ml susp
6
Preferred
   
Penicillins [Penicilinas]
amoxicillin 125 mg/5ml susp,   200 mg/5ml susp, 250 mg cap, 250 mg/5ml susp, 400 mg/5ml susp, 500 mg cap, 500 mg tab, 875 mg tab
1
Preferred
AMOXIL
 
amoxicillin-pot clavulanate 200-28.5 mg/5ml susp, 40057 mg/5ml susp, 500-125 mg tab, 875-125 mg tab
1
Preferred
AUGMENTIN
 
ampicillin 125 mg/5ml susp, 250 mg cap, 250 mg/5ml susp, 500 mg cap
1
Preferred
PRINCIPEN
 
penicillin v potassium 125 mg/5ml soln, 250 mg tab, 250 mg/5ml soln, 500 mg tab
1
Preferred
VEETIDS
 
amoxicillin-pot clavulanate 250-125 mg tab, 250-62.5 mg/5ml susp
3
Preferred
AUGMENTIN
 
BICILLIN L-A 600000 unit/ml im susp
3
Non-Preferred
   
penicillin g procaine 600000 unit/ml im susp
3
Non-Preferred
BICILLIN LA
 
BICILLIN L-A 1200000 unit/2ml im susp
4
Non-Preferred
   
BICILLIN L-A 2400000 unit/4ml im susp
5
Non-Preferred
   
Quinolones [Quinolonas]
ciprofloxacin hcl 250 mg tab,   500 mg tab, 750 mg tab
1
Preferred
CIPRO
 
levofloxacin 250 mg tab, 500 mg tab, 750 mg tab
1
Preferred
LEVAQUIN
 
ciprofloxacin 500 mg/5ml (10%) susp
3
Preferred
CIPRO
 
 
Página 2 de 14
Revisado 5/18/2017

NEFROLOGIA

Drug Name [Nombre del
Medicamento]
Net Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/
Límites]
ciprofloxacin 250 mg/5ml (5%) susp
4
Preferred
CIPRO
 
Second Generation Cephalosporins [Cefalosporinas De Segunda Generación]
cefaclor 250 mg cap, 500   mg cap
2
Preferred
CECLOR
 
cefprozil 125 mg/5ml susp, 250 mg tab, 250 mg/5ml susp, 500 mg tab
2
Preferred
CEFZIL
 
Sulfonamides [Sulfonamidas]
sulfamethoxazole   -tmp ds 800-160 mg tab
1
Preferred
SEPTRA
 
sulfamethoxazoletrimethoprim 200-40 mg/5ml susp, 400-80 mg tab
1
Preferred
SEPTRA
 
Third Generation Cephalosporins [Cefalosporinas De Tercera Generación]
cefdinir 125 mg/5ml susp,   300 mg cap
2
Preferred
OMNICEF
 
cefdinir 250 mg/5ml susp
3
Preferred
OMNICEF
 
ANTIDIABETIC AGENTS [AGENTES ANTIDIABÉTICOS]
Alpha-Glucosidase Inhibitors [Inhibidores De Alfa Glucosidasa]
acarbose 100 mg tab, 25 mg   tab, 50 mg tab
2
Preferred
PRECOSE
 
Biguanides [Biguanidas]
metformin hcl 1000 mg tab,   500 mg tab, 850 mg tab
1
Preferred
GLUCOPHAGE
 
metformin hcl er 500 mg tab er 24 hr, 750 mg tab er 24 hr
1
Preferred
GLUCOPHAGE XR
 
Dipeptidyl Peptidase-4 (Dpp-4) Inhibitors [Inhibidores De Dpp-4]
KOMBIGLYZE XR 2.5   -1000 mg tab er 24 hr, 5-1000 mg tab er 24 hr, 5-500 mg tab er 24 hr
3
Preferred
 
ST, P
ONGLYZA 2.5 mg tab, 5 mg tab
3
Preferred
 
ST, P
Insulin Mixtures [Mezclas De Insulinas]
HUMULIN 70/30 (70   -30) 100 unit/ml sc susp
2
Preferred
 
P
 
Página 3 de 14
Revisado 5/18/2017

NEFROLOGIA

Drug Name [Nombre del
Medicamento]
Net Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/
Límites]
HUMALOG MIX 75/25 (7525) 100 unit/ml sc susp
3
Preferred
 
P
HUMALOG MIX 50/50 (5050) 100 unit/ml sc susp
4
Preferred
 
P
Insulin Sensitizing Agents [Agentes Sensibilizantes De Insulin]
pioglitazone hcl 15 mg tab,   30 mg tab, 45 mg tab
1
Preferred
ACTOS
 
Intermediate-Acting Insulins [Insulinas De Duración Intermedia]
HUMULIN N 100 unit/ml sc   susp
2
Preferred
 
P
Long-Acting Insulins [Insulinas De Larga Duración]
LANTUS SOLOSTAR 100   unit/ml subcutaneous solution pen-injector
2
Preferred
 
P
LANTUS 100 unit/ml sc soln
3
Preferred
 
P
Rapid-Acting Insulins [Insulinas De Rápida Duración]
HUMALOG 100 unit/ml   subcutaneous solution cartridge
2
Preferred
 
P
HUMALOG 100 unit/ml sc soln
3
Preferred
 
P
Short-Acting Insulins [Insulinas De Corta Duración]
HUMULIN R 100 unit/ml inj   soln
2
Preferred
 
P
 
Página 4 de 14
Revisado 5/18/2017

NEFROLOGIA

Sulfonylureas [Sulfonilureas]
glimepiride 1 mg tab, 2 mg   tab, 4 mg tab
1
Preferred
AMARYL
 
glipizide 10 mg tab, 5 mg tab
1
Preferred
GLUCOTROL
 
ANTIEMETICS [ANTIEMÉTICOS]
           Miscellaneous Antiemetics [Antieméticos Misceláneos]
metoclopramide hcl 10 mg   tab, 10 mg/10ml soln, 5 mg tab, 5 mg/5ml soln, 5 mg/ml inj soln
1
Preferred
REGLAN
 

Drug Name [Nombre del
Medicamento]
Net Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/
Límites]
ANTIHYPERTENSIVES [ANTIHIPERTENSIVOS]
Alpha-Adrenergic Blocking Agents [Bloqueadores Alfa Adrenérgicos]
terazosin hcl 1 mg cap, 10   mg cap, 2 mg cap, 5 mg cap
1
Preferred
HYTRIN
 
Angiotensin II Receptor Blockers (Arb) [Antagonistas Del Receptor Angiotensina II]
losartan potassium 100 mg tab, 25 mg tab, 50 mg tab
1
Preferred
COZAAR
losartan potassium-hctz 100-12.5 mg tab, 100-25 mg tab, 50-12.5 mg tab
1
Preferred
HYZAAR
 
Angiotensin-Converting Enzyme (Ace) Inhibitors [Inhibidores De La Enzima Convertidora De Angiotensin]
fosinopril sodium 10 mg tab,   20 mg tab, 40 mg tab
1
Preferred
MONOPRIL
 
lisinopril 10 mg tab, 2.5 mg tab, 20 mg tab, 30 mg tab, 40 mg tab, 5 mg tab
1
Preferred
ZESTRIL
 
lisinopril-hydrochlorothiazide 10-12.5 mg tab, 20-12.5 mg tab, 20-25 mg tab
1
Preferred
ZESTORETIC
 
Calcium Channel Blocking Agents [Bloqueadores De Canales De Calcio]
amlodipine besylate 10 mg   tab, 2.5 mg tab, 5 mg tab
1
Preferred
NORVASC
 
 
Página 5 de 14
Revisado 5/18/2017

NEFROLOGIA

diltiazem hcl 120 mg tab, 30 mg tab, 60 mg tab, 90 mg tab
1
Preferred
CARDIZEM
 
diltiazem hcl er 120 mg cap er 24 hr, 180 mg cap er 24 hr, 240 mg cap er 24 hr
1
Preferred
DILACOR XR
 
diltiazem hcl er beads 120 mg cap er 24 hr
1
Preferred
TIAZAC
 
diltiazem hcl er coated beads 120 mg cap er 24 hr, 180 mg cap er 24 hr, 240 mg cap er 24 hr
1
Preferred
CARDIZEM CD
 
dilt-xr 120 mg cap er 24 hr, 180 mg cap er 24 hr, 240 mg cap er 24 hr
1
Preferred
DILACOR XR
 

Drug Name [Nombre del
Medicamento]
Net Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/
Límites]
nifedipine er osmotic 30 mg tab er 24 hr
1
Preferred
PROCARDIA XL
 
verapamil hcl 120 mg tab, 40 mg tab, 80 mg tab
1
Preferred
CALAN
 
verapamil hcl er 120 mg tab er, 180 mg tab er, 240 mg tab er
1
Preferred
CALAN SR
 
diltiazem hcl er beads 180 mg cap er 24 hr, 240 mg cap er 24 hr, 300 mg cap er 24 hr, 360 mg cap er 24 hr
2
Preferred
TIAZAC
 
diltiazem hcl er coated beads 300 mg cap er 24 hr
2
Preferred
CARDIZEM CD
 
nifedipine er osmotic 60 mg tab er 24 hr, 90 mg tab er 24 hr
2
Preferred
PROCARDIA XL
 
Cardioselective Beta Blocking Agents [Bloqueadores Beta Cardioselectivos]
atenolol 100 mg tab, 25 mg   tab, 50 mg tab
1
Preferred
TENORMIN
 
 
Página 6 de 14
Revisado 5/18/2017

NEFROLOGIA

metoprolol succinate er 25 mg tab er 24 hr, 50 mg tab er 24 hr
1
Preferred
LOPRESSOR
 
metoprolol tartrate 100 mg tab, 25 mg tab, 50 mg tab
1
Preferred
LOPRESSOR
 
metoprolol succinate er 100 mg tab er 24 hr, 200 mg tab er 24 hr
2
Preferred
LOPRESSOR
 
Cardioselective Beta-Adrenergic Blocking Agents [Bloqueadores Beta-Adrenérgicos Cardioselectivos]
atenolol -chlorthalidone 10025 mg tab, 50-25 mg tab
1
Preferred
TENORETIC
 
metoprolol- hydrochlorothiazide 50-25 mg tab
2
Non-Preferred
LOPRESSOR HCT
 
metoprololhydrochlorothiazide 100-25 mg tab, 100-50 mg tab
3
Non-Preferred
LOPRESSOR HCT
 

Drug Name [Nombre del
Medicamento]
Net Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/
Límites]
Loop Diuretics [Diuréticos Del Asa]
bumetanide 0.5 mg tab, 1   mg tab, 2 mg tab
1
Non-Preferred
BUMEX
 
furosemide 10 mg/ml soln, 20 mg tab, 40 mg tab, 80 mg tab
1
Preferred
LASIX
 
Nonselective Beta Blocking Agents [Bloqueadores Beta No-Selectivos]
propranolol hcl 10 mg tab,   20 mg tab, 20 mg/5ml soln, 40 mg tab, 40 mg/5ml soln,
80 mg tab
1
Preferred
INDERAL
 
propranolol hcl 60 mg tab
2
Preferred
INDERAL
 
Nonselective Beta-Adrenergic Blocking Agents [Bloqueadores Beta-Adrenérgicos No- Selectivos]
Thiazide Diuretics [Diuréticos Tiazidas]
chlorothiazide 250 mg tab,   500 mg tab
1
Preferred
DIURIL
 
 
Página 7 de 14
Revisado 5/18/2017

NEFROLOGIA

chlorthalidone 25 mg tab, 50 mg tab
1
Non-Preferred
HYGROTON
 
DIURIL 250 mg/5ml susp
1
Preferred
   
hydrochlorothiazide 25 mg tab, 50 mg tab
1
Preferred
MICROZIDE
 
metolazone 2.5 mg tab, 5 mg tab
1
Non-Preferred
ZAROXOLYN
 
chlorthalidone 100 mg tab
2
Non-Preferred
HYGROTON
 
metolazone 10 mg tab
2
Non-Preferred
ZAROXOLYN
 
Vasodilator Beta Blockers [Bloqueadores Beta Vasodilatadores]
carvedilol 12.5 mg tab, 25   mg tab, 3.125 mg tab, 6.25 mg tab
1
Preferred
COREG
 
BENIGN PROSTATIC HYPERTROPHY AGENTS [AGENTES PARA HIPERTROFIA PROSTÁTICA BENIGNA]
Alpha 1-Adrenoceptor Antagonists [Bloqueadores Alfa1-Adrenérgicos]
tamsulosin hcl 0.4 mg cap           
1
Preferred
FLOMAX
 

Drug Name [Nombre del
Medicamento]
Net Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/
Límites]
BLOOD MODIFIERS [MODIFICADORES DE LA SANGRE]
Cobalamins [Cobalaminas]
cyanocobalamin 1000   mcg/ml inj soln
1
Preferred
VIT B-12
 
Erythropoiesis-Stimulating Agents [Agentes Estimulantes De Eritropoiesis]
ARANESP (ALBUMIN FREE) 100 mcg/0.5ml inj soln
1
Preferred
 
PA, P
PROCRIT 2000 unit/ml inj soln, 3000 unit/ml inj soln, 4000 unit/ml inj soln
5
Preferred
 
PA, P
ARANESP (ALBUMIN FREE) 25 mcg/0.42ml inj soln, 25 mcg/ml inj soln
6
Preferred
 
PA, P
PROCRIT 10000 unit/ml inj soln
6
Preferred
 
PA, P
 
Página 8 de 14
Revisado 5/18/2017

NEFROLOGIA

ARANESP (ALBUMIN FREE) 40 mcg/0.4ml inj soln
7
Preferred
 
PA, P
ARANESP (ALBUMIN FREE) 40 mcg/ml inj soln, 60 mcg/ml inj soln
8
Preferred
 
PA, P
ARANESP (ALBUMIN FREE) 150 mcg/0.75ml inj soln, 200 mcg/0.4ml inj soln, 200 mcg/ml inj soln, 300 mcg/0.6ml inj soln, 300 mcg/ml inj soln, 500 mcg/ml inj soln, 60 mcg/0.3ml inj soln
9
Preferred
 
PA, P
PROCRIT 20000 unit/ml inj soln
9
Preferred
 
PA, P
ARANESP (ALBUMIN FREE) 100 mcg/ml inj soln
11
Preferred
 
PA, P
PROCRIT 40000 unit/ml inj soln
11
Preferred
 
PA, P
Folates [Folatos]
 folic acid 1 mg tab, 400 mcg   tab, 800 mcg tab
1
Preferred
FOLIC ACID
OTC

Drug Name [Nombre del
Medicamento]
Net Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/
Límites]
Iron [Hierro]
iron 325 (65 fe) mg tab
1
Preferred
IRON
 
DEXFERRUM 50 mg/ml inj soln
5
Non-Preferred
   
INFED 50 mg/ml inj soln
5
     
CHEMOTHERAPIES [QUIMIOTERAPIAS]
Antineoplastic Progestins [Antineoplásicos De Progestina]
megestrol acetate 20 mg   tab, 40 mg tab
1
Preferred
MEGACE
 
megestrol acetate 40 mg/ml susp, 400 mg/10ml susp
2
Preferred
MEGACE
 
DIABETES SUPPLIES [SUMINISTROS PARA DIABETES]
Needles & Syringes [Agujas Y Jeringuillas]
insulin syringe/needle
1
Preferred
.
 
 
Página 9 de 14
Revisado 5/18/2017

NEFROLOGIA
 
DYSLIPIDEMICS [DISLIPIDÉMICOS]
Bile Acid Sequestrants [Secuestradores De Acidos Biliares]
cholestyramine 4 gm pckt, 4   gm/dose oral pwdr
3
Preferred
QUESTRAN
 
Fibric Acid Derivatives [Derivados De Ácido Fíbrico]
gemfibrozil 600 mg tab
1
Preferred
LOPID
 
Hmg Coa Reductase Inhibitors [Inhibidores De La Reductasa De Hmg Coa]
atorvastatin calcium 10 mg   tab, 20 mg tab, 40 mg tab, 80 mg tab
1
Preferred
LIPITOR
 
pravastatin sodium 10 mg tab, 20 mg tab, 80 mg tab
1
Non-Preferred
PRAVACHOL
 
simvastatin 10 mg tab, 20 mg tab, 40 mg tab, 5 mg tab, 80 mg tab
1
Preferred
ZOCOR
 
pravastatin sodium 40 mg tab
2
Non-Preferred
PRAVACHOL
 
GASTROINTESTINAL AGENTS [AGENTES GASTROINTESTINALES]
Histamine2 (H2) Receptor Antagonists [Antagonistas Del Receptor De H2]
famotidine 20 mg tab, 40 mg tab
1
Preferred
PEPCID
 
 
Drug Name [Nombre del
Medicamento]
Net Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/
Límites]
ranitidine hcl 15 mg/ml syr, 150 mg/10ml syr, 300 mg tab, 75 mg/5ml syr
1
Preferred
ZANTAC
 
GENITOURINARY AGENTS [AGENTES GENITOURINARIOS]
Phosphate Binder Agents [Enlazadores De Fosfato]
RENVELA 0.8 gm pckt
6
Preferred
 
PA, P
RENVELA 2.4 gm pckt, 800 mg tab
7
Preferred
 
PA, P
 
Página 10 de 14
Revisado 5/18/2017

NEFROLOGIA
 
calcium acetate 667 mg cap.
3
Non-Preferred
PHOSLO
 
HORMONAL AGENTS [AGENTES HORMONALES]
Calcimimetics [Calcimiméticos]
SENSIPAR 30 mg tab
7
Preferred
 
PA
SENSIPAR 60 mg tab
9
Preferred
 
PA
SENSIPAR 90 mg tab
10
Preferred
 
PA
Mineralocorticoids [Mineralocorticoides]
fludrocortisone acetate 0.1   mg tab
1
Preferred
FLORINEF
 
Vasopressin Analogs [Análogos De Vasopresina]
desmopressin acetate 4   mcg/ml inj soln
2
Non-Preferred
DDAVP
 
desmopressin acetate 0.2 mg tab
3
Non-Preferred
DDAVP
 
desmopressin ace spray refrig 0.01 % nasal soln
4
Non-Preferred
DDAVP
 
desmopressin acetate 0.1 mg tab
4
Non-Preferred
DDAVP
 
desmopressin acetate spray
0.01 % nasal soln
4
Non-Preferred
DDAVP
 
STIMATE 1.5 mg/ml nasal soln
7
Non-Preferred
 
PA
IMMUNOSUPPRESSANTS [IMMUNOSUPRESORES]
Cyclosporine Analogs [Análogos De Ciclosporina]
cyclosporine modified 25 mg   cap, 50 mg cap
3
Preferred
NEORAL
PA, P
cyclosporine modified 25 mg cap, 50 mg cap
3
Preferred
NEORAL
PA
NEORAL 25 mg cap
3
Preferred
 
PA, P

Drug Name [Nombre del
Medicamento]
Net Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/
Límites]
cyclosporine 25 mg cap
4
Preferred
SANDIMMUNE
PA
cyclosporine modified 100 mg cap, 100 mg/ml soln
4
Preferred
NEORAL
PA
cyclosporine 100 mg cap
5
Preferred
SANDIMMUNE
PA
 
Página 11 de 14
Revisado 5/18/2017

NEFROLOGIA

cyclosporine modified 100 mg cap
5
Preferred
NEORAL
PA, P
NEORAL 100 mg cap
5
Preferred
 
PA, P
cyclosporine 100 mg cap, 25 mg cap
6
Preferred
SANDIMMUNE
PA, P
SANDIMMUNE 100 mg cap, 100 mg/ml soln, 25 mg cap
6
Preferred
 
PA, P
cyclosporine modified 100 mg/ml soln
7
Preferred
NEORAL
PA, P
NEORAL 100 mg/ml soln
7
Preferred
 
PA, P
Glucocorticosteroids [Glucocorticoides]
dexamethasone 0.5 mg tab   , 0.5 mg/5ml oral elix, 0.5 mg/5ml soln, 0.75 mg tab, 1 mg tab, 1.5 mg tab, 2 mg tab, 4 mg tab, 6 mg tab
1
Preferred
DECADRON
 
MEDROL 2 mg tab
1
Preferred
   
methylprednisolone 32 mg tab, 4 mg tab
1
Preferred
MEDROL
 
methylprednisolone (pak) 4 mg tab
1
Preferred
MEDROL
 
prednisolone 15 mg/5ml soln, 15 mg/5ml syr
1
Preferred
PRELONE
 
prednisone 1 mg tab, 10 mg tab, 2.5 mg tab, 20 mg tab, 5 mg tab, 50 mg tab
1
Preferred
DELTASONE
 
prednisone (pak) 10 mg tab, 5 mg tab
1
Preferred
DELTASONE
 
hydrocortisone 10 mg tab, 20 mg tab, 5 mg tab
2
Preferred
CORTEF
 
methylprednisolone 16 mg tab, 8 mg tab
2
Preferred
MEDROL
 
Organ Transplant Agents [Agentes Para Trasplantes]
azathioprine 50 mg tab
1
Preferred
IMURAN
 
 
Página 12 de 14
Revisado 5/18/2017

NEFROLOGIA

Drug Name [Nombre del
Medicamento]
Net Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/
Límites]
mycophenolate mofetil 250 mg cap, 500 mg tab
2
Preferred
CELLCEPT
PA
tacrolimus 0.5 mg cap
3
Non-Preferred
PROGRAF
PA
MYFORTIC   180 mg tab dr
4
Preferred
 
PA, P
tacrolimus 1 mg cap
4
Non-Preferred
PROGRAF
PA
mycophenolic acid 180 mg tab dr
5
Preferred
MYFORTIC
PA
sirolimus 0.5 mg tab, 1 mg tab, 2 mg tab
5
Non-Preferred
RAPAMUNE
PA
MYFORTIC   360 mg tab dr
6
   
PA, P
tacrolimus 5 mg cap
6
Non-Preferred
PROGRAF
PA
mycophenolic acid 360 mg tab dr
7
Preferred
MYFORTIC
PA
RAPAMUNE 1 mg/ml soln
8
Non-Preferred
 
PA
MINERALS & ELECTROLYTES [MINERALES Y ELECTROLITOS]
Calcium Regulating Agents [Agentes Reguladores De Calcio]
calcitriol 0.25 mcg cap
1
Preferred
ROCALTROL
 
calcitriol 0.5 mcg cap
2
Preferred
ROCALTROL
 
calcitriol 1 mcg/ml soln
5
Preferred
ROCALTROL
 
Electrolytes/Minerals Replacement [Reemplazo De Electrolitos/Minerales]
potassium chloride 20   meq/15ml (10%) oral liquid, 20 meq/15ml (10%) soln
1
Preferred
KAY-CIEL
 
potassium chloride crys er 10 meq tab er, 20 meq tab er
1
Preferred
KLOR-CON
 
potassium chloride er 10 meq tab er, 8 meq tab er
1
Preferred
KLOR-CON
 
potassium chloride er 10 meq cap er, 8 meq cap er
2
Preferred
MICRO-K
 
potassium chloride 40 meq/15ml (20%) oral liquid
4
Preferred
KAON CL
 
Potassium Removing Resins [Resinas Removedoras De Potasio]
kalexate oral pwdr
3
Preferred
KAYEXALATE
 
sodium polystyrene sulfonate oral pwdr, 15 gm/60ml susp
3
Preferred
KAYEXALATE
 
 
Página 13 de 14
Revisado 5/18/2017

NEFROLOGIA
 
 
 
 

ONCOLOGIA
 
Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/
Límites]
THERAPEUTIC CATEGORY [CATEGORÍA TERAPÉUTICA]
Therapeutic Class [Clase Terapéutica]
ANALGESICS [ANALG   ÉSICOS]
Nonsteroidal Anti-Inflammatory Agents (NSAIDS) [Anti-Inflamatorios No Esteroidales]
ibuprofen 400 mg tab, 600 mg tab, 800 mg tab
1
Preferred
MOTRIN
QL=15 días  No refills
nabumetone 500 mg tab, 750 mg tab
1
Preferred
RELAFEN
 
naproxen 250 mg tab, 375 mg tab, 500 mg tab
1
Preferred
NAPROSYN
QL=15 días  No refills
naproxen dr 375 mg tab dr, 500 mg tab dr
1
Preferred
NAPROSYN
QL=15 días  No refills
sulindac 150 mg tab, 200 mg tab
1
Preferred
CLINORIL
 
meloxicam7.5 mg tab, 15 mg tab
1
Preferred
MOBIC
QL=15 días  No refills
indomethacin 25 mg cap, 50 mg cap
1
Non-Preferred
INDOCIN
Opioid Analgesics, Long-Acting [Analgésicos Opiodes, Larga Duración]
fentanyl 25 mcg/hr td patch   72 hr
2
Preferred
DURAGESIC
 
oxycodone hcl 10 mg tab
2
Preferred
DAZIDOX
QL=15 días No refills
fentanyl 50 mcg/hr td patch 72 hr, 75 mcg/hr td patch 72 hr
3
Preferred
DURAGESIC
 
morphine sulfate er 15 mg tab er
3
Preferred
MORPHINE
 
oxycodone hcl 20 mg tab
3
Preferred
DAZIDOX
QL=15 días No refills
fentanyl 100 mcg/hr td patch 72 hr
4
Preferred
DURAGESIC
 
 
1 de 17

Revisado: 5 de mayo de 2017
ONCOLOGIA

Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/ Límites]
morphine sulfate er 30 mg tab er
4
Preferred
MORPHINE
 
morphine sulfate er 60 mg tab er
5
Preferred
MORPHINE
 
morphine sulfate er 100 mg tab er
6
Preferred
MORPHINE
 
Short-Acting Opioid Analgesics [Analgésicos Opiodes De Corta Duración]
acetaminophen    -codeine 120-12 mg/5ml soln, 300-15 mg tab, 300-30 mg tab, 300- 60 mg tab
1
Preferred
TYLENOL-CODEINE
QL=15 días No refills
acetaminophen-codeine #2 300-15 mg tab
1
Preferred
TYLENOL-CODEINE
QL=15 días No refills
acetaminophen-codeine #3 300-30 mg tab
1
Preferred
TYLENOL-CODEINE
QL=15 días No refills
acetaminophen-codeine #4 300-60 mg tab
1
Preferred
TYLENOL-CODEINE
QL=15 días No refills
hydrocodoneacetaminophen 10-325 mg tab, 5-325 mg tab, 7.5-325 mg tab, 7.5-500 mg/15ml soln
1
Preferred
VICODIN
QL=15 días No refills
hydromorphone hcl 2 mg tab, 4 mg tab
1
Preferred
DILAUDID
 
meperidine hcl 50 mg/ml inj soln
1
Preferred
DEMEROL
 
morphine sulfate 15 mg tab, 30 mg tab
1
Preferred
MORPHINE
 
oxycodone-acetaminophen 5-325 mg tab
1
Preferred
PERCOCET
QL=15 días No refills
tramadol hcl 50 mg tab
1
Preferred
ULTRAM
 
codeine sulfate 15 mg tab, 30 mg tab, 60 mg tab
2
Preferred
CODEINE
 
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 9 for monthly net cost range [Ver página 9 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 
Página 2 de 17

Revisado: 5 de mayo de 2017
ONCOLOGIA

Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/
Límites]
meperidine hcl 100 mg/ml inj soln
2
Preferred
DEMEROL
 
morphine sulfate 10 mg/5ml soln
2
Preferred
MORPHINE
 
morphine sulfate (concentrate) 100 mg/5ml soln, 20 mg/ml soln
2
Preferred
MORPHINE
 
hydromorphone hcl 8 mg tab
3
Preferred
DILAUDID
 
oxycodone-acetaminophen 10-325 mg tab, 7.5-325 mg tab
3
Preferred
PERCOCET
QL=15 días No refills
hydromorphone hcl 1 mg/ml oral liquid
4
Preferred
DILAUDID
 
ANESTHETICS [ANESTÉSICOS]
Local Anesthetics [Anestésicos Locales]
lidocaine viscous 2 %
mouth/throat soln 1 Preferred XYLOCAINE
ANTIBACTERIALS [ANTIBACTERIANOS]
Macrolides [Macrólidos]
azithromycin 250 mg tab,   500 mg tab
1
Preferred
ZITHROMAX
 
azithromycin 1 gm pckt, 100 mg/5ml susp, 200 mg/5ml susp, 600 mg tab
2
Preferred
ZITHROMAX
 
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 9 for monthly net cost range [Ver página 9 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 
Página 3 de 17

Revisado: 5 de mayo de 2017
ONCOLOGIA

clarithromycin 125 mg/5ml susp, 250 mg tab, 500 mg tab
2
Preferred
BIAXIN
 
clarithromycin 250 mg/5ml susp
3
Preferred
BIAXIN
 
ERY-TAB 500 mg tab dr
3
Preferred
   
erythromycin base 250 mg cap dr prt, 250 mg tab, 500 mg tab
3
Preferred
ERY-TAB
 

Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/
Límites]
erythromycin ethylsuccinate 400 mg tab
3
Preferred
E.E.S.
 
ERYTHROCIN STEARATE 250 mg tab
4
Non-Preferred
   
E.E.S. GRANULES 200 mg/5ml susp
5
Preferred
   
ERYPED 200 200 mg/5ml susp
5
Preferred
   
ERYPED 400 400 mg/5ml susp
6
Preferred
   
Penicillins [Penicilinas]
amoxicillin 125 mg/5ml susp,   200 mg/5ml susp, 250 mg cap, 250 mg/5ml susp, 400 mg/5ml susp, 500 mg cap, 500 mg tab, 875 mg tab
1
Preferred
AMOXIL
 
amoxicillin-pot clavulanate, 200-28.5 mg/5ml susp, 40057 mg/5ml susp, 500-125 mg tab, 875-125 mg tab
1
Preferred
AUGMENTIN
 
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 9 for monthly net cost range [Ver página 9 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 
Página 4 de 17

Revisado: 5 de mayo de 2017
ONCOLOGIA

ampicillin 125 mg/5ml susp, 250 mg cap, 250 mg/5ml susp, 500 mg cap
1
Preferred
PRINCIPEN
 
penicillin v potassium 125 mg/5ml soln, 250 mg tab, 250 mg/5ml soln, 500 mg tab
1
Preferred
VEETIDS
 
amoxicillin-pot clavulanate 250-125 mg tab, 250-62.5 mg/5ml susp
3
Preferred
AUGMENTIN
 
BICILLIN L-A 600000 unit/ml im susp
3
Non-Preferred
   
penicillin g procaine 600000 unit/ml im susp
3
Non-Preferred
BICILLIN LA
 

Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/
Límites]
BICILLIN L-A 1200000 unit/2ml im susp
4
Non-Preferred
   
BICILLIN L-A 2400000 unit/4ml im susp
5
Non-Preferred
   
Quinolones [Quinolonas]
ciprofloxacin hcl 250 mg tab,   500 mg tab, 750 mg tab
1
Preferred
CIPRO
 
levofloxacin 250 mg tab, 500 mg tab, 750 mg tab
1
Preferred
LEVAQUIN
 
ciprofloxacin 500 mg/5ml (10%) susp
3
Preferred
CIPRO
 
ciprofloxacin 250 mg/5ml (5%) susp
4
Preferred
CIPRO
 
Sulfonamides [Sulfonamidas]
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 9 for monthly net cost range [Ver página 9 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 
Página 5 de 17

Revisado: 5 de mayo de 2017
ONCOLOGIA

sulfamethoxazole -tmp ds 800-160 mg tab
1
Preferred
SEPTRA
 
sulfamethoxazoletrimethoprim 200-40 mg/5ml susp, 400-80 mg tab
1
Preferred
SEPTRA
 
sulfadiazine 500 mg tab
4
Preferred
SULFADIAZINE
 
ANTICONVULSANTS [ANTICONVULSIVANTES]
Anticonvulsants [Anticonvulsivantes  
gabapentin 100 mg cap, 300   mg cap, 400 mg cap, 600 mg tab, 800 mg tab
1
Preferred
NEURONTIN
 
DILANTIN 30 mg cap
2
Preferred
   
gabapentin 250 mg/5ml soln
2
Preferred
NEURONTIN
 
phenytoin 125 mg/5ml susp, 50 mg tab chew
2
Preferred
DILANTIN
 
phenytoin sodium extended 100 mg cap
2
Preferred
DILANTIN
 

Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/
Límites]
ANTIEMETICS [ANTIEMÉTICOS]
5-Hydroxytryptamine 3 (5-HT3) Antagonists [Antagonistas De 5-HT3]
ondansetron 4 mg odt, 8 mg   odt
1
Preferred
ZOFRAN ODT
 
ondansetron hcl 24 mg tab, 4 mg tab, 8 mg tab
1
Preferred
ZOFRAN
 
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 9 for monthly net cost range [Ver página 9 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 
Página 6 de 17

Revisado: 5 de mayo de 2017
ONCOLOGIA

Miscellaneous Antiemetics [Antieméticos Misceláneos]
metoclopramide hcl 10 mg   tab, 10 mg/10ml soln, 5 mg tab, 5 mg/5ml soln, 5 mg/ml inj soln
1
Preferred
REGLAN
 
promethazine hcl 25 mg/ml inj soln, 50 mg/ml inj soln
1
Preferred
PHENERGAN
 
promethazine hcl 12.5 mg tab, 25 mg tab, 50 mg tab, 6.25 mg/5ml soln, 6.25 mg/5ml syr
1
Preferred
PHENERGAN
 
trimethobenzamide hcl 300 mg cap
1
Preferred
TIGAN
 
Phenothiazines [Fenotiazinas]
prochlorperazine edisylate 5   mg/ml inj soln
1
Preferred
COMPAZINE
 
prochlorperazine maleate 10 mg tab, 5 mg tab
1
Preferred
COMPAZINE
 
prochlorperazine 25 mg rect supp
4
Non-Preferred
COMPAZINE
 
ANTIMYCOBACTERIALS [ANTIMICOBACTERIANOS]
Miscellaneous Antimycobacterials [Antimicobacterianos Misceláneos]
dapsone 100 mg tab, 25 mg   tab
2
Preferred
DAPSONE
 
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 9 for monthly net cost range [Ver página 9 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 
Página 7 de 17

Revisado: 5 de mayo de 2017
ONCOLOGIA

Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/
Límites]
ANTIMYCOTIC AGENTS [ANTIMICÓTICOS]
Antifungals [Antifungales]
fluconazole 10 mg/ml susp,   100 mg tab, 150 mg tab, 200 mg tab, 50 mg tab
1
Preferred
DIFLUCAN
 
ketoconazole 200 mg tab
1
Preferred
NIZORAL
 
terbinafine hcl 250 mg tab
1
Preferred
LAMISIL
 
fluconazole 40 mg/ml susp
2
Preferred
DIFLUCAN
 
ANTIVIRALS [ANTIVIRALES]
Antiherpetic Agents [Agentes Antiherpéticos]
acyclovir 200 mg cap, 400   mg tab, 800 mg tab
1
Preferred
ZOVIRAX
 
acyclovir 200 mg/5ml susp
2
Preferred
ZOVIRAX
 
BLOOD MODIFIERS [MODIFICADORES DE LA SANGRE]
Cobalamins [Cobalaminas]
cyanocobalamin 1000   mcg/ml inj soln
1
Preferred
VIT B-12
 
Colony Stimulating Factors [Estimulantes Mieloides]
NEUPOGEN 300 mcg/0.5ml  inj soln, 300 mcg/ml inj soln, 480 mcg/1.6ml inj soln
10
Preferred
 
PA, P
NEULASTA 6 mg/0.6ml sc soln
12
Preferred
 
PA, P
NEUPOGEN 480 mcg/0.8ml inj soln
12
Preferred
 
PA, P
Erythropoiesis-Stimulating Agents [Agentes Estimulantes De Eritropoiesis]
ARANESP (ALBUMIN FREE) 100 mcg/0.5ml inj soln
1
Preferred
 
PA, P
PROCRIT 2000 unit/ml inj soln, 3000 unit/ml inj soln, 4000 unit/ml inj soln
5
Preferred
 
PA, P
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 9 for monthly net cost range [Ver página 9 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 
Página 8 de 17

Revisado: 5 de mayo de 2017
ONCOLOGIA

Drug Name [Nombre del
Medicamento]
Net
Cost
[Cost
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/
Límites]
ARANESP (ALBUMIN FREE) 25 mcg/0.42ml inj soln, 25 mcg/ml inj soln
6
Preferred
 
PA, P
PROCRIT 10000 unit/ml inj soln
6
Preferred
 
PA, P
ARANESP (ALBUMIN FREE) 40 mcg/0.4ml inj soln
7
Preferred
 
PA, P
ARANESP (ALBUMIN FREE) 40 mcg/ml inj soln, 60 mcg/ml inj soln
8
Preferred
 
PA, P
ARANESP (ALBUMIN FREE) 150 mcg/0.3ml inj soln, 150 mcg/0.75ml inj soln, 200 mcg/0.4ml inj soln, 200 mcg/ml inj soln, 300 mcg/0.6ml inj soln, 300 mcg/ml inj soln, 500 mcg/ml inj soln, 60 mcg/0.3ml inj soln
9
Preferred
 
PA, P
PROCRIT 20000 unit/ml inj soln
9
Preferred
 
PA, P
ARANESP (ALBUMIN FREE) 100 mcg/ml inj soln
11
Preferred
 
PA, P
PROCRIT 40000 unit/ml inj soln
11
Preferred
 
PA, P
Folates [Folatos]
 folic acid 1 mg tab, 400 mcg   tab, 800 mcg tab
1
Preferred
FOLIC ACID
OTC
Iron [Hierro]
iron 325 (65 fe) mg tab
1
Preferred
IRON
 
DEXFERRUM 50 mg/ml inj soln
5
Non-Preferred
   
INFED 50 mg/ml inj soln
5
Preferred
   
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 9 for monthly net cost range [Ver página 9 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 
Página 9 de 17

Revisado: 5 de mayo de 2017
ONCOLOGIA

Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/
Límites]
CHEMOTHERAPIES [QUIMIOTERAPIAS]
Alkylating Agents [Agentes Alquilantes]
lomustine 10 mg cap
3
Non-Preferred
CEENU
 
ALKERAN 2 mg tab
4
Non-Preferred
   
temozolomide 5 mg cap
4
Non-Preferred
TEMODAR
PA
lomustine 40 mg cap
5
Non-Preferred
CEENU
 
LEUKERAN 2 mg tab
6
Non-Preferred
   
lomustine 100 mg cap
6
Non-Preferred
CEENU
 
MYLERAN 2 mg tab
7
Preferred
   
temozolomide 20 mg cap
9
Non-Preferred
TEMODAR
PA
temozolomide 250 mg cap
11
Non-Preferred
TEMODAR
PA
temozolomide 140 mg cap
13
Non-Preferred
TEMODAR
PA
temozolomide 100 mg cap, 180 mg cap
14
Non-Preferred
TEMODAR
PA
Angiogenesis Inhibitors [Inhibidores de Angiogénesis]
STIVARGA 40 mg tab
21
Preferred
 
PA, P
Antiandrogens [Antiandrógenos]
bicalutamide 50 mg tab
2
Preferred
CASODEX
 
flutamide 125 mg cap
4
Non-Preferred
EULEXIN
PA
Antiestrogens [Antiestrógenos]
tamoxifen citrate 10 mg tab,   20 mg tab
1
Preferred
NOLVADEX
 
Antimetabolites [Antimetabolitos]
hydroxyurea 500 mg cap
2
Preferred
HYDREA
 
mercaptopurine 50 mg tab
2
Preferred
PURINETHOL
 
methotrexate 2.5 mg tab
2
Preferred
METHOTREXATE
 
capecitabine 150 mg tab
7
Preferred
XELODA
PA
capecitabine 500 mg tab
11
Preferred
XELODA
PA
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 9 for monthly net cost range [Ver página 9 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 
Página 10 de 17

Revisado: 5 de mayo de 2017
ONCOLOGIA
 
Antineoplastic Enzyme Inhibitors [Antineoplásicos Inhibidores De Enzimas]
SPRYCEL 20 mg tab
10
Preferred
 
PA, P
SPRYCEL 50 mg tab
13
Preferred
 
PA, P
imatinib 100 mg tab
13
Non-Preferred
GLEEVEC
PA
 
Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/
Límites]
SPRYCEL 70 mg tab
14
Preferred
 
PA, P
TASIGNA 200 mg cap
15
Preferred
 
PA, P
SPRYCEL 80 mg tab
17
Preferred
 
PA, P
TASIGNA 150 mg cap
18
Preferred
 
PA, P
SPRYCEL 100 mg tab
19
Preferred
 
PA, P
AFINITOR 2.5 mg tab
20
Preferred
 
PA, P
NEXAVAR 200 mg tab
20
Preferred
 
PA, P
SPRYCEL 140 mg tab
20
Preferred
 
PA, P
AFINITOR 10 mg tab, 5 mg tab, 7.5 mg tab
21
Preferred
 
PA, P
imatinib 400 mg tab
23
Non-Preferred
GLEEVEC
PA
Antineoplastic Progestins [Antineoplásicos De Progestina]
megestrol acetate 20 mg   tab, 40 mg tab
1
Preferred
MEGACE
 
megestrol acetate 40 mg/ml susp, 400 mg/10ml susp
2
Preferred
MEGACE
 
Aromatase Inhibitors [Inhibidores De La Aromatasa]
anastrozole 1 mg tab
1
Preferred
ARIMIDEX
 
Folic Acid Antagonists Rescue Agents [Antagonistas De Ácido Fólico]
leucovorin calcium 5 mg tab
3
Preferred
LEUCOVORIN
 
leucovorin calcium 10 mg tab, 15 mg tab
4
Preferred
LEUCOVORIN
 
leucovorin calcium 25 mg tab
9
Preferred
LEUCOVORIN
 
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 9 for monthly net cost range [Ver página 9 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 
Página 11 de 17

Revisado: 5 de mayo de 2017
ONCOLOGIA

Luteinizing Hormone-Releasing (Lhrh) Analogs [Análogos De Lhrh]
LUPRON DEPOT 11.25 mg im kit, 3.75 mg im kit
6
Preferred
 
PA, P
LUPRON DEPOT-PED 11.25 mg im kit, 15 mg im kit, 7.5 mg im kit
8
Preferred
 
PA, P
LUPRON DEPOT 22.5 mg im kit, 30 mg im kit
9
Preferred
 
PA, P

Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/
Límites]
leuprolide acetate 1 mg/ 0.2 ml inj kit
 
Non-preferred
 
PA
ZOLADEX 3.6 mg, 10.8 mg subcutaneous implant
7
Non-preferred
 
PA
Miscellaneous Antineoplastics [Antineoplásicos Misceláneos]
MATULANE 50 mg cap
10
Non-Preferred
 
PA
ACTIMMUNE 2000000 unit/0.5ml sc soln
25
Non-Preferred
 
PA
Mitotic Inhibitors [Inhibidores Mitóticos]
etoposide 50 mg cap
4
Non-Preferred
VEPESID
 
DENTAL AND ORAL AGENTS [AGENTES DENTALES Y ORALES]
Antifungals [Antifungales]
clotrimazole 10 mg   mouth/throat lozenge, 10 mg mouth/throat troche
1
Preferred
MYCELEX
OTC
nystatin 100000 unit/ml mouth/throat susp
1
Preferred
MYCOSTATIN
 
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 9 for monthly net cost range [Ver página 9 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 
Página 12 de 17

Revisado: 5 de mayo de 2017
ONCOLOGIA

DERMATOLOGICAL AGENTS [AGENTES DERMATOLÓGICOS]
Dermatological Skin Cancer Agents [Dermatológicos Para Cáncer De La Piel]
fluorouracil 2 % soln, 5 %   soln
3
Preferred
EFUDEX
 
fluorouracil 5 % crm
4
Non-Preferred
EFUDEX
 
GASTROINTESTINAL AGENTS [AGENTES GASTROINTESTINALES]
Anti-Ulcer Agents [Agentes Anti-Ulceras]
misoprostol 100 mcg tab,   200 mcg tab
1
Preferred
CYTOTEC
 
sucralfate 1 gm tab
1
Preferred
CARAFATE
 
CARAFATE 1 gm/10ml susp
3
Non-Preferred
   
Histamine2 (H2) Receptor Antagonists [Antagonistas Del Receptor De H2]
famotidine   20 mg tab, 40 mg tab
1
Preferred
PEPCID
 

Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/
Límites]
ranitidine hcl 15 mg/ml syr, 150 mg/10ml syr, 300 mg tab, 75 mg/5ml syr
1
Preferred
ZANTAC
 
Proton Pump Inhibitors [Inhibidores De La Bomba De Protones]
omeprazole 10 mg cap dr, 20 mg cap dr
1
Preferred
PRILOSEC
QL=180 caps/ 365 días
omeprazole 40 mg cap dr
1
Preferred
PRILOSEC
QL=180 caps/ 365 días
HORMONAL AGENTS [AGENTES HORMONALES]
Mineralocorticoids [Mineralocorticoides]
fludrocortisone acetate 0.1   mg tab
1
Preferred
FLORINEF
 
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 9 for monthly net cost range [Ver página 9 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 
Página 13 de 17

Revisado: 5 de mayo de 2017
ONCOLOGIA

IMMUNOSUPPRESSANTS [IMMUNOSUPRESORES]
Cyclosporine Analogs [Análogos De Ciclosporina]
NEORAL     25 mg cap
3
Preferred
 
PA, P
cyclosporine modified 25 mg cap, 50 mg cap
3
Preferred
NEORAL
PA
cyclosporine 25 mg cap
4
Preferred
SANDIMMUNE
PA
cyclosporine modified 100 mg cap, 100 mg/ml soln
4
Preferred
NEORAL
PA
cyclosporine 100 mg cap
5
Preferred
SANDIMMUNE
PA
NEORAL 100 mg cap
5
Preferred
 
PA, P
cyclosporine 100 mg cap, 25 mg cap
6
Preferred
SANDIMMUNE
PA
SANDIMMUNE 100 mg cap, 100 mg/ml soln, 25 mg cap
6
Preferred
 
PA, P
NEORAL 100 mg/ml soln
7
Preferred
 
PA, P

Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/
Límites]
Glucocorticosteroids [Glucocorticoides]
dexamethasone 0.5 mg tab,   0.5 mg/5ml oral elix, 0.5 mg/5ml soln, 0.75 mg tab, 1 mg tab, 1.5 mg tab, 2 mg tab, 4 mg tab, 6 mg tab
1
Preferred
DECADRON
 
MEDROL 2 mg tab
1
Preferred
   
methylprednisolone 32 mg tab, 4 mg tab
1
Preferred
MEDROL
 
methylprednisolone (pak) 4 mg tab
1
Preferred
MEDROL
 
prednisolone 15 mg/5ml soln, 15 mg/5ml syr
1
Preferred
PRELONE
 
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 9 for monthly net cost range [Ver página 9 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 
Página 14 de 17

Revisado: 5 de mayo de 2017
ONCOLOGIA

prednisone 1 mg tab, 10 mg tab, 2.5 mg tab, 20 mg tab, 5 mg tab, 50 mg tab
1
Preferred
DELTASONE
 
prednisone (pak) 10 mg tab, 5 mg tab
1
Preferred
DELTASONE
 
hydrocortisone 10 mg tab, 20 mg tab, 5 mg tab
2
Preferred
CORTEF
 
methylprednisolone 16 mg tab, 8 mg tab
2
Preferred
MEDROL
 
Organ Transplant Agents [Agentes Para Trasplantes]
azathioprine 50 mg tab
1
Preferred
IMURAN
 
mycophenolate mofetil 200 mg/ml susp, 250 mg cap, 500 mg tab
2
Preferred
CELLCEPT
PA
tacrolimus 0.5 mg cap
3
Non-Preferred
PROGRAF
PA
MYFORTIC 180 mg tab dr
4
Preferred
 
PA, P
tacrolimus 1 mg cap
4
Non-Preferred
PROGRAF
PA
sirolimus 0.5 mg tab, 1 mg tab, 2 mg tab
5
Non-Preferred
RAPAMUNE
PA
MYFORTIC 360 mg tab dr
6
Preferred
 
PA, P
 
Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/
Límites]
tacrolimus 5 mg cap
6
Non-Preferred
PROGRAF
PA
RAPAMUNE 1 mg/ml soln
8
Non-Preferred
 
PA
MINERALS & ELECTROLYTES [MINERALES Y ELECTROLITOS]
Calcium Regulating Agents [Agentes Reguladores De Calcio]
calcitriol   0.25 mcg cap
1
Preferred
ROCALTROL
 
calcitriol 0.5 mcg cap
2
Preferred
ROCALTROL
 
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 9 for monthly net cost range [Ver página 9 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 
Página 15 de 17

Revisado: 5 de mayo de 2017
ONCOLOGIA
 
Página 16 de 17

Revisado: 5 de mayo de 2017
 
ONCOLOGIA
 
 
 

OB-GYN
 
Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/
Límites]
THERAPEUTIC CATEGORY [CATEGORÍA TERAPÉUTICA]
Therapeutic Class [Clase Terapéutica]
ANALGESICS [ANALGÉSICOS]
Short-Acting Opioid Analgesics [Analgésicos Opiodes De Corta Duración]
oxycodone -acetaminophen 5-325 mg tab
1
Preferred
PERCOCET
QL=15 días No refills
oxycodone-acetaminophen 10-325 mg tab, 7.5-325 mg tab
3
Preferred
PERCOCET
QL=15 días No refills
ANTIANXIETY AGENTS [AGENTES PARA LA ANXIEDAD]
Miscellaneous Anxiolytics [Ansiolíticos Misceláneos]
hydroxyzine pamoate 100   mg cap, 25 mg cap, 50 mg cap
1
Preferred
VISTARIL
 
ANTIBACTERIALS [ANTIBACTERIANOS]
First Generation Cephalosporins [Cefalosporinas De Primera Generación]
cephalexin 125 mg/5ml   susp, 250 mg cap, 500 mg cap
1
Preferred
KEFLEX
 
cephalexin 250 mg/5ml susp
2
Preferred
KEFLEX
 
Macrolides [Macrólidos]
azithromycin 250 mg tab,   500 mg tab
1
Preferred
ZITHROMAX
 
azithromycin 1 gm pckt, 100 mg/5ml susp, 200 mg/5ml susp, 600 mg tab
2
Preferred
ZITHROMAX
 
ERY-TAB 500 mg tab dr
3
Preferred
   
erythromycin base 250 mg cap dr prt, 250 mg tab, 500 mg tab
3
Preferred
ERY-TAB
 
erythromycin ethylsuccinate 400 mg tab
3
Preferred
E.E.S.
 
ERYTHROCIN STEARATE 250 mg tab
4
Non-Preferred
   
 
Página 1 de 15

Revisado: 1 de mayo de 2017
OB-GYN
 
Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/
Límites]
E.E.S. GRANULES 200 mg/5ml susp
5
Preferred
   
ERYPED 200 200 mg/5ml susp
5
Preferred
   
ERYPED 400 400 mg/5ml susp
6
Preferred
   
Miscellaneous Antibacterials [Antibacterianos Misceláneos]
clindamycin hcl 150 mg cap,   300 mg cap, 75 mg cap
1
Preferred
CLEOCIN
 
MACRODANTIN 25 mg cap
1
Preferred
   
metronidazole 250 mg tab, 500 mg tab
1
Preferred
FLAGYL
 
nitrofurantoin macrocrystal 50 mg cap
1
Preferred
MACRODANTIN
 
nitrofurantoin macrocrystal 100 mg cap
2
Preferred
MACRODANTIN
 
nitrofurantoin monohyd macro 100 mg cap
2
Preferred
MACROBID
 
nitrofurantoin oral
suspension 25 MG/5ML
6
Non-Preferred
FURADANTIN
 
Penicillins [Penicilinas]
amoxicillin 125 mg/5ml susp            , 200 mg/5ml susp, 250 mg cap, , 250 mg/5ml susp, 400 mg/5ml susp, 500 mg cap, 500 mg tab, 875 mg tab
1
Preferred
AMOXIL
 
amoxicillin-pot clavulanate 200-28.5 mg/5ml susp, 40057 mg/5ml susp, 500-125 mg tab, 875-125 mg tab
1
Preferred
AUGMENTIN
 
ampicillin 125 mg/5ml susp, 250 mg cap, 250 mg/5ml susp, 500 mg cap
1
Preferred
PRINCIPEN
 
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 9 for monthly net cost range [Ver página 9 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 
Página 2 de 15

Revisado: 1 de mayo de 2017
OB-GYN

Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/
Límites]
penicillin v potassium 125 mg/5ml soln, 250 mg tab, 250 mg/5ml soln, 500 mg tab
1
Preferred
VEETIDS
 
amoxicillin-pot clavulanate 250-125 mg tab, 250-62.5 mg/5ml susp
3
Preferred
AUGMENTIN
 
BICILLIN L-A 600000 unit/ml im susp
3
Non-Preferred
   
penicillin g procaine 600000 unit/ml im susp
3
Non-Preferred
BICILLIN LA
 
BICILLIN L-A 1200000 unit/2ml im susp
4
Non-Preferred
   
BICILLIN L-A 2400000 unit/4ml im susp
5
Non-Preferred
   
Second Generation Cephalosporins [Cefalosporinas De Segunda Generación]
cefaclor 250 mg cap, 500   mg cap
2
Preferred
CECLOR
 
cefprozil 125 mg/5ml susp, 250 mg tab, 250 mg/5ml susp, 500 mg tab
2
Preferred
CEFZIL
 
Sulfonamides [Sulfonamidas]
sulfamethoxazole   -tmp ds 800-160 mg tab
1
Preferred
SEPTRA
 
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 9 for monthly net cost range [Ver página 9 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 
Página 3 de 15

Revisado: 1 de mayo de 2017
OB-GYN

sulfamethoxazoletrimethoprim 200-40 mg/5ml susp, 400-80 mg tab
1
Preferred
SEPTRA
 
Third Generation Cephalosporins [Cefalosporinas De Tercera Generación]
cefdinir 125 mg/5ml susp,   300 mg cap
2
Preferred
OMNICEF
 
cefdinir 250 mg/5ml susp
3
Preferred
OMNICEF
 
Vaginal Antibiotics [Antibióticos Vaginales]
metronidazole 0.75 % vag   gel
2
Preferred
VANDAZOLE
 

Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/
Límites]
clindamycin phosphate 2 % vag crm
3
Preferred
CLEOCIN
 
ANTIDIABETIC AGENTS [AGENTES ANTIDIABÉTICOS]
Insulin Mixtures [Mezclas De Insulinas]
HUMULIN 70/30 (70 -30) 100 unit/ml sc susp
3
Preferred
 
P
HUMALOG MIX 75/25 (7525) 100 unit/ml sc susp
4
Preferred
 
P
HUMALOG MIX 50/50 (5050) 100 unit/ml sc susp
4
Preferred
 
P
Intermediate-Acting Insulins [Insulinas De Duración Intermedia]
HUMULIN N 100 unit/ml sc   susp
2
Preferred
 
P
Long-Acting Insulins [Insulinas De Larga Duración]
LANTUS SOLOSTAR 100   unit/ml subcutaneous solution pen-injector
3
Preferred
 
P
LANTUS 100 unit/ml sc soln
3
Preferred
 
P
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 9 for monthly net cost range [Ver página 9 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 
Página 4 de 15

Revisado: 1 de mayo de 2017
OB-GYN

Rapid-Acting Insulins [Insulinas De Rápida Duración]
HUMALOG 100 unit/ml sc   soln
4
Preferred
 
P
Short-Acting Insulins [Insulinas De Corta Duración]
HUMULIN R 100 unit/ml inj   soln
2
Preferred
 
P
ANTIEMETICS [ANTIEMÉTICOS]
Miscellaneous Antiemetics [Antieméticos Misceláneos]
metoclopramide hcl 10 mg   tab, 10 mg/10ml soln, 5 mg tab, 5 mg/5ml soln, 5 mg/ml inj soln
1
Preferred
REGLAN
 
trimethobenzamide hcl 300 mg cap
1
Preferred
TIGAN
 

Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/
Límites]
Phenothiazines [Fenotiazinas]
prochlorperazine edisylate 5   mg/ml inj soln
1
Preferred
COMPAZINE
 
prochlorperazine maleate 10 mg tab, 5 mg tab
1
Preferred
COMPAZINE
 
prochlorperazine 25 mg rect supp
4
Non-Preferred
COMPAZINE
 
ANTIHYPERTENSIVES [ANTIHIPERTENSIVOS]
Alpha-Adrenergic Agonists [Agonistas Alfa Adrenérgicos]
methyldopa 250 mg tab, 500   mg tab
1
Preferred
ALDOMET
 
Cardioselective Beta Blocking Agents [Bloqueadores Beta Cardioselectivos]
atenolol 100 mg tab, 25 mg tab, 50 mg tab
1
Preferred
TENORMIN
 
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 9 for monthly net cost range [Ver página 9 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 
Página 5 de 15

Revisado: 1 de mayo de 2017
OB-GYN

metoprolol succinate er 25 mg tab er 24 hr, 50 mg tab er 24 hr
1
Preferred
LOPRESSOR
 
metoprolol tartrate 100 mg tab, 25 mg tab, 50 mg tab
1
Preferred
LOPRESSOR
 
metoprolol succinate er 100 mg tab er 24 hr, 200 mg tab er 24 hr
2
Preferred
LOPRESSOR
 
Cardioselective Beta-Adrenergic Blocking Agents [Bloqueadores Beta-Adrenérgicos Cardioselectivos]
atenolol -chlorthalidone 10025 mg tab, 50-25 mg tab
1
Preferred
TENORETIC
 
metoprolol-hydrochlorothiazide 50-25 mg tab
2
Non-Preferred
LOPRESSOR HCT
 
metoprololhydrochlorothiazide 100-25 mg tab, 100-50 mg tab
3
Non-Preferred
LOPRESSOR HCT
 

Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/
Límites]
Nonselective Beta Blocking Agents [Bloqueadores Beta No-Selectivos]
propranolol hcl 10 mg tab   , 20 mg tab, 40 mg tab, 80 mg tab
1
Preferred
INDERAL
 
propranolol hcl 60 mg tab
2
Preferred
INDERAL
 
Vasodilator Beta Blockers [Bloqueadores Beta Vasodilatadores]
carvedilol 12.5 mg tab, 25   mg tab, 3.125 mg tab, 6.25 mg tab 1 Preferred COREG
Vasodilators [Vasodilatadores]
hydralazine hcl 10 mg tab,   100 mg tab, 25 mg tab, 50 mg tab
1
Preferred
APRESOLINE
 
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 9 for monthly net cost range [Ver página 9 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 
Página 6 de 15

Revisado: 1 de mayo de 2017
OB-GYN
 
ANTIMYCOBACTERIALS [ANTIMICOBACTERIANOS]
Antituberculars [Antituberculosos]
isoniazid 100 mg tab, 300   mg tab
1
Preferred
ISONIAZID
 
rifampin 150 mg cap
1
Preferred
RIFADIN
 
ethambutol hcl 100 mg tab
2
Non-Preferred
MYAMBUTOL
 
rifampin 300 mg cap
2
Preferred
RIFADIN
 
ethambutol hcl 400 mg tab
3
Non-Preferred
MYAMBUTOL
 
isoniazid 50 mg/5ml syr
5
Non-Preferred
ISONIAZID
 
rifabutin 150 mg cap
6
Preferred
MYCOBUTIN
Puerto Rico Health
Department
Tuberculosis
Control Program
RIFAMATE 50-300 mg cap
     
TRECATOR 250 mg tab
     
Miscellaneous Antimycobacterials [Antimicobacterianos Misceláneos]
dapsone 100 mg tab, 25 mg   tab
2
Preferred
DAPSONE
 
ANTIMYCOTIC AGENTS [ANTIMICÓTICOS]
Vaginal Antifungals [Antifungales Vaginales]
terconazole 0.4 % vag crm, 0.8 % vag crm
2
Preferred
TERAZOL
 

Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/
Límites]
ANTIPARASITICS [ANTIPARASITARIOS]
Antiprotozoals - Non-Antimalarials [Antiprotozoarios No-Antimalaráricos]
NEBUPENT 300 mg inh soln
4
Preferred
 
PA
ANTIVIRALS [ANTIVIRALES]
Antiherpetic Agents [Agentes Antiherpéticos]
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 9 for monthly net cost range [Ver página 9 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 
Página 7 de 15

Revisado: 1 de mayo de 2017
OB-GYN

acyclovir 200 mg cap, 400   mg tab, 800 mg tab
1
Preferred
ZOVIRAX
 
acyclovir 200 mg/5ml susp
2
Preferred
ZOVIRAX
 
Anti-Influenza Agents [Agentes Antiinfluenza]
RELENZA DISKHALER 5 mg/blister inh aer pwdr
3
Preferred
   
oseltamivir phosphate 30 mg cap, 45 mg cap, 75 mg cap
4
Preferred
TAMIFLU
 
TAMIFLU 6 mg/ ml susp
5
Non-Preferred
   
Nucleoside/Nucleotide Reverse Transcriptase Inhibitors [Inhibidores Nucleósidos/Nucleótidos De La Transcriptasa Reversa]
zidovudine 300 mg tab
2
Non-Preferred
RETROVIR
 
zidovudine 100 mg cap, 50 mg/5ml syr
4
Non-Preferred
RETROVIR
 
BLOOD MODIFIERS [MODIFICADORES DE LA SANGRE]
Anticoagulants [Anticoagulantes]
heparin sodium (porcine)   1000 unit/ml inj soln
2
Preferred
HEPARIN
 
heparin sodium (porcine) 10000 unit/ml inj soln, 5000 unit/ml inj soln
3
Preferred
HEPARIN
 
heparin sodium (porcine) pf 5000 unit/0.5ml inj soln
3
Preferred
HEPARIN
 
heparin sodium (porcine) 2000 unit/ml iv soln
8
Preferred
HEPARIN
 
Cobalamins [Cobalaminas]
cyanocobalamin 1000   mcg/ml inj soln
1
Preferred
VIT B-12
 
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 9 for monthly net cost range [Ver página 9 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 
Página 8 de 15

Revisado: 1 de mayo de 2017
OB-GYN

Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/
Límites]
Folates [Folatos]
 folic acid 1 mg tab, 400 mcg   tab, 800 mcg tab
1
Preferred
FOLIC ACID
OTC
Iron [Hierro]
iron 325 (65 fe) mg tab
1
Preferred
IRON
 
DEXFERRUM 50 mg/ml inj soln
5
Non-Preferred
   
INFED 50 mg/ml inj soln
5
Preferred
   
BONE DENSITY REGULATORS [REGULADORES DE DENSIDAD ÓSEA]
Bisphosphonates [Bifosfonatos]
alendronate sodium 10 mg   tab, 35 mg tab, 5 mg tab, 70 mg tab
1
Preferred
FOSAMAX
 
CHEMOTHERAPIES [QUIMIOTERAPIAS]
Folic Acid Antagonists Rescue Agents [Antagonistas De Ácido Fólico]
leucovorin calcium 5 mg tab
3
Preferred
LEUCOVORIN
 
leucovorin calcium 10 mg tab, 15 mg tab
4
Preferred
LEUCOVORIN
 
leucovorin calcium 25 mg tab
9
Preferred
LEUCOVORIN
 
leucovorin calcium 50 mg inj, 100 mg inj, 200 mg inj, 350 mg inj, 500 mg inj
9
Non-Preferred
LEUCOVORIN
 
Luteinizing Hormone-Releasing (Lhrh) Analogs [Análogos De Lhrh]
LUPRON DEPOT 11.25 mg
im kit, 3.75 mg im kit
6
Preferred
 
PA, P
ZOLADEX 3.6 mg, 10.8 mg subcutaneous implant
7
Non-preferred
 
PA
DERMATOLOGICAL AGENTS [AGENTES DERMATOLÓGICOS]
Antihistamines [Antihistamínicos]
hydroxyzine hcl 10 mg tab,   10 mg/5ml soln, 10 mg/5ml syr, 25 mg tab, 50 mg tab
1
Preferred
ATARAX
 
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 9 for monthly net cost range [Ver página 9 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 
Página 9 de 15

Revisado: 1 de mayo de 2017
OB-GYN
 
Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/
Límites]
Topical Antifungals [Antifungales Tópicos]
clotrimazole 1 % crm
1
Preferred
LOTRIMIN
OTC ( crm )
nystatin 100000 unit/gm oint
1
Preferred
MYCOSTATIN
 
DIABETES SUPPLIES [SUMINISTROS PARA DIABETES]
Needles & Syringes [Agujas Y Jeringuillas]
insulin syringe/needle  
1
Preferred
.
 
GASTROINTESTINAL AGENTS [AGENTES GASTROINTESTINALES]
Anti-Ulcer Agents [Agentes Anti-Ulceras]
sucralfate 1 gm tab
1
Preferred
CARAFATE
 
CARAFATE 1 gm/10ml susp
3
Non-Preferred
   
Histamine2 (H2) Receptor Antagonists [Antagonistas Del Receptor De H2]
famotidine 20 mg tab, 40 mg   tab
1
Preferred
PEPCID
 
ranitidine hcl 15 mg/ml syr, 150 mg/10ml syr, 300 mg tab, 75 mg/5ml syr
1
Preferred
ZANTAC
 
Rectal Anti-Inflammatories [Anti-Inflamatorios Rectales]
hydrocortisone ace   pramoxine 1-1 % rect crm, 2.5-1 % rect crm
2
Preferred
ANALPRAM-HC
 
pramcort 1-1 % rect crm
2
Preferred
ANALPRAM-HC
 
HORMONAL AGENTS [AGENTES HORMONALES]
Dysmenorrhea Agents [Agentes Para La Dismenorrea]
medroxyprogesterone   acetate 10 mg tab, 2.5 mg tab, 5 mg tab
1
Preferred
PROVERA
 
alyacen 1/35 1-35 mg-mcg tab
2
Preferred
ARANELLE
PA
CRYSELLE-28 0.3-30 mgmcg tab
2
Preferred
 
PA
ELINEST 0.3-30 mg-mcg tab
2
Preferred
 
PA
LOW-OGESTREL 0.3-30 mg-mcg tab
2
Preferred
 
PA
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 9 for monthly net cost range [Ver página 9 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 
Página 10 de 15

Revisado: 1 de mayo de 2017
OB-GYN

Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/
Límites]
Estrogens [Estrógenos]
estradiol 1 mg tab, 2 mg tab
1
Preferred
ESTRACE
 
estropipate 0.75 mg tab, 1.5 mg tab
1
Preferred
ESTROPIPATE
 
estropipate 3 mg tab
2
Preferred
ESTROPIPATE
 
Estrogens and Progestins [Estrógenos y Progestinas]
 
estradiol   -norethindrone acet 1-0.5 mg tab
4
Non-Preferred
ACTIVELLA
 
Glucocorticosteroids [Glucocorticoides]
betamethasone sod phos &   acet 6 (3-3) mg/ml inj susp
2
Preferred
CELESTONE
 
Mineralocorticoids [Mineralocorticoides]
fludrocortisone acetate 0.1   mg tab
1
Preferred
FLORINEF
 
Thyroid Hormones [Hormona Tiroidea]
levothyroxine sodium 100   mcg tab, 112 mcg tab, 125 mcg tab, 137 mcg tab, 150 mcg tab, 175 mcg tab, 200 mcg tab, 25 mcg tab, 300 mcg tab, 50 mcg tab, 75 mcg tab, 88 mcg tab
1
Preferred
SYNTHROID
 
SYNTHROID 100 mcg tab, 112 mcg tab, 125 mcg tab,137 mcg tab, 150 mcg tab, 175 mcg tab, 200 mcg tab, 25 mcg tab, 300 mcg tab, 50 mcg tab, 75 mcg tab, 88 mcg tab
1
Preferred
 
P
Vaginal Estrogens [Estrógenos Vaginal]
VAGIFEM 10 mcg vag tab
3
Non-Preferred
   
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 9 for monthly net cost range [Ver página 9 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 
Página 11 de 15

Revisado: 1 de mayo de 2017
OB-GYN
Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/
Límites]
IMMUNOSUPPRESSANTS [IMMUNOSUPRESORES]
Glucocorticosteroids [Glucocorticoides]
dexamethasone 0.5 mg tab,   0.5 mg/5ml oral elix, 0.5 mg/5ml soln, 0.75 mg tab, 1 mg tab, 1.5 mg tab, 2 mg tab, 4 mg tab, 6 mg tab
1
Preferred
DECADRON
 
dexamethasone sodium phosphate 120 mg/30ml inj soln, 20 mg/5ml inj soln, 4 mg/ml inj soln
1
Preferred
DECADRON
 
KENALOG 10 mg/ml inj susp
1
Non-Preferred
   
MEDROL 2 mg tab
1
Preferred
   
methylprednisolone 32 mg tab, 4 mg tab
1
Preferred
MEDROL
 
methylprednisolone (pak) 4 mg tab
1
Preferred
MEDROL
 
prednisolone 15 mg/5ml soln, 15 mg/5ml syr
1
Preferred
PRELONE
 
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización
Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 9 for monthly net cost range [Ver página 9 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 
Página 12 de 15

Revisado: 1 de mayo de 2017
OB-GYN

prednisone 1 mg tab, 10 mg tab, 2.5 mg tab, 20 mg tab, 5 mg tab, 50 mg tab
1
Preferred
DELTASONE
 
prednisone (pak) 10 mg tab, 5 mg tab
1
Preferred
DELTASONE
 
hydrocortisone 10 mg tab, 20 mg tab, 5 mg tab
2
Preferred
CORTEF
 
methylprednisolone 16 mg tab, 8 mg tab
2
Preferred
MEDROL
 
KENALOG 40 mg/ml inj susp
5
Non-Preferred
   
Immune Globulins [Immunoglobulinas]
RHOGAM ultra-filtered plus im soln 1500 unit
4
Preferred
   

Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/
Límites]
MINERALS & ELECTROLYTES [MINERALES Y ELECTROLITOS]
Prenatal Vitamins [Vitaminas Prenatales]
prenatal tab
1
Preferred
PRENATAL VITAMINS
 
RESPIRATORY AGENTS [AGENTES RESPIRATORIOS]
Anticholinergic Bronchodilators [Broncodilatadores Anticolinérgicos]
ipratropium bromide 0.02 %   inh soln
1
Non-Preferred
ATROVENT
 
Inhaled Corticosteroids [Corticosteroides Inhalados]
FLOVENT DISKUS 100 mcg/blist inh aer pwdr, 250 mcg/blist inh aer pwdr, 50 mcg/blist inh aer pwdr
3
Preferred
 
QL = 1 pompa / 30 días, P
FLOVENT HFA 110 mcg/act inh aer, 44 mcg/act inh aer
3
Preferred
 
QL = 1 pompa / 30 días, P
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 9 for monthly net cost range [Ver página 9 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 
Página 13 de 15

Revisado: 1 de mayo de 2017
OB-GYN

ADVAIR DISKUS 100-50 mcg/dose inh aer pwdr, 25050 mcg/dose inh aer pwdr
4
Preferred
 
QL = 1 pompa / 30 días, ST, P
ADVAIR HFA 115-21 mcg/act inh aer, 45-21 mcg/act inh aer
4
Preferred
 
QL = 1 pompa / 30 días, ST, P
budesonide 0.25 mg/2ml inh susp, 0.5 mg/2ml inh susp,
4
Non-Preferred
PULMICORT
AL ≤ 12 años
budesonide 1mg/2ml inh susp
8
Non-Preferred
PULMICORT
AL ≤ 12 años
FLOVENT HFA 220 mcg/act inh aer
4
Preferred
 
QL = 1 pompa / 30 días, P
ADVAIR DISKUS 500-50 mcg/dose inh aer pwdr
5
Preferred
 
QL = 1 pompa / 30 días, ST, P
ADVAIR HFA 230-21 mcg/act inh aer
5
Preferred
 
QL = 1 pompa / 30 días, ST, P
Nonsedating Histamine1 Blocking Agents [Bloqueadores De Histamina1 No-Sedantes]
loratadine 10 mg tab
1
Preferred
CLARITIN
OTC

Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/
Límites]
Sedating Histamine1 Blocking Agents [Sedantes Bloqueadores Histamine1]
promethazine hcl 12.5 mg   tab, 25 mg tab, 50 mg tab, 6.25 mg/5ml soln, 6.25 mg/5ml syr
1
Preferred
PHENERGAN
 
Sympathomimetic Bronchodilators [Broncodilatadores Simpatomiméticos]
albuterol sulfate (2.5   mg/3ml) 0.083% inh neb soln, (5 mg/ml) 0.5% inh neb soln
1
Preferred
ALBUTEROL
 
terbutaline sulfate 2.5 mg tab, 5 mg tab
1
Preferred
BRETHINE
 
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 9 for monthly net cost range [Ver página 9 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 
Página 14 de 15

Revisado: 1 de mayo de 2017
OB-GYN
 
VENTOLIN HFA 108 (90 base) mcg/act inh aer
1
Preferred
 
QL = 1 pompa / 30 días, P
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 9 for monthly net cost range [Ver página 9 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]

Página 15 de 15

SALUD FÍSICA
 
Drug Name [Nombre del
 Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
 [Nombre de
Referencia]
Requirements/
Limits
[Requerimientos /
Límites]
THERAPEUTIC CATEGORY [CATEGORÍA TERAPÉUTICA]
Therapeutic Class [Clase Terapéutica]
ANALGESICS [ANA    LGÉSICOS]
Nonsteroidal Anti-Inflammatory Agents (NSAIDs) [Anti-Inflamatorios No Esteroidales]
ibuprofen 400 mg tab, 600 mg tab, 800 mg tab
1
Preferred
MOTRIN
QL=15 días No refills
indomethacin 25 mg cap, 50 mg cap
1
Non-Preferred
INDOCIN
 
nabumetone 500 mg tab, 750 mg tab
1
Preferred
RELAFEN
 
naproxen 250 mg tab, 375 mg tab, 500 mg tab
1
Preferred
NAPROSYN
QL=15 días No refills
naproxen dr 375 mg tab dr, 500 mg tab dr
1
Preferred
NAPROSYN
QL=15 días No refills
salsalate 500 mg tab, 750 mg tab
1
Preferred
DISALCID
 
sulindac 150 mg tab, 200 mg tab
1
Preferred
CLINORIL
 
meloxicam7.5 mg tab, 15 mg tab
1
Preferred
MOBIC
QL=15 días No refills
Long-Acting Opioid Analgesics [Analgésicos Opiodes de Larga Duración]
fentanyl 25 mcg/hr td patch   72 hr
2
Preferred
DURAGESIC
 
fentanyl 50 mcg/hr td patch 72 hr, 75 mcg/hr td patch 72 hr
3
Preferred
DURAGESIC
 
morphine sulfate er 15 mg tab er
3
Preferred
MORPHINE
 
fentanyl 100 mcg/hr td patch 72 hr
4
Preferred
DURAGESIC
 
morphine sulfate er 30 mg tab er
4
Preferred
MORPHINE
 
morphine sulfate er 60 mg tab er
5
Preferred
MORPHINE
 
morphine sulfate er 100 mg tab er
6
Preferred
MORPHINE
 
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización    Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age    Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página de 53 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017
 

SALUD FÍSICA
 
Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos /
Límites]
methadone hcl oral tablet 10 mg
 
Preferred
METHADONE
ASSMCA
methadone hcl oral solution 10 mg/ 5ml
 
Preferred
METHADONE
ASSMCA
Short-Acting Opioid Analgesics [Analgésicos Opiodes de Corta Duración]
test  
acetaminophen-codeine 120-12 mg/5ml soln, 30015 mg tab, 300-30 mg tab,
300-60 mg tab
1
Preferred
TYLENOL-CODEINE
 
QL=15 días No refills
hydrocodoneacetaminophen 10-325 mg tab, 5-325 mg tab, 7.5-325 mg tab, 7.5-500 mg/15ml soln
1
Preferred
VICODIN
QL=15 días  No refills
hydromorphone hcl 2 mg tab, 4 mg tab
1
Preferred
DILAUDID
 
meperidine hcl 50 mg/ml inj soln
1
Preferred
DEMEROL
 
morphine sulfate 15 mg tab, 30 mg tab
1
Preferred
MORPHINE
 
oxycodone-acetaminophen 5-325 mg tab
1
Preferred
OXYCODONE APAP
QL=15 días  No refills
tramadol hcl 50 mg tab
1
Preferred
ULTRAM
 
butalbital-apap-caffeine 50325-40 mg cap, 50-325-40 mg tab
2
Preferred
FIORICET
QL=15 días  No refills
codeine sulfate 15 mg tab, 30 mg tab, 60 mg tab
2
Preferred
CODEINE
 
meperidine hcl 100 mg/ml inj soln
2
Preferred
DEMEROL
 
morphine sulfate 10 mg/5ml soln
2
Preferred
MORPHINE
 
morphine sulfate (concentrate) 100 mg/5ml soln, 20 mg/ml soln
2
Preferred
MORPHINE
 
hydromorphone hcl 8 mg tab
3
Preferred
DILAUDID
 
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización    Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age    Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página 2 de 53  para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017
 

SALUD FÍSICA
 
Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
 [Nombre de
Referencia]
Requirements/
Limits
[Requerimientos /
Límites]
oxycodone-acetaminophen 10-325 mg tab, 7.5-325 mg tab
3
Preferred
OXYCODONE APAP
QL=15 días  No refills
hydromorphone hcl 1 mg/ml oral liquid
4
Preferred
DILAUDID
 
ANESTHETICS [ANESTÉSICOS]
 
  Local Anesthetics [Anestésicos Locales]
 
lidocaine viscous 2 % mouth/throat soln
1
Preferred
XYLOCAINE
 
ANTIANXIETY AGENTS [AGENTES PARA LA ANSIEDAD]
 
Benzodiazepines [Ben   zodiazepinas]
 
clonazepam 0.5 mg tab, 1 mg tab, 2mg tab
1
Preferred
KLONOPIN
diazepam 1 mg/ml soln, 10 mg tab, 2 mg tab, 5 mg tab, 5 mg/ml oral conc
1
Preferred
VALIUM
MENTAL/SUBMENTAL QL=5días
flurazepam hcl 15 mg cap, 30 mg cap
1
Preferred
DALMANE
MENTAL/SUBMENTAL QL=5días
lorazepam 0.5 mg tab, 1 mg tab
1
Preferred
ATIVAN
MENTAL/SUBMENTAL QL=5días
midazolam hcl 10 mg/10ml inj soln, 2 mg/2ml inj soln, 5 mg/5ml inj soln, 5 mg/ml inj soln
1
Preferred
VERSED
QL 5ml / 30días
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización    Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age    Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página 3 de 53 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017

SALUD FÍSICA
 
Miscellaneous Anxiolytics [Ansiolíticos Misceláneos]
hydroxyzine pamoate 100   mg cap, 25 mg cap, 50 mg cap
1
Preferred
VISTARIL
 
ANTIBACTERIALS [ANTIBACTERIANOS]
 
Aminoglycosides [Aminoglucósidos]
 
tobramycin 300 mg/5ml inh neb soln
18
Non-Preferred
TOBI
PA
 
Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos /
Límites]
First Generation Cephalosporins [Cefalosporinas de Primera Generación]
cephalexin 125 mg/5ml   susp, 250 mg cap, 500 mg cap
1
Preferred
KEFLEX
 
cefadroxil 250 mg/5ml susp
2
Non-Preferred
DURICEF
AL ≤ 12 años
cephalexin 250 mg/5ml susp
2
Preferred
KEFLEX
 
cefadroxil 500 mg/5ml susp
3
Non-Preferred
DURICEF
AL ≤ 12 años
Macrolides [Macrólidos]
azithromycin 250 mg tab,   500 mg tab
1
Preferred
ZITHROMAX
 
azithromycin 1 gm pckt, 100 mg/5ml susp, 200 mg/5ml susp, 600 mg tab
2
Preferred
ZITHROMAX
 
clarithromycin 125 mg/5ml susp, 250 mg tab, 500 mg tab
2
Preferred
BIAXIN
 
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización    Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age    Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página 4 de 53 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017
 

SALUD FÍSICA
 
 clarithromycin 250 mg/5ml susp
3
Preferred
BIAXIN
 
erythromycin base 250 mg cap dr prt, 250 mg tab, 500 mg tab
3
Preferred
ERY-TAB
 
erythromycin ethylsuccinate 400 mg tab
3
Preferred
E.E.S.
 
ERYTHROCIN STEARATE 250 mg tab
4
Non-Preferred
   
Miscellaneous Antibacterials [Antibacterianos Misceláneos]
clindamycin hcl 150 mg   cap, 300 mg cap, 75 mg cap
1
Preferred
CLEOCIN
 
MACRODANTIN 25 mg cap
1
Preferred
   
metronidazole 250 mg tab, 500 mg tab
1
Preferred
FLAGYL
 
nitrofurantoin macrocrystal 50 mg cap
1
Preferred
MACRODANTIN
 

Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos /
Límites]
nitrofurantoin macrocrystal 100 mg cap
2
Preferred
MACRODANTIN
 
nitrofurantoin monohyd macro 100 mg cap
2
Preferred
MACROBID
 
nitrofurantoin oral suspension 25 MG/5ML
6
Non-Preferred
FURADANTIN
 
vancomycin hcl 125 mg cap
9
Non-Preferred
VANCOCIN
 
vancomycin hcl 250 mg cap
10
Non-Preferred
VANCOCIN
 
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización    Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age    Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página 5 de 53   para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017
 

SALUD FÍSICA
 
Penincillinis [Penicilinas]
amoxicillin 125 mg/5ml susp, 200 mg/5ml susp, 250 mg cap, 250 mg/5ml susp, 400 mg/5ml susp, 500 mg cap, 500 mg tab, 875 mg tab
1
 
Preferred
AMOXIL
 
amoxicillin-pot clavulanate 200-28.5 mg/5ml susp, 400-57 mg/5ml susp, 500125 mg tab, 600-42.9 mg/5ml susp, 875-125 mg tab
1
Preferred
AUGMENTIN
 
ampicillin 125 mg/5ml susp, 250 mg cap, 250 mg/5ml susp, 500 mg cap
1
Preferred
PRINCIPEN
 
penicillin v potassium 125 mg/5ml soln, 250 mg tab, 250 mg/5ml soln, 500 mg tab
1
Preferred
VEETIDS
 
amoxicillin-pot clavulanate 250-125 mg tab, 250-62.5 mg/5ml susp
3
Preferred
AUGMENTIN
 
BICILLIN L-A 600000 unit/ml im susp
3
Non-Preferred
   
penicillin g procaine 600000 unit/ml im susp
3
Non-Preferred
BICILLIN LA
 

Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos
/Límites]
BICILLIN L-A 1200000 unit/2ml im susp
4
Non-Preferred
   
BICILLIN L-A 2400000 unit/4ml im susp
5
Non-Preferred
   
Quinolones [Quinolonas]
ciprofloxacin hcl 250 mg   tab, 500 mg tab, 750 mg tab
1
Preferred
CIPRO
 
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización   Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age    Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página 6 de 53  para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017
 

SALUD FÍSICA
 
levofloxacin 250 mg tab, 500 mg tab, 750 mg tab
1
Preferred
LEVAQUIN
 
ciprofloxacin 500 mg/5ml (10%) susp
3
Preferred
CIPRO
 
ciprofloxacin 250 mg/5ml (5%) susp
4
Preferred
CIPRO
 
Second Generation Cephalosporins [Cefalosporinas de Segunda Generación]
cefaclor 250 mg cap, 500   mg cap
2
Preferred
CECLOR
 
cefprozil 125 mg/5ml susp, 250 mg tab, 250 mg/5ml susp, 500 mg tab
2
Preferred
CEFZIL
 
Sulfonamides [Sulfonamidas]
sulfamethoxazole    -tmp ds 800-160 mg tab
1
Preferred
SEPTRA
 
sulfamethoxazoletrimethoprim 200-40 mg/5ml susp, 400-80 mg tab
1
Preferred
SEPTRA
 
sulfadiazine 500 mg tab
4
Preferred
SULFADIAZINE
 
Tetracyclines [Tetraciclinas]
minocycline hcl 100 mg   cap, 50 mg cap, 75 mg cap
1
Preferred
MINOCIN
 
doxycycline monohydrate 50  mg cap, 100 mg cap
2
Non-Preferred
MONODOX
 
Third Generation Cephalosporins [Cefalosporinas de Tercera Generación]
cefdinir 125 mg/5ml susp,   300 mg cap
2
Preferred
OMNICEF
 
cefdinir 250 mg/5ml susp
3
Preferred
OMNICEF
 

Drug Name
[Nombre del
 Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos
/Límites]
Vaginal Antibiotics [Antibióticos Vaginales]
metronidazole 0.75 % vag   gel
2
Preferred
VANDAZOLE
 
clindamycin phosphate 2 % vag crm
3
Non-Preferred
CLEOCIN
 
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización   Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age    Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página 7 de 53  para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017
 

SALUD FÍSICA
 
ANTICONVULSANTS [ANTICONVULSIVANTES]
Anticonvulsants [Anticonvulsivantes]
carbamazepine 100 mg tab   chew, 200 mg tab
1
Preferred
TEGRETOL
 
clonazepam 0.5 mg tab, 1 mg tab, 2 mg tab
1
Preferred
KLONOPIN
 
divalproex sodium 125 mg tab dr, 250 mg tab dr, 500 mg tab dr
1
Preferred
DEPAKOTE
 
gabapentin 100 mg cap, 300 mg cap, 400 mg cap, 600 mg tab, 800 mg tab
1
Preferred
NEURONTIN
 
lamotrigine 100 mg tab, 150 mg tab, 200 mg tab, 25 mg tab
1
Preferred
LAMICTAL
 
lamotrigine chew tab 5 mg, 25 mg
3
Non-Preferred
LAMICTAL
 
levetiracetam 250 mg tab, 500 mg tab
1
Preferred
KEPPRA
 
levetiracetam er 24 hrs 500 mg tab, 750 mg
3
Non-Preferred
KEPPRA XR
 
oxcarbazepine 150 mg tab
1
Preferred
TRILEPTAL
 
phenobarbital 100 mg tab, 15 mg tab, 16.2 mg tab, 30 mg tab, 32.4 mg tab, 60 mg tab, 64.8 mg tab, 97.2 mg tab
1
Preferred
PHENOBARBITAL
 
primidone 250 mg tab, 50 mg tab
1
Preferred
MYSOLINE
 
topiramate 100 mg tab, 200 mg tab, 25 mg tab, 50 mg tab
1
Preferred
TOPAMAX
 
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización   Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age    Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página 8 de 53  para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017
 

SALUD FÍSICA
 
Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos
/Límites]
valproic acid 250 mg cap, 250 mg/5ml syr
1
Preferred
DEPAKENE
 
zonisamide 50 mg cap
1
Preferred
ZONEGRAN
 
DILANTIN 30 mg cap
2
Preferred
   
gabapentin 250 mg/5ml soln
2
Preferred
NEURONTIN
 
levetiracetam 100 mg/ml soln, 1000 mg tab, 750 mg tab
2
Preferred
KEPPRA
 
oxcarbazepine 300 mg tab, 600 mg tab
2
Preferred
TRILEPTAL
 
phenytoin 125 mg/5ml susp, 50 mg tab chew
2
Preferred
DILANTIN
 
phenytoin sodium extended 100 mg cap, 200 mg cap, 300 mg cap
2
Preferred
DILANTIN
 
zonisamide 100 mg cap, 25 mg cap
2
Preferred
ZONEGRAN
 
carbamazepine er 200 mg tab er 12 hr
3
Preferred
TEGRETOL
 
ethosuximide 250 mg cap, 250 mg/5ml soln
3
Preferred
ZARONTIN
 
phenobarbital 20 mg/5ml oral elix, 20 mg/5ml soln
3
Preferred
PHENOBARBITAL
 
carbamazepine 100 mg/5ml susp
4
Preferred
TEGRETOL
 
carbamazepine er 400 mg tab er 12 hr
4
Preferred
TEGRETOL
 
oxcarbazepine 300 mg/5ml susp
4
Preferred
TRILEPTAL
 
VIMPAT 10 mg/ml soln,100 mg tab, 150 mg tab,50 mg tab
5
Preferred
 
PA, C
VIMPAT 200 mg tab, 200 mg/20ml iv soln
6
Preferred
 
PA, C
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización   Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age    Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página 9 de 53  para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017
 

SALUD FÍSICA
 
Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos
 /Límites]
ANTIDEMENTIA AGENTS [AGENTES ANTIDEMENCIA]
Antidementia Agents [Agen   tes Antidemencia]
ergoloid mesylates 1 mg   tab
6
Non-Preferred
HYDERGINE
 
Cholinesterase Inhibitors [Inhibidores de Colinesterasa]
donepezil hcl 10 mg tab,   10 mg odt, 5 mg tab, 5 mg odt
1
Preferred
ARICEPT
 
rivastigmine tartrate 1.5 mg cap, 3 mg cap, 4.5 mg cap, 6 mg cap
3
Preferred
EXELON
 
NMDA Receptor Antagonists [Antagonista del Receptor NMDA]
memantine   10 mg tab, 5 mg tab
1
Preferred
NAMENDA
 
memantine TITRATIONPAK 5 (28)-10 (21) mg tab
1
Preferred
NAMENDA
 
ANTIDEPRESSANTS [ANTIDEPRESIVOS]
Antidepressants [Antidepresivos]
amitriptyline hcl 10 mg tab,   100 mg tab, 150 mg tab, 25 mg tab, 50 mg tab, 75 mg tab
1
Preferred
ELAVIL
MENTAL, SUB MENTAL
doxepin hcl 10 mg cap, 10 mg/ml oral conc, 25 mg cap, 50 mg cap, 75 mg cap
1
Preferred
SINEQUAN
MENTAL, SUB MENTAL
imipramine hcl 10 mg tab, 25 mg tab, 50 mg tab
1
Preferred
TOFRANIL
MENTAL, SUB MENTAL
nortriptyline hcl 10 mg cap, 10 mg/5ml soln, 25 mg cap, 50 mg cap, 75 mg cap
1
Preferred
PAMELOR
MENTAL, SUB MENTAL
doxepin hcl 100 mg cap, 150 mg cap
2
Preferred
SINEQUAN
MENTAL, SUB MENTAL
duloxetine 20 mg cap, 30 mg cap, 60 mg cap
2
Non-Preferred
CYMBALTA
 
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización   Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age    Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página de 53  para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017
 

SALUD FÍSICA
 
Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos
/Límites]
ANTIDIABETIC AGENTS [AGENTES ANTIDIABÉTICOS]
 
Alpha-Glucosidase Inhibitors [Inhibidores de Alfa Glucosidasa]
acarbose 100 mg tab, 25   mg tab, 50 mg tab
2
Preferred
PRECOSE
 
Biguanides [Biguanidas]
metformin hcl 1000 mg tab,   500 mg tab, 850 mg tab
1
Preferred
GLUCOPHAGE
 
metformin hcl er 500 mg tab er 24 hr, 750 mg tab er 24 hr
1
Preferred
GLUCOPHAGE XR
 
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors [Inhibidores de DPP-4]
KOMBIGL   YZE XR 2.51000 mg tab er 24 hr, 5-1000 mg tab er 24 hr, 5-500 mg tab er 24 hr
3
Preferred
 
ST, C
ONGLYZA 2.5 mg tab, 5 mg tab
3
Preferred
 
ST, C
Glycemic Agents [Agentes Glicémicos]
 
GLUCAGON EMERGENCY 1 mg inj kit
4
Preferred
   
Insulin Mixtures [Mezclas de Insulinas]
 
HUMULIN 70/30 (70   -30) 100 unit/ml sc susp
3
Preferred
 
C
HUMALOG MIX 75/25 (7525) 100 unit/ml sc susp
4
Preferred
 
C
HUMALOG MIX 50/50 (5050) 100 unit/ml sc susp
4
Preferred
 
C
Insulin Sensitizing Agents [Agentes Sensibilizantes de Insulin]
pioglitazone hcl 15 mg tab,   30 mg tab, 45 mg tab
1
Preferred
ACTOS
 
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización   Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age    Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página de 53  para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017
 

SALUD FÍSICA
 
Intermediate-Acting Insulins [Insulinas de Duración Intermedia]
HUMULIN N    100 unit/ml sc susp
2
Preferred
 
C
Long-Acting Insulins [Insulinas de Larga Duración]
 
LANTUS SOLOSTAR 100   unit/ml subcutaneous solution pen-injector
2
Preferred
 
C
 
Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
 [Nombre de
Referencia]
Requirements/
Limits
[Requerimientos
/Límites]
LANTUS 100 unit/ml sc soln
3
Preferred
 
C
Rapid-Acting Insulins [Insulinas de Rápida Duración]
HUMALOG 100 unit/ml sc   soln
3
Preferred
 
C
Short-Acting Insulins [Insulinas de Corta Duración]
HUMULIN R 100 unit/ml inj soln 2 Preferred  C
Sulfonylureas [Sulfonilureas]
glimepiride 1 mg tab, 2 mg   tab, 4 mg tab
1
Preferred
AMARYL
 
glipizide 10 mg tab, 5 mg tab
1
Preferred
GLUCOTROL
 
DIABETES SUPPLIES [SUMINISTROS PARA DIABETES]
Needles & Syringes [Agujas y Jeringuillas]
insulin syringe/needle
1
Preferred
   
ANTIEMETICS [ANTIEMÉTICOS]
5-Hydroxytryptamine 3 (5-HT3) Antagonists [Antagonistas de 5-HT3]
ondansetron 4 mg odt, 8   mg odt
1
Preferred
ZOFRAN ODT
 
ondansetron hcl 24 mg tab, 4 mg tab, 8 mg tab
1
Preferred
ZOFRAN
 
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización   Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age    Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página de 53  para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017
 

SALUD FÍSICA
 
Miscellaneous Antiemetics [Antieméticos Misceláneos]
metoclopramide hcl 10 mg   tab, 10 mg/10ml soln, 5 mg tab, 5 mg/5ml soln, 5 mg/ml inj soln
1
Preferred
REGLAN
 
promethazine hcl 12.5 mg tab, 25 mg tab, 50 mg tab, 6.25 mg/5ml soln, 6.25 mg/5ml syr, 25 mg/ml  inj soln, 50 mg/ml inj soln
1
Preferred
PHENERGAN
 
trimethobenzamide hcl 300 mg cap
1
Preferred
TIGAN
 
Phenothiazines [Fenotiazinas]
prochlorperazine edisylate   5 mg/ml inj soln
1
Preferred
COMPAZINE
 

Drug Name [Nombre del
 Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos
/Límites]
prochlorperazine maleate 10 mg tab, 5 mg tab
1
Preferred
COMPAZINE
 
prochlorperazine 25 mg rect supp
4
Non-Preferred
COMPAZINE
 
ANTIGOUT AGENTS [AGENTES ANTIGOTA]
Antigout Agents [Agentes Antigota]
allopurinol 100 mg tab, 300   mg tab
1
Preferred
ZYLOPRIM
 
colchicine 0.6 mg cap
3
Preferred
MITIGARE
PA
colchicine 0.6 mg tab
3
Non-Preferred
COLCRYS
QL= 3 tab, 15días
Uricosurics [Uricosúricos]
probenecid 500 mg tab
1
Preferred
BENEMID
 
ANTIHYPERTENSIVES [ANTIHIPERTENSIVOS]
Alpha-Adrenergic Agonists [Agonistas Alfa Adrenérgicos]
clonidine hcl 0.1 mg tab, 0.2 mg tab, 0.3 mg tab
1
Preferred
CATAPRESS
 
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización   Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age    Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página de 53 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017
 

SALUD FÍSICA

methyldopa 250 mg tab, 500 mg tab
1
Preferred
ALDOMET
 
Alpha-Adrenergic Blocking Agents [Bloqueadores Alfa Adrenérgicos]
terazosin hcl 1 mg cap, 10   mg cap, 2 mg cap, 5 mg cap
1
Preferred
HYTRIN
 
Angiotensin II Receptor Blockers (ARB) [Antagonistas Del Receptor Angiotensina II]
losartan potassium 100 mg tab, 25 mg tab, 50 mg tab
1
Preferred
COZAAR
 
losartan potassium-hctz 100-12.5 mg tab, 100-25 mg tab, 50-12.5 mg tab
1
Preferred
HYZAAR
 
Angiotensin-Converting Enzyme (ACE) Inhibitors [Inhibidores de la Enzima Convertidora de Angiotensin]
fosinopril sodium 10 mg   tab, 20 mg tab, 40 mg tab
1
Preferred
MONOPRIL
 
lisinopril 10 mg tab, 2.5 mg tab, 20 mg tab, 30 mg tab, 40 mg tab, 5 mg tab
1
Preferred
ZESTRIL
 

Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
 [Nombre de
Referencia]
Requirements/
Limits
[Requerimientos
/Límites]
lisinopril-hydrochlorothiazide 1012.5 mg tab, 20-12.5 mg tab, 20-25 mg tab
1
Preferred
ZESTORETIC
 
Calcium Channel Blocking Agents [Bloqueadores de Canales de Calcio]
amlodipine besylate 10 mg   tab, 2.5 mg tab, 5 mg tab
1
Preferred
NORVASC
 
diltiazem hcl 120 mg tab, 30 mg tab, 60 mg tab, 90 mg tab
1
Preferred
CARDIZEM
 
diltiazem hcl er 120 mg cap er 24 hr, 180 mg cap er 24 hr, 240 mg cap er 24 hr
1
Preferred
DILACOR XR
 
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización   Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age    Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página de 53  para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017
 

SALUD FÍSICA
 
diltiazem hcl er beads 120 mg cap er 24 hr
1
Preferred
TIAZAC
 
diltiazem hcl er coated beads 120 mg cap er 24 hr, 180 mg cap er 24 hr, 240 mg cap er 24 hr
1
Preferred
CARDIZEM CD
 
dilt-xr 120 mg cap er 24 hr, 180 mg cap er 24 hr, 240 mg cap er 24 hr
1
Preferred
DILACOR XR
 
nifedipine er osmotic 30 mg tab er 24 hr
1
Preferred
PROCARDIA XL
 
verapamil hcl 120 mg tab, 40 mg tab, 80 mg tab
1
Preferred
CALAN
 
verapamil hcl er 120 mg tab er, 180 mg tab er, 240 mg tab er
1
Preferred
CALAN SR
 
diltiazem hcl er beads 180 mg cap er 24 hr, 240 mg cap er 24 hr, 300 mg cap er 24 hr, 360 mg er 24 hr
2
Preferred
TIAZAC
 
diltiazem hcl er coated beads 300 mg cap er 24 hr
2
Preferred
CARDIZEM CD
 

Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
 [Nombre de
Referencia]
Requirements/
Limits
[Requerimientos
/Límites]
nifedipine er osmotic 60 mg tab er 24 hr, 90 mg tab er 24 hr
2
Preferred
PROCARDIA XL
 
Carbonic Anhydrase Inhibitors Diuretics [Diuréticos Inhibidores de Anhidrasa Carbónica]
acetazolamide 125 mg tab,   250 mg tab
3
Preferred
DIAMOX
 
Cardioselective Beta Blocking Agents [Bloqueadores Beta Cardioselectivos]
atenolol 100 mg tab, 25 mg   tab, 50 mg tab
1
Preferred
TENORMIN
 
metoprolol succinate er 25 mg tab er 24 hr, 50 mg tab er 24 hr
1
Preferred
TOPROL XL
 
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización   Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age    Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página de 53   para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017
 

SALUD FÍSICA
 
metoprolol tartrate 100 mg tab, 25 mg tab, 50 mg tab
1
Preferred
LOPRESSOR
 
metoprolol succinate er 100 mg tab er 24 hr, 200 mg tab er 24 hr
2
Non-Preferred
TOPROL XL
 
Cardioselective Beta-Adrenergic Blocking Agents [Bloqueadores Beta-Adrenérgicos Cardioselectivos]
atenolol   -chlorthalidone 100-25 mg tab, 50-25 mg tab
1
Preferred
TENORETIC
 
metoprolol-hydrochlorothiazide 50-25 mg tab
2
Non-Preferred
LOPRESSOR HCT
 
metoprolol-hydrochlorothiazide 100-25 mg tab, 100-50 mg tab
3
Non-Preferred
LOPRESSOR HCT
 
Loop Diuretics [Diuréticos del Asa]
bumetanide 0.5 mg tab, 1   mg tab, 2 mg tab
1
Non-Preferred
BUMEX
 
furosemide 10 mg/ml soln, 20 mg tab, 40 mg tab, 80 mg tab
1
Preferred
LASIX
 

Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
 [Nombre de
Referencia]
Requirements/
Limits
[Requerimientos
 /Límites]
Nonselective Beta Blocking Agents [Bloqueadores Beta No-Selectivos]
propranolol hcl 10 mg tab,   20 mg tab, 20 mg/5ml soln, 40 mg tab, 40 mg/5ml soln,
80 mg tab
1
Preferred
INDERAL
 
propranolol hcl 60 mg tab
2
Non-Preferred
INDERAL
 
Potassium-Sparing Diuretics [Diuréticos Conservadores de Potasio]
spironolactone 100 mg tab,   25 mg tab, 50 mg tab
1
Preferred
ALDACTONE
 
triamterene-hctz 37.5-25 mg cap, 37.5-25 mg tab, 75-50 mg tab
1
Preferred
MAXZIDE
 
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización   Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age    Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página de 53  para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017
 

SALUD FÍSICA
 
Thiazide Diuretics [Diuréticos Tiazidas]
chlorothiazide 250 mg tab,   500 mg tab
1
Preferred
DIURIL
 
chlorthalidone 25 mg tab, 50 mg tab
1
Non-Preferred
HYGROTON
 
DIURIL 250 mg/5ml susp
1
Preferred
   
hydrochlorothiazide 12.5 mg tab, 25 mg tab, 50 mg tab
1
Preferred
MICROZIDE
 
indapamide 1.25 mg tab,2.5 mg tab
1
Preferred
LOZOL
 
metolazone 2.5 mg tab, 5 mg tab
1
Non-Preferred
ZAROXOLYN
 
chlorthalidone 100 mg tab
2
Non-Preferred
HYGROTON
 
metolazone 10 mg tab
2
Non-Preferred
ZAROXOLYN
 
Vasodilator Beta Blockers [Bloqueadores Beta Vasodilatadores]
carvedilol 12.5 mg tab, 25   mg tab, 3.125 mg tab, 6.25 mg tab
1
Preferred
COREG
 
Vasodilators [Vasodilatadores]
hydralazine hcl 10 mg tab,   100 mg tab, 25 mg tab, 50 mg tab
1
Preferred
APRESOLINE
 
minoxidil 10 mg tab, 2.5 mg tab
1
Preferred
LONITEN
 

Drug Name [Nombre del Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos /Límites]
ANTIMIGRAINE AGENTS [AGENTES ANTIMIGRAÑA]
Beta-Adrenergic Blocking Agents [Bloqueadores Beta Adrenérgicos]
divalproex sodium 125 mg   tab dr, 250 mg tab dr, 500 mg tab dr
1
Preferred
DEPAKOTE
 
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización   Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age    Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página de 53  para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017
 

SALUD FÍSICA
 
topiramate 100 mg tab, 200 mg tab, 25 mg tab, 50 mg tab
1
Preferred
TOPAMAX
 
Serotonin (5-HT) Receptor Agonists [Agonistas Del Receptor De Serotonina]
sumatriptan succinate 100   mg tab, 25 mg tab, 50 mg tab
1
Preferred
IMITREX
QL= 6 tab
ANTIMYASTHENIC AGENTS [AGENTES ANTIMIASTÉNICOS]
Parasympathomimetics [Parasimpatomiméticos]
pyridostigmine   bromide 60 mg tab
2
Preferred
MESTINON
 
MESTINON 60 mg/5ml syr
4
Non-Preferred
   
pyridostigmine bromide 180 mg tab er
6
Non-Preferred
MESTINON
 
ANTIMYCOBACTERIALS [ANTIMICOBACTERIANOS]
  Antituberculars [Antituberculosos]
isoniazid 100 mg tab, 300   mg tab
1
Preferred
ISONIAZID
 
rifampin 150 mg cap
1
Preferred
RIFADIN
 
ethambutol hcl 100 mg tab
2
Non-Preferred
MYAMBUTOL
 
pyrazinamide 500 mg tab
2
Non-Preferred
PYRAZINAMIDE
 
rifampin 300 mg cap
2
Preferred
RIFADIN
 
ethambutol hcl 400 mg tab
3
Non-Preferred
MYAMBUTOL
 
isoniazid 50 mg/5ml syr
5
Non-Preferred
ISONIAZID
 
rifabutin 150 mg cap
   
MYCOBUTIN
Puerto Rico Health
Department
Tuberculosis
Control Program
cycloserine 250 mg cap
   
SEROMYCIN
RIFAMATE 50-300 mg cap
     
TRECATOR 250 mg tab
     
CAPASTAT 1 gm inj
     
Miscellaneous Antimycobacterials [Antimicobacterianos Misceláneos]
dapsone 100 mg tab, 25   mg tab
2
Preferred
DAPSONE
 
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización   Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age    Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página de 53  para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017
 

SALUD FÍSICA
 
Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
 [Nombre de
Referencia]
Requirements/
Limits
[Requerimientos
/Límites]
ANTIMYCOTIC AGENTS [ANTIMICÓTICOS]
Antifungals [Antifungales]
fluconazole 10 mg/ml susp, 100 mg tab, 150 mg tab,200 mg tab, 50 mg tab
1
Preferred
DIFLUCAN
 
ketoconazole 200 mg tab
1
Preferred
NIZORAL
 
nystatin 100000 unit/gm crm
1
Preferred
MYCOSTATIN
 
terbinafine hcl 250 mg tab
1
Preferred
LAMISIL
 
fluconazole 40 mg/ml susp
2
Preferred
DIFLUCAN
 
itraconazole 100 mg cap
 
Preferred
SPORANOX
SIDA
Vaginal Antifungals [Antifungales Vaginales]
terconazole 0.4 % vag crm, 0.8 % vag crm
2
Preferred
TERAZOL
 
Antimalarials [Antimaláricos]
chloroquine phosphate 250   mg tab, 500 mg tab
1
Preferred
ARALEN
 
hydroxychloroquine sulfate 200 mg tab
1
Preferred
PLAQUENIL
 
DARAPRIM 25 mg tab
19
Non-Preferred
 
PA
Antiprotozoals - Non-Antimalarials [Antiprotozoarios No-Antimalaráricos]
NEBUPENT 300 mg inh   soln
4
Non-Preferred
 
PA
ANTIPARASITICS [ANTIPARASITARIOS]
Anthelmintics [Antihelmínticos]
PIN-X 720.5 mg chew tab
1
Preferred
 
 OTC
REESES PINWORM MEDICINE 144 mg/ml Susp
1
Preferred
 
 OTC
BILTRICIDE 600 mg tab
7
Non-Preferred
 
PA
ANTIPARKINSON AGENTS [AGENTES ANTIPARKINSON]
Anticholinergics [Anticolinérgicos]
benztropine mesylate 0.5   mg tab, 1 mg tab, 2 mg tab
1
Preferred
COGENTIN
 
Antiparkinson Dopaminergics [Dopaminérgicos Antiparkinson]
amantadine hcl 50 mg/5ml   syr
1
Preferred
SYMMETREL
 
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización   Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age    Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página de 53 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017
 

SALUD FÍSICA
 
Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
 [Nombre de
Referencia]
Requirements/
Limits
[Requerimientos
 /Límites]
pramipexoledihydrochloride 0.125 mg tab, 0.25 mg tab, 0.5 mg tab, 0.75 mg tab, 1 mg tab,1.5 mg tab
1
Preferred
MIRAPEX
 
ropinirole hcl 0.25 mg tab, 0.5 mg tab, 1 mg tab, 3 mg tab, 4 mg tab, 5 mg tab
1
Preferred
REQUIP
 
ropinirole hcl 2 mg tab
2
Preferred
REQUIP
 
amantadine hcl 100 mg cap
3
Preferred
SYMMETREL
 
bromocriptine mesylate 2.5 mg tab
3
Preferred
PARLODEL
 
carbidopa-levodopaentacapone 18.75-75-200 mg tab
4
Non-Preferred
STALEVO
 
carbidopa-levodopaentacapone 12.5-50-200 mg tab, 25-100-200 mg tab, 31.25-125-200 mg tab,37.5-150-200 mg tab, 50200-200 mg tab
5
Non-Preferred
STALEVO
 
Dopamine Precursors [Precursores de Dopamina]
carbidopa   -levodopa 10- 100 mg tab, 25-100 mg tab
1
Preferred
SINEMET
 
carbidopa-levodopa 25250 mg tab
2
Preferred
SINEMET
 
carbidopa-levodopa er 25100 mg tab er, 50-200 mg tab er
2
Preferred
SINEMET CR
 
Monoamine Oxidase B (MAO-B) Inhibitors [Inhibidores de MAO-B]
selegiline hcl 5 mg tab  
3
Non-Preferred
CARBEX
 
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización   Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age    Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página 20 de 53 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017
 

SALUD FÍSICA
 
ANTIVIRALS [ANTIVIRALES]
Anti-Influenza Agents [Age   ntes Anti-Infuenza]
oseltamivir phosphate 30 mg cap, 45 mg cap, 75 mg cap
4
Preferred
TAMIFLU
 
TAMIFLU 6 mg/ ml susp
13
Non-Preferred
   

Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
 [Nombre de
Referencia]
Requirements/
Limits
[Requerimientos
 /Límites]
Anti-Cytomegalovirus (CMV) Agents [Agentes Anti-Citomegalovirus]
valganciclovir hcl 450 mg   tab
13
Non-Preferred
VALCYTE
PA
Antiherpetic Agents [Agentes Antiherpéticos]
acyclovir 200 mg cap, 400   mg tab, 800 mg tab
1
Preferred
ZOVIRAX
 
acyclovir 200 mg/5ml susp
2
Preferred
ZOVIRAX
 
Antiretroviral Combinations [Combinaciones Antiretrovirales]
EPZICOM 600-300 mg tab
     
CENTROS DE
PREVENCIÓN Y
TRATAMIENTO
- CLÍNICAS DE
IMMUNOLOGÍA
ATRIPLA 600-200-300 mg tab
     
Integrase Inhibitors [Inhibidores de la Integrasa]
ISENTRESS potassium 400 mg tab
     
CENTROS DE
PREVENCIÓN Y
TRATAMIENTO
- CLÍNICAS DE
IMMUNOLOGÍA
Miscellaneous Anti-HIV Agents [Agentes Anti-VIH Misceláneos]
SELZENTRY 300 mg tab
     
CENTROS DE
PREVENCIÓN Y
TRATAMIENTO
- CLÍNICAS DE
IMMUNOLOGÍA
FUZEON subcutaneous kit 90 mg
     
Non-Nucleoside Reverse Transcriptase Inhibitors [Inhibidores No Nucleósidos de la TransciptasaReversa]
nevirapine 200 mg tab  
1
Preferred
VIRAMUNE
 
nevirapine 50 mg/5ml susp
5
Non-Preferred
VIRAMUNE
 
RESCRIPTOR 200 mg tab
6
Non-Preferred
   
SUSTIVA 50 mg cap, 200 mg cap
6
Preferred
 
C  
nevirapine er, 100 mg tab er 24 hr, 400 mg tab er 24 hr
7
Non-Preferred
VIRAMUNE XR
 
SUSTIVA 600 mg tab
7
Preferred
 
C  
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización   Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age    Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página 2 de 53   para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017
 

SALUD FÍSICA
 
Drug Name [Nombre del
 Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos
 /Límites]
INTELENCE   200 mg tab
     
CENTROS DE
PREVENCIÓN Y
TRATAMIENTO
- CLÍNICAS DE
IMMUNOLOGÍA
Nucleoside/Nucleotide Reverse Transcriptase Inhibitors [Inhibidores Nucleósidos/Nucleótidos de la
Transcriptasa Reversa]
zidovudine 300 mg tab
2
Non-Preferred
RETROVIR
 
stavudine 1 mg/ml soln, 15 mg cap, 20 mg cap, 30 mg cap, 40 mg cap
3
Preferred
ZERIT
 
didanosine 125 mg cap dr, 200 mg cap dr, 250 mg cap dr
4
Non-Preferred
ZIAGEN
 
lamivudine 10 mg/ml soln
5
Preferred
EPIVIR
 
lamivudine 150 mg tab
4
Preferred
EPIVIR
 
zidovudine 100 mg cap, 50 mg/5ml syr
4
Non-Preferred
RETROVIR
 
abacavir sulfate 300 mg tab
5
Preferred
ZIAGEN
 
didanosine 400 mg cap dr
5
Non-Preferred
ZIAGEN
 
lamivudine 300 mg tab
5
Preferred
EPIVIR
 
VIDEX 2 gm soln
5
Non-Preferred
   
lamivudine 100 mg tab
6
Preferred
EPIVIR
PA
lamivudine-zidovudine 150-300 mg tab
6
Preferred
COMBIVIR
 
abacavir-lamivudinezidovudine 300-150-300 mg tab
10
Non-Preferred
TRIZIVIR
 
EMTRIVA 200 mg cap
     
CENTROS DE
PREVENCIÓN Y
TRATAMIENTO
- CLÍNICAS DE
IMMUNOLOGÍA
VIREAD 300 mg tab
     
TRUVADA 200-300 mg tab
   
TRUVADA
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización   Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age    Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página 22 de 53  para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017
 

SALUD FÍSICA
 
BENIGN PROSTATIC HYPERTROPHY AGENTS [AGENTES PARA HIPERTROFIA PROSTÁTICA
BENIGNA]
5-Alpha Reductase Inhibitors [Inhibidores de 5-Alfa Reductasa]
finasteride 5 mg tab
1
Preferred
PROSCAR
 

Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos
/Límites]
Alpha-Adrenergic Blocking Agents [Bloqueadores Alfa Adrenérgicos]
tamsulosin hcl 0.4 mg cap  
1
Preferred
FLOMAX
 
terazosin hcl 1 mg cap, 10 mg cap, 2 mg cap, 5 mg cap
1
Preferred
HYTRIN
 
BLOOD MODIFIERS [MODIFICADORES DE LA SANGRE]
Anticoagulants [Anticoagulantes]
warfarin sodium 1 mg tab,   10 mg tab, 2 mg tab, 2.5 mg tab, 3 mg tab, 4 mg tab, 5 mg tab, 6 mg tab, 7.5 mg tab
1
Preferred
COUMADIN
 
heparin sodium (porcine) 1000 unit/ml inj soln
2
Preferred
HEPARIN
 
heparin sodium (porcine)10000 unit/ml inj soln,5000 unit/ml inj soln
3
Preferred
HEPARIN
 
heparin sodium (porcine) pf 5000 unit/0.5ml inj soln
3
Preferred
HEPARIN
 
heparin sodium (porcine) 2000 unit/ml iv soln
8
Preferred
HEPARIN
 
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización   Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age    Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página 23 de 53  para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017
 

SALUD FÍSICA
 
Cobalamins [Cobalaminas]
cyanocobalamin 1000   mcg/ml inj soln
1
Preferred
VIT B-12
 
Colony Stimulating Factors [Estimulantes Mieloides]
NEUPOGEN 300 mcg/0.5ml inj soln, 300 mcg/ml inj soln, 480 mcg/1.6ml inj soln
10
Preferred
 
PA, C
NEULASTA 6 mg/0.6ml sc soln
15
Preferred
 
PA, C
NEULASTA DELIVERYKIT6 mg/0.6ml sc soln
15
Preferred
 
PA, C
NEUPOGEN 480mcg/0.8ml inj soln
12
Preferred
 
PA, C

Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
 [Nombre de
Referencia]
Requirements/
Limits
[Requerimientos
/Límites]
Erythropoiesis-Stimulating Agents [Agentes Estimulantes de Eritropoiesis]
ARANESP (ALBUMIN FREE) 100 mcg/0.5ml inj soln
1
Preferred
 
PA, C
PROCRIT 2000 unit/ml inj soln, 3000 unit/ml inj soln, 4000 unit/ml inj soln
6
Preferred
 
PA, C
ARANESP (ALBUMINFREE) 25 mcg/0.42ml inj soln, 25 mcg/ml inj soln
6
Preferred
 
PA, C
PROCRIT 10000 unit/ml inj soln
7
Preferred
 
PA, C
ARANESP (ALBUMINFREE) 40 mcg/0.4ml inj soln
7
Preferred
 
PA, C
ARANESP (ALBUMINFREE) 40 mcg/ml inj soln, 60 mcg/ml inj soln
8
Preferred
 
PA, C
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización   Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age    Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página 24 de 53  para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017
 

SALUD FÍSICA
 
ARANESP (ALBUMINFREE) 150 mcg/0.3ml inj soln, 150 mcg/0.75ml inj soln, 200 mcg/0.4ml inj soln, 200 mcg/ml inj soln, 300 mcg/0.6ml inj soln, 300 mcg/ml inj soln, 500 mcg/ml inj soln, 60 mcg/0.3ml inj soln
9
Preferred
 
PA, C
PROCRIT 20000 unit/ml inj soln
9
Preferred
 
PA, C
ARANESP (ALBUMIN
FREE) 100 mcg/ml inj soln
11
Preferred
 
PA, C
PROCRIT 40000 unit/ml inj soln
10
Preferred
 
PA, C
Factor Xa Inhibitors [Inhibidores Del Factor Xa]
ELIQUIS 2.5 mg tab
4
Preferred
 
PA, C
ELIQUIS 5 mg tab
4
Preferred
 
PA, C

Drug Name [Nombre del Me
dicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos
/Límites]
Folates [Folatos]
folic acid 1 mg tab, 400   mcg tab, 800 mcg tab
1
Preferred
FOLIC ACID
OTC
Iron [Hierro]
ferrous sulfate 325 (65 fe)   mg tab
1
Preferred
IRON
OTC
INFED 50 mg/ml inj soln
5
Non-Preferred
   
Low Molecular Weight Heparins [Heparinas de Bajo Peso Molecular]
enoxaparin sodium 30   mg/0.3ml sc soln, 40 mg/0.4ml sc soln
5
Non-Preferred
LOVENOX
PA
enoxaparin sodium 300 mg/3ml inj soln, 60 mg/0.6ml sc soln, 80 mg/0.8ml sc soln
7
Non-Preferred
LOVENOX
PA
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización   Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age    Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página 25 de 53  para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017
 

SALUD FÍSICA
 
enoxaparin sodium 100 mg/ml sc soln
9
Non-Preferred
LOVENOX
PA
enoxaparin sodium 120 mg/0.8ml sc soln
10
Non-Preferred
LOVENOX
PA
enoxaparin sodium 150 mg/ml sc soln
14
Non-Preferred
LOVENOX
PA
Platelet Modifying Agents [Modificadores de Plaquetas]
aspirin 325 mg tab, 325 mg   tab dr, 81 mg tab dr
1
Preferred
ASPIRIN
OTC
aspirin low dose 81 mg tab, 81 mg tab dr
1
Preferred
ASPIRIN
OTC
cilostazol 100 mg tab, 50 mg tab
1
Preferred
PLETAL
 
clopidogrel bisulfate 75 mg tab
1
Preferred
PLAVIX
 
BONE DENSITY REGULATORS [REGULADORES DE DENSIDAD ÓSEA]
Bisphosphonates [Bifosfonatos]
alendronate sodium 10 mg   tab, 35 mg tab, 5 mg tab, 70 mg tab
1
Preferred
FOSAMAX
 

Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos
 /Límites]
CARDIOVASCULAR AGENTS [AGENTES CARDIOVASCULARES]
Antiarrhythmics Class II [Antiarrítmicos Clase II]
propranolol hcl 10 mg tab,   20 mg tab, 40 mg tab, 80 mg tab
1
Preferred
INDERAL
 
sotalol hcl 120 mg tab, 160 mg tab, 240 mg tab, 80 mg tab
1
Preferred
BETAPACE
 
propranolol hcl 60 mg tab
2
Preferred
INDERAL
 
Antiarrhythmics Type I-A [Antiarrítmicos Tipo I-A]
quinidine sulfate 200 mg   tab, 300 mg tab
1
Preferred
QUINIDINE SULFATE
 
quinidine gluconate er 324 mg tab er
2
Preferred
QUINAGLUTE
 
quinidine sulfate er 300 mg tab er
2
Preferred
QUINIDINE SULFATE
 
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización   Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age    Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página 26 de 53  para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017
 

SALUD FÍSICA
 
Antiarrhythmics Type I-B [Antiarrítmicos Tipo I-B]
mexiletine hcl 150 mg cap  
2
Preferred
MEXITIL
 
mexiletine hcl 200 mg cap
3
Preferred
MEXITIL
 
Antiarrhythmics Type I-C [Antiarrítmicos Tipo I-C]
flecainide acetate 100 mg   tab, 50 mg tab
1
Preferred
TAMBOCOR
 
propafenone hcl 150 mg tab, 225 mg tab
1
Preferred
RYTHMOL
 
flecainide acetate 150 mg tab
2
Preferred
TAMBOCOR
 
propafenone hcl 300 mg tab
3
Preferred
RYTHMOL
 
Antiarrhythmics Type III [Antiarrítmicos Tipo III]
amiodarone hcl 200 mg tab
1
Preferred
CORDARONE
 
Intermittent Claudication Agents [Agentes Para La Claudicación Intermitente]
pentoxifylline er 400 mg   tab er
1
Preferred
TRENTAL
 
Miscellaneous Cardiovascular Agents [Agentes Cardiovasculares Misceláneos]
digox 125 mcg tab, 250   mcg tab
2
Preferred
LANOXIN
 

Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos
/Límites]
digoxin 0.05 mg/ml soln, 125 mcg tab, 250 mcg tab
2
Preferred
LANOXIN
 
Pulmonary Hypertension Agents [Agentes Para Hipertensión Pulmonar]
sildenafil citrate 20 mg tab
3
Preferred
REVATIO
PA
ADEMPAS 0.5 mg tab
15
Preferred
 
PA, C
ADEMPAS 1 mg tab, 1.5 mg tab, 2 mg tab
18
Preferred
 
PA, C
ADEMPAS 2.5 mg tab
20
Preferred
 
PA, C
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización   Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age    Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página 27 de 53 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017
 

SALUD FÍSICA
 
Vasodilators [Vasodilatadores]
isosorbide mononitrate 10   mg tab, 20 mg tab
1
Preferred
IMDUR
 
isosorbide mononitrate er 120 mg tab er 24 hr, 30 mg tab er 24 hr, 60 mg tab er 24 hr
1
Preferred
IMDUR
 
nitroglycerin 0.2 mg/hr td patch 24hr
1
Preferred
NITRODUR
 
NITROSTAT 0.3 mg tab subl, 0.4 mg tab subl, 0.6 mg tab subl
1
Preferred
   
nitroglycerin 0.1 mg/hr td patch 24hr, 0.4 mg/hr td patch 24hr, 0.6 mg/hr td patch 24hr
2
Non-Preferred
NITRODUR
 
CENTRAL NERVOUS SYSTEM AGENTS [AGENTES SISTEMA NERVIOSO CENTRAL]
Multiple Sclerosis Agents [Agentes para Esclerosis Múltiple]
AMPYRA   10 tab er 12hr
9
Preferred
 
PA, C
COPAXONE 20 mg/ml sc kit
17
Preferred
 
PA, C
COPAXONE 40 mg/ml subcutaneous solution prefilled syringe
14
Preferred
 
PA, C
AVONEX 30 mcg im kit
13
Preferred
 
PA, C
AVONEX PEN 30 mcg/0.5ml im kit
13
Preferred
 
PA, C
AVONEX PREFILLED 30 mcg/0.5ml im kit
13
Preferred
 
PA, C
GILENYA 0.5 mg cap
15
Preferred
 
PA, C
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización   Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age    Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página 28 de 53  para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017
 

SALUD FÍSICA
 
Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos
/Límites]
TYSABRI intravenous concentrate 300 mg/15ml
15
Preferred
 
PA, C
TECFIDERA 120 mg cap dr
14
Preferred
 
PA, C
TECFIDERA 240 mg cap dr
14
Preferred
 
PA, C
TECFIDERA 120-240 MG misc
14
Preferred
 
PA, C
BETASERON 0.3 mg sc kit
13
Preferred
 
PA, C
CHEMOTHERAPIES [QUIMIOTERAPIAS]
Alkylating Agents [Agentes Alquilantes]
lomustine 10 mg cap
3
Non-Preferred
CEENU
 
ALKERAN 2 mg tab
4
Non-Preferred
   
temozolomide 5 mg cap
4
Non-Preferred
TEMODAR
PA
lomustine 40 mg cap
5
Non-Preferred
CEENU
 
LEUKERAN 2 mg tab
6
Non-Preferred
   
lomustine 100 mg cap
6
Non-Preferred
CEENU
 
MYLERAN 2 mg tab
7
Non-Preferred
   
temozolomide 20 mg cap
9
Non-Preferred
TEMODAR
PA
temozolomide 250 mg cap
11
Non-Preferred
TEMODAR
PA
temozolomide 140 mg cap
13
Non-Preferred
TEMODAR
PA
temozolomide 100 mg cap, 180 mg cap
14
Non-Preferred
TEMODAR
PA
Angiogenesis Inhibitors [Inhibidores de Angiogénesis]
STIVARGA 40 mg tab  
15
Preferred
 
PA, C
Antiandrogens [Antiandrógenos]
 
bicalutamide 50 mg tab  
2
Preferred
CASODEX
 
flutamide 125 mg cap
4
Non-Preferred
EULEXIN
 
Antiestrogens [Antiestrógenos]
 
tamoxifen    citrate 10 mg tab, 20 mg tab
1
Preferred
NOLVADEX
 
Vaginal Estrogens [Estrógenos Vaginal]
 
VAGIFEM 10 mcg vag tab 
3
Non-Preferred
   
Antimetabolites [Antimetabolitos]
 
hydroxyurea 500 mg cap  
2
Preferred
HYDREA
 
mercaptopurine 50 mg tab
2
Preferred
PURINETHOL
 
methotrexate 2.5 mg tab
2
Preferred
METHOTREXATE
 
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización   Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age    Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página 29 de 53  para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017
 

SALUD FÍSICA
 
Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
 [Nombre de
Referencia]
Requirements/
Limits
[Requerimientos
 /Límites]
capecitabine 150 mg tab
7
Non-Preferred
XELODA
PA
capecitabine 500 mg tab
11
Non-Preferred
XELODA
PA
Antineoplastic Enzyme Inhibitors [Antineoplásicos Inhibidores de Enzimas]
SPRYCEL 20 mg tab
14
Preferred
 
PA, C
SPRYCEL 50 mg tab
21
Preferred
 
PA, C
imatinib 100 mg tab
18
Non-Preferred
GLEEVEC
PA
SPRYCEL 70 mg tab
17
Preferred
 
PA, C
SPRYCEL 80 mg tab
25
Preferred
 
PA, C
TASIGNA 150 mg cap
22
Preferred
 
PA, C
SPRYCEL 100 mg tab
25
Preferred
 
PA, C
AFINITOR 2.5 mg tab
25
Preferred
 
PA, C
NEXAVAR 200 mg tab
25
Preferred
 
PA, C
SPRYCEL 140 mg tab
25
Preferred
 
PA, C
AFINITOR 10 mg tab, 5 mg tab, 7.5 mg tab
23
Preferred
 
PA, C
TASIGNA 200 mg cap
19
Preferred
 
PA, C
imatinib 400 mg tab
25
Non-Preferred
GLEEVEC
PA
Apetite Stimulants [Estimulantes de Apetito]
megestrol acetate 20 mg   tab, 40 mg tab
1
Preferred
MEGACE
 
megestrol acetate 40 mg/ml susp, 400 mg/10ml susp
2
Preferred
MEGACE
 
Aromatase Inhibitors [Inhibidores de la Aromatasa]
anastrozole 1 mg tab   
1   Preferred ARIMIDEX  
Folic Acid Antagonists Rescue Agents [Antagonistas de Ácido Fólico]
leucovorin calcium 5 mg   tab
3
Preferred
LEUCOVORIN
 
leucovorin calcium 10 mg tab, 15 mg tab
4
Preferred
LEUCOVORIN
 
leucovorin calcium 25 mg tab
9
Preferred
LEUCOVORIN
 
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización   Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age    Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página 30 de 53  para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017
 

SALUD FÍSICA
 
Luteinizing Hormone-Releasing (LHRH) Analogs [Análogos De LHRH]
LUPRON DEPOT 45 mg  im kit
2
Preferred
 
PA, C
LUPRON DEPOT 11.25 mg im kit, 3.75 mg im kit
6
Preferred
 
PA, C

Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
 [Nombre de
Referencia]
Requirements/
Limits
[Requerimientos
/Límites]
LUPRON DEPOT-PED 11.25 mg im kit, 15 mg im kit, 7.5 mg im kit
8
Preferred
 
PA, C
LUPRON DEPOT 22.5 mg im kit, 30 mg im kit
9
Preferred
 
PA, C
LUPRON DEPOT-PED 11.25 mg (ped) im kit
9
Preferred
 
PA, C
LUPRON DEPOT-PED 30 mg (ped) im kit
10
Preferred
 
PA, C
leuprolide acetate 1 mg/ 0.2 ml inj kit
7
Non-preferred
 
PA
ZOLADEX 3.6 mg, 10.8 mg subcutaneous implant
7
Non-preferred
 
PA
Miscellaneous Antineoplastics [Antineoplásicos Misceláneos]
MATULANE 50 mg cap
10
Non-Preferred
 
PA
ACTIMMUNE 2000000 unit/0.5ml sc soln
25
Non-Preferred
 
PA
INTRON A  6000000 unit/ml, 10000000 unit, 18000000 unit, 50000000 unit
 
Non-Preferred
 
PA
Mitotic Inhibitors [Inhibidores Mitóticos]
etoposide 50 mg cap    
4     Non-Preferred VEPESID   
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización   Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age    Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página 3 de 53  para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017

SALUD FÍSICA
 
DENTAL AND ORAL AGENTS [AGENTES DENTALES Y ORALES]
Antifungals [Antifungales]
clotrimazole 10 mg   mouth/throat lozenge, 10 mg mouth/throat troche
1
Preferred
MYCELEX
 
nystatin 100000 unit/ml mouth/throat susp
1
Preferred
MYCOSTATIN
 
Oral Antiseptics [Antisépticos Orales]
chlorhexidine gluconate  0.12 % mouth/throat soln 1 Preferred PERIDEX
Xerostomia [Xerostomía]
pilocarpine 5 mg tab
3
Preferred
SALAGEN
 

Drug Name [Nombre del
 Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos
/Límites]
DERMATOLOGICAL AGENTS [AGENTES DERMATOLÓGICOS]
Acne Antibiotics [Antibióticos para Acné]
sulfacetamide sodium   sulfur 10-5 % external emulsion
1
Preferred
SULFACET R
 
clindamycin phosphate 1 % soln
2
Preferred
CLEOCIN T
 
erythromycin 2 % gel, 2 % soln
2
Preferred
ERYGEL
 
Acne Products [Productos para el Acné]
tretinoin 0.05 % crm,
2
Preferred
RETIN A
AL < 21 años
isotretinoin 10 mg cap, 20 mg cap, 30 mg cap
6
Preferred
Zenatane
 
Antihistamines [Antihistamínicos]
hydroxyzine hcl 10 mg tab,   10 mg/5ml soln, 10 mg/5ml syr, 25 mg tab, 50 mg tab
1
Preferred
ATARAX
 
Antipsoriatics [Antipsoriáticos]
methoxsalen 10 m cap
 
Preferred
Oxsoralen
 
Antiseborrheic Products [Productos Antiseborrea]
selenium sulfide 2.5 % lot  
1
Preferred
SELSUN
 
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización   Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age    Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página 32 de 53  para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017
 

SALUD FÍSICA
 
nystatin 100000 unit/gm oint, crm
1
Preferred
MYCOSTATIN
 
Dermatological Skin Cancer Agents [Dermatológicos para Cáncer de la Piel]
fluorouracil 2 % soln, 5 %   soln
3
Preferred
EFUDEX
 
fluorouracil 5 % crm
4
Non-Preferred
EFUDEX
 
Very High Potency Topical Glucocorticoids [Glucocorticoides Tópicos de Muy Alta Potencia]
betamethasone dipropionate aug 0.05 % crm
3
Non-Preferred
DIPROLENE
 
betamethasone dipropionate aug 0.05 % oint
4
Non-Preferred
DIPROLENE
 
High Potency Topical Glucocorticoids [Glucocorticoides Tópicos de Alta Potencia]
mometasone furoate 0.1 % oint, 0.1% crm, 0.1% soln
1
Preferred
ELOCON
 

Drug Name [Nombre del
 Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
 [Nombre de
Referencia]
Requirements/
Limits
[Requerimientos
 /Límites]
Medium Potency Topical Glucocorticoids [Glucocorticoides Tópicos de Mediana Potencia]
triamcinolone acetonide   0.1 % crm, 0.1 % oint, 0.5 % crm, 0.5 % oint
1
Preferred
KENALOG
 
betamethasone valerate 0.1 % crm, 0.1 % lot, 0.1 % oint
1
Preferred
DIPROLENE
 
Low Potency Topical Glucocorticoids [Glucocorticoides Tópicos de Baja Potencia]
hydrocortisone 2.5 % crm,  2.5 % lot, 2.5 % oint
1
Preferred
HYDROCORTISONE
 
Pediculicides and Scabicides [Pediculicidas y Escabicidas]
permethrin 5 % crm  
3
Preferred
ELIMITE
QL= 60 gm.
lindane 1 % lot
4
Non-Preferred
LINDANE
QL = 60 cc, 30días,  ST
Topical Skin Antibiotics [Antibióticos Tópicos para la piel]
mupirocin 2 % oint   
1
Preferred
BACTROBAN
 
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización   Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age    Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página 33 de 53  para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017

SALUD FÍSICA
 
silver sulfadiazine 1 % crm
1
Preferred
SILVADENE
 
metronidazole 0.75 % crm, 0.75 % gel, 0.75 % lot
4
Non-Preferred
METROLOTION
 
Topical Antifungals [Antifungales Tópicos]
clotrimazole 1 % crm  
1
Preferred
LOTRIMIN
OTC ( crm )
nystatin 100000 unit/gm oint, crm
1
Preferred
MYCOSTATIN
 
Topical Antipsoriatics [Antipsoriáticos Tópicos]
calcipotriene 0.005 % crm  
6
Non-Preferred
DOVONEX
 
acitretin 10 mg cap, 17.5 mg cap, 25 mg cap
7
Non-Preferred
SORIATANE
 
DYSLIPIDEMICS [DISLIPIDÉMICOS]
  Bile Acid Sequestrants [Secuestradores de Acidos Biliares]
cholestyramine 4 gm pckt,   4 gm/dose oral pwdr
3
Preferred
QUESTRAN
 
Fibric Acid Derivatives [Derivados de Ácido Fíbrico]
gemfibrozil 600 mg tab
1
Preferred
LOPID
 
HMG-CoA Reductase Inhibitors [Inhibidores de la Reductasa De HMG-CoA]
atorvastatin calcium 10 mg   tab, 20 mg tab, 40 mg tab, 80 mg tab
1
Preferred
LIPITOR
 

Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos
 /Límites]
pravastatin sodium 10 mg tab, 20 mg tab, 80 mg tab
1
Non-Preferred
PRAVACHOL
 
simvastatin 10 mg tab, 20 mg tab, 40 mg tab, 5 mg tab, 80 mg tab
1
Preferred
ZOCOR
 
pravastatin sodium 40 mg tab
2
Non-Preferred
PRAVACHOL
 
GASTROINTESTINAL AGENTS [AGENTESGASTROINTESTINALES]
Antispasmodics [Antiespasmódicos]
dicyclomine hcl 10 mg cap,   20 mg tab
1
Preferred
BENTYL
 
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización   Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age    Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página 34 de 53  para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017
 

SALUD FÍSICA
 
dicyclomine hcl 10 mg/5ml soln
2
Preferred
BENTYL
 
Anti-Ulcer Agents [Agentes Anti-Ulceras]
misoprostol 100 mcg tab,   200 mcg tab
1
Preferred
CYTOTEC
 
sucralfate 1 gm tab
1
Preferred
CARAFATE
 
 1 gm/10ml susp
3
Non-Preferred
   
Digestive Enzymes [Enzimas Digestivas]
CREON 12000 unit cap dr   prt, 6000 unit cap dr prt
3
Preferred
 
C
CREON 24000 unit cap dr prt, 36000 unit cap dr prt, 3000-9500 unit cap dr prt
5
Preferred
 
C
Histamine2 (H2) Receptor Antagonists [Antagonistas del Receptor de H2]
famotidine   20 mg tab, 40 mg tab
1
Preferred
PEPCID
 
ranitidine hcl 15 mg/ml syr, 150 mg/10ml syr, 300 mg tab, 75 mg/5ml syr
1
Preferred
ZANTAC
 
Miscellaneous Gastrointestinal Agents [Agentes Gastrointestinales Misceláneos]
ursodiol 300 mg cap
4
Preferred
ACTIGALL
PA
cromolyn sodium 100 mg/5ml oral conc
6
Non-Preferred
GASTROCROM
PA

Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos
/Límites]
Proton Pump Inhibitors [Inhibidores de la Bomba de Protones]
omeprazole 10 mg cap dr, 20 mg cap dr,40 mg cap dr
1
Preferred
PRILOSEC
QL=180 caps/ 365 días
Rectal Anti-Inflammatories [Anti-Inflamatorios Rectales]
hydrocortisone ace   pramoxine 1-1 % rect crm, 2.5-1 % rect crm
2
Preferred
ANALPRAM-HC
 
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización   Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age    Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página 35 de 53  para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017
 

SALUD FÍSICA
 
GENITOURINARY AGENTS [AGENTES GENITOURINARIOS]
Miscellaneous Genitourinary Agents [Agentes Genitourinarios Misceláneos]
phenazopyridine hcl 100   mg tab, 200 mg tab
1
Preferred
PYRIDIUM
QL= 6 tab.
Phosphate Binder Agents [Enlazadores de Fosfato]
RENVELA   0.8 gm pckt
8
Preferred
 
PA, C
RENVELA 2.4 gm pckt, 800 mg tab
8
Preferred
 
PA, C
calcium acetate 667 mg cap.
3
Non-Preferred
PHOSLO
 
Urinary Antibiotics [Antibióticos Urinarios]
ur n   -c 81.6 mg tab
1
Preferred
URIN D/S
 
URETRON D/S tab
1
Preferred
   
URIMAR-T 120 mg tab
1
Preferred
   
urin ds tab
1
Preferred
URIN D/S
 
Urinary Antispasmodics [Antiespasmódicos Urinarios]
oxybutynin chloride 5 mg   tab, 5 mg/5ml syr
1
Preferred
DITROPAN
 
HEMATOLOGICAL AGENTS [AGENTES HEMATOLÓGICOS]
Antihemophilic Products [Productos Antithemofílicos]
ADVATE 250 unit iv soln,   500 unit iv soln, 1000 unit iv soln, 1500 unit iv soln, 2000 unit iv soln, 3000 unit iv soln, 4000 unit iv soln
25
Preferred
 
PA, C

Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
 [Nombre de
Referencia]
Requirements/
Limits
[Requerimientos
 /Límites]
ALPHANATE/VWF COMPLEX/HUMAN 250 unit iv soln, 500 unit iv soln, 1000 unit iv soln, 1500 unit iv soln, 2000 unit iv soln
25
Non-Preferred
 
PA
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización   Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age    Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página 36 de  53 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017
 

SALUD FÍSICA
 
KOGENATE FS 1000 unit intravenous kit, 2000 unit intravenous kit, 250 unit intravenous kit, 3000 unit intravenous kit, 500 unit intravenous kit
25
Preferred
 
PA, C
KOGENATE FS BIO-SET 1000 unit intravenous kit, 2000 unit intravenous kit, 250 unit intravenous kit, 3000 unit intravenous kit, 500 unit intravenous kit
25
Preferred
 
PA, C
BENEFIX 250 unit intravenous kit, 500 unit intravenous kit, 1000 unit intravenous kit, 2000 unit intravenous kit, 3000 unit intravenous kit
25
Preferred
 
PA, C
ANTIINHIBITOR COAGULANT COMPLEX for inj
25
Non-Preferred
 
PA
ANTIHEMOPHILIC FACTOR VIII for inj.
25
Non-Preferred
 
PA
Hemostatics [Hemostáticos]
tranexamic acid  650 mg tab, 1000 mg/ ml IV soln
4
Non-Preferred
LYSTEDA
PA
AMICAR 500 mg tab,   0.25 gm/ml oral soln
5
Non-Preferred
PA
AMICAR 0.25 gm/ml oral soln
8
Non-Preferred
PA
tranexamic acid   100 mg/ml IV soln
Non-Preferred
CYKLOKAPRON
PA
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización   Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age    Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página 37 de  53 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017
 

SALUD FÍSICA
 
Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
 [Nombre de
Referencia]
Requirements/
Limits
[Requerimientos
 /Límites]
HORMONAL AGENTS [AGENTES HORMONALES]
Androgens [Andrógenos]
testosterone cypionate 100   mg/ml im soln, 200 mg/ml im soln
2
Preferred
DEPO- TESTOSTERONE
 
Antithyroid Agents [Agentes Antitiroide]
methimazole 10 mg tab, 5   mg tab
1
Preferred
TAPAZOLE
 
propylthiouracil 50 mg tab
2
Preferred
PROPYLTHIOURACIL
 
Calcimimetics [Calcimiméticos]
 
SENSIPAR 30 mg tab
7
Preferred
 
PA, C
SENSIPAR 60 mg tab
9
Preferred
 
PA, C
SENSIPAR 90 mg tab
10
Preferred
 
PA, C
Dopamine Agonists [Agonistas de Dopamina]
bromocriptine mesylate 2.5   mg tab
3
Preferred
PARLODEL
 
cabergoline 0.5 mg tab
3
Preferred
DOSTINEX
 
Dysmenorrhea Agents [Agentes para la Dismenorrea]
medroxyprogesterone   acetate 10 mg tab, 2.5 mg tab, 5 mg tab
1
Preferred
PROVERA
 
alyacen 1/35 1-35 mg-mcg tab
2
Preferred
ARANELLE
PA
CRYSELLE-28 0.3-30 mgmcg tab
2
Preferred
 
PA
LOW-OGESTREL 0.3-30 mg-mcg tab
2
Preferred
 
PA
medroxyprogesterone acetate 150mg/ml susp
5
Preferred
DEPO-PROVERA
PA
Estrogens [Estrógenos]
estradiol 0.5 mg tab, 1 mg   tab, 2 mg tab
1
Preferred
ESTRACE
 
estropipate 0.75 mg tab, 1.5 mg tab
1
Preferred
ESTROPIPATE
 
estropipate 3 mg tab
2
Preferred
ESTROPIPATE
 
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización   Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age    Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página 38 de  53 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017
 

SALUD FÍSICA
 
Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
 [Nombre de
Referencia]
Requirements/
Limits
[Requerimientos
/Límites]
Estrogens and Progestins [Estrógenos y Progestinas]
estradiol    -norethindrone acet 1-0.5 mg tab
4
Non-Preferred
ACTIVELLA
 
Growth Hormones Analogs [Análogos de Hormona de Crecimiento]
NORDITROPIN FLEXPRO 5 mg/1.5ml sc soln
5
Preferred
 
PA, C
NORDITROPIN FLEXPRO 30 mg/3ml sc soln
8
Preferred
 
PA, C
NORDITROPIN NORDIFLEX 30 mg/3ml sc soln
9
Preferred
 
PA, C
NORDITROPIN FLEXPRO 10 mg/1.5ml sc soln, 15 mg/1.5ml sc soln
8
Preferred
 
PA, C
Mineralocorticoids [Mineralocorticoides]
fludrocortisone acetate 0.1   mg tab
1
Preferred
FLORINEF
 
Prostaglandins [Prostaglandinas]
misoprostol 100 mcg tab,   200 mcg tab
1
Preferred
CYTOTEC
 
Somatostatic Analogs [Análogos de Somastatina]
octreotide acetate 50   mcg/ml inj soln
3
Preferred
SANDOSTATIN
PA
octreotide acetate 100 mcg/ml inj soln, 1000 mcg/5ml inj soln, 200 mcg/ml inj soln, 500 mcg/ml inj soln
6
Preferred
SANDOSTATIN
PA
octreotide acetate 1000 mcg/ml inj soln
8
Preferred
SANDOSTATIN
PA
SANDOSTATIN LAR DEPOT 10 mg im kit
11
Non-Preferred
 
PA
SANDOSTATIN LAR DEPOT 30 mg im kit
14
Non-Preferred
 
PA
SANDOSTATIN LAR DEPOT 20 mg im kit
16
Non-Preferred
 
PA
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización   Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age    Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página 39 de 53  para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017
 

SALUD FÍSICA
 
Drug Name [Nombre del Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name [Nombre de
Referencia]
Requirements/
Limits
[Requerimientos /Límites]
Thyroid Hormones [Hormona Tiroidea]
levothyroxine sodium 100   mcg tab, 112 mcg tab, 125 mcg tab, 137 mcg tab, 150 mcg tab, 175 mcg tab, 200 mcg tab, 25 mcg tab, 300 mcg tab, 50 mcg tab, 75 mcg tab, 88 mcg tab
1
Preferred
SYNTHROID
 
SYNTHROID 100 mcg tab, 112 mcg tab, 125 mcg tab, 137 mcg tab, 150 mcg tab, 175 mcg tab, 200 mcg tab, 25 mcg tab, 300 mcg tab, 50 mcg tab, 75 mcg tab, 88 mcg tab
1
Preferred
 
C
Vasopressin Analogs [Análogos de Vasopresina]
desmopressin   acetate 4 mcg/ml inj soln
2
Non-Preferred
DDAVP
 
desmopressin acetate 0.2 mg tab
3
Non-Preferred
DDAVP
 
desmopressin ace rhinal tube 0.01 % nasal soln
4
Non-Preferred
DDAVP
 
desmopressin ace spray refrig 0.01 % nasal soln
4
Non-Preferred
DDAVP
 
desmopressin acetate 0.1 mg tab
4
Non-Preferred
DDAVP
 
desmopressin acetate spray 0.01 % nasal soln
4
Non-Preferred
DDAVP
 
STIMATE 1.5 mg/ml nasal soln
7
Non-Preferred
   
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización   Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age    Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página 40 de 53  para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017
 

SALUD FÍSICA
 
IMMUNOLOGICAL AGENTS [AGENTES INMUNOLÓGICOS]
  Immunomodulators (TNF and Non-TNF) [Inmunomoduladores (TNF y No-TNF)]
ENBREL   25 mg sc kit, 25mg/0.5ml sc sol
9
Preferred
 
PA, C
ENBREL 50mg/ml sc soldermat
9
Preferred
 
PA, C
 
Drug Name [Nombre del
 Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos
/Límites]
HUMIRA 10 mg/0.2ml sc kit, 20 mg/0.4ml sc kit, 40 mg/0.8ml sc kit
9
Preferred
 
PA, C
REMICADE 100 mg iv soln
16
Preferred
 
PA, C
IMMUNOSUPPRESSANTS [IMMUNOSUPRESORES]
Organ Transplant Agents
cyclosporine modified 25   mg cap, 50 mg cap
3
Preferred
NEORAL
a PA
cyclosporine modified 25 mg cap, 50 mg cap
3
Preferred
NEORAL
aPA
NEORAL 25 mg cap
4
Preferred
 
aPA, C
cyclosporine 25 mg cap
4
Preferred
SANDIMMUNE
aPA
cyclosporine modified 100 mg cap, 100 mg/ml soln
4
Preferred
NEORAL
aPA
cyclosporine 100 mg cap
5
Preferred
SANDIMMUNE
aPA
cyclosporine modified 100 mg cap
5
Preferred
NEORAL
aPA
NEORAL 100 mg cap
5
Preferred
 
aPA, C
cyclosporine 100 mg cap, 25 mg cap
6
Preferred
SANDIMMUNE
aPA
SANDIMMUNE 100 mg
cap, 100 mg/ml soln, 25 mg cap
6
Preferred
 
aPA, C
cyclosporine modified 100 mg/ml soln
7
Preferred
NEORAL
aPA
NEORAL 100 mg/ml soln
8
Preferred
 
aPA, C
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización   Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age    Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página 4 de 53  para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017
 

SALUD FÍSICA
 
Glucocorticosteroids [Glucocorticoides]
dexamethasone 0.5 mg   tab, 0.5 mg/5ml oral elix, 0.5 mg/5ml soln, 0.75 mg tab, 1 mg tab, 1.5 mg tab, 2 mg tab, 4 mg tab, 6 mg tab
1
Preferred
DECADRON
 
dexamethasone sodium phosphate 120 mg/30ml inj soln, 20 mg/5ml inj soln, 4 mg/ml inj soln
1
Preferred
DECADRON
OB-GYN
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización  Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age  Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página 42 de 53 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017
 

SALUD FÍSICA
 
Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
 [Nombre de
Referencia]
Requirements/
Limits
[Requerimientos
/Límites]
KENALOG 10 mg/ml inj susp
1
Preferred
   
MEDROL 2 mg tab
1
Preferred
   
methylprednisolone 32 mg tab, 4 mg tab
1
Preferred
MEDROL
 
methylprednisolone (pak) 4 mg tab
1
Preferred
MEDROL
 
prednisolone 15 mg/5ml soln, 15 mg/5ml syr
1
Preferred
PRELONE
 
prednisone 1 mg tab, 10 mg tab, 2.5 mg tab, 20 mg tab, 5 mg tab, 50 mg tab
1
Preferred
DELTASONE
 
prednisone (pak) 10 mg tab, 5 mg tab
1
Preferred
DELTASONE
 
hydrocortisone 10 mg tab, 20 mg tab, 5 mg tab
2
Preferred
CORTEF
 
methylprednisolone 16 mg tab, 8 mg tab
2
Preferred
MEDROL
 
cortisone acetate 25 mg tab
3
Non-Preferred
CORTISONE
 
KENALOG 40 mg/ml inj susp
5
Non-Preferred
   
betamethasone sod phos & acet 6 mg/ml inj susp
2
Preferred
CELESTONE SOLUSPAN
OB-GYN
Organ Transplant Agents [Agentes para Trasplantes]
azathioprine 50 mg tab
1
Preferred
IMURAN
 
AZASAN 75 mg, 100 mg
 
Non-Preferred
   
mycophenolate mofetil 200 mg/ml susp, 250 mg cap, 500 mg tab
2
Preferred
CELLCEPT
aPA
tacrolimus 0.5 mg cap
3
Non-Preferred
PROGRAF
aPA
 MYFORTIC 180 mg tab dr
4
Preferred
 
aPA, C
tacrolimus 1 mg cap
4
Non-Preferred
PROGRAF
aPA
sirolimus 0.5 mg tab, 1 mg tab, 2 mg tab
5
Non-Preferred
RAPAMUNE
aPA
 MYFORTIC   360 mg tab dr
6
Preferred
 
aPA, C
tacrolimus 5 mg cap
6
Non-Preferred
PROGRAF
aPA
RAPAMUNE 1 mg/ml soln
8
Non-Preferred
 
aPA
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización   Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age    Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página 43 de 53 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017
 

SALUD FÍSICA
 
Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos
 /Límites]
INFLAMMATORY BOWEL DISEASE [ENFERMEDAD INFLAMATORIA INTESTINAL]
Aminosalicylates [Aminosalicilatos]
mesalamine   rectal enema 4 gm
4
Preferred
ROWASA
 
DELZICOL 400 mg cap dr
5
Preferred
 
C
ASACOL HD 800 mg tab dr
6
Preferred
 
C
Immunomodulators (TNF and Non-TNF) [Inmunomoduladores (TNF y No-TNF)]
ENBREL   25 mg sc kit, 25mg/0.5ml sc sol
8
Preferred
 
PA, C
ENBREL 50mg/ml sc sol
9
Preferred
 
PA, C
HUMIRA 10 mg/0.2 ml sc kit, 20 mg/0.4ml sc kit, 40 mg/0.8ml sc kit
11
Preferred
 
PA, C
HUMIRA PEDIATRIC CROHNS START 40 mg/0.8ml sc kit
11
Preferred
 
PA, C
HUMIRA PEN 40 mg/0.8ml sc kit
11
Preferred
 
PA, C
HUMIRA PEN-CROHNS STARTER 40 mg/0.8ml sc kit
11
Preferred
 
PA, C
HUMIRA PEN-PSORIASIS STARTER 40 mg/0.8ml sc kit
11
Preferred
 
PA, C
REMICADE 100 mg iv soln
13
Preferred
 
PA, C
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización   Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age    Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página 44 de 53  para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017
 

SALUD FÍSICA
 
Intrarectal Low Potency Glucocorticoids [Glucocorticoides Intrarectales de Baja Potencia]
hydrocortisone 100   mg/60ml rect enema
2
Preferred
COLOCORT
 
Sulfonamides [Sulfonamidas]
sulfasalazine 500 mg tab,   500 mg tab dr
1
Preferred
AZULFIDINE
 
MINERALS & ELECTROLYTES [MINERALES Y ELECTROLITOS]
Calcium Regulating Agents [Agentes Reguladores de Calcio]
calcitriol 0.25 mcg cap           
1
Preferred
ROCALTROL
 
calcitriol 0.5 mcg cap
2
Preferred
ROCALTROL
 

Drug Name [Nombre del
 Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos
/Límites]
Carnitine Deficiency [Deficiencia de Carnitina]
levocarnitine 1 gm/10ml soln, 330 mg tab
3
Preferred
CARNITOR
 
Chelating Agents [Agentes Quelantes]
DEPEN TITRATABS    250 mg tab
25
Preferred
 
PA
Electrolytes/Minerals Replacement [Reemplazo de Electrolitos/Minerales]
potassium chloride 20   meq/15ml (10%) oral liquid, 20 meq/15ml (10%) soln
1
Preferred
KAY-CIEL
 
potassium chloride crys er 10 meq tab er, 20 meq tab er
1
Preferred
KLOR-CON
 
potassium chloride er 10 meq cap er, 8 meq cap er
2
Preferred
MICRO-K
 
potassium chloride 40 meq/15ml (20%) oral solution
4
Preferred
KAON CL
 
Potassium Removing Resins [Resinas Removedoras de Potasio]
sodium polystyrene   sulfonate 15 gm/60ml susp
3
Preferred
KAYEXALATE
 
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización   Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age    Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página 45 de 53  para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017
 

SALUD FÍSICA
 
Prenatal Vitamins [Vitaminas Prenatales]
classic     prenatal 28-0.8 mg tab
1
Preferred
PRENATAL VITAMINS
OB-GYN
prenatal 27-0.8 mg tab, 271 mg tab, 28-0.8 mg tab
1
Preferred
PREPLUS
OB-GYN
prenatal 19 tab chew, tab, 29-1 mg tab chew, 29-1 mg tab
1
Preferred
PRENATAL VITAMINS
OB-GYN
prenatal formula 28-0.8 mg tab
1
Preferred
PRENATAL VITAMINS
OB-GYN
prenatal low iron 27-0.8 mg tab, 27-1 mg tab
1
Preferred
PREPLUS
OB-GYN
prenatal plus iron 29-1 mg tab
1
Preferred
PRENATABS
OB-GYN
prenatal vitamins 0.8 mg tab, 28-0.8 mg tab
1
Preferred
PRENATAL VITAMINS
OB-GYN

Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
 [Nombre de
Referencia]
Requirements/
Limits
[Requerimientos
 /Límites]
Vitamin K [Vitamina K]
MEPHYTOIN 5 mg tab           
6
Non-Preferred
   
MUSCLE RELAXANTS [RELAJANTES MUSCULARES]
Antispasticity Agents [Agentes Antiespasticidad]
baclofen 10 mg tab, 20 mg   tab
1
Preferred
LIORESAL
 
dantrolene sodium 25 mg cap, 50 mg cap
2
Preferred
DANTRIUM
 
dantrolene sodium 100 mg cap
3
Preferred
DANTRIUM
 
Skeletal Muscle Relaxants [Relajantes Musculoesqueletales]
cyclobenzaprine hcl 10 mg   tab
1
Preferred
FLEXERIL
 
NASAL AGENTS [AGENTES NASALES]
Nasal Anticholinergics [Anticolinérgicos Nasales]
ipratropium bromide 0.03   % nasal soln
2
Non-Preferred
ATROVENT
 
Nasal Mast Cell Stabilizers [Estabilizadores Nasales de Mastocitos]
cromolyn sodium    5.2 mg/act nasal aerosol sol
1
Preferred
NASALCROM
 
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización   Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age    Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página 46 de 53  para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017
 

SALUD FÍSICA
 
Nasal Steroids [Esteroides Nasales]
fluticasone propionate 50   mcg/act nasal susp
1
Preferred
FLONASE
QL = 1 pompa / 30 días
OPHTHALMIC AGENTS [AGENTES OFTÁLMICOS]
Antiglaucoma Agents [Agentes Antiglaucoma]
brimonidine tartrate 0.2 %   ophth soln
1
Preferred
ALPHAGAN
 
dorzolamide hcl 2 % ophth soln
1
Preferred
TRUSOPT
 
levobunolol hcl 0.25 % ophth soln, 0.5 % ophth soln
1
Preferred
BETAGAN
 
timolol maleate 0.25 % ophth soln, 0.5 % ophth soln
1
Preferred
TIMOPTIC
 
dorzolamide hcl-timolol mal ophth sol 22.3-6.8 mg/ml
1
Preferred
COSOPT
 

Drug Name [Nombre del
 Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos
/Límites]
betaxolol hcl 0.5 % ophth soln
2
Non-Preferred
BETOPTIC
 
Miotics [Mióticos]
pilocarpine hcl 1 % ophth   soln, 2 % ophth soln, 4 % ophth soln
3
Preferred
ISOPTOCARPINE
 
Mydriatics [Midriáticos]
atropine sulfate 1 % ophth   oint, 1 % ophth soln
1
Preferred
ISO-ATROPINE
 
Nonsteroidal Anti-Inflammatory Agents (NSAIDs) [Anti-Inflamatorios No Esteroidales]
diclofenac sodium 0.1 %   ophth soln
1
Preferred
VOLTAREN
QL = max 30 días / 365 días
ketorolac tromethamine 0.5 % ophth soln
1
Preferred
ACULAR
QL = max 30 días / 365 días
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización   Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age    Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página 47 de 53  para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017
 

SALUD FÍSICA
 
Ophthalmic Antibiotics [Antibióticos Oftálmicos]
ciprofloxacin hcl 0.3 %   ophth soln
1
Preferred
CILOXAN
 
gentamicin sulfate 0.3 % ophth oint, 0.3 % ophth soln
1
Preferred
GARAMYCIN
 
ofloxacin 0.3 % ophth soln
1
Preferred
OCUFLOX
 
polymyxin b-trimethoprim 10000-0.1 unit/ml-% ophth soln
1
Preferred
POLYTRIM
 
tobramycin 0.3 % ophth soln
1
Preferred
TOBREX
 
bacitracin 500 unit/gm ophth oint
3
Non-Preferred
BACITRACIN
 
Ophthalmic Antivirals [Antivirales Oftálmicos]
trifluridine 1 % ophth soln  
4
Non-Preferred
VIROPTIC
PA
Ophthalmic Prostaglandins [Prostaglandinas Oftálmicas]
latanoprost 0.005 % ophth   soln
1
Preferred
XALATAN
 

Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos
/Límites]
Ophthalmic Steroids [Esteroides Oftálmicos]
neomycin    -polymyxindexamethasone 3.5- 10000-0.1 ophth oint, 3.5- 10000-0.1 ophth susp
1
Preferred
MAXITROL
 
prednisolone acetate 1 % ophth susp
2
Preferred
PRED FORTE
 
prednisolone sodium phosphate 1 % ophth soln
2
Preferred
INFLAMASE
 
fluorometholone 0.1 % ophth susp
3
Preferred
FML LIQUIFILM
 
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización   Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age    Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página 48 de 53  para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017
 

SALUD FÍSICA
 
OTIC AGENTS [AGENTES OTICOS]
  Miscellaneous Otic Agents [Agentes Oticos Misceláneos]
acetic acid 2 % otic soln    
2
Preferred
VOSOL
 
Otic Antibiotics [Antibióticos Oticos]
neomycin    -polymyxin-hc 1 % otic soln, 3.5-10000-1 otic soln, 3.5-10000-1 otic susp
2
Preferred
CORTISPORIN
 
cipro hc  0.2-1 % otic susp
1
Preferred
   
RESPIRATORY AGENTS [AGENTES RESPIRATORIOS]
  Anticholinergic Bronchodilators [Broncodilatadores Anticolinérgicos]
ipratropium bromide 0.02   % inh soln
1
Preferred
ATROVENT
 
Antileukotrienes [Antileukotrienos]
montelukast sodium 10 mg   tab, 4 mg tab chew, 5 mg tab chew
1
Preferred
SINGULAIR
 
Antitussive-Expectorant [Expectorantes Antitusivos]
benzonatate   100 mg cap
1
Preferred
TESSALON
 
guaifenesin-codeine 10010 mg/5ml soln
1
Preferred
CHERATUSSIN
 
Bronchiolitis Agents [Agentes para Bronquiolitis]
SYNAGIS 50 mg/0.5ml im   soln
9
Preferred
 
PA, C
SYNAGIS 100 mg/ml im soln
11
Preferred
 
PA, C

Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos
/Límites]
Inhaled Corticosteroids [Corticosteroides Inhalados]
FLOVENT DISKUS 100  mcg/blist inh aer pwdr, 250 mcg/blist inh aer pwdr, 50 mcg/blist inh aer pwdr
3
Preferred
 
QL = 1 pompa / 30 días, C
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización   Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age    Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página 49 de 53 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017
 

SALUD FÍSICA
 
FLOVENT HFA 110 mcg/act inh aer, 44 mcg/act inh aer
3
Preferred
 
QL = 1 pompa / 30 días, C
ADVAIR DISKUS 100-50 mcg/dose inh aer pwdr, 250-50 mcg/dose inh aer pwdr
4
Preferred
 
QL= 1 pompa / 30 días, ST, C
ADVAIR HFA 115-21 mcg/act inh aer, 45-21 mcg/act inh aer
4
Preferred
 
QL= 1 pompa / 30 días, ST, C
budesonide 0.25 mg/2ml inh susp, 0.5 mg/2ml inh susp
4
Non-Preferred
PULMICORT
AL ≤ 12 años
budesonide 1mg/2ml inh susp
8
Non-Preferred
PULMICORT
AL ≤ 12 años
FLOVENT HFA 220 mcg/act inh aer
4
Preferred
 
QL= 1 pompa / 30 días, C
ADVAIR DISKUS 500-50 mcg/dose inh aer pwdr
5
Preferred
 
QL= 1 pompa / 30 días, ST, C
ADVAIR HFA 230-21 mcg/act inh aer
5
Preferred
 
QL= 1 pompa / 30 días, ST, C
Nonsedating Histamine1 Blocking Agents [Bloqueadores de Histamina1 No-Sedantes]
cetirizine HCl oral soln 1 MG/ML (5 MG/5ML)
1
Preferred
ZYRTEC
OTC
loratadine 5 mg/5ml soln, 5 mg/5ml syr
1
Preferred
CLARITIN
OTC
loratadine 10 mg tab
1
Preferred
CLARITIN
OTC
Phosphodiesterase Inhibitors [Inhibidores de la Fosfodiesterasa]
theophylline er 100 mg tab   er 12 hr, 200 mg tab er 12 hr, 300 mg tab er 12 hr, 450 mg tab er 12 hr
1
Preferred
THEO-DUR
 
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización   Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age    Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página 50 de 53  para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017
 

SALUD FÍSICA
 
Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
 [Nombre de
Referencia]
Requirements/
Limits
[Requerimientos
/Límites]
Sympathomimetic Bronchodilators [Broncodilatadores Simpatomiméticos]
albuterol sulfate (2.5   mg/3ml) 0.083% inh neb soln, (5 mg/ml) 0.5% inh neb soln, 2 mg/5ml syr
1
Preferred
ALBUTEROL
 
terbutaline sulfate 2.5 mg tab, 5 mg tab
1
Preferred
BRETHINE
 
VENTOLIN HFA 108 (90 base) mcg/act inh aer
2
Preferred
 
QL = 1 pompa / 30 días, C
RHEUMATOID ARTHRITIS AGENTS [AGENTES PARA ARTRITIS REUMATOIDE]
Immunomodulators (TNF And Non-TNF) [Inmunomoduladores (TNF Y No-TNF)]
ENBREL 25 mg sc kit, 25mg/0.5ml sc sol
8
Preferred
 
PA, C
ENBREL 50mg/ml sc sol
9
Preferred
 
PA, C
ORENCIA 125 mg/ml subcutaneous solution prefilled syringe, 125 mg/ml ClickJect sc sol Autoinjector
10
Preferred
 
PA, C
HUMIRA 10 mg/ 0.2ml sc kit, 20 mg/0.4ml sc kit, 40 mg/0.8ml sc kit
11
Preferred
 
PA, C
REMICADE 100 mg iv soln
13
Preferred
 
PA, C
Non-Biologic Agents [Agentes No-Biológicos]
methotrexate 2.5 mg tab
2
Preferred
METHOTREXATE
leflunomide 10 mg tab, 20 mg tab
4
Non-Preferred
ARAVA
PA
DEPEN TITRATABS 250 mg tab
25
Preferred
 
PA
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización   Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age    Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página 51 de 53  para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017
 

SALUD FÍSICA
 
 
Page 52 of 53 
Revisado 5/18/2017
 

SALUD FÍSICA

 
 
Page 53 of 53 
Revisado 5/18/2017
 


MENTAL HEALTH
 
Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
 [Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/
Límites]
THERAPEUTIC CATEGORY [CATEGORÍA TERAPÉUTICA]
Therapeutic Class [Clase  Terapéutica]
ANTI-ADDICTION AGENTS [AGENTES   CONTRA LA ADDICIÓN]
Opioid Antagonist [Antagonistas De Opioides]
buprenorphine hcl 2 mg tab   subl, 8 mg tab subl
3
Preferred
SUBUTEX
PA
SUBOXONE subl film 2-0.5 mg, 8-2 mg, 4-1 mg, 12-3 mg
4
Preferred
 
PA, C
Detox Treatment [Tratamiento De Detox]
b-1 100 mg tab
1
Preferred
THIAMINE
QL
clonidine hcl 0.1 mg tab
1
Preferred
CATAPRESS
 
folic acid 1 mg tab
1
Preferred
FOLIC ACID
QL
ibuprofen 800 mg tab
1
Preferred
MOTRIN
QL
loperamide hcl 2 mg cap
1
Preferred
IMODIUM
QL
ANTIANXIETY AGENTS [AGENTES PARA LA ANXIEDAD]
Benzodiazepines [Benzodiazepinas]
clonazepam 0.5 mg tab, 1   mg tab, 2mg tab
1
Preferred
KLONOPIN
 
diazepam 10 mg tab, 2 mg tab, 5 mg tab
1
Preferred
VALIUM
 
lorazepam 0.5 mg tab, 1 mg tab
1
Preferred
ATIVAN
 
diazepam 1 mg/ml soln
2
Non-Preferred
VALIUM
 
DIAZEPAM INTENSOL 5 mg/ml oral conc
2
Non-Preferred
   
lorazepam 2 mg/ml oral conc
2
Non-Preferred
ATIVAN
 
Sedating Histamine 1 Blocking Agents [Sedantes Bloqueadores Histamine 1]
hydroxyzine pamoate 100   mg cap, 25 mg cap, 50 mg cap
1
Preferred
VISTARIL
 
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 9 for monthly net cost range [Ver página 9 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 


MENTAL HEALTH
 
Drug Name [Nombre del
 Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/
 Límites]
ANTIDEPRESSANTS [ANTIDEPRESIVOS]
Miscellaneous Antidepressants [Antidepresivos Misceláneos]
bupropion hcl 75 mg tab
1
Preferred
WELLBUTRIN
 
bupropion hcl er (sr) 100 mg tab er 12 hr, 150 mg tab er 12 hr, 200 mg tab er 12 hr
1
Preferred
WELLBUTRIN SR
 
escitalopram oxalate 5mg tab, 10 mg tab, 20 mg tab
1
Preferred
LEXAPRO
 
mirtazapine 15 mg tab, 30 mg tab, 45 mg tab, 7.5 mg tab
1
Preferred
REMERON
 
trazodone hcl 100 mg tab, 150 mg tab, 50 mg tab
1
Preferred
DESYREL
 
bupropion hcl 100 mg tab
2
Non-Preferred
WELLBUTRIN
 
bupropion hcl er (xl) 150 mg tab er 24 hr, 300 mg tab er 24 hr
2
Non-Preferred
WELLBUTRIN XL
 
mirtazapine 15 mg odt, 30 mg odt, 45 mg odt
3
Non-Preferred
REMERON
 
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 9 for monthly net cost range [Ver página 9 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 
Page 2 of 11


MENTAL HEALTH
 
Serotonin and/or Norepinephrine Modulators [Moduladores De Serotonina y/o Norepinefrina]
citalopram hydrobromide   10 mg tab, 20 mg tab, 40 mg tab
1
Preferred
CELEXA
 
fluoxetine hcl 10 mg cap, 20 mg cap
1
Preferred
PROZAC
 
paroxetine hcl 10 mg tab, 20 mg tab, 30 mg tab, 40 mg tab
1
Preferred
PAXIL
 
sertraline hcl 100 mg tab, 25 mg tab, 50 mg tab
1
Preferred
ZOLOFT
 
sertraline hcl oral concentrate 20 mg/ml
2
Non-Preferred
ZOLOFT
 

Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/
 Límites]
venlafaxine hcl 100mg tab, 25mg tab, 37.5mg tab, 50mg tab, 75mg tab
1
Preferred
EFFEXOR
 
venlafaxine hcl er 150 mg cap er 24 hr, 37.5 mg cap er 24 hr, 75 mg cap er 24 hr
1
Preferred
EFFEXOR XR
 
duloxetine 20 mg cap, 30 mg cap, 60 mg cap
2
Non-Preferred
CYMBALTA
 
Tricyclic Agents [Tricíclicos]
amitriptyline hcl 10 mg tab,   100 mg tab, 150 mg tab, 25 mg tab, 50 mg tab, 75 mg tab
1
Preferred
ELAVIL
 
doxepin hcl 10 mg cap, 10 mg/ml oral conc, 25 mg cap, 50 mg cap, 75 mg cap
1
Preferred
SINEQUAN
 
imipramine hcl 10 mg tab, 25 mg tab, 50 mg tab
1
Preferred
TOFRANIL
 
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 9 for monthly net cost range [Ver página 9 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 
Page 3 of 11


MENTAL HEALTH
 
nortriptyline hcl 10 mg cap, 10 mg/5ml soln, 25 mg cap, 50 mg cap, 75 mg cap
1
Preferred
PAMELOR
 
doxepin hcl 100 mg cap, 150 mg cap
2
Preferred
SINEQUAN
 
ANTIPARKINSON AGENTS [AGENTES ANTIPARKINSON]
Anticholinergics [Anticolinérgicos]
benztropine mesylate 0.5 mg tab, 1 mg tab, 2 mg tab
1
Preferred
COGENTIN
 
ANTIPSYCHOTICS [ANTIPSICÓTICOS]
Atypical - Second Generation [Atípicos - Segunda Generación]
 
olanzapine 10 mg tab, 15 mg tab, 2.5 mg tab, 20 mg tab, 5 mg tab, 7.5 mg tab
1
Preferred
ZYPREXA
 
quetiapine fumarate 25 mg tab
1
Preferred
SEROQUEL
 

Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
 [Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/
Límites]
risperidone 0.25 mg tab, 0.5 mg tab, 1 mg tab, 2 mg tab, 3 mg tab, 4 mg tab
1
Preferred
RISPERDAL
 
quetiapine fumarate 50 mg tab
2
Preferred
SEROQUEL
 
risperidone 1 mg/ml soln
2
Preferred
RISPERDAL
 
quetiapine fumarate 100 mg tab
3
Preferred
SEROQUEL
 
LATUDA 120 mg tab, 20 mg tab, 40 mg tab, 60 mg tab, 80 mg tab
4
Preferred
PA
PA, P
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 9 for monthly net cost range [Ver página 9 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 
Page 4 of 11


MENTAL HEALTH
 
quetiapine fumarate 200 mg tab
4
Preferred
SEROQUEL
 
quetiapine fumarate 300 mg tab
5
Preferred
SEROQUEL
 
quetiapine fumarate 400 mg tab
6
Preferred
SEROQUEL
 
aripriprazole 2 mg tab, 5 mg tab, 10 mg tab, 15 mg tab, 20 mg tab, 30 mg tab
7
Non-Preferred
ABILIFY
PA
 aripiprazole 1 mg/ml soln
10
Non-Preferred
ABILIFY
PA
Typical - First Generation [Típicos - Primera Generación]
fluphenazine hcl 1 mg tab,   10 mg tab, 2.5 mg tab, 5
mg tab
1
Preferred
PROLIXIN
 
haloperidol 0.5 mg tab, 1 mg tab, 2 mg tab, 2 mg/ml oral conc
1
Preferred
HALDOL
 
thioridazine hcl 10 mg tab, 25 mg tab, 50 mg tab
1
Preferred
MELLARIL
 
thiothixene 1 mg cap, 2 mg cap, 5 mg cap
1
Preferred
NAVANE
 
trifluoperazine hcl mg tab, 2 mg tab, 5 mg tab, 10 mg tab
2
Preferred
STELAZINE
 

Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
 [Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/
Límites]
chlorpromazine hcl 25 mg tab
2
Preferred
THORAZINE
 
haloperidol 5 mg tab
2
Preferred
HALDOL
 
haloperidol decanoate 50 mg/ml im soln
2
Preferred
HALDOL DECANOATE
 
 
 • PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 9 for monthly net cost range [Ver página 9 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 
Page 5 of 11


MENTAL HEALTH
 
thioridazine hcl 100 mg tab
2
Preferred
MELLARIL
 
thiothixene 10 mg cap
2
Preferred
NAVANE
 
chlorpromazine hcl 100 mg tab, 50 mg tab
3
Preferred
THORAZINE
 
haloperidol 10 mg tab
3
Preferred
HALDOL
 
haloperidol decanoate 100 mg/ml im soln
3
Preferred
HALDOL DECANOATE
 
chlorpromazine hcl 200 mg tab
4
Preferred
THORAZINE
 
haloperidol 20 mg tab
4
Preferred
HALDOL
 
MOOD STABILIZERS [ESTABILIZADORES DEL ÁNIMO]
Bipolar Agents [Agentes Para Bipolaridad]
divalproex sodium 125 mg   tab dr, 250 mg tab dr, 500 mg tab dr
1
Preferred
DEPAKOTE
 
lamotrigine 100 mg tab, 150 mg tab, 200 mg tab, 25 mg tab
1
Preferred
LAMICTAL
 
lamotrigine chew tab 5 mg, 25 mg
3
Non-Preferred
LAMICTAL
 
lithium carbonate 150 mg cap, 300 mg cap, 300 mg tab, 600 mg cap
1
Preferred
LITHIUM
 
lithium carbonate er 300 mg tab er, 450 mg tab er
1
Preferred
LITHIUM
 
olanzapine 10 mg tab, 15 mg tab, 2.5 mg tab, 20 mg tab, 5 mg tab, 7.5 mg tab
1
Preferred
ZYPREXA
 
quetiapine fumarate 25 mg tab
1
Preferred
SEROQUEL
 
 
 • PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 9 for monthly net cost range [Ver página 9 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 
Page 6 of 11


MENTAL HEALTH
 
Drug Name [Nombre del
 Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/
Límites]
risperidone 0.25 mg tab, 0.5 mg tab, 1 mg tab, 2 mg tab, 3 mg tab, 4 mg tab
1
Preferred
RISPERDAL
 
valproic acid 250 mg cap, 250 mg/5ml soln, 250 mg/5ml syr
1
Preferred
DEPAKENE
 
quetiapine fumarate 50 mg tab
2
Preferred
SEROQUEL
 
risperidone 1 mg/ml soln
2
Preferred
RISPERDAL
 
quetiapine fumarate 100 mg tab
3
Preferred
SEROQUEL
 
quetiapine fumarate 200 mg tab
4
Preferred
SEROQUEL
 
quetiapine fumarate 300 mg tab
5
Preferred
SEROQUEL
 
quetiapine fumarate 400 mg tab
6
Preferred
SEROQUEL
 
aripriprazole 10 mg tab, 15 mg tab, 2 mg tab, 5 mg tab, 20 mg tab, 30 mg tab
7
Non-Preferred
ABILIFY
PA
aripiprazole 1 mg/ml soln
10
Non-Preferred
ABILIFY
PA
PSYCHOSTIMULANTS [PSICOESTIMULANTES]
ADHD Amphetamines [Anfetaminas ADHD]
amphetamine    - dextroamphetamine 15 mg tab, 30 mg tab
2
Preferred
ADDERALL
AL 4-20años
amphetamine- dextroamphetamine 10 mg tab, 12.5 mg tab, 20 mg tab, 5 mg tab, 7.5 mg tab
3
Preferred
ADDERALL
AL 4-20 años
dextroamphetamine sulfate 10 mg tab, 5 mg tab
3
Preferred
DEXEDRINE
AL 4-20 años
dextroamphetamine sulfate er 5 mg cap er 24 hr, 10 mg cap er 24 hr
4
Non-Preferred
DEXEDRINE SR
AL 4-20 años
 
 • PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 9 for monthly net cost range [Ver página 9 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 
Page 7 of 11


MENTAL HEALTH
 
Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/
Límites]
dextroamphetamine sulfate er 15 mg cap er 24 hr
5
Non-Preferred
DEXEDRINE SR
AL 4-20 años
DYANAVEL XR oral susp.er 2.5 mg/ mL
4
Non-Preferred
DYANAVEL XR
PA, AL 6-20 años
ADHD Non-Amphetamines [No-Anfetaminas ADHD]
clonidine hcl 0.1 mg tab           
1
Preferred
CATAPRESS
 
dexmethylphenidate hcl 2.5 mg tab, 5 mg tab
2
Preferred
FOCALIN
AL 6-20 años
methylphenidate hcl 5 mg tab
2
Preferred
RITALIN
AL 6-20 años
dexmethylphenidate hcl 10 mg tab
3
Preferred
FOCALIN
AL 6-20 años
methylphenidate hcl 10 mg tab, 20 mg tab
3
Preferred
RITALIN
AL 6-20 años
methylphenidate soln 5mg/5ml, 10 mg/5ml
 
Non-Preferred
METHYLIN
 
STRATTERA 10 mg cap, 100 mg cap, 18 mg cap, 25 mg cap, 40 mg cap, 60 mg cap, 80 mg cap
4
Preferred
 
PA, AL 6-20 años, P
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 9 for monthly net cost range [Ver página 9 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 
Page 8 of 11


MENTAL HEALTH
 
SLEEP DISORDER AGENTS [DESORDENES DEL SUEÑO]
Benzodiazepines [Benzodiazepinas]
flurazepam hcl 15 mg cap,   30 mg cap
1
Preferred
DALMANE
 
temazepam 15 mg cap, 30 mg cap
1
Preferred
RESTORIL
 
Miscellaneous Sleep Disorder Agents [Agentes Misceláneos Desordenes Del Sueño]
doxepin hcl 10 mg cap, 10   mg/ml oral conc, 25 mg cap, 50 mg cap, 75 mg cap
1
Preferred
SINEQUAN
 
zolpidem tartrate 10 mg tab, 5 mg tab
1
Preferred
AMBIEN
 
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 9 for monthly net cost range [Ver página 9 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 
Page 9 of 11

SALUD MENTAL
 
Page 10 of 11

SALUD MENTAL
 
 
Page 11 of 11

SALUD FÍSICA

Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/
 Límites]
THERAPEUTIC CATEGORY [CATEGORÍA TERAPÉUTICA]
Therapeutic Class [Clase Terapéutica]
ANALGESICS [ANALG   ÉSICOS]
Nonsteroidal Anti-Inflammatory Agents (NSAIDs) [Anti-Inflamatorios No Esteroidales]
ibuprofen 400 mg tab, 600   mg tab
1
Preferred
MOTRIN
QL=5 días
nabumetone 500 mg tab, 750 mg tab
1
Preferred
RELAFEN
QL=5 días
naproxen 250 mg tab, 375 mg tab, 500 mg tab
1
Preferred
NAPROSYN
QL=15 días No repeticiones
salsalate 500 mg tab, 750 mg tab
1
Preferred
DISALCID
QL=5 días
indomethacin 25 mg cap, 50 mg cap
1
Non-Preferred
INDOCIN
 
Short-Acting Opioid Analgesics [Analgésicos Opiodes De Corta Duración]
acetaminophen   -codeine 120-12 mg/5ml soln, 300-15 mg tab, 300-30 mg tab, 300-
60 mg tab
1
Preferred
TYLENOL-CODEINE
QL=5 días
acetaminophen-codeine #2 300-15 mg tab
1
Preferred
TYLENOL-CODEINE
QL=5 días
acetaminophen-codeine #3 300-30 mg tab
1
Preferred
TYLENOL-CODEINE
QL=5 días
acetaminophen-codeine #4 300-60 mg tab
1
Preferred
TYLENOL-CODEINE
QL=5 días
butalbital-apap-caffeine 50325-40 mg tab
1
Preferred
FIORICET
QL=5 días
tramadol hcl 50 mg tab
1
Preferred
ULTRAM
QL=5 días
butalbital-apap-caffeine 50325-40 mg cap
2
Preferred
FIORICET
QL=5 días
margesic 50-325-40 mg cap
2
Preferred
FIORICET
QL=5 días
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización  Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age   Página 1 de 22 Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 9 for monthly net cost range [Ver página 9    Revisado 5/12/2017 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 

SALUD FÍSICA
 
Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/
Límites]
ANESTHETICS [ANESTÉSICOS]
Local Anesthetics [Anestésicos Locales]
lidocaine viscous 2 % mouth/throat soln
1
Preferred
XYLOCAINE
QL=5 días
ANTIBACTERIALS [ANTIBACTERIANOS]
First Generation Cephalosporins [Cefalosporinas De Primera Generación]
cephalexin 125 mg/5ml   susp, 250 mg cap, 500 mg cap
1
Preferred
KEFLEX
QL=5 días
cefadroxil 250 mg/5ml susp
2
Non-Preferred
DURICEF
QL=5 días, AL 012 años
cephalexin 250 mg/5ml susp
2
Preferred
KEFLEX
QL=5 días
cefadroxil 500 mg/5ml susp
3
Non-Preferred
DURICEF
QL=5 días, AL 0-12 años
Macrolides [Macrólidos]
azithromycin 250 mg tab,   500 mg tab
1
Preferred
ZITHROMAX
QL=5 días
azithromycin 1 gm pckt, 100 mg/5ml susp, 200 mg/5ml susp, 600 mg tab
2
Preferred
ZITHROMAX
QL=5 días
clarithromycin 125 mg/5ml susp, 250 mg tab, 500 mg tab
2
Preferred
BIAXIN
QL=5 días
clarithromycin 250 mg/5ml susp
3
Preferred
BIAXIN
QL=5 días
erythromycin base 250 mg cap dr prt, 250 mg tab, 500 mg tab
3
Preferred
ERY-TAB
QL=5 días
erythromycin ethylsuccinate 400 mg tab
3
Preferred
E.E.S.
QL=5 días
ERYTHROCIN STEARATE 250 mg tab
4
Non-Preferred
 
QL=5 días
Miscellaneous Antibacterials [Antibacterianos Misceláneos]
clindamycin hcl 150 mg cap,   300 mg cap, 75 mg cap
1
Preferred
CLEOCIN
QL=5 días
MACRODANTIN 25 mg cap
1
Preferred
 
QL=5 días
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización  Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age   Página 2 de 22 Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 9 for monthly net cost range [Ver página 9    Revisado 5/12/2017 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 

SALUD FÍSICA
 
Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/
Límites]
metronidazole 250 mg tab, 500 mg tab
1
Preferred
FLAGYL
QL=5 días
nitrofurantoin macrocrystal 50 mg cap
1
Preferred
MACRODANTIN
QL=5 días
nitrofurantoin macrocrystal 100 mg cap
2
Preferred
MACRODANTIN
QL=5 días
nitrofurantoin monohyd macro 100 mg cap
2
Preferred
MACROBID
QL=5 días
Penicillins [Penicilinas]
amoxicillin 125 mg/5ml susp,   200 mg/5ml susp, 250 mg cap, 250 mg/5ml susp, 400 mg/5ml susp, 500 mg cap, 500 mg tab, 875 mg tab
1
Preferred
AMOXIL
QL=5 días
amoxicillin-pot clavulanate 200-28.5 mg/5ml susp, 40057 mg/5ml susp, 500-125 mg tab, 600-42.9 mg/5ml susp, 875-125 mg tab
1
Preferred
AUGMENTIN
QL=5 días
ampicillin 125 mg/5ml susp, 250 mg cap, 250 mg/5ml susp, 500 mg cap
1
Preferred
PRINCIPEN
QL=5 días
penicillin v potassium 125 mg/5ml soln, 250 mg tab, 250 mg/5ml soln, 500 mg tab
1
Preferred
VEETIDS
QL=5 días
amoxicillin-pot clavulanate 250-125 mg tab, 250-62.5 mg/5ml susp
3
Preferred
AUGMENTIN
QL=5 días
Quinolones [Quinolonas]
ciprofloxacin hcl 250 mg tab,   500 mg tab, 750 mg tab
1
Preferred
CIPRO
QL=5 días
levofloxacin 250 mg tab, 500 mg tab, 750 mg tab
1
Preferred
LEVAQUIN
QL=5 días
ciprofloxacin 500 mg/5ml (10%) susp
3
Preferred
CIPRO
QL=5 días
ciprofloxacin 250 mg/5ml (5%) susp
4
Preferred
CIPRO
QL=5 días
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización  Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age   Página 3 de 22 Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 9 for monthly net cost range [Ver página 9    Revisado 5/12/2017 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 

SALUD FÍSICA
 
Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/
Límites]
Second Generation Cephalosporins [Cefalosporinas De Segunda Generación]
cefaclor 250 mg cap, 500   mg cap
2
Preferred
CECLOR
QL=5 días
cefprozil 125 mg/5ml susp, 250 mg tab, 250 mg/5ml susp, 500 mg tab
2
Preferred
CEFZIL
QL=5 días
Sulfonamides [Sulfonamidas]
sulfamethoxazole-tmp ds 800-160 mg tab
1
Preferred
SEPTRA
QL=5 días
sulfamethoxazoletrimethoprim 200-40 mg/5ml susp, 400-80 mg tab
1
Preferred
SEPTRA
QL=5 días
Third Generation Cephalosporins [Cefalosporinas De Tercera Generación]
cefdinir 125 mg/5ml susp,   300 mg cap
2
Preferred
OMNICEF
QL=5 días
cefdinir 250 mg/5ml susp
3
Preferred
OMNICEF
QL=5 días
ANTICONVULSANTS [ANTICONVULSIVANTES]
Anticonvulsants [Anticonvulsivantes]
carbamazepine 100 mg tab   chew, 200 mg tab
1
Preferred
TEGRETOL
QL=5 días
gabapentin 100 mg cap, 300 mg cap, 400 mg cap, 600 mg tab, 800 mg tab
1
Preferred
NEURONTIN
QL=5 días
levetiracetam 250 mg tab, 500 mg tab
1
Preferred
KEPPRA
QL=5 días
oxcarbazepine 150 mg tab
1
Preferred
TRILEPTAL
QL=5 días
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización  Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age   Página 4 de 22 Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 9 for monthly net cost range [Ver página 9    Revisado 5/12/2017 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]

SALUD FÍSICA
 
phenobarbital 100 mg tab, 15 mg tab, 16.2 mg tab, 30 mg tab, 32.4 mg tab, 60 mg tab, 64.8 mg tab, 97.2 mg tab
1
Preferred
PHENOBARBITAL
QL=5 días
primidone 250 mg tab, 50 mg tab
1
Preferred
MYSOLINE
QL=5 días
topiramate 100 mg tab, 200 mg tab, 25 mg tab, 50 mg tab
1
Preferred
TOPAMAX
QL=5 días
DILANTIN 30 mg cap
2
Preferred
 
QL=5 días

Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/
 Límites]
levetiracetam 1000 mg tab, 750 mg tab
2
Preferred
KEPPRA
QL=5 días
oxcarbazepine 300 mg tab, 600 mg tab
2
Preferred
TRILEPTAL
QL=5 días
phenytoin 125 mg/5ml susp, 50 mg tab chew
2
Preferred
DILANTIN
QL=5 días
phenytoin sodium extended 100 mg cap, 200 mg cap, 300 mg cap
2
Preferred
DILANTIN
QL=5 días
phenytoin sodium extended 100 mg cap, 200 mg cap, 300 mg cap
2
Preferred
DILANTIN
QL=5 días
ethosuximide 250 mg cap, 250 mg/5ml soln
3
Preferred
ZARONTIN
QL=5 días
phenobarbital 20 mg/5ml oral elix, 20 mg/5ml soln
3
Preferred
PHENOBARBITAL
QL=5 días
ANTIDEMENTIA AGENTS [AGENTES ANTIDEMENCIA]
Cholinesterase Inhibitors [Inhibidores De Colinesterasa]
donepezil hcl 10 mg tab, 5   mg tab
1
Preferred
ARICEPT
QL=5 días
rivastigmine tartrate 1.5 mg cap, 3 mg cap, 4.5 mg cap, 6 mg cap
3
Preferred
EXELON
QL=5 días
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización  Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age   Página 5 de 22 Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 9 for monthly net cost range [Ver página 9    Revisado 5/12/2017 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 

SALUD FÍSICA
 
ANTIDEPRESSANTS [ANTIDEPRESIVOS]
Monoamine Oxidase (Mao) Inhibitors [Inhibidores De Mao]
selegiline   hcl 5 mg tab
3
Non-Preferred
CARBEX
QL=5 días
ANTIDIABETIC AGENTS [AGENTES ANTIDIABÉTICOS]
Alpha-Glucosidase Inhibitors [Inhibidores De Alfa Glucosidasa]
acarbose 100 mg tab, 25 mg   tab, 50 mg tab
2
Preferred
PRECOSE
QL=5 días
Biguanides [Biguanidas]
metformin hcl 1000 mg tab,   500 mg tab, 850 mg tab
1
Preferred
GLUCOPHAGE
QL=5 días

Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/
 Límites]
Dipeptidyl Peptidase-4 (Dpp-4) Inhibitors [Inhibidores De Dpp-4]
KOMBIGLYZE XR 2.5   -1000 mg tab er 24 hr, 5-1000 mg tab er 24 hr, 5-500 mg tab er 24 hr
3
Preferred
 
QL=5 días, ST, P
ONGLYZA 2.5 mg tab, 5 mg tab
3
Preferred
 
QL=5 días, ST, P
Insulin Mixtures [Mezclas De Insulinas]
HUMULIN 70/30 (70    -30) 100 unit/ml sc susp
2
Preferred
 
QL= 1 vial / 30 días, P
Insulin Sensitizing Agents [Agentes Sensibilizantes De Insulin]
pioglitazone hcl 15 mg tab,   30 mg tab, 45 mg tab
1
Preferred
ACTOS
QL=5 días
Intermediate-Acting Insulins [Insulinas De Duración Intermedia]
HUMULIN N 100 unit/ml sc   QL= 1 vial / susp 2 Preferred  30 días, P
Short-Acting Insulins [Insulinas De Corta Duración]
HUMULIN R 100 unit/ml inj   soln
2
Preferred
 
QL= 1 vial / 30 días, P
Sulfonylureas [Sulfonilureas]
glimepiride 1 mg tab, 2 mg   tab, 4 mg tab
1
Preferred
AMARYL
QL=5 días
glipizide 10 mg tab, 5 mg tab
1
Preferred
GLUCOTROL
QL=5 días
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización  Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age   Página 6 de 22 Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 9 for monthly net cost range [Ver página 9    Revisado 5/12/2017 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]

SALUD FÍSICA
 
ANTIEMETICS [ANTIEMÉTICOS]
Miscellaneous Antiemetics [Antieméticos Misceláneos]
metoclopramide hcl 10 mg   tab, 5 mg tab, 5 mg/ml inj soln
1
Preferred
REGLAN
QL=5 días
trimethobenzamide hcl 300 mg cap
1
Preferred
TIGAN
QL=5 días
Phenothiazines [Fenotiazinas]
prochlorperazine maleate 10   mg tab, 5 mg tab
1
Preferred
COMPAZINE
QL=5 días
prochlorperazine 25 mg rect supp
4
Non-Preferred
COMPAZINE
QL=5 días

Drug Name [Nombre del Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name [Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/ Límites]
ANTIGOUT AGENTS [AGENTES ANTIGOTA]
Antigout Agents [Agentes Antigota]
allopurinol 100 mg tab, 300   mg tab
1
Preferred
ZYLOPRIM
QL=5 días
colchicine 0.6 mg cap
3
Preferred
MITIGARE
PA
colchicine 0.6 mg tab
3
Non-Preferred
COLCRYS
QL= 3 tab, 15días
Uricosurics [Uricosúricos]
probenecid 500 mg tab
1
Preferred
BENEMID
QL=5 días
ANTIHYPERTENSIVES [ANTIHIPERTENSIVOS]
Alpha-Adrenergic Agonists [Agonistas Alfa Adrenérgicos]
clonidine hcl 0.2 mg tab, 0.3   mg tab
1
Preferred
CATAPRESS
QL=5 días
methyldopa 250 mg tab, 500 mg tab
1
Preferred
ALDOMET
QL=5 días
Alpha-Adrenergic Blocking Agents [Bloqueadores Alfa Adrenérgicos]
terazosin hcl 1 mg cap, 10   mg cap, 2 mg cap, 5 mg cap
1
Preferred
HYTRIN
QL=5 días
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización  Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age   Página 7 de 22 Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 9 for monthly net cost range [Ver página 9    Revisado 5/12/2017 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 

SALUD FÍSICA
 
Angiotensin II Receptor Blockers (Arb) [Antagonistas Del Receptor Angiotensina II]
losartan potassium  100 mg tab, 25 mg tab, 50 mg tab
1
Preferred
COZAAR
QL=5 días
losartan potassium-hctz 100-12.5 mg tab, 100-25 mg tab, 50-12.5 mg tab
1
Preferred
HYZAAR
QL=5 días
Angiotensin-Converting Enzyme (Ace) Inhibitors [Inhibidores De La Enzima Convertidora De Angiotensin]
lisinopril 10 mg tab, 2.5 mg   tab, 20 mg tab, 30 mg tab, 40 mg tab, 5 mg tab
1
Preferred
ZESTRIL
QL=5 días
lisinopril-hydrochlorothiazide 10-12.5 mg tab, 20-12.5 mg tab, 20-25 mg tab
1
Preferred
ZESTORETIC
QL=5 días
Calcium Channel Blocking Agents [Bloqueadores De Canales De Calcio]
amlodipine besylate 10 mg   tab, 2.5 mg tab, 5 mg tab
1
Preferred
NORVASC
QL=5 días

Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/
 Límites]
diltiazem hcl 120 mg tab, 30 mg tab, 60 mg tab, 90 mg tab
1
Preferred
CARDIZEM
QL=5 días
verapamil hcl 120 mg tab, 40 mg tab, 80 mg tab
1
Preferred
CALAN
QL=5 días
Carbonic Anhydrase Inhibitors Diuretics [Diuréticos Inhibidores De Anhidrasa Carbónica]
acetazolamide 125 mg tab,   250 mg tab
3
Preferred
DIAMOX
QL=5 días
Cardioselective Beta Blocking Agents [Bloqueadores Beta Cardioselectivos]
atenolol 100 mg tab,  25 mg tab, 50 mg tab
1
Preferred
TENORMIN
QL=5 días
metoprolol succinate er 25 mg tab er 24 hr, 50 mg tab er 24 hr
1
Preferred
LOPRESSOR
QL=5 días
metoprolol tartrate 100 mg tab, 25 mg tab, 50 mg tab
1
Preferred
LOPRESSOR
QL=5 días
metoprolol succinate er 100 mg tab er 24 hr, 200 mg tab er 24 hr
2
Preferred
LOPRESSOR
QL=5 días
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización  Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age   Página 8 de 22 Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 9 for monthly net cost range [Ver página 9    Revisado 5/12/2017 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 

SALUD FÍSICA
 
Cardioselective Beta-Adrenergic Blocking Agents [Bloqueadores Beta-Adrenérgicos Cardioselectivos]
atenolol    -chlorthalidone 10025 mg tab, 50-25 mg tab
1
Preferred
TENORETIC
QL=5 días
metoprolol- hydrochlorothiazide 50-25 mg tab
2
Non-Preferred
LOPRESSOR HCT
QL=5 días
metoprolol- hydrochlorothiazide 100-25 mg tab, 100-50 mg tab
3
Non-Preferred
LOPRESSOR HCT
QL=5 días
Loop Diuretics [Diuréticos Del Asa]
furosemide 10 mg/ml soln,   20 mg tab, 40 mg tab, 80 mg tab
1
Preferred
LASIX
QL=5 días
Nonselective Beta Blocking Agents [Bloqueadores Beta No-Selectivos]
propranolol hcl 10 mg tab,   20 mg tab, 40 mg tab, 80 mg tab
1
Preferred
INDERAL
QL=5 días
propranolol hcl 60 mg tab
2
Preferred
INDERAL
QL=5 días

Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
 [Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/
 Límites]
Potassium-Sparing Diuretics [Diuréticos Conservadores De Potasio]
spironolactone 100 mg tab,   25 mg tab, 50 mg tab
1
Preferred
ALDACTONE
QL=5 días
triamterene-hctz 37.5-25 mg cap, 37.5-25 mg tab, 75-50 mg tab
1
Preferred
MAXZIDE
QL=5 días
Thiazide Diuretics [Diuréticos Tiazidas]
chlorothiazide 250 mg tab,   500 mg tab
1
Preferred
DIURIL
QL=5 días
chlorthalidone 25 mg tab, 50 mg tab
1
Preferred
HYGROTON
QL=5 días
DIURIL 250 mg/5ml susp
1
Preferred
 
QL=5 días
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización  Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age   Página 9 de 22 Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 9 for monthly net cost range [Ver página 9    Revisado 5/12/2017 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 

SALUD FÍSICA
 
hydrochlorothiazide 12.5 mg tab, 25 mg tab, 50 mg tab
1
Preferred
MICROZIDE
QL=5 días
indapamide 1.25 mg tab, 2.5 mg tab
1
Preferred
LOZOL
QL=5 días
metolazone 2.5 mg tab, 5 mg tab
1
Non-Preferred
ZAROXOLYN
QL=5 días
chlorthalidone 100 mg tab
2
Preferred
HYGROTON
QL=5 días
metolazone 10 mg tab
2
Non-Preferred
ZAROXOLYN
QL=5 días
Vasodilator Beta Blockers [Bloqueadores Beta Vasodilatadores]
carvedilol 12.5 mg tab, 25   mg tab, 3.125 mg tab, 6.25 mg tab
1
Preferred
COREG
QL=5 días
Vasodilators [Vasodilatadores]
hydralazine hcl 10 mg tab,   100 mg tab, 25 mg tab, 50 mg tab
1
Preferred
APRESOLINE
QL=5 días
ANTIMIGRAINE AGENTS [AGENTES ANTIMIGRAÑA]
Beta-Adrenergic Blocking Agents [Bloqueadores Beta Adrenérgicos]
topiramate 100 mg tab, 200   mg tab, 25 mg tab, 50 mg tab 1 Preferred TOPAMAX QL=5 días
ANTIMYASTHENIC AGENTS [AGENTES ANTIMIASTÉNICOS]
Parasympathomimetics [Parasimpatomiméticos]
pyridostigmine bromide 60   mg tab
2
Preferred
MESTINON
QL=5 días

Drug Name [Nombre del Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name [Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/ Límites]
pyridostigmine bromide 180 mg tab er
6
Non-Preferred
MESTINON
 
ANTIMYCOBACTERIALS [ANTIMICOBACTERIANOS]
Antituberculars [Antituberculosos]
isoniazid 100 mg tab, 300   mg tab
1
Preferred
ISONIAZID
QL=5 días
rifampin 150 mg cap
1
Preferred
RIFADIN
QL=5 días
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización  Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age   Página 10 de 22 Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 9 for monthly net cost range [Ver página 9    Revisado 5/12/2017 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]

SALUD FÍSICA
 
pyrazinamide 500 mg tab
2
Non-Preferred
PYRAZINAMIDE
QL=5 días
rifampin 300 mg cap
2
Preferred
RIFADIN
QL=5 días
isoniazid 50 mg/5ml syr
5
Non-Preferred
ISONIAZID
QL=5 días
rifabutin 150 mg cap
   
MYCOBUTIN
Puerto Rico Health
Department
Tuberculosis Program
cycloserine 250 mg cap
   
SEROMYCIN
CAPASTAT SULFATE 1 gm inj
     
RIFAMATE 150-300 mg cap
     
TRECATOR 250 mg tab
     
ANTIPARASITICS [ANTIPARASITARIOS]
Antimalarials [Antimaláricos]
chloroquine phosphate 250   mg tab, 500 mg tab
1
Preferred
ARALEN
QL=5 días
hydroxychloroquine sulfate 200 mg tab
1
Preferred
PLAQUENIL
QL=5 días
DARAPRIM 25 mg tab
7
Non-Preferred
 
QL=5 días
ANTIPARKINSON AGENTS [AGENTES ANTIPARKINSON]
Antiparkinson Dopaminergics [Dopaminérgicos Antiparkinson]
amantadine hcl 50 mg/5ml   syr
1
Preferred
SYMMETREL
QL=5 días
pramipexole dihydrochloride 0.125 mg tab, 0.25 mg tab, 0.5 mg tab, 0.75 mg tab, 1 mg tab, 1.5 mg tab
1
Preferred
MIRAPEX
QL=5 días
ropinirole hcl 0.25 mg tab, 0.5 mg tab, 1 mg tab, 3 mg tab, 4 mg tab, 5 mg tab
1
Preferred
REQUIP
QL=5 días
ropinirole hcl 2 mg tab
2
Preferred
REQUIP
QL=5 días
amantadine hcl 100 mg cap
3
Preferred
SYMMETREL
QL=5 días

Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
 [Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/
 Límites]
bromocriptine mesylate 2.5 mg tab
3
Preferred
PARLODEL
QL=5 días
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización  Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age   Página 11 de 22 Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 9 for monthly net cost range [Ver página 9    Revisado 5/12/2017 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 

SALUD FÍSICA
 
carbidopa-levodopaentacapone 18.75-75-200 mg tab
4
Non-Preferred
STALEVO
QL=5 días
carbidopa-levodopaentacapone 12.5-50-200 mg tab, 25-100-200 mg tab, 31.25-125-200 mg tab, 37.5150-200 mg tab, 50-200-200 mg tab
5
Non-Preferred
STALEVO
QL=5 días
Dopamine Precursors [Precursores De Dopamina]
carbidopa    -levodopa 10-100 mg tab, 25-100 mg tab
1
Preferred
SINEMET
QL=5 días
carbidopa-levodopa 25-250 mg tab
2
Preferred
SINEMET
QL=5 días
carbidopa-levodopa er 25100 mg tab er, 50-200 mg tab er
2
Preferred
SINEMET CR
QL=5 días
Monoamine Oxidase B (Mao-B) Inhibitors [Inhibidores De Mao-B]
selegiline hcl 5 mg tab           
3
Preferred
CARBEX
QL=5 días
ANTIVIRALS [ANTIVIRALES]
Anti-Cytomegalovirus (Cmv) Agents [Agentes Anti-Citomegalovirus]
valganciclovir hcl 450 mg   tab
13
Non-Preferred
VALCYTE
PA, QL=5 días
Antiherpetic Agents [Agentes Antiherpéticos]
acyclovir 200 mg cap, 400   mg tab, 800 mg tab
1
Preferred
ZOVIRAX
QL=5 días
acyclovir 200 mg/5ml susp
2
Preferred
ZOVIRAX
QL=5 días
Anti-Influenza Agents [Agentes Antiinfluenza]
amantadine hcl 50 mg/5ml   syr
1
Preferred
SYMMETREL
QL=5 días
amantadine hcl 100 mg cap
3
Preferred
SYMMETREL
QL=5 días
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización  Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age   Página 12 de 22 Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 9 for monthly net cost range [Ver página 9    Revisado 5/12/2017 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 

SALUD FÍSICA

 
Drug Name [Nombre del
 Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/
Límites]
BENIGN PROSTATIC HYPERTROPHY AGENTS [AGENTES PARA HIPERTROFIA
PROSTÁTICA BENIGNA]
Alpha-Adrenergic Blocking Agents [Bloqueadores Alfa Adrenérgicos]
terazosin hcl 1 mg cap, 10   mg cap, 2 mg cap, 5 mg cap
1
Preferred
HYTRIN
QL=5 días
BLOOD MODIFIERS [MODIFICADORES DE LA SANGRE]
Anticoagulants [Anticoagulantes]
warfarin sodium 1 mg tab,   10 mg tab, 2 mg tab, 2.5 mg tab, 3 mg tab, 4 mg tab, 5 mg tab, 6 mg tab, 7.5 mg tab
1
Preferred
COUMADIN
QL=5 días
heparin sodium (porcine) 1000 unit/ml inj soln
2
Preferred
HEPARIN
QL=5 días
heparin sodium (porcine) 10000 unit/ml inj soln, 5000 unit/ml inj soln
3
Preferred
HEPARIN
QL=5 días
heparin sodium (porcine) pf 5000 unit/0.5ml inj soln
3
Preferred
HEPARIN
QL=5 días
heparin sodium (porcine) 2000 unit/ml iv soln
8
Preferred
HEPARIN
QL=5 días
Colony Stimulating Factors [Estimulantes Mieloides]
NEULASTA 6 mg/0.6ml sc   soln
12
Preferred
 
PA, QL=5 días, P
NEULASTA DELIVERY KIT 6 mg/0.6ml sc soln
12
Preferred
 
PA, QL=5 días, P
Platelet Modifying Agents [Modificadores De Plaquetas]
cilostazol 100            mg tab, 50 mg tab
1
Preferred
PLETAL
QL=5 días
clopidogrel bisulfate 75 mg tab
1
Preferred
PLAVIX
QL=5 días
CARDIOVASCULAR AGENTS [AGENTES CARDIOVASCULARES]
Antiarrhythmics Class II [Antiarrítmicos Clase II]
propranolol hcl 10 mg tab,   20 mg tab, 40 mg tab, 80 mg tab
1
Preferred
INDERAL
QL=5 días
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización  Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age   Página 13 de 22 Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 9 for monthly net cost range [Ver página 9    Revisado 5/12/2017 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]

SALUD FÍSICA
 
Drug Name [Nombre del
 Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/
Límites]
sotalol hcl 120 mg tab, 160 mg tab, 240 mg tab, 80 mg tab
1
Preferred
BETAPACE
QL=5 días
sotalol hcl (af) 120 mg tab, 160 mg tab, 80 mg tab
1
Preferred
BETAPACE
QL=5 días
propranolol hcl 60 mg tab
2
Preferred
INDERAL
QL=5 días
Antiarrhythmics Type I-A [Antiarrítmicos Tipo I-A]
quinidine sulfate 200            mg tab, 300 mg tab
1
Preferred
QUINIDINE SULFATE
QL=5 días
quinidine gluconate er 324 mg tab er
2
Preferred
QUINAGLUTE
QL=5 días
quinidine sulfate er 300 mg tab er
2
Preferred
QUINIDINE SULFATE
QL=5 días
Antiarrhythmics Type I-B [Antiarrítmicos Tipo I-B]
mexiletine hcl 150 mg cap           
2
Preferred
MEXITIL
QL=5 días
mexiletine hcl 200 mg cap
3
Preferred
MEXITIL
QL=5 días
Antiarrhythmics Type I-C [Antiarrítmicos Tipo I-C]
flecainide acetate 100 mg   tab, 50 mg tab
1
Preferred
TAMBOCOR
QL=5 días
propafenone hcl 150 mg tab, 225 mg tab
1
Preferred
RYTHMOL
QL=5 días
flecainide acetate 150 mg tab
2
Preferred
TAMBOCOR
QL=5 días
propafenone hcl 300 mg tab
3
Preferred
RYTHMOL
QL=5 días
Antiarrhythmics Type III [Antiarrítmicos Tipo III]
amiodarone hcl 200 mg tab           
1
Preferred
CORDARONE
QL=5 días
Miscellaneous Cardiovascular Agents [Agentes Cardiovasculares Misceláneos]
digox 125 mcg tab, 250 mcg   tab
2
Preferred
LANOXIN
QL=5 días
digoxin 125 mcg tab, 250 mcg tab
2
Preferred
LANOXIN
QL=5 días
Vasodilators [Vasodilatadores]
isosorbide mononitrate 10   mg tab, 20 mg tab
1
Preferred
ISORDIL
QL=5 días
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización  Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age   Página 14 de 22 Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 9 for monthly net cost range [Ver página 9    Revisado 5/12/2017 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 

SALUD FÍSICA
 
Drug Name [Nombre del Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name [Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/
 Límites]
isosorbide mononitrate er 120 mg tab er 24 hr, 30 mg tab er 24 hr, 60 mg tab er 24 hr
1
Preferred
IMDUR
QL=5 días
NITROSTAT 0.3 mg tab subl, 0.4 mg tab subl, 0.6 mg tab subl
1
Preferred
 
QL=5 días
DENTAL AND ORAL AGENTS [AGENTES DENTALES Y ORALES]
Antifungals [Antifungales]
clotrimazole 10 mg   mouth/throat lozenge, 10 mg mouth/throat troche
1
Preferred
MYCELEX
QL=5 días, OTC
nystatin 100000 unit/ml mouth/throat susp, 100000 unit/ml crm
1
Preferred
NYSTATIN
QL=5 días
DERMATOLOGICAL AGENTS [AGENTES DERMATOLÓGICOS]
  Topical Antibiotics [Antibióticos Tópicos]
mupirocin 2 % oint           
1
Preferred
BACTROBAN
QL=5 días
silver sulfadiazine 1 % crm
1
Preferred
SILVADENE
QL=5 días
gentamicin sulfate 0.1 % crm
2
Preferred
GARAMYCIN
QL=1 frasco / 5 días
gentamicin sulfate 0.1 % oint
2
Preferred
GARAMYCIN
QL=1 tubo / 5 días
DYSLIPIDEMICS [DISLIPIDÉMICOS]
Bile Acid Sequestrants [Secuestradores De Acidos Biliares]
cholestyramine 4 gm pckt, 4   gm/dose oral pwdr
3
Preferred
QUESTRAN
QL=5 días
cholestyramine light 4 gm pckt, 4 gm/dose oral pwdr
3
Preferred
QUESTRAN
QL=5 días
Fibric Acid Derivatives [Derivados De Ácido Fíbrico]
gemfibrozil 600 mg tab           
1
Preferred
LOPID
QL=5 días
Hmg-Coa Reductase Inhibitors [Inhibidores De La Hmg-Coa Reductasa]
atorvastatin calcium 10 mg   tab, 20 mg tab, 40 mg tab, 80 mg tab
1
Preferred
LIPITOR
QL=5 días
simvastatin 10 mg tab, 20 mg tab, 40 mg tab, 5 mg tab
1
Preferred
ZOCOR
QL=5 días
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización  Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age   Página 15 de 22 Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 9 for monthly net cost range [Ver página 9    Revisado 5/12/2017 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 

SALUD FÍSICA
 
Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
 [Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/
 Límites]
GASTROINTESTINAL AGENTS [AGENTES GASTROINTESTINALES]
Histamine2 (H2) Receptor Antagonists [Antagonistas Del Receptor De H2]
famotidine            20 mg tab, 40 mg tab
1
Preferred
PEPCID
QL=5 días
ranitidine hcl 15 mg/ml syr, 150 mg/10ml syr, 300 mg tab, 75 mg/5ml syr
1
Preferred
ZANTAC
QL=5 días
Miscellaneous Gastrointestinal Agents [Agentes Gastrointestinales Misceláneos]
ursodiol 300 mg cap           
2
Preferred
ACTIGALL
PA, QL=5 días
Proton Pump Inhibitors [Inhibidores De La Bomba De Protones]
omeprazole 10 mg cap dr,   20 mg cap dr
1
Preferred
PRILOSEC
QL=5 días
GENITOURINARY AGENTS [AGENTES GENITOURINARIOS]
Miscellaneous Genitourinary Agents [Agentes Genitourinarios Misceláneos]
phenazopyridine hcl 100 mg   tab, 200 mg tab
1
Preferred
PYRIDIUM
QL=3 días
HORMONAL AGENTS [AGENTES HORMONALES]
Antithyroid Agents [Agentes Antitiroide]
methimazole 10 mg tab, 5   mg tab
1
Preferred
TAPAZOLE
QL=5 días
propylthiouracil 50 mg tab
2
Preferred
PROPYLTHIOURA CIL
QL=5 días
Calcimimetic Agents [Agentes Calcimiméticos]
SENSIPAR 30 mg tab           
7
   
PA, QL=5 días
SENSIPAR 60 mg tab
9
   
PA, QL=5 días
SENSIPAR 90 mg tab
10
   
PA, QL=5 días
Dopamine Agonists [Agonistas De Dopamina]
bromocriptine mesylate 2.5   mg tab
3
Preferred
PARLODEL
QL=5 días
Thyroid Hormones [Hormona Tiroidea]
levothyroxine sodium 100   mcg tab, 112 mcg tab, 125 mcg tab, 137 mcg tab, 150 mcg tab, 175 mcg tab, 200 mcg tab, 25 mcg tab, 300 mcg tab, 50 mcg tab, 75 mcg tab, 88 mcg tab
1
Preferred
SYNTHROID
QL=5 días
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización  Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age   Página 16 de 22 Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 9 for monthly net cost range [Ver página 9    Revisado 5/12/2017 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 

SALUD FÍSICA
 
Drug Name [Nombre del
 Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
 [Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/
 Límites]
SYNTHROID 100 mcg tab, 112 mcg tab, 125 mcg tab, 137 mcg tab, 150 mcg tab, 175 mcg tab, 200 mcg tab, 25 mcg tab, 300 mcg tab, 50 mcg tab, 75 mcg tab, 88 mcg tab
1
Preferred
 
QL=5 días
IMMUNOSUPPRESSANTS [IMMUNOSUPRESORES]
Glucocorticosteroids [Glucocorticoides]
dexamethasone 0.5 mg tab,   0.5 mg/5ml oral elix, 0.5 mg/5ml soln, 0.75 mg tab, 1 mg tab, 1.5 mg tab, 2 mg tab, 4 mg tab, 6 mg tab
1
Preferred
DECADRON
QL=5 días
methylprednisolone 32 mg tab, 4 mg tab
1
Preferred
MEDROL
QL=5 días
prednisone 1 mg tab, 10 mg tab, 2.5 mg tab, 20 mg tab, 5 mg tab, 50 mg tab
1
Preferred
DELTASONE
QL=5 días
prednisone (pak) 10 mg tab, 5 mg tab
1
Preferred
DELTASONE
QL=5 días
methylprednisolone 16 mg tab, 8 mg tab
2
Preferred
MEDROL
QL=5 días
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización  Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age   Página 17 de 22 Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 9 for monthly net cost range [Ver página 9    Revisado 5/12/2017 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 

SALUD FÍSICA
 
INFLAMMATORY BOWEL DISEASE [ENFERMEDAD INFLAMATORIA INTESTINAL]
Aminosalicylates [Aminosalicilatos]
DELZICOL 400 mg cap dr           
5
Preferred
 
QL=5 días, P
ASACOL HD 800 mg tab dr
6
Preferred
 
QL=5 días, P
Sulfonamides [Sulfonamidas]
sulfasalazine 500 mg tab,   500 mg tab dr
1
Preferred
AZULFIDINE
QL=5 días
MINERALS & ELECTROLYTES [MINERALES Y ELECTROLITOS]
MUSCLE RELAXANTS [RELAJANTES MUSCULARES]
Antispasticity Agents [Agentes Antiespasticidad]
baclofen 10 mg tab, 20 mg   tab
1
Preferred
LIORESAL
QL=5 días
dantrolene sodium 25 mg cap, 50 mg cap
2
Preferred
DANTRIUM
QL=5 días

Drug Name [Nombre del Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name [Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/ Límites]
dantrolene sodium 100 mg cap
3
Preferred
DANTRIUM
QL=5 días
Skeletal Muscle Relaxants [Relajantes Musculoesqueletales]
 
cyclobenzaprine hcl 10 mg   tab
1
Preferred
FLEXERIL
QL=5 días
OPHTHALMIC AGENTS [AGENTES OFTÁLMICOS]
           Antiglaucoma Agents [Agentes Antiglaucoma]
 
brimonidine tartrate 0.2 %   ophth soln
1
Preferred
ALPHAGAN
QL=1 frasco 5 ml / 15 días
dorzolamide hcl 2 % ophth soln
1
Preferred
TRUSOPT
QL=1 frasco / 30 días
levobunolol hcl 0.5 % ophth soln
1
Preferred
BETAGAN
QL=1 frasco / 15 días
levobunolol hcl 0.25 % ophth soln
1
Preferred
BETAGAN
QL=1 frasco / 15 días
timolol maleate 0.5 % ophth soln
1
Preferred
TIMOPTIC
QL=1 frasco / 30 días
timolol maleate 0.25 % ophth soln
1
Preferred
TIMOPTIC
QL=1 frasco / 25 días
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización  Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age   Página 18 de 22 Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 9 for monthly net cost range [Ver página 9    Revisado 5/12/2017 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 

SALUD FÍSICA
 
dorzolamide hcl-timolol mal ophth sol 22.3-6.8 mg/ml
1
Preferred
COSOPT
QL=1 frasco / 30 días
betaxolol hcl 0.5 % ophth soln
2
Non-Preferred
BETOPTIC
QL=1 frasco / 15 días
Ophthalmic Antibiotics [Antibióticos Oftálmicos]
 
gentamicin sulfate 0.3 %   ophth oint
1
Preferred
GARAMYCIN
QL=5 días
gentamicin sulfate 0.3 % ophth soln
1
Preferred
GARAMYCIN
QL=5 días
tobramycin 0.3 % ophth soln
1
Preferred
TOBREX
QL=1 frasco / 5 días
Ophthalmic Prostaglandins [Prostaglandinas Oftálmicas]
latanoprost 0.005 % ophth   soln
1
Preferred
XALATAN
QL=1 frasco / 25 días
Ophthalmic Steroids [Esteroides Oftálmicos]
 
neomycin   -polymyxindexamethasone 3.5-100000.1 ophth oint, 3.5-100000.1 ophth susp
1
Preferred
MAXITROL
 

Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/
Límites]
prednisolone acetate 1 % ophth susp
2
Preferred
PRED FORTE
QL=1 frasco 5ml / 25 días
OTIC AGENTS [AGENTES OTICOS]
Miscellaneous Otic Agents [Agentes Oticos Misceláneos]
 
acetic acid 2 % otic soln
2
Preferred
VOSOL
QL= 1 frasco / 10 días
Otic Antibiotics [Antibióticos Oticos]
neomycin      -polymyxin-hc 1 % otic soln, 3.5-10000-1 otic soln, 3.5-10000-1 otic susp
2
Preferred
CORTISPORIN
QL=1 frasco / 10 días
RESPIRATORY AGENTS [AGENTES RESPIRATORIOS]
Anticholinergic Bronchodilators [Broncodilatadores Anticolinérgicos]
 
 • PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización  Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age   Página 19 de 22 Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 9 for monthly net cost range [Ver página 9    Revisado 5/12/2017 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 

SALUD FÍSICA
 
ipratropium bromide 0.02 %   inh soln
1
Non-Preferred
ATROVENT
QL=5 días
Antileukotrienes [Antileukotrienos]
montelukast sodium   10 mg tab, 4 mg tab chew, 5 mg tab chew
1
Preferred
SINGULAIR
QL=5 días
Antitussive-Expectorant [Expectorantes Antitusivos]
guaifenesin   -codeine 100-10 mg/5ml soln
1
Preferred
CHERATUSSIN
QL=5 días
Inhaled Corticosteroids [Corticosteroides Inhalados]
FLOVENT DISKUS 100  mcg/blist inh aer pwdr, 250 mcg/blist inh aer pwdr, 50 mcg/blist inh aer pwdr
3
Preferred
 
QL=1 pompa / 30 días, P
FLOVENT HFA 110 mcg/act inh aer
3
Preferred
 
QL=1 pompa / 30 días, P
FLOVENT HFA 44 mcg/act inh aer
3
Preferred
 
QL=1 pompa / 30 días, P
budesonide 0.25 mg/2ml inh susp, 0.5 mg/2ml inh susp,
4
Non-Preferred
PULMICORT
QL=5 días, AL 012 años
budesonide 1mg/2ml inh susp
8
Non-Preferred
PULMICORT
AL 0-12 años
FLOVENT HFA 220 mcg/act inh aer
4
Preferred
 
QL=1 pompa / 30 días, P
 
 • PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización  Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age   Página 20 de 22 Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 9 for monthly net cost range [Ver página 9    Revisado 5/12/2017 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 

SALUD FÍSICA
 
Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/
 Límites]
Sedating Histamine1 Blocking Agents [Sedantes Bloqueadores Histamine1]
promethazine hcl 12.5 mg   tab, 25 mg tab, 50 mg tab, 6.25 mg/5ml soln, 6.25 mg/5ml syr
1
Preferred
PHENERGAN
QL=5 días
Sympathomimetic Bronchodilators [Broncodilatadores Simpatomiméticos]
albuterol sulfate (2.5   mg/3ml) 0.083% inh neb soln, (5 mg/ml) 0.5% inh neb soln, 2 mg/5ml syr
1
Preferred
PROVENTIL
QL=5 días
terbutaline sulfate 2.5 mg tab, 5 mg tab
1
Preferred
BRETHINE
QL=5 días
VENTOLIN HFA 108 (90 base) mcg/act inh aer
1
Preferred
 
QL=1 frasco / 30 días, P
 
 • PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización  Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age   Página 21 de 22 Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 9 for monthly net cost range [Ver página 9    Revisado 5/12/2017 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 

SALUD FÍSICA


 

SUB MENTAL

Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/
Límites]
THERAPEUTIC CATEGORY [CATEGORÍA TERAPÉUTICA]
Therapeutic Class [Clase Terapéutica]
ANTIANXIETY AGENTS [AGENTES   PARA LA ANXIEDAD]
Benzodiazepines [Benzodiazepinas]
diazepam 10 mg tab, 2 mg   tab, 5 mg tab
1
Preferred
VALIUM
QL=5 días
lorazepam 0.5 mg tab, 1 mg tab
1
Preferred
ATIVAN
QL=5 días
Sedating Histamine 1 Blocking Agents [Sedantes Bloqueadores Histamine 1]
hydroxyzine pamoate 100 mg cap, 25 mg cap, 50 mg cap
1
Preferred
VISTARIL
QL=30 días
ANTIDEPRESSANTS [ANTIDEPRESIVOS]
Miscellaneous Antidepressants [Antidepresivos Misceláneos]
bupropion hcl 75 mg tab
1
Preferred
WELLBUTRIN
QL=30 días
bupropion hcl er (sr) 100 mg tab er 12 hr, 150 mg tab er 12 hr, 200 mg tab er 12 hr
1
Preferred
WELLBUTRIN SR
QL=30 días
mirtazapine 15 mg tab, 30 mg tab, 45 mg tab, 7.5 mg tab
1
Preferred
REMERON
QL=30 días
trazodone hcl 100 mg tab, 150 mg tab, 50 mg tab
1
Preferred
DESYREL
QL=30 días
bupropion hcl 100 mg tab
2
Non-Preferred
WELLBUTRIN
QL=30 días
bupropion hcl er (xl) 150 mg tab er 24 hr, 300 mg tab er 24 hr
2
Non-Preferred
WELLBUTRIN XL
QL=30 días
mirtazapine 15 mg odt, 30 mg odt, 45 mg odt
3
Non-Preferred
REMERON
QL=30 días
 
Página 1 de 7

SUB MENTAL
 
Serotonin and/or Norepinephrine Modulators [Moduladores De Serotonina y/o
Norepinefrina]
citalopram hydrobromide 10 mg tab, 20 mg tab, 40 mg tab
1
Preferred
CELEXA
QL=30 días
fluoxetine hcl 10 mg cap, 20 mg cap
1
Preferred
PROZAC
QL=30 días
 Página
 
Página 2 de 7

SUB MENTAL

Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
 [Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/
Límites]
paroxetine hcl 20 mg tab, 30 mg tab, 40 mg tab
1
Preferred
PAXIL
QL=30 días
sertraline hcl 100 mg tab, 25 mg tab, 50 mg tab
1
Preferred
ZOLOFT
QL=30 días
venlafaxine hcl 100 mg tab, 25 mg tab, 37.5 mg tab, 50 mg tab, 75 mg tab
1
Preferred
EFFEXOR
QL=30 días
Tricyclic Agents [Tricíclicos]
amitriptyline hcl 10 mg tab, 100 mg tab, 150 mg tab, 25 mg tab, 50 mg tab, 75 mg tab
1
Preferred
ELAVIL
QL=30 días
doxepin hcl 10 mg cap, 25 mg cap, 50 mg cap, 75 mg cap
1
Preferred
SINEQUAN
QL=30 días
imipramine hcl 10 mg tab, 25 mg tab, 50 mg tab
1
Preferred
TOFRANIL
QL=30 días
nortriptyline hcl 10 mg cap, 25 mg cap, 50 mg cap, 75 mg cap
1
Preferred
PAMELOR
QL=30 días
doxepin hcl 100 mg cap, 150 mg cap
2
Preferred
SINEQUAN
QL=30 días
ANTIPARKINSON AGENTS [AGENTES ANTIPARKINSON]
Anticholinergics [Anticolinérgicos]
benztropine mesylate 0.5 mg tab, 1 mg tab, 2 mg tab
1
Preferred
COGENTIN
QL=30 días
ANTIPSYCHOTICS [ANTIPSICÓTICOS]
Atypical - Second Generation [Atípicos - Segunda Generación]
risperidone 0.25 mg tab, 0.5 mg tab, 1 mg tab, 2 mg tab, 3 mg tab, 4 mg tab
1
Preferred
RISPERDAL
QL=5 días
Typical - First Generation [Típicos - Primera Generación]
haloperidol 0.5 mg tab, 1 mg tab, 2 mg tab
1
Preferred
HALDOL
QL=5 días
haloperidol 5 mg tab
2
Preferred
HALDOL
QL=5 días
haloperidol 10 mg tab
3
Preferred
HALDOL
QL=5 días
haloperidol 20 mg tab
4
Preferred
HALDOL
QL=5 días
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 7 for monthly net cost range [Ver  Página 3 de 7  página 7 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/12/2017
 
Página 3 de 7

SUB MENTAL
 
Drug Name [Nombre del
 Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
 [Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/
Límites]
DETOX TREATMENT [TRATAMIENTO DE DETOX]
Detox Treatment [Tratamiento De Detox]
clonidine hcl 0.1 mg tab
1
Preferred           
CATAPRESS
QL=7 días
folic acid 1 mg tab
1
Preferred
FOLIC ACID
QL=7 días
ibuprofen 800 mg tab
1
Preferred
MOTRIN
QL=7 días
loperamide hcl 2 mg cap
1
Preferred
IMODIUM
QL=7 días
vitamin b-1 100 mg tab
1
Preferred
THIAMINE
QL=7 días
MOOD STABILIZERS [ESTABILIZADORES DEL ÁNIMO]
           Bipolar Agents [Agentes Para Bipolaridad]
divalproex sodium 125 mg tab dr, 250 mg tab dr, 500 mg tab dr
1
Preferred
DEPAKOTE
QL=30 días
lamotrigine 100 mg tab, 150 mg tab, 200 mg tab, 25 mg tab
1
Preferred
LAMICTAL
QL=30 días
valproic acid 250 mg cap, 250 mg/5ml soln, 250 mg/5ml syr
1
Preferred
DEPAKENE
QL=30 días
PSYCHOSTIMULANTS [PSICOESTIMULANTES]
ADHD Amphetamines [Anfetaminas ADHD]
amphetamine- dextroamphetamine 15 mg tab, 30 mg tab
2
Preferred
ADDERALL
QL=30 días, AL 4-20 años, PA ≥ 21 años
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 7 for monthly net cost range [Ver  Página 4 de7 página 7 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/12/2017
 
Página 4 de 7

SUB MENTAL
 
amphetaminedextroamphetamine 10 mg tab, 12.5 mg tab, 20 mg tab, 5 mg tab, 7.5 mg tab
3
Preferred
ADDERALL
QL=30 días, AL 4-20 años, PA ≥ 21 años
dextroamphetamine sulfate 10 mg tab, 5 mg tab
3
Preferred
DEXEDRINE
QL=30 días, AL 4-20 años, PA ≥ 21 años
dextroamphetamine sulfate er 5 mg cap er 24 hr, 10 mg cap er 24 hr
4
Non-Preferred
DEXEDRINE SR
QL=30 días, AL 4-20 años, PA ≥ 21 años
dextroamphetamine sulfate er 15 mg cap er 24 hr
5
Non-Preferred
DEXEDRINE SR
QL=30 días, AL 4-20 años, PA ≥ 21 años
DYANAVEL XR oral susp. er 2.5 mg/ mL
4
Non-Preferred
DYANAVEL XR
PA, AL 6-20 años
 
Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/
 Límites]
ADHD Non-Amphetamines [No-Anfetaminas ADHD]
clonidine hcl 0.1 mg tab
1
Preferred           
CATAPRESS
QL=7 días
dexmethylphenidate hcl 2.5 mg tab, 5 mg tab
2
Preferred
FOCALIN
QL=30 días,
AL 6-20 años,
PA ≥ 21 años
methylphenidate hcl 5 mg tab
2
Preferred
RITALIN
QL=30 días,
AL 6-20 años,
PA ≥ 21 años
dexmethylphenidate hcl 10 mg tab
3
Preferred
FOCALIN
QL=30 días,
AL 6-20 años,
PA ≥ 21 años
methylphenidate hcl 10 mg tab, 20 mg tab
3
Preferred
RITALIN
QL=30 días,
AL 6-20 años,
PA ≥ 21 años
STRATTERA 10 mg cap, 100 mg cap, 18 mg cap, 25 mg cap, 40 mg cap, 60 mg cap, 80 mg cap
4
Preferred
 
PA, QL=30 días, AL 6-20
años, PA ≥ 21 años, P
 
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 7 for monthly net cost range [Ver  Página 5 de7 página 7 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/12/2017
 
Página 5 de 7

SUB MENTAL
 
SLEEP DISORDER AGENTS [DESORDENES DEL SUEÑO]
           Benzodiazepines [Benzodiazepinas]
flurazepam hcl 15 mg cap, 30 mg cap
1
 
Preferred
DALMANE
QL=5 días
temazepam 15 mg cap, 30 mg cap
1
Preferred
RESTORIL
QL=5 días
Miscellaneous Sleep Disorder Agents [Agentes Misceláneos Desordenes Del Sueño]
zolpidem tartrate 10 mg tab, 5 mg tab
1
Preferred
AMBIEN
QL=5 días
          
• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 7 for monthly net cost range [Ver  Página 6 de7 página 7 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/12/2017
 
Página 6 de 7

 

 
Página 7 de 7

DENTAL
 
Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
 
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/
 Límites]
THERAPEUTIC CATEGORY [CATEGORÍA TERAPÉUTICA]
Therapeutic Class [Clase Terapéutica]
ANALGESICS [ANALGÉSICOS]
 Nonsteroidal Anti-Inflammatory Agents (Nsaids) [Anti-Inflamatorios No Esteroidales]
ibuprofen 400 mg tab, 600   mg tab, 800 mg tab
1
Preferred
MOTRIN
QL=7 días
naproxen 250 mg tab, 375 mg tab, 500 mg tab
1
Preferred
NAPROSYN
QL=7 días
naproxen dr 375 mg tab dr, 500 mg tab dr
1
Preferred
NAPROSYN
QL=7 días
Short-Acting Opioid Analgesics [Analgésicos Opiodes De Corta Duración]
acetaminophen   -codeine 120-12 mg/5ml soln, 300-15 mg tab, 300-30 mg tab, 300- 60 mg tab
1
Preferred
TYLENOL- CODEINE
QL=7 días
acetaminophen-codeine #2 300-15 mg tab
1
Preferred
TYLENOL- CODEINE
QL=7 días
acetaminophen-codeine #3 300-30 mg tab
1
Preferred
TYLENOL- CODEINE
QL=7 días
acetaminophen-codeine #4 300-60 mg tab
1
Preferred
TYLENOL- CODEINE
QL=7 días
hydrocodone- acetaminophen 10-325 mg tab, 5-325 mg tab, 7.5-325 mg tab
1
Preferred
VICODIN
QL=7 días
ANTIBACTERIALS [ANTIBACTERIANOS]
First Generation Cephalosporins [Cefalosporinas De Primera Generación]
cephalexin 125 mg/5ml   susp, 250 mg cap, 500 mg cap
1
Preferred
KEFLEX
 
cefadroxil 250 mg/5ml susp
2
Non-Preferred
DURICEF
AL ≤ 12 años
cephalexin 250 mg/5ml susp
2
Preferred
KEFLEX
 
cefadroxil 500 mg/5ml susp
3
Non-Preferred
DURICEF
AL ≤ 12 años
Macrolides [Macrólidos]
ERY   -TAB 500 mg tab dr
3
Preferred
   
 

DENTAL
 
Drug Name [Nombre del Medicamento]
Net
Cost
[Costo
Neto]
 
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos/ Límites]
erythromycin base 250 mg cap dr prt, 250 mg tab, 500 mg tab
3
Preferred
ERY-TAB
 
erythromycin ethylsuccinate 400 mg tab
3
Preferred
E.E.S.
 
ERYTHROCIN STEARATE 250 mg tab
4
Non-Preferred
   
E.E.S. GRANULES 200 mg/5ml susp
5
Preferred
   
ERYPED 200 200 mg/5ml susp
5
Preferred
   
ERYPED 400 400 mg/5ml susp
6
Preferred
   
Miscellaneous Antibacterials [Antibacterianos Misceláneos]
clindamycin hcl 150 mg cap,   300 mg cap, 75 mg cap
1
Preferred
CLEOCIN
 
Penicillins [Penicilinas]
amoxicillin 125 mg/5ml susp,   200 mg/5ml susp, 250 mg cap, 250 mg/5ml susp, 400 mg/5ml susp, 500 mg cap, 500 mg tab, 875 mg tab
1
Preferred
AMOXIL
 
ampicillin 125 mg/5ml susp, 250 mg cap, 250 mg/5ml susp, 500 mg cap
1
Preferred
PRINCIPEN
 
penicillin v potassium 125 mg/5ml soln, 250 mg tab, 250 mg/5ml soln, 500 mg tab
1
Preferred
VEETIDS
 


DENTAL
 
 

 
FORMULARIO DE EMERGENCIA INTEGRADO (FEI)

Drug Name [Nombre del
 Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos /
Límites]
THERAPEUTIC CATEGORY [CATEGORÍA TERAPÉUTICA]
Therapeutic Class [Clase  Terapéutica]
ANALGESICS [ANALG ÉSICOS]
Nonsteroidal Anti-Inflammatory Agents (Nsaids) [   Anti-Inflamatorios No Esteroidales]
ibuprofen 400 mg tab, 600 mg tab, 800 mg tab
1
Preferred
MOTRIN
QL = 5 días
indomethacin 25 mg cap, 50 mg cap
1
Non-Preferred
INDOCIN
QL = 5 días
nabumetone 500 mg tab, 750 mg tab
1
Preferred
RELAFEN
QL = 5 días
naproxen 250 mg tab, 375 mg tab, 500 mg tab
1
Preferred
NAPROSYN
QL = 5 días
naproxen sodium 275 mg tab, 550 mg tab
1
Preferred
ANAPROX
QL = 5 días
salsalate 500 mg tab, 750 mg tab
1
Preferred
DISALCID
QL = 5 días
Short-Acting Opioid Analgesics [Analgésicos Opiodes De Corta Duración]
acetaminophen    -codeine 120-12 mg/5ml soln, 300-15 mg tab, 300-30 mg tab, 300-
60 mg tab
1
Preferred
TYLENOL- CODEINE
QL = 5 días
acetaminophen-codeine #2 300-15 mg tab
1
Preferred
TYLENOL- CODEINE
QL = 5 días
acetaminophen-codeine #3 300-30 mg tab
1
Preferred
TYLENOL- CODEINE
QL = 5 días
acetaminophen-codeine #4 300-60 mg tab
1
Preferred
TYLENOL- CODEINE
QL = 5 días
butalbital-apap-caffeine 50325-40 mg tab
1
Preferred
FIORICET
QL = 5 días
tramadol hcl 50 mg tab
1
Preferred
ULTRAM
QL = 5 días
butalbital-apap-caffeine 50325-40 mg cap
2
Preferred
FIORICET
QL = 5 días
 
• PA - Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL - Quantity Limit [Límite de Cantidad] • ST - Step Therapy [Terapia Escalonada] • AL - Age Limit [Límite de Edad] • Net Cost [Costo Neto] - Please refer to page #12 for monthly net cost range [Ver página #12 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 
Página 1 de 28

 
FORMULARIO DE EMERGENCIA INTEGRADO (FEI)
 
Drug Name [Nombre
del Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos /
Límites]
ANESTHETICS [ANESTÉSICOS]
Local Anesthetics [Anestésicos Locales]
lidocaine viscous 2 %   mouth/throat soln
1
Preferred
XYLOCAINE
QL = 5 días
ANTIANXIETY AGENTS [AGENTES PARA LA ANXIEDAD]
Benzodiazepines [Benzodiazepinas]
clonazepam 0.5 mg tab, 1   mg tab, 2mg tab
1
Preferred
KLONOPIN
QL = 5 días
diazepam 10 mg tab, 2 mg tab, 5 mg tab
1
Preferred
VALIUM
QL = 5 días
lorazepam 0.5 mg tab, 1 mg tab
1
Preferred
ATIVAN
QL = 5 días
temazepam 15 mg cap, 30 mg cap
1
Preferred
RESTORIL
QL = 5 días
Miscellaneous Anxiolytics [Ansiolíticos Misceláneos]
hydroxyzine pamoate 100   mg cap, 25 mg cap, 50 mg cap
1
Preferred
VISTARIL
QL = 5 días
ANTIBACTERIALS [ANTIBACTERIANOS]
First Generation Cephalosporins [Cefalosporinas De Primera Generación]
cephalexin 125 mg/5ml   susp, 250 mg cap, 500 mg cap
1
Preferred
KEFLEX
QL = 5 días
 
• PA - Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL - Quantity Limit [Límite de Cantidad] • ST - Step Therapy [Terapia Escalonada] • AL - Age Limit [Límite de Edad] • Net Cost [Costo Neto] - Please refer to page #12 for monthly net cost range [Ver página #12 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 
Página 2 de 28

 
FORMULARIO DE EMERGENCIA INTEGRADO (FEI)
 
cefadroxil 250 mg/5ml susp
2
Non-Preferred
DURICEF
QL = 5 días, AL ≤ 12
cephalexin 250 mg/5ml susp
2
Preferred
KEFLEX
QL = 5 días
cefadroxil 500 mg/5ml susp
3
Non-Preferred
DURICEF
QL = 5 días, AL ≤ 12
Macrolides [Macrólidos]
azithromycin 250 mg tab,   500 mg tab
1
Preferred
ZITHROMAX
QL = 5 días
azithromycin 1 gm pckt, 100 mg/5ml susp, 200 mg/5ml susp, 600 mg tab
2
Preferred
ZITHROMAX
QL = 5 días

Drug Name [Nombre
del Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos /
Límites]
clarithromycin 125 mg/5ml susp, 250 mg tab, 500 mg tab
2
Preferred
BIAXIN
QL = 5 días
clarithromycin 250 mg/5ml susp
3
Preferred
BIAXIN
QL = 5 días
erythromycin base 250 mg cap dr prt, 250 mg tab, 500 mg tab
3
Preferred
ERY-TAB
QL = 5 días
erythromycin ethylsuccinate 400 mg tab
3
Preferred
E.E.S.
QL = 5 días
ERYTHROCIN STEARATE 250 mg tab
4
Non-Preferred
 
QL = 5 días
Miscellaneous Antibacterials [Antibacterianos Misceláneos]
clindamycin hcl 150 mg cap,   300 mg cap, 75 mg cap
1
Preferred
CLEOCIN
QL = 5 días
MACRODANTIN 25 mg cap
1
Preferred
 
QL = 5 días
 
 • PA - Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL - Quantity Limit [Límite de Cantidad] • ST - Step Therapy [Terapia Escalonada] • AL - Age Limit [Límite de Edad] • Net Cost [Costo Neto] - Please refer to page #12 for monthly net cost range [Ver página #12 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 
Página 3 de 28

 
FORMULARIO DE EMERGENCIA INTEGRADO (FEI)
 
metronidazole 250 mg tab, 500 mg tab
1
Preferred
FLAGYL
QL = 5 días
nitrofurantoin macrocrystal 50 mg cap
1
Preferred
MACRODANTIN
QL = 5 días
nitrofurantoin macrocrystal 100 mg cap
2
Preferred
MACRODANTIN
QL = 5 días
nitrofurantoin oral
suspension 25 MG/5ML
6
Non-Preferred
FURADANTIN
 
nitrofurantoin monohyd macro 100 mg cap
2
Preferred
MACROBID
QL = 5 días
Penicillins [Penicilinas]
amoxicillin 125 mg/5ml susp,   200 mg/5ml susp, 250 mg cap, 250 mg/5ml susp, 400 mg/5ml susp, 500 mg cap, 500 mg tab, 875 mg tab
1
Preferred
AMOXIL
QL = 5 días

Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
 [Nombre de
Referencia]
Requirements/
Limits
[Requerimientos /
Límites]
amoxicillin-pot clavulanate 200-28.5 mg/5ml susp, 40057 mg/5ml susp, 500-125 mg tab, 600-42.9 mg/5ml susp, 875-125 mg tab
1
Preferred
AUGMENTIN
QL = 5 días
ampicillin 125 mg/5ml susp, 250 mg cap, 250 mg/5ml susp, 500 mg cap
1
Preferred
PRINCIPEN
QL = 5 días
penicillin v potassium 125 mg/5ml soln, 250 mg tab, 250 mg/5ml soln, 500 mg tab
1
Preferred
VEETIDS
QL = 5 días
amoxicillin-pot clavulanate 250-125 mg tab, 250-62.5 mg/5ml susp
3
Preferred
AUGMENTIN
QL = 5 días
 
 • PA - Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL - Quantity Limit [Límite de Cantidad] • ST - Step Therapy [Terapia Escalonada] • AL - Age Limit [Límite de Edad] • Net Cost [Costo Neto] - Please refer to page #12 for monthly net cost range [Ver página #12 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 
Página 4 de 28

 
FORMULARIO DE EMERGENCIA INTEGRADO (FEI)
 
Quinolones [Quinolonas]
ciprofloxacin hcl 250 mg tab,   500 mg tab, 750 mg tab
1
Preferred
CIPRO
QL = 5 días
levofloxacin 250 mg tab, 500 mg tab, 750 mg tab
1
Preferred
LEVAQUIN
QL = 5 días
ciprofloxacin 500 mg/5ml (10%) susp
3
Preferred
CIPRO
QL = 5 días
ciprofloxacin 250 mg/5ml (5%) susp
4
Preferred
CIPRO
QL = 5 días
Second Generation Cephalosporins [Cefalosporinas De Segunda Generación]
cefaclor 250 mg cap, 500   mg cap
2
Preferred
CECLOR
QL = 5 días
cefprozil 125 mg/5ml susp, 250 mg tab, 250 mg/5ml susp, 500 mg tab
2
Preferred
CEFZIL
QL = 5 días
Sulfonamides [Sulfonamidas]
sulfamethoxazole    -tmp ds 800-160 mg tab
1
Preferred
SEPTRA
QL = 5 días

Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos /
Límites]
sulfamethoxazoletrimethoprim 200-40 mg/5ml susp, 400-80 mg tab
1
Preferred
SEPTRA
QL = 5 días
Third Generation Cephalosporins [Cefalosporinas De Tercera Generación]
cefdinir 125 mg/5ml susp,   300 mg cap
2
Preferred
OMNICEF
QL = 5 días
cefdinir 250 mg/5ml susp
3
Preferred
OMNICEF
QL = 5 días
 
 • PA - Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL - Quantity Limit [Límite de Cantidad] • ST - Step Therapy [Terapia Escalonada] • AL - Age Limit [Límite de Edad] • Net Cost [Costo Neto] - Please refer to page #12 for monthly net cost range [Ver página #12 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
Página 5 de 28

 
FORMULARIO DE EMERGENCIA INTEGRADO (FEI)
 
ANTICONVULSANTS [ANTICONVULSIVANTES]
Anticonvulsants [Anticonvulsivantes]
carbamazepine 100 mg tab   chew, 200 mg tab
1
Preferred
TEGRETOL
QL = 5 días
clonazepam 0.5 mg tab, 1 mg tab, 2mg tab
1
Preferred
KLONOPIN
QL = 5 días
divalproex sodium 125 mg tab dr, 250 mg tab dr, 500 mg tab dr
1
Preferred
DEPAKOTE
QL = 5 días
gabapentin 100 mg cap, 300 mg cap, 400 mg cap, 600 mg tab, 800 mg tab
1
Preferred
NEURONTIN
QL = 5 días
lamotrigine 100 mg tab, 150 mg tab, 200 mg tab, 25 mg tab
1
Preferred
LAMICTAL
QL = 5 días
lamotrigine chew tab 5 mg, 25 mg
3
Non-Preferred
LAMICTAL
 
levetiracetam 250 mg tab, 500 mg tab
1
Preferred
KEPPRA
QL = 5 días
levetiracetam er 24 hrs 500 mg tab, 750 mg
3
Non-Preferred
KEPPRA XR
 
oxcarbazepine 150 mg tab
1
Preferred
TRILEPTAL
QL = 5 días
phenobarbital 100 mg tab, 15 mg tab, 16.2 mg tab, 30 mg tab, 32.4 mg tab, 60 mg tab, 64.8 mg tab, 97.2 mg tab
1
Preferred
PHENOBARBITAL
QL = 5 días

Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos /
Límites]
primidone 250 mg tab, 50 mg tab
1
Preferred
MYSOLINE
QL = 5 días
 
 • PA - Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL - Quantity Limit [Límite de Cantidad] • ST - Step Therapy [Terapia Escalonada] • AL - Age Limit [Límite de Edad] • Net Cost [Costo Neto] - Please refer to page #12 for monthly net cost range [Ver página #12 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 
Página 6 de 28

 
FORMULARIO DE EMERGENCIA INTEGRADO (FEI)
 
topiramate 100 mg tab, 200 mg tab, 25 mg tab, 50 mg tab
1
Preferred
TOPAMAX
QL = 5 días
valproic acid 250 mg cap, 250 mg/5ml soln, 250 mg/5ml syr
1
Preferred
DEPAKENE
QL = 5 días
zonisamide 50 mg cap
1
Preferred
ZONEGRAN
QL = 5 días
DILANTIN 30 mg cap
2
Preferred
 
QL = 5 días
levetiracetam 1000 mg tab, 750 mg tab
2
Preferred
KEPPRA
QL = 5 días
oxcarbazepine 300 mg tab, 600 mg tab
2
Preferred
TRILEPTAL
QL = 5 días
phenytoin 125 mg/5ml susp, 50 mg tab chew
2
Preferred
DILANTIN
QL = 5 días
phenytoin sodium extended 100 mg cap, 200 mg cap, 300 mg cap
2
Preferred
DILANTIN
QL = 5 días
zonisamide 100 mg cap, 25 mg cap
2
Preferred
ZONEGRAN
QL = 5 días
ethosuximide 250 mg cap, 250 mg/5ml soln
3
Preferred
ZARONTIN
QL = 5 días
phenobarbital 20 mg/5ml oral elix, 20 mg/5ml soln
3
Preferred
PHENOBARBITAL
QL = 5 días
ANTIDEMENTIA AGENTS [AGENTES ANTIDEMENCIA]
Cholinesterase Inhibitors [Inhibidores De Colinesterasa
donepezil hcl 10 mg tab, 5   mg tab
1
Preferred
ARICEPT
QL = 5 días
rivastigmine tartrate 1.5 mg cap, 3 mg cap, 4.5 mg cap, 6 mg cap
3
Preferred
EXELON
QL = 5 días
 
 • PA - Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL - Quantity Limit [Límite de Cantidad] • ST - Step Therapy [Terapia Escalonada] • AL - Age Limit [Límite de Edad] • Net Cost [Costo Neto] - Please refer to page #12 for monthly net cost range [Ver página #12 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 
Página 7 de 28

 
FORMULARIO DE EMERGENCIA INTEGRADO (FEI)
 
Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos /
Límites]
ANTIDEPRESSANTS [ANTIDEPRESIVOS]
Miscellaneous Antidepressants [Antidepresivos Misceláneos]
trazodone hcl 100 mg tab,   150 mg tab, 50 mg tab
1
Preferred
DESYREL
QL = 5 días
Monoamine Oxidase (Mao) Inhibitors [Inhibidores De Mao]
selegiline hcl 5 mg tab
3
Non-Preferred          
CARBEX
QL = 5 días
ANTIDIABETIC AGENTS [AGENTES ANTIDIABÉTICOS]
Alpha-Glucosidase Inhibitors [Inhibidores De Alfa Glucosidasa]
acarbose 100 mg tab, 25 mg   tab, 50 mg tab
2
Preferred
PRECOSE
QL = 5 días
Biguanides [Biguanidas]
metformin hcl 1000 mg tab,   500 mg tab, 850 mg tab
1
Preferred
GLUCOPHAGE
QL = 5 días
Dipeptidyl Peptidase-4 (Dpp-4) Inhibitors [Inhibidores De Dpp-4]
KOMBIGLYZE XR 2.5   -1000 mg tab er 24 hr, 5-1000 mg tab er 24 hr, 5-500 mg tab er 24 hr
3
Preferred
 
QL = 5 días, ST, P
ONGLYZA 2.5 mg tab, 5 mg tab
3
Preferred
 
QL = 5 días, ST, P
Insulin Mixtures [Mezclas De Insulinas]
HUMULIN 70/30 (70            -30) 100 unit/ml sc susp
2
Preferred
 
QL = 1 Vial 10 ML/30 días, P
Insulin Sensitizing Agents [Agentes Sensibilizantes De Insulin]
pioglitazone hcl 15 mg tab,   30 mg tab, 45 mg tab
1
Preferred
ACTOS
QL = 5 días
Intermediate-Acting Insulins [Insulinas De Duración Intermedia]
HUMULIN N 100 unit/ml sc   susp
2
Preferred
 
QL = 1 Vial 10 ML/30 días, P
Short-Acting Insulins [Insulinas De Corta Duración]
HUMULIN R 100 unit/ml inj   soln
2
Preferred
 
QL = 1 Vial 10 ML/30 días, P
 
 • PA - Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL - Quantity Limit [Límite de Cantidad] • ST - Step Therapy [Terapia Escalonada] • AL - Age Limit [Límite de Edad] • Net Cost [Costo Neto] - Please refer to page #12 for monthly net cost range [Ver página #12 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 
Página 8 de 28

 
FORMULARIO DE EMERGENCIA INTEGRADO (FEI)
 
Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos /
Límites]
Sulfonylureas [Sulfonilureas]
glimepiride 1 mg tab, 2 mg   tab, 4 mg tab
1
Preferred
AMARYL
QL = 5 días
glipizide 10 mg tab, 5 mg tab
1
Preferred
GLUCOTROL
QL = 5 días
ANTIEMETICS [ANTIEMÉTICOS]
  Miscellaneous Antiemetics [Antieméticos Misceláneos]
metoclopramide hcl 10 mg   tab, 5 mg tab, 5 mg/ml inj soln
1
Preferred
REGLAN
QL = 5 días
ormir 50 mg cap
1
Preferred
BENADRYL
QL = 5 días
pharbedryl 50 mg cap
1
Preferred
BENADRYL
QL = 5 días
trimethobenzamide hcl 300 mg cap
1
Preferred
TIGAN
QL = 5 días
Phenothiazines [Fenotiazinas]
prochlorperazine maleate 10   mg tab, 5 mg tab
1
Preferred
COMPAZINE
QL = 5 días
prochlorperazine 25 mg rect supp
4
Non-Preferred
COMPAZINE
QL = 5 días
 
 • PA - Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL - Quantity Limit [Límite de Cantidad] • ST - Step Therapy [Terapia Escalonada] • AL - Age Limit [Límite de Edad] • Net Cost [Costo Neto] - Please refer to page #12 for monthly net cost range [Ver página #12 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 
Página 9 de 28

 
FORMULARIO DE EMERGENCIA INTEGRADO (FEI)
 
ANTIGOUT AGENTS [AGENTES ANTIGOTA]
Antigout Agents [Agentes Antigota]
allopurinol 100 mg tab, 300   mg tab
1
Preferred
ZYLOPRIM
QL = 5 días
colchicine 0.6 mg cap
3
Preferred
MITIGARE
PA
COLCRYS 0.6 mg tab
4
Non-Preferred
 
QL= 3 tab, 15días
Uricosurics [Uricosúricos]
probenecid 500 mg tab           
1
Preferred
BENEMID
QL = 5 días
ANTIHYPERTENSIVES [ANTIHIPERTENSIVOS]
  Alpha-Adrenergic Agonists [Agonistas Alfa Adrenérgicos]
clonidine hcl 0.1 mg tab, 0.2   mg tab, 0.3 mg tab
1
Preferred
CATAPRESS
QL = 5 días
methyldopa 250 mg tab, 500 mg tab
1
Preferred
ALDOMET
QL = 5 días
 
Drug Name [Nombre del
 Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos /
Límites]
Alpha-Adrenergic Blocking Agents [Bloqueadores Alfa Adrenérgicos]
terazosin hcl 1 mg cap, 10   mg cap, 2 mg cap, 5 mg cap
1
Preferred
HYTRIN
QL = 5 días
Angiotensin II Receptor Blockers (ARB) [Antagonistas Del Receptor Angiotensina II]
losartan potassium 100 mg   tab, 25 mg tab, 50 mg tab
1
Preferred
COZAAR
QL = 5 días
losartan potassium-hctz 100-12.5 mg tab, 100-25 mg tab, 50-12.5 mg tab
1
Preferred
HYZAAR
QL = 5 días
 
 • PA - Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL - Quantity Limit [Límite de Cantidad] • ST - Step Therapy [Terapia Escalonada] • AL - Age Limit [Límite de Edad] • Net Cost [Costo Neto] - Please refer to page #12 for monthly net cost range [Ver página #12 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 
Página 10 de 28

 
FORMULARIO DE EMERGENCIA INTEGRADO (FEI)
 
Angiotensin-Converting Enzyme (ACE) Inhibitors [Inhibidores De La Enzima Convertidora
De Angiotensina]
lisinopril 10 mg tab, 2.5 mg   tab, 20 mg tab, 30 mg tab, 40 mg tab, 5 mg tab
1
Preferred
ZESTRIL
QL = 5 días
lisinopril-hydrochlorothiazide 10-12.5 mg tab, 20-12.5 mg tab, 20-25 mg tab
1
Preferred
ZESTORETIC
QL = 5 días
Calcium Channel Blocking Agents [Bloqueadores De Canales De Calcio]
amlodipine besylate 10 mg   tab, 2.5 mg tab, 5 mg tab
1
Preferred
NORVASC
QL = 5 días
diltiazem hcl 120 mg tab, 30 mg tab, 60 mg tab, 90 mg tab
1
Preferred
CARDIZEM
QL = 5 días
verapamil hcl 120 mg tab, 40 mg tab, 80 mg tab
1
Preferred
CALAN
QL = 5 días
Carbonic Anhydrase Inhibitors Diuretics [Diuréticos Inhibidores De Anhidrasa Carbónica]
acetazolamide 125 mg tab, 250 mg tab
3
Preferred
DIAMOX
QL = 5 días
Cardioselective Beta Blocking Agents [Bloqueadores Beta Cardioselectivos]
atenolol 100 mg tab, 25 mg   tab, 50 mg tab
1
Preferred
TENORMIN
QL = 5 días
 
Drug Name [Nombre del Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos /
Límites]
metoprolol succinate er 25 mg tab er 24 hr, 50 mg tab er 24 hr
1
Preferred
LOPRESSOR
QL = 5 días
metoprolol tartrate 100 mg tab, 25 mg tab, 50 mg tab
1
Preferred
LOPRESSOR
QL = 5 días
 
 • PA - Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL - Quantity Limit [Límite de Cantidad] • ST - Step Therapy [Terapia Escalonada] • AL - Age Limit [Límite de Edad] • Net Cost [Costo Neto] - Please refer to page #12 for monthly net cost range [Ver página #12 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 
Página 11 de 28

 
FORMULARIO DE EMERGENCIA INTEGRADO (FEI)
 
metoprolol succinate er 100 mg tab er 24 hr, 200 mg tab er 24 hr
2
Preferred
LOPRESSOR
QL = 5 días
Cardioselective Beta-Adrenergic Blocking Agents [Bloqueadores Beta-Adrenérgicos
Cardioselectivos]
atenolol   -chlorthalidone 10025 mg tab, 50-25 mg tab
1
Preferred
TENORETIC
QL = 5 días
metoprolol- hydrochlorothiazide 50-25 mg tab
2
Non-Preferred
LOPRESSOR HCT
QL = 5 días
metoprololhydrochlorothiazide 100-25 mg tab, 100-50 mg tab
3
Non-Preferred
LOPRESSOR HCT
QL = 5 días
Loop Diuretics [Diuréticos Del Asa]
furosemide 10 mg/ml soln,   20 mg tab, 40 mg tab, 80 mg tab
1
Preferred
LASIX
QL = 5 días
Nonselective Beta Blocking Agents [Bloqueadores Beta No-Selectivos]
propranolol hcl 10 mg tab,   20 mg tab, 40 mg tab, 80 mg tab
1
Preferred
INDERAL
QL = 5 días
propranolol hcl 60 mg tab
2
Preferred
INDERAL
QL = 5 días
Potassium-Sparing Diuretics [Diuréticos Conservadores De Potasio]
spironolactone 100 mg tab,   25 mg tab, 50 mg tab
1
Preferred
ALDACTONE
QL = 5 días
triamterene-hctz 37.5-25 mg cap, 37.5-25 mg tab, 75-50 mg tab
1
Preferred
MAXZIDE
QL = 5 días
 
• PA - Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL - Quantity Limit [Límite de Cantidad] • ST - Step Therapy [Terapia Escalonada] • AL - Age Limit [Límite de Edad] • Net Cost [Costo Neto] - Please refer to page #12 for monthly net cost range [Ver página #12 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 
Página 12 de 28

 
FORMULARIO DE EMERGENCIA INTEGRADO (FEI)
 
Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
 [Nombre de
Referencia]
Requirements/
Limits
[Requerimientos /
Límites]
Thiazide Diuretics [Diuréticos Tiazidas]
chlorothiazide 250 mg tab,   500 mg tab
1
Preferred
DIURIL
QL = 5 días
chlorthalidone 25 mg tab, 50 mg tab
1
Non-Preferred
HYGROTON
QL = 5 días
DIURIL 250 mg/5ml susp
1
Preferred
 
QL = 5 días
hydrochlorothiazide 12.5 mg tab, 25 mg tab, 50 mg tab
1
Preferred
MICROZIDE
QL = 5 días
indapamide 1.25 mg tab, 2.5 mg tab
1
Preferred
LOZOL
QL = 5 días
metolazone 2.5 mg tab, 5 mg tab
1
Non-Preferred
ZAROXOLYN
QL = 5 días
chlorthalidone 100 mg tab
2
Non-Preferred
HYGROTON
QL = 5 días
metolazone 10 mg tab
2
Non-Preferred
ZAROXOLYN
QL = 5 días
Vasodilator Beta Blockers [Bloqueadores Beta Vasodilatadores]
carvedilol 12.5 mg tab, 25   mg tab, 3.125 mg tab, 6.25 mg tab
1
Preferred
COREG
QL = 5 días
Vasodilators [Vasodilatadores]
hydralazine hcl 10 mg tab,   100 mg tab, 25 mg tab, 50 mg tab
1
Preferred
APRESOLINE
QL = 5 días
ANTIMIGRAINE AGENTS [AGENTES ANTIMIGRAÑA]
Beta-Adrenergic Blocking Agents [Bloqueadores Beta Adrenérgicos]
divalproex sodium 125 mg   tab dr, 250 mg tab dr, 500 mg tab dr
1
Preferred
DEPAKOTE
QL = 5 días
topiramate 100 mg tab, 200 mg tab, 25 mg tab, 50 mg tab
1
Preferred
TOPAMAX
QL = 5 días, ST
ANTIMYASTHENIC AGENTS [AGENTES ANTIMIASTÉNICOS]
Parasympathomimetics [Parasimpatomiméticos]
pyridostigmine bromide 60   mg tab
2
Preferred
MESTINON
QL = 5 días
 
• PA - Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL - Quantity Limit [Límite de Cantidad] • ST - Step Therapy [Terapia Escalonada] • AL - Age Limit [Límite de Edad] • Net Cost [Costo Neto] - Please refer to page #12 for monthly net cost range [Ver página #12 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 
Página 13 de 28

 
FORMULARIO DE EMERGENCIA INTEGRADO (FEI)
 
Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos /
Límites]
MESTINON 60 mg/5ml syr
4
Non-Preferred
 
QL = 5 días
pyridostigmine bromide 180 mg tab er
6
Non-Preferred
MESTINON
QL = 5 días
ANTIMYCOBACTERIALS [ANTIMICOBACTERIANOS]
           Antituberculars [Antituberculosos]
CAPASTAT SULFATE 1 gm
inj soln
     
QL = 5 días
Puerto Rico
Department
Tuberculosis
Control Program
cycloserine 250 mg cap
   
SEROMYCIN
RIFAMATE 150-300 mg cap
     
TRECATOR 250 mg tab
     
rifabutin 150 mg cap
7
 
MYCOBUTIN
isoniazid 100 mg tab, 300 mg tab
1
Preferred
ISONIAZID
QL = 5 días
rifampin 150 mg cap
1
Preferred
RIFADIN
QL = 5 días
ethambutol hcl 100 mg tab
2
Non-Preferred
MYAMBUTOL
QL = 5 días
pyrazinamide 500 mg tab
2
Non-Preferred
PYRAZINAMIDE
QL = 5 días
rifampin 300 mg cap
2
Preferred
RIFADIN
QL = 5 días
ethambutol hcl 400 mg tab
3
Non-Preferred
MYAMBUTOL
QL = 5 días
isoniazid 50 mg/5ml syr
5
Non-Preferred
ISONIAZID
QL = 5 días
ANTIPARASITICS [ANTIPARASITARIOS]
           Antimalarials [Antimaláricos]
chloroquine phosphate 250   mg tab, 500 mg tab
1
Preferred
ARALEN
QL = 5 días
 
• PA - Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL - Quantity Limit [Límite de Cantidad] • ST - Step Therapy [Terapia Escalonada] • AL - Age Limit [Límite de Edad] • Net Cost [Costo Neto] - Please refer to page #12 for monthly net cost range [Ver página #12 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 
Página 14 de 28

 
FORMULARIO DE EMERGENCIA INTEGRADO (FEI)
 
hydroxychloroquine sulfate 200 mg tab
1
Preferred
PLAQUENIL
QL = 5 días
quinine sulfate 324 mg cap
4
Preferred
QUININE
QL = 5 días
DARAPRIM 25 mg tab
7
Non-Preferred
 
PA, QL = 5 días
ANTIPARKINSON AGENTS [AGENTES ANTIPARKINSON]
           Anticholinergics [Anticolinérgicos]
benztropine mesylate 0.5   mg tab, 1 mg tab, 2 mg tab
1
Preferred
COGENTIN
QL = 5 días
Antiparkinson Dopaminergics [Dopaminérgicos Antiparkinson]
amantadine hcl 50 mg/5ml   syr
1
Preferred
SYMMETREL
QL = 5 días

Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos /
Límites]
pramipexole dihydrochloride 0.125 mg tab, 0.25 mg tab, 0.5 mg tab, 0.75 mg tab, 1 mg tab, 1.5 mg tab
1
Preferred
MIRAPEX
QL = 5 días
ropinirole hcl 0.25 mg tab, 0.5 mg tab, 1 mg tab, 3 mg tab, 4 mg tab, 5 mg tab
1
Preferred
REQUIP
QL = 5 días
ropinirole hcl 2 mg tab
2
Preferred
REQUIP
QL = 5 días
amantadine hcl 100 mg cap
3
Preferred
SYMMETREL
QL = 5 días
bromocriptine mesylate 2.5 mg tab
3
Preferred
PARLODEL
QL = 5 días
carbidopa-levodopaentacapone 18.75-75-200 mg tab
4
Non-Preferred
STALEVO
QL = 5 días
carbidopa-levodopaentacapone 12.5-50-200 mg tab, 25-100-200 mg tab, 31.25-125-200 mg tab, 37.5150-200 mg tab, 50-200-200 mg tab
5
Non-Preferred
STALEVO
QL = 5 días
 
• PA - Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL - Quantity Limit [Límite de Cantidad] • ST - Step Therapy [Terapia Escalonada] • AL - Age Limit [Límite de Edad] • Net Cost [Costo Neto] - Please refer to page #12 for monthly net cost range [Ver página #12 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 
Página 15 de 28

 
FORMULARIO DE EMERGENCIA INTEGRADO (FEI)
 
Dopamine Precursors [Precursores De Dopamina]
carbidopa    -levodopa 10-100 mg tab, 25-100 mg tab
1
Preferred
SINEMET
QL = 5 días
carbidopa-levodopa 25-250 mg tab
2
Preferred
SINEMET
QL = 5 días
carbidopa-levodopa er 25100 mg tab er, 50-200 mg tab er
2
Preferred
SINEMET CR
QL = 5 días
ANTIPSYCHOTICS [ANTIPSICÓTICOS]
           Atypical - Second Generation [Atípicos - Segunda Generación]
risperidone 0.25 mg tab, 0.5   mg tab, 1 mg tab, 2 mg tab, 3 mg tab, 4 mg tab
1
Preferred
RISPERDAL
QL = 5 días

Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
 [Nombre de
Referencia]
Requirements/
Limits
[Requerimientos /
Límites]
Typical - First Generation [Típicos - Primera Generación]
haloperidol 0.5 mg tab, 1 mg   tab, 2 mg tab
1
Preferred
HALDOL
QL = 5 días
haloperidol 5 mg tab
2
Preferred
HALDOL
QL = 5 días
haloperidol 10 mg tab
3
Preferred
HALDOL
QL = 5 días
haloperidol 20 mg tab
4
Preferred
HALDOL
QL = 5 días
 
• PA - Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL - Quantity Limit [Límite de Cantidad] • ST - Step Therapy [Terapia Escalonada] • AL - Age Limit [Límite de Edad] • Net Cost [Costo Neto] - Please refer to page #12 for monthly net cost range [Ver página #12 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 
Página 16 de 28

 
FORMULARIO DE EMERGENCIA INTEGRADO (FEI)
 
ANTIVIRALS [ANTIVIRALES]
Anti-Cytomegalovirus (Cmv) Agents [Agentes Anti-Citomegalovirus]
valganciclovir hcl 450 mg   tab
13
Non-Preferred
VALCYTE
PA, QL = 5 días
Antiherpetic Agents [Agentes Antiherpéticos]
acyclovir 200 mg cap, 400   mg tab, 800 mg tab
1
Preferred
ZOVIRAX
QL = 5 días
acyclovir 200 mg/5ml susp
2
Preferred
ZOVIRAX
QL = 5 días
Anti-Influenza Agents [Agentes Antiinfluenza]
amantadine hcl 50 mg/5ml   syr
1
Preferred
SYMMETREL
QL = 5 días
amantadine hcl 100 mg cap
3
Preferred
SYMMETREL
QL = 5 días
oseltamivir phosphate 30 mg cap, 45 mg cap, 75 mg
4
Preferred
TAMIFLU
 
TAMIFLU 6 mg/ ml susp
5
Non-Preferred
   
BENIGN PROSTATIC HYPERTROPHY AGENTS [AGENTES PARA HIPERTROFIA
PROSTÁTICA BENIGNA]
Alpha-Adrenergic Blocking Agents [Bloqueadores Alfa Adrenérgicos]
terazosin hcl 1 mg cap, 10   mg cap, 2 mg cap, 5 mg cap
1
Preferred
HYTRIN
QL = 5 días
BLOOD MODIFIERS [MODIFICADORES DE LA SANGRE]
Anticoagulants [Anticoagulantes]
warfarin sodium 1 mg tab,   10 mg tab, 2 mg tab, 2.5 mg tab, 3 mg tab, 4 mg tab, 5 mg tab, 6 mg tab, 7.5 mg tab
1
Preferred
COUMADIN
QL = 5 días
heparin sodium (porcine) 1000 unit/ml inj soln
2
Preferred
HEPARIN
QL = 5 días
 
• PA - Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL - Quantity Limit [Límite de Cantidad] • ST - Step Therapy [Terapia Escalonada] • AL - Age Limit [Límite de Edad] • Net Cost [Costo Neto] - Please refer to page #12 for monthly net cost range [Ver página #12 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 
Página 17 de 28

 
FORMULARIO DE EMERGENCIA INTEGRADO (FEI)
 
Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos /
Límites]
heparin sodium (porcine) 10000 unit/ml inj soln, 5000 unit/ml inj soln
3
Preferred
HEPARIN
QL = 5 días
heparin sodium (porcine) pf 5000 unit/0.5ml inj soln
3
Preferred
HEPARIN
QL = 5 días
heparin sodium (porcine) 2000 unit/ml iv soln
8
Preferred
HEPARIN
QL = 5 días
Colony Stimulating Factors [Estimulantes Mieloides]
NEULASTA 6 mg/0.6ml sc   soln
12
Preferred
 
PA, QL = 5 días, P
NEULASTA DELIVERY KIT 6 mg/0.6ml sc soln
12
Preferred
 
PA, QL = 5 días, P
Platelet Modifying Agents [Modificadores De Plaquetas]
cilostazol 100 mg tab, 50 mg   tab
1
Preferred
PLETAL
QL = 5 días
clopidogrel bisulfate 75 mg tab
1
Preferred
PLAVIX
QL = 5 días
CARDIOVASCULAR AGENTS [AGENTES CARDIOVASCULARES]
Antiarrhythmics Class Ii [Antiar rítmicos Clase Ii]
propranolol hcl 10 mg tab,   20 mg tab, 40 mg tab, 80 mg tab
1
Preferred
INDERAL
QL = 5 días
sotalol hcl 120 mg tab, 160 mg tab, 240 mg tab, 80 mg tab
1
Preferred
BETAPACE
QL = 5 días
sotalol hcl (af) 120 mg tab, 160 mg tab, 80 mg tab
1
Preferred
BETAPACE
QL = 5 días
propranolol hcl 60 mg tab
2
Preferred
INDERAL
QL = 5 días
Antiarrhythmics Type I-A [Antiarrítmicos Tipo I-A]
quinidine sulfate 200 mg tab,   300 mg tab
1
Preferred
QUINIDINE SULFATE
QL = 5 días
quinidine gluconate er 324 mg tab er
2
Preferred
QUINAGLUTE
QL = 5 días
quinidine sulfate er 300 mg tab er
2
Preferred
QUINIDINE SULFATE
QL = 5 días
 
• PA - Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL - Quantity Limit [Límite de Cantidad] • ST - Step Therapy [Terapia Escalonada] • AL - Age Limit [Límite de Edad] • Net Cost [Costo Neto] - Please refer to page #12 for monthly net cost range [Ver página #12 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 
Página 18 de 28

 
FORMULARIO DE EMERGENCIA INTEGRADO (FEI)
 
Drug Name [Nombre del
 Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos /
Límites]
Antiarrhythmics Type I-B [Antiarrítmicos Tipo I-B]
mexiletine hcl 150 mg cap    
2
Preferred
MEXITIL
QL = 5 días
mexiletine hcl 200 mg cap
3
Preferred
MEXITIL
QL = 5 días
Antiarrhythmics Type I-C [Antiarrítmicos Tipo I-C]
flecainide acetate 100 mg   tab, 50 mg tab
1
Preferred
TAMBOCOR
QL = 5 días
propafenone hcl 150 mg tab, 225 mg tab
1
Preferred
RYTHMOL
QL = 5 días
flecainide acetate 150 mg tab
2
Preferred
TAMBOCOR
QL = 5 días
propafenone hcl 300 mg tab
3
Preferred
RYTHMOL
QL = 5 días
Antiarrhythmics Type Iii [Antiarrítmicos Tipo Iii]
amiodarone hcl 200 mg tab
1
Preferred
CORDARONE
QL = 5 días
Miscellaneous Cardiovascular Agents [Agentes Cardiovasculares Misceláneos]
digoxin 125            mcg tab, 250 mcg tab
2
Preferred
LANOXIN
QL = 5 días
Vasodilators [Vasodilatadores]
isosorbide mononitrate 10   mg tab, 20 mg tab
1
Preferred
ISORDIL
QL = 5 días
 
• PA - Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL - Quantity Limit [Límite de Cantidad] • ST - Step Therapy [Terapia Escalonada] • AL - Age Limit [Límite de Edad] • Net Cost [Costo Neto] - Please refer to page #12 for monthly net cost range [Ver página #12 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 
Página 19 de 28

 
FORMULARIO DE EMERGENCIA INTEGRADO (FEI)
 
isosorbide mononitrate er 120 mg tab er 24 hr, 30 mg tab er 24 hr, 60 mg tab er 24 hr
1
Preferred
IMDUR
QL = 5 días
NITROSTAT 0.3 mg tab subl, 0.4 mg tab subl, 0.6 mg tab subl
1
Preferred
 
QL = 5 días
DENTAL AND ORAL AGENTS [AGENTES DENTALES Y ORALES]
           Antifungals [Antifungales]
clotrimazole 10 mg   mouth/throat lozenge, 10 mg mouth/throat troche
1
Preferred
MYCELEX
QL = 5 días
nystatin 100000 unit/ml mouth/throat susp, 100000 unit/ml crm
1
Preferred
NYSTATIN
QL = 5 días

Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos /
Límites]
 DERMATOLOGICAL AGENTS [AGENTES DERMATOLÓGICOS]
  Pediculicides And Scabicides [Pediculicidas Y Escabicidas]
permethrin 5 % crm   
3
Preferred
ELIMITE
QL = 5 días
Topical Antibiotics [Antibióticos Tópicos]
mupirocin 2 % oint
1
Preferred
BACTROBAN
QL = 5 días
silver sulfadiazine 1 % crm
1
Preferred
SILVADENE
QL = 5 días
terbinafine 1% crm
1
Preferred
LAMISIL
OTC, QL = 5días
DYSLIPIDEMICS [DISLIPIDÉMICOS]
Bile Acid Sequestrants [Secuestradores De Ácidos Biliares]
cholestyramine 4 gm pckt, 4   gm/dose oral pwdr
3
Preferred
QUESTRAN
QL = 5 días
 
• PA - Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL - Quantity Limit [Límite de Cantidad] • ST - Step Therapy [Terapia Escalonada] • AL - Age Limit [Límite de Edad] • Net Cost [Costo Neto] - Please refer to page #12 for monthly net cost range [Ver página #12 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 
Página 20 de 28

 
FORMULARIO DE EMERGENCIA INTEGRADO (FEI)
 
cholestyramine light 4 gm pckt, 4 gm/dose oral pwdr
3
Preferred
QUESTRAN
QL = 5 días
Fibric Acid Derivatives [Derivados De Ácido Fíbrico]
gemfibrozil 600 mg tab
1
Preferred
LOPID
QL = 5 días
Hmg-Coa Reductase Inhibitors [Inhibidores De La Hmg-Coa Reductasa]
atorvastatin    calcium 10 mg tab, 20 mg tab, 40 mg tab, 80 mg tab
1
Preferred
LIPITOR
QL = 5 días
simvastatin 10 mg tab, 20 mg tab, 40 mg tab, 5 mg tab
1
Preferred
ZOCOR
QL = 5 días
GASTROINTESTINAL AGENTS [AGENTES GASTROINTESTINALES]
Histamine2 (H2) Receptor Antagonists [Antagonistas Del Receptor De H2]
famotidine 20 mg tab, 40 mg   tab
1
Preferred
PEPCID
QL = 5 días
ranitidine hcl 15 mg/ml syr, 150 mg/10ml syr, 300 mg tab, 75 mg/5ml syr
1
Preferred
ZANTAC
QL = 5 días
Miscellaneous Gastrointestinal Agents [Agentes Gastrointestinales Misceláneos]
 
ursodiol 300 mg cap           
2
Preferred
ACTIGALL
PA, QL = 5 días

Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
 [Nombre de
Referencia]
Requirements/
Limits
[Requerimientos /
Límites]
Proton Pump Inhibitors [Inhibidores De La Bomba De Protones]
omeprazole 10 mg cap dr, 20 mg cap dr, 40 mg cap dr
1
Preferred
PRILOSEC
QL=180 caps/ 365 días
GENITOURINARY AGENTS [AGENTES GENITOURINARIOS]
Miscellaneous Genitourinary Agents [Agentes Genitourinarios Misceláneos]
 
• PA - Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL - Quantity Limit [Límite de Cantidad] • ST - Step Therapy [Terapia Escalonada] • AL - Age Limit [Límite de Edad] • Net Cost [Costo Neto] - Please refer to page #12 for monthly net cost range [Ver página #12 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 
Página 21 de 28

 
FORMULARIO DE EMERGENCIA INTEGRADO (FEI)
 
phenazopyridine hcl 100 mg   tab, 200 mg tab
1
Preferred
PYRIDIUM
QL = 3 días
HORMONAL AGENTS [AGENTES HORMONALES]
Antithyroid Agents [Agentes Antitiroide]
methimazole 10 mg tab, 5   mg tab
1
Preferred
TAPAZOLE
QL = 5 días
propylthiouracil 50 mg tab
2
Preferred
PROPYLTHIOURA CIL
QL = 5 días
Calcimimetic Agents [Agentes Calcimiméticos]
SENSIPAR 30   mg tab
7
Preferred
 
PA, QL = 5 días
SENSIPAR 60 mg tab
9
Preferred
 
PA, QL = 5 días
SENSIPAR 90 mg tab
10
Preferred
 
PA, QL = 5 días
Dopamine Agonists [Agonistas De Dopamina]
bromocriptine mesylate 2.5   mg tab
3
Preferred
PARLODEL
QL = 5 días
Thyroid Hormones [Hormona Tiroidea]
SYNTHROID 100 mcg tab,  112 mcg tab, 125 mcg tab, 137 mcg tab, 150 mcg tab, 175 mcg tab, 200 mcg tab, 25 mcg tab, 300 mcg tab, 50 mcg tab, 75 mcg tab, 88 mcg tab
1
Preferred
 
QL = 5 días, P
 
• PA - Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL - Quantity Limit [Límite de Cantidad] • ST - Step Therapy [Terapia Escalonada] • AL - Age Limit [Límite de Edad] • Net Cost [Costo Neto] - Please refer to page #12 for monthly net cost range [Ver página #12 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 
Página 22 de 28

 
FORMULARIO DE EMERGENCIA INTEGRADO (FEI)
 
Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
 [Nombre de
Referencia]
Requirements/
Limits
[Requerimientos /
Límites]
IMMUNOSUPPRESSANTS [IMMUNOSUPRESORES]
Glucocorticosteroids [Glucocorticoides]
dexamethasone 0.5 mg tab,   0.5 mg/5ml oral elix, 0.5 mg/5ml soln, 0.75 mg tab, 1 mg tab, 1.5 mg tab, 2 mg tab, 4 mg tab, 6 mg tab
1
Preferred
DECADRON
QL = 5 días
methylprednisolone 32 mg tab, 4 mg tab
1
Preferred
MEDROL
QL = 5 días
prednisone 1 mg tab, 10 mg tab, 2.5 mg tab, 20 mg tab, 5 mg tab, 50 mg tab
1
Preferred
DELTASONE
QL = 5 días
prednisone (pak) 10 mg tab, 5 mg tab
1
Preferred
DELTASONE
QL = 5 días
methylprednisolone 16 mg tab, 8 mg tab
2
Preferred
MEDROL
QL = 5 días
Immune Globulins [Immunoglobulinas]
RHOGAM ultra-filtered plus im soln 1500 unit
4
Preferred
   
INFLAMMATORY BOWEL DISEASE [ENFERMEDAD INFLAMATORIA INTESTINAL]
Aminosalicylates [Aminosalicilatos]
DELZICOL 400 mg cap dr          
5
Preferred
 
QL = 5 días, P
ASACOL HD 800 mg tab dr
6
Preferred
 
QL = 5 días, P
Sulfonamides [Sulfonamidas]
sulfasalazine 500 mg tab,   500 mg tab dr
1
Preferred
AZULFIDINE
QL = 5 días
MINERALS & ELECTROLYTES [MINERALES Y ELECTROLITOS]
Calcium Regulating Agents [Agentes Reguladores De Calcio]
vitamin d 400 unit cap           
1
Preferred
VITAMIN D
QL = 5 días
MUSCLE RELAXANTS [RELAJANTES MUSCULARES]
Antispasticity Agents [Agentes Antiespasticidad]
baclofen 10 mg tab, 20 mg   tab
1
Preferred
LIORESAL
QL = 5 días
 
• PA - Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL - Quantity Limit [Límite de Cantidad] • ST - Step Therapy [Terapia Escalonada] • AL - Age Limit [Límite de Edad] • Net Cost [Costo Neto] - Please refer to page #12 for monthly net cost range [Ver página #12 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 
Página 23 de 28

 
FORMULARIO DE EMERGENCIA INTEGRADO (FEI)
 
Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos /
Límites]
dantrolene sodium 25 mg cap, 50 mg cap
2
Preferred
DANTRIUM
QL = 5 días
dantrolene sodium 100 mg cap
3
Preferred
DANTRIUM
QL = 5 días
Skeletal Muscle Relaxants [Relajantes Musculoesqueletales]
cyclobenzaprine hcl 10 mg   tab
1
Preferred
FLEXERIL
QL = 5 días
OPHTHALMIC AGENTS [AGENTES OFTÁLMICOS]
Antiglaucoma Agents [Agentes Antiglaucoma]
brimonidine tartrate 0.2 %   ophth soln
1
Preferred
ALPHAGAN
QL = 1 Frasco 5 ML/15 días
dorzolamide hcl 2 % ophth soln
1
Preferred
TRUSOPT
QL = Frasco 10 ML/30 días
levobunolol hcl 0.5 % ophth soln
1
Preferred
BETAGAN
QL = 1 Frasco 5 ML/25 días
levobunolol hcl 0.25 % ophth soln
1
Preferred
BETAGAN
QL = 1 Frasco 5 ML/15 días
timolol maleate 0.5 % ophth soln
1
Preferred
TIMOPTIC
QL = 1 Frasco 5 ML/30 días
dorzolamide hcl-timolol mal ophth sol 22.3-6.8 mg/ml
1
Preferred
COSOPT
QL = 1 Frasco 5 ML/30 días
timolol maleate 0.25 % ophth soln
1
Preferred
TIMOPTIC
QL = 1 Frasco 5 ML/25 días
betaxolol hcl 0.5 % ophth soln
2
Non-Preferred
BETOPTIC
QL = 1 Frasco 5 ML/15 días
Ophthalmic Antibiotics [Antibióticos Oftálmicos]
gentamicin sulfate 0.3 %   ophth oint
1
Preferred
GARAMYCIN
QL = 1 Tubo 3.5 GM/5 días
gentamicin sulfate 0.3 % ophth soln
1
Preferred
GARAMYCIN
QL = 1 Frasco 5 ML/5 días
tobramycin 0.3 % ophth soln
1
Preferred
TOBREX
QL = 1 Frasco 5 ML/5 días
Ophthalmic Prostaglandins [Prostaglandinas Oftálmicas]
latanoprost 0.005 % ophth   soln
1
Preferred
XALATAN
QL = 1 Frasco/25 días
 
• PA - Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL - Quantity Limit [Límite de Cantidad] • ST - Step Therapy [Terapia Escalonada] • AL - Age Limit [Límite de Edad] • Net Cost [Costo Neto] - Please refer to page #12 for monthly net cost range [Ver página #12 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 
Página 24 de 28

 
FORMULARIO DE EMERGENCIA INTEGRADO (FEI)
 
Drug Name [Nombre del
Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
[Nombre de
Referencia]
Requirements/
Limits
[Requerimientos /
Límites]
Ophthalmic Steroids [Esteroides Oftálmicos]
neomycin   -polymyxindexamethasone 3.5-100000.1 ophth oint, 3.5-100000.1 ophth susp
1
Preferred
MAXITROL
QL = 1Frasco 5ML/5 días
prednisolone acetate 1 % ophth susp
2
Preferred
PRED FORTE
QL = 1 Frasco 5 ML/5 días
OTIC AGENTS [AGENTES OTICOS]
           Miscellaneous Otic Agents [Agentes Oticos Misceláneos]
acetic acid 2 % otic soln
2
Preferred
VOSOL
QL = 1 Frasco 15 ML/10 días
Otic Antibiotics [Antibióticos Oticos]
neomycin     -polymyxin-hc 1 % otic soln, 3.5-10000-1 otic soln, 3.5-10000-1 otic susp
2
Preferred
CORTISPORIN
QL = 1 Frasco 10 ML/10 días
RESPIRATORY AGENTS [AGENTES RESPIRATORIOS]
           Anticholinergic Bronchodilators [Broncodilatadores Anticolinérgicos]
ipratropium bromide 0.02 %   inh soln
1
Non-Preferred
ATROVENT
QL = 5 días
 
• PA - Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL - Quantity Limit [Límite de Cantidad] • ST - Step Therapy [Terapia Escalonada] • AL - Age Limit [Límite de Edad] • Net Cost [Costo Neto] - Please refer to page #12 for monthly net cost range [Ver página #12 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 
Página 25 de 28

 
FORMULARIO DE EMERGENCIA INTEGRADO (FEI)
 
Antileukotrienes [Antileukotrienos]
montelukast sodium 10 mg   tab, 4 mg tab chew, 5 mg tab chew 1 Preferred SINGULAIR QL = 5 días
Antitussive-Expectorant [Expectorantes Antitusivos]
benzonatate   100 mg cap
1
Preferred
TESSALON
QL = 5 días
guaifenesin-codeine 100-10 mg/5ml soln
1
Preferred
CHERATUSSIN
QL = 5 días
Inhaled Corticosteroids [Corticosteroides Inhalados]
FLOVENT DISKUS 100
mcg/blist inh aer pwdr, 250 mcg/blist inh aer pwdr, 50 mcg/blist inh aer pwdr
3
Preferred
 
QL = 1 Inh 60 EA/30 días, P
 
Drug Name [Nombre del
 Medicamento]
Net
Cost
[Costo
Neto]
Tier [Tier]
Reference Name
 [Nombre de
Referencia]
Requirements/
Limits
[Requerimientos /
Límites]
FLOVENT HFA 110 mcg/act inh aer
3
Preferred
 
QL = 1 Inh 12 EA/30 días, P
FLOVENT HFA 44 mcg/act  inh aer
3
Preferred
 
QL = 1 Inh 10.6 EA/30 días, P
budesonide 0.25 mg/2ml inh susp, 0.5 mg/2ml inh susp,
1mg/2ml inh susp
4
 
Non-Preferred
PULMICORT
AL </=12
budesonide 1mg/2ml inh susp
8
Non-Preferred
PULMICORT
AL </=12
FLOVENT HFA 220 mcg/act inh aer
4
Preferred
 
QL = 1 Inh 12EA/30 días, P
 
• PA - Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL - Quantity Limit [Límite de Cantidad] • ST - Step Therapy [Terapia Escalonada] • AL - Age Limit [Límite de Edad] • Net Cost [Costo Neto] - Please refer to page #12 for monthly net cost range [Ver página #12 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
 
Página 26 de 28

 
FORMULARIO DE EMERGENCIA INTEGRADO (FEI)
 
Sedating Histamine1 Blocking Agents [Sedantes Bloqueadores Histamine1]
promethazine hcl 12.5 mg   tab, 25 mg tab, 50 mg tab, 6.25 mg/5ml soln, 6.25 mg/5ml syr
1
Preferred
PHENERGAN
QL = 5 días
Sympathomimetic Bronchodilators [Broncodilatadores Simpatomiméticos]
albuterol sulfate (2.5   mg/3ml) 0.083% inh neb soln, (5 mg/ml) 0.5% inh neb soln, 2 mg/5ml syr
1
Dl
ALBUTEROL
QL = 5 días
terbutaline sulfate 2.5 mg tab, 5 mg tab
1
Preferred
BRETHINE
QL = 5 días
VENTOLIN HFA 108 (90 base) mcg/act inh aer
1
Preferred
 
QL = 1 Inh 18 EA/30 días, P
 
• PA - Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL - Quantity Limit [Límite de Cantidad] • ST - Step Therapy [Terapia Escalonada] • AL - Age Limit [Límite de Edad] • Net Cost [Costo Neto] - Please refer to page #12 for monthly net cost range [Ver página #12 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]
Página 27 de 28

 

 

 PUERTO RICO MEDICAID PROGRAM

 Cost Sharing Policy (Copayments) for Medicaid and CHIP Beneficiaries

  Introduction

On July 15, 2013, the Centers for Medicare and Medicaid Services (CMS) published the final rule to update and simplify the Medicaid premium and cost sharing requirements, to promote the most effective use of services, and to assist states in identifying cost sharing flexibilities, (78 Federal Register page 42,100).

The federal regulation defines " cost sharing" as any copayment, coinsurance, deductible, or other similar charge.  Copayment is a fixed amount (for example, $1) that the beneficiary pays directly to a provider for each covered health care service, usually when he or she receives at the time of the service.

The Puerto Rico Medicaid State Plan dictates that Medicaid beneficiaries may pay cost sharing.  The Puerto Rico Department of Health (PRDoH), through the Puerto Rico Medicaid Program (Medicaid Program), and the Puerto Rico Health Insurance Administration (PRHIA, Administración de Seguros de Salud de Puerto Rico , or ASES , from its acronym in Spanish) have issued this "Cost Sharing Policy (Copayments) for Medicaid and CHIP Beneficiaries" to establish copayment rules, as required by:

1.
The Social Security Act (SSA), Sections 1916 and 1916A.

2.
The federal regulation, 42 CFR §§447.50-447.57 (excluding 42 CFR §447.55) of the federal regulation.

3.
The Puerto Rico State Plan Amendment (SPA) for Cost Sharing.

4.
The New Cost Sharing (Copayment) Structure for Medicaid and CHIP Beneficiaries.

The federal regulation addresses the following topics:

Medicaid Premiums and Cost Sharing

42 CFR §447.50 Premiums and cost sharing: Basis and purpose.
 
Page 1

42 CFR §447.51
Definitions.
   
42 CFR §447.52 Cost sharing.
   
42 CFR §447.53  Cost sharing for drugs.
   
42 CFR §447.54   Cost sharing for services furnished in a hospital emergency department.
   
42 CFR §447.55  
Premiums.
   
42 CFR §447.56   Limitations on premiums and cost sharing.
   
42 CFR §447.57 Beneficiary and public notice requirements.
 
The Policy establishes the following copayments rules, among others:

1.
Medicaid beneficiaries are only subject to copayments and to no other form of cost sharing, such as coinsurances or deductibles.

2.
CHIP beneficiaries (Children Health Insurance Program or Medicaid Optional Targeted Low-Income Children) do not pay cost sharing or any other form of cost sharing, such as coinsurances or deductibles.

3.
Certain beneficiaries and services are exempt from any cost sharing, which mean that no copayment will be charged in these instances.

4.
Copayment amounts can vary by coverage codes and   by   the type of covered health care service.

5.
This Policy does not apply to individuals eligible for the Government Health Plan (GHP) as State or Commonwealth beneficiary.

  Medicaid and CHIP Cost Sharing (Copayments) Structure Prior to July 1, 2016

Cost Sharing (Copayments) Policy for Medicaid and CHIP Beneficiaries:

1.
The Cost Sharing (Copagos) Structure, coverage codes, and copayment amounts applied to all Medicaid and CHIP beneficiaries, were effective from November 1, 2011 through June 30, 2016.
 
Page 2

2.
The coverage codes were determined on the basis of the beneficiary Eligibility Monthly Income and the number of Members in the Family Unit.  For example: if the Eligibility Income of a Medicaid beneficiary is $300 per month and the Members in the Family Unit is two (2), the coverage code assigned is 110.  The evaluation uses Table I as follows:

a.
Eligibility Monthly Income = $300;

b.
Members in Family Unit = 2;

c.
Position on the row for Members in Family Unit of 2;

d.
Determine in which column of Coverage Codes on the row the Eligibility Monthly Income of $300 fits;

e.
The eligibility monthly income of $300 fits in range $249-UP which is under column 110; and

f.
Therefore, the beneficiary is assigned coverage code 110.

3.
It does not apply to anyone who is eligible as a State or Commonwealth beneficiary.

The following three (3) tables illustrate the Cost Sharing (Copayments) Structure for Medicaid and CHIP Beneficiaries prior July 1, 2016:

1.
Table I - Medicaid Coverage Codes, determined on the basis of eligibility monthly income and the number of members in the beneficiary’s family unit.

2.
Table II - CHIP Coverage Codes, determined on the basis of eligibility monthly income and the number of members in the beneficiary’s family unit.

3.
Table III - Medicaid and CHIP Coverage Codes and the applicable copayment amounts for each service.
 
Page 3

  TABLE I
Medicaid Cost Sharing (Copayments) Structure Prior to July 1 st , 2016
Coverage Codes and Its Determination
Members in Family Unit
Eligibility Monthly Income Range by Coverage Code
100
110
1
$0-$200
$201-UP
2
$0-$248
$249-UP
3
$0-$295
$296-UP
4
$0-$343
$344-UP
5
$0-$390
$391-UP
6
$0-$438
$439-UP
7
$0-$485
$486-UP
8
$0-$533
$534-UP
9
$0-$580
$581-UP
10
$0-$628
$629-UP
11
$0-$675
$676-UP
12
$0-$723
$724-UP
13
$0-$770
$771-UP
14
$0-$818
$819-UP
15
$0-$865
$866-UP
 
Page 4

 
TABLE II
CHIP Cost Sharing Structure (Copayments) Prior to July 1 st , 2016
Coverage Codes and Its Determination
Members in Family Unit
 
Eligibility Monthly Income Range by Coverage Code
230
1
$551-$1,100
2
$551-$1,300
3
$551-$1,500
4
$551-$1,700
5
$551-$1,900
6
$551-$2,100
7
$551-$2,300
8
$551-$2,500
9
$551-$2,700
10
$551-$2,900
11
$551-$3,100
12
$551-$3,300
13
$551-$3,500
14
$551-$3,700
15
$551-$3,900
 
  TABLE III
Medicaid and CHIP Cost Sharing (Copayments) Structure Prior to July 1 st , 2016 Applicable
Copayment Amounts for Each Service by Coverage Code
Service
Coverage Codes and Copayments Amounts
Medicaid
CHIP
100
110
230
Hospital Admission, (per entire stay)
$0.00
$3.00
$0.00
Non-emergency Services Provided in a Hospital Emergency Room (ER), (per visit)
$3.80
$3.80
$0.00
Visit to Primary Care Physician (PCP), (per visit)
$0.00
$1.00
$0.00
Visit to Specialist, (per visit)
$0.00
$1.00
$0.00
Visit to Sub-Specialist, (per visit)
$0.00
$1.00
$0.00
High-Tech Laboratories, (per procedure)
$0.00
$0.50
$0.00
 
Page 5

TABLE III
Medicaid and CHIP Cost Sharing (Copayments) Structure Prior to July 1 st , 2016 Applicable
Copayment Amounts for Each Service by Coverage Code
Service
Coverage Codes and Copayments Amounts
Medicaid
CHIP
100
110
230
Clinical Laboratories, (per procedure)
$0.00
$0.50
$0.00
X-Rays, (per procedure)
$0.00
$0.50
$0.00
Special Diagnostic Test, (per procedure)
$0.00
$1.00
$0.00
Therapy - Physical, (per procedure)
$0.00
$1.00
$0.00
Therapy - Respiratory, (per procedure)
$0.00
$1.00
$0.00
Therapy - Occupational, (per procedure)
$0.00
$1.00
$0.00
Dental - Preventative, (per procedure)
$0.00
$1.00
$0.00
Dental - Restorative, (per procedure)
$0.00
$1.00
$0.00
Pharmacy - Generic, (per drug)
$1.00
$1.00
$0.00
Pharmacy - Brand, (per drug)
$3.00
$3.00
$0.00
All Other Services or Items Not Specified Above
$0.00
$0.00
$0.00
 
Medicaid and CHIP Cost Sharing (Copagos) Structure to be Effective On and After July 1, 2016

The New Cost Sharing Structure (Copayments) will apply to all Medicaid and CHIP beneficiaries and:

1.
Be effective on July 1 st , 2016; except for those Medicaid dual beneficiaries with Medicare Part A and B and who are enrolled in a Medicare Advantage (MA) Plan contracted with ASES, commonly known as Platino Plan.  In Platino Plans, the New Cost Sharing Structure will be implemented on January 1 st , 2017.
 
Page 6

2.
Assign the Medicaid and CHIP Coverage Codes on the basis of:

a.
MAGI: Obamacare provides a new method for determining eligibility of individuals for Medicaid and CHIP, based on what is called Modified Adjusted Gross Income (MAGI).

b.
At July 1, 2016 and until implementation of MAGI Methodologies for determining Medicaid and CHIP eligibility, the Medicaid Program will continue assigning Medicaid and CHIP Coverage Codes for a beneficiary on the basis of the eligibility monthly income and the number of members in the family unit of the beneficiary, as illustrates on Tables I and II.

c.
On and after implementation of MAGI Methodologies for determining Medicaid and CHIP eligibility:

(1)
The Medicaid Program will be assigned the Medicaid and CHIP Coverage Codes for an individual on the basis of MAGI Monthly Income and MAGI Household Size of the individual.

(2)
Coverage Codes vary by household monthly income ranges.

(3)
Medicaid and CHIP Coverage Codes are based on ranges of MAGI Monthly Income as a percentage of the Puerto Rico Poverty Level (PRPL) in effect.

(4)
Example: if the MAGI Monthly Income of a Medicaid beneficiary is $300 per month with a MAGI household size of two (2) the coverage code assigned is 110.  The evaluation uses Table IV as follows:

(a)
MAGI Monthly Income = 300;

(b)
MAGI household size = 2;

(c)
Position on the row for MAGI Household Size of 2;

(d)
Determine in which column of Coverage Code 100, 110, 120 ó 130 on the row, the MAGI Monthly Income of $300 fits;

(e)
MAGI Monthly Income of $300 fits in range $272-$542 which is under column 110; and,

(f)
Therefore, the beneficiary is assigned coverage code 110.

3.
Expand the number of coverage codes:

a.
The new coverage codes 120, 130, and 220 and the copayments amounts associate with these codes will be implemented on and after MAGI eligibility evaluation system go-lives.
 
Page 7

b.
The new coverage codes will be assigned on the basis of MAGI Monthly Income and MAGI Household Size of the individual.

4.
Revise some copayments amounts on existing coverage codes, and establish copayment amounts on new coverage codes.

a.
Starting on July 1 st , 2016:

(1)
All Medicaid beneficiaries with the coverage codes 100 or 110 will pay the new the copayments amounts associate with these codes, as illustrate on Table VI.

(2)
All CHIP beneficiaries with the coverage code 230 will continue paying the copayments amounts associate with this code, which remains as zero ($0) as illustrate on Table VI.

b.
On and after the implementation of MAGI methodologies for determining Medicaid or CHIP eligibility:

(1)
All Medicaid beneficiaries assigned the new coverage codes 120 and 130 will pay the copayment amounts associate with these codes, as illustrate on Table VI.

(2)
All CHIP beneficiaries with the coverage code 220 will pay the copayments amounts associate with this codes, which is zero ($0) as illustrate on Table VI.

5.
Copayment amount vary by coverage codes and by service.

The following three (3) tables illustrate the Cost Sharing (Coapyments) Structure for Medicaid or CHIP Beneficiaries to be effective on and after July 1 st , 2016:

1.
Table IV - Medicaid Coverage Codes, determined on the basis of MAGI Monthly Income and the MAGI Household Size of the individual.  Coverage codes are assigned according to monthly income ranges defines as a percentage of the PRPL.

2.
Table V - CHIP Coverage Codes, determined on the basis of MAGI Monthly Income and the MAGI Household Size of the individual.  Coverage codes are assigned according to income ranges defines as a percentage of the PRPL.

3.
Table VI - Medicaid and CHIP Coverage Codes and the applicable copayment amounts for each service.
 
Page 8

  TABLE IV
Medicaid Cost Sharing Structure (Copayments) to be Effective On and After July 1, 2016
Coverage Codes and Its Determination
MAGI  Household Size
Puerto Rico
Poverty Level
(PRPL)
MAGI Monthly Income Range by Coverage Code
100
110
120
130
Percentage of PRPL
0%-50%
51%-100%
101%-150%
151%-UP
1
$0-$459
$0-$230
$231-$459
$460-$689
$690-UP
2
$0-$542
$0-$271
$272-$542
$543-$813
$814-UP
3
$0-$626
$0-$313
$314-$626
$627-$939
$940-UP
4
$0-$709
$0-$355
$356-$709
$710-$1,064
$1,065-UP
5
$0-$792
$0-$396
$397-$792
$793-$1,188
$1,189-UP
6
$0-$876
$0-$438
$438-$876
$877-$1,314
$1,315-UP
7
$0-$959
$0-$480
$481-$959
$960-$1,439
$1,440-UP
8
$0-$1,043
$0-$522
$523-$1,043
$1,044-$1,565
$1,566-UP
9
$0-$1,126
$0-$563
$564-$1,126
$1,127-$1,689
$1,690-UP
10
$0-$1,210
$0-$605
$606-$1,210
$1,211-$1,815
$1,816-UP
11
$0-$1,293
$0-$647
$648-$1,293
$1,294-$1,940
$1,941-UP
12
$0-$1,377
$0-$689
$690-$1,377
$1,378-$2,066
$2,067-UP
13
$0-$1,460
$0-$730
$731-$1,460
$1,461-$2,190
$2,191-UP
TABLE IV
Medicaid Cost Sharing Structure (Copayments) to be Effective On and After July 1, 2016
Coverage Codes and Its Determination
MAGI  Household Size
Puerto Rico
Poverty Level
(PRPL)
MAGI Monthly Income Range by Coverage Code
100
110
120
130
Percentage of PRPL
0%-50%
51%-100%
101%-150%
151%-UP
14
$0-$1,544
$0-$772
$773-$1,544
$1,545-$2,316
$2,317-UP
15
$0-$1,627
$0-$814
$815-$1,627
$1,628-$2,441
$2,442-UP
 
Page 9

  TABLE V
CHIP Cost Sharing Structure (Copayments) to be Effective On and After July 1, 2016
Coverage Codes and Its Determination
MAGI  Household Size
Puerto Rico Poverty Level (PRPL)
MAGI Monthly Income Range by  Coverage Code
220
230
Percentage of PRPL
0%-150%
151%-UP
1
$0-$459
$0-$689
$690-UP
2
$0-$542
$0-$813
$814-UP
3
$0-$626
$0-$939
$940-UP
4
$0-$709
$0-$1,064
$1,065-UP
5
$0-$792
$0-$1,188
$1,189-UP
6
$0-$876
$0-$1,314
$1,315-UP
7
$0-$959
$0-$1,439
$1,440-UP
8
$0-$1,043
$0-$1,565
$1,566-UP
9
$0-$1,126
$0-$1,689
$1,690-UP
10
$0-$1,210
$0-$1,815
$1,816-UP
11
$0-$1,293
$0-$1,940
$1,941-UP
12
$0-$1,377
$0-$2,066
$2,067-UP
13
$0-$1,460
$0-$2,190
$2,191-UP
14
$0-$1,544
$0-$2,316
$2,317-UP
15
$0-$1,627
$0-$2,441
$2,442-UP
 
Page 10

  TABLE VI
Medicaid and CHIP Cost Sharing Structure (Copayments) to be Effective On and After July 1, 2016
Applicable Copayment Amounts for Each Service by Coverage Code
Service
Coverage Codes and Copayments Amounts
Medicaid
CHIP
100
110
120
130
220
230
Hospital Admission, (per entire stay)
$0.00
$4.00
$5.00
$8.00
$0.00
$0.00
Non-Emergency Services Provided in a Hospital Emergency Room, (per visit)
$0.00
$4.00
$5.00
$8.00
$0.00
$0.00
Non-Emergency Services Provided in a non-Hospital / Freestanding Emergency Room, (per visit)
$0.00
$2.00
$3.00
$4.00
$0.00
$0.00
Visit to Primary Care Physician (PCP), (per visit)
$0.00
$1.00
$1.50
$2.00
$0.00
$0.00
Visit to Specialist, (per visit)
$0.00
$1.00
$1.50
$2.00
$0.00
$0.00
Visit to Sub-Specialist, (per visit)
$0.00
$1.00
$1.50
$2.00
$0.00
$0.00
High-Tech Laboratories, (per procedure)
$0.00
$0.50
$1.00
$1.50
$0.00
$0.00
Clinical Laboratories, (per procedure)
$0.00
$0.50
$1.00
$1.50
$0.00
$0.00
X-Rays, (per procedure)
$0.00
$0.50
$1.00
$1.50
$0.00
$0.00
Special Diagnostic Test, (per procedure)
$0.00
$1.00
$1.50
$2.00
$0.00
$0.00
Therapy - Physical, (per procedure)
$0.00
$1.00
$1.50
$2.00
$0.00
$0.00
Therapy - Respiratory, (per procedure)
$0.00
$1.00
$1.50
$2.00
$0.00
$0.00
Therapy - Occupational, (per procedure)
$0.00
$1.00
$1.50
$2.00
$0.00
$0.00
Dental - Preventative, (per procedure)
$0.00
$1.00
$1.50
$2.00
$0.00
$0.00
Dental - Restorative, (per procedure)
$0.00
$1.00
$1.50
$2.00
$0.00
$0.00
Pharmacy - Preferred Drugs, (per drug)
$0.00
$1.00
$2.00
$3.00
$0.00
$0.00
Pharmacy - Non-Preferred Drugs, (per drug)
$0.00
$3.00
$4.00
$6.00
$0.00
$0.00
All Other Services or Items Not Specified Above
$0.00
$0.00
$0.00
$0.00
$0.00
$0.00
 
Page 11

Contracts between ASES and Managed Care Organizations (MCOs), Medicare Advantage Organizations (MAOs), Pharmacy Benefit Managers (PBMs), Managed Behavioral Healthcare Organizations (MBHOs), and Third Party Administrators (TPAs), among others, shall include this Cost Sharing Policy.  Each entity is required by contract to make this Cost Sharing (Copayments) Policy known to beneficiaries and providers.  Compliance with this Cost Sharing Policy will be monitored by ASES.

 Medicaid Beneficiaries Enrolled in a Platino Plan

The Medicaid dual beneficiaries with Medicare Part A and B have the option to be enrolled in a Medicare Advantage (MA) Plan contracted with ASES, commonly known as Platino Plan.  For Platino Plans, the New Cost Sharing Structure will be implemented on January 1, 2017.

MAO contracts, or Platino Plan contracts, are based on calendar year, from January 1 st to December 31 st of each year.  The January 1 st , 2017 implementation date will allow the changes in copayments to be incorporated under premiums and contract negotiation with each MAO, which will take effect in 2017.

Therefore, from July 1 st to December 31 s , 2016, MAOs will continue using the Cost Sharing Structure as indicated in Table I, II and III for the Platino Plans.  The beneficiary will continue using his/her Platino ID Card up to December 31, 2016.  If during the period from July 1 st to December 31 st 2016 the Medicaid Program:

1.
Performs a Medicaid beneficiary determination or redetermination on a beneficiary who enrolls in, or is enrolled in, a Platino Plan, and

2.
The beneficiary is assigned a coverage 120 or 130,

3.
The MAO will treat that beneficiary as if the coverage code was assigned as 110.
 
Page 12

On January 1 st , 2017:

1.
The MAOs will implement the New Cost Sharing Structure, as indicated in Tables IV, VI, and VI.

2.
The MAOs will issue to each beneficiary a new ID Card with (i) the coverage code assigned by the Medicaid Program and (ii) copayments amount applicable to such code, as indicated in Table VI.

4.
The beneficiary will discard the old ID Card and use the new ID Card.

5.
The beneficiary will only be liable to pay the Table VI's copayments amount as a maximum.

A Platino beneficiary can submit a reimbursement request as soon as he/she believes he/she has exceeded the 5% limit per quarter as it is described under the section "Five Percent (5%) Limit or Cap Per Quarter on all Copayments".

MAOs cannot impose cost sharing requirements on specified Medicaid beneficiary with a Platino Plan that would exceed the amounts permitted under the Medicaid State Plan for Medicaid beneficiaries not enrolled in a Platino Plan.  Therefore, MAOs are not allowed to charge any other cost sharing for Medicaid covered services except for the copayment amounts establish in the Puerto Rico Medicaid State Plan, as described in this "Cost Sharing Policy for Medicaid and CHIP Beneficiaries".

Contracts between ASES and MAOs shall include this Cost Sharing Policy.  The MAOs are required by contract to make this Cost Sharing Policy knows to beneficiaries, providers, and any other person that provides health care services to beneficiaries.  Compliance with this Cost Sharing Policy will be monitored by ASES.

 Beneficiaries Copayments Exemptions

Pursuant to the federal regulation, 42 CFR §447.56(a)(1), Puerto Rico Medicaid State Plan states that certain groups of individuals are exempted from any copayments.  No copayment will be charged to the following Medicaid or CHIP beneficiaries:

1.
Children from 0 to less than 21 years of age.

2.
Pregnant women, during pregnancy and the post-partum period.  The post-partum period begins on the last day of pregnancy and extends through the end of the month in which a 60-day period following the last day of pregnancy ends.  Example: If March 3 is the last day of pregnancy, May 2 is the end of the 60-days, and May 31 is the last day of the month in which post-partum ends.

3.
Institutionalized Individuals, such as a nursing home.

4.
Beneficiaries receiving hospice care.  As defined in Section 1905(o) of the Social Security Act, hospice care means the care furnished by a hospice program to a terminally ill individual who has voluntarily elected to have payment made for hospice care.
 
Page 13

5.
American Indians and Alaskan Natives (AI/AN).

Contracts between ASES and MCOs, MAOs and PBMs include the requirement to exempt these group of beneficiaries, as defined at 42 CFR §447.56(a)(1).  MCOs, MAOs, and PBMs are required by contract to make these exemptions known to beneficiaries, providers, and any other person that provides health care services to beneficiaries.  Compliance with these cost sharing exemptions will be monitored by ASES.

 Health Care Services Copayments Exemptions

Pursuant to the federal regulation, 42 CFR §447.56(a)(2), Puerto Rico Medicaid State Plan establishes that certain health care services are exempted from any copayments.  All Medicaid and CHIP beneficiaries are exempt from copayments for the following services:

1.
Emergency services, (including ambulatory, hospital, and post-stabilization services), as defined at Section 1932(b)(2) of the Social Security Act and in the federal regulation, 42 CFR §438.114(a).

2.
Family planning services and supplies as described in Section 1905(a)(4)(C) of the Social Security Act, including contraceptives and pharmaceuticals for which the Puerto Rico claims or could claim Federal match at the enhanced rate under Section 1903(a)(5) of the Social Security Act for family planning services and supplies.

3.
Preventive services provided to children under 18 years of age, as described in the federal regulation at 42 CFR §457.520 of chapter D.

4.
Pregnancy-related services, including those services as defined in the federal regulation, 42 CFR §440.210(a)(2) and 42 CFR §440.250(p), and counseling services and drugs for cessation of tobacco use.  All services provided to pregnant women, during pregnancy and the 60-day post-partum period, will be considered as pregnancy-related.

5.
Provider-preventable services as defined in the federal regulation, 42 CFR §447.26(b).

Contracts between ASES and MCOs, MAOs and PBMs include the requirement to exempt these services, as defined in 42 CFR §447.56(a)(2).  MCOs, MAOs, and PBMs are required by contract to make these exemptions known to beneficiaries, providers, and any other person that provides health care services to beneficiaries.  Compliance with these cost sharing exemptions will be monitored by ASES.
 
Page 14

  Other Copayments Exemptions

Preferred Provider Network (PPN) Copayment Exemption :

1.
The Preferred Provider Network is a subset of providers within the MCO General Network of Providers.  The objectives of the Preferred Provider model are to:

a.
Increase access to Providers and needed services;

b.
Improve timely receipt of services;

c.
Improve the quality of beneficiary care;

d.
Enhance continuity of care; and

e.
Facilitate effective exchange of personal health information between providers and the MCO.

2.
Copayments do not apply to any service provided to a Medicaid beneficiary by a provider participating in the Preferred Provider Network.

3.
A provider who is a member of the Preferred Provider Network provides services to beneficiaries without the requirement for referrals and copayments.

4.
The MCO’s contracts with a provider who is a member of the Preferred Provider Network shall prohibit the provider from collecting copayments from Medicaid beneficiary.

5.
The Medicaid beneficiary is not required to use the Preferred Provider Network.  But, if the Medicaid beneficiary chooses a provider from the MCO General Network of Providers, he/she is subject to the applicable copayments amount.

6.
If the Medicaid beneficiary needs a covered service and cannot have access to a specialist within the Preferred Provider Network within thirty (30) calendar days, the beneficiary shall have access to the specialist within the MCO General Network of Providers, without the imposition of copayments, but shall return to the PPN specialist once the PPN specialist is available to treat the beneficiary.

7.
Dentists and Pharmacies are not part of the Preferred Provider Network.

8.
For a Platino Plan, MAOs have to be in compliance with this exemption, if they operate a Preferred Provider Network model.

Medical Advice Service Line Copayment Exemption :

1.
The Puerto Rico Medicaid State Plan does not allow charging copayment for non-emergency services provided in a hospital emergency room to a Medicaid or CHIP beneficiary when the beneficiary:

a.
Calls the MCO Medical Advice Service Line, prior to visiting the hospital emergency room;
 
Page 15

b.
Receives a code or an identification number;

c.
Presents such number at the time of the visit to the hospital emergency room; and

d.
The hospital emergency room will waive the beneficiary copayment for non-emergency services provided in a hospital emergency room.

2.
Regardless of whether the beneficiary uses or does not use the MCO Medical Advice Service Line, under no circumstance will a copayment be imposed on a Medicaid or CHIP Beneficiary for the treatment of an Emergency Medical Condition or Psychiatric Emergency provided.

3.
For a Platino Plan, MAOs will comply with the "Medical Advice Service Line Copayment Exemption", as described herein.

Preventive Services:

All Medicaid beneficiaries do not pay copayments for the following diagnostics tests when these services are required as part of a preventive service.

1.
High-Tech Laboratories.

2.
Clinical Laboratories.

3.
X-Rays.

4.
Special Diagnostic Test.

Contracts between ASES and MCOs, MAOs, and PBMs include the requirement to exempt Medicaid beneficiaries from these copayments when he/she complies with the rules as described under this section.  MCOs, MAOs, and PBMs are required by contract to make these exemptions known to beneficiaries, providers, and any other person that provides health care services to the beneficiaries.  Compliance with this Policy Cost Sharing section will be monitored by ASES.

 Copayment for Non-Emergency Services Provided in a Hospital Emergency Room (ER)

Pursuant the federal regulation, 42 CFR §447.51, N on-Emergency Services means any care or services that are not considered emergency services, as it concept is defined and described in 42 CFR §438.114 (Emergency and Post-Stabilization Services).  Non-Emergency Services do not include any services furnished in a hospital emergency department that are required to be provided as an appropriate medical screening examination or stabilizing examination and treatment under Section 1867 of the Social Security Act, (Examination and Treatment for Emergency Medical Conditions and Women In Labor, also known as EMTALA).

Page 16

Emergency and Post-Stabilization Services are defined as follows:

1.
Emergency medical condition means a medical condition manifesting itself by acute symptoms of sufficient severity (including severe pain) that a prudent layperson, who possesses an average knowledge of health and medicine, could reasonably expect the absence of immediate medical attention to result in the following:

a.
Placing the health of the individual (or, with respect to a pregnant woman, the health of the woman or her unborn child) in serious jeopardy;

b.
Serious impairment to bodily functions; and

c.
Serious dysfunction of any bodily organ or part.

2.
Emergency services means covered inpatient and outpatient services that are:
a.
Furnished by a provider that is qualified to furnish these services under 42 CFR §438.114 and
b.
Needed to evaluate or stabilize an emergency medical condition.

3.
Post-Stabilization care services means covered services, related to an emergency medical condition that are provided after an enrollee is stabilized in order to maintain the stabilized condition, or to improve or resolve the enrollee's condition.

The Puerto Rico Medicaid State Plan allows charging cost sharing for non-emergency services provided in the hospital emergency room.  It is expected that all participating hospital emergency rooms will charge the applicable copayment amount to all non-exempt Medicaid beneficiaries for the non-emergency services provided in a hospital emergency room.

The Puerto Rico Medicaid State Plan does not allow charging cost sharing for non-emergency services provided in the hospital emergency room in the following instances:

1.
To Medicaid beneficiary when he/she:

a.
Calls the MCO Medical Advice Service Line, previous to visit the hospital emergency room,

b.
Receives a code or an identification number, and

c.
Presents such number at the time of the visit to the hospital emergency room.  In this instance, the copayment is waived.
 
Page 17

2.
To Medicaid exempted groups of individuals listed in this Cost Sharing Policy under section "Copayments Are Not Charged To The Following Beneficiaries".

3.
Copayments do not apply to any service provided to a Medicaid beneficiary by a hospital emergency room participating in the Preferred Provider Network (PPN).

4.
For Medicaid beneficiaries with a Platino Plan, MAOs have to be in compliance with the "Preferred Provider Network (PPN) Copayment Exemption" and the "Medical Advice Service Line Copayment Exemption", as described under section "Other Copayments Exemptions".

If the beneficiary does not follow the copayment exemption describes under section "Medical Advice Service Line Copayment Exemption" of this Cost Sharing Policy, the non-preferred hospital's emergency room may charge the applicable copayment for this service only if, before providing non-emergency services and imposing the applicable copayment for such services, the hospital's emergency room must complies with the following requirements:

1.
First, conducts an appropriate medical screening to determine
a.
Whether or not an emergency medical condition exists as required under 42 CFR §489.24 subpart G and  b. That the individual does not need emergency services.

2.
Second, if not an emergency medical condition exists and before providing non-emergency services and imposing cost sharing for such services, the hospital's emergency room:

a.
Informs the beneficiary of the amount of his or her copayment obligation for non-emergency services provided in the hospital emergency room;

b.
Provides the beneficiary with the name and location of an available and accessible alternative non-emergency services provider;

c.
Determines that the alternative provider can provide services to the individual in a timely manner with the imposition of a lesser copayment amount or no copayment if the beneficiary is otherwise exempt from copayment; and

d.
Provides a referral to coordinate scheduling for treatment by the alternative provider.

3.
The federal regulation, 42 CFR §447.51, defines Alternative Non-Emergency Services Provider as a Medicaid provider, such as a physician's office, health care clinic, community health center, hospital outpatient department, or similar provider that can provide clinically appropriate services in a timely manner.

4.
Therefore, the hospital emergency room cannot charge the copayment if it does not follow and comply with the process as described herein.
 
Page 18

The Puerto Rico Medicaid Program and ASES ensure that:

1.
Before providing non-emergency services and imposing the applicable copayment for such services the hospital's emergency room will comply with the above mentioned requirements.

2.
There is a process in place to identify hospital emergency room services as non-emergency's room services for purposes of imposing cost sharing.  This process does not:

a.
Limit hospital's obligations for screening and stabilizing treatment of an emergency medical condition under section 1867 of the Social Security Act (EMTALA); or

b.
Modify any obligations under either state or federal standards relating to the application of a prudentlayperson standard for payment or coverage of emergency medical services by any MCO (MAO for a Platino Plan).

3.
As part of the New Cost Sharing Structure, all participating hospital emergency rooms located in Puerto Rico will have their payments reduced by the copayment amount for non-emergency services provided at the hospital emergency room.

4.
Contracts between ASES and MCOs and MAOs include the non-emergency hospital emergency room copayment rules.  MCOs and MAOs are required by contract to make these rules know to beneficiaries and providers.  Compliance with these cost sharing rules will be monitored by ASES.

The Puerto Rico Medicaid State Plan does not allow charging the copayment for "Non-Emergency Services Provided in a Hospital Emergency Room" when the non-emergency services is provided in a nonhospital/freestanding emergency room.  In non-hospital/freestanding emergency room facilities, the provider can only charge, per visit, the copayment applicable for "Non-Emergency Services Provided in a nonHospital/Freestanding Emergency Room", as indicated in "TABLE VI".

The List of Hospital Emergency Rooms by MCO, that may charge the copayment for non-emergency services provided in the hospital emergency room, is available in any of the Medicaid Local Offices throughout the Island or at the ASES Central Office (physical address: #1549 Calle Alda, Urbanización Caribe, Río Piedras, Puerto Rico  00926-2712).  Additionally, the list of MCO's Hospital Emergency Rooms can be downloaded, reviewed, and printed from the Medicaid Program website (https://www.medicaid.pr.gov/) or the ASES website (http://www.asespr.org/ or http://ases.pr.gov/).

The List of Hospital Emergency Rooms by MCO may be changed to add or remove its participating Hospital Emergency Rooms at any time.  ASES will notify and post such changes through its ASES website.

Each MCO will post its Hospital Emergency Rooms List through its website, as well as any change to add or remove its participating Hospital Emergency Rooms at any time.
 
Page 19

Each MAO will post its Hospital Emergency Rooms List through its website not later than January 1 st , 2017, as well as any change to add or remove its participating Hospital Emergency Rooms at any time.

Contracts between ASES and MCOs, MAOs, and PBMs include these copayment rules.  MCOs, MAOs, and PBMs are required by contract to make these rules known to beneficiaries, providers, and any other person that provides health care services to the beneficiaries.  Compliance with these copayment rules will be monitored by ASES.

  Preferred Drug List

Pursuant to the federal regulation, 42 CFR §447.51, p referred drugs means drugs that the state has identified on a publicly available schedule as being determined by a pharmacy and therapeutics committee for clinical efficacy as the most cost effective drugs within each therapeutically equivalent or therapeutically similar class of drugs.

The Medicaid Program and ASES differentiate between preferred and non-preferred drugs.  The Preferred Drug List (PDL) was revised to produce a new Drugs Formulary ( “Formulario de Medicamentos en Cubierta del Plan de Salud del Gobierno de PR ”).  The review was performed by ASES’ Pharmacy Administrative Committee, composed of a clinical pharmacist, an epidemiology analyst, a medical doctor from the Pharmacy Program Administrator (PPA), two clinical pharmacists, a system implementation manager from the contracted PBM, ASES Clinical Medical Doctor Representative, and ASES Clinical Department Manager.  All drugs included have been previously approved by the ASES Pharmacy and Therapeutics Committee, composed of thirteen (13) voluntary community representatives, community medical doctors, and pharmacist representatives.  All decisions have been managed and documented under the contracted PBM for such purposes.

For the determination of which medication will be covered as preferred or non-preferred drug, the Pharmacy Administrative Committee evaluated each therapeutic category based on the amount of alternatives available with similar efficacy, utilization frequency, and total cost impact.  As a result of such analysis the majority of the generic drugs were considered as preferred drugs, with some exceptions where other more cost-effective drugs were available within the same therapeutic category.  All branded products with contracted rebates were considered preferred drugs, but depending on availability on a class category, some non-rebatable, branded drugs were also considered preferred drugs.

The drugs in the Formulary   are divided into two categories (Tiers): Preferred and Non-preferred drugs, as permitted by the federal regulation applicable to Medicaid.  The criteria used for the drug classifications were based on their safety profile, established efficacy (cost-effectiveness), generic drug availability, and treatment cost.  The Medicaid Program and ASES define both categories as follows:
 
Preferred Drugs means:

1.
All generic drugs, except for:
 
Page 20

 
a.
Those with a significantly higher cost compared to their therapeutic alternatives, in which case they are classified as non-preferred drugs.

b.
Those with a low safety profile compared to their therapeutic alternatives, in which case they are classified as non-preferred drugs.

2.
Branded drugs that:

a.
Have no generic available and their net cost does not exceed a certain limit, otherwise they are classified as non-preferred.

b.
Their generic drug alternative is more expensive.

c.
Are contracted by ASES.

3.
Specialty drugs contracted by ASES.

Non-Preferred Drugs means:

1.
Branded drugs, except for:

a.
Those that have no generic drug available and their cost does not exceed a certain limit, in which case they are classified as preferred drug.

b.
Those with a more expensive generic (net cost), in which case they are classified as preferred drug.

c.
Are contracted by ASES, in which case they are classified as preferred drugs.

2.
Generic drugs that their established safety, efficacy, and cost profile (cost-effectiveness) are low compared to their therapeutic alternatives.

3.
Specialty drugs not contracted by ASES.

The Puerto Rico Medicaid State Plan allows charging copayments for preferred and non-preferred drugs.  However, the Medicaid State Plan does not allow charging those copayments in the following instances:

1.
To Medicaid beneficiaries exempted groups of individuals listed in this Cost Sharing (Copayments) Policy under section Beneficiaries Copayments Exemptions

2.
To Medicaid exempted services as described in this Cost Sharing (Copayments) Policy under section Health Care Services Copayments Exemptions, such as contraceptives for family planning services and drugs for cessation of tobacco use.
 
Page 21

3.
For Platino Plans, MAOs will comply with this rule on January 1 st , 2017.

The Puerto Rico Medicaid State Plan requires charging the applicable copayment for preferred drug instead of the non-preferred drug copayment in the following instances:

1.
The beneficiary's prescribing provider determines based on medical necessity that:

a.
A Formulary non-preferred drug can be covered when a Formulary preferred drug for treatment of the same health condition either: (i) is less effective for the beneficiary health condition, (ii) has adverse effects for the beneficiary, or (iii) both.

b.
A non-Formulary drug can be covered when a Formulary preferred or non-preferred drug for treatment of the same health condition either: (i) is less effective for the beneficiary health condition, (ii) has adverse effects for the beneficiary, or (iii) both.

2.
The MCOs and the provider follow the usual pre-authorization procedure to consider these cases.

a.
The exception process is utilized when there is an indication that there is a medically necessary reason to cover a non-preferred drug or non-Formulary drug.

b.
When an exception is requested by the beneficiary, the MCO will do a clinical evaluation to consider and review the justification given by the prescribing provider, beneficiary's medical records, and any other relevant documentation to determine medical necessity based on the following criteria:

(1)
Contraindications to the medication listed in the Formulary.

(2)
History of adverse reactions to the medication listed in the Formulary.

(3)
Therapeutic failure of all available alternatives in the Formulary.

(4)
Non-existence of alternative therapy in the Formulary.

c.
If the documents and information provided supports the exception, the preauthorization is granted.

d.
The beneficiary has the right to file an appeal and request a fair hearing to review the determination that has been notified by the MCO.

3.
If the authorization is granted, the Medicaid Program and ASES have a timely process in place in which the pharmacy only charges to the Medicaid beneficiary the copayment applicable to a preferred drug, which is: $1 to beneficiaries with coverage code 110, $2 with coverage code 120, and $3 with coverage code 130.

Page 22

4.
According with the federal regulation, 42 CFR §447.53(e), the Medicaid Program and ASES certify that in such cases the reimbursement to the pharmacy is based on the appropriate copayment amount.

5.
For Platino Plans, MAOs will comply with this rule on January 1 st , 2017.

In addition to, the Puerto Rico Medicaid State Plan indicates that:

1.
In the event a beneficiary needs a drug or medicine that is not included in Puerto Rico Medicaid Formulary, the MCOs and providers will follow the usual pre-authorization procedure to allow beneficiaries to obtain drugs not included in the Formulary.

2.
The use of bioequivalent medications and drugs approved by the FDA and local regulations is authorized, unless contraindicated for the beneficiary by the physician or dentist who prescribed the medication.

3.
The absence of bioequivalent medications and drugs in stock does not exonerate the pharmacist from dispensing the medication nor does it entail the payment of additional surcharges by beneficiaries.

4.
Brand name drugs will be dispensed if the bioequivalent is not available at the pharmacy.

5.
All prescriptions shall be filled and dispensed at a participating pharmacy properly licensed under the laws of Puerto Rico freely chosen by the beneficiary.

6.
Pharmacies and Dentists are not part of the Preferred Provider Network.

7.
The MCO and/or provider cannot establish a different drug formulary nor limit in any way the drugs and medications included in the Puerto Rico Medicaid Formulary.

The Drugs Formulary is available in any of the Medicaid Local Offices throughout the Island or at ASES Central Office (physical address: #1549 Calle Alda, Urbanización Caribe, Río Piedras, Puerto Rico  00926-2712).  Additionally, the Drugs Formulary can be downloaded, reviewed, and printed from the Medicaid Program website (https://www.medicaid.pr.gov/) or the ASES website (http://www.asespr.org/ or http://ases.pr.gov/).

The Drugs Formulary may be amended to add or remove drugs, as well as to classify a drug as a preferred or non-preferred, at any time according to the ASES' Pharmacy Administrative Committee.  ASES will notify and post such changes through its ASES website.

Each MCO and PBM will post the “Formulario de Medicamentos en Cubierta del Plan de Salud del Gobierno de PR ”, as well as any amendment approved by the ASES' Pharmacy Administrative Committee to add or remove drugs or to classify a drug as a preferred or non-preferred, through its website.

Each MAO has its own drugs formulary that has to be in compliance with Medicare and Medicaid federal regulation.  The Medicaid beneficiaries with a Platino Plan will use the MAO's Drugs Formulary.  The MAO's Drugs Formulary, as well as any amendment, will be posted through the MAO's website.  Pursuant the federal regulation, each MAO must be in compliance with the copayment rules state under the Puerto Rico Medicaid State Plan and this Cost Sharing Policy.

Page 23

Contracts between ASES and MCOs, MAOs, and PBMs include these copayment rules.  MCOs, MAOs, and PBMs are required by contract to make these rules known to beneficiaries, providers, and any other person that provides health care services to the beneficiaries.  Compliance with these copayment rules will be monitored by ASES.

 Five Percent (5%) Limit or Cap Per Quarter on all Copayments

The federal regulation, 42 CFR §447.56(f), provides that Medicaid or CHIP copayments incurred by all eligible beneficiary in his/her Medicaid and CHIP household may not exceed an aggregate limit of five percent (5%) of the household's income applied on a quarterly basis.  The 5% cap on total copayments per quarter is determined on the basis of:

1.
At July 1 st , 2016 and until implementation of MAGI Methodologies for determining Medicaid & CHIP eligibility, the Medicaid Program will continue determining the 5% cap on total copayments per quarter for a beneficiary on the basis of the eligibility monthly income and the number of members in the family unit of the beneficiary.

2.
On and after implementation of MAGI Methodologies for determining Medicaid & CHIP eligibility, the Medicaid Program will determine the 5% cap on total copayments per quarter for a beneficiary on the basis of his/her MAGI Monthly Income and his/her MAGI Household Size.

3.
For example: if a beneficiary Monthly Income is $300 per month, his/her quarterly copayment limit will be $45 ($300 x 3 months = $900 x 5% = $45).

Each beneficiary has his/her own quarters, which are based on the eligibility month.  For example, if the
Medicaid Program determines that the individual is eligible starting in February, he/she's quarters are: February, March, and April (first quarter); May, June, and July (second quarter); August, September and October (third quarter); and November, December, and January (fourth quarter).

Any Medicaid beneficiary can request to the Medicaid Program a reassessment of his/her aggregate limit of 5 percent (5%) if he/she has a change in circumstances, such as:

1.
Increase or decrease in income.

2.
Increase or decrease in household size.
 
Page 24

A beneficiary's 5% cap or limit will be reached, if copayments paid in a quarter by his/her family unit or MAGI household members who are Medicaid and CHIP are summed together and the result exceeds the calculated 5% cap amount per quarter.

The New Cost Sharing Structure does not place beneficiaries at risk of reaching the copayment aggregate limit of 5% per quarter of the family unit or MAGI household income applied on a quarterly basis.  The Medicaid Program and ASES have a "Process for Requesting Reimbursement of Excess Cost Sharing Payments" for individuals that believe they have incurred cost sharing over the aggregate limit for a quarterly cap period, which includes an explanation of his/her right to appeal any decision and request a fair hearing.

If, over the course of a period of Medicaid or CHIP eligibility, a Medicaid or CHIP beneficiary believes that copayments in a quarter have been paid in excess of the 5% cap, he/she can submit a Cost Sharing Reimbursement Request, which will be evaluated by ASES.  The Process for Requesting Reimbursement of Excess Cost Sharing Payments establishes that:

1.
The reimbursement requests must be submitted no later than two (2) calendar months after the end of the quarter.

2.
Reimbursement requests must include all minimum mandatory information, as instructed on the reimbursement request form, and can be submitted:

a.
In person: at ASES Central Office (physical address: #1549 Calle Alda, Urbanización Caribe, Río Piedras, Puerto Rico 00926-2712) or in any of the Medicaid Local Offices throughout the Island;

b.
By mail, to following postal address: ASES Client Services, PO Box 195661, San Juan, PR, 00919-5661; or

c.
By Facsimile (Fax), to ASES Fax number: 787-474-3347.

3.
ASES will conduct an investigation to evaluate reimbursement requests which will be completed no later than four (4) months from the end of the quarter for which the reimbursement request is made.  The results of the investigation of any reimbursement request will be notified to the beneficiary no later than fifteen (15) calendar days from the limit date for the investigation.  ASES will send a written communication to the beneficiary explaining the results of the reimbursement process investigation, and:

a.
If the amount to be reimbursed is five dollars ($5) or more, ASES will issue a reimbursement and will send a written communication to the beneficiary explaining the results of the reimbursement process investigation.

b.
If the amount to be reimbursed is less than five dollars ($5), the amount will be kept as a credit for a two
(2) years period and can be added to the result of reimbursement request for another quarter.
 
Page 25

4.
The individual has the right to file an appeal and request a fair hearing to review the determination that has been notified by ASES.  The appeal must be presented in writing and within a period of thirty (30) days, counting from the date of the ASES' notice.  The appeal may be submitted:

a.
In person: at the ASES Central Office (physical address: #1549 Calle Alda, Urbanización Caribe, Río Piedras, Puerto Rico, 00926-2712);

b.
By mail, to following postal address: ASES Client Services, PO Box 195661, San Juan, PR, 00919-5661; or

c.
By Facsimile (Fax), to ASES Fax number: 787-474-3347.

5.
The determination will be final if the individual does not appeal within the term of thirty (30) days.

The "Process for Requesting Reimbursement of Excess Cost Sharing Payments" and the reimbursement request form (in English or Spanish) are available in any of the Medicaid Local Offices throughout the Island or at the ASES Central Office (physical address: #1549 Calle Alda, Urbanización Caribe, Río Piedras, Puerto Rico  00926-2712).  These documents can also be downloaded, reviewed, and printed from the Medicaid Program website (https://www.medicaid.pr.gov/) or the ASES website (http://www.asespr.org/ or http://ases.pr.gov/).

 The Consequences for a Beneficiary Who Does Not Pay a Cost Sharing Charge

A Medicaid beneficiary is expected to pay a copayment at the time of receiving the health care service.  Therefore, the provider may request and collect the copayment amount each time a beneficiary receives a service.

A beneficiary does not have to pay copayments for any service provided by a provider participating in the Preferred Provider Network.  The MCO’s (MAO for a Platino Plan) contracts with a provider who is a member of the Preferred Provider Network shall prohibit the provider from collecting copayments from Medicaid beneficiary.

The Medicaid beneficiary, who chooses a provider from MCO's General Network of Providers (MAO for a Platino Plan) and with coverage code 110, 120 or 130, is subject to the applicable copayments amount.

Pursuant the federal regulation, 42 CFR §447.52(e), the Puerto Rico Medicaid State Plan dispone:

1.
Beneficiaries with an eligibility monthly income at or below 100 percent (100%) of the PRPL:

a.
When copayment charge is allowed or the beneficiary is not part of an otherwise exempt group, the provider, including a pharmacy or dentist, may request the applicable copayment amount, but cannot not deny services to a beneficiary on account of the his/her inability to pay the copayment amount at the time of receiving a service.
 
Page 26

b.
The beneficiary will receive the health care service without paying the cost sharing at the time of receiving the service.

c.
Although services may not be denied, the beneficiary is still obligated to pay the cost sharing unless it is waived by the provider.

d.
If the copayment is not waived, the provider may ask the beneficiary for outstanding copayments amount the next time the beneficiary comes in for a service and/or send a bill to the beneficiary.

e.
In these cases, a hospital can charge the applicable copayment for non-emergency services furnished in its emergency room, if the conditions under 42 CFR 447.54(d) and the copayment rules for this service have been satisfied.

f.
Nothing prohibits a provider from choosing to reduce or to waive the copayment on a case-by-case basis.

g.
Medicaid beneficiaries identified by coverage code 100:

(1)
Prior MAGI Implementation and as illustrate on Table VII, all Medicaid beneficiaries identified by coverage code 100 have an Eligibility Monthly Income unit below 100% of the PRPL.

(2)
On and After MAGI Implementation and as illustrate on Table VIII, all Medicaid beneficiaries identified by coverage code 100 have a MAGI household monthly income below 100% of the PRPL.

h.
Medicaid beneficiaries identified by coverage code 110:

(1)
Prior MAGI Implementation and as illustrate on Table VII, there are some Medicaid beneficiaries identified by coverage code 110 have an Eligibility Monthly Income at or below 100% of the PRPL.

(2)
On and After MAGI Implementation and as illustrate on Table VIII, all Medicaid beneficiaries identified by coverage code 110 have a MAGI household monthly income at or below 100% of the PRPL.

2.
Beneficiaries with MAGI household monthly income above 100 percent (100%) of the PRPL:

a.
When copayment charge is allowed or the beneficiary is not part of an otherwise exempt group, the provider, including a pharmacy and a dentist, may request the applicable copayment amount as a condition for receiving the service.

b.
In these cases, a hospital can charge the applicable copayment for non-emergency services furnished in its emergency room, if the conditions under 42 CFR 447.54(d) and the copayment rules for this service have been satisfied.
 
Page 27

c.
Nothing prohibits a provider from choosing to reduce or to waive the copayment on a case-by-case basis.

d.
Medicaid beneficiaries identified by coverage code 110: Prior MAGI Implementation and as illustrate on Table VII, there are some Medicaid beneficiaries identified by coverage code 110 have an Eligibility Monthly Income above 100% of the PRPL.

e.
Medicaid beneficiaries identified by coverage code 120 or 130: On and After MAGI Implementation and as illustrate on Table VIII, all Medicaid beneficiaries identified by coverage code 120 or 130 have a MAGI household monthly income above 100% of the PRPL.

3.
The following tables show Puerto Rico Poverty Level (PRPL) for Medicaid and CHIP and the coverage codes:

a.
Table VII: Puerto Rico Poverty Level (PRPL) Prior MAGI Implementation.

b.
Table VIII: Puerto Rico Poverty Level (PRPL) On and After MAGI Implementation.

TABLE VII
 
 
Puerto Rico Poverty Level (PRPL) Prior MAGI Implementation
Member in
Family Unit
Puerto Rico Poverty Level (PRPL)
Eligibility Monthly Income Ranges by Coverage Codes
At or Below 100% of the PRPL
Above 100% of the PRPL
100
110
Ranges Above 100% PRPL
110
1
$0-$413.53
$0-$200
$201-$413.53
$413.54-UP
$413.54-$550
2
$0-$488.72
$0-$248
$249-$488.72
$488.73-UP
$488.73-$650
3
$0-$563.91
$0-$295
$296-$563.91
$563.92-UP
$563.92-$750
4
$0-$639.10
$0-$343
$344-$639.10
$639.11-UP
$639.11-$850
5
$0-$714.29
$0-$390
$391-$714.29P
$714.30-UP
$714.30-$950
6
$0-$789.47
$0-$438
$439-$789.47
$789.48-UP
$789.48-$1,050
7
$0-$864.66
$0-$485
$486-$864.66
$864.67-UP
$864.67-$1,150
8
$0-$939.85
$0-$533
$534-$939.85
$939.86-UP
$939.86-$1,250
9
$0-$1,015.04
$0-$580
$581-$1,015.04
$1,015.05-UP
$1,015.05-$1,350
10
$0-$1,090.23
$0-$628
$629-$1,090.23
$1,090.24-UP
$1,090.24-$1,450
11
$0-$1,165.41
$0-$675
$676-$1,165.41
$1,165.42-UP
$1,165.42-$1,550
12
$0-$1,240.60
$0-$723
$724-$1,240.60
$1,240.61-UP
$1,240.61-$1,650
13
$0-$1,315.79
$0-$770
$771-$1,315.79
$1,315.79-UP
$1,315.79-$1,750
14
$0-$1,390.98
$0-$818
$819-$1,390.98
$1,390.98-UP
$1,390.98-$1,850
15
$0-$1,466.17
$0-$865
$866-$1,466.17
$1,466.17-UP
$1,466.17-$1,950
 
Page 28

  TABLE VIII
Puerto Rico Poverty Level (PRPL) To Be Effective Implemented On and After MAGI Implementation
MAGI Household
Size
Puerto Rico
Poverty Level
(PRPL)
MAGI Monthly Income Range by Coverage Code
100
110
120
130
At or Below 100% of the PRPL
Above 100% of the PRPL
0%-50%
51%-100%
101%-150%
151%-UP
1
$0-$459
$0-$230
$231-$459
$460-$689
$690-UP
2
$0-$542
$0-$271
$272-$542
$543-$813
$814-UP
3
$0-$626
$0-$313
$314-$626
$627-$939
$940-UP
TABLE VIII
Puerto Rico Poverty Level (PRPL) To Be Effective Implemented On and After MAGI Implementation
MAGI Household
Size
Puerto Rico
Poverty Level
(PRPL)
MAGI Monthly Income Range by Coverage Code
100
110
120
130
At or Below 100% of the PRPL
Above 100% of the PRPL
0%-50%
51%-100%
101%-150%
151%-UP
4
$0-$709
$0-$355
$356-$709
$710-$1,064
$1,065-UP
5
$0-$792
$0-$396
$397-$792
$793-$1,188
$1,189-UP
6
$0-$876
$0-$438
$438-$876
$877-$1,314
$1,315-UP
7
$0-$959
$0-$480
$481-$959
$960-$1,439
$1,440-UP
8
$0-$1,043
$0-$522
$523-$1,043
$1,044-$1,565
$1,566-UP
9
$0-$1,126
$0-$563
$564-$1,126
$1,127-$1,689
$1,690-UP
10
$0-$1,210
$0-$605
$606-$1,210
$1,211-$1,815
$1,816-UP
11
$0-$1,293
$0-$647
$648-$1,293
$1,294-$1,940
$1,941-UP
12
$0-$1,377
$0-$689
$690-$1,377
$1,378-$2,066
$2,067-UP
13
$0-$1,460
$0-$730
$731-$1,460
$1,461-$2,190
$2,191-UP
14
$0-$1,544
$0-$772
$773-$1,544
$1,545-$2,316
$2,317-UP
15
$0-$1,627
$0-$814
$815-$1,627
$1,628-$2,441
$2,442-UP
 
Page 29

 ASES requires that the MCOs, MAOs, and PBMs inform providers whether the copayment for a specific service may be imposed on a beneficiary and whether the provider may require the beneficiary to pay the copayment, as a condition for receiving the service, through an indicator:

1.
In the Eligibility and Enrollment System;

2.
In the Eligibility Verification System; and

3.
On the Beneficiary Identification Card.

Contracts between ASES and MCOs, MAOs, and PBMs include this copayment rule.  MCOs, MAOs, and PBMs are required by contract to make these rules known to beneficiaries, providers, and any other person that provides health care services to the beneficiaries.  Compliance with these copayment rules will be monitored by ASES.

 Mechanisms for Required Cost Sharing Charges and Payments to Providers

The MCOs, MAOs, and PBMs contracted by ASES may impose copayments on beneficiaries up to the amounts specified under the Puerto Rico Medicaid State Plan, and the requirements set forth in 42 CFR 447.50 through 447.57”as presented in this Policy.
 
Page 30

Therefore, the ASES' contract with these entities will provide that any copayment charges the MCO, MAO or PBM impose on Medicaid and CHIP beneficiaries are implemented and administered in accordance with:
 
1.
The Social Security Act (SSA), Sections 1916 and 1916A.

2.
The federal regulation, 42 CFR §§447.50-447.57 (excluding 42 CFR §447.55) of the federal regulation.

3.
The Puerto Rico Medicaid and CHIP State Plans.
El Plan Estatal Medicaid y el de CHIP de Puerto Rico.

4.
Cost Sharing Policy (Copayments) for Medicaid and CHIP Beneficiaries.

5.
The New Cost Sharing (Copayment) Structure for Medicaid and CHIP Beneficiaries.

Payments to MCOs and MAOs:

1.
ASES has contracted with more than one MCO (MAO for a Platino Plan) to deliver the health care services establish under Puerto Rico Medicaid State Plan.

2.
ASES provides assurance that it calculates the payments to MCOs (MAOs for a Platino Plan) to take into account the copayments established under the Medicaid State Plan for beneficiaries or services not exempt from copayment, regardless of whether the MCO (MAO for a Platino Plan) imposes the copayment or the copayment is collected by the providers.

3.
Any MCO, MAO, or PBM contracted by ASES is allowed to impose copayments on beneficiaries up to the amounts specified in this Cost Sharing (Copagos) Policy, but such MCO, MAO, or PBM cannot exceed the copayment amounts established under the Puerto Rico Medicaid State Plan, as shown in this Policy.

4.
Contracts between ASES and MCOs, MAOs, and PBMs shall include this Cost Sharing Policy.

5.
MCOs and PBMs are required by contract:

a.
To make these rules know to beneficiaries and providers.

b.
To comply with this Cost Sharing Policy and the Puerto Rico Medicaid State Plan.

6.
For Platino Plans, MAOs have to be in compliance with this rule on January 1 st , 2017.

7.
ASES will monitor the compliance with this Cost Sharing Policy.
 

 
 
Page 31

Payments to Providers:

1.
Except as provided under federal regulation 42 CFR §§447.56(c)(2) and (c)(3), each MCO must reduce the payment it makes to a provider by the amount of a beneficiary's copayment obligation, regardless of whether the provider has collected the copayment or has waived the copayment.  Where the MCO contracts a provider on a capitated basis, the beneficiary’s copayment obligation is taken into account in calculating capitated rates.

2.
Contracts between ASES and MCOs shall include this Cost Sharing (Copagos) Policy.  ASES will monitor the MCOs compliance with this Cost Sharing Policy's requirement.

3.
Contracts between ASES and MCOs and providers shall include this Cost Sharing Policy.  MCOs will monitor the providers' compliance with this Cost Sharing Policy's requirement.

4.
For Platino Plans, MAOs have to be in compliance with this rule on January 1 st , 2017.  ASES will monitor the MCOs compliance with this Cost Sharing Policy's requirement.


Notice of the Results of Coverage Code and Cost Sharing (Copayments) Determination

The Medicaid or CHIP Beneficiary is notified to his/her coverage code and copayments amount through:

1.
The Medicaid Program notifies the beneficiary the "Results of Cost Sharing Determination" through the MA-10 Form (Notification of Action Taken on Application and/or Recertification), which is provided after a determination or redetermination of eligibility or when the Results of Cost Sharing Determination   is revised.

2.
ASES notifies to the beneficiary the assign coverage code and the copayments amounts through the ID Card, which is provided by the MCO (MAO for a Platino Plan).

Before July 1 st , 2016, each MCO contracted by ASES will send a certification coverage letter to the beneficiary to notify the coverage code assigned by the Medicaid Program and the copayments amount applicable to such code for each service.  The beneficiary will use said letter as his/her ID Card up to his/her eligibility redetermination, when the MCO will issue a new ID Card.  ASES will monitor the MCOs compliance with this Cost Sharing Policy's requirement.

For Platino Plans, the MAOs will implement the New Cost Sharing (Copayments) Structure on January 1 st , 2017.
The MAOs will issue to each beneficiary a new ID Card with the coverage code assigned by the Medicaid Program and copayments amount, as applicable to such code.  The beneficiary will discard the old ID Card and use the new ID Card.  ASES will monitor the MCOs compliance with this Cost Sharing Policy's requirement.

ASES requires that the MCOs, MAOs, and PBMs inform providers whether the copayment for a specific service may be imposed on a beneficiary and whether the provider may require the beneficiary to pay the copayment, as a condition for receiving the service, through an indicator:
 
Page 32

1.
In the Eligibility and Enrollment System;

2.
In the Eligibility Verification System; and

3.
On the Beneficiary Identification Card.

  Right to Appeal Coverage Code and Cost Sharing (Copayments) Determination

The beneficiary is entitled to file an appeal and to request a fair hearing to the Medicaid Program to review the "Results of Cost Sharing Determination" that it is notified through the MA-10 Form (Notification of Action Taken on Application and/or Recertification) when he/she is not in agreement with the decision made in his/her case.

The request for review must be presented in writing and within a period of thirty (30) days, counting from the Certification Date shown on the MA-10.  This request for review can be submitted:

1.
In person: at any Puerto Rico Medicaid Program Local Office throughout the Island;

2.
By mail, to the following postal address: Medicaid Program, Puerto Rico Department of Health, P.O. Box 70184, San Juan, P.R.  00936-8184; or

3.
By Facsimile (Fax) to: (787) 759-8361.

  Access to the Cost Sharing (Copayment) Policy

The Medicaid and CHIP Beneficiaries have access to the New Cost Sharing Structure (Copayments) through the Enrollee Handbook or Guide, which is provided by the MCO (MAO for a Platino Plan).

The Cost Sharing Policy and the Puerto Rico Medicaid SPA for a New Cost Sharing Structure are available in any of the Medicaid Local Offices throughout the Island or at the ASES Central Office (physical address: #1549 Calle Alda, Urbanización Caribe, Río Piedras, Puerto Rico, 00926-2712).  These documents can also be downloaded, reviewed, and printed from the Medicaid Program website (https://www.medicaid.pr.gov/) or the ASES website (http://www.asespr.org/ or http://ases.pr.gov/).

In compliance with the federal regulation, 42 CFR §435.905(b), the Medicaid Program will provided access to this Policy, upon request, to individuals living with disabilities through the provision of auxiliary aids and services at no cost to the individual in accordance with the Americans with Disabilities Act and Section 504 of the Rehabilitation Act.
 
Page 33

Attestation The Medicaid Program and ASES assure that:

1.
They administer the Medicaid and CHIP Cost Sharing (Copagos) Policy in accordance with:

a.
The Social Security Act (SSA), Sections 1916 and 1916A

b.
The federal regulation, 42 CFR §§447.50-447.57 (excluding 42 CFR §447.55) of the federal regulation,

c.
The Puerto Rico Medicaid and CHIP State Plan.

2.
The cost sharing amount established for each service is always less than the amount that is paid for the service.

3.
The contracts with the MCOs, MAOs, and PBMs provide that any copayment charges imposes on Medicaid or CHIP beneficiaries are in accordance with the Puerto Rico Medicaid State Plan and this Cost Sharing (Copayments) Policy.

The Medicaid Program and ASES, as required by the federal regulation (42 CFR 447.57):

1.
Issued a Public Notice, in English and Spanish, to inform the beneficiaries, applicants, providers, and general public of the Cost Sharing SPA that specifies, among other topics:

a.
The copayment amounts for each service by coverage code.

b.
The beneficiaries who are subject to the copayment charges.

c.
The consequences, if any, for a beneficiary who does not pay a copayment amount.

2.
Have provided a reasonable opportunity for stakeholder comments about the Medicaid SPA for the New Cost Sharing Structure.

Effective Date

This Cost Sharing (Copagos) Policy is effective on July 1 st , 2016.

 
Page 34




ENROLLMENT MANUAL
 

Table of Contents
 
TABLE OF CONTENTS
 
   
Page #
I.
INTRODUCTION
5
      
II.
DEFINITIONS
7
      
III.
ELIGIBILITY
16
       
 
1.  ELIGIBILITY CONCEPTS
17
   
1.1 Eligibility Determination
 
   
1.2 MA-10
 
   
1.3 Eligibility Effective Date
 
   
1.4 Certification Date and its Relation with the Effective Date
 
   
1.5 Eligibility Effective Date in the Case of a Newborn
 
       
 
2.  MAGI ELIGIBILITY RULES
19
   
2.1 Transfer of Eligibility Files from Medicaid
 
   
2.2 Medicaid Family Record Changes
 
   
2.3 Medicaid Member Record Changes
 
   
2.4 Eligibility Records Concerning Household
 
   
2.5 Additional Health Insurance Record
 
       
 
3.  MEDICAID/CHIP RETROACTIVE ELIGIBILITY
23
   
3.1 Medicaid or CHIP’s Retroactive Eligibility Effective Date
 
   
3.2 Group of Records for Retroactive Periods
 
       
 
4.TERMINATION OF ELIGIBILITY AND RECERTIFICATION PROCESS
24
       
 
5. ELIGIBILITY PERIOD EXTENSION
23
   
5 .1   Appeals Process for Re-Certification
 
   
5.2 Appealing a Certification
   
5.3 Eligibility Extension Due to Pregnancy
 
       
 
6. ELIGIBILITY PERIOD TERMINATION..
26
       
IV. ENROLLMENT PROCESSES
     
 
7. DATA EXCHANGE
27
       
 
8. VALIDATION PROCESS
28
       
 
9. ENROLLMENT FILES
30
 
 
9.1   Enrollment Files (.sus)
 
   
9.2 Eligibility Files (.ref)
 
   
9.3 Data Export Files (.exp)
 
   
9.4 Rejected Enrollment File (.rjc)
 
 

Table of Contents
 
   
9.5 Eligibility Query File (.query)
 
   
9.6 Eligibility Query Response File (.res)
 
       
 
10. GHIP PLAN BENEFICIARY ENROLLMENT
31
   
10.1 Effective Date of Enrollment
 
   
10.2 Date of Enrollment in the Case of Newborns
 
   
10.3 Date of Re-enrollment of Dependent Children in Pregnancy Status
 
   
10.4 Date of Re-enrollment in Cases of Loss of Eligibility
 
   
10.5 PCP/PMG Change Enrollment Effective Date
 
   
10.6 Changes in Coverage Codes and Enrollment
 
   
10.7 Process Date
 
       
 
11. MEDICARE PLATINO ENROLLMENT PROCESS
32
   
11.1 Eligibility Query Preceding a Medicare Platino Enrollment
 
   
11.2 Transfer of Beneficiaries to Platino Products
 
   
11.3 Effective Date of Medicare Platino Enrollment
 
   
11.4 Recovery of Eligibility and Prospective Enrollment
 
  12. RETROACTIVE ENROLLMENT 34
   
12.1 Retroactive Enrollment for Federal and State Category
 
   
12.2 Retroactive Enrollment for Platino Plans
 
       
 
13. ENROLLMENT RECORD
36
       
 
14. ENROLLMENT RECORD FIELDS
37
       
 
15. REJECTION OF AN ENROLLMENT RECORD
43
       
 
16. REJECTED ENROLLMENTS MANAGEMENT
43
       
 
17. ERROR CODES
43
       
 
18. NEW ERROR CODES UNDER MAGI
44
       
 
19. ERROR CODES TABLE
44
       
 
20. DISENROLLMENT
55
   
20.1 Disenrollment under GHIP and Medicare Platino
 
   
20.2 Effective Date of Disenrollment
 
       
 
21. GHIP PLAN DISENROLLMENT
55
   
21.1 Disenrollment Made by ASES or Medicaid
 
   
21.2 Effective Date of the Programmatic Disenrollment
 
       
 
22. MEDICARE PLATINO DISENROLLMENT
57
   
22.1 Disenrollment by Beneficiary Request
 
   
22.2 Automatic Disenrollment
 
   
22.3 Retroactive Disenrollment
 
       
 
23. UPDATES TO NEW ENROLLMENT AND ENROLLING OMITTED BENEFICIARIE
58
 

Table of Contents
 
 
24. CARRIERS RESPONSIBILITIES IN THE ENROLLMENT PROCESSES
59
       
V. PREMIUM PAYMENT
61
       
 
25 PREMIUM PAYMENTS GENERAL
62
       
 
26. TYPES OF PAYMENT
62
   
26.1 Monthly Payments
 
   
26.2 Prorated Payments
 
   
26.3 Retroactive Payments
 
   
26.4 Prorated-retroactive payment
 
   
26.5 Adjustments
 
   
26.6 Special Adjustments
 
   
26.7 Reasons why ASES will not execute a premium payment
 
   
26.8 EDI 820 Payment File
 
       
VI. SYSPREM: ENROLLMENT IN HISTORICAL DATA
65
       
 
27. ENROLLMENT IN HISTORICAL DATA
65
   
27.1 SYSPREM Functionality
 
   
27.2 Carrier’s Eligibility File
 
   
27.3 Premium Payment for SYSPREM
 
   
27.4 SYSPREM Error Codes
 
 

I. Introduction

 
I.
INTRODUCTION
 
Enrollment Manual
6

I. Introduction

 
I. INTRODUCTION

 
The Puerto Rico Health Insurance Administration, hereinafter known as PRHIA or ASES, is a government corporation created in accordance with the Act No. 72 of September 7, 1993 as amended, also known as the “Puerto Rico Health Insurance Administration Act”. PRHIA is created with the purpose of management, negotiation and contracting of health insurance plans that enable it to obtain, for its beneficiaries, particularly the medically needy, quality hospital and other medical services.

This document constitutes a reference manual, which establishes the requirements in the development of the systems, between the Information Systems Office of PRHIA and the contracted insurers, in the different products according to contract. This includes processes of eligibility, subscription, premium payment.  Any conflicts between this document and the applicable statutes, regulations and guidance from the Centers for Medicare and Medicaid Services (CMS) or Contracts for the Provision of Physical and Behavioral Health Services Under the Government Health Plan Program as between PRHIA and the Managed Medicaid managed care organizations shall be resolved in favor of CMS guidance and such contracts, as amended.

Changes are incorporated as required by CMS for Modified Adjusted Gross Income (MAGI) effective July 1, 2017.
 
Enrollment Manual
7

II Definitions

 
 
II.
DEFINITIONS
 
Enrollment Manual
8

II Definitions

 
II. DEFINITIONS

Adjusted Payment
Reversal of a payment that has been adjudicated during the payment process of a previous premium payment cycle.

ASES
Administración de Seguros de Salud de Puerto Rico (the Puerto Rico Health Insurance Administration (PRHIA), the entity in the Commonwealth responsible for oversight and administration of the Government Health Insurance Plan (GHIP) or its Agent.

Auto-Assignment
The assignment of an Enrollee to a PMG and a PCP by the carrier, normally at the same time that ASES or the carrier auto-enrolls the person in the GHIP.

Auto-Enrollment
The enrollment of a Potential Beneficiary in the GHIP by the carrier's database, in compliance with Article 5 of the Contract between ASES and the carriers, without any action by the Potential Beneficiary .

Beneficiary
A person who is eligible and receives services in the health plan, as established in Section 1.3.1 of the contract between ASES and contracted insurers.

Business Day
Traditional workdays, including Monday, Tuesday, Wednesday, Thursday and Friday.  Puerto Rico Holidays are excluded.

Calendar Days
The seven days of the week.

Capitation
A contractual agreement through which a carrier or provider agrees to provide specified health care services to members for a fixed payment per month.

Carrier
Provides Managed Care Services in an ASES region. It is responsible for contracting with PMG’s, PCP’s and other providers.

Centers for Medicare and Medicaid Services (“CMS”)
The agency within the U.S. Department of Health and Human Services which is responsible for the Medicare, Medicaid and the Children’s Health Insurance Program (CHIP).

Certification
A decision by the Puerto Rico Medicaid Office, that a person is eligible for services under the GHIP because the person is Medicaid Eligible, CHIP Eligible, or a member of the Commonwealth Population.
 
Enrollment Manual
9

II Definitions

 
Certification Date
Date when the Medicaid Office completes a beneficiary’s evaluation of eligibility for healthcare services.

Children's Health Insurance Program (“CHIP”)
The Children’s Health Insurance Program established pursuant to Title XXI of the Social Security Act.

Copayment
A cost-sharing requirement that constitutes a fixed amount paid by the beneficiary to a provider for the provision of medical services covered by the health plan. Copayments are defined by ASES for each of the coverage codes.

Coverage Code
Code assigned by the Puerto Rico Medicaid Office to eligible beneficiaries, according to Federal, CHIP and State indigence criteria. Under GHIP, the coverage code will coincide with the Plan Version.

Daily Run Processes Date
It is the date of the day, when the eligibility process is received, received by the Medicaid Office and the subscriptions submitted by the contracted insurers. These processes are performed in the Office of Information Systems.

Deemed newborns
Are children born to a mother with Medicaid eligibility.

Disenrollment
The termination of an individual’s enrollment in the GHIP or carrier’s plan.

Dual Eligible Beneficiary
An Enrollee or potential enrollee eligible for both Medicaid and Medicare.

Effective Date of Disenrollment
The date on which an Enrollee ceases to be covered under the carrier’s plan.

Effective Date of Eligibility
The date of eligibility of the beneficiary in the GHIP, described in the contract established with the corresponding insurer.

Enrollment Effective Date
The date when you subscribe to the eligible beneficiary in the contracted insurer's database.

PCP Effective Date
Date on which a PCP1 or PCP2 change becomes effective.

Recertification Effective Date
Date the Medicaid Office reevaluates the eligibility of the beneficiary.
 
Enrollment Manual
10

II Definitions

 
Eligibility
Eligibility is determined by the Medicaid Office of the Puerto Rico Department of Health except for populations covered under code 400.

Eligible Person
A person who meets the requirements and standards established by the Medicaid Office to be eligible for the GHIP. Eligibility for populations covered under code 400 are not determined by the Medicaid Office of the Puerto Rico Department of Health.

Enrollee
A person who is eligible and is enrolled in the GHIP.

Enrollment
The process by which an eligible person becomes an Enrollee.

Federal Category
Classification established by the Medicaid Office of the Puerto Rico Department of Health for a beneficiary, according to established criteria of indigence levels.

Government Health Insurance Plan (GHIP)
The Government Health Services Program (also known as “La Reforma” or “Mi Salud”) offered by the Government of Puerto Rico, and administered by ASES, which serves mixed population of Medicaid Eligible, CHIP Eligible, and other Eligible Persons, and emphasizes integrated delivery of physical and behavioral health services.

Health Insurance Claim Number (HICN)
I s a Medicare beneficiary’s identification number, appears in the beneficiary's insurance card. All Medicare beneficiary claims are processed according to this number.

Identification Card (ID)
A card bearing an Enrollee’s name, contract number, and co-payment amounts, and a customer service telephone number, which is used to identify the Enrollee in connection with the provision of services.

Managed Care Organization (MCO)
An entity that is organized for the purpose of providing health care and is licensed as an insurer by Puerto Rico Commissioner of Insurance (“PRICO”), which contracts with ASES for provision of Coverage Services and Benefits in designated Service Regions on the basis of PMPM Payments, under the GHIP.

MA-10
Form issued by the Puerto Rico Medicaid Office, entitled “Notice of Action Taken or Application and/or Recertification” containing the Certification decision (whether a person was determined eligible or ineligible for Medicaid, CHIP, or the Commonwealth Population).

MAGI
Modified Adjusted Gross Income is a method that is used to standardize the way in which income is calculated to determine Medicaid/CHIP eligibility. This new method introduces changes to the real structure of addressing and complying with the specifications established by the Centers for Medicare & Medicaid Services (CMS).
 
Enrollment Manual
11

II Definitions

 
Master Patient Index (MPI)
Master Patient Index. Unique number which identifies a Member in ASES and the Medicaid Office databases.

Medicaid Office
The medical assistance federal/state joint government program established by Title XIX of the Social Security Act.

Medicare
The Federal Program of medical assistance for persons over sixty-five (65) and certain disabled persons under Title XVIII of the Social Security Act.

Medicare Beneficiaries
People older than sixty-five (65) years of age or disabled or people who have end state renal disease (ESRD), who are eligible for Medicare Part A coverage which covers hospital services or Parts A and B, which cover hospital, ambulatory and medical care services.

Medicare Part A
The part of the Medicare program that covers inpatient hospital stays, skilled nursing facilities, home health and hospice care.

Medicare Part B
The part of the Medicare program that covers physician, laboratories, outpatient, and preventive services.

Medicare Part C
The part of the Medicare program that permits Medicare recipients to select coverage among various private insurance plans.

Medicare Part D
The Medicare prescription outpatient drug benefit.

Medicare Platino
A program administered by ASES for Dual Eligible Beneficiaries, in which MCOs or other carriers under contract with ASES function as Part C plans to provide services covered by Medicare, and also to provide a “wrap-around” Benefit of Covered Services and Benefits under the GHIP.

Newborn
For purposes of the agreement, is a child born during the eligibility period of his/her mother to the GHIP.

Participating Provider
All of the healthcare service providers contracted by the carriers to provide healthcare services to the beneficiaries represented by ASES.
 
Enrollment Manual
12

II Definitions


Plan Type
Code 01 to identify members with GHIP and code 02 to identify member with Medicare Platino.

Plan Version
Product identification number that corresponds with the Plan Type. For GHIP, the Plan Version will be the same as the coverage code assigned to the beneficiaries by the Medicaid Office. For Platino Plans, ASES will assign a Plan Version code for each contracted product.

Platino Health Plans
Specific health plans offered by Medicare   Advantage Organizations contracted by ASES that cover beneficiaries with dual eligibility (Medicaid and Medicare Part A and Part B). ASES pays a monthly premium to these insurance companies to cover the differential between Medicaid coverage and Medicare Advantage coverage.

Platino Plan Beneficiaries
Medicaid beneficiaries covered by Medicare Part A and Part B who are 65 years old or older or disabled.  Commonwealth Beneficiaries funded solely through state funds are not eligible to be enrolled in a Platino Plan.

PMPM Premium (“Per Member Per Month” Payment)
The fixed monthly amount that the Contracted Insurer is paid by ASES for each Enrollee to ensure that benefits under this contract are provided. This payment is made regardless of whether the enrollee receives benefits during the period covered by the payment.

Potential Enrollee
A person who has been certified   by the Puerto Rico Medicaid Office as eligible to enroll in the GHIP (whether on the basis of Medicaid Eligibility, CHIP eligibility or eligibility as a member of the Commonwealth Population, but who has not yet enrolled with the Contracted Insurer.

Primary Care Physician (PCP)
A licensed medical doctor (MD) who is a Provider and who, within the scope of practice and in accordance with Puerto Rico Certification and licensure requirements, is responsible for providing all required care to Enrollees.  The PCP is responsible for determining services required by Enrollees, provides continuity of care, and provides Referrals for Enrollees when Medically Necessary.  A PCP may be a general practitioner, family physician, internal medicine physician, obstetrician/gynecologist, or pediatrician.

Primary Medical Group (PMG)
A grouping of associated Primary Care Physicians and other Providers for the delivery of services to GHIP Enrollees using a coordinated care model. PMGs may be organized as Provider care organizations, or as another group of Providers who have contractually agreed to offer a coordinated care model to GHIP Enrollees under the terms of the Contract. This Type of provider is contracted by the Carrier on a PMPM basis.

Process Date
The date on which the beneficiary acquires the cover of services with the contracted insurer.
 
Enrollment Manual
13

II Definitions


Prorated Payment
A back payment that covers a fraction of the month prior to the month in which the premium payment is made.

Provider
Any physician, hospital, facility, or other Health Care Provider who is licensed or otherwise authorized to provide physical or Behavioral Health Services in the jurisdiction in which they are furnished.

Puerto Rico Medicaid Office
The subdivision of the Health Department that conducts eligibility determinations under GHP for Medicaid, CHIP, and the Commonwealth Population.

Re-enrollment
Refers to the process of re-enrollment for a beneficiary of Federal GHIP populations (Medicaid or CHIP), state funded GHIP beneficiaries (Commonwealth), or Platino beneficiaries who have lost eligibility for a period of two (2) months.

Recertification
A determination by the Puerto Rico Medicaid Office that a person previously enrolled in the GHIP is again eligible for services under the GHIP.

Redetermination
The periodic redetermination of eligibility of an individual for Medicaid, CHIP or the Commonwealth Population, conducted by the Puerto Rico Medicaid Office.

Retroactive Payment
Refers to a payment that corresponds to a period prior to the month in which the premium payment is made.

Retroactivity
Identifying a premium payment that corresponds to a period prior to the current one.

Special PMG
The assignment of a PMG (“Primary Medical Group”) to a beneficiary who does not belong with the PMG assigned to his family.

State/Commonwealth Population: A group eligible to participate in the GHIP as well as other eligible individuals, who do not receive federal coverage, made up by low income people and other groups listed in Section 1.3.1.2 of the contract between ASES and carriers.

Suspension of Healthcare Services
The culmination of the eligibility period allowed by the Medicaid Office.
 
Enrollment Manual
14

II Definitions


SYSPREM
System that provides for the enrollment of a beneficiary in historical data. It allows the update and/or enrollment of data that corresponds to eligibility periods prior to the cancellation period of the eligibility of a beneficiary or before an enrollment to a different carrier comes into effect.
 

Enrollment Manual
15

III. Eligibility

 
III.
ELIGIBILITY
Enrollment Manual
16

III. Eligibility


1. ELIGIBILITY CONCEPTS

1.1 Eligibility Determination

 The Medicaid Office, which administers the Puerto Rico Medical Assistance Program, is the body with authority to determine whether a person is eligible to receive medical services under the GHIP, either in the federal category (Medicaid and CHIP) or in the Commonwealth Population. This includes certification of beneficiaries with Medicare Platino coverage.

 The eligibility criteria for the beneficiaries are set by CMS requirements, including their level of indigence. In Medicare Platino, the age of the applicant (aged 65 or older) or the disability status as mentioned in Title XVIII of the Social Security Act is considered.

Medicaid, CHIP and state funded Commonwealth beneficiaries are annually certified for an eligibility period of twelve (12) months.   The Medicare or Medicaid eligibility period may be less than twelve (12) months in situations where:  the beneficiary notifies that his/her circumstances have changed and adversely affect his/her eligibility, persons with medical expenses fail to qualify under the "spend down" method, deceased or incarcerated persons, or others as determined by the Medicaid Office. Children identified as Deemed Newborn are certified until thirteen (13) months of age.

1.2 MA-10

The eligibility determination of the Puerto Rico Medicaid Office granted to an applicant for the GHIP or Medicare Platino is contained in Form MA-10, and is provided to the beneficiary on the day he/she is certified.

The beneficiary will continue to receive coverage for services based on the day they were certified by the Medicaid Office, as written on the Form MA-10, until the day they receive their health insurance card by regular mail. The MA-10 form may be used for a period of 30 days from the date of certification for the purpose of demonstrating eligibility and receiving services without an identification card issued by an MCO.

We will have two (2) MA-10 models in force. The current (rev. 10/2015): These are the MA-10 forms that were issued between July 1, 2016 and June 30, 2017, which will continue to be valid until the beneficiary is re-evaluated and recertified following the rules of MAGI. The new (Rev. 6/2017): These are the MA-10 forms that will be issued after July 1, 2017, after the applicant or beneficiary has been evaluated or recertified following the MAGI rules.
 
Enrollment Manual
17

III. Eligibility


1.3   Eligibility Effective Date

The Effective Date for purposes of a Medicaid or CHIP Enrollee is the first of the month in which the Medicaid Office determines eligibility.  This should be the same date indicated as the period of eligibility on the MA-10 form. For purposes of a state funded Commonwealth beneficiary, it is the Date of Certification.

When a re-certification is filed, and the person is again eligible for Medicaid/CHIP, the eligibility date is generally the 1st of the month after eligibility expires.  However, if the Enrollee’s eligibility was lost for less than two (2) months, enrollment should be effective as of the eligibility period specified on the MA-10, and the person should be automatically enrolled in its previous PCP/PMG.

A person may apply for Medicaid/CHIP on behalf of a person who has died in the same month in which they apply or up to three months retroactively in the event the person would have been eligible in those months. The eligibility period will be from the first (1st) day of the month of the application until the date of death. This provision does not apply to state funded Commonwealth beneficiaries.

All pregnant women under both federal Medicaid/CHIP and State-funded) may have a period of eligibility greater than twelve 12 months when adding the required 60 days of postpartum coverage. The expiration date will be the last day of the month at the end of these 60 days.

Retroactivity on the effective date is granted when the applicant indicates that he/she has medical expenses prior to the effective date, including any Medicaid-covered service that has not been paid for. The effective date will be within three (3) months before the month in which the Enrollee is applying. If the applicant is Medicaid or CHIP eligible in the month in which the service was eligible, the applicant will be granted retroactivity. This retroactive benefit does not apply to eligible state category.

In a recertification for state funded Commonwealth beneficiaries in which the person is eligible again, the effective date is the first day of the month after the current eligibility expires.

The date of certification for state category will be when the evaluation is completed.

No retroactive eligibility is contemplated in the state funded category for Commonwealth beneficiaries.
 
Enrollment Manual
18

III. Eligibility


1.4 Certification Date and its Relation with the Effective Date

The date when the Medicaid Office issued an eligibility determination is known as the Certification Date. In the state funded category for Commonwealth beneficiaries, the Effective Date will always coincide with the Date of Certification and would mark the beginning of the eligibility period granted to the beneficiary. In the Medicaid/CHIP category, the Effective Date will be the first day of the month in which the beneficiary was certified by the Medicaid Office. In both cases, the Certification Date is provided on Form MA-10.

1.5 Eligibility Effective Date in the Case of a Newborn

The eligibility to be granted to the child is the same as the mother’s at the time of birth. A newborn born to a mother who is a Medicaid Enrollee shall have an Eligibility Effective Date of the date of birth. In the event that the mother is retroactively eligible as a federal Medicaid beneficiary at the time of the newborn’s birth, the newborn’s eligibility shall also have an Eligibility Effective Date retroactive to the date of birth.  All federally eligible newborns are auto-enrolled into the program and provided coverage from the date of birth. 1 If the mother was a state funded Commonwealth beneficiary, the Eligibility Effective Date of the newborn shall be the Certification Date.

2. MAGI ELIGIBILITY RECORDS CHANGES

2.1 Transfer of Eligibility Files from Medicaid

Once eligibility processes are completed by the Medicaid Office, the data of certified beneficiaries are received via FTP Server by ASES, where ASES, in turn, completes a daily process of updating the data received in their systems.

ASES - "ASSIST" systems and Office of Medicaid - "MEDITI" systems currently handle eligibility using the concept of FAMILY. For this purpose, they will be kept in the same concept, in that each FAMILY will consist of a single member and the suffix "01", a constant that will remain in each register of the member. The FAMILY code will become the last 11 digits of the MPI number.



1 See Sections 5.2.2.2 and 5.2.6.2 of the GHIP Contract.
 
Enrollment Manual
19

III. Eligibility


As of the date of change to MAGI, ASES will convert the data from January 2010 to the present. Data prior to 2010 will be archived. This will be the definition:

RECORD TYPE
CODE
A Family Record
(F)- Required
A Member Record
(M)-Required
A Household Record (A group of related members)
(O)-Required
One or several additional insurance records.
(I)- If applicable
One or several  Spend-Down Records
(S)- If applicable

2.2 Medicaid Family Record Changes since July 1 st , 2017

There will be fields that will not be used. These are labeled in the layout specification for the file and will remain as zeros or spaces. There will be a family register per group. See the changes below in the family log design.
 
FIELD
DESCRIPTION
Record_type
It is labeled with the letter “F” in the Record_type column .
Family Code
The last 11 digits of the MPI Number will be included in the family code column.
Tran_id
New values (‘1’, ‘2’, ‘3’) were added to the Tran_id column to identify retroactive eligibility periods. This will be explained further below, in the MAGI Retroactive Eligibility Period Section.
Contact last name 1
P aternal surname of the contact person. Required .
Contact last name 2
M aternal surname of the contact person. Required.
Contact first name
F irst name of the contact person. Required.
Residence-zip
Postal zone of the physical address. Required .
Residence-zip4
Additional digits for the postal zone.
PCT-of-poverty-level
This field will not be used. It must be filled with zeroes.
Deductible-level-code
This field will not be used. It must be filled with zeroes.
ELA_errors
This field will not be used. It must be fill with zeroes.
Mancomunado
This field will not be used. It must be fill with zeroes.
Application Number [new field]
 This number corresponds to a unique number, linked to the way people fill out in the Medicaid Office, when they request the GHIP or when a recertification occurs. This number changes each time the "Family" group is to be re-certified.
 
Enrollment Manual
20

III. Eligibility


2.3 Medicaid Member Record Changes since July 1 st , 2017

There is a member record per group. There are many fields in this record that will no longer be in use. These are labeled in the layout specification for the file and will remain as zeroes or spaces. See changes below to the member record layout.

FIELD
DESCRIPTION
Record Type
 This record is identified with the letter "M" in this column.
Member suffix
The content of the Member suffix column will always be “01”.
Tran_id
New values (‘1’, ‘2’, ‘3’) were added to the Tran_id column to identify retroactive eligibility periods. This will be explained further below.
Contact Member
New field. The MPI number of the contact member will be included in this field. If the contact person or guardian does not belong to the medically indigent population, Medicaid will assign him/her a number. This field is tied to the contact name in the family record.
Relationship
This field will not be used. Its content will consist of zeroes or spaces.
Place-of-Birth
This field will not be used. Its content will consist of zeroes or spaces.
Category
This field will not be used. Its content will consist of zeroes or spaces.
Category-2
This field will not be used. Its content will consist of zeroes or spaces.
Condition
This field will not be used. Its content will consist of zeroes or spaces.
Med-ins-code
This field will not be used. Its content will consist of zeroes or spaces.
Policy
This field will not be used. Its content will consist of zeroes or spaces.
Class
This field will not be used. Its content will consist of zeroes or spaces.
Class-2
This field will not be used. Its content will consist of zeroes or spaces.
Denial-cat
This field will not be used. Its content will consist of zeroes or spaces.
Denial-cat 2
This field will not be used. Its content will consist of zeroes or spaces.
Pilot-cat
This field will not be used. Its content will consist of zeroes or spaces.
Pilot-class
This field will not be used. Its content will consist of zeroes or spaces.
Pilot-denial
This field will not be used. Its content will consist of zeroes or spaces.
Cost-Sharing Flag
New Field.  The accepted values are:
N = No exception,
C = Child,
P =  Pregnant,
A = American Indian,
I =   Institutionalized,
H = Hospice.  For the moment, this piece of information will remain informational in nature.
Max-copay
New field. This is the maximum co-pay amount that a beneficiary can pay within a given period. For the moment, this piece of information will remain informational in nature.
Extension-Flag
New field. Its content will be:
N = Not undergoing an appeals process
A = Currently undergoing an appeals process
U = Close of the appeal
P = Extension due to pregnancy
X = Extension due to other reasons
The appeals process will be explained further below (See Section 8.1).
Spend Down Flag
New field. This field indicates whether or not “S” (“Spend-down”) records are included. If it does not contain this type of record, this field will show the letter “N”. If it does contain this type of record, it will show the letter “S”.
 
Enrollment Manual
21

III. Eligibility


2.4. Eligibility Records Concerning Household, new record since July 1 st , 2017
A Household record will be included in each group of records. It contains all the MPI’s related to the member at the time that his/her eligibility is evaluated. See changes below to the household record layout.

FIELD
DESCRIPTION
Record_type
It is labeled with the letter “O”.
Tran_id
This field will have the same content as the Family and Member records.
Process_date
Will have the same date contained in the Family and Member records.
MPI_1 al MPI_18
These are the MPIs of each member related to the member in the Member_id field at the time during which the eligibility evaluation is being carried out at Medicaid ’s Offices.
 
Enrollment Manual
22

III. Eligibility


2.5 Additional Health Insurance Record ( Insurance Record )
There can be more than one additional health insurance record in the group. See changes below to the additional health insurance record layout.

FIELD
DESCRIPTION
Record_type
It is labeled with the letter “I”.
Tran_id
New values (‘1’, ‘2’, ‘3’) were added to the Tran_id column to identify retroactive eligibility periods. This will be explained further below in Medicaid or CHIP Retroactive Eligibility Record.

NOTE:
The file layouts are in the Appendix 9 for GHIP contract and Appendix K for Platino contract

3. MEDICAID /CHIP’S RETROACTIVE ELIGIBILITY

The new MAGI changes have implications for the treatment of enrollments and payments related to periods of retroactive eligibility under the federal Medicaid and CHIP category. The new rules applicable to this topic are described below.

3.1 Medicaid/CHIP’s Retroactive Eligibility Effective Date

Under Medicaid or CHIP, the Effective Date of the Eligibility for the enrollments that correspond to a retroactive period will be determined month by month. Each retroactive period or record shall correspond to one (1) calendar month. The Medicaid Office may grant up to four (4) eligibility periods for the same beneficiary which may be comprised of three (3) retroactive periods and one (1) record for the current period. Each record of retroactivity will mark the beginning and end of the eligibility in relation to the period to which it corresponds. That is, each of the retroactive periods of eligibility granted will determine the start and completion of the Eligibility Effective Date for that particular period.

3.2 Group of Records for Retroactive Periods – if applicable.

Each retroactive eligibility period involves a group of records. The beneficiary labeled as Federal (Medicaid, CHIP) could have one (1) to three (3) retroactive eligibility periods. Each retroactivity period runs from the first day of the month until the last. Each retroactivity period is evaluated separately. Therefore, there can be a change in coverage from one period to the next.

The evaluation of the retroactive eligibility period is independent from that of the current period. A member can have retroactive eligibility periods and not be currently eligible.
 
Enrollment Manual
23

III. Eligibility


Retroactive eligibility periods will be confirmed and sent to insurance carriers in the daily eligibility file (.exp). Each period will have a group of records labeled with the ‘1’, ‘2’, ‘3’ indicators in the Tran_id column. The indicators are unrelated to the order of the periods; they are only used to unify the group of records.

ASES could receive, for a single member, up to three (3) retroactive eligibility enrollment records and one (1) current eligibility enrollment record in an enrollments file. A member may be eligible for one (1) to three (3) retroactive periods and not be eligible for the current term. In this case, sets of records for the retroactive periods may be received but none for the current eligibility period. Retroactive eligibility period will be from the first day of the month of retroactive eligibility until the last day of the month of retroactivity.
 
4. TERMINATION OF ELIGIBILITY AND RECERTIFICATION PROCESS

After a period of eligibility is granted to a beneficiary, a Recertification Process will be initiated whereby a new eligibility evaluation will be carried out, which will allow the renewal of the health services for the corresponding period. The Re-certification Effective Date refers to the date Medicaid re-evaluates a beneficiary's eligibility. This date is provided on the MA-10 form. The Eligibility Expiration Date refers to the expiration date of the eligibility period granted to the beneficiary by the Medicaid Office

A federal beneficiary of the GHIP (Medicaid or CHIP), or a beneficiary of the GHIP whose coverage is funded solely through state funds (Commonwealth) who, as a result of a Recertification Process, receives a negative eligibility determination for GHIP, will continue to be eligible to receive services under the GHIP until the date specified in the document titled Negative Redetermination Decision on MA-10 issued by the Puerto Rico Medicaid Office. The cancellation of health services transaction due to the expiration of the eligibility period will be notified by the Medicaid Office and will be reflected in the ASES databases on the last day of each month. Only the Medicaid Office may cancel and provide notice of the cancellation of a beneficiary's eligibility.

5. ELIGIBILITY PERIOD EXTENSION

5.1 Appeals Process for Re-Certification

When a beneficiary does not qualify during his/her re-certification process, he/she has the right to appeal his/her eligibility within a term of fifteen (15) days. If a previously eligible Medicaid or CHIP member appeals within fifteen (15) days of an adverse eligibility determination, content “A” or “X” will be sent to the insurance carrier in the Extension_flag field. The member may not be cancelled during the appeals process even if the expiration date passes. When the appeals process is completed, Medicaid will send an update of the member’s status to ASES. If the appeal is presented after the first fifteen (15) days after the adverse eligibility determination, no extension will be issued. In this case, a cancellation will be received from Medicaid at the end of eligibility period or fifteen (15) days after the evaluation for disenrollment exceptions.
 
Enrollment Manual
24

III. Eligibility


(1) If the appeal finds in favor of the beneficiary: the expiration date will be updated to the appropriate one. He/she will be identified as eligible and the termination of the appeals process will be labeled with a “U” and a new eligibility period. If there were to be a change in coverage, a new enrollment with the new coverage must be sent, just as is currently done.

(2) If the appeal finds against the beneficiary: the Medicaid Office will send a cancellation with the original expiration date. He/she will be identified as ineligible and the termination of the appeals process will be labeled with a “U”. The insurance carrier will keep offering services to the beneficiary until it receives the cancellation in the eligibility file sent by ASES. ASES will continue paying premiums until the cancellation is received from Medicaid Office. Only Medicaid Office may cancel a beneficiary. The cancellation’s effective date will reflect the date in which ASES receives said cancellation.

(3) If the appeal is resolved only after a cancellation, the insurance carrier will receive the eligibility information only if the appeal is in favor of the beneficiary and with updated dates with the new eligibility period.

5.2 Appealing a Certification (either new or not active at the time)

If a person who is not active in the Medicaid Program requests eligibility and he/she does not qualify, he/she has the right to appeal the result of the evaluation. This type of appeal is an internal Medicaid Office process. The Medicaid Office will not send to ASES records of these processes unless the appeal is decided in the person’s favor. In the case of Medicaid or CHIP eligible beneficiaries, a group of records will arrive with an effective date that may be retroactive to the first day of the month corresponding to the certification date. If the beneficiary has used medical services, the insurance carrier will treat the enrollment as an emergency ( special enroll = ‘E’), since the retroactivity could go back more than three (3) months. In the event the person is certified as a state funded Commonwealth beneficiary, the date of eligibility after a favorable appeal shall be prospective from the date of the favorable determination.

5.3 Eligibility Extension Due to Pregnancy
 
If a pregnant woman is undergoing re-certification and she is determined to be ineligible, she cannot be terminated until sixty (60) days after the date on which she gives birth or loses the fetus.   These cases will be labeled with the letter “P” in the Extension flag field. The Medicaid Office will send ASES cancellation at the appropriate point.
 
Enrollment Manual
25

III. Eligibility


Important Note:
Neither ASES nor insurance carriers may cancel a beneficiary until Medicaid Office sends a cancellation, even if the expiration date has already passed.

6. ELIGIBILITY PERIOD TERMINATION

In those cases where it is determined that a beneficiary of the GHIP is no longer eligible to continue receiving services after a Recertification Process has been performed by the Medicaid Office, the beneficiary will maintain his or her eligibility until the date specified in the document entitled Negative Redetermination on MA-10 issued by the Puerto Rico Medicaid Office.

On a daily basis, ASES receives a file with the eligibility status of the beneficiaries, including the cases in which the eligibility period has ended. In such cases, ASES will send to the carriers the contents of the files of those beneficiaries who have received a Negative Redetermination Decision within a period of twenty-four (24) hours from the time it receives the file from the Medicaid Office.   2


2 See Section 5.1.4 of the GHIP Contract.
Enrollment Manual
26

IV. Enrollments Processes

 
IV.
 ENROLLMENT PROCESSES
 
 
Enrollment Manual
27

IV. Enrollments Processes


 7. DATA EXCHANGE

The eligibility files described in the previous sections are entered into the daily run cycle and are evaluated through an editing and verification program at the Information Systems Office at ASES. After receiving and processing the eligibility data of each beneficiary, ASES creates an electronic record that includes information which the carrier can use to enroll the beneficiary, such as information about the Plan Type [federally funded GHIP (Medicaid and CHIP), state funded GHIP (Commonwealth), or Platino]and Plan Version along with their respective effective dates and other related data elements. ASES sends accepted enrollments, new eligibility, updates and cancellations data to carriers in a file (.exp) that shows the activity generated in a daily manner.

Under the automatic assignment, carriers update their database, assign a Primary Medical Group (PMG) and a Primary Care Physician (PCP) based on the beneficiaries' physical address, and issue the plan identification cards for each beneficiary. These cards are sent to the beneficiaries by postal mail in an approximate period of five (5) days. The beneficiaries, in turn, have ninety (90) days to request a change of the PMG or the PCP, if they so desire. The carrier then produces the electronic enrollment record and submits it to ASES in a file (.sus) that accounts for the enrollments made. 3

Generally, carriers have a twenty-four (24) hour period to remit membership records to ASES. They must notify ASES of the information about the new beneficiaries enrolled and send information about any changes performed on a record previously enrolled. Such notification must be sent on the next business day.

In the case that the carrier has to update the information previously sent to ASES in relation to a new enrollment, or when it is appropriate to add a new beneficiary that has been previously omitted, that update must occur the next business day after the information has been updated or that a new beneficiary has been added. In these cases, ASES reserves the right not to accept new additions or corrections to the enrollment data after sixty (60) calendar days after the Effective Date of the Enrollment indicated in the carrier's notification to ASES. Likewise, the beneficiary’s PMG and/or PCP changes will take effect as stated in Section 13.5. 4

Records that are accepted without changes or modifications during the editing process are updated in the databases at ASES and the beneficiaries are duly enrolled. Enrolled Medicaid and CHIP beneficiaries, beneficiaries of the GHIP funded solely through state funds (Commonwealth), and Platino beneficiaries are those that are listed as eligible in the ASES databases. Any record that is accepted during the editing and verification processes will be stored in the current and historical data tables.
 

3 See Section 5.2.5 of the GHIP Contract.
4 See Section Sec. 5.4.1.3 of the GHIP Contract.
Enrollment Manual
28

IV. Enrollments Processes


The records that are rejected are returned to the carrier with the applicable reject codes in a file (.rjc). The carrier must correct any errors in the enrollment record and send the information back to ASES in a file (.sus) within 24 hours. ASES will only pay the premiums related to those beneficiaries who are enrolled in the databases at ASES. Therefore, the execution of the payment of the corresponding premium for these rejected records will be stopped until they are sent back with the correction of the indicated errors.

The exchange of data regarding eligibility and enrollment processes between the Medicaid Office, ASES and the contracted carriers occurs on a daily basis. In Figure 1, which is provided below, the information exchange processes described in the previous subsections are presented.

Figure 1 ASES Information Flow


This process of information exchange is quite similar in both the GHIP and the Platino Medicare programs with the exception of the need to comply with the additional requirements applicable in the case of the latter. Before a beneficiary of a Platino Plan can be enrolled, the carrier must perform the procedures described later in this document.
 
Enrollment Manual
29

IV. Enrollments Processes

 
8. VALIDATION PROCESS

Carriers are responsible for transmitting enrollment files of their beneficiaries to ASES on a daily basis. For proper processing of the enrollment transactions, carriers must keep the eligibility information of the beneficiaries who are referred to ASES daily updated in their respective databases. To that end, they should use the following conventions related to the file submission process.

9. ENROLLMENT FILES

Definition of the nomenclature of the data files to be exchanged between Medicaid, ASES and carriers

9.1 ENROLLMENT FILE [CCYYMMDD.sus]
a.          CC =    Carrier Code
b.          YY =   Year
c.          MM =  Month
d.          DD =   Day
e.          .SUS = Identifies the file as an enrollment file. The enrollment file may contain records
belonging to any of the regions contracted by the carrier.
Notes:
Files received at 9:00 am are entered in the ASES daily cycle.
If a file is received after 9:00 am, it will be entered in the next day's cycle.

9.2 ELIGIBILITY FILE [VYYMMDD.ref]
a. V = indicates that it is an eligibility file
b. YY =  Year
c. MM = Month
d. DD =  Day
e. .ref = Indicates that it is a file containing the records of the beneficiaries’ eligibility.

9.3 DATA EXPORT FILE [RRCCYYMMDD.exp]
a. RR = region code
b. CC = carrier code
c. YY =  Year
d. MM = Month
e. DD =  Day
f. .exp = Indicates that it is a file containing all the eligibility and enrollment transactions processed during the daily run.
 
Enrollment Manual
30

IV. Enrollments Processes


9.4 REJECTED ENROLLMENTS FILE [*.rjc]
a. CC=   Carrier Code
b. YY =  Year
c. MM = Month
d. DD =  Day
e. .rjc= Indicates that it is a file containing the records of the beneficiaries who have been rejected.
Notes: ASES runs a separate edition and update cycle for each contracted region. Enrollments are filtered through various editing and verification programs and identified as valid or rejected. This process produces a file (.rjc) that contains all the records that are rejected.

9.5 ELIGIBILITY QUERY FILE [CCYYMMDD.qry]
a. CC= Carrier Code
b. YY=Year
c. MM=Month
d. DD=Day
e. .qry =Indicates that is a file for eligibility verification.
Notes: A '.query' file is submitted by the carriers to verify a person's eligibility for the Medicare Platino Plan and the GHIP if necessary. Consequently, ASES generates a response in a '.res' (response) file with the requested information.

9.6 ELIGIBILITY QUERY RESPONSE FILE [CCYYMMDD.res]
a. CC=Carrier Code
b. YY=Year
c. MM=Month
d. DD=Day
e. .res = Indicates that it is a query response file.
Notes: This file is sent by ASES in response to a query file.

10. GHIP BENEFICIARY ENROLLMENT

In order for an enrollment record to be accepted during the editing and validation processes, it is important to take into account the following considerations regarding concepts related to the enrollment processes:

10.1 Effective Date of Enrollment

The Effective Date of an Enrollment refers to the date that a carrier establishes as the beginning of the coverage period for a beneficiary. Generally, this date concurs with the beginning of the eligibility period as defined by the Medicaid Office for the Federal and State categories. For the federal population, this date will be the first of the month in which the beneficiary applied for health services coverage. For the Commonwealth population, this date will be the same as the Certification Date. Also, this date refers to the date on which a change of PMG, PCP or Plan Version will be effective. The Effective Date of the Enrollment of these changes will fall as described in Section 13.5.
 
Enrollment Manual
31

IV. Enrollments Processes


10.2 Date of Enrollment in the Case of Newborns

In newborns, the Effective Date of the Enrollment will be on the day of birth for babies of federal mom and Certification Date for state mom, unless in the newborn evaluation turns to be CHIP. In this case, the newborn could have retroactive periods if there were utilization 5

10.3 Date of Re-enrollment in Cases of Loss of Eligibility

In the cases of re-enrollment of federal beneficiaries (Medicaid and CHIP), state funded Commonwealth beneficiaries, or beneficiaries who have lost eligibility for a period not exceeding two (2) months, the beneficiary will be auto-assigned to the same PMG as previously assigned to.  The Effective Date of the Enrollment will fall on the same eligibility period specified in the MA-10. 6

10.4 PCP/PMG Change Enrollment Effective Date

If an enrollee changes PCP/PMG during the first five (5) days of the month, the change will be effective in the next subsequent month. If an enrollee changes PCP/PMG after the fifth (5th) day of the month, the change will be effective in the second subsequent month of the change. The enrollees can still receive services until the change is effective through the original PCP/PMG assigned by the contractor during the Auto-Enrollment process. 7

10.5 Changes in Coverage Codes and Enrollment
If the coverage code of a GHIP beneficiary changes, the insurer must send a subscription with the new plan version (that is equal to the coverage code) with the effective date of the first day of the next month. For Platino beneficiaries, the insurer must send the plan version corresponding to the product that the beneficiary has. The effective date is also the first day of the next month,

10.6 Process Date

The Process Date has relevance both in cases of new enrollment of a beneficiary and in cases of changes of PMG, PCP or Plan Version in relation to a record of enrollment of a beneficiary. This is a date provided by the carrier that identifies the day on which a new enrollment or a change in the record of a beneficiary's enrollment was processed in its databases. For GHIP beneficiaries, the Process Date must be equal to or before the Effective Date, but after the three (3) months preceding the Effective Date.

In the case of a new enrollment under a Platino Plan, it refers to the date on which the beneficiary contracted the coverage services with the corresponding carrier. In Platino plans, the Process Date must be prior to the Effective Date of the new enrollment or the change in question, but subsequent to the three (3) months prior to the Effective Date of the new enrollment or change.
 

5 See Section 5.2.2.2 of the GHIP Contract.
6 See Section 5.2.2.4 of the GHIP Contract.
7 See Section 5.4.1.4 of the 2015 Contract Amendment.
 
Enrollment Manual
32

IV. Enrollments Processes


11. MEDICARE PLATINO ENROLLMENT PROCESS

ASES is able to employ a variety of methods for the purpose of subscribing persons who are eligible to receive coverage under Medicare Platino plans. This includes enrollment assisted by Platino carriers, enrollment by ASES or a combination of both. The procedure used for the enrollment under the Platino Medicare Program is described in the Appendix F which accompanies the contract entered into between ASES and the Platino carriers 8 . Relevant considerations are highlighted throughout this manual.

11.1 Eligibility Query Preceding a Medicare Platino Enrollment

(1)
Query: through a file (".query"), the carrier requests a verification of a beneficiary’s eligibility for the Medicaid Office.

(2)
Response: ASES processes this query file and sends a response to the request in a file (.res). This file includes information regarding the beneficiary’s eligibility for the Medicaid Office, Medicaid Office specification for which the beneficiary is eligible (federal or local), and the data that identifies the beneficiary in the database, both at Medicaid Office and ASES.

(3)
Platino Product Enrollment: If the beneficiary is eligible for Medicaid coverage and has Medicare Part A and Part B benefits (dual-eligible beneficiary), the carrier will complete an enrollment record that will include data corresponding to the health plan under which the beneficiary is to be enrolled.

(4)
Enrollment Update: Subsequently, ASES will edit and update the data in the electronic enrollment record to identify the individual as a Platino Medicare beneficiary using CMS data file in monthly based. A daily eligibility file is then sent to the carrier that contains the data that shows the beneficiary's enrollment to Medicare Platino.

(5)
Rejected Enrollments: The enrollment records sended by carriers, are evaluated. If the enrolment file contain errors will be returned to the carriers for corresponding corrections.
 

8 See Section 6.1.1 of the Platino Contract.
 
Enrollment Manual
33

IV. Enrollments Processes

 
11.2 Transfer of Beneficiaries to Platino Products

Medicare Advantage beneficiaries who are granted Medicaid coverage may elect to transfer to the Medicare Platino products offered by their preferred carrier or may enroll to Medicare Platino products available to dual eligible individuals. In these cases, the carrier must process a new enrollment for the purpose of transferring the beneficiary of the Medicare Advantage product to Medicare Platino. To the extent possible, such enrollments will be effective on the first day of the month in which the beneficiary's Medicaid coverage is effective. 9

11.3 Effective Date of Medicare Platino Enrollment

The Effective Date for a beneficiary’s Enrollment under a Platino Medicare Plan will fall on the first day of the month in which the name of the beneficiary appears on the CMS Prepaid Premium Plans List and on the first day of the month in which it appears enrolled in the Platino Medicare plan of the carrier in question. 10

11.4 Recovery of Eligibility and Prospective Enrollment

In those cases in which the enrollment of a Platino Medicare beneficiary is canceled due to the loss of eligibility as a Medicaid beneficiary, but recovers that eligibility within a period of two (2) consecutive months, the beneficiary may be enrolled automatically and prospectively under the Platino Medicare plan of the carrier in question. 11

12. RETROACTIVE ENROLLMENT

The retroactive enrollment processes involve the processing of an enrollment in the ASES databases for a period prior to the current eligibility period. It is important to distinguish between the terms granted for the retroactive enrollment processes and the periods of retroactive eligibility granted by the Medicaid Office, as they represent retroactivity in different contexts.
 

9 See Section 6.8.1 of the Platino Contract.
10 See Section 6.4 of the Platino Contract.
11   See Section 6.6.1 of the GHIP Contract.
 
Enrollment Manual
34

IV. Enrollments Processes

12.1 Retroactive Enrollment for Federal and State Category

Under the federal Medicaid and CHIP programs, and the state funded Commonwealth population, this date may be extended retroactively up to three (3) months prior to the date the enrollment is processed at ASES, provided that the period to be enrolled falls within the period of eligibility granted by Medicaid Office.

In the same subscription file, no more than one subscriber may be included for the same member unless it is a subscription for a current eligibility period and one to three subscriptions for retroactive eligibility periods.

The letters “E” or “C” will be included for retroactive eligibility period enrollments, just like in SYSPREM cases. Retroactive period enrollments will be labeled with the letter “T” in the Special_enroll field.

Each enrollment with retroactive eligibility period will be validated against the member’s eligibility history. Therefore, the insurance carrier’s effective date for each enrollment must correspond to the date of each retroactive period in ASES’s member history.

12.2 Retroactive Enrollment for Platino Plans

For Platino plans, the enrollment may be extended retroactively from six (6) to eighteen (18) months prior to the date on which the beneficiary's enrollment is processed at ASES. That is, the Information Systems Office of ASES may accept an enrollment of a beneficiary of the Platino Plan for up to eighteen (18) retroactive months as long as the limits of the period to be enrolled fall within the period of eligibility granted by the Medicaid Office.

For a better understanding of the concept of retroactivity in eligibility and retroactivity in enrollment as discussed in the preceding sections, Table 1 is provided with the applicable periods granted.
 
Enrollment Manual
35

IV. Enrollments Processes

 
Table 1: Retroactivity in Eligibility and Retroactivity in Enrollment

 
PLAN
RETROACTIVITY
 Eligibility
      Enrollment
Yes
No
Yes
No
Federal GHIP
(Medicaid and CHIP)
(Up to Three (3) months)
 
(3)
months
 
State GHIP
(State Population)
 
   
(3)
months
 
Platino
(65 years old, disabled, dual)
(3)
months
 
(6-18)
months
 

13. ENROLLMENT RECORD

The enrollment record that is used by carriers to notify ASES of the enrollment of a beneficiary contains a series of data that are used for the purpose of informing the details of the enrollment made and to verify their accuracy and certainty. A beneficiary can be enrolled in one of two (2) types of plans available:

Table 2: Plan Types

Code
Plan
01
State (Commonwealth Population) y Federal (Medicaid or CHIP).
02
Platino SNP (Special Needs Plan).

Under this diversity of plans, the carriers can offer different products that are identified by their Plan Version number. ASES assigns a Plan Version number for each contracted Platino product. In the cases that fall under any of the GHIP, the Plan Version must be equal to the coverage code assigned to the beneficiaries by the Medicaid Office.

Some of the plans contracted with ASES may require the assignment of Primary Medical Group (PMGs) and/or Primary Care Physicians (PCPs) to beneficiaries by the carriers. The enrollment record includes these fields as well as the Plan Type and Plan Version noted above. The enrollment record also reports the date a beneficiary has been processed by the carrier and the Effective Date of Enrollment.
 
Enrollment Manual
36

IV. Enrollments Processes


14. ENROLLMENT RECORD FIELDS

The record of each beneficiary's enrollment contains the following information that must be provided by the carrier:

1. RECORD_TYPE In every case, and regardless of the transaction in question, this field requires the insertion of code "E" that identifies the entry as an enrollment record for both new enrollments of beneficiaries and changes on records of beneficiaries previously enrolled.

2. TRAN_ID - This field allows the ASES systems to identify the action to take on the record submitted. It can contain one of the values listed below:

a.       E = New Enrollment. This value identifies that the record is a new enrollment for a beneficiary who has not been previously enrolled or that is currently inactive.   It could also imply that this is a retroactive enrollment record for transactions not previously enrolled. For transactions previously enrolled, either by the same or one that is different from the previous enrollment, a "C" would be inserted.

b.      C = Carrier Change. Used when the beneficiary has selected a different carrier than the one in which he/she is presently enrolled. It is also used for initial enrollment in Platino Plans when the beneficiaries were previously enrolled in a GHIP and they opt to change to Platino. It could also identify a retroactive enrollment record in cases that are carried out by a carrier different than that arising from the ASES database or by the same carrier if it has to make a change on a previous enrollment.

c.     P = Changes in the Plan Type. It is used when a member enrolled under a particular carrier changes from a product the carrier offers to one which is identified under a different Plan Type under the same carrier.

d.     V = Plan Version Change. For GHIP carriers, it implies a change from a product the carrier offers to one which is identified under the same Plan Type. This transaction code is also used when a GHIP beneficiary’s coverage code changes. In these cases, the carrier must reissue a health plan ID card displaying the new benefits, and submit a version change enrollment record to ASES where the Version number should be equal to the new coverage code. Failure to submit said information to ASES, will trigger an automatic disenroll of the beneficiary from the carrier that omits the timely submission. While in these circumstances the beneficiary continues being eligible to receive the medical services, the carrier will remain unable to claim a premium payment for said beneficiary until a submission of the required information is performed.

e.     I = PMG (Primary Medical Group) Change. It is used to register, in ASES, a change in the beneficiaries’ selected PMG under the same carrier, Plan Type and Version.
 
Enrollment Manual
37

IV. Enrollments Processes


f.       1 = PCP1 change. It is used to register, in ASES, a change in the beneficiaries’ selected PCP1 under the same carrier, Plan Type, Version and PMG.

g.      2 = PCP2 change. It is used to register, in ASES, a change in the beneficiaries’ selected PCP2 under the same carrier, Plan Type, Version and PMG.

h.      3 = PCP1 and PCP2 change. It is used to register, in ASES, a change in the beneficiaries’ selected PCP1 and PCP2 under the same carrier, Plan Type, Version and PMG.

As we have seen, the content of the Tran_id field determines what type of transaction is going to be executed through the enrollment record sent to ASES. Some of the authorized transactions are broken down below. Table 3 below identifies the information that each change will require and states the fields that will be impacted by each one.

Table 3: Hierarchy Table

TRAN_ID
CARRIER
Plan_Type
VERSION
Primary
Center
PCP1
PCP2
E - New Enrollment
Y
Y
Y
Y
Y
O
C - Change Carrier
Must be different from ASES DB
Y
Y
Y
Y
O
P - Plan Change
Must be the same as in ASES DB
Must be different from ASES DB
Y
Y
Y
O
 V - Version Change
Must be the same as in ASES DB
Must be the same as in ASES DB
Must be different from ASES DB
Y
Y
O
I - Change Primary Medical Group
Must be the same as in ASES DB
Must be the same as in ASES DB
Must be the same as in ASES DB
Must be different from ASES DB
Y
O
1 - Change PCP1
Must be the same as in ASES DB
Must be the same as in ASES DB
Must be the same as in ASES DB
Must be the same as in ASES DB
Y
N
2 - Change PCP2
Must be the same as in ASES DB
Must be the same as in ASES DB
Must be the same as in ASES DB
Must be the same as in ASES DB
N
Y
3 - Change PCP1 & PCP2
Must be the same as in ASES DB
Must be the same as in ASES DB
Must be the same as in ASES DB
Must be the same as in ASES DB
Y
Y
 
Legend:
Y = Information required for the transaction type specified.
O = Optional information.
N = Information that should not be sent for the transaction type specified.
 
Enrollment Manual
38

IV. Enrollments Processes

 
(A) New enrollment ("E"): The system will require all fields related to information about the Carrier, Plan Type, Plan Version, Primary Medical Group and PCP1 to be completed. The PCP2 information will remain as optional information for some cases.

(B) Change of Carrier ("C"): The system will require registering the name of the new carrier and inserting information regarding the Plan Type, Plan Version, Primary Medical Group, PCP1 and PCP2 (optional).

(C) Change of Plan Type ("P"): It will be necessary to insert the same code of the carrier that submits the change with the new information of the Type of Plan that corresponds to the beneficiary. Also, the information of Plan Version, Primary Medical Group and PCP (optional) must be included.

(D) Plan Version Change ("V"): The carrier code and Plan Type information provided must match the information in the ASES databases. Only information regarding the new assigned Plan Version will be provided. Information should also be provided in relation to the Primary Medical Group and PCP1 Center.

(E) Primary Medical Group Change ("I"): Information regarding the Carrier, Plan Type and Plan Version must match the information contained in the ASES databases. Only new information will be sent to ASES regarding the new Primary Medical Group (PMG) that corresponds to the beneficiary.

(F) Change of PCP1 ("1"): It will be necessary that the information of Carrier, Plan Type, Plan Version and Primary Medical Group provided coincide with the information contained in the ASES databases. It will be necessary to submit the new information regarding the change in PCP1 and it will not be necessary to provide information on the PCP2.

(G) Change of PCP2 ("2"): It will not be necessary to provide information about the PCP1. The only information allowed to differ with the one contained in the ASES records will be the one related to the PCP2.

(H) Change of PCP1 and PCP2 ("3"): It will be necessary to submit new information regarding the assigned PCP1 and PCP2. The information provided regarding the other fields should remain unchanged.
 
Enrollment Manual
39

IV. Enrollments Processes


3 . PROCESS_DATE – Process Date. Refers to the date on which the beneficiary contracted the coverage services with the corresponding carrier. It also refers to the date on which the carrier processed a change in PMG, Plan Version, Plan Type or PCP.

4. REGION – Contains the region code assigned by ASES. This code must correspond to the region assigned to the beneficiary in the ASES database. ASES is responsible for assigning this code to Platino carriers. The Platino Plan carriers obtain this code directly from ASES after a request process initiated for these purposes. See Table 4 below for more information about the Region Codes.

Table 4: Region Codes

Region Name
 
Region Codes
Used in the Data
Region Codes
Used for the Filenames
North
A
AR
Metro-North
B
BA
East
E
ES
Northeast
F
FA
San Juan
J
SJ
Southeast
G
GU
Southwest
S
SO
Special
P
PX
West
Z
MA

5. CARRIER – Two digit carrier code assigned by ASES to each of the carriers with the purpose of identification.

6. MEMBER_PRIMARY_CENTER Up to four digits code assigned by carrier to identify their Primary Medical Groups (PMGs). Not required for some Plan Types/Versions.

7. ODSI_FAMILY_ID – Eleven digit family identification code assigned by the Medicaid Office. This is the first part of the identifier for the beneficiaries in the ASES database. Platino carriers obtain this code from the ASES query response.

8. MEMBER_SSN - Social Security number of the member. It is required that this number matches with the one for the member in the ASES database.

9. MEMBER_SUFFIX – Two digit number which identifies a member within a family. This is the second part of the identifier for the beneficiaries in the ASES database.
 
Enrollment Manual
40

IV. Enrollments Processes


10. EFFECTIVE_DATE – Date in which the carriers start providing coverage for the beneficiary under the enrolled Plan or the change for which the enrollment record was submitted becomes effective. For the Federal GHIP population, this date will be on the first of the month that the beneficiary applied for services coverage. For the GHIP population funded solely through state funds, this date will concur with the Certification Date. This date also refers to the date in which the PMG, PCP or Plan Version change becomes effective. For Tran_Id’s other than “E” in GHIP enrollment the Effective Date must be 1 st of the month following the enrollment.

11. PLAN_TYPE – Plan Type code that identifies the one under which the member is enrolled.

12. PLAN_VERSION – Plan version code that identifies the one under which the member is enrolled.

13. MPI - Master Patient Index. It is a unique number that identifies a member in the ASES and Medicaid Office’s databases.

14. PCP1 Fifteen digit number assigned by carriers. It is used to identify the PCP1 selected by the beneficiaries.

15. PCP1_EFFECTIVE_DATE Date in which the PCP1 assignment became effective. If there is a change of PCP1, the initial PCP1 Effective Date will be kept until the Effective Date of the PCP1 Change has been reached .

16. PCP2 Fifteen digit number assigned by carriers. It is used to identify the PCP2 selected by the beneficiaries.

17. PCP2_EFFECTIVE_DATE Date in which the PCP2 assignment was effective. If there is a change of PCP2, the initial PCP2 Effective Date will be kept until the Effective Date of the PCP2 Change has been reached .

18. FAMILY_PRIMARY_CENTER PMG assigned by the carrier to the beneficiary.

19. FAM_PRIMARY_CENTER_EFF_DATE Date in which the assignment of the beneficiary’s PMG became effective.

20. IPA_PCP_CHANGE_REASON Not in use currently.

21. INDICADOR MEDICARE Required for Platino enrollments only. (01=A&B, 03=A, 09=B).

22. NÚMERO HIC Medicare Health Insurance Claim Number. It is required for Platino beneficiaries’ enrollment.
 
Enrollment Manual
41

IV. Enrollments Processes


23. IPA_ESPECIAL A code “1” indicates that the member is assigned to a special IPA which is not the family IPA. Used for GHIP enrollment.

24. CONTRACT NUMBER Contract number assigned by the carrier. It should be the number by which the member is identified in the carriers’ ID card and internally in their database.

25.  SPECIAL ENROLL – It is used to identify (1) the enrollment for newborns that are beneficiaries of the Federal CHIP Program; (2) to process the cases of utilization before the Certification Date (emergencies) for the federal population and (3) to identify the cases of retroactive periods under MAGI. The inclusion of an “N” in this field will allow the enrollment of the newborn from his/her birthdate. The inclusion of an “E” will allow the enrollment of emergency cases from the Eligibility Effective Date notified by the Medicaid Office and the insertion of a “T” will allow the enrollment on a retroactive period under MAGI.

26. Other data elements complimented by ASES – When a beneficiary’s record is validated, the ASES system enters the following data in the enrollment record:

a.
Reject Identifier - As a result of the validations, the record could be accepted or rejected. This field contains the codes that specify the result of said validation.

"A" = Accepted;
"M" = Accepted Retroactively;
“T” = Retroactive Eligibility Period Enrollment
"R" = Rejected;

Identifier = “A”
Identifies an accepted enrollment that will be applied on a current or future effective date. In this case, the update process moves the enrollment fields of the carrier, Plan Type, Plan Version, PMG and PCP to the fields intended for new enrollments in the beneficiary record. Until such time as the new Effective Date is reached, the beneficiary will remain under the current enrollment condition (same carrier, Plan, Version, PMG and PCP). During the end-of-month cycle, the new fields are moved to the current fields and the enrollment becomes effective.

Identifier = “M”
Indicates a retroactive enrollment. In these cases, Enrollment data (Carrier, Plan Type, Plan Version, PMG and PCP) are updated directly in the beneficiary's historical record.

Identifier = “T”
Under MAGI, it identifies a successfully processed retroactive enrollment.

Identifier "R"
In cases when an enrollment record is not successfully processed because an error has been identified, it indicates a record returned for correction.
 
Enrollment Manual
42

IV. Enrollments Processes


b. Record Key – Internal number assigned by the ASES system.

c.   Error Codes one (1) to ten (10) – It is possible to record up to ten error codes.

d.   Update Date – Date for which the validation is run. Corresponds to the date of the daily cycle the validation run was a part of.

e. Update User – ASES internal user code.

15. REJECTION OF AN ENROLLMENT RECORD

An enrollment record related to any type of enrollment, modification or update transaction could be rejected if it does not pass the validation tests at the ASES systems. As mentioned above, rejected enrollments are sent daily to carriers in a file (.rjc) that includes error codes for records that have not successfully passed the validation process. Carriers must correct identified errors and resubmit the corrected records to ASES with the next file submission, meaning the next business day. For the adequate correction of these errors please refer to the Error Codes Table provided in Section 22.

16. REJECTED ENROLLMENTS MANAGEMENT

The daily process of carriers in relation to rejected enrollments should include:

 
(1)
Receipt of rejected enrollment records;
 
(2)
Evaluation of rejection codes received;
 
(3)
Identification of situations in which rejection is not clear for consultation with ASES;
 
(4)
Timely correction of identified errors;
 
(5)
Transfer of the corrected records to ASES in a 24 hour period.

 17. ERROR CODES

This section addresses the error codes produced by the ASES validation process. In addition to the error codes known so far and as a result of the new changes involved in the implementation of MAGI, two (2) new error codes have been introduced and could appear as the result of the processes of validation and verification of the enrollment records.
 
Enrollment Manual
43

IV. Enrollments Processes


18. NEW ERROR CODES UNDER MAGI

Code 023: If code "T", corresponding to a retroactive transaction, has been entered in the "Special Enroll" field, the field “Tran_ID” should be filled with code “E” or “C”, accordingly.

Code 109: In the 'Special Enroll' field it is necessary to insert a 'T' code when dealing with transactions for retroactive eligibility periods (1, 2 or 3). The notification of this error suggests that the "T" code was not found in the field 'Special Enroll' for an enrollment corresponding to retroactive eligibility periods on eligibility history files.

19. ERROR CODES TABLE

The following table contains the error codes produced by the validation program. Additional descriptions and possible corrective actions have been included to assist in the correction process.

Table 5: ErrorCodes
 
Error Code
Error Message
Additional Description
Possible Corrective Actions
011
(Record Type)
Invalid Record Type Code.
This field is required to be filled with code “E” in every case.
Fill with code “E”.
021
(Tran_ID)
Tran_ID field is blank.
This field is required to be filled with information about the type of transaction being processed.
Fill this field with the corresponding code.
022
(Tran_ID)
Invalid “Tran ID”.
An invalid transaction code has been identified.
Fill this field with a valid transaction code.
023
MAGI
If the field “Special Enroll” has been filled with code “T”, then the field “Tran_ID” should contain code “E” for new enrollments or code “C” if the transaction is about a carrier change.
For retroactive transactions (“T”), the field Tran_ID should be filled with code “E” or “C”, accordingly.
 
Verify and correct the information contained in the field.
 
 
031
(Process_ Date)
Process date field is blank.
   
032
(Process_Date)
Invalid process date.
   
033
(Process_Date)
Except for the cases about newborns, for GHIP transactions, the process date should be lesser or equal to the effective date of the new enrollment or the change that is notified and greater or equal to three months before the effective date.
For GHIP (Plan Type = 01) the process date should be lesser or equal to the effective date of the new enrollment or the change notified. The process date should fall within three (3) months before the effective date.
Compare the process date with the effective date of the new subscription or the change about the record notified.

Enrollment Manual
44

IV. Enrollments Processes


034
(Process_Date)
For GHIP transactions with Tran_Id = “E” and process date greater or equal to ‘11/16/2006’, the effective date cannot be equal to ‘11/01/2006’.
Special code for the coverage code conversion of November 2006.
Verify the effective date.
035
(Process_Date)
For Platino transactions, the process date should be within three (3) months before the effective date.
For Platino (Plan Type = 02 or 03) the process date should be before the effective date. The process date of the new enrollment or change in the enrollment record should fall within three months before the effective date.
Compare the process date to the effective date and correct.
 
 
041
(Region)
Region code field is blank.
 
Fill the field with the corresponding region code.
042
(Region)
Invalid region code.
 
Verify and fill the field with the corresponding region code.
051
(Carrier)
Carrier code field is blank.
 
Verify and fill the field with the corresponding carrier code.
052
(Carrier)
Invalid carrier code provided.
 
Verify and fill the field with the corresponding carrier code.
053
(Carrier)
The carrier has notified that a change of carrier has been performed but the carrier notifying the change is the same as the one registered in ASES’s database.
The enrollment has code “C” (carrier change) in the “Tran_ID” field and the carrier is the same as the one identified in the beneficiary’s record in ASES.
Verify if the record should have been sent with another “Tran_ID” (V or I, for example). If that’s not the case, the beneficiary is already enrolled in the database with the submitting carrier and no further action is required.
054
(Carrier)
If the “Plan Type” = 01, the “Tran_ID” is “C” or “D” and the enrollment effective date (“Effective Date”) is in the future, this date should on or before the first of the month three months in the future from the current date.
The future disenrollment or carrier change transactions should have effective dates on or before the first of the month three months in the future from the current date.
The effective date of the future disenrollment or carrier change transactions should fall on or before the first of the month three months in the future from the current date.
061
(IPA o PHO code)
It has been identified that the “Tran_ID” is “E”, “C”, “P”, “V” or “I”. These changes require that the Primary Medical Group (PMG) field contains PMG information.
Specifying the Primary Medical Group is required when the enrollment for a GHIP carrier, or a Platino carrier for which the PMG is required,  has a “Tran_ID” “E”, “C”, “P”, “V” or “I”.
Provide the corresponding PMG code.
 
Enrollment Manual
45

IV. Enrollments Processes

 
062
(IPA o PHO Code)
The “Tran_ID” is “1”, “2” or “3” and the specified PMG is different from the PMG enrolled in the ASES databases.
 
The enrollment is about a PCP change but the transaction contains a PMG different from the one that is currently enrolled in the ASES records.
The PCP changes are accepted in the ASES databases if the record concurs with the carrier code, Plan Type, Version and PMG that is registered in the current data. Verify if the intention is to change both the PMG and the PCP and submit a PMG change (Tran_ID=I) with new PMG and PCP codes. If that is not the case, then correct the PMG field.
063
(IPA o PHO Code)
The “Tran_ID” is “I” and the Primary Medical Group (PMG) specified is equal to the Primary Medical Group stated in the current data from the ASES databases.
 
The carrier has sent a PMG change related to a beneficiary but the PMG stated in the current data from ASES databases concurs with the one sent.
Verify if the record should have been sent with another “Tran_ID”. If that is not the case, the beneficiary is already enrolled in the databases with the corresponding PMG and no further action is required
064
(IPA o PHO Code)
If the transaction is about a disenrollment (Tran_ID=”D”), the field “Member Primary Center” should be blank.
 
Verify if the transaction is about a disenrollment. If that is the case, remove the PMG information.
071
(ODSI_Family_ID)
 “Family ID” information is required and the corresponding field is blank.
 
 
Include the eleven (11) characters code corresponding to the “Family ID” assigned by ASES.
072
(ODSI_Family_ID)
The “Family ID” code provided does not contain eleven (11) characters.
 
Include the eleven (11) characters code corresponding to the “Family ID” assigned by ASES.
073
(ODSI_Family_ID)
The “Family ID” was not found at the region specified.
The “Family_ID” was not found under the corresponding region in the ASES eligibility records.
Verify if the “Family ID” sent is the correct one. Verify if the region code corresponds with the beneficiary.
081
(Member_SSN)
The beneficiary’s social security number is required and the field is blank.
 
 
Include the beneficiary’s social security number.
082
(Member_SSN)
The beneficiary’s social security number does not contain nine (9) characters.
 
 
Verify this information and provide the beneficiary’s social security number.
 
Enrollment Manual
46

IV. Enrollments Processes

 
091
(Member_Suffix)
The information related to the suffix that identifies the beneficiary is required and the corresponding field is blank.
 
Provide the suffix that identifies the beneficiary.
092
(Member_Suffix)
The suffix that identifies the beneficiary that was provided by the carrier does not contain two (2) characters.
 
Provide the two (2) characters suffix that identifies the beneficiary.
093
(Member_Suffix)
The suffix that identifies the beneficiary was not found in the ASES eligibility records databases under the region and family identifier specified.
A record for the beneficiary’s suffix was not found, under the region and family identifier specified, in the ASES database.
 
Verify that the suffix assigned in the carrier’s database concurs with the one registered in the ASES database. If the “Family_ID” contains an error this error code will appear.
101
(Effective_Date)
The effective date information is required and the field is blank.
 
Provide the effective date.
102
(Effective_Date)
Invalid Effective Date.
 
Provide a valid effective date.
 
103
(Effective_Date)
For new enrollments under a GHIP plan, the effective date should be before the daily run date (“Run Process Date”) at ASES.
 
For a new enrollment under the GHIP plan (Plan Type=01) and Tran_ID=E the effective date should be before the daily run date at ASES. It is presumed that a beneficiary has been enrolled with the carrier before the enrollment record has been sent to ASES. The new enrollments should not be sent with future effective dates.
Verify the dates and proceed to correct.
104
(Effective_Date)
For transactions related to the GHIP plan (Plan Type=01) which  “Tran_ID” is not “1”, “2”, “3”, “E”, “O” o “D”, the effective date should be after the enrollment process date and it should be on the first of the following month.
 
Only applies to GHIP plans and only when the transaction is not about a PCP change, a new enrollment or a disenroll (“D”).
For transactions related to the GHIP plan (Plan Type=01) which  “Tran_ID” is not “1”, “2”, “3”, “E”, “O” o “D”, the effective date should be after the process date and it should be on the first of the following month after the process date at ASES.
Verify the dates and proceed to correct.
105
(Effective_Date)
The Platino plans enrollment effective date that does not have Tran_ID “1”, “2”, “3" or "D", should be on the first of the month of the beneficiary’s enrollment.
 
Verify that the Platino enrollment effective date is on the first of the month of the beneficiary’s enrollment.
106
(Effective_Date)
For a disenrollment transaction (TRAN_ID=”D”), the transaction effective date should be on the first of the following month.
   
107
(Effective_Date)
The enrollment effective date of the transaction sent should fall within the family group’s last eligibility period.
The eligibility of the family, to which the beneficiary corresponds, was cancelled after the effective date of the enrollment sent.
These cases will be submitted as candidates for enrollment in the historical data under the enrollment system (SYSPREM).
 
Enrollment Manual
47

IV. Enrollments Processes

 
109
MAGI
 
(Effective_Date)
A code ‘T’ was not included in the ‘Special Enroll’ field and a SYSRETRO record, specifying an eligibility period that covers the enrollment effective date sent by the carrier, has been identified.
A code ‘T’ was not included in the ‘Special Enroll’ field for an enrollment that corresponds to a SYSRETRO period.
Verify if the transaction is about a retroactive enrollment under MAGI. If that is the case, include code “T” in the “Special Enroll” field.
10A
(Effective_Date)
Emergencias
If the field “Special_Enroll” =”E”, then, for GHIP beneficiaries funded through state funds ,   the effective date should be greater or equal than the Certification Date. For federally funded GHIP beneficiaries (Medicaid and CHIP), the Effective Date should be greater or equal than the Eligibility Effective Date.
For emergency cases the effective date cannot be before the certification date (State funded GHIP) or the eligibility effective date (Federally GHIP, Medicaid and CHIP).
Verify the effective dates and certification date and proceed to correct.
 
 
10B
(Effective_Date)
If the field “Special_Enroll” =”N”, the effective date should be greater or equal than the beneficiary’s birth date and it should not surpass the period of a year calculated from the birth date.
The newborn enrollments’ effective date cannot be before the birth date nor can it extend for more than one (1) year calculated from the birth date.
Verify that the effective date concurs with the birth date and that it does not surpass the period of one (1) year calculated from the birth date.
111
(Plan_Type)
The Plan Type code is required and the field is blank.
 
Include the required information related to the Plan Type.
112
(Plan _Type)
The provided Plan Type code does not contain two (2) characters.
 
Verify and provide the corresponding Plan Type code.
113
(Plan_Type)
The provided Plan Type, Carrier Code and Plan Version are incorrect.
The enrollment records are required to correspond with the Plan Type and Plan Version contracted with ASES by the carrier.
 
The Plan Version code, for Platino plans, should concur with the Plan Version code assigned by ASES; for GHIP plans, this code should equate to the coverage code assigned by the Medicaid Office.
Verify this information and correct.
 
 
 
 
 
114
(Plan_Type)
For disenrollment transactions (Tran_ID =”D”), code “01” (GHIP) should be included in the “Plan Type” field.
 
Verify the transaction type and include code 01 (GHIP) in the Plan Type field.
121
(Plan_Version)
The Plan Version code is required and the field is blank.
 
Include the information corresponding with the Plan Version.
122
(Plan_Version)
The Plan Version code does not contain three (3) characters.
 
Verify the information and provide the three (3) characters code corresponding to the Plan Version.
 
Enrollment Manual
48

IV. Enrollments Processes

 
123
(Plan_Version)
The provided Plan Version code is invalid for the specified Effective Date.
The Plan Version code should be one that is active at the Effective Date indicated.
Verify the Plan Version code and/or Effective Date.
 
124
(Plan_Version)
Invalid Plan Version code. If the transaction is about a disenrollment (Tran_ID=”D”), the plan version code should be 001.
If the transaction is about a disenrollment (Tran_ID =D), then the Plan Version field should contain the code “001”.
Verify the transaction type and include the corresponding code.
131
(MPI)
The provided “MPI Number” does not contain thirteen (13) characters.
 
Verify the included code. Provide the thirteen (13) characters code of the corresponding MPI Number.
132
(MPI)
The “MPI Number” does not concur with the ASES records for the region specified.
 
 
 
Verify that the correct MPI Number has been provided. Verify if the region code sent corresponds with the region to which the beneficiary corresponds.
141
(PCP1)
The PCP1 field is blank and the transaction is not type “2” or “D” (which require this field to be blank).
The PCP1 field should not be blank if the PCP1 is required and the transaction is not type “2” or “D”.
Verify the transaction type and include the corresponding PCP1 code.
142
(PCP1)
The PCP1 should be blank when the Tran ID is “2” or “D”.
If the transaction is about a PCP2 change or a disenrollment, the PCP1 field should be blank.
Verify the transaction type. If the transaction is about a PCP2 change, remove the information included in the PCP1 field.
151
(PCP1_Effective Date)
 
The PCP1 field is blank and the Tran_ID is neither “2” nor “D”.
 
 
The PCP1 field is blank or the provided date is invalid in a transaction for which the PCP1 information was required.
Verify and correct.
152
(PCP1_Effective Date)
An invalid effective date was provided for the PCP1 Effective Date and this information was required.
The PCP1 effective date field is blank or the provided date is invalid.
Verify the error and correct.
153
(PCP1_Effective Date)
 
There is information in the PCP1 effective date field and the transaction is not about a PCP2 change or a disenrollment and the PCP1 is not required.
The PCP1 effective date should be blank when the enrollment does not imply a PCP2 change and the PCP1 is not required.
Verify and correct.
154
(PCP1_Effective Date)
The field corresponding with the PCP1 effective date should be blank when the transaction is about a PCP2 change or a disenrollment.
The PCP1 effective date should be blank when the transaction is about a PCP2 change or a disenrollment.
Verify and correct.
 
Enrollment Manual
49

IV. Enrollments Processes

 
155
(PCP1_Effective Date)
For transactions of new enrollment, the PCP1 effective date should be before the daily run process date at ASES.
For the GHIP plan (“Plan Type=01”) the date for a new enrollment should be before the daily run process date at ASES. It is presumed that the beneficiary was enrolled before the enrollment record was sent to ASES. New enrollment records are not performed with future dates.
Verify and correct.
156
(PCP1_Effective Date)
Barring new enrollment transactions, the PCP1 effective date should concur with the first day of the following month.
For transactions about a PCP1 change, the PCP1 effective date should be on the first day of the month following the notification of the change.
Verify the effective date provided for the PCP1 change.
157
(PCP1_Effective Date)
If the PCP1 field is not blank, the field corresponding with the PCP1 effective date should not be blank.
When there is data in the PCP1 field, there should be a valid date in the PCP1 effective date field and vice versa.
If the transaction is about the PCP1, verify and include the information in the appropriated field.
158
(PCP1_Effective Date)
 
For enrollments having Tran_ID 'E','C' or 'I', in which the PCP1 field is not blank, the PCP1 effective date should be equal to the effective date of the enrollment to be applied. For enrollments having Tran_ID 'P','V','1','3', in which the PCP1 field is not blank, the PCP1 effective date  should be greater or equal than the existing enrollment effective date.
For enrollments having Tran_ID 'E','C' or 'I', in which the PCP1 field is not blank, the PCP1 effective date should be equal to the effective date of the enrollment to be applied. For enrollments having Tran_ID 'P','V','1','3', in which the PCP1 field is not blank, the PCP1 effective date  should be greater or equal than the existing enrollment effective date.
Verify the provided PCP1 effective date.
161
(PCP2)
The PCP2 field is blank and the transaction is about a PCP2 change or a PCP1 and PCP2 change (Tran_ID= “2” or “3”).
The transactions about a PCP2 change or a PCP1 and PCP2 change require information in the PCP2 field.
Verify and include the information missing in the PCP2 field.
162
(PCP2_Effective Date)
 
The PCP2 field should be blank when the transaction is not about a PCP2 change or a PCP1 and PCP2 change (Tran_ID= “2” or “3”).
If the transaction is about a PCP1 change or a disenrollment (Tran_ID=“1” or “D”) the PCP2 field should be blank.
 
Verify if the transaction is about a PCP1 change or a disenrollment. If that is the case, remove the information from the PCP2 field.
171
(PCP2_Effective Date)
The PCP2 effective date field is blank and the transaction is about a PCP2 change or a PCP1 and PCP2 change (Tran_ID “2” or “3”).
The transactions about a PCP2 change or a PCP1 and PCP2 change (Tran_ID “2” or “3”) require a valid effective date in the PCP2 effective date field.
Verify and correct.
172
(PCP2_Effective Date)
Invalid PCP2 effective date.
An invalid date has been found in the PCP2 effective date field.
Verify the PCP2 effective date and correct.
173
(PCP2_Effective Date)
For transactions of new enrollment in which the PCP1 field is not blank, the PCP2 effective date should be before the daily run process date at ASES.
 
 
For new enrollments (Tran_ID=E) under a GHIP plan (“Plan Type=01) the PCP2 effective date should be before the daily run process date at ASES. It is presumed that the beneficiary was enrolled before the enrollment record was sent to ASES. The system will not be able to process new enrollments with future dates in this field.
Verify these dates and proceed to correct.
 
 
Enrollment Manual
50

IV. Enrollments Processes

 
174
(PCP2_Effective Date)
 
Barring new enrollment transactions, the PCP2 effective date should concur with the first day of the month following the notification of the change.
 
For transactions about a PCP2 change, the PCP2 effective date should be on the first day of the month following the notification of the change.
Verify that the PCP2 effective date is on the first day of the month following the notification of the change.
175
(PCP2_Effective Date)
If the PCP2 field is not blank, the field corresponding with the PCP1 effective date should not be blank and vice versa.
When there is data in the PCP2 field, there should be a valid date in the PCP2 effective date field and vice versa.
Verify the related fields and proceed to include the missing information.
176
(PCP2_Effective Date)
If the transaction is about a disenrollment (Tran_ID=”D”), then the PCP2 effective date field should be blank.
 
Verify the transaction type and remove any PCP2 information that is not required.
177
(PCP2_Effective Date)
It has been identified that the beneficiary is already enrolled with another carrier for a date equal or after the Effective Date of the enrollment sent. This error applies to cases of new enrollment and carrier change.
The beneficiary is already enrolled at ASES with another carrier for a date equal or after the effective date of the enrollment sent.
 
Verify that the effective date sent to ASES corresponds with the appropriated date.
178
(PCP2_Effective Date)
 
For enrollments having Tran_ID 'E','C' or 'I', in which the PCP2 field is not blank, the PCP2 effective date should be equal to the effective date of the enrollment to be applied. For enrollments having Tran_ID 'P','V','2','3', in which the PCP2 field is not blank, the PCP2 effective date  should be greater or equal than the existing enrollment effective date.
For enrollments having Tran_ID 'E','C' or 'I', in which the PCP2 field is not blank, the PCP2 effective date should be equal to the effective date of the enrollment to be applied. For enrollments having Tran_ID 'P','V','2','3', in which the PCP2 field is not blank, the PCP2 effective date  should be greater or equal than the existing enrollment effective date.
Verify the provided PCP2 effective date.
181
(Family_Primary_
Center)
For GHIP plans, it is required to provide information about the Family Primary Medical Group.
 
For GHIP plans, the information about the Family Primary Medical Group is required.
 
Include the corresponding Primary Medical Group code for the corresponding Family.
182
(Family_Primary_
Center)
The transaction did not require information about the Family Primary Medical Group and information was provided for said field.
 
Verify the transaction type and remove the information not required from the corresponding field.
183
(Family_Primary_
Center)
If the transaction is about a disenrollment (Tran_ID=”D”), the Primary Medical Group field should be blank.
The transaction is about a disenrollment “D” and there is information in the Primary Medical Group field.
Verify the transaction type and remove the information not required from the PMG field.
 
Enrollment Manual
51

IV. Enrollments Processes

 
191
(Family_Primary_
Center Effective _Date)
The effective date for the Family Primary Medical Group is clank and the information in this field is required.
 
Include a valid effective date in the Family Primary Medical Group field.
192
(Family_Primary_
Center Effective _Date)
The Family Primary Medical Group effective date included is not valid.
 
An invalid date was found in the Family Primary Medical Group effective date field.
Verify the PMG effective date and provide the corresponding date.
193
(Family_Primary_
Center Effective _Date)
The information for the Family Primary Medical Group is not required and there should be no information in this field.
The information for the Family Primary Medical Group is not required and there is information in this field.
If this information should not be sent, remove the information provided in this field.
194
(Family_Primary_
Center Effective _Date)
If the transaction is about a disenrollment (Tran_ID=”D”) this field should be blank.
 
If the transaction is about a disenrollment, remove the information provided in this field.
200
200
(IPA PCP Change Reason)
If the transaction is about a disenrollment (Tran_ID=”D”), then the PMG or PCP Change Reason field should be blank.
If the transaction is about a disenrollment, then the PMG or PCP Change Reason field should be blank.
If the transaction is about a disenrollment, remove the information provided in the PMG or PCP Change Reason field should be blank.
211
Medicaid_IND
The Plan Version and Type are incorrect. The beneficiary does not receive medical services under Federal Medicaid.
 
The Plan Version and Type codes provided by the carrier require that the beneficiary is eligible to receive services under Federal Medicaid and the ASES database states that the beneficiary is not eligible for that coverage.
Verify and submit the corresponding information.
221
(Relationship Edit)
Duplicate enrollment.
 
Two or more enrollment records with the same Family_ID and suffix were identified in the same daily run process cycle at ASES.
Verify this information.
222
The transaction is about a new enrollment and the beneficiary is already enrolled under the same carrier trying to enroll it through this transaction.
The transaction is about a new enrollment and it has been identified that the beneficiary is already enrolled under the same carrier as the one sending the enrollment.
Verify if the record should have been sent with another “Tran_ID” like, for example, “V” or “I”. If that is not the case, the beneficiary is already enrolled and no further action is required.
223
The transaction is about a new enrollment and the beneficiary is already enrolled with another carrier.
The transaction is about a new enrollment (Tran_ID = “E”) and beneficiary records of enrollment under another carrier have been found at the ASES database.
Verify if the enrollment record should have been sent with a carrier change code included in the “Tran_ID”.
224
The beneficiary was not eligible for the effective date indicated by the carrier.
 
Verify the effective date.
225
(Member_SSN)
The social security number provided was not found in the ASES databases current data.
 
Verify and correct the social security number.
 
226
(MPI)
The MPI Number sent was not found in the ASES databases current data.
 
Verify and correct the MPI Number.
 
Enrollment Manual
52

IV. Enrollments Processes

 
227
(Plan Type change)
The transaction is about a Plan Type change and the carrier sending it is different from the carrier currently enrolled in the ASES databases.
Only the carrier registered in the ASES database at the moment a Plan Type change is submitted may submit a Plan Type change in the enrollment record.
Verify if the record should have been sent with another Tran_ID.
228
(Plan Version change)
The transaction is about a plan version change (Trans_ID= “V”) and the carrier or plan type submitted do not concur with the data found in the ASES database.
 
 
 
The plan type changes are accepted by the system if they are sent by the same carrier and under the same plan type registered in the current data at ASES.
 
Only the carrier registered in the ASES database at the moment a Plan Version change is submitted may submit a Plan Version change in the enrollment record.
Verify if the record should have been sent with another Tran_ID.
 
 
 
229
(IPA change)
The transaction is about a PMG change (Trans_ID= “I”) and the carrier, plan type or plan version submitted do not concur with the data found in the ASES database.
 
 
 
The PMG changes are permitted if they are sent by the carrier, plan type and plan version registered in the current data at ASES.
 
Only the carrier registered in the ASES database at the moment a PMG change is submitted may submit a PMG change in the enrollment record.
Verify if the record should have been sent with another Tran_ID.
 
22A
(PCP1, PCP2 o PCP1 y PCP2 Change)
The transaction is about a PCP1, PCP2 or PCP1 and PCP2 change (“Tran_ID” =“1”, “2” o “3”) and the carrier, Plan Type, Plan Version and PMG do not concur with the current data in the ASES databases.
 
The PCP changes are permitted under the same carrier, Plan Type, Plan Version and PMG as stated by the beneficiary’s current data at ASES. This error suggests that the beneficiary is currently enrolled under another carrier, Plan Type, Plan Version or PMG in the ASES database.
Verify if the record should have been sent with another Tran_ID.
22B
(PCP1 Effective Date; PCP2_Effective_Date)
If the transaction is about a PCP1 and PCP2 change (Tran ID=3), both the PCP1 and PCP2 effective dates should be future or retroactive dates.
Both the PCP1 and PCP2 effective dates should be future or retroactive dates.
Verify the dates for PCP1 and PCP2 and correct.
22D
Invalid date values for enrollments of future effect. This error applies to all the transactions that are not of type “D”.
The PCP, PMG, Plan Version and carrier changes cannot be sent with dates more than four (4) months into the future.   This error applies to all the transactions that are not of type “D”.
 
22E
If the plan type is GHIP (“Plan Type” =01), then the plan version should be equal to the “Coverage Code”.
For the GHIP enrollment record (“Plan Type” 01) the plan version code should concur with the coverage code registered in ASES database for the beneficiary being enrolled.
Verify and correct.
 
Enrollment Manual
53

IV. Enrollments Processes

 
22F
All GHIP beneficiaries from a same family group will be rejected if a record corresponding to any of them is marked with an error code.
 
 
When a GHIP beneficiary’s enrollment record contains an error, every record from beneficiaries belonging to the same family group receives a 22F error code. This has the effect of maintaining all the beneficiary records under a same family record and avoids the partial processing of the family in a same daily run process cycle at ASES.
Verify and correct every additional error identified other than the 22F codes for every GHIP beneficiary in the family.
250
(HIC Number)
If the transaction is about a disenrollment (Tran_ID=”D”) the HIC Number field should be blank.
There should be no information in the “HIC Number” field if the transaction is about a disenrollment (“D”).
If the transaction is about a disenrollment (“D”), remove the information provided in the HIC Number field.
260
(IPA_Special)
If the transaction is about a disenrollment (Tran_ID=”D”) the IPA_SPECIAL field should be blank.
There should be no information in the IPA_SPECIAL field if the transaction is about a disenrollment (“D”).
If the transaction is about a disenrollment (“D”), remove the information provided in the IPA_SPECIAL field.
270
(Medicare Indicator)
If the transaction is about a disenrollment (“Tran_ID” = “D”) the “Medicare Indicator” field should be blank.
 
There should be no information in the Medicare Indicator field if the transaction is about a disenrollment (“D”).
If the transaction is about a disenrollment “D”, remove the information provided in the Medicare Indicator field.
280
The family should be eligible at the moment the record is being processed.
Family not eligible at the moment the record is being processed.
 
281
The beneficiary should be eligible at the moment the record is being processed.
Beneficiary not eligible at the moment the record is being processed.
 
998
Record number is blank.
Transaction without Record Number. Does not constitute an error. No further action required.
No action required.
999
The record number sent does not concur with a previous record number from a previous transfer.
The record number sent does not concur with a record number from a previous transfer. Does not constitute an error. No further action required.
No action required.
 
 
Enrollment Manual
54

IV. Enrollments Processes


20. DISENROLLMENT (Cancellation)

20.1 Disenrollment under GHIP and Medicare Platino

The process of a disenrollment occurs only when the Medicaid Office determines that a beneficiary is no longer eligible for GHIP or Medicare Platino or in those cases where a disenrollment from the plan is requested by the Carrier or the beneficiary and has been approved by ASES. 12

Medicaid will notify the disenrollment to ASES, and ASES will notify the carrier of the disenrollment. Such notification shall be effected by means of a daily transfer of files to the carrier together with files containing information on new beneficiaries to be enrolled. This will be done within five (5) calendar days after a final determination on the disenrollment. 13
Only the Medicaid Office may notify and cancel eligibility. However, both ASES and the carriers may continue to process disaffiliations that do not have the effect of cancelling the eligibility of a beneficiary to receive medical services.

20.2 Effective Date of Disenrollment:

This is the date, as defined in Section 5.3.3 of the contract signed between ASES and the carriers, in which the coverage of a beneficiary under a contracted carrier ends. The effective date of the cancellation is the date ASES notifies to carriers.

21. GHIP DISENROLLMENT (Cancellation)

21.1 Disenrollment Made by Medicaid Office

A GHIP disenrollment occurs when the Medicaid Office determines that (1) a beneficiary has lost eligibility to receive medical services coverage under the GHIP; (2) the eligibility period granted by the Medicaid Office has expired or (3) a request for re-enrollment has been received from a beneficiary or a new carrier as set forth in Sections 5.3.4 and 5.3.5 of the agreement signed between ASES and the carriers.
In general, a disenrollment will be  notified to the carriers by ASES Any disenrollment shall take effect as of its Effective Date specified in the notice issued by ASES to the carrier in that respect.

In cases where ASES notifies the carrier of the disenrollment on or before the last working day of the month in which the beneficiary's eligibility expires, said disenrollment shall be effective on the first day of the following month.
 

12 See sections 5.3.4 y 5.3.5 of the GHIP contract between ASES and the carriers.
13 See section 5.3.2 of the contract between ASES and the carriers.
 
Enrollment Manual
55


When the disenrollment is made at the request of the carrier or the beneficiary, as provided in Sections 5.3.4 and 5.3.5 of the contract signed between ASES and carriers, the disenrollment shall take effect no later than the first day of the second month following the month in which the request was made.
Table 6: Examples of GHIP Effective Dates of Disenrollment

GHIP Disenrollment Reason
GHIP Disenrollment Effective Date
Notified by ASES (not notified on the last business day of the month).
Date Specified in the ASES Disenrollment Notification.
Notified by ASES (on the last business day of the month).
First day of the following month.
Requested by Beneficiary or Carrier.
No later than the first day of the second month in which the Carrier or Beneficiary has requested disenrollment.
Death of the Beneficiary
Federal and state funded Commonwealth beneficiaries are disenrolled from the first day after death.
Move of the Beneficiary.
 
Since the contract covers all regions on the island any move within the island has no impact. If the move causes a change of region, then the effective date is the date notified by Medicaid.
Beneficiary moved outside of Puerto Rico.
Federal and state funded Commonwealth beneficiaries will be disenrolled as of the first day of ineligibility as notified by the Medicaid Office.
Incarceration of the Beneficiary
Federal and state funded Commonwealth beneficiaries will be disenrolled as of the first day of ineligibility as notified by the Medicaid Office.
After completing the pregnancy and post-natal care eligibility extension
If at re-certification a woman becomes ineligible for GHIP and is pregnant, the eligibility is extended for 60 days after the baby is born or after a pregnancy loss.

21.2 Effective Date of the Programmatic Disenrollment (Disaffiliation)

For programmatic purposes of the ASES Information Systems Office, this Disenrollment Effective Date also refers to the day on which a beneficiary ceases to be enrolled under a particular carrier in the ASES databases. This disenrollment takes place in those cases in which the Medicaid Office has sent a change of coverage code for a beneficiary and the carrier has not submitted an enrollment with the new plan version related to the change of coverage.

Although in cases of programmatic disenrollment the eligibility period will continue for the beneficiaries who are disenrolled, the premium payment cannot be processed until a new beneficiary enrollment is sent by the carrier with the information of the new plan version related to the change of coverage.
 
Enrollment Manual
56

IV. Enrollments Processes


22. MEDICARE PLATINO DISENROLLMENT

22.1 Disenrollment by Beneficiary Request

Platino Medicare beneficiaries may under certain circumstances require the termination of the enrollment agreement that covers their services. The Effective Date of these disenrollment will fall on the first day of the month following the disenrollment request. However, in spite of the above, the Effective Date of the Disenrollment shall in no case fall on a date after the first day of the following month after the one in which the beneficiary has made the disenrollment request.

22.2 Automatic Disenrollment

The carrier shall automatically process disenrollment in cases of death of a beneficiary, loss of eligibility, for the causes outlined in Schedule F of the Draft Agreement between ASES and Platino carriers, termination of the eligibility period Granted by Medicaid, or in case of disenrollment of the Medicare Platino product it offers. The Effective Date of the Disenrollment in these cases will fall on the last day of the month in which any of the events mentioned above takes place.

22.3 Retroactive Disenrollment
Retroactive disenrollment occurs exceptionally and only if a beneficiary has been enrollment and is ineligible to receive medical services, in circumstances in which he or she has been retroactively deprived of the Advantage product of the carrier in question and in Cases of incarceration or death of the beneficiary, etc. The Effective Date in these cases is discussed in Table 7 below.
 
Enrollment Manual
57

IV. Enrollments Processes

 
Table 7: Medicare Platino Effective Dates of Disenrollment'
 
Reason for Disenrollment
Effective Date of Disenrollment
Death of the Beneficiary
First day after death.
Incarceration of the Beneficiary
First day of ineligibility as notified by Medicaid.
Beneficiary enters or stated in a residential institution under circumstances which rendered the individual ineligible for enrollment in Medicare Advantage, including when an enrollee is admitted to the hospital that (1) is certified by Medicare as a long term care hospital and (2) has an average stay for all patients greater than ninety-five (95) days.
First day of ineligibility as notified by Medicaid.
Beneficiary enrollment while being eligible
Effective Date of Enrollment in the Platino Plan Carriers.
Move of the Beneficiary.
Since the contract covers all regions on the island any move within the island has no impact.
Beneficiary moved outside of Puerto Rico.
First day of ineligibility as notified by Medicaid.
Expedite Disenrollment: - Urgent Medical Need
First day of the next month after determination except where medical need requires an earlier disenrollment.
Expedite Disenrollment: - Non-consensual enrollment
Retroactive to the first day of the month
Expedite Disenrollment: - Disenrollment from the carrier Medicare Platino
Concurrent with the Effective Date of Disenrollment from the carrier Medicare Advantage Product.

23. UPDATES TO NEW ENROLLMENTS AND ENROLLING OMITTED BENEFICIARIES

In cases in which the carrier must update the information previously sent to ASES on a new enrollment, or that it must add a new beneficiary previously omitted, that update must occur on the next Business Day after the information has been updated or a new beneficiary has been added. ASES reserves the discretion of not accepting new additions or corrections to the enrollment data sixty (60) calendar days after the Enrollment Effective Date indicated in the carrier's notification to ASES.
 
Enrollment Manual
58

IV. Enrollments Processes

 
24. CARRIERS RESPONSIBILITIES IN THE ENROLLMENT PROCESSES

In summary, as part of the enrollment process, it will be the responsibility of the carriers to ensure compliance with the duties described in Table 8 below.

Table 8: Carriers Responsibilities about an Enrollment Transaction
 
Change or Modification
Action Required
1. Transfer of Daily Eligibility Files.
Daily Update of Eligibility Files in the carrier’s databases.
2. New Enrollments.
 
GHIP carriers should start the enrollment process with the beneficiary and verify each of the enrollments made including the enrollment of newborns and emergency cases. They must also enroll beneficiaries who have an Effective Date prior to a cancellation period.
3. Carrier Change.
Identify the beneficiaries who have requested a change of carrier and take action on behalf of these. The carrier that lost the beneficiary must identify the loss of the beneficiary in the corresponding file.
4. Changes to the enrollment data. (Change of Plan Type, Plan Version, PMG and/or PCP).
 
Identify beneficiaries who have changed coverage code, Plan Type, Plan Version, PMG or PCP (1 or 2) and notify these changes. The carrier's system must be updated in accordance with these modifications as failure to do so may lead to the rejection of the enrollment record in future transactions.
5. Change in the demographic data of a beneficiary. This information is received from the Medicaid Office but does not cause a change in the enrollment.
The carrier must update the beneficiary’s record with the new data in its database.
6. Rejected Records
Correct the rejected records.
7. Cancellation of Beneficiary:
Only the Medicaid Office may cancel the eligibility of a beneficiary, having the effect that until such notice of Medicaid is received the beneficiary will remain active in the databases of both ASES and the carriers even when the period of eligibility granted has expired.
Identify the cases of beneficiaries canceled or denied coverage and take action on behalf of these.
 
The carriers must perform follow-up to the beneficiaries in case the cancellation is caused by the expiration of the Certification Date.
8. Programmatic Disenrollment: Change in the coverage code.
 
 
Carriers should identify when a record received has a different coverage code than is recorded in their databases.
 
In these cases, carriers must assess whether the new coverage code requires the beneficiary to be enrolled in a different "Plan Version". If so, they must re-enroll these beneficiaries under the new "Plan Version" to correspond with the new coverage code. Subsequently, a change of "Plan Version" must be sent to ASES before the end of the current month.
 
Beneficiaries who are not registered with a "Plan Version" that corresponds with the coverage code will be disenrolled in the run of the end-of-month cycle in the ASES databases.
 
The carrier should enroll the beneficiaries that have been disenrolled.
9. Beneficiary Disenrollment.
 
End of Month: When a record of a beneficiary is received with the field corresponding to the carrier empty and it is identified that the beneficiary was previously enrolled in the ASES databases it should be understood that a process of disaffiliation of this beneficiary has been carried out in response to the fact that no information has been received in response to a change of coverage in ASES.
 
Carrier change: When a beneficiary's data is received with a different carrier code from the one that appears in the carrier’s database, it means that the beneficiary has been enrolled with a different carrier (this usually applies to Platino plans). In this case, the previous carrier must disenroll the beneficiary in its database.
 
Enrollment Manual
59

V. Premium Payment

V.   
PREMIUM PAYMENT
 
Enrollment Manual
60

V. Premium Payment


25. PREMIUM PAYMENT

The premium payment system operates under the concept that premiums are calculated and paid only in relation to beneficiaries who are already enrolled before the first day of the month to which the payment corresponds. Beneficiaries enrolled after that date will be considered for the next payment of the corresponding premium.

On a monthly basis, the system performs an automatic execution of payment in which the payment that corresponds to each one of the carriers is calculated by region according to the beneficiaries that are enrolled under each one of the regions in the ASES databases.

Premium payments will be made on the first day of the month following the acceptance of the enrollment by ASES. ASES is not obligated to pay premiums on beneficiaries who are not duly enrolled according to ASES’s databases nor for beneficiaries whose records contain transactions that have been rejected in the ASES databases and have not been corrected within the periods established by contract.

The payment system calculates several payment categories as listed below:

The reconciliation processes carried out with the insurers must be based on the payment file for a given month and must take into consideration the status of the subscriptions of the beneficiaries in ASES. Premium payments will be made on the first day of the month following the acceptance of the ASES subscription.
 
The payment system calculates several payment categories as listed below:

26. TYPES OF PAYMENT

26.1 Monthly payments

In this case the system produces a payment for those beneficiaries whose enrollment has already taken effect before the first day of the month for which the payment transaction is executed. The execution of premium payment is made on the first day of the month.

26.2 Prorated Payments

Prorated payments are specifically calculated for beneficiaries of the GHIP funded solely through state funds (Commonwealth) who have been enrolled at some point in a month prior to the month in which the premium payments are to be made. The payment in these cases will satisfy a portion of the month and not a month in its entirety. Under the state-funded GHIP a daily prorated premium is calculated from the certification date of the enrollment that falls on that previous month. This type of payment is not made for federal beneficiaries of the GHIP (Medicaid or CHIP) or Platino Plan because under these plans, payments are made based on full monthly periods. The only scenario in which a prorated payment will occur for the federal population will be in cases of a region change.
 
Enrollment Manual
61

V. Premium Payment


However, in the event of a deceased or incarcerated beneficiary, loss of eligibility by exceptions or one that has moved from Puerto Rico’s jurisdiction, all populations including Medicaid, CHIP, and state funded Commonwealth beneficiaries will be subject to the rule of proration regarding effective dates of eligibility and disenrollment.

26.3 Retroactive Payments

These payments are calculated when the Effective Date of the Enrollment falls on a period prior to the month for which the payment transaction is being executed. In other words, this type of payment is executed when payments are identified corresponding to months prior to the month in which a premium payment is made. The retroactive payments will be computed based on the Enrollment Effective Date. GHIP retroactive payments are always made for periods of up to three (3) months before the month of payment. The system will process the premiums for enrolled beneficiaries with an Effective Date prior to the payment date in the case of monthly premiums or prorated premiums that have not been previously paid within the time limits for retroactive payments. Retroactive payments may result in an adjusted payment if they are the result of a carrier's cancelation of a previous enrollment or a region change due to move.

Premiums are paid retroactively when a carrier has submitted a late enrollment in relation to newborn beneficiaries and to cases of utilization prior to the MA-10 Certification Date (emergencies) under the federal portion of the GHIP (Medicaid and CHIP). In the first case the payment can only extend retroactively for up to three (3) months. For the case of emergencies, this payment can only extend retroactively for up to twelve (12) months.

Deemed Newborns- newborns born to a Medicaid-eligible mother shall be provided coverage from the date of birth. The Medicaid identification number of the mother serves as the child's identification number, and all claims for covered services provided to the child may be submitted and paid under such number, unless and until the state issues the child a separate identification number.

26.4 Prorated-retroactive payment

The prorated retroactive payment is calculated taking into consideration the cases in which the Enrollment Effective Date falls on the first month considered for a retroactive payment. This is a partial payment of the first month that starts a series of months of pending payments. Usually, this type of payment is used for GHIP State funded Commonwealth beneficiaries.
 
Enrollment Manual
62

V. Premium Payment


26.5 Adjustments

A payment adjustment is calculated when there is a need to reverse a payment that was awarded to a carrier during a previous premium payment process. It occurs when, as a result of a retroactive payment calculation, a payment made in relation to the same beneficiary is identified within the same period that has been effected under a different carrier, type of plan or Plan Version. The adjustments are calculated for those cases where a beneficiary changes carrier retroactively after ASES had disbursed payment to the first carrier in a previous payment transaction. In these cases an adjustment of premium paid to the first carrier is made.

26.6 Special Adjustments

Generally, the special adjustments are carried out as a result of internal audit processes that reveal that a wrongly adjudicated payment (like for example, deceased beneficiaries or duplicate payments, etc.) must be reverted or that, on the contrary, an omitted payment must be adjudicated.

26.7 Reasons why ASES will not execute a premium payment:

A premium payment will not be executed in favor of a carrier in the following circumstances:

 
(1)
If the beneficiary is not enrolled in the ASES databases on the first day of the month for which the payment transaction is being executed;
 
(2)
If the beneficiary is enrolled on a date after the date of payment;
 
(3)
If the enrollment had been rejected by ASES and a new enrollment was not submitted by the carrier with the relevant corrections  (4) If from of the ASES eligibility data arises that the beneficiary had a cancellation or changed the carrier

26.8 EDI 820 Payment File

The reconciliation process carried out between ASES and the carriers in relation to the payment of premiums must take into account the content of the EDI 820 files. This file is produced monthly by region, carrier and Plan Type. It includes details of the types of payment that correspond to each of the beneficiaries assigned to the carriers contracted for the month in question.

In this file, a distinction is not made about if the payment corresponds to an adjustment from a regular premium payment process or a special adjustment. Thus, in cases when special adjustments proceed, ASES will provide a separated file for the special adjustments to the carrier.
 
Enrollment Manual
63

VI. SYSPREM

VI.  
  SYSPREM ENROLLMENT IN HISTORICAL DATA
 
Enrollment Manual
64

VI. SYSPREM


27. SYSPREM: ENROLLMENT IN HISTORICAL DATA

Generally, enrollments are applied to the current eligibility data contained in the ASES databases. That is transactions related to federal beneficiaries of the GHIP (Medicaid and CHIP), GHIP beneficiaries covered solely through state funds (Commonwealth) and Medicare Platino are only processed based on a beneficiary's current eligibility period. The eligibility period starts from the first notification of eligibility in ASES, as the first record received about a beneficiary or after a cancellation period in cases of beneficiaries who have been canceled and then re-certified, and extends until a cancellation that is related to say eligibility is made.

When a carrier does not send an enrollment on time or a record is not corrected in a timely manner, the beneficiary's enrollment data will remain unregistered in the ASES databases, which will prevent the processing of the corresponding premium payment. This is due to the fact that the payment system does not make premium payments for beneficiaries who are not enrolled at the moment in which it corresponds to process the premium payment. As an example, in these cases, if a beneficiary is canceled or is enrolled by a second carrier, the first carrier will be prevented, during the validation phase of the system, from enrolling the beneficiary in a period previous to the cancellation or the enrollment from the second carrier. The main function of SYSPREM will be to allow the registration of the beneficiary’s enrollment in historical data in those cases that cannot be processed as current enrollments.

27.1 SYSPREM Functionality

Among the main functions of this system is the identification of enrollment records that are candidates for processing in historical data because they are enrollments that do not correspond to a current period of eligibility.

27.2 Carriers Eligibility File

The carrier's daily eligibility file will include beneficiary information updated in historical data by the SYSPREM subsystem. In these transactions, the Tran_id field will contain an "H" to identify the historical data. Carriers must modify their systems so that the SYSPREM data is not included as current data when processing the eligibility file. Once a transaction is received, which must be processed through SYSPREM, a process of verification and validation of the information that is contained in the record is carried out. Once the validation tests have been passed, the record, in the database, containing the information corresponding to historical transactions is updated. Those records that do not successfully complete the verification processes will be sent in a file of rejected enrollments to the corresponding carrier for correction.

The figure below shows the validation process performed for the purpose of processing a candidate record for SYSPREM.
 
Enrollment Manual
65

VI. SYSPREM


Figure 2: Validation Process under SYSPREM


27.3 Premium Payment for SYSPREM

The run for the monthly premium payment will include all SYSPREM records that have been processed during the previous month. The payment for these transactions is calculated based on monthly periods from the Enrollment Effective Date of the SYSPREM to:

(1)
The month in which the beneficiary was enrolled with a different carrier,
(2)
The month in which the beneficiary is cancelled or
(3)
Until the date of current billing.

27.4 SYSPREM Error Codes
 
The following is a breakdown of the Error Codes that will trigger an evaluation under SYSPREM:

Table 9: Primary Error Codes for SYSPREM
 
Code
Primary Error Description
107
Effective Date prior to the current family eligibility period.
108
Effective date prior to the current beneficiary eligibility period.
280
The family must be eligible in the current eligibility data.
281
The beneficiary must be eligible in the current eligibility data.
177
Enrolled with another carrier on or after the effective date.

Enrollment Manual
66

VI. SYSPREM

 
Table 10: Secondary Error Codes for SYSPREM
 
Code
Secondary Error Description
083
Social Security Number Not Found.
093
Suffix not found.
132
MPI Not Found.
222
Currently enrolled with the same carrier
223
Currently enrolled with another carrier
225
Incorrect Social Security Number
226
Incorrect MPI Number
22F
Error found in other beneficiaries of the family (GHIP).

The following is a breakdown of the Error Codes that could appear during an evaluation under SYSPREM:

Table 11: SYSPREM Error Codes
 
Code
New Error Codes Description
996
Sysprem record successfully inserted in history.
980
The Process Date of the enrollment record must be greater than the Process Date of the previous enrollment record for the beneficiary who appears previously enrolled for the month corresponding to the Effective Date of the enrollment.
981
The beneficiary must not have beneficiaries of his family with errors not acceptable by SYSPREM in the same enrollment file.
982
The enrollment record must not have an Effective Date prior to 01/01/2006.
983
Enrolled in history for the Effective Date of the enrollment record.
984
It is a New Enrollment, the Effective Date is not first of the month and the beneficiary is already subscribed in another carrier at the Effective Date specified.
985
It is a New Enrollment and the Effective Date should be at least as recent as the beneficiary’s Certification Date at the specified Effective Date.
986
For SYSPREM processing, the Enrollment Effective Date should be before the Effective Date of the current enrolled record at the ASES databases.

In summary, SYSPREM will process and/or enroll transactions in history in those cases in which the enrollment cannot be applied to current data or to current periods of eligibility. Some beneficiaries will not appear as enrolled in history because they are not eligible for the Effective Date or because they are enrolled with a different carrier. Carriers need to evaluate the cases rejected by SYSPREM in order to identify errors in the assigned Effective Date and the correctness of the beneficiaries' data included in the enrollment record.
 
Enrollment Manual
67
 
 

 

ATTACHMENT 11
Per Member Per Month Payments per Region
 
Region
 
Contracted PMPM
 
Metro-North
 
$
183.38
 
West
 
$
148.99
 
 

PUERTO RICO HEALTH INSURANCE ADMINISTRATION
COMMONWEALTH OF PUERTO RICO
PLANNING AND QUALITY AFFAIRS OFFICE
 
QUALITY INCENTIVE PROGRAM
 
FY 2017
 

TABLE OF CONTENTS
 
Contents
 
I.
INTRODUCTION
1
II.
REPORTING TIMEFRAMES
2
III.
EVALUATION & POINT DISTRIBUTION
2
IV.
RETENTION FUND & COMPLIANCE PERCENTAGE
3
V.
DEFINITIONS
4
VI.
PERFORMANCE MEASURES
5
VII.
PREVENTIVE CLINICAL PROGRAMS
12
A.
DISEASE MANAGEMENT PROGRAM
12
B.
PHYSICIAN INCENTIVE PLAN
16
VIII.
ER QUALITY INITIATIVE PROGRAM
16
IX.
CONCLUSION
17
X.
APPENDIX A
18
 

I.
INTRODUCTION
 
The Puerto Rico Government Health Plan (GHP) is focus on providing quality care services that are patient centered aimed at increasing appropriate use of screening and prevention delivered in a timely manner to all Medicaid, Children’s Health Insurance Program (CHIP) and Medicare-Medicaid Dual Eligible enrollees in Puerto Rico.

 This Quality Improvement Procedure Manual has the sole purpose of providing the necessary guidelines for attaining the required performance indicators for each of the categories measured under the Quality Incentive Program (QIP), as described in Article 12 of the contract executed between the MCO and the Puerto Rico Health Insurance Administration (ASES, by its acronym in Spanish). ASES shall maintain a Retention Fund of the Per Member per Month (PMPM) each month as part of the QIP described in Section 12.5.3. A portion of the retained amount shall be associated with each of the QIP initiatives outlined below:

Performance measures (Section 12.5.4.1)

Preventive Clinical Programs (Section 12.5.4.2)

Physician Incentive Program

Disease Management Program

Emergency Room Use Indicators (Section 12.5.4.3)

 ASES will reimburse the MCO according to compliance with each of the categories of performance indicators in section 12.5.  The Planning and Quality Affairs Office will audit the results of the data in the timeframes stated in Section 12.5 of the Contract for the performance indicators in the following categories: Performance measures, Preventive clinical program measures, and ER Utilization measures. This Manual describes in detail the requirements and the specific metrics for each category of the Quality Incentive Program. The Quality Improvement Procedure Manual will enter in effect the Effective Date of the Contract and will be revised every contract year at ASES’ discretion unless required in another timeframe by law or regulation.
 
Page 1
Definition reference in this manual are from the Puerto Rico Health Insurance
Administration Contract and NCQA (National Committee for Quality Assurance)

II.
REPORTING TIMEFRAMES
Quarter
Incurred Service Time Period
Payment as of:
Submission Date
 
Baseline Data Analysis: Calendar Year 2016*
August 30, 2017
Q1
7/1/2017 through 9/30/2017
December 31, 2017
January 30, 2018
Q2
10/1/2017 through 12/31/2017
March 31, 2018
April 30, 2018
Q3
1/1/2018 through 3/30/2018
June 30, 2018
July 30, 2018
Q4
4/1/2018 through 6/30/2018
September 30, 2018
October 30, 2018
*For Performance Measures, the baseline may be adjusted removing members that have reach compliance
 
from January 1 st to June 30, 2017.

III.
EVALUATION & POINT DISTRIBUTION

The evaluation process of the QIP is divided in three categories; Performance Measures, Preventive Clinical Programs and Emergency Room Quality Incentive Program. This evaluation methodology has been developed to meet the requirements established in section 23.1 of the GHP Contract. The scale of values per indicator as determined by ASES, is divided in three levels as follows:

For metrics with a value of two (2) points:

 
2 Points = Full compliance with expected goal, meets or exceeds (90%-100%) expected goal as define in the QIP Manual.
 
1 point = Partial compliance, results reported are 70% or over  but less than 90% (70.00% - 89.99%) of the established goal.
 
0 point = Fails; results reported are less than 70% (0% - 69.99%) of the established goal.
 
For metrics with a value of 1 (1) point:
 
1 Points = Full compliance with expected goal, meets or exceeds (90% - 100%) expected goal as define in the QIP Manual.
 
O.5 point = Partial compliance, results reported are 70% or over  but less than 90% (70.00% - 89.99%) of the established goal.
 
0 point = Fails; results reported are less than 70% (0% - 69.99%) of the established goal.
 
The point distribution by program is as follows:
 
Program
Points
Performance Measures
16
Preventive Clinical Programs
31
ER Quality Incentive Program
5
 
Page 2
Definition reference in this manual are from the Puerto Rico Health Insurance
Administration Contract and NCQA (National Committee for Quality Assurance)

IV.
R ETENTION FUND & COMPLIANCE PERCENTAGE
 
ASES will withhold a portion of the PMPM otherwise payable to the MCO in order to incent the MCO to meet performance targets under the Quality Incentive Program. The retention fund will be reimbursed to the MCO when a determination is made by ASES that the MCO has complied with the quality standards and criteria established by ASES in accordance with 23.1 of the contract. On a quarterly basis the MCO will submit a quarterly Retention Fund Report in accordance to 18.2.9.4 of the contract.

On a monthly basis, ASES will withhold a retention fund equivalent to two (2) percent of the total PM/PM of each region. A portion of the retained amount will be associated with each of the Quality Incentive initiatives outlined below for each of the specified timeframes as per section 22.4.1 of the contract:
Time Period (Incurred service from Contract Term)
Monthly Retention Fund Percentage
7/1/2017 through 6/30/2018
2%
QIP Initiative
Retention Fund Breakdown
Performance Measures
40%
Clinical Programs
30%
Emergency Room Use Indicators
30%

No later than thirty (30) calendar days after receipt of the Contractor’s quarterly reports,   ASES shall determine if the MCO has met the applicable performance objectives for each quality incentive initiative for that period. The evaluation result and compliance will determine the percent to be disbursed to the MCO as described in the following table:
Compliance Percent
Disbursement Percentage of Monthly PM/PM
100-90%
100%
89.9-80%
75%
79.9-70%
50%
69.9 and below %
0%

For the first quarter (July 1 st to September 30, 2017), ASES will reimburse corresponding period retention fund subject to the submission of the required reporting templates regardless of the compliance with the established goals. This waiver is provided to allow the MCOs to finish the programming, population identification, develop strategies, communication to providers, start interventions with identified members and all other activities related to this QIP necessary to comply with its requirements.
 
Page 3
Definition reference in this manual are from the Puerto Rico Health Insurance
Administration Contract and NCQA (National Committee for Quality Assurance)

V.
DEFINITIONS
 
The following definitions apply to measures of the Quality Improvement Manual:
 
  1.
Disease Management: An administrative function comprised of a set of Enrollee-centered steps to provide coordinated care to Enrollees suffering from diseases listed in Section [7.8.3] of the Contract.
 
2.
Hot Spotting: The ability to identify in a timely manner heavy users of the systems and their patterns of utilization to provide targeted interventions and care through mapping data.
 
3.
Incurred date : Is the date in which the service was provided.
 
4.
Intervention: activities targeted at the achievement of client stability, wellness, and autonomy through advocacy, assessment, planning, communication, education, resource management, care coordination, collaboration, and service facilitation.
 
5.
Performance measures :  periodic measurement of outcomes and results used to assess the effectiveness and efficiency of quality initiatives on selected indicators.
 
6.
Per member per month payment (PMPM): The fixed monthly amount that the MCO is paid by ASES for each enrollee to ensure that benefits under the Contract are provided.  This payment is made regardless of whether the enrollee receives benefits during the period covered by the payment.
 
7.
Preventive Services :  Health care services provided by a physician or other provider within the scope of his or her practice under Puerto Rico law to detect or prevent disease, disability, behavioral health conditions, or other health conditions; and to promote physical and behavioral health and efficiency.
 
8.
Primary Care Physician: A licensed medical doctor (MD) who is a provider and who, within the scope of practice and in accordance with Puerto Rico Certification and licensure requirements, is responsible for providing all required primary care to enrollees. The PCP is responsible for determining services required by enrollees, provides continuity of care, and provides referrals for enrollees when medically necessary.  A PCP may be a general practitioner, family physician, internal medicine physician, obstetrician/gynecologist, or pediatrician.
 
9.
Retention Fund : The amount of withhold by ASES of the monthly Per Member per Month Payments otherwise payable to the MCO in order to incentivize the MCO to meet performance targets under the Quality Incentive Program described in Section [12.5.3].  This amount shall be equal to the percent of that portion of the total Per Member per Month Payment that is determined to be attributable to the MCO’s administration of the Quality Incentive Program described in Sections [12.5 and 22.3]. Amounts withheld will be reimbursed to the MCO in whole or in part (as set forth in Sections [12.5 and 22.3]) in the event of a determination by ASES that the MCO has complied with the quality standards and criteria established by Section [12.5].
 
10.
Special Coverage: A component of Covered Services provided by the MCO, described in Section [7.7], which are more extensive than the Basic Coverage services, and for which Enrollees are eligible only by “registering.” Registration for Special Coverage is based on intensive medical needs occasioned by serious illness.
 
11.
Quality Incentive Program :  mechanism to improve the quality of services provided to Enrollees. The program shall consist of three (3) categories of performance indicators: performance measures, preventive clinical program measures and ER Utilization measures.
 
12.
Active Member : GHP member with continuous enrollment during the measurement quarter.
 
Page 4
Definition reference in this manual are from the Puerto Rico Health Insurance
Administration Contract and NCQA (National Committee for Quality Assurance)

VI.
PERFORMANCE MEASURES
 
The reporting templates for each of the performance measures mentioned below will be provided to the MCO through the ASES ShareFile site. Each reporting template will be in Excel format. ASES shall reimburse the MCO the percent applicable of the Retention Fund, as shown on page 3, in accordance with Section 22.3 of the contract for successful compliance with the performance measures below based upon quarterly evaluation of this criterion.  The MCO shall demonstrate an increase in the measurement year as described in the next table, for the following performance measures:

PM1. Breast Cancer Screening
PM2. Cervical Cancer Screening
PM3. Cholesterol Management
PM4. Diabetes Care Management
PM5. Access to Preventive Care Visits
PM6. Asthma Management
PM7. Follow up after Hospitalization for Mental Health

The Performance Measures reports are based on claims incurred in the measurement period for each region. The MCO shall provide data for each region.

For each reported submission, the MCO shall use the same template that was submitted in previous quarter(s). The MCO may not update data submitted for previous reporting periods.

The MCO will report the amounts individually for each quarter. For evaluation purposes, to determine compliance, ASES will consider cumulative percentages by quarter (roll over). In the event that the MCO achieve the annual goal before the last quarter of the year, the MCO must demonstrate at least any increase in the percentage during the remaining quarter(s).

Definition Requirements by Performance Measure
(Codes are subject to continuous update revision)

PM1. Breast Cancer
Breast Cancer
Definition for Baseline
Total women 50–74 years of age who has not have a mammogram to screen for breast cancer any time on the year prior the measurement year.
Numerator
The number of active women with a Breast Cancer Screening during the measurement period.
Denominator
Indicate the number of active women without a Breast Cancer screening the year prior to the measurement period for whom the screening has not been performed during previous quarters.
Codes
 
ICD-10-CM Diagnosis:
Z12.31
CPT CODES: 77055,77056, 77057
HCPCS: G0202, G0204, G0206
 
Page 5
Definition reference in this manual are from the Puerto Rico Health Insurance
Administration Contract and NCQA (National Committee for Quality Assurance)

PM2.  Cervical Cancer Screening

Cervical Cancer
Definition for Baseline
Total of women 21–64 years of age who were not screened for cervical cancer the year prior to the measurement year .
Numerator
The number of active women in the denominator with a cervical cancer screening during the measurement year.
Denominator
Indicate the number of active women without a Cervical cancer screening the year prior to the measurement period for whom the screening has not been performed during previous quarters.
Codes
 
ICD-10-CM  Diagnosis: Z12.4
 
CPT CODES: 88141-88143, 88147, 88148, 88150, 88152-88154, 88164-88167, 88174, 88175
HCPCS:  G0123, G0124, G0141, G0143-G0145, G0147, G0148, P3000, P3001, Q0091
 
M3. Cholesterol Management
Cholesterol Management
Definition for Baseline
Total members 18-75 years with a high risk diagnose who have not had a LDL-C test during year prior to the measurement period.
Numerator
Numerator 1: Indicate the number of active members in the denominator with Diabetes Mellitus and a LDL-C test done during the measurement period.
Numerator 2: Indicate the number of active members in the denominator with a Cardiovascular Condition and a LDL-C test done during the measurement period.
Numerator 3: Indicate the number of active members in the denominator with Arterial Hypertension and a LDL-C test done during the measurement year.
Denominator
Denominator 1: Indicate the number of active members with Diabetes Mellitus and without a LDL-C test done the year prior to the measurement year   for whom the screening has not been performed during previous quarters.
Denominator 2: Indicate the number of active members with a Cardiovascular Condition and without a LDL-C test done the year prior to the measurement year for whom the screening has not been performed during previous quarters.
Denominator 3: Indicate the number of active members with Hypertension and without a LDL-C test done the year prior to the measurement year for whom the screening has not been performed during previous quarters.
Codes
ICD-10-CM Diagnosis:       Z13.220 & Codes for DM (E10 y E11), CVD (I70, II75), HBP (I10, I11,  I12, I13, I15)
 
CPT CODES: 80061 - Lipid Panel,  82465 Cholesterol,  83718 HDL Cholesterol, 83719 LDL, 83721 VLDL, 84478 Triglycerides , 83698 Lipoprotein Associated Phospholipase A2, 83700 Lipoprotein, blood; electrophoretic, 83704 quantitation of lipoprotein particle numbers and lipoprotein subclasses when measured.
 
Page 6
Definition reference in this manual are from the Puerto Rico Health Insurance
Administration Contract and NCQA (National Committee for Quality Assurance)

PM4. Diabetes Care Management
Diabetes Care Management
Definition for Baseline
Total members 18-75 years of age with Diabetes Mellitus (E10 Type 1 Diabetes Mellitus  or E11 Type 2 Diabetes Mellitus ) who have not had each of the following the year prior the measurement period: Comprehensive Diabetes Care (CDC):
           Hemoglobin A1c (HbA1c) testing
           Eye exam (retinal) performed by an eye care provider ( Z01.01 Encounter Examination of eye)
•          Medical attention for nephropathy – either evidence of nephrology medical evaluation or a nephropathy screening test
Numerator
The number of active members in the denominator who have had a HgA1c Test, Eye Exam and Nephropathy Screening Test during the measurement period.
Denominator
HgA1c Test Denominator: Indicate the number of active members without a HgA1c test the year prior to the measurement year for whom the screening has not been performed during previous quarters.
Eye Exam Denominator: Indicate the number of active members without an Eye Exam the year prior to the measurement year for whom the screening has not been performed during previous quarters. Nephropathy screening test (Urine Microalbumin Testing) Denominator: Indicate the number of active members without a Microalbumin test the year prior to the measurement year for whom the screening has not been performed during previous quarters.
Codes
ICD-10-CM Diagnosis Diabetes: Use the appropriate code family: E10, E11
 
HbA1C Testing
CPT CODES 83036, 83037,  CPT II Codes 3044F (<7.0%), 3045F (7.0-9.0), 3046F (>9%)
 
Nephropathy Screening
CPT CODES: 3060F, 3061F, 3062F, 3066F, 4010F
Nephropathy Screening test:82042, 82043, 82044, 84156
 
Nephropathy Exclusion: CKD stages 4  and 5
 
Retinal Eye Exam
CPT CODES:   67028, 67030, 67031, 67036, 67039-67043, 67101, 67105, 67107, 67108, 67110, 67112,
67113, 67121, 67141, 67145, 67208, 67210, 67218, 67220, 67221, 67227, 67228, 92002, 92004, 92012, 92014, 92018, 92019, 92134, 92225-92228, 92230, 92235, 92240,92250, 92260, 99203-99205, 9921399215, 99242-99245
CPT II: 2022F, 2024F, 2026F, 3072F
HCPCS S0620, S0621, S0625, S3000
 
Page 7
Definition reference in this manual are from the Puerto Rico Health Insurance
Administration Contract and NCQA (National Committee for Quality Assurance)

PM5. Access to Preventive Care Visits

Access to Preventive Care Visits
Definition for Baseline
Total members who have not had at least one preventive care visit with a PCP the year prior during the measurement period.
Numerator
The number of active members in the denominator with a preventive care visit with a PCP during the measurement period.
Denominator
Indicate the number of active members without a preventive care visit with a PCP the year prior to the measurement period for whom the screening has not been performed during previous quarters.
Codes
ICD-10-CM Diagnosis
"General Medical Exam:Z00.00, Z00.01, Z00.121, Z00.129, Z00.5, Z00.8, Z02.0-Z02.6, Z02.71, Z02.79, Z02.81, Z02.82, Z02.83, Z02.89, Z02.9 "
ICD-10-CM Procedure Other Exams: Z00.5, Z00.8, Z02.0, Z02.2, Z02.3, Z02.4, Z02.5, Z02.6, Z02.71, Z02.79, Z02.81, Z02.82, Z02.83, Z02.89, Z02.9
CPT CODES: 99201-99205, 99211-99215, 99241-99245, 99341-99345, 99347-99350, 9938199387, 99391-99397, 99401-99404, 99411, 99412, 99214, 99304-99310, 99315, 99316, 99318, 99324-99328, 99334-99337
HCPCS G0402, G0438, G0439, G0463, T1015
 
Page 8
Definition reference in this manual are from the Puerto Rico Health Insurance
Administration Contract and NCQA (National Committee for Quality Assurance)

PM6. Asthma Management
Asthma Management
Definition for Baseline
Percentage of members with at least one monthly prescription of drugs use for prevention of bronchial asthma, of all members identified with a reported medical evaluation with a diagnosis of Persistent Moderate or Severe Bronchial Asthma during the baseline year 2016.
Numerator
The amount of members with at least one monthly prescriptions of drugs used for Bronchial Asthma prevention, on active members identified on baseline, with Moderate or Severe Persistent Bronchial Asthma diagnosis during the reporting period.
Denominator
The number of active members on baseline, who are identify with Moderate and Severe persistent Bronchial Asthma for the reporting period.
Codes
ICD-10-CM Diagnosis: J45.4; J45.5
Drugs for prevention of Bronchial Asthma to be provided  with the NDC codes.
 
Page 9
Definition reference in this manual are from the Puerto Rico Health Insurance
Administration Contract and NCQA (National Committee for Quality Assurance)

PM7. Follow up after Hospitalization for Mental Health
Follow up after Hospitalization for Mental Health
Definition for Baseline
Percent of members who were discharge of acute mental health care facility and were seen on an outpatient basis by a psychiatrist or a physician within thirty days after discharge.
Numerator
The number of discharges in the denominator followed by an outpatient encounter with a psychiatrist or a physician within thirty days after discharge. (This amount shall include visits performed 30 days after the end of the quarter.)
Denominator
The number of discharges from an acute mental health care facility during the quarter.
Codes
ICD-10 F32.0 – F32.4, F32.9, F33.0-F33.3, F33.41, F33.9
 
Page 10
Definition reference in this manual are from the Puerto Rico Health Insurance
Administration Contract and NCQA (National Committee for Quality Assurance)

The point distribution for each of the measure is as follows:
Program: Performance Measures
Improvement Rate Target FY 2017/2018
 
Points
PM1. Breast Cancer Screening
Calendar year 2016: Baseline
Q2-Q4: Incurred services by quarter
Goal: 15%  improvement
Quarterly reimbursement will be based on achieving a minimum of 5% of the established goal on each trimester.
2 points
PM2. Cervical Cancer Screening
Calendar year 2016: Baseline
Q2-Q4: Incurred services by quarter
Goal: 15% improvement
Quarterly reimbursement will be based on achieving a minimum of 5% of the established goal on each trimester.
2 points
PM3. Cholesterol Management
Calendar year 2016: Baseline
Q2-Q4: Incurred services by quarter
Goal: 30% improvement
Quarterly reimbursement will be based on achieving a minimum of 10% of the established goal on each trimester.
3 points
PM4. Diabetes Care Management
Calendar year 2016: Baseline
Q2-Q4: Incurred services by quarter
Goal: 30% improvement
Quarterly reimbursement will be based on achieving a minimum of 10% of the established goal on each trimester.
3 points
PM5. Access to Preventive Care Visits
Calendar year 2016: Baseline
Q2-Q4: Incurred services by quarter
Goal: 15% improvement
Quarterly reimbursement will be based on achieving a minimum of 5% of the established goal on each trimester.
2 points
PM6. Asthma Management
Calendar year 2016: Baseline
Q2-Q4: Incurred services by quarter
Goal: 7.5 % improvement
Quarterly reimbursement will be based on achieving a minimum increment of
2.5% of the established goal on each trimester.
2 points
PM7. Follow up after Hospitalization for Mental Health
Calendar year 2016: Baseline
Q2-Q4: Incurred services by quarter
Goal: 9% improvement
Quarterly reimbursement will be based on achieving a minimum of 3% of the established goal each trimester.
2 points
Total points
 
16 points
 
Page 11
Definition reference in this manual are from the Puerto Rico Health Insurance
Administration Contract and NCQA (National Committee for Quality Assurance)

VII.
PREVENTIVE CLINICAL PROGRAMS
 
The MCO shall comply with the objectives of each of the following Preventive Clinical Programs as stated in the GHP Contract in section 12.5.4.2. The Preventive Clinical Programs are:

 
A.
DISEASE MANAGEMENT PROGRAM (7.8.3 OF THE CONTRACT)

Disease Management is an approach that aims to provide better care while reducing the costs of caring for the chronically ill. The MCO shall develop a Disease Management Program designed to:
 
  a.
Improve the health of persons with specific chronic conditions and
  b.
Reduce health care service use and costs associated with avoidable complications, such as emergency room visits and hospitalizations.

As a first step, the MCOs Disease Management Program needs to identify the population that will be enrolled in each of the selected conditions. Through a Hot Spotting technique the MCO will provide ASES the demographic characteristics and PMG information of identified members who will benefit from a disease management program.

The second step of the MCO’s DM Program is the design of disease management interventions that improve the overall health status of the identified members. The MCO shall develop interventions that impact the following areas: a) Member related (education and patient coaching), b) PCP related (Care Plan discussion and revision) and c) Clinical related measures (UM Review).

For purpose of the Quality Incentive Program Retention Fund, ASES will consider the UM Review metrics described below for compliance and release to the applicable percent of the retained amount for this particular program.
 
Rule: Report unique patients by category . Patients with multiple conditions will be include only in one Program using the MCO established hierarchy process.

1.   Physical Health DM Metrics  A. Percent of Active Severe Members by DM condition
 
Formula: Total number (cumulative) of active severe members who are participants in DM by condition during the measurement year/ Total number of severe members identified by DM condition on the baseline.

Baseline for FY 2017: Calendar year 2016 members identified as DM Candidate in the category of severe. (Candidate is a members diagnose with a DM condition and categorized as severe that is not a participant in the DM Program.)

The following table defines the baselines, numerator and denominators for the Disease Management conditions to be measured.
 
Page 12
Definition reference in this manual are from the Puerto Rico Health Insurance
Administration Contract and NCQA (National Committee for Quality Assurance)

DM Condition
Baseline
Numerator
Denominator
DM1. Asthma (Bronchial Asthma)
 
Calendar year 2016  Members with the diagnosis of Asthma in the category of severe
Total number of active members with the diagnosis of Asthma in the category of severe who are  participants of the DM Program in the measurement period.
Number of active members with the diagnosis of Asthma in the category of severe as identified in the baseline.
DM2. Diabetes Mellitus (Type 1 or 2)
 
Calendar year 2016  Members with the diagnosis of Diabetes Mellitus (Type 1 or 2) in the category of severe
Total number of active members with the diagnosis of Diabetes Mellitus (Type 1 or 2) in the category of severe who are participants of the DM   Program in the measurement period
Number of active members with the diagnosis of Diabetes Mellitus (Type 1 or 2) in the category of severe as identified in the baseline.
DM3. Congestive Heart Failure
 
Calendar year 2016  Members with the diagnosis of Congestive Heart Failure in the category of severe
Total number of active members with the diagnosis of Congestive Heart Failure in the category of severe who are participants of the DM Program in the measurement period
Number of active members with the diagnosis of Congestive Heart Failure in the category of severe as identified in the baseline.
DM4. Arterial Hypertension
Calendar year 2016  Members with the diagnosis of Arterial Hypertension  in the category of severe
Total number of active members with the diagnosis of Arterial Hypertension in the category of severe who are participants of the DM Program in the measurement period
Number of active members with the diagnosis of Arterial Hypertension in the category of severe as identified in the baseline.
DM5. Major Depression (DEP)
Calendar year 2016  Members with the diagnosis of Major Depression in the category of severe
Total number of active members with the diagnosis of Major Depression in the category of severe who are participants of the DM Program in the measurement period.
Number of active members with the diagnosis of Major Depression in the category of severe as identified in the baseline.
Note: Reference definition for the numerator:
 
☐Participants = Member contacted by the MCO who have a care plan developed.

Goal: To enroll and maintain in DM program at least 22.5% of active severe members by condition at the end of the year. Quarterly reimbursement will be based on achieving at minimum 7.5% of the established goal by quarter.

Note: The MCO will report the amount of members enrolled each quarter. For evaluation purposes, ASES will add any percentage in excess of the goal on the previous quarter to the next quarter (roll over). Minimum goal per quarter must be achieved.
 
Page 13
Definition reference in this manual are from the Puerto Rico Health Insurance
Administration Contract and NCQA (National Committee for Quality Assurance)

Score: 2 points by condition
 
 
B.
UM Metrics
 
Note: ER Visits and Hospital admissions to be included are those related to or a complication of the DM condition being reported.

1. ER Visit Metrics by region and condition for each Physical Health DM
 
Formula:  Number of ER Visits of severe identified  DM members  annualized /     x 1,000
Number of DM members with severe  classification

Baseline for FY 2017:  Rate of ER visits of members identified as DM candidate from calendar year 2016

Goal by 2017-2018  Q1-Q4: At least 2 % decrease of active severe members ER visits by condition in each quarter.
Score: 2 points by condition
 
2. Hospital Admission Metrics by region and condition for Physical Health (2 points)
 
Formula: Number of hospital admissions of severe DM members  annualized /     x 1,000
Number of hospital admissions of DM members with severe classification

Baseline for FY 2017:  Rate of Hospital Admissions of members identified as DM candidate from calendar year 2016

Goal by 2017-2018 Q1-Q4: At least 2% decrease of active severe members hospital admission by condition in each quarter

Score: 2 points by condition
 
2. For Mental Health DM Metrics are as follows: A.
 
Percent of participants with Major Depression
 
Formula:  Total number of active members with the diagnosis of Major Depression in the category of severe who are participants of the DM Program in the measurement period / Number of active members with the diagnosis of Major Depression in the category of severe as identified in the baseline.

Baseline for FY 2017: Calendar year 2016 members with diagnosis of Major Depression identified as DM Candidate in the category of severe
 
Page 14
Definition reference in this manual are from the Puerto Rico Health Insurance
Administration Contract and NCQA (National Committee for Quality Assurance)

Goal by 2017-2018  Q2-Q4: To enroll and maintain in DM program at least 22.5% of active severe members by condition at the end of the year. Quarterly reimbursement will be based on achieving at minimum 7.5% of the established goal by quarter.

Note: The MCO will report the amount of members enrolled each quarter.For evaluation purposes, ASES will add any percentage in excess of the goal on the previous quarter to the next quarter (roll over).

Score: 2 points
 
B.   UM Metric

Note: Hospital admissions to be included are those related to or a complication of the DM condition being reported.

1.   Hospital Admission
 
Formula: Number of hospital admissions of severe Major Depression in DM  annualized /     x 1000
Number of hospital admissions of members with severe Major Depression
 
Goal by 2017-2018 Q1-Q4: At least 2% decrease of hospital admissions  of members with severe Major Depression
 
Score: 2 points

2. Timely and Accurate Hot Spotting Report:
Submit a timely and accurate Hot Spotting Report by region, PMG number, PMG name, PMG population and municipality of residence of members identified as severe in the following conditions:
 
Physical and Mental Health DM
DM1. Asthma (Bronchial Asthma)
DM2. Diabetes Mellitus (Type 1 or 2)
DM3. Congestive Heart Failure
DM4. Arterial Hypertension
DM5. Major Depression

This report will include for each condition: number of members, percent of the PMGs population, number of active cases and number of interventions.

Score: 1point
 
Page 15
Definition reference in this manual are from the Puerto Rico Health Insurance
Administration Contract and NCQA (National Committee for Quality Assurance)

B.PHYSICIAN INCENTIVE PLAN
 
Physician Incentive Programs are designed to recognize and reward Primary Care Providers who are committed to Preventive Services and improving the quality of the services to all their members.  The MCO shall design a Physician Incentive Program that addresses the following key objectives:
 
 
Improve the delivery of care to members for preventive services and chronic conditions • Align with national quality measures such as those of the Centers for Medicare & Medicaid       Services (CMS) and National Committee for Quality Assurance (NCQA).
Improve patient Care coordination
Electronic Health Record (EHR)

For purpose of the Quality Incentive Program Retention Fund, ASES will consider the process outcomes described by the MCOs’ Incentive Plan and ASES’s requirements described below for compliance and release to the applicable percent of the retained amount for this particular program Process outcome(s) requirements from ASES:

  1.
Evaluate 100% of the PCPs (with 100 lives as minimum) through Medical Record Review for compliance with clinical and administrative performance measures identified by the Health Plan.
  §
The MCO will submit quarterly the reports on the number of PCP eligible by region  and those  scores obtained on the reported quarter.

Score: 1 points
 
2.
The MCO shall ensure at a minimum seventy percent (70%) of PCP will be in compliance with eighty percent (80%) scorecard on those indicators approved by ASES and included in the  Health Plan Audit during the Contract year.
§
MCO will provide a list by PMG and by region of the certified PCP eligible for the financial incentive that received the preventive services auditing with the percentage of compliance for each PCP evaluated during the reporting period.
              Score: 1 points

Total points for this program 2 points.

VIII.
ER QUALITY INITIATIVE PROGRAM

The ER Quality Initiative Program shall be design to identify high users of Emergency Services (including behavioral health) to allow for early interventions of members and physician (PCP) in order to ensure appropriate utilization of services and resources. The program design required by ASES for the ER Quality Initiative will be based on the “Hot Spotting Model of the Camden Coalition of Health Providers”. The MCO will submit to ASES for approval a work plan with detailed activities and interventions aimed to High ER Utilizers.  The activities and interventions of work plan shall include, but not limited to, the following:
 
1.
Educational campaign to educate consumers about healthcare options available to them when a primary care physician isn’t available. The intent of the campaign is to let consumers know the emergency room is not the only alternative when seeking treatment. Options include retail health clinics, walk-in doctor's offices and urgent care centers – all of which, officials say, can provide the same care in less time and less out-of-pocket expense than an ER visit.
 
Page 16
Definition reference in this manual are from the Puerto Rico Health Insurance
Administration Contract and NCQA (National Committee for Quality Assurance)

2.
One on One Care management interventions
 
3.
PCPs interventions on identifying high users or potential high users of ER services.
 
4.
Changes on access to urgent care at PCP offices with extended hours or urgent clinics.
 
For purpose of the Quality Incentive Program Retention fund, ASES will consider the ER Report and UM Metrics described below for compliance and release to the applicable percent of the retained amount for this particular program .
 
1.
Through a timely and accurate Hot Spotting Report all MCOs will provide ASES the demographic characteristics and PMG information of identified High ER Utilizers by severity level (1 point):
 
Member identification will be as follows:
 
Severity  Criteria ER Visits
Level 1: Mild           
3-6 visits a year
Level 2: Moderate
7-11 visits a year
Level 3: Severe
12 or more visits a year
          
2.
Ambulatory Visits Rate (2 points):
Total Number of Non-Emergency  Ambulatory Visits incurred by Active Severe ER Utilizers  / Total members on Active Severe ER Utilizers
Baseline: Calendar year 2016: Rate of ambulatory visits per severe ER Utilizers
Goal:     3% quarterly increase in the rate of non-emergency ambulatory visits per severe ER utilizers (Each quarter will be evaluated independently and roll over does not appy to this metric.)
 
3.
Annualized ER Rate on frequent ER users (2 points):
Total Number of ER Visits incurred by members with 7 or more ER Visits / Total members with 7 or more ER Visits  x 1,000
Baseline: Calendar year 2016: Annual rate per thousand of ER visits of members in moderate and severe categories
Goal:   3% quarterly decrease in number of annualized ER Visits incurred by members with 7 or more ER Visits (Each quarter will be evaluated independently and roll over does not appy to this metric.) Total points in this program 5 points
 
IX
CONCLUSION
 
The compliance with the quality categories established in this Manual will be measured and shall be accomplished by the MCO on a quarterly basis. MCO shall comply with the required quarterly metrics in order to receive the reimbursement of the amount retained by ASES for each quarter as defined in Section 23.1 of the Contract.
 
Page 17
Definition reference in this manual are from the Puerto Rico Health Insurance
Administration Contract and NCQA (National Committee for Quality Assurance)

X
APPENDIX A

Disease Management Member Identification and Severity Criteria
 
Reminder: Events must be related to the DM Condition (based on the diagnosis code)
 
1.
Asthma (Bronchial Asthma) Member Identification Criteria:
 
Diagnostic Code:
Medical encounters with any of the following ICD10:  J45
Age
 5-56
With at least one of the following events:
Medications
4 or more  asthma medications
ER
At least one visits (CPT:  99281-99285,  99288)
Hospital Admission
At least one hospital admission (CPT:  99221-99223, 99231-99233,
99238-99239, 99251-99255,  99261-99263, 99261-99263,
99291,99292)
Outpatient visits
At least four (4) outpatient encounters (CPT: 99201-99205, 99211-
99215, 99217-99220, 99241-99245, 99341-99345, 99347-99350,
999382-99386, 99392-99396, 99401-99404, 99411, 99412, 99420, 99429.)
 
Page 18
Definition reference in this manual are from the Puerto Rico Health Insurance
Administration Contract and NCQA (National Committee for Quality Assurance)

Severity  Criteria:
Severity
Hospital
Admissions
ER Visits
Outpatient
Pharmacy
(Therapeutic categories)
Mild: Comply with all of the following:
0
1
0-3
1
Moderate: Comply with two of the following:
1
2
4-5
2
Severe: Comply with at least one of the following:
≥2
≥3
≥6
≥3 combined categories at least any three months during the baseline year

Exclusions
 
Patients with emphysema, COPD, Chronic Bronchitis, Cystic Fibrosis and Acute Respiratory Failure
 
2.
Diabetes Mellitus (Type 1 and 2) Member Identification Criteria
 
Diagnostic Codes
Medical encounters with any of the following ICD10:   E10,  E11, E13
Age
0-75
With at least one of the following events:
Medications
1 or more
ER Visits
1 or more
Hospital Admission
At least one hospital admission
Outpatient Visits
2 or more
 
Page 19
Definition reference in this manual are from the Puerto Rico Health Insurance
Administration Contract and NCQA (National Committee for Quality Assurance)

Severity Criteria: At least one of the following
Severity
Hospital
Admissions
ER Visits
Pharmacy
(Therapeutic categories)
Complications*
Mild: Comply with all of the following:
0
0
1
0
Moderate: Comply with two of the following:
0
1 o  2
2
1-2
Severe: Comply with at least two of the following:
≥1
≥3
≥3
≥ 3
*Diabetes related complications including ophthalmic, renal, cardiovascular, skin and neurological.
 
3.
Congestive Heart Failure Member Identification:
 
Diagnostic Code
Medical encounters with any of the following ICD10:
I50, I11.0,  I13.0,  I13.2
Age
≥18
Medications
1 or more
With at least one of the following events:
ER Visit
1 visit or more
Hospital Admission
1 admission or more
Outpatient Visit
1 or more
 
Page 20
Definition reference in this manual are from the Puerto Rico Health Insurance
Administration Contract and NCQA (National Committee for Quality Assurance)

Severity Criteria: At least one of the following
Severity
Hospital
Admissions
ER Visits
Pharmacy
(Therapeutic categories)
Complications*
Mild: Comply with all of the following:
0
0-1
0-1
0
Moderate: Comply with two of the following:
1
2
2
1-2
Severe: Comply with at least two of the following:
≥ 2
≥ 3
≥3
≥ 3
* CHF related complications including Renal Failure, Heart Valve Disease, Heart Arrhythmia and Liver Disease
 
Page 21
Definition reference in this manual are from the Puerto Rico Health Insurance
Administration Contract and NCQA (National Committee for Quality Assurance)

4.
Arterial Hypertension Member Identification

Diagnostic
Codes
Medical encounters with any of the following ICD10:
I10, I11,  I12, I13, I15,
Age
18+
Medications
1 or more
With at least one of the following events:
ER Visits
1 or more
Hospital Admissions
1 admission
Outpatient visits
1 or more
 
Severity Criteria: At least one of the following
Severity
Hospital
Admissions
ER Visits
Pharmacy
(Therapeutic
Categories)
Complications*
Mild: Comply with all of the following:
0
0-1
0-2
0
Moderate: Comply with two of the following:
1
1 -4
3
1-3
Severe: Comply with at least one of the following:
≥ 2
≥ 5
≥ 4
≥ 4
*Arterial Hypertension related conditions including Myocardial Infarct, Cerebrovascular Accidents, Arterial Aneurism, Renal Disease, Hyperlipidemia and Metabolic Syndrome
 
Exclusions
 
Patients with I11.0, I13.0, I13.2
 
Page 22
Definition reference in this manual are from the Puerto Rico Health Insurance
Administration Contract and NCQA (National Committee for Quality Assurance)

5.
Major Depression
 
Diagnostic Codes
Medical encounters with any of the following ICD10:   F33, F32
Age
≥ 12
Medications
1 or more
With at least one of the following events:
ER Visits
1 or more
Hospital Admission
1 or more
Outpatient Visits
1 or more

Severity Criteria: At least one of the following
Severity
Hospital
Admissions
ER
Visits
Pharmacy
(Therapeutic
Categories)
Complications*
Mild: Comply with all of the following:
0
1
1
0
Moderate: Comply with two of the following:
1
2
2
1-2
Severe: Comply with at least one of the following:
≥ 2
≥ 3
≥3
≥ 3
*Complications including chronic pain, chronic physical illness, alcohol or drug abuse, anxiety, panic disorder or social phobias, self-mutilation, suicidal attempts, antisocial disorders
 
 
Page 23
Definition reference in this manual are from the Puerto Rico Health Insurance
Administration Contract and NCQA (National Committee for Quality Assurance)


Exhibit 21
 
LIST OF SUBSIDIARIES OF TRIPLE-S MANAGEMENT CORPORATION (“TSM”) *

·
Triple-S Salud, Inc. (“TSS”), a wholly-owned subsidiary of TSM.

·
Triple-S Advantage, Inc. (“TSA”), a wholly-owned subsidiary of TSS.

·
Triple-S Vida, Inc., a wholly-owned subsidiary of TSM.

·
Triple-S Propiedad, Inc., a wholly-owned subsidiary of TSM.

All of these subsidiaries are incorporated under the laws of the Commonwealth of Puerto Rico.

*
Pursuant to Item 601(b)(21)(ii) of Regulation S-K, the names of other subsidiaries of Triple-S Management Corporation are omitted because, considered in the aggregate, they would not constitute a significant subsidiary as of the end of the year covered by this report.
 
 


Exhibit 23.1
 
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in Registration Statement No. 333-151032 and 333-217891 on Form S-8 of our reports dated March 7 , 2018, relating to the consolidated financial statements and financial statement schedules of Triple-S Management Corporation and its subsidiaries, and the effectiveness of  Triple-S Management Corporation's internal control over financial reporting, appearing in this Form 10-K of Triple-S Management Corporation for the year ended December 31, 2017.

/s/ DELOITTE & TOUCHE LLP

San Juan, Puerto Rico
March 7 , 2018
 
 


Exhibit 31.1
 
CERTIFICATION

I, Roberto García-Rodríguez, certify that:

1.
I have reviewed this Annual Report on Form 10-K of Triple-S Management Corporation (“the registrant”);

2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.
The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a.
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c.
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.
The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a.
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b.
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date:
March 7, 2018
 
By:
/s/ Roberto García-Rodríguez
       
Roberto García-Rodríguez
       
President and Chief Executive Officer



Exhibit 31.2
 
CERTIFICATION

I, Juan J. Román-Jiménez, certify that:

1.
I have reviewed this Annual Report on Form 10-K of Triple-S Management Corporation (“the registrant”);

2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.
The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a.
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c.
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.
The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a.
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b.
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date:
March 7, 2018
 
By:
/s/ Juan J. Román-Jiménez
       
Juan J. Román-Jiménez
       
Executive Vice President and Chief Financial Officer



Exhibit 32.1
 
CERTIFICATION

PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Triple-S Management Corporation (the “Company”) on Form 10-K for the period ended December 31, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Roberto García-Rodríguez , President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

a)
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

b)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date:
March 7, 2018
 
By:
/s/ Roberto García-Rodríguez
       
Roberto García-Rodríguez
       
President and Chief Executive Officer

A signed original of this written statement required by Section 906 has been provided to the Corporation and will be retained by the Corporation and furnished to the Securities and Exchange Commission or its staff upon request.



Exhibit 32.2
 
CERTIFICATION

PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Triple-S Management Corporation (the “Company”) on Form 10-K for the period ended December 31, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Juan J. Román-Jiménez, Executive Vice President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

a)
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

b)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date:
March 7, 2018
 
By:
/s/ Juan J. Román-Jiménez
       
Juan J. Román-Jiménez
       
Executive Vice President and Chief Financial Officer

A signed original of this written statement required by Section 906 has been provided to the Corporation and will be retained by the Corporation and furnished to the Securities and Exchange Commission or its staff upon request.